risperidone has been researched along with Dementia Praecox in 2669 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Risperidone has antiserotonergic and antidopaminergic properties that may make it more effective than conventional antipsychotic agents in the treatment of the negative symptoms of schizophrenia." | 10.17 | Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. ( Carman, J; Peuskens, J; Vangeneugden, A, 1995) |
| "The aim of this study was to explore the effectiveness and safety of pentoxifylline as an adjuvant to risperidone in mitigating the negative symptoms in patients with chronic schizophrenia." | 9.69 | Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial. ( Abdallah, MS; El-Berri, EI; Hassan, A; Mosalam, EM; Omara-Reda, H; Ramadan, AN; Samman, WA; Zidan, AA, 2023) |
| "Eighty chronic schizophrenia inpatients were equally assigned to receive risperidone (6 mg/day) plus either L-theanine (400 mg/day) or matched placebo in this 8-week, randomized, parallel-group, double-blind, placebo-controlled trial." | 9.69 | L-Theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial. ( A Basti, F; Akhondzadeh, S; Fallahpour, B; Fattollahzadeh-Noor, S; Khodaei Ardakani, MR; Shamabadi, A, 2023) |
| "These results suggest that the antioxidant defense system may have predictive value for the weight gain of ANFE SCZ patients after risperidone treatment." | 9.51 | Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study. ( Gao, Y; Guan, X; Li, X; Liu, H; Thomas, K; Xiu, M; Yu, R; Zhang, X, 2022) |
| "To evaluate long-term efficacy, safety and tolerability of Risperidone ISM® in patients with schizophrenia, a multicenter, open-label extension of the PRISMA-3 study was conducted." | 9.51 | Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. ( Anta, L; Correll, CU; Filts, Y; Litman, RE; Martínez, J; Naber, D, 2022) |
| "This 8-week (trial timepoints: baseline, week 4, week 8), double-blind, placebo-controlled clinical trial randomized patients with schizophrenia in a 1:1 ratio to compare the efficacy and safety of 600 mg twice a day of PEA and matched placebo alongside a stable dose of risperidone." | 9.51 | Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. ( Akhondzadeh, S; Bagheri, S; Khodaei Ardakani, MR; Moradi, K; Namaei, P; Salehi, A; TaghaviZanjani, F, 2022) |
| "We completed a 12-month randomized controlled trial of cognitive remediation and of long-acting injectable (LAI) risperidone with 60 patients with a recent first episode of schizophrenia." | 9.51 | A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning. ( Bell, MD; Boucher, ML; Casaus, LR; Gretchen-Doorly, D; Hayata, JN; Luo, J; Medalia, A; Nuechterlein, KH; Subotnik, KL; Turner, LR; Ventura, J, 2022) |
| "Risperidone has been significant correlated with a direct effect of interleukin-6 (IL-6) levels in patients with schizophrenia." | 9.41 | Effect of risperidone on serum IL-6 levels in individuals with schizophrenia: a systematic review and meta-analysis. ( Castillo-Avila, RG; Genis-Mendoza, AD; González-Castro, TB; Juárez-Rojop, IE; López-Narváez, ML; Martínez-Magaña, JJ; Ramos-Méndez, MA; Tovilla-Zárate, CA; Villar-Juárez, GE; Villar-Soto, M, 2023) |
| "We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of blonanserin and risperidone for the treatment of schizophrenia and to provide reliable pharmacotherapeutic evidence for in the clinical treatment of schizophrenia." | 9.41 | Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. ( Deng, SW; Hong, B; Jiang, WL; Li, BH; Sun, DW; Xu, Q; Yang, HB, 2023) |
| "Patients with an acute episode of schizophrenia (n=11) and predominating positive symptoms were randomized to a 6-week add-on treatment with memantine (10 mg twice a day) versus placebo and patients with chronic schizophrenia (n=13) and negative symptoms were randomized to a 24-week add-on treatment with memantine (10 mg twice a day) versus placebo." | 9.34 | Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
| "To report the efficacy and safety of blonanserin in patients with schizophrenia compared with risperidone in a Japanese multicenter, randomized, double-blind study based on post hoc sensitivity analysis in addition to the previous results reported by Miura and discuss the current approaches for schizophrenia treatment." | 9.34 | Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study. ( Harvey, PD; Miura, S; Nakamura, H, 2020) |
| "Hospitalized schizophrenia patients aged 18-65 were randomized to 6 weeks of double-blind, double-dummy, flexible-dose treatment with lurasidone (40 or 80 mg/day) or risperidone (2, 4 or 6 mg/day)." | 9.34 | Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia. ( Deng, W; Feng, Y; Li, K; Li, L; Liu, Q; Liu, X; Luo, X; Ning, Y; Shi, J; Tan, Y; Wang, G; Wang, L; Wang, X; Xie, S; Xu, X; Zhang, X; Zhao, J, 2020) |
| "This study examined randomized controlled trial data for blonanserin and risperidone in Chinese schizophrenia patients (N = 264)." | 9.34 | Model-based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double-blind study. ( Lei, L; Li, H; Li, Y; Shen, Y; Yu, W; Yu, Y, 2020) |
| "This was an eight-week randomised, double-blind, placebo-controlled, parallel-group clinical trial, in which 78 inpatients with chronic schizophrenia were stabilised with risperidone (4-6 mg/day) for two months before being assigned to adjunctive vortioxetine (10 mg b." | 9.34 | Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. ( Akhondzadeh, S; Bayanati, S; Mesgarpour, B; Moazen-Zadeh, E; Rezaei, F; Ziafat, K, 2020) |
| "In a randomized, double-blind, and placebo-controlled setting, schizophrenia patients were assigned to receive either 200 mg/d resveratrol or matched placebo in addition to a stable dose of risperidone for 8 weeks." | 9.34 | Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial. ( Akhondzadeh, S; Alikhani, R; Ashraf-Ganjouei, A; Bagheri, S; Moradi, K; Mousavi, SB; Rezaei, F; Samaei, A, 2020) |
| "A double-blind, placebo-controlled study involved 75 patients with schizophrenia who randomly received low dose (100 mg/day) or high dose minocycline (200 mg/day) or placebo added to risperidone." | 9.30 | The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia. ( Kosten, TR; Wu, R; Zhang, L; Zhang, XY; Zhao, J; Zheng, H, 2019) |
| "This study aimed to investigate the efficacy and tolerability of aripiprazole, olanzapine and risperidone in first-episode schizophrenia (FES)." | 9.30 | An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. ( Cai, S; Cheng, Z; Correll, CU; Deng, H; Han, X; Lu, Z; Wang, C; Xiang, Y; Yang, F; Yang, L; Yu, X; Yuan, Y; Zhao, J, 2019) |
| "Hospitalized patients (N = 460) with schizophrenia were randomized to 6 weeks of fixed-dose lurasidone 40 mg/d, lurasidone 80 mg/d, risperidone 4 mg/d, or placebo." | 9.30 | Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial. ( Chen, HK; Chen, JY; Chen, TT; Chou, YH; Higuchi, T; Huang, SY; Ishigouoka, J; Iyo, M; Katoh, T; Kwon, JS; Lee, JS; Saeki, Y; Tanaka, H; Wang, TS; Wu, BJ, 2019) |
| "A subcutaneous risperidone implant (RI) formulation was developed to improve medication adherence in schizophrenia." | 9.27 | Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia. ( Adera, M; Dammerman, R; Kim, S; Schwarz, A, 2018) |
| "This study examined the effect of adjunctive minocycline on body metabolism in risperidone-treated patients with schizophrenia." | 9.27 | No Effect of Adjunctive Minocycline Treatment on Body Metabolism in Patients With Schizophrenia. ( Fan, X; Liu, F; Ruan, Y; Xie, L; Xu, X; Zeng, Y; Zhang, B; Zhao, J, 2018) |
| "Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted." | 9.27 | L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. ( Afarideh, M; Akhondzadeh, S; Alavi, AR; Ghajar, A; Ghazizadeh-Hashemi, M; Khoaie-Ardakani, MR; Shahmoradi, Z; Shalbafan, MR, 2018) |
| "This clinical trial was performed on 68 patients with chronic schizophrenia, treated with risperidone at 22 Bahman Hospital of Qazvin, Iran during 2015 to 2016." | 9.27 | Evaluation of the Effect of Fluvoxamine in Patients With Schizophrenia Under Risperidone Treatment: A Clinical Trial. ( Haji Seyed Javadi, A; Khanshir, ZF; Shafikhani, AA; Zamir, SM, 2018) |
| "To evaluate the effects of treatment with risperidone and aripiprazole on serum prolactin, testosterone and estradiol levels in female patients with schizophrenia in China." | 9.27 | Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia. ( Hu, JQ; Jiang, XJ; Lin, WC; Shang, DW; Shi, L; Wen, YG; Wu, FX; Xiao, B; Zhang, JP; Zhu, HZ, 2018) |
| "Schizophrenia patients showed a significant improvement in negative symptoms with the addition of minocycline to risperidone." | 9.27 | Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. ( Kosten, TR; Wu, R; Zhang, L; Zhang, XY; Zhao, J; Zheng, H; Zhu, F, 2018) |
| "Paliperidone palmitate 3-monthly (PP3M) injectable formulation offers an advantage of improved medication adherence and lower relapse risk in patients with schizophrenia." | 9.27 | Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis. ( Alphs, L; Gopal, S; Hough, D; Mathews, M; Nuamah, I; Pei, H; Savitz, A, 2018) |
| "In a double-blind and placebo-controlled study, patients with stable schizophrenia (DSM-5) were randomized to receive either 2,500 mg/day citicoline or placebo in addition to risperidone for 8 weeks." | 9.27 | Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. ( Afarideh, M; Akhondzadeh, S; Ghajar, A; Ghazizadeh-Hashemi, M; Gholamian, F; Rezaei, F; Tabatabei-Motlagh, M, 2018) |
| "Risperidone and paliperidone have been the mainstay treatment for schizophrenia and their potential role in neuroprotection could be associated with brain-derived neurotrophic factor (BDNF) and N400 (an event-related brain potential component)." | 9.27 | Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia. ( Chen, C; Chen, GD; Chen, XS; Huang, ZY; Lin, CG; Lin, XD; Lin, ZG; Wu, RQ; Xu, DL; Zhang, LJ; Zhang, MD; Zhang, W, 2018) |
| "To evaluate the efficacy and safety of cilostazol, a selective inhibitor of phosphodiesterase III, as an adjunctive to risperidone in alleviating the negative symptoms of schizophrenia." | 9.24 | Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study. ( Akhondzadeh, S; Jeddian, A; Mesgarpour, B; Mohammadinejad, P; Rezaei, F; Salardini, E; Shahriari, M; Zeinoddini, A; Zeionoddini, A, 2017) |
| "Our study aimed at estimating differences in quality-adjusted life year (QALY) gain for patients with predominant negative symptoms of schizophrenia treated with cariprazine compared with risperidone." | 9.24 | Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. ( Akehurst, R; Götze, Á; Horváth, M; Kóczián, K; Molnár, A; Németh, B; Németh, G; Vokó, Z, 2017) |
| "There have been few studies of pregnenolone therapy in schizophrenia and those that exist have been subject to several critical limitations, thus yielding inconsistent results." | 9.24 | Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial. ( Akhondzadeh, S; Karkhaneh-Yousefi, MA; Kashani, L; Khodaie-Ardakani, MR; Moazen-Zadeh, E; Rahiminejad, F; Rezaei, F; Sadighi, G; Shams, N, 2017) |
| "This study aimed to investigate remission following the treatment of schizophrenia patients with risperidone." | 9.24 | Symptomatic remission in schizophrenia: Results from a risperidone maintenance treatment study. ( Bo, Q; Dong, F; He, F; Li, A; Li, F; Li, X; Ma, X; Wang, C; Wang, Z, 2017) |
| "This study compares the efficacy and tolerability of olanzapine versus risperidone among patients with schizophrenia who are established in outpatient psychiatric care and entering supported employment." | 9.24 | Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. ( Glynn, SM; Marder, SR; Noordsy, DL; O'Keefe, CD; Sugar, CA, 2017) |
| " Because early response to antipsychotics represents a sufficiently reliable index of the subsequent treatment response in patients with schizophrenia, we undertook a real-world, genome-wide association study (GWAS) with the aim of identifying genetic predictors of response to risperidone after 2 weeks in 86 patients with schizophrenia." | 9.24 | The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. ( Calza, S; Gennarelli, M; Magri, C; Minelli, A; Sacchetti, E; Traversa, M; Valsecchi, P; Vita, A, 2017) |
| "Our results support the efficacy of cariprazine in the treatment of predominant negative symptoms of schizophrenia." | 9.24 | Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. ( Barabássy, Á; Bitter, I; Czobor, P; Debelle, M; Durgam, S; Fleischhacker, WW; Harsányi, J; Laszlovszky, I; Marder, S; Németh, G; Szalai, E; Szatmári, B, 2017) |
| "1 channels play a role in the therapeutic action of antipsychotic drugs, particularly risperidone, and further highlight the promise of optimizing response with genotype-guided therapy for schizophrenia patients." | 9.22 | Differential Response to Risperidone in Schizophrenia Patients by KCNH2 Genotype and Drug Metabolizer Status. ( Bigos, KL; Carr, VJ; Green, MJ; Heide, J; Mann, SA; Shannon Weickert, C; Vandenberg, JI; Weinberger, DR; Zhang, F, 2016) |
| "In acute psychotic schizophrenia patients we investigated if the combination of triiodothyronine (T3) plus risperidone was more effective when compared to risperidone monotherapy." | 9.22 | Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia. ( Bunevicius, A; Bunevicius, R; Nemeroff, CB; Prange, AJ; Savickas, A; Steibliene, V, 2016) |
| "The aim of this study was to compare the effects of risperidone long-acting injection (RLAI) and paliperidone palmitate (PP) on non-acute-phase social functioning in patients with schizophrenia." | 9.22 | The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. ( Fabbri, C; Kato, M; Kinoshita, T; Koshikawa, Y; Nishida, K; Onohara, A; Sakai, S; Serretti, A; Sunada, N; Takekita, Y; Yoshimura, M, 2016) |
| "The risperidone maintenance treatment in schizophrenia study was designed to identify the duration of maintenance treatment required with an initial therapeutic dose in contrast to reducing the dose over time." | 9.22 | Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study. ( Bo, QJ; Li, AN; Li, XB; Ma, X; Wang, CY; Wang, ZM, 2016) |
| "In this randomized, double-blind, placebo-controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks." | 9.22 | The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. ( Akhondzadeh, S; Esalatmanesh, S; Farokhnia, M; Goguol, A; Iranpour, N; Khodaie-Ardakani, MR; Mohammadinejad, P; Salehi, B; Yekehtaz, H; Zandifar, A; Zeinoddini, A; Zeionoddini, A, 2016) |
| "RBP-7000 is a sustained-release formulation of risperidone for the treatment of schizophrenia, designed to be administered by once-monthly subcutaneous injection using the ATRIGEL delivery system." | 9.22 | Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study. ( Fava, M; Fudala, PJ; Heidbreder, C; Henderson, DC; Kouassi, A; Nasser, AF; Twumasi-Ankrah, P, 2016) |
| "Duloxetine adjuvant to risperidone seems to be a tolerable and efficacious treatment for primary negative symptoms of schizophrenia." | 9.22 | Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study. ( Akhondzadeh, S; Arabzadeh, S; Ghaleiha, A; Khalili, Z; Mohammadinejad, P; Nikbakhat, MR; Rezaei, F; Zeinoddini, A, 2016) |
| "We compared clozapine (n = 53) to risperidone (n = 54) in a randomized, double-blind, 29-week trial in schizophrenia patients (diagnosed using DSM-IV) at 3 research outpatient clinics." | 9.22 | Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. ( Ames, D; Baker, RW; Chengappa, KN; Kane, JM; Marder, SR; McMeniman, M; Parepally, H; Petrides, G; Schooler, NR; Umbricht, D; Wirshing, WC, 2016) |
| "The aim of this study was to characterize the pharmacokinetics and to evaluate the safety of risperidone ISM in patients with schizophrenia or schizoaffective disorder after a single gluteal intramuscular injection at three different dose strengths (50, 75, and 100 mg)." | 9.22 | Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ( Anta, L; Ayani, I; Gutierro, I; Ivanov, M; Llaudó, J; Martínez, J; Morozova, M; Schronen, J, 2016) |
| "In this 4-week, double-blind, randomized controlled trial conducted in psychiatric care from September 2012 to March 2015, 103 patients with schizophrenia (ICD-10) who did not respond to olanzapine 10 mg/d or risperidone 3 mg/d were randomly allocated to a dose-increment or -continuation group." | 9.22 | Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial. ( Bies, RR; Kapur, S; Mimura, M; Pollock, BG; Sakurai, H; Suzuki, T; Uchida, H, 2016) |
| "This study aimed to investigate prolactin related symptoms (PRS) in individuals with schizophrenia during risperidone maintenance treatment for one year, as well as to identify the risk factors for PRS." | 9.22 | Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia. ( Bo, Q; Dong, F; Li, X; Ma, X; Wang, C; Wang, Z, 2016) |
| "The present analysis assessed the efficacy of extended-release quetiapine fumarate (quetiapine XR) versus risperidone in patients with schizophrenia and depressive symptoms [Hamilton Depression Rating Scale (HAM-D) score≥20 and a HAM-D item 1 score≥2]." | 9.20 | Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. ( Di Fiorino, M; Kasper, S; Montagnani, G; Trespi, G, 2015) |
| "In this prospective multicentre, open-label, 6-month study (Paliperidone Palmitate Flexible Dosing in Schizophrenia [PALMFlexS]), tolerability, safety and treatment response with paliperidone palmitate (PP) were explored in patients with acute symptoms of schizophrenia following switching from previously unsuccessful treatment with oral antipsychotics." | 9.20 | Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. ( Bergmans, P; Bez, Y; Carpiniello, B; Cherubin, P; Hargarter, L; Keim, S; Parellada, E; Rancans, E; Schreiner, A; Vidailhet, P, 2015) |
| "The present findings suggest that clozapine demonstrates superior antidepressant effects to quetiapine and comparable effects to olanzapine and risperidone in chronic schizophrenia regardless of presence of MDE." | 9.20 | Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. ( Caravaggio, F; Chung, JK; Fervaha, G; Gerretsen, P; Graff-Guerrero, A; Iwata, Y; Mihashi, Y; Mulsant, B; Nakajima, S; Plitman, E; Remington, G; Takeuchi, H, 2015) |
| "The objective of this study was to evaluate the effectiveness and impact of once- versus twice-daily dosing of risperidone and olanzapine on clinical outcomes in patients with schizophrenia." | 9.20 | Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. ( Agid, O; Fervaha, G; Lee, J; Remington, G; Takeuchi, H, 2015) |
| "PALMFlexS, a prospective multicentre, open-label, 6-month, phase IIIb interventional study, explored tolerability, safety and treatment response in adults (n = 231) with non-acute but symptomatic schizophrenia switching to flexibly dosed paliperidone palmitate (PP) after unsuccessful treatment with risperidone long-acting injectable therapy (RLAT) or conventional depot antipsychotics (APs)." | 9.20 | Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics. ( Bergmans, P; Cherubin, P; Corrivetti, G; Cosar, B; Hargarter, L; Keim, S; Llorca, PM; Petralia, A; Schreiner, A, 2015) |
| "To compare the clinical efficacy of the long-acting injectable formulation of risperidone with the oral formulation in the early course of schizophrenia." | 9.20 | Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. ( Casaus, LR; Gretchen-Doorly, D; Hellemann, GS; Luo, JS; Marder, S; Nuechterlein, KH; Subotnik, KL; Ventura, J, 2015) |
| "Ninety-five patients with DSM-IV-TR diagnoses of schizophrenia and alcohol use disorder were randomized to 6 months of oral or LAI risperidone between 2005 and 2008." | 9.20 | Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. ( Brunette, MF; Buckley, P; Dawson, R; Green, AI; Hafez, H; Herz, M; Narasimhan, M; Noordsy, DL; O'Keefe, C; Sommi, RW; Steinbook, RM; Wallace, AE; Weeks, M, 2015) |
| "This randomized, double-blind study compared the efficacy and safety of blonanserin and risperidone to treat Chinese schizophrenia patients aged ≥18 and < 65 years." | 9.20 | Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial. ( Gu, N; Li, H; Li, J; Li, K; Li, L; Liu, C; Luo, X; Qi, S; Shi, J; Wang, C; Wang, L; Wang, Q; Yang, F; Yao, C; Zhang, H, 2015) |
| "The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia." | 9.20 | Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial. ( Ai, X; Ding, M; Ding, S; Gu, X; Huang, G; Li, X; Lv, L; Pang, L; Song, X; Zhao, J, 2015) |
| "Using the recommended dosing regimens for PP and RLAI, both PP and oral risperidone (used during RLAI initiation) improved symptoms of schizophrenia in markedly-to-severely ill subjects at days 4-22." | 9.19 | Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. ( Alphs, L; Bossie, CA; Fu, DJ; Kern Sliwa, J; Ma, YW, 2014) |
| "We aimed to assess the efficacy and tolerability of riluzole, an anti-glutamate agent with neuroprotective properties, as an adjunct to risperidone in improving negative symptoms of schizophrenia." | 9.19 | A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. ( Akhondzadeh, S; Farokhnia, M; Hosseini, SM; Khodaie-Ardakani, MR; Pourmahmoud, H; Rezaei, F; Sabzabadi, M; Salehi, B; Tabrizi, M; Yekehtaz, H, 2014) |
| "This study was to evaluate the effects on clinical symptoms and cognitive function of switching the treatment of elderly patients with schizophrenia from risperidone to paliperidone (PAL)." | 9.19 | The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. ( Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Suzuki, H, 2014) |
| "The purpose of this prospective study was to evaluate the effects of switching from oral risperidone to flexibly dosed oral paliperidone extended-release (ER) in Brazilian adults with schizophrenia because of lack of efficacy, intolerability, or nonadherence after a minimum trial of 30 days on adequate (labeled) doses of oral risperidone, according to individual clinical judgment." | 9.19 | Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study. ( Appolinário, JC; Bressan, RA; Campos, JA; de Oliveira, IR; Elkis, H; Gattaz, WF; Grabowski, HM; Henna, E; Lacerda, AL; Lawson, FL; Louzã, MR; Périco, Cde A; Quevedo, J; Rocha, FL; Ruschel, SI; Sacomani, E; Zorzetto Filho, D, 2014) |
| "The present study aimed to examine the changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia." | 9.19 | Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia. ( Fan, X; Gao, J; Harrington, A; Li, X; Lv, L; Song, X; Zhang, W; Zhao, J; Ziedonis, D, 2014) |
| "Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders." | 9.19 | Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. ( Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S, 2014) |
| "This study aimed to investigate changes in plasma concentrations of risperidone and 9-hydroxy-risperidone (9-OHR) and the associated clinical effects when switching from oral risperidone to extended-release (ER) paliperidone in patients with schizophrenia." | 9.19 | Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia. ( Kwak, KH; Lee, SJ; Lim, MS; Seong, SJ; Yang, DS; Yoon, YR, 2014) |
| "A long-term randomized trial of unstable patients with schizophrenia found no benefit of long-acting injectable (LAI) risperidone over oral treatment in preventing or delaying time to psychiatric hospitalizations or on clinical outcomes." | 9.19 | Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. ( Krystal, JH; Leatherman, SM; Lew, RA; Liang, MH; Rosenheck, RA; Thwin, SS; Valley, D, 2014) |
| "We examined the difference between the effects of olanzapine (OLZ) and risperidone (RIS) on PR and QT intervals among patients with stable schizophrenia using a cohort analysis." | 9.19 | Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia. ( Fukui, N; Ono, S; Saito, M; Sawamura, K; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J, 2014) |
| " The goal of this 8-week, randomized, multicenter, open-label study was to examine the effects of aripiprazole and risperidone on social cognition and neurocognition in individuals with schizophrenia." | 9.19 | Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. ( Aleman, A; Cahn, W; Gijsman, HJ; Hovens, JE; Kahn, RS; Maat, A, 2014) |
| "RBP-7000 is a long-acting formulation of risperidone administered once monthly via subcutaneous (SC) injections for the treatment of schizophrenia." | 9.19 | Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. ( Fudala, PJ; Gomeni, R; Heidbreder, C; Laffont, CM; Nasser, AF; Zheng, B, 2014) |
| "The objective of this study was to assess the efficacy and tolerability of minocycline add-on to risperidone in treatment of negative symptoms of patients with chronic schizophrenia." | 9.19 | Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Farokhnia, M; Hosseini, SM; Khodaie-Ardakani, MR; Mirshafiee, O; Modabbernia, A; Rezaei, F; Salehi, B; Tabrizi, M; Tajdini, M; Yekehtaz, H, 2014) |
| "Ninety-two patients with early stage schizophrenia treated with risperidone entered this 16-week, double blind, randomized, placebo-controlled clinical trial." | 9.19 | Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. ( Guo, X; Liu, F; Ou, J; Ruan, Y; Wu, R; Xie, L; Xu, X; Yang, J; Yang, L; Yang, S; Zeng, Y; Zhang, B; Zhang, L; Zhao, J; Zheng, Y, 2014) |
| "In a 12-week randomized open-label trial, adults diagnosed with schizophrenia experiencing inadequate efficacy and/or poor tolerability on risperidone, olanzapine, or aripiprazole were randomized to switch to iloperidone either gradually (ie, down-titration of current therapy over the first 2weeks [to 50% on Day 1, 25% by Week 1, 0% by Week 2]) or immediately." | 9.19 | A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. ( Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A, 2014) |
| "This study was designed to investigate long-term clinical outcomes of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder." | 9.19 | A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. ( Ahn, YM; Cho, SJ; Chung, YC; Jung, IK; Kim, CY; Kim, DH; Kim, SH; Kim, YS; Lee, DG; Lee, NY; Lee, YH; Lim, WJ; Na, YS; Shin, SE; Woo, JM; Yoon, BH; Yoon, JS, 2014) |
| "Sixty-one patients with schizophrenia stably treated with risperidone or olanzapine were randomly assigned to dose-reduction-by-half group or dose maintenance group." | 9.19 | Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia. ( Mimura, M; Remington, G; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K, 2014) |
| "Antipsychotics, such as aripiprazole and risperidone, are often used to treat individuals with schizophrenia." | 9.19 | Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. ( Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W, 2014) |
| "In this study, we assessed the efficacy of 2 pharmacodynamically different antidepressants, citalopram (a selective serotonin reuptake inhibitor) and reboxetine (a norepinephrine reuptake inhibitor), as adjunctive therapy to risperidone and olanzapine for the treatment of negative symptoms in schizophrenia." | 9.19 | Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. ( Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J, 2014) |
| "In this secondary study of an open-label, 28-week, randomized, controlled trial conducted between April 2009 and August 2011, clinically stable patients with schizophrenia (DSM-IV) treated with risperidone or olanzapine were randomly assigned to the reduction group (dose reduced by 50%) or maintenance group (dose kept constant)." | 9.19 | Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ( Bies, RR; Mimura, M; Remington, G; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K, 2014) |
| "There are contradictory reports about the efficacy of minocycline for treating schizophrenia." | 9.19 | Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. ( Dehbozorgi, S; Ghanizadeh, A; OmraniSigaroodi, M; Rezaei, Z, 2014) |
| "We investigated the clinical efficacy and safety of switching to paliperidone (PAL) in elderly schizophrenia patients receiving risperidone." | 9.17 | Study of the efficacy and safety of switching from risperidone to paliperidone in elderly patients with schizophrenia. ( Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Otomo, M; Suzuki, H, 2013) |
| "The objective of this study was to assess the efficacy and tolerability of tropisetron add-on to risperidone on negative symptoms in patients with chronic stable schizophrenia." | 9.17 | A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. ( Akhondzadeh, S; Ashrafi, M; Farokhnia, M; Ghasemi, S; Hosseini, SM; Khodaie-Ardakani, MR; Mirshafiee, O; Modabbernia, A; Noroozian, M; Rezaei, F; Salehi, B; Tabrizi, M; Tajdini, M; Yekehtaz, H, 2013) |
| "We aimed to evaluate the efficacy of memantine add-on in the treatment of primary negative symptoms of patients with stable schizophrenia." | 9.17 | Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Hajiaghaee, R; Hammidi, S; Modabbernia, A; Mohammad-Karimi, M; Motasami, H; Rezaei, F; Salehi, B; Seddighi, S; Tabrizi, M, 2013) |
| "We sought to assess the effect of the addition of a fixed dose of 5 mg daily of aripiprazole on hyperprolactinemia induced by risperidone long-acting injectable (RLAI) treatment in patients with chronic psychoses and the adverse events related to the addition of aripiprazole and its impact on the disease." | 9.17 | Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. ( Bonete Llácer, JM; García Escudero, MA; Martínez Pastor, CJ; Ziadi Trives, M, 2013) |
| "The current study compared the long-term effectiveness, safety, and tolerability of paliperidone extended-release (ER) among patients with schizophrenia who had switched from risperidone (risperidone group) or other antipsychotic medications (non-risperidone group) due to lack of efficacy, intolerability, or non-adherence." | 9.17 | Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents. ( Ahn, YM; Chang, SM; Joo, EJ; Kim, EY; Kim, JJ; Kim, YS; Shim, JC, 2013) |
| " Our research group is developing a non-commercial, multicentric and open label study on the differential efficacy between clozapine and risperidone in first-episode schizophrenia." | 9.17 | Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. ( Aragües, M; Del Alamo, C; Molina, V; Ovejero, S; Palomo, T; Sanz-Fuentenebro, J; Taboada, D, 2013) |
| "We examined clinical characteristics including serum olanzapine concentrations for acute schizophrenia patients who required above conventional doses." | 9.17 | The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia. ( Hatta, K; Hirata, T; Ito, S; Kasuya, M; Katayama, S; Kuga, H; Morikawa, F; Nakamura, H; Nakamura, M; Nakase, R; Ohnuma, T; Sawa, Y; Shirai, Y; Sudo, Y; Takebayashi, H; Usui, C, 2013) |
| "This randomised 12-month open study analysed the effectiveness of quetiapine XR (400-800 mg) versus risperidone (2-6 mg) on subjective well-being in schizophrenia (NCT00600756)." | 9.17 | Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER). ( Goltz, M; Haro, JM; Krüger, H; Lambert, M; Naber, D; Peuskens, J; Schwarzmann, N, 2013) |
| " In the primary analyses based on intention to treat groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster decreases of the mean hallucination scores than the risperidone group." | 9.17 | Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. ( Hugdahl, K; Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM; Sinkeviciute, I, 2013) |
| "The objective of this study was to assess the efficacy and tolerability of oxytocin intranasal spray (given as an adjuvant to risperidone) in patients with schizophrenia." | 9.17 | Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Ghaleiha, A; Hosseini, SM; Jafarinia, M; Modabbernia, A; Rezaei, F; Salehi, B; Tabrizi, M; Tajdini, M, 2013) |
| "Clozapine, the most widely used option in treatment-resistant schizophrenia, has been shown to be superior to other antipsychotic medications in improving cognitive function in patients." | 9.17 | Clozapine and visuospatial processing in treatment-resistant schizophrenia. ( Bourque, J; Champagne, J; Lakis, N; Lalonde, P; Lipp, O; Mendrek, A; Stip, E, 2013) |
| "To evaluate depressive symptoms regarding their association with the acute outcome in first-episode schizophrenia comparing risperidone and haloperidol." | 9.16 | Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Maier, W; Mayr, A; Möller, HJ; Riedel, M; Sauer, H; Schennach-Wolff, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| " Aripiprazole, which is a partial dopamine D2 receptor agonist, may have an impact on cognitive dysfunction in patients with schizophrenia." | 9.16 | Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. ( Kaneda, A; Kaneko, S; Sugawara, N; Tomita, T; Yasui-Furukori, N, 2012) |
| " This 53-wk, Phase-III double-blind study was designed to assess the non-inferiority of PP to risperidone long-acting injectable (RIS-LAI) in schizophrenia treatment." | 9.16 | A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. ( Eerdekens, M; Fleischhacker, WW; Gassmann-Mayer, C; Gopal, S; Hough, D; Lane, R; Lim, P; Remmerie, B, 2012) |
| "Patients with schizophrenia (DSM-IV) were assessed during 2006 and 2007 for response/nonresponse (defined as ≥ 20%/<20% improvement in Positive and Negative Syndrome Scale [PANSS] total score) after 2 weeks of risperidone treatment (2 to 6 mg/d)." | 9.16 | Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. ( Conley, RR; Fijal, BA; Hoffmann, VP; Houston, JP; Kinon, BJ; Stauffer, VL; Witte, MM; Zhao, F, 2012) |
| "In recent years, evidence suggests that modafinil may be useful for certain symptom domains of schizophrenia, especially for the negative and cognitive symptoms." | 9.16 | A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. ( Ahmadi-Abhari, SA; Akhondzadeh, S; Arbabi, M; Bagheri, M; Khalighi-Sigaroudi, F; Rezaei, F; Tabrizi, M, 2012) |
| "Haloperidol or trifluoperazine demonstrated similar efficacy as risperidone or olanzapine for patients with schizophrenia who had failed their first trial with a FGA." | 9.16 | Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics. ( Chan, HY; Chen, CH; Chen, JJ; Gau, SS; Hwu, HG, 2012) |
| "Patients with an acute psychotic episode underwent HOMA testing for insulin sensitivity (IS) prior to and after 3 weeks of treatment with olanzapine (n = 7) or risperidone (n = 7)." | 9.16 | The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study. ( Deuschle, M; Kopf, D; Paslakis, G; Rüsse, S; Thome, J, 2012) |
| "This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (RIS-OS) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to RIS-OS." | 9.16 | Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. ( Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S, 2012) |
| "Groups of schizophrenia patients treated with risperidone, olanzapine, clozapine or typical antipsychotics did not differ on the Positive and Negative Syndrome Scale or the Mini Mental State Exam (MMSE) but scored lower than controls on the MMSE." | 9.16 | Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics. ( Barry, RJ; Beninger, RJ; Bradford, L; Delva, NJ; Wasserman, JI, 2012) |
| " This study evaluated the efficacy and safety of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms." | 9.16 | Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. ( Chen, C; Li, G; Li, X; Mitchell, P; Wu, HZ; Xiao, S; Xue, H; Yuan, C; Zhang, M, 2012) |
| " The trial evaluated non-acute adult patients with psychotic disorders treated with a stable olanzapine dose who required a treatment change." | 9.16 | Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. ( Rosa, F; Schreiner, A; Sherif, T; Thomas, P, 2012) |
| "We examined whether augmentation with olanzapine would be superior to increased risperidone dose among acute schizophrenia patients showing early non-response to risperidone." | 9.16 | A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone. ( Hata, K; Hatta, K; Hayakawa, T; Hayashi, H; Hirata, T; Ishii, R; Kasuya, M; Kuga, H; Morikawa, F; Nakamura, H; Nakamura, M; Otachi, T; Sawa, Y; Sudo, Y; Takebayashi, H; Usui, C, 2012) |
| "Patients with schizophrenia or schizoaffective disorder in Australia who were prescribed risperidone long-acting injection (RLAI) between 2003 and 2007 were assessed 12-months retrospectively, at baseline and 24-months prospectively at 3-monthly intervals." | 9.16 | Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. ( Butcher, B; Emmerson, B; Hustig, H; Jacobs, A; Lambert, T; Resseler, S, 2012) |
| "We applied 2D-CSI MR spectroscopy in 17 recurrent-episode schizophrenia patients off antipsychotics at baseline and at follow-up after 6 weeks, during which 7 patients were treated with haloperidol (10-16 mg/d) and 10 with risperidone (4-6 mg/d)." | 9.16 | Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients. ( Burmeister, HP; Gussew, A; Langbein, K; Reichenbach, JR; Rzanny, R; Sauer, H; Smesny, S, 2012) |
| "There is evidence to suggest that clozapine is underutilized in treatment-refractory schizophrenia." | 9.16 | Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial. ( Hermes, E; Rosenheck, R, 2012) |
| "The main aim was to study the effects of COMT polymorphisms on response of risperidone treatment for schizophrenia and investigate the correlation between memory function of schizophrenia patients and COMT polymorphisms." | 9.16 | Impact of catechol-o-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance. ( Cheng, J; Dong, J; Gao, S; Guo, J; Hu, Z; Huang, M; Li, Z; Liu, S; Xie, S; Xu, Y; Zhou, W, 2012) |
| "Veterans Health Administration patients with unstable schizophrenia or schizoaffective disorder established by the Structured Clinical Interview for DSM-IV (N = 369) were randomized between 2006 and 2009 to long-acting risperidone or physician's choice of oral antipsychotic." | 9.16 | Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. ( Barnett, PG; Krystal, JH; Rosenheck, RA; Scott, JY, 2012) |
| "This study aims to determine the effectiveness of paliperidone extended release (ER) on cognitive function in patients with schizophrenia in comparison with risperidone." | 9.16 | Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. ( Bae, KY; Chung, YC; Kim, JM; Kim, SW; Kim, SY; Lee, JH; Lee, YH; Shin, IS; Yoon, JS, 2012) |
| "Evaluation of risperidone efficacy at psychopathological symptoms, cognitive impairment and formal thought disorder in adolescents with schizophrenia spectrum diagnosis." | 9.16 | Cognition and communication dysfunctions in early-onset schizophrenia: effect of risperidone. ( Namysłowska, I; Remberk, B; Rybakowski, F, 2012) |
| "In the treatment of acute schizophrenia, risperidone and aripiprazole are both placed the first line antipsychotics." | 9.16 | Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia. ( Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Takeuchi, S; Watanabe, K, 2012) |
| "The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies of 205 white patients with diagnoses other than schizophrenia who were generally likely to have had limited previous antipsychotic exposure." | 9.16 | Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. ( Bishop, JR; Conley, RR; Ellingrod, VL; Fijal, BA; Houston, JP; Kohler, J; Ostbye, KM; Poole Hoffmann, V; Zhao, F, 2012) |
| "In this 6-week, multicenter, randomized, rater single-blind study, a total of 119 patients with schizophrenia were randomly assigned to quetiapine (n = 60, 750 mg/day) or risperidone (n = 59, 4 mg/day)." | 9.16 | Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study. ( Li, H; Li, Y; Liu, Y; Qian, M; Yan, X; Yue, Y, 2012) |
| "This study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching the treatment of schizophrenia patients from haloperidol decanoate depot to risperidone long-acting injection (RLAI) compared with a control group that continued receiving haloperidol decanoate depot." | 9.16 | The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. ( Gen, K; Suzuki, H, 2012) |
| " The present study evaluates the comparative efficacy, effects on neurocognitive function, and adverse effects of aripiprazole and risperidone in the treatment of hospitalized patients with schizophrenia." | 9.16 | The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia. ( Okamoto, Y; Sato, G; Yamashita, H; Yamawaki, S; Yoshimura, S, 2012) |
| " The sample comprised 16 chronic schizophrenia patients treated with risperidone long-acting injections (RLAI), 16 patients treated with conventional antipsychotic depots (CONV) and 16 healthy controls (HC)." | 9.15 | Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication. ( Anilkumar, AP; Chu, EM; David, AS; Ecker, C; Evans, A; Marshall, N; McDonald, C; Phillips, ML; Surguladze, SA; Timehin, C, 2011) |
| "In this multicenter, phase 3, randomized, double-blind, parallel-group study, only patients with DSM-IV schizophrenia who had failed an adequate antipsychotic treatment within the previous 6 months and who had not responded positively to haloperidol during screening were eligible for enrollment." | 9.15 | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. ( Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG, 2011) |
| "Galantamine, a reversible cholinesterase inhibitor with effects on nicotinic receptors, has shown mixed effects on cognitive impairments in patients with schizophrenia." | 9.15 | Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. ( Khan, A; Lindenmayer, JP, 2011) |
| "This study was designed to investigate the effect of sildenafil added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind and randomized clinical trial." | 9.15 | Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. ( Akhondzadeh, S; Esfandiari, GR; Ghayyoumi, R; Ghebleh, F; Maroufi, A; Modabbernia, AH; Naderi, M; Rezaei, F; Rezazadeh, SA; Salehi, B; Tabrizi, M, 2011) |
| ") injectable atypical antipsychotic paliperidone palmitate (PP) versus risperidone long-acting injectable (RIS-LAI) in adult patients with schizophrenia." | 9.15 | A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. ( Gassmann-Mayer, C; Gopal, S; Hough, D; Lane, R; Pandina, G; Remmerie, B; Simpson, G, 2011) |
| "This preliminary study aimed to determine if adding mirtazapine to risperidone might improve negative and cognitive symptoms in schizophrenia." | 9.15 | Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. ( Cho, SJ; Choi, TK; Kim, B; Kim, YW; Lee, JE; Lee, KS; Lee, SH; Suh, S; Yook, K; Yook, KH, 2011) |
| " This was a 6-month, open label, multicenter, phase IV trial in recent-onset schizophrenia treated with flexible doses of risperidone long-acting injectable (25-50 mg every 14 days)." | 9.15 | Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable. ( Baylé, FJ; Burba, B; Cavallaro, R; Fischel, T; Martinez, G; Napryeyenko, O; Neznanov, NG; Rabinowitz, J; Schreiner, A; Smeraldi, E, 2011) |
| "This open-label, rater-blinded, parallel-group study was designed to evaluate noninferiority of paliperidone palmitate (PP), a once-monthly injectable atypical antipsychotic, to once-biweekly risperidone long-acting injectable (RIS-LAI) in adult Chinese patients with acute schizophrenia." | 9.15 | A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. ( Gu, N; Li, H; Ning, X; Rui, Q; Xu, H, 2011) |
| "Long-acting injectable risperidone, a second-generation antipsychotic agent, may improve adherence to treatment and outcomes in schizophrenia, but it has not been tested in a long-term randomized trial involving patients with unstable disease." | 9.15 | Long-acting risperidone and oral antipsychotics in unstable schizophrenia. ( Barnett, PG; Fiore, L; Krystal, JH; Lew, R; Liang, MH; Rosenheck, RA; Thwin, SS; Valley, D; Vertrees, JE, 2011) |
| "The plasma levels of ADA in patients with chronic schizophrenia who received clozapine were significantly higher than patients who received haloperidol." | 9.15 | Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. ( Akhondzadeh, S; Boroumand, MA; Ghaleiha, A; Honarbakhsh, N; Jafarinia, M; Raznahan, M; Rezaei, F; Tabrizi, M, 2011) |
| "In newly admitted patients with acute schizophrenia, non-response to risperidone using CGI-I at 2 weeks can predict subsequent response." | 9.15 | Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. ( Ashizawa, Y; Hamakawa, H; Hatta, K; Hayakawa, T; Hayashi, N; Hirata, T; Ito, S; Nakamura, H; Nakase, R; Otachi, T; Sawa, Y; Sudo, Y; Takebayashi, H; Usui, C, 2011) |
| "To assess changes in insulin sensitivity in non-diabetic adults with schizophrenia or schizoaffective disorder treated with olanzapine or risperidone." | 9.15 | Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. ( Campbell, GM; Forrester, TD; Hardy, TA; Henry, RR; Kryzhanovskaya, LA; Marks, DM; Mudaliar, S, 2011) |
| "The purpose of this study is to compare the efficacy of olanzapine and risperidone for the acute treatment of first-episode schizophrenia patients with cannabis use disorders." | 9.15 | Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. ( Kane, J; McCormack, J; Miller, R; Napolitano, B; Robinson, DG; Sevy, S; Sunday, S, 2011) |
| "This study aimed to characterize weight changes in schizophrenia patients taking risperidone as part of a randomized, controlled, open-label clinical trial." | 9.15 | Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. ( Bo, QJ; Chiu, HF; Dixon, LB; Kreyenbuhl, JA; Lai, KY; Lee, EH; Ungvari, GS; Wang, CY; Xiang, YT, 2011) |
| "To examine efficacy and safety of acute treatment with paliperidone palmitate in subjects with schizophrenia whose disease remained symptomatic despite recent treatment with oral risperidone." | 9.15 | Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. ( Alphs, L; Bossie, CA; Ma, YW; Sliwa, JK, 2011) |
| "OBJECTIVE To identify whether sarsasapogenin, a sapogenin from the Chinese medicinal herb Anemarrhena Asphodeloides Bunge, would augment the efficacy of risperidone and significantly improve cognitive functions in patients with negative symptoms dominated schizophrenia." | 9.15 | A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. ( Chen, C; Li, GJ; Li, X; Xiao, SF; Xue, HB; Yuan, CM; Zhang, MY, 2011) |
| "To evaluate effectiveness outcomes in a real-world setting in patients with schizophrenia initiating risperidone long-acting therapy (RLAT)." | 9.15 | Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. ( Crivera, C; DeSouza, C; Dirani, RD; Kozma, CM; Macfadden, W; Mao, L; Rodriguez, SC, 2011) |
| "The efficacy, safety and tolerability of ziprasidone versus the comparators olanzapine, risperidone or quetiapine were investigated in adult patients with chronic schizophrenia, schizoaffective and schizophreniform disorders, with lack of efficacy or intolerance to their previous antipsychotic treatment based on clinical judgement of the investigator." | 9.14 | Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. ( Haug, HJ; Kolb, SA; Koponen, H; Lublin, H; Sigmundsson, T, 2009) |
| "Hyperprolactinemia, an adverse effect associated with the use of typical antipsychotics and the atypical antipsychotic risperidone, has both acute and chronic clinical consequences." | 9.14 | Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. ( Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R, 2009) |
| "The objective of this study was to evaluate the efficacy and safety of divalproex sodium extended release (divalproex ER) vs placebo in combination with olanzapine or risperidone for the treatment of acute exacerbations of schizophrenia." | 9.14 | Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. ( Abi-Saab, W; Baker, J; Casey, DE; Daniel, DG; Greco, N; Kane, JM; Redden, L; Saltarelli, M; Tamminga, C; Tran-Johnson, T; Wozniak, P, 2009) |
| "This randomized, double-blind, multicentre extension study compared the efficacy, tolerability, and safety of ziprasidone and risperidone for schizophrenia or schizoaffective disorder." | 9.14 | A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. ( Addington, DE; Johnson, G; Kulkarni, J; Labelle, A; Loebel, A; Mandel, FS, 2009) |
| "This randomized, 24-week, flexible-dose study compared changes in glucose metabolism in patients with DSM-IV schizophrenia receiving initial exposure to olanzapine, quetiapine, or risperidone." | 9.14 | A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. ( Brecher, M; Emsley, R; Eriksson, JW; Leong, RW; Leonova-Edlund, J; Meulien, D; Miller, F; Newcomer, JW; Ratner, RE, 2009) |
| "Clinical trial data were evaluated for the association between 22 single-nucleotide polymorphisms (SNPs) and response in acutely ill patients diagnosed with schizophrenia, schizoaffective disorder or schizophreniform disorder, who were treated with oral risperidone." | 9.14 | Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. ( Conley, RR; Fijal, BA; Houston, JP; Jamal, HH; Kane, JM; Kapur, S; Kinon, BJ; Stauffer, VL; Witte, MM, 2009) |
| "This study evaluated the safety/tolerability and effectiveness of aripiprazole titrated-dose versus fixed-dose switching strategies from risperidone in patients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues." | 9.14 | Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. ( Kahn, JP; Kerselaers, W; Lissens, J; McQuade, RD; Modell, S; Ryckmans, V; Sanchez, R; Werner, C, 2009) |
| "Risperidone treatment can improve disgust recognition deficits in patients with schizophrenia." | 9.14 | Effect of risperidone on emotion recognition deficits in antipsychotic-naïve schizophrenia: a short-term follow-up study. ( Arasappa, R; Behere, RV; Gangadhar, BN; Reddy, N; Venkatasubramanian, G, 2009) |
| "Perospirone was as effective as risperidone against positive and negative symptoms in patients with schizophrenia." | 9.14 | Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. ( Kato, M; Kinoshita, T; Kishimoto, T; Koh, J; Matsumoto, N; Morikawa, M; Okugawa, G; Shinosaki, K; Wakeno, M; Yoneda, H, 2009) |
| "To evaluate the quality of life, efficacy and safety of Warm-Supplementing Kidney Yang (WSKY) added to risperidone in patients with schizophrenia." | 9.14 | Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial. ( Chen, ZH; Huo, YX; Li, L; Mei, HB; Wang, GH; Wang, XP; Yang, MH, 2009) |
| "To evaluate the maintenance of efficacy of risperidone long-acting injectable (RLAI) in stable patients with schizophrenia or schizoaffective disorders." | 9.14 | Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. ( Bagalà, A; Bernareggi, MM; Del Curatolo, V; Giustra, MG; Rossi, A; Scapati, F, 2009) |
| "To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long-acting injectable risperidone (LAIR) in patients with schizophrenia." | 9.14 | Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. ( Kim, JM; Kim, SW; Lee, SH; Lee, YH; Shin, IS; Yang, SJ; Yoon, JS, 2009) |
| "Comparisons of diabetic potential, glucose related metabolic levels, and insulin resistance between olanzapine and risperidone have produced variable results in cross-sectional and epidemiologic studies." | 9.14 | Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. ( Cornwell, J; Davis, JM; Hu, Q; Kelly, E; Khan, A; Lindenmayer, JP; Smith, RC; Vaidhyanathaswamy, S; Viviano, TF, 2009) |
| "We identified novel candidate genes for treatment response to risperidone and provide evidence that one of these additionally may confer susceptibility to schizophrenia." | 9.14 | Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. ( Arinami, T; Hashimoto, R; Honda, H; Ikeda, M; Iwata, N; Kinoshita, Y; Koga, M; Mouri, A; Nabeshima, T; Nakamura, J; O'Donovan, MC; Okochi, T; Owen, MJ; Ozaki, N; Takeda, M; Tomita, Y; Williams, HJ; Yamanouchi, Y; Yoshimura, R, 2010) |
| "In this multicenter, double-blind, 16-week, placebo-controlled study conducted at 43 American sites from July 2006 to October 2007, patients with chronic, stable schizophrenia or schizoaffective disorder diagnosed with DSM-IV-TR were randomly assigned to receive aripiprazole (2-15 mg/d) or placebo in addition to a stable regimen of quetiapine (400-800 mg/d) or risperidone (4-8 mg/d)." | 9.14 | A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. ( Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E, 2009) |
| "Stable patients with psychotic disorders requiring medication change were switched to open-label RLAI in the switch to risperidone microspheres (StoRMi) trial." | 9.14 | Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. ( De Marinis, T; Lambert, M; Naber, D; Pfeil, J; Schreiner, A, 2010) |
| "Patients receiving care from old age psychiatrists for their schizophrenia were randomised to treatment with olanzapine or risperidone and were followed for up to 3(1/2) years." | 9.14 | Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration. ( Ames, D; Cheesman, N; Harrigan, S; Macfarlane, S; Mastwyk, M; Ritchie, CW, 2010) |
| "It has been reported that mirtazapine would be helpful for treating negative symptoms in schizophrenia." | 9.14 | The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. ( Abbasi, SH; Akhondzadeh, S; Behpournia, H; Ghoreshi, A; Raznahan, M; Rezaei, F; Rezazadeh, SA; Salehi, B, 2010) |
| "To assess treatment retention on risperidone long-acting injection (RLAI) and outcomes in schizophrenia patients for whom 24 months of follow-up data in the electronic Schizophrenia Treatment Adherence Registry (e-STAR) were available." | 9.14 | Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. ( Akhras, K; Bij de Weg, H; Eriksson, L; Jacobs, A; Olivares, JM; Pecenak, J; Peuskens, J; Resseler, S; Tuma, I, 2010) |
| "The aim of this study was to evaluate the efficacy and safety of two dose ranges of risperidone in adolescents with schizophrenia." | 9.14 | A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. ( Armenteros, J; Copenhaver, MD; Haas, M; Kushner, SF; Quiroz, JA; Unis, AS, 2009) |
| "The objective of this open-label study was to evaluate treatment benefits of risperidone long-acting injectable (RLAI) in patients with schizophrenia following direct transition from oral risperidone (RIS) compared with transition from other oral second generation antipsychotics." | 9.14 | Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? ( Diekamp, B; Gerwe, M; Ibach, B; Schmauss, M; Schreiner, A, 2010) |
| "The study aimed to evaluate the efficacy of long-acting injectable risperidone (LAR) in Asian patients with schizophrenia spectrum disorders." | 9.14 | Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients. ( Abdin, E; Chong, SA; Lee, N; Sim, K; Su, A; Subramaniam, M; Verma, S, 2010) |
| "The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design." | 9.14 | Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. ( Bahk, WM; Cho, HS; Jeon, YW; Jon, DI; Jung, HY; Kim, CH; Kim, HC; Kim, SH; Kim, YH; Kim, YK; Kwon, JS; Lee, SH; Lee, SY; Yang, J; Yi, JS; Yoon, BH, 2010) |
| "A total of 72 patients with a first episode of schizophreniform psychosis (schizophrenia spectrum disorder) with less than 2 weeks of exposure to antipsychotic medication were randomized to quetiapine or risperidone in a single-blind 12-week controlled trial." | 9.14 | Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. ( Craig, TK; Elanjithara, T; Gafoor, R; Landau, S; McGuire, P; Power, P, 2010) |
| "To evaluate the efficacy and tolerability of armodafinil, the longer-lasting isomer of modafinil, as adjunctive therapy in patients with schizophrenia." | 9.14 | Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. ( D'Souza, DC; Kane, JM; Keefe, RS; Patkar, AA; Tiller, JM; Yang, R; Youakim, JM, 2010) |
| "The incidence of suicide attempts (fatal and non-fatal) was analysed in a prospective cohort of patients with schizophrenia randomly assigned to sertindole (4905 patients) or risperidone (4904 patients) in a parallel-group open-label study with blinded classification of outcomes (the sertindole cohort prospective study--SCoP)." | 9.14 | Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. ( Crocq, MA; Drici, M; Everitt, B; Hall, GC; Lader, MH; Le Jeunne, C; Mann, R; Mittoux, A; Moore, ND; Naber, D; Peuskens, J; Priori, S; Sturkenboom, M; Tanghøj, P; Thibaut, F; Thomas, SH; Toumi, M, 2010) |
| "The role of partial agonism at 5-HT1A receptors in general and of buspirone in particular remains unclear in the treatment of negative symptoms of schizophrenia." | 9.14 | A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. ( Akhondzadeh, S; Farnaghi, F; Ghaleiha, A; Hajiazim, M; Noorbala, AA, 2010) |
| "In this open-label study, 17 patients with treatment-refractory schizophrenia, who failed to respond to a sequential monotherapy with olanzapine, quetiapine and risperidone, were subsequently treated with a combination therapy with olanzapine plus risperidone for at least 8 weeks." | 9.13 | Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. ( Kashima, H; Nakajima, S; Nomura, K; Suzuki, T; Takeuchi, H; Tanabe, A; Uchida, H; Watanabe, K; Yagi, G, 2008) |
| "The current study evaluated the efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia." | 9.13 | Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. ( Casey, DE; Heisterberg, J; Sands, EE; Yang, HM, 2008) |
| "To examine whether subjective well-being and craving for cannabis were different in patients with schizophrenia or related disorders treated with either olanzapine or risperidone." | 9.13 | Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. ( de Haan, L; Linszen, D; van Beveren, NJ; van den Brink, W; van der Helm, M; van Nimwegen, LJ, 2008) |
| "Long-acting risperidone administered intramuscularly biweekly is approved for the management of schizophrenia." | 9.13 | Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. ( Kapur, S; Labelle, A; Mamo, DC; Mann, SW; Mannaert, EJ; Remington, G; Shammi, C; Uchida, H, 2008) |
| "To evaluate the effect of metformin treatment on the risperidone-induced body weight gain in patients." | 9.13 | A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. ( Arman, S; Koleini, N; Nadi, M; Sadramely, MR, 2008) |
| " This study was designed to investigate the effect of ritanserin added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double blind and randomized clinical trial." | 9.13 | Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. ( Akhondzadeh, S; Ghoreishi, A; Malek-Hosseini, M; Raznahan, M; Rezazadeh, SA, 2008) |
| "Aripiprazole should be considered as first line treatment in some patients affected by psychotic disorders visited in the emergency psychiatric setting." | 9.13 | Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting. ( Azzoni, A; Raja, M, 2008) |
| "The aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (SOC), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (The Schizophrenia Trial of Aripiprazole [STAR] study [NCT00237913])." | 9.13 | The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). ( Hanssens, L; Kerselaers, W; L'Italien, G; Loze, JY; Marcus, RN; Pans, M, 2008) |
| "This study seeks to replicate previous results indicating that T102C in the serotonin 2A receptor (HTR2A) and Ser9Gly in the dopamine D3 receptor (DRD3) were associated with a risperidone response to acutely exacerbated schizophrenia, and to determine whether possession of these alleles predicts clinical improvement in a naturalistic setting." | 9.13 | Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. ( Choi, EY; Joo, YH; Kim, B; Kim, CY; Song, K, 2008) |
| "This was a randomized, flexible-dose, rater-blind, parallel-group, quasi-naturalistic trial comparing the efficacy, safety, and tolerability of quetiapine, risperidone, and olanzapine in patients with schizophrenia hospitalized for severe psychotic symptoms." | 9.13 | A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial. ( Parrinello, G; Sacchetti, E; Valsecchi, P, 2008) |
| "It has been reported that selegiline, a Selective Monoamine Oxidase Inhibitor B (MAOI-B), at low doses would be helpful for treating negative symptoms in schizophrenia." | 9.13 | Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. ( Akhondzadeh, S; Amiri, A; Derakhshan, MK; Ghoreishi, A; Hajiazim, M; Khodaie-Ardakani, MR; Nejatisafa, AA; Noorbala, AA; Raznahan, M, 2008) |
| "Newly diagnosed patients with first-episode schizophrenia treated with antipsychotic medication-olanzapine, risperidone, or haloperidol-and matched healthy controls were followed for 6 weeks." | 9.13 | Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. ( Akhtar, S; Ameen, S; Saddichha, S, 2008) |
| "This post-hoc analysis used data from the risperidone arm of a randomized, open-label, 1-year study of patients with schizophrenia." | 9.13 | Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. ( Ascher-Svanum, H; Faries, DE; Kinon, BJ; Nyhuis, AW, 2008) |
| "This multicentre, observational, prospective, nonrandomized study compared the effectiveness and tolerability of quetiapine and risperidone in the acute and long-term treatment of schizophrenia in a clinical setting." | 9.13 | A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. ( Cañas, F; Perez, V; Tafalla, M, 2008) |
| "The use of ketamine for depression has increased rapidly in the past decades." | 9.12 | Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021) |
| "We searched MEDLINE, Central, EMBASE and PsycINFO until December 2020 for randomised placebo-controlled trials of Risperidone, Paliperidone or Paliperidone palmitate in patients with schizophrenia or bipolar disorder." | 9.12 | Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports. ( Heneghan, C; Hodkinson, A; Kontopantelis, E; Mahtani, KR; Panagioti, M, 2021) |
| "Celecoxib augmentation therapy has been reported to enhance the rate of clinical response for patients with schizophrenia." | 9.12 | The effects of celecoxib augmentation on cytokine levels in schizophrenia. ( Ahmadpour, O; Bresee, CJ; Delrahim, K; Dolnak, D; Maddux, RE; Rapaport, MH, 2006) |
| "Sertindole is a non-sedating atypical antipsychotic effective in the management of schizophrenia and is associated with placebo-level incidence of extrapyramidal symptoms (EPS)." | 9.12 | A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. ( Azorin, JM; Loft, H; Strub, N, 2006) |
| "Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effects." | 9.12 | A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. ( Ames, D; Chiu, E; Hall, K; Halliday, G; Harrigan, S; Hassett, A; Hustig, H; MacFarlane, S; Mastwyk, M; Nagalingam, V; O'Connor, DW; Opie, J; Ritchie, CW; Snowdon, J, 2006) |
| "In this short-term study, the addition of risperidone to clozapine did not improve symptoms in patients with severe schizophrenia." | 9.12 | Clozapine alone versus clozapine and risperidone with refractory schizophrenia. ( Bergmann, A; Chan, RC; Chen, EY; Falkai, P; Honer, WG; MacEwan, GW; McKenna, PJ; Pomarol-Clotet, E; Procyshyn, R; Stip, E; Thornton, AE; Wasan, K; Williams, R; Wong, JO, 2006) |
| "This open-label, prospective, 4-month study in hyperprolactinemic patients with schizophrenia explored whether prolactin levels decrease after switching antipsychotic therapy to olanzapine." | 9.12 | Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. ( Ahl, J; Kinon, BJ; Liu-Seifert, H; Maguire, GA, 2006) |
| "When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine." | 9.12 | Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| "Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason." | 9.12 | Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| " This study aimed to simultaneously explore the effects of multiple candidate genes and environment factors on body weight of schizophrenia patients who received risperidone, a commonly used atypical antipsychotic agent." | 9.12 | Risperidone-related weight gain: genetic and nongenetic predictors. ( Chang, WH; Chang, YC; Huang, CL; Lane, HY; Liu, YC; Lu, CT; Wu, PL, 2006) |
| "The purpose of this study was to assess the effect of switching to risperidone in the treatment of first-episode schizophrenia who had failed to respond to an initial-prescribed antipsychotic, olanzapine." | 9.12 | Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. ( Higuchi, H; Ishigooka, J; Takahashi, H; Yoshida, K, 2006) |
| "This study compared the effects of atypical antipsychotics (risperidone or quetiapine) with placebo and with each other in recently exacerbated patients with schizophrenia requiring hospitalization." | 9.12 | A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. ( Bossie, CA; Burtea, V; Davidson, M; Gharabawi, GM; Greenspan, AJ; Kosik-Gonzalez, C; Mahmoud, R; Potkin, SG; Rupnow, MF; Trivedi, JK; Zhu, Y, 2006) |
| " Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)." | 9.12 | Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006) |
| "To compare the efficacy and tolerability of quetiapine and risperidone in the treatment of schizophrenia." | 9.12 | Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. ( Hamer, RM; Lieberman, JA; Sweitzer, DE; Zhong, KX, 2006) |
| "This study aimed to compare the efficacy of long-acting risperidone and zuclopenthixol in subjects with schizophrenia and substance abuse." | 9.12 | Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. ( Alamo, C; Jiménez-Arriero, MA; López-Muñoz, F; Martínez, I; Ponce, G; Rubio, G, 2006) |
| "This study examined the effects of 2 doses of long-acting risperidone injection in patients with schizophrenia or schizoaffective disorder." | 9.12 | A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. ( Bossie, CA; Gharabawi, GM; Kujawa, M; Lasser, RA; Mahmoud, RA; Rodriguez, S; Simpson, GM; Turkoz, I, 2006) |
| "The effect of lamotrigine on the steady-state plasma concentrations of the atypical antipsychotics clozapine, olanzapine, and risperidone was investigated in patients with schizophrenia or bipolar disorder stabilized on chronic treatment with clozapine (200-500 mg/day; n = 11), risperidone (3-6 mg/day; n = 10) or olanzapine (10-20 mg/day; n = 14))." | 9.12 | Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ( D'Amico, G; D'Arrigo, C; Micò, U; Migliardi, G; Muscatello, MR; Perucca, E; Santoro, V; Spina, E, 2006) |
| "Subjects were patients with schizophrenia or schizoaffective disorder enrolled in extension studies (Study A and Study B) after participating in 12-week studies of long-acting injectable risperidone [Kane, J." | 9.12 | Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. ( Eerdekens, M; Khan, A; Kushner, S; Lindenmayer, JP; Van Hove, I, 2007) |
| " In this study we evaluated the role of six polymorphisms of the DRD2 gene in 125 risperidone-treated Chinese schizophrenia patients following the hypothesis that variation in the DRD2 gene could affect drug response." | 9.12 | The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. ( Duan, S; Feng, G; Gao, J; Gao, R; He, L; Li, H; Meng, J; Qian, X; Qin, W; Wong, S; Wu, S; Xing, Q; Xu, M, 2007) |
| "The efficacy and safety of switching to olanzapine were investigated in patients with first-episode schizophrenia who failed to attain an adequate clinical response to an initial therapeutic trial of risperidone (2-6 mg/day for 12 weeks)." | 9.12 | Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. ( Higuchi, H; Ishigooka, J; Kamata, M; Takahashi, H; Yoshida, K, 2006) |
| "The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders." | 9.12 | Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. ( Gunduz-Bruce, H; Kane, JM; Khadivi, A; Lesser, ML; Lorell, BS; McCormack, J; Mendelowitz, A; Miller, R; Napolitano, B; Patel, RC; Robinson, DG; Schooler, NR; Sevy, SM; Soto-Perello, JM; Woerner, MG, 2006) |
| "To investigate the effects of risperidone on the polysomnography (PSG) in the patients with first-episode schizophrenia." | 9.12 | [Effects of risperidone on polysomnography in patients with first-episode schizophrenia]. ( Chen, C; Chen, XS; Chen, XW; Gao, CY; Liang, JH; Liu, L; Liu, P; Liu, XW; Lou, FY; Wang, HX; Wang, JJ; Zhang, MD, 2006) |
| "Adjunctive treatment with risperidone for 6 weeks in patients with schizophrenia who had received chronic treatment with clozapine does not significantly improve cognitive function." | 9.12 | A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. ( Akdede, BB; Alptekin, K; Anil Yağcioğlu, AE; Göğüş, A; Jayathilake, K; Meltzer, HY; Tümüklü, M; Tunca, Z; Turgut, TI; Yazici, MK, 2006) |
| "Risperidone augmentation of clozapine in refractory schizophrenia has theoretical but only inconsistent support from clinical trials." | 9.12 | Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. ( Culhane, MA; Freudenreich, O; Goff, DC; Henderson, DC; Walsh, JP, 2007) |
| "Subjects with schizophrenia (N=114) who had been randomly assigned to and then discontinued perphenazine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were reassigned randomly to double-blinded treatment with olanzapine, 7." | 9.12 | Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. ( Belz, I; Capuano, GA; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007) |
| "Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen." | 9.12 | Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. ( DeVane, CL; Horner, MD; Markowitz, JS; McGurk, SR; Nahas, Z; Palecko, S; Risch, SC, 2007) |
| "To evaluate the clinical efficacy of modified Daotan Decoction (DD) combining low dosage of risperidone in treating chronic schizophrenia patients of phlegm-dampness blockage type, and compare with patients treated with risperidone alone." | 9.12 | [Clinical observation on effect of modified Daotan Decoction combined with small dose risperidone in treating chronic schizophrenia]. ( Liu, JL; Ma, L; Wang, Y, 2007) |
| "To compare olanzapine and risperidone outcome on some neurocognitive dimensions in chronic schizophrenia patients with prominent negative symptoms." | 9.12 | Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. ( Alvarez, E; Bousoño, M; Carlos Gómez, J; Ciudad, A; Gurpegui, M; Olivares, JM, 2007) |
| "To compare long-acting risperidone and oral olanzapine in 377 patients with DSM-IV schizophrenia or schizoaffective disorder." | 9.12 | Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. ( Ingham, M; Karcher, K; Keks, NA; Khan, A, 2007) |
| "To determine the effectiveness of amisulpride on depression in patients with schizophrenia, in comparison to risperidone." | 9.12 | Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. ( Hwang, MY; Kim, JM; Kim, SW; Lee, JH; Lee, SH; Shin, IS; Yang, SJ; Yoon, BH; Yoon, JS, 2007) |
| "The efficacy and safety of risperidone, quetiapine, and placebo were compared in a 14-day monotherapy phase in patients experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder." | 9.12 | Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. ( Gharabawi, GM; Greenspan, A; Kosik-Gonzalez, C; Rupnow, MF; Stahl, SM; Zhu, Y, 2007) |
| "The objective of the study was to compare the antiaggressive efficacy of risperidone monotherapy versus risperidone plus valproate in patients with schizophrenia." | 9.12 | Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. ( Citrome, L; Czobor, P; Nolan, KA; Shope, CB; Volavka, J, 2007) |
| "This 6-week trial assessed the efficacy, tolerability, and safety of the investigational psychopharmacologic agent asenapine versus placebo and risperidone in patients with acute schizophrenia (DSM-IV criteria)." | 9.12 | Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. ( Cohen, M; Panagides, J; Potkin, SG, 2007) |
| " Accordingly, the hypothesis of whether 1-year relapse rate in first-episode schizophrenia under maintenance treatment with risperidone is lower compared to haloperidol in low dose was tested." | 9.12 | Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Bechdolf, A; Bender, S; Buchkremer, G; Degner, D; Eickhoff, M; Falkai, P; Gaebel, W; Häfner, H; Jäger, M; Jockers-Scherübl, MC; Klimke, A; Klingberg, S; Köpcke, W; Kühn, KU; Lemke, M; Maier, W; Möller, HJ; Ohmann, C; Riesbeck, M; Salize, HJ; Schlösser, R; Schmidt, LG; Schmitt, A; Schneider, F; von Wilmsdorff, M; Wölwer, W, 2007) |
| "This post hoc analysis explored the role of insight as a mediator of functioning in a 52-week, double-blind, international trial of 323 patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable." | 9.12 | The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. ( Bossie, C; Gharabawi, G; Kujawa, M; Mahmoud, R; Simpson, G; Turkoz, I, 2007) |
| "Risperidone doses for acute schizophrenia were rather high in most recent studies." | 9.11 | Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants. ( Chang, WH; Chang, YC; Chiu, CC; Lane, HY; Lee, SH; Lin, CY, 2004) |
| "To test the hypothesis that administration of risperidone to healthy subjects produces reductions in metabolism in the frontal cortex similar to those produced by administration of risperidone to patients experiencing a first episode of schizophrenia." | 9.11 | Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia. ( Lane, CJ; Liddle, PF; Ngan, ET; Ruth, TJ; Yatham, LN, 2004) |
| "Clinical trials indicate that glycine site agonists of the N-methyl-D-aspartate (NMDA) receptors may reduce negative and cognitive symptoms in treatment-resistant schizophrenia when used as adjuvants to conventional antipsychotics but possibly not to clozapine." | 9.11 | High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. ( Bar, G; Ermilov, M; Heresco-Levy, U; Javitt, DC; Lichtenberg, P, 2004) |
| "Treatment-resistant patients (133 men, 24 women) diagnosed with DSM-IV schizophrenia or schizoaffective disorder participated in a double-blind, randomized, 14-week trial comparing clozapine (N = 40), olanzapine (N = 39), risperidone (N = 41), and haloperidol (N = 37)." | 9.11 | Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. ( Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2004) |
| "In a 6-week open-label trial, sildenafil was administered to 12 male schizophrenia (DSM-IV) patients, treated with risperidone and reporting erectile dysfunction." | 9.11 | An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. ( Aviv, A; Shelef, A; Weizman, A, 2004) |
| "Over 3 months, 41 patients with schizophrenia were randomized to treatment with risperidone 1-12 mg (n=21) or haloperidol 2-20 mg (n=20) daily." | 9.11 | Adverse effects of risperidone and haloperidol treatment in schizophrenia. ( Chong, MY; Lung, FW; Yen, YC, 2004) |
| "This study compared the specific antihostility effects of atypical antipsychotic monotherapy (olanzapine or risperidone) with that of combination treatment with divalproex sodium among patients with schizophrenia experiencing an acute psychotic episode." | 9.11 | Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. ( Casey, DE; Citrome, L; Daniel, DG; Kochan, LD; Tracy, KA; Wozniak, P, 2004) |
| "To assess changes in cognitive function in stable outpatients with schizophrenia switched to ziprasidone from conventional antipsychotics (n = 108), olanzapine (n = 104), or risperidone (n = 58) because of suboptimal efficacy or poor tolerability." | 9.11 | Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. ( Harvey, PD; Loebel, A; Meltzer, H; Potkin, SG; Romano, SJ; Simpson, GM; Siu, C, 2004) |
| "In two double-blind studies, 552 adult and elderly patients with schizophrenia or schizoaffective disorder were randomly assigned to risperidone or olanzapine treatment for 8 weeks." | 9.11 | Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. ( Gharabawi, G; Lasser, RA; Mao, L, 2004) |
| "Treatment outcome was evaluated in outpatients with chronic schizophrenia during long-term administration of risperidone in a study reflecting clinical practice." | 9.11 | Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone. ( Libretto, SE; Reveley, MA, 2004) |
| "We investigated the impact of treatment with long-acting, injectable risperidone versus placebo on health-related quality of life (HRQoL) in patients with schizophrenia." | 9.11 | Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. ( Duchesne, I; Eerdekens, M; Janagap, C; Mehnert, A; Nasrallah, HA, 2004) |
| "The aim of this study was to compare the effects of olanzapine and risperidone on cognitive functions in patients with schizophrenia." | 9.11 | A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia. ( Kang, BJ; Kim, YT, 2004) |
| " In a multicentre, open-label study of 725 patients with schizophrenia or schizoaffective disorder, patients received 25-75 mg of long-acting risperidone every 2 weeks for up to 50 weeks, with performance of standard safety and efficacy assessments." | 9.11 | Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. ( Bossie, CA; Lasser, RA; van Os, J, 2004) |
| "This UK multicenter, noncomparative, open-trial study assessed risperidone in 74 first-psychotic-episode patients (DSM-IV schizophrenia) treated with flexible doses." | 9.11 | A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. ( Huq, ZU, 2004) |
| "The pharmacokinetics and tolerability of long-acting risperidone (Risperdal Consta) were evaluated in a multicenter, prospective, open-label, 15-week study of 86 patients with schizophrenia." | 9.11 | Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. ( Eerdekens, M; Mannaert, E; Remmerie, B; Van Hove, I, 2004) |
| "From April 1996 to August 1997, seventy-eight inpatients with a diagnosis of chronic schizophrenia (DSM-III-R) were randomly assigned to 12 weeks of treatment with 6 mg/day of risperidone or 20 mg/day of haloperidol." | 9.11 | Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2004) |
| "The safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications." | 9.11 | Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. ( Berry, SA; Eerdekens, E; Eerdekens, M; Lindenmayer, JP, 2004) |
| "To assess the efficacy and safety of long-acting injectable risperidone in elderly patients with psychotic disorders." | 9.11 | Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. ( Bossie, CA; Davidson, M; Eerdekens, M; Gharabawi, G; Lasser, RA; Zhu, Y, 2004) |
| "Sixteen male patients with schizophrenia, who were receiving stable, physician-optimized risperidone (1-4 mg twice daily), and 15 healthy age- and weight-matched male controls, received donepezil HCl 5 mg daily for 7 days." | 9.11 | Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ( Cullen, EI; Khan, A; Kumar, D; Perdomo, CA; Pratt, RD; Preskorn, SH; Reyes, JF, 2004) |
| "The authors evaluated the efficacy and safety of augmenting clozapine with risperidone in patients with treatment-resistant schizophrenia." | 9.11 | Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. ( Dadvand, M; Joseph, A; Josiassen, RC; Kohegyi, E; Paing, WW; Shaughnessy, RA; Stokes, S, 2005) |
| " Thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder." | 9.11 | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. ( Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ, 2004) |
| "This study prospectively examined the effectiveness of treatment with olanzapine versus risperidone in reducing violent behavior among patients with schizophrenia under "usual care" conditions in the community." | 9.11 | Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. ( Elbogen, EB; Swanson, JW; Swartz, MS; Van Dorn, RA, 2004) |
| "Thyroid function was assessed in 38 adult DSM-IV-diagnosed schizophrenia patients after 6 weeks of prospective, double-blind, randomized treatment with quetiapine (400 mg/day), risperidone (4 mg/day), or fluphenazine (12." | 9.11 | Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. ( Conley, RR; Kelly, DL, 2005) |
| "Thirteen patients with schizophrenia received injections of 25, 50, or 75 mg of long-acting risperidone every 2 wk." | 9.11 | Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ( Björner, A; Eerdekens, M; Eriksson, B; Gefvert, O; Helldin, L; Mannaert, E; Nyberg, S; Persson, P; Remmerie, B, 2005) |
| "Thirty-nine risperidone- or olanzapine-treated schizophrenia patients participated in a double-blind, placebo-controlled, 6-week crossover trial with 30 mg/kg/day D-serine added to their antipsychotic medication." | 9.11 | D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. ( Bar, G; Catinari, S; Ebstein, R; Ermilov, M; Heresco-Levy, U; Javitt, DC; Lichtenberg, P; Vass, A, 2005) |
| "An open-label study was performed to investigate the clinical efficacy and mechanisms of risperidone liquid in ameliorating positive symptoms in the acute phase of schizophrenia." | 9.11 | An open study of risperidone liquid in the acute phase of schizophrenia. ( Egami, H; Goto, M; Kaji, K; Kakihara, S; Kohara, K; Maeda, H; Nakamura, J; Ninomiya, H; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2005) |
| "The purpose of this investigation was to evaluate the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia." | 9.11 | The effects of clozapine and risperidone on spatial working memory in schizophrenia. ( Carter, C; Goldman, R; Green, MF; Kane, JM; Marder, SR; McGurk, SR; Schooler, NR; Xie, H, 2005) |
| "This study investigated the effect of clozapine on working memory in 15 subjects with schizophrenia, using an event related potential paradigm designed to separate components reflecting working memory updating from components related to target detection and response." | 9.11 | Clozapine improves working memory updating in schizophrenia. ( Clark, CR; Galletly, CA; McFarlane, AC, 2005) |
| "In a 50-week, open-label trial, stable patients with schizophrenia or schizoaffective disorder who received long-acting risperidone injection every 2 weeks were assessed using the Positive and Negative Syndrome Scale (PANSS)." | 9.11 | Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. ( Bossie, CA; Gharabawi, GM; Kane, JM; Lasser, RA, 2005) |
| " Injection site pain, other skin reactions and patient satisfaction with treatment were assessed in two large, multicentre studies of long-acting injectable risperidone (Risperdal CONSTA, Janssen Pharmaceutica Products, Titusville, New Jersey, USA), the first available long-acting atypical antipsychotic agent." | 9.11 | Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. ( Bossie, CA; Jarboe, K; Lasser, R; Lindenmayer, JP; Mehnert, A; Zhu, Y, 2005) |
| "This analysis aimed to assess the relationship between race and clinical response to long-acting, injectable risperidone treatment in patients with schizophrenia or schizoaffective disorder." | 9.11 | Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. ( Bossie, CA; Ciliberto, N; Lasser, RA; Urioste, R, 2005) |
| " This study evaluated treatment practices over 7 years of initial treatment with oral risperidone in acutely exacerbated patients with schizophrenia and in a subgroup of highly agitated, tense, and aggressive patients." | 9.11 | Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. ( Degner, D; Pajonk, FG; Peters, S; Rettig, K; Rüther, E; Schreiner, A, 2005) |
| "In a 1-year, open-label, international multicentre trial of long-acting risperidone in 615 stable adult patients with schizophrenia, self-rated functioning and well-being were measured every 3 months using the Short Form 36-item questionnaire (SF-36)." | 9.11 | Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. ( Eerdekens, M; Fleischhacker, WW; Kemmler, G; Mehnert, A; Rabinowitz, J, 2005) |
| "As monotherapy, both olanzapine and risperidone were superior to haloperidol and clozapine in reducing aggression." | 9.11 | Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). ( Bitter, I; Czobor, P; Dossenbach, M; Volavka, J, 2005) |
| "The primary aim of this study was to compare the effectiveness of 12 months' treatment with olanzapine, risperidone, quetiapine, or haloperidol in preventing relapse of schizophrenia." | 9.11 | Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. ( Aguilar, J; Arango-Dávila, C; Assunção, S; Caro, O; Dossenbach, M; Landa, E; Leadbetter, J; Silva Ibarra, H, 2005) |
| "To compare the efficacy of two atypical antipsychotic drugs, olanzapine and risperidone, in schizophrenic patients with post-psychotic depression." | 9.11 | Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. ( Chabot, B; Déal, C; Dollfus, S; Olivier, V; Perrin, E, 2005) |
| "The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (< or = 3 years)." | 9.11 | Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. ( Andrezina, R; Gaebel, W; Glue, P; Masiak, M; Medori, R; Milanova, V; Parellada, E; Turner, MS, 2005) |
| "Agents that enhance N-methyl-D-aspartate (NMDA) function through the glycine modulatory site (D-serine, glycine, or D-cycloserine) or through glycine transporter 1 (sarcosine) improve the symptoms of patients with stable chronic schizophrenia." | 9.11 | Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. ( Chang, YC; Chiu, CC; Lane, HY; Liu, YC; Tsai, GE, 2005) |
| "To assess treatment discontinuation and concomitant use of other antipsychotics among individuals initiated on olanzapine or risperidone for the treatment of schizophrenia." | 9.11 | Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. ( Abdous, B; Cooper, D; Gaudet, M; Grégoire, JP; Moisan, J, 2005) |
| "The aim of this article was to examine the effects of switching from the antipsychotic olanzapine to risperidone on the prevalence of the metabolic syndrome in high-risk overweight or obese patients with schizophrenia or schizoaffective disorder." | 9.11 | Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. ( Bossie, CA; Greenspan, A; Meyer, JM; Pandina, G; Turkoz, I, 2005) |
| "We conducted a 6-week, open-label pilot study comparing risperidone with typical neuroleptics in a sample of withdrawn cocaine-dependent schizophrenia patients." | 9.10 | Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. ( Davis, CW; Kaune, M; Losonczy, MF; Smelson, DA; Williams, J; Ziedonis, D, 2002) |
| "The purpose of this study was to assess the significance of the hippocampal volume differences and its relation with risperidone treatment in schizophrenia." | 9.10 | Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study. ( Canan, S; Erbagci, H; Gumusburun, E; Herken, H; Inaloz, S; Savas, HA; Unal, B; Zoroglu, SS, 2002) |
| "We investigated the efficacy and safety of augmenting risperidone with fluvoxamine for the treatment of residual positive and negative symptoms in patients with chronic schizophrenia who had shown an incomplete response to risperidone." | 9.10 | Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. ( Higuchi, H; Shimizu, T; Sugita, T; Takahashi, H, 2002) |
| "This multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (DSM IV) with a recent worsening of symptoms." | 9.10 | Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. ( Fleurot, O; Lecrubier, Y; Peuskens, J; Rein, W; Sechter, D, 2002) |
| "We have previously reported that risperidone might improve negative symptoms in schizophrenia by influencing noradrenergic neurons." | 9.10 | Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. ( Nakamura, J; Shinkai, K; Ueda, N; Yoshimura, R, 2003) |
| "The prevalence of hyperprolactinemia during treatment with conventional antipsychotic drugs or risperidone is under-recognized and requires further investigation." | 9.10 | Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. ( Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H, 2003) |
| "The results suggest that lower initial body weight, younger age, undifferentiated subtype, higher dosage, and treatment response (for positive, negative, and cognitive symptoms and social functioning) are associated with greater weight gain in acutely ill patients treated with risperidone." | 9.10 | Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. ( Chang, WH; Chang, YC; Cheng, YC; Lane, HY; Lin, XR; Liu, GC, 2003) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 9.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "This study examined the possible association between the polymorphism in the dopamine receptor DRD4 gene and response to risperidone among 24 Israeli Jewish adolescent inpatients with first-episode schizophrenia." | 9.10 | DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. ( Bensason, D; Frisch, A; Gothelf, D; Lev-Ran, S; Martin, A; Michaelovsky, E; Nahshoni, E; Tyano, S; Weizman, A; Zalsman, G, 2003) |
| "To demonstrate the effects upon motor side-effects, efficacy, safety and quality of life (QOL) of switching elderly patients with schizophrenia from conventional antipsychotics to olanzapine or risperidone." | 9.10 | The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. ( Ames, D; Chiu, E; Hall, K; Harrigan, S; Hassett, A; Macfarlane, S; Mastwyk, M; O'Connor, DW; Opie, J; Ritchie, CW, 2003) |
| "Thirty-nine subjects with early phase schizophrenia were randomly assigned to double blind treatment with haloperidol, risperidone, or olanzapine." | 9.10 | Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. ( Lindborg, SR; Purdon, SE; Stip, E; Woodward, N, 2003) |
| "Aripiprazole is effective, safe, and well tolerated for the positive and negative symptoms in schizophrenia and schizoaffective disorder." | 9.10 | Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J, 2003) |
| "Risperidone (RIS) alone was administered to patients with neuroleptic-naïve, first-episode schizophrenia who visited the outpatient clinic of the Department of Psychiatry, Jikei University School of Medicine Hospital between April 1998 and December 2001, and the effectiveness of the drug in alleviating anxiety symptoms was prospectively examined." | 9.10 | [A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone]. ( Katsu, H; Nakayama, K; Sannomiya, M, 2003) |
| "This was a 2-year, randomized, double-blind comparison of 6 mg of risperidone versus haloperidol in 63 patients with stabilized DSM-IV schizophrenia." | 9.10 | Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. ( Blair, KE; Glynn, SM; Liberman, RP; Marder, SR; Mintz, J; Ross, D; Widmark, C; Wirshing, DA; Wirshing, WC, 2003) |
| "To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder." | 9.10 | Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003) |
| " typical (haloperidol) antipsychotic medication on facial emotion perception in schizophrenia (n=28) and healthy control (n=28) groups." | 9.10 | Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. ( Gordon, E; Green, MJ; Harris, AW; Loughland, CM; Williams, LM, 2003) |
| "The symptom response and side-effects of olanzapine and risperidone were compared in patients with recent onset schizophrenia." | 9.10 | Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. ( Dingemans, P; Gersons, B; Linszen, D; Tijssen, J; van Bruggen, J, 2003) |
| "Data on risperidone's efficacy and tolerability in adolescents with schizophrenia are scarce." | 9.10 | Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. ( Bensason, D; Carmon, E; Martin, A; Tyano, S; Weizman, A; Zalsman, G, 2003) |
| "The long-term safety and efficacy of long-acting injectable risperidone, the first long-acting second-generation antipsychotic, were evaluated in stable patients with schizophrenia." | 9.10 | Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. ( Chrzanowski, W; Eerdekens, M; Fleischhacker, WW; Gefvert, O; Karcher, K; Llorca, PM; Martin, S; Remington, G, 2003) |
| "Randomized controlled trial comparing risperidone and haloperidol regarding relapse in patients with schizophrenia treated with flexible doses during one year." | 9.10 | Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol. ( de Sena, EP; Miranda-Scippa, A; Oliveira, IR; Quarantini, Lde C; Santos-Jesus, R, 2003) |
| " We performed a long-term comparison of a newer, atypical antipsychotic drug, risperidone, and an older, conventional neuroleptic drug, haloperidol, in terms of the rate of relapse in patients with schizophrenia and schizoaffective disorder." | 9.10 | A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. ( Brenner, R; Csernansky, JG; Mahmoud, R, 2002) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 9.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "The authors investigated the clinical effects of D-cycloserine when added to treatment with conventional neuroleptics, olanzapine, or risperidone for treatment-resistant schizophrenia." | 9.10 | Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. ( Ermilov, M; Heresco-Levy, U; Javitt, DC; Shapira, B; Shimoni, J; Silipo, G, 2002) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 9.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "The results suggest that risperidone treatment is not associated with weight gain among elderly persons with chronic psychosis." | 9.10 | No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. ( Barak, Y, 2002) |
| "The effect of risperidone on polydipsia-hyponatremia was evaluated in six hospitalized schizophrenic patients." | 9.10 | Risperidone failed to improve polydipsia-hyponatremia of the schizophrenic patients. ( Baba, A; Kawai, N; Suzuki, T, 2002) |
| "This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction." | 9.10 | Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. ( Bahk, WM; Chae, JH; Dickson, RA; Jun, TY; Kim, DJ; Kim, KS; Pae, CU, 2002) |
| "Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments." | 9.10 | Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002) |
| "In a prospective, double-blind evaluation, 50 patients with an acute exacerbation of schizophrenia were randomly assigned to either risperidone plus celecoxib or risperidone plus placebo." | 9.10 | Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. ( Brandstätter, B; Engel, RR; Krampe, K; Möller, HJ; Müller, N; Riedel, M; Scheppach, C; Schwarz, MJ; Sokullu, S; Ulmschneider, M, 2002) |
| " The purpose of this study was to examine the effects of D-cycloserine when added to risperidone on negative symptoms of schizophrenia." | 9.10 | D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. ( Amico, E; Evins, AE; Goff, DC; Posever, TA; Toker, R, 2002) |
| "Clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia." | 9.09 | Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. ( Adler, CM; Breier, AF; Clifton, A; Elman, I; Lafargue, RT; Malhotra, AK; Pickar, D; Pinals, DA; Su, TP, 1999) |
| "There is little information regarding the effects of risperidone addition to neuroleptic treatment in chronic schizophrenia." | 9.09 | Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. ( Oga, T; Okada, M; Takahashi, N; Terao, T, 1999) |
| "The authors evaluated the safety, tolerability, and efficacy of risperidone in 103 elderly patients (mean age, 71 years) with schizophrenia (75%) or schizoaffective disorder (25%)." | 9.09 | Risperidone in the treatment of elderly patients with psychotic disorders. ( Brecher, M; Brenner, R; Kasckow, J; Kunik, M; Madhusoodanan, S; Negrón, AE; Pomara, N, 1999) |
| "To evaluate the short-term efficacy and safety of risperidone in a group of Asian patients with schizophrenia in an 8-week open-label, prospective study." | 9.09 | Clinical evaluation of risperidone in Asian patients with schizophrenia in Singapore. ( Chan, AO; Chee, KT; Chong, SA; Choo, CH; Low, BL; Mahendran, R; Wong, KE; Yap, HL, 1999) |
| "The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia." | 9.09 | Risperidone in treatment-refractory schizophrenia. ( Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC, 1999) |
| "To investigate the effects of a newer antipsychotic drug, risperidone (a potent serotonin 5-HT2A/2C and dopamine D2-receptor blocker), on the quantity and quality of sleep in patients with schizophrenia." | 9.09 | Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: a pilot study. ( Burke, JG; Dursun, SM; Patel, JK; Reveley, MA, 1999) |
| "Risperidone and olanzapine have each been demonstrated to be efficacious and safe in the treatment of patients with chronic schizophrenia." | 9.09 | A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. ( Andreasen, NC; Ho, BC; Miller, D; Nopoulos, P, 1999) |
| "Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia." | 9.09 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999) |
| "To help determine whether sustained attention deficits as measured with the Continuous Performance Test (CPT) are stable vulnerability indicators of schizophrenia, we compared the CPT performance of schizophrenic patients before and after treatment with risperidone or haloperidol." | 9.09 | Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. ( Chang, CJ; Chen, WJ; Lin, HN; Liu, SK, 2000) |
| "The optimal risperidone dosing strategy for acute schizophrenia requires elucidation." | 9.09 | Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. ( Chang, WH; Chiu, WC; Chou, JC; Lane, HY; Su, MH; Wu, ST, 2000) |
| "This study compared the long-term (12 months) effectiveness of risperidone (RP) with that of conventional neuroleptics (CNs) in a population with chronic schizophrenia who had shown suboptimal response to CNs." | 9.09 | Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. ( Bouchard, RH; Cliche, D; Demers, MF; Filteau, MJ; Gauthier, Y; Labelle, A; Maziade, M; Mérette, C; Pourcher, E; Roy, MA; Roy-Gagnon, MH; Villeneuve, J, 2000) |
| " The atypical antipsychotic risperidone may constitute an alternative to clozapine, the current treatment of choice for refractory schizophrenia." | 9.09 | Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. ( Ahokas, A; Cheine, M; Joffe, G; Rimón, R; Tuisku, K; Wahlbeck, K, 2000) |
| "To compare the clinical and economic outcomes associated with olanzapine and risperidone treatment for schizophrenia." | 9.09 | Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. ( Andersen, SW; Breier, A; Dulisse, B; Edgell, ET; Johnstone, BM; Revicki, D, 2000) |
| "From a cohort of 126 patients, 2 groups of 19 first-episode DSM-III-R/DSM-IV schizophrenia patients matched for age, gender, length of illness, and length of treatment and treated with either a typical antipsychotic or risperidone for a minimum of 1 year were compared on a number of outcome dimensions during their course of treatment and at follow-up." | 9.09 | A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. ( Kotteda, V; Malla, AK; Norman, RM; Scholten, DJ; Zirul, S, 2001) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 9.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "Atypical antipsychotics, such as risperidone, have been shown to be more effective for the treatment of the symptoms of schizophrenia and have a greater beneficial effect on neurocognition compared to the conventional antipsychotics." | 9.09 | Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. ( Andreasen, NC; Boles Ponto, LL; Hichwa, RD; Miller, DD; O'Leary, DS; Watkins, GL, 2001) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 9.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 9.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "This prospective, double-blind, multicenter, parallel-group study compared the efficacy and safety of therapeutic doses of clozapine and risperidone in patients with severe chronic schizophrenia and poor previous treatment response." | 9.09 | A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. ( Azorin, JM; Bourdeix, I; Giguere, M; Péré, JJ; Remington, G; Spiegel, R; Vanelle, JM, 2001) |
| "Given the renewed interest in the role of sex differences in schizophrenia, we undertook a post hoc analysis to determine whether sex differences in treatment response were present among outpatients with schizophrenia who received risperidone in an 8-week, open-label, Phase IV clinical study." | 9.09 | Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response. ( Dunbar, F; Labelle, A; Light, M, 2001) |
| "A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial." | 9.09 | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001) |
| "This study compares the antipsychotic efficacy and the tolerability of risperidone and clozapine in patients with schizophrenia." | 9.08 | Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. ( Heinrich, K; Kinzler, E; Klieser, E; Lehmann, E; Wurthmann, C, 1995) |
| "In a multi-national, parallel-group, double-blind study, patients with chronic schizophrenia (DSM-III-R) were randomly assigned to risperidone 1, 4, 8, 12 or 16 mg or haloperidol 10 mg daily for 8 weeks." | 9.08 | Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. ( Peuskens, J, 1995) |
| "Risperidone was used to treat 11 elderly hospitalized patients between 61 and 79 years of age who manifested signs of psychoses related to schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia." | 9.08 | Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. ( Abaza, A; Araujo, L; Brenner, R; Madhusoodanan, S, 1995) |
| "The subjects were 20 outpatients with schizophrenia or schizoaffective disorder who were clinically stable on a regimen of clozapine at the time of screening." | 9.08 | Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. ( Daniel, DG; Goldberg, TE; Kleinman, JE; Lubick, LJ; Pickar, D; Weinberger, DR; Williams, TS, 1996) |
| "Although risperidone has been shown to be an effective antipsychotic medication in schizophrenia, the clinical studies performed for the Food and Drug Administration's approval process focused on only a mixed group of schizophrenic patients." | 9.08 | Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. ( Bhattacharyya, A; Chua, JW; Lipetsker, B; Smith, RC, 1996) |
| "To assess critically the short-term efficacy and safety of risperidone in adolescents with schizophrenia." | 9.08 | Risperidone in adolescents with schizophrenia: an open pilot study. ( Armenteros, JL; Gorman, J; Stedge, DJ; Welikson, M; Whitaker, AH, 1997) |
| "The efficacy and safety of risperidone have previously been demonstrated in controlled clinical trials in hospitalized chronic schizophrenia patients who met strict research criteria." | 9.08 | A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting. ( Brecher, M; Clyde, C; Jeste, DV; Jones, R; Klausner, M, 1997) |
| "The purpose of this study was to determine the prevalence of extrapyramidal signs or symptoms (EPS) and clinical symptoms in first-episode schizophrenia, before any treatment, during and after treatment with a novel antipsychotic, risperidone." | 9.08 | Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. ( Good, KP; Honer, WG; Kopala, LC, 1997) |
| "In two double-blind trials conducted in North America, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo." | 9.08 | The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. ( Chouinard, G; Davis, JM; Marder, SR, 1997) |
| " Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks." | 9.08 | Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. ( Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H, 1997) |
| "Clozapine and risperidone are used in treatment-resistant schizophrenia." | 9.08 | An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. ( Altman, S; Flynn, SW; Fredrikson, DH; Honer, WG; Kopala, LC; MacEwan, GW; Smith, GN, 1998) |
| "In a controlled double-blind, multicenter study, 86 inpatients with chronic schizophrenia (DSM-III-R), who were resistant to or intolerant of conventional neuroleptics, were randomly assigned to receive risperidone or clozapine for 8 weeks after a 7-day washout period." | 9.08 | Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. ( Baumann, P; Billeter, U; Bondolfi, G; Dufour, H; Eap, CB; May, JP; Patris, M, 1998) |
| "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia." | 9.08 | A syndrome of increased affect in response to risperidone among patients with schizophrenia. ( Ashleigh, EA; Larsen, PD, 1998) |
| "Since most clinical trials of atypical antipsychotics have been conducted in hospitalized patients, a Phase-IV, multicentre, 8-week, open-label, flexible-dose study was performed to assess the efficacy and safety of risperidone in outpatients with schizophrenia." | 9.08 | Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. ( Beauclair, L; Chouinard, G; Johnson, SV; Kopala, L; Labelle, A; Singh, KI, 1998) |
| "Clinical improvement (20% reduction in total scores on the Positive and Negative Syndrome Scale for Schizophrenia) at the study end point was shown by 35% of the patients receiving 2 mg of risperidone, 57% receiving 6 mg, 40% receiving 10 mg, and 51% receiving 16 mg; and by 30% receiving haloperidol and 22% receiving placebo." | 9.07 | Risperidone in the treatment of schizophrenia. ( Marder, SR; Meibach, RC, 1994) |
| " IL-6 levels were compared in patients with schizophrenia before and after risperidone treatment." | 9.05 | Effects of risperidone on blood levels of interleukin-6 in schizophrenia: A meta-analysis. ( Feng, Z; Hao, W; Liu, Z; Long, Q; Ma, Y; Teng, Z; You, X; Zeng, Y; Zhang, W; Zhang, Y, 2020) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | 8.95 | Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| "To compare the effects of chlorpromazine with atypical or second generation antipsychotic drugs, for the treatment of people with schizophrenia." | 8.93 | Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. ( Bo, L; Saha, KB; Sampson, S; Xia, J; Zaman, RU; Zhao, S, 2016) |
| "To examine the effects of depot risperidone for treatment of schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medication." | 8.93 | Risperidone (depot) for schizophrenia. ( Davis, JM; Furtado, VA; Hosalli, P; Sampson, S, 2016) |
| "To measure the outcomes (both beneficial and harmful) of the clinical effectiveness, safety and cost-effectiveness of oral fluphenazine versus atypical antipsychotics for schizophrenia." | 8.93 | Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. ( Furtado, VA; Li, BG; Sampford, JR; Sampson, S; Xia, J; Zhao, S, 2016) |
| "To determine the clinical effects, safety and cost-effectiveness of risperidone compared with placebo for treating schizophrenia." | 8.93 | Risperidone versus placebo for schizophrenia. ( Jayaram, MB; Li, BG; Rattehalli, RD; Sampson, S; Xia, J; Zhao, S, 2016) |
| "To conduct meta-analyses of all published association studies on the HTR2C -759C/T (rs3813829) polymorphism and olanzapine-induced weight gain in schizophrenia patients and on the HTR2C -759C/T, -697G/C (rs518147) and rs1414334:C> G polymorphisms and olanzapine/clozapine/risperidone-induced metabolic syndrome in schizophrenia patients." | 8.90 | HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. ( Gui, X; Hu, G; Ma, X; Maimaitirexiati, T; Xu, G; Zhang, R; Zhang, W, 2014) |
| "We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses." | 8.89 | Aripiprazole versus other atypical antipsychotics for schizophrenia. ( El-Sayeh, HG; Hunger, H; Khanna, P; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S, 2013) |
| "To compare the effects of paliperidone palmitate with any other treatment for people with schizophrenia and schizophrenia-like illnesses." | 8.88 | Paliperidone palmitate for schizophrenia. ( Nussbaum, AM; Stroup, TS, 2012) |
| "To evaluate the effects of risperidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis." | 8.87 | Risperidone versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2011) |
| "Although risperidone is commonly used in the acute and maintenance treatment of schizophrenia, the role of therapeutic drug monitoring has yet to be elucidated." | 8.87 | Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? ( Dumontet, J; Ensom, MH; Seto, K, 2011) |
| "To examine the clinical effects of oral risperidone for people with schizophrenia and schizophrenia-like psychoses in comparison with placebo." | 8.86 | Risperidone versus placebo for schizophrenia. ( Jayaram, MB; Rattehalli, RD; Smith, M, 2010) |
| "We included all randomised trials that used at least single-blind (rater-blind) design, comparing oral olanzapine with oral forms of amisulpride, aripiprazole, clozapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis." | 8.86 | Olanzapine versus other atypical antipsychotics for schizophrenia. ( Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| "We included only randomised clinical controlled trials that compared zotepine with any forms of amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole or ziprasidone in people suffering from only schizophrenia or schizophrenia-like psychoses." | 8.86 | Zotepine versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S; Subramanian, S, 2010) |
| "To compare the clinical effects of clozapine with other atypical antipsychotics (such as amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine) in the treatment of schizophrenia and schizophrenia-like psychoses." | 8.86 | Clozapine versus other atypical antipsychotics for schizophrenia. ( Asenjo Lobos, C; Hunger, H; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| "Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)." | 8.85 | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009) |
| "Risperidone has been approved by the Food and Drug Administration for the treatment of schizophrenia in the adolescent population." | 8.85 | Risperidone: a review of efficacy studies in adolescents with schizophrenia. ( Madaan, V, 2009) |
| "We included all randomised trials comparing oral sertindole with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychosis." | 8.85 | Sertindole versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lewis, R; Rummel-Kluge, C; Schmidt, F; Schwarz, S, 2009) |
| "Although clozapine has been shown to be the treatment of choice in people with schizophrenia that are resistant to treatment, one third to two thirds of people still have persistent positive symptoms despite clozapine monotherapy of adequate dosage and duration." | 8.85 | Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. ( Barbui, C; Boso, M; Cipriani, A, 2009) |
| "We included all randomised trials comparing oral aripiprazole with oral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychoses." | 8.85 | Aripiprazole versus other atypical antipsychotics for schizophrenia. ( El-Sayeh, HG; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2009) |
| "We included all randomised, at least single-blind, controlled trials comparing oral ziprasidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone or zotepine in people with schizophrenia or schizophrenia-like psychoses." | 8.85 | Ziprasidone versus other atypical antipsychotics for schizophrenia. ( Bhoopathi, PS; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S, 2009) |
| "Risperidone is a widely used antipsychotic drug for people with schizophrenia." | 8.85 | Risperidone dose for schizophrenia. ( Li, C; Wang, J; Xia, J, 2009) |
| "This study aimed to retrospectively explore the relationship between clinical efficacy and plasma concentration-dose ratio of risperidone (RIS) in 252 patients with schizophrenia taking RIS orally." | 8.84 | Relationship between clinical efficacy and plasma concentration-dose ratio of risperidone in patients with schizophrenia. ( Chen, Q; Min, J; Shen, Y; Shu, M; Xia, W; Yin, H, 2024) |
| "The aim of this review was to discuss data from double-blind, randomized controlled trials (RCTs) that have investigated the effects of oral and long-acting injectable risperidone on cognitive and psychomotor functioning in patients with schizophrenia or schizoaffective disorder." | 8.84 | Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. ( Houthoofd, SA; Morrens, M; Sabbe, BG, 2008) |
| "In the 10 studies analyzed, the taste of RD risperidone tablets was found to be acceptable in the majority of healthy subjects and patients with schizophrenia or schizoaffective disorder." | 8.84 | Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. ( D'Hoore, P; Kushner, S; Mannaert, E; Remmerie, B; Thyssen, A, 2007) |
| " We aimed to establish the dose-response relationship for oral risperidone in relapsed schizophrenia." | 8.83 | Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. ( Ezewuzie, N; Taylor, D, 2006) |
| "To determine the clinical effects, safety and cost effectiveness of risperidone compared with olanzapine for treating schizophrenia." | 8.83 | Risperidone versus olanzapine for schizophrenia. ( Hosalli, P; Jayaram, MB; Stroup, S, 2006) |
| " A post hoc pooled analysis of 4 randomized, double-blind, 24- to 28-week schizophrenia clinical trials included 822 olanzapine-treated and 805 risperidone-, quetiapine-, or ziprasidone-treated patients." | 8.83 | Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. ( Adams, DH; Citrome, L; Kinon, BJ; Liu-Seifert, H, 2006) |
| "To evaluate the effects of risperidone for schizophrenia in comparison to 'conventional' neuroleptic drugs." | 8.82 | Risperidone versus typical antipsychotic medication for schizophrenia. ( Gilbody, SM; Hunter, RH; Joy, CB; Kennedy, E; Song, F, 2003) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 8.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| "To examine the clinical effects of depot risperidone for people with schizophrenia and schizophrenia-like psychoses." | 8.82 | Depot risperidone for schizophrenia. ( Davis, JM; Hosalli, P, 2003) |
| "Long-acting risperidone (Risperdal Consta) is a novel, intramuscular formulation of the atypical antipsychotic risperidone, which has shown efficacy in the treatment of patients with schizophrenia." | 8.82 | Long-acting risperidone: a review of its use in schizophrenia. ( Goa, KL; Harrison, TS, 2004) |
| "To review the literature on the healthcare costs associated with olanzapine and risperidone in treating schizophrenia." | 8.82 | Cost comparisons of olanzapine and risperidone in treating schizophrenia. ( Christensen, DB; Liu, GG; Luo, X; Sun, SX, 2004) |
| "Antipsychotic medication is a mainstay of treatment for schizophrenia and risperidone and olanzapine are the most popular treatment choice of the new generation drugs." | 8.82 | Risperidone versus olanzapine for schizophrenia. ( Hosalli, P; Jayaram, MB, 2005) |
| "Risperidone and olanzapine are novel antipsychotic medications that compete as first-line agents in treating patients with schizophrenia." | 8.82 | Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. ( Gibson, JP; Gibson, PJ; Hargreaves, WA, 2005) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 8.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| " In the present quantitative review the published evidence regarding the effects of risperidone on hostility and aggression in schizophrenia is evaluated." | 8.81 | Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. ( Aleman, A; Kahn, RS, 2001) |
| "Combined data on efficacy were available from 12 double-blind short-term (maximum 8 weeks) trials comparing risperidone and other antipsychotics in patients with chronic schizophrenia." | 8.81 | Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. ( Glick, ID; Lemmens, P; Vester-Blokland, E, 2001) |
| "To summarize published data to date by Canadian authors and from Canadian sources on risperidone, a novel neuroleptic indicated in the management of schizophrenia and related psychotic disorders." | 8.80 | The Canadian experience with risperidone for the treatment of schizophrenia: an overview. ( Hux, M; Iskedjian, M; Remington, GJ, 1998) |
| "Despite its high acquisition cost, risperidone does not increase, and may even reduce, overall treatment costs of schizophrenia by reducing hospitalisation compared with standard treatment regimens." | 8.80 | Risperidone. A pharmacoeconomic review of its use in schizophrenia. ( Foster, RH; Goa, KL, 1998) |
| "To evaluate the effectiveness of risperidone for schizophrenia in comparison to 'conventional' neuroleptic drugs." | 8.80 | Risperidone versus typical antipsychotic medication for schizophrenia. ( Clarke, A; Gilbody, S; Hunter, R; Kennedy, E; Song, F, 2000) |
| "Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics." | 8.80 | Risperidone versus other atypical antipsychotic medication for schizophrenia. ( Bagnall, AM; Duggan, L; Gilbody, SM; Tuunainen, A, 2000) |
| "The effects of olanzapine, risperidone, and haloperidol on PRL were assessed in patients with schizophrenia or related psychoses participating in 3 double-blind clinical trials: (1) a 6-week acute trial comparing olanzapine 5 to 20 mg/d (n = 1,336) and haloperidol 5 to 20 mg/d (n = 660), with a 1-year, open-label olanzapine extension for responders; (2) a 54-week study comparing olanzapine 5 to 20 mg/d (n = 21), risperidone 4 to 10 mg/d (n = 21), and haloperidol 5 to 20 mg/d (n = 23) in early illness; and (3) a 28-week study comparing olanzapine 10 to 20 mg/d (n = 172) and risperidone 4 to 12 mg/d (n = 167)." | 8.80 | The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. ( Breier, A; David, SR; Kinon, BJ; Taylor, CC, 2000) |
| "The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia." | 8.80 | Effects of risperidone on affective symptoms in patients with schizophrenia. ( De Smedt, C; Lemmens, P; Peuskens, J; Van Baelen, B, 2000) |
| "To review pharmacologic, pharmacokinetic, therapeutic, and safety information for the antipsychotic agent risperidone and to evaluate its place in the treatment of schizophrenia." | 8.79 | Risperidone: review and assessment of its role in the treatment of schizophrenia. ( Cardoni, AA, 1995) |
| "This study evaluates the relative effectiveness and side-effects of risperidone as compared with conventional neuroleptics in the treatment of schizophrenia, by meta-analysis of 11 double-blind, randomized controlled trials." | 8.79 | Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. ( Song, F, 1997) |
| "Our study suggests that switching from risperidone to PP in patients with schizophrenia is associated with an improvement in social functioning and cognitive performance." | 8.31 | Switching from risperidone to paliperidone palmitate in schizophrenia: Changes in social functioning and cognitive performance. ( Aguayo, R; Álvarez, A; Barbero, JD; Gabernet, R; González-Rodríguez, A; Izquierdo, E; Labad, J; Merodio, I; Monreal, JA; Montalvo, I; Palao, D; Tost, M, 2023) |
| "Forty-two treatment-naive first-episode schizophrenia patients were scanned by TI weighted (T1W) imaging and DTI before and after 8-week risperidone monotherapy, and their peripheral blood genomic DNAm values were examined in parallel with MRI scanning." | 8.31 | Virtual histology of morphometric similarity network after risperidone monotherapy and imaging-epigenetic biomarkers for treatment response in first-episode schizophrenia. ( Duan, X; Hu, M; Kang, L; Li, L; Liu, Z; Ma, S; Nie, Z; Yao, T; Zhang, J; Zhang, N; Zheng, J; Zong, X, 2023) |
| " The present study examined the hypothesis that schizophrenia itself but not risperidone, an extensively employed SGA, is accountable for metabolic abnormalities." | 8.31 | Effects of Early Risperidone Treatment on Metabolic Parameters in Socially Isolated Rats-Implication of Antipsychotic Intervention across Developmental Stages of Schizophrenia. ( Hsieh, PS; Lin, CC; Liu, YP; Tzeng, NS; Yang, YY, 2023) |
| "This study aimed to assess weight changes following antipsychotic treatment in first-episode schizophrenia (FES) patients and make a comparison of aripiprazole, risperidone and olanzapine." | 8.31 | Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China. ( Cheng, Z; Gao, T; Huang, B; Huang, Z; Pu, C; Shi, C; Yu, X; Zhang, D; Zheng, Y; Zhou, E; Zhou, T, 2023) |
| " Risperidone, a currently used atypical antipsychotic agent for schizophrenia, is also known to inhibit the activity of D-amino acid oxidase, which degrades certain D-amino acids." | 8.31 | Association Between Risperidone Use and Kidney Function Decline in Patients with Schizophrenia: A Retrospective Cohort Study. ( Hara, A; Horikoshi, K; Iwata, Y; Kikuchi, M; Kinoshita, M; Kitajima, S; Minami, T; Mita, M; Miyagawa, T; Nakada, M; Nakade, Y; Nakagawa, S; Ogura, H; Oshima, M; Sakai, N; Shimizu, M; Toyama, T; Wada, T; Yomogida, D; Yuasa, T, 2023) |
| "These results indicate that after treatment with risperidone, changes in GPx activity were associated with treatment response, suggesting that changes in GPx may be a predictor of response to risperidone treatment in female patients with ANFE schizophrenia." | 8.12 | Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study. ( Chen, Z; Jiang, S; Li, X; Liu, H; Lu, Y; Su, L; Wang, X; Xiu, M; Zhang, X, 2022) |
| "Risperidone is routinely used in the clinical management of schizophrenia, but the treatment response is highly variable among different patients." | 8.12 | Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study. ( Fu, C; He, L; Huai, C; Li, M; Li, X; Ma, J; Qin, S; Shen, L; Shen, R; Tang, T; Wu, H; Wu, S; Yang, K; Zhang, N; Zhao, M; Zhou, W; Zhu, W, 2022) |
| "Second generation antipsychotics such as risperidone are first-line pharmacotherapy treatment choices for schizophrenia." | 8.12 | Risperidone-induced changes in DNA methylation in peripheral blood from first-episode schizophrenia patients parallel changes in neuroimaging and cognitive phenotypes. ( Bishop, JR; Chen, C; Chen, X; Giase, G; He, Y; Hu, M; Li, B; Li, Z; Liao, Y; Liu, C; Rubin, LH; Sweeney, JA; Tang, J; Wang, Y; Xia, Y; Zong, X, 2022) |
| "Risperidone and amisulpride caused hyperprolactinemia and macroprolactinemia; thus, detection of MPRL in the clinical setting should be performed as this phenomenon appears early in treatment (the second week) and continues, that can avoid unnecessary examination and treatment for asymptomatic patients with macroprolactinemia." | 8.12 | Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride. ( Haiying, J; Haizhi, C; Jianhua, L; Jianjun, L; Jing, L; Lilei, L; Xiaocong, F; Zhenhua, W, 2022) |
| "To study plasma adipokines (adiponectin, leptin, adipsin) in patients with the first episode of schizophrenia treated with haloperidol and risperidone." | 8.02 | [Changes in adipokines in the blood of patients with the first episode of schizophrenia during treatment with haloperidol and risperidone]. ( Govorin, NV; Ozornin, AS; Sakharov, AV; Tereshkov, PP, 2021) |
| "The study included 23 clozapine-treated schizophrenia patients (CT-SCZ), 19 risperidone-treated schizophrenia patients (RT-SCZ), 23 never-treated schizophrenia patients (NT-SCZ), and 35 healthy controls (HCs)." | 8.02 | Characteristics of the corpus callosum in chronic schizophrenia treated with clozapine or risperidone and those never-treated. ( Cao, H; Gong, Q; Lencer, R; Lui, S; Tao, B; Xiao, Y; Yang, C; Zhang, W, 2021) |
| "To explore pharmacogenetic relationships of NRG1 genotypes with neurocognitive performance and clinical symptoms after 12 week treatment of risperidone in Chinese Han first-episode schizophrenia." | 8.02 | Pharmacogenetic associations of NRG1 polymorphisms with neurocognitive performance and clinical symptom response to risperidone in the untreated schizophrenia. ( Kang, C; Lin, Y; Wei, Y; Wu, C; Xu, L; Yang, J; Yuan, J; Zeng, L; Zhang, Y; Zhou, F, 2021) |
| "A retrospective self-controlled study was conducted on 90 patients with schizophrenia from a single-center treated with olanzapine or clozapine monotherapy, or combined with aripiprazole or ziprasidone which has a small metabolic impact." | 8.02 | The effect of prohibiting outside food during COVID-19 pandemic on the body weight of schizophrenic patients taking olanzapine or clozapine: a retrospective self-controlled study. ( Ding, W; Hu, C; Hu, M; Li, H; Sun, X; Wang, Q; Wang, X; Wu, M; Zhang, C, 2021) |
| "We found very common hyperprolactinemia and hypoprolactinemia in the risperidone or paliperidone group and aripiprazole group, respectively." | 8.02 | Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. ( Shimoda, K; Shinozaki, M; Sugawara, N; Tasaki, M; Yasui-Furukori, N; Yokoyama, S, 2021) |
| "Risperidone is an atypical antipsychotic agent clinically used to treat schizophrenia, bipolar diseases, and autism." | 8.02 | Determining the release kinetics of risperidone controlled release matrices to treat schizophrenia. ( Akhtar, H; Ali, MM; Ali, SI; Arif, H; Inayat, S; Iqbal, MS; Kashif, SS; Naz, A; Nisa, Z; Perveen, S; Rizvi, M; Shahnaz, S; Sheikh, S; Swaleh, MM; Zehra, A, 2021) |
| "Longitudinal study of the dFC of insular subdivisions was conducted in 42 treatment-naive first-episode patients with schizophrenia at baseline and after 8 weeks of risperidone treatment based on resting-state functional magnetic resonance image (fMRI)." | 7.96 | Effect of Risperidone Monotherapy on Dynamic Functional Connectivity of Insular Subdivisions in Treatment-Naive, First-Episode Schizophrenia. ( Chen, H; Chen, X; Dong, X; Duan, X; He, C; Hu, M; Huang, X; Li, H; Su, C; Tang, J; Xiao, J; Zong, X, 2020) |
| "Brexpiprazole is an oral atypical antipsychotic (OAA) for the treatment of schizophrenia (SCZ)." | 7.96 | Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy. ( Broder, MS; Chang, E; Greene, M; Houle, CR; Tarbox, MH; Waters, HC; Yan, T, 2020) |
| "Antipsychotic medications, including risperidone, are widely used in the treatment of psychiatric disorders, including schizophrenia." | 7.96 | Severe hypothermia, bradycardia and cardiac arrest in association with risperidone. ( Bhat, S; Ochieng, P; Ravi, D; Sharma, N, 2020) |
| " CASE REPORT A 27-year-old woman with schizophrenia on risperidone presented to our Emergency Department with a sensation of choking and respiratory distress, mimicking a panic attack." | 7.96 | Risperidone-Induced Acute Laryngeal Dystonia: A Case Report. ( Alkharboush, GA; Alsalamah, MA, 2020) |
| " This study sought to explore the characteristics of white matter structural networks in chronic never-treated schizophrenia and those treated with clozapine or risperidone, and its potential association with cognitive function." | 7.96 | Characteristics of White Matter Structural Networks in Chronic Schizophrenia Treated With Clozapine or Risperidone and Those Never Treated. ( Gong, Q; Hu, N; Lencer, R; Li, S; Lui, S; Luo, C; Xiao, Y; Zhang, W, 2020) |
| " To explore further, the present study aimed to assess the influence of DRD2 -141 C Ins/Del, Taq1A and HTR2A -1438 G/A, 102T/C and HTR2C -759 C/T genetic polymorphisms in response to risperidone in patients with schizophrenia." | 7.91 | Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia. ( Adithan, S; Alladi, CG; Bellivier, F; Marie-Claire, C; RajKumar, RP; Shewade, DG, 2019) |
| "The aim of this study was to explore the effectiveness and tolerability of long-acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients while comparing the results with the oral antipsychotic risperidone." | 7.91 | Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients. ( Gačo, N; Graovac, M; Kaštelan, A; Petrić, D; Rački, V, 2019) |
| "This study aimed to assess the comparative effectiveness of risperidone (RIS) versus aripiprazole (ARP) in patients with recent-onset or chronic schizophrenia during maintenance treatment and to examine the interaction between illness duration and the effectiveness of the treatment." | 7.88 | Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study. ( Aoki, S; Harada, T; Kishi, Y; Nomura, A; Sato, K; Takeda, T; Washida, K; Yada, Y; Yoshimura, B; Yoshimura, Y, 2018) |
| "The aim of the nationwide retrospective matched cohort study was to evaluate health service utilization and medical costs between patients with schizophrenia who received long-acting injectable (LAI) risperidone and those who took risperidone orally." | 7.88 | Health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone: a nationwide retrospective matched cohort study in Taiwan. ( Chang, HC; Fan, SJ; Huang, KC; Lu, N; Tang, CH, 2018) |
| " We report a case of an antipsychotic-naive patient with schizophrenia who developed leukopenia after a single dose of olanzapine, which worsened during subsequent treatment with risperidone." | 7.88 | Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction? ( Chan, LF; Deang, KT; Gan, LLY; Tee, CK; Woon, LS, 2018) |
| "Risperidone and paliperidone palmitate are two antipsychotic drugs well tolerated in the management of schizophrenia and other psychiatric conditions." | 7.88 | Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability. ( Tagne Nouemssi, AB, 2018) |
| " After 24-week risperidone treatment, there were significant increases in body weight, BMI, fasting blood-glucose, triglycerides, LDL, hs-CRP, SOD and HOMA-IR (p < 0." | 7.88 | Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia. ( Fan, X; Hei, G; Huang, XF; Kumar, BU; Li, X; Liu, Y; Lv, L; Song, X; Wang, Y; Yuan, X; Zhang, P, 2018) |
| "Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia." | 7.88 | Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018) |
| "We examined whether memantine add-on to antipsychotic treatment is beneficial in schizophrenia treatment." | 7.85 | Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. ( Iwata, N; Kishi, T; Matsuda, Y, 2017) |
| "Risperidone is most commonly used as an antipsychotic in India for treatment of schizophrenia." | 7.85 | Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India. ( Aneja, J; Chavan, BS; Garg, PD; Gautam, S; Gupta, D; Gupta, R; Kaur, G; Khurana, H; Margoob, MA; Prasad, R; Sinhmar, V; Tripathi, A, 2017) |
| "Nowadays, risperidone is an atypical antipsychotic drug that has been increasingly used for treatment and maintenance therapy in schizophrenia." | 7.85 | Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients. ( Cui, D; He, L; Huo, R; Li, M; Li, W; Qin, S; Shen, L; Shi, Y; Song, C; Xing, Q; Xu, Q; Zhao, J, 2017) |
| "The present study demonstrates that co-administration of risperidone and escitalopram may be used to treat positive and negative symptoms of schizophrenia and will allow to minimize the drugs' side effects." | 7.85 | Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects. ( Górska, A; Gołembiowska, K; Jurczak, A; Kamińska, K; Noworyta-Sokołowska, K; Rogóż, Z, 2017) |
| "The aim of this study was to determine whether the incidence of pneumonia in patients taking clozapine was more frequent compared with those taking risperidone or no atypical antipsychotics at all before admission to a tertiary care medical center." | 7.85 | Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. ( Colon, E; George, WT; Jancik, J; O'Brien, JB; Rasimas, JJ; Stoecker, ZR, 2017) |
| "The study was a non-randomized, naturalistic, rater blinded, prospective, 8-12 weeks, comparative trial between the risperidone and aripiprazole in patients with schizophrenia." | 7.85 | A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia. ( Kumar C, N; Kumar P B, S; Kumar P T, S; Pandey, RS; Thirthalli, J, 2017) |
| "This study aims to determine the optimal tolerability dose ranges of risperidone (RIS) and olanzapine (OLZ) administered during schizophrenia maintenance phase." | 7.85 | Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study. ( Aoki, S; Harada, T; Kishi, Y; Nomura, A; Sato, K; Takeda, T; Washida, K; Yada, Y; Yoshimura, B; Yoshimura, Y, 2017) |
| "32 per cent mean reduction in Positive and Negative Syndrome Scale (PANSS) for Schizophrenia total score while risperidone led to 56." | 7.83 | Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study. ( Chavan, BS; Kalra, P; Kaur, G; Sahni, S; Sidana, A, 2016) |
| "Previous studies showed functional improvement in stable patients with schizophrenia treated with risperidone long-acting injection (LAI)." | 7.83 | Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study). ( Dassa, D; De Vathaire, F; Garay, RP; Giraud-Baro, E; Obeid, J, 2016) |
| "To describe abnormalities in large scale functional networks in unmedicated patients with schizophrenia and to examine effects of risperidone on networks." | 7.83 | Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone. ( Falola, B; Hadley, JA; Knight, D; Kraguljac, NV; Lahti, AC; ver Hoef, L; Visscher, K; White, DM, 2016) |
| "Scores on the Positive and Negative Syndrome Scale, executive functioning, and social functioning were obtained from 24 patients with schizophrenia receiving either risperidone (n = 12) or trifluoperazine (n = 12), before their social behavior was measured in the interactive Tangrams Game." | 7.83 | Different mechanisms of risperidone result in improved interpersonal trust, social engagement and cooperative behavior in patients with schizophrenia compared to trifluoperazine. ( Bond, AJ; Chan, CK; Chan, F; Pang, AH; Tse, WS; Wong, AS, 2016) |
| "This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia." | 7.83 | Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. ( Guo, Q; Li, C; Ouyang, Q; Qiao, Y; Shen, W; Sheng, J; Wen, H; Yang, F; Zhu, S, 2016) |
| "Hyperprolactinemia is commonly seen in patients with schizophrenia on risperidone." | 7.83 | Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia. ( Chandrasekaran, A; Charan, A; Rajkumar, RP; Shewade, DG, 2016) |
| "Clozapine is the gold-standard antipsychotic medication for treatment-refractory schizophrenia (TRS)." | 7.83 | Fever, confusion, acute kidney injury: is this atypical neuroleptic malignant syndrome following polypharmacy with clozapine and risperidone? ( Cherry, S; Halangoda, P; Siskind, D; Spivak, V; Wysoczanski, D, 2016) |
| "This retrospective longitudinal cohort study aimed to compare treatment patterns, healthcare resource utilization (HRU), and costs in patients with schizophrenia treated with second-generation antipsychotic long-acting injectables (SGA-LAIs): biweekly risperidone LAI versus once-monthly paliperidone palmitate." | 7.83 | Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. ( Benson, C; Joshi, K; Pan, X; Wang, R; Yang, E, 2016) |
| "We conducted a cross-sectional study to compare the subjective experiences and clinical effects of first-generation long-acting injectable (FGA-LAI) antipsychotics with those of risperidone long-acting injectables (RIS-LAIs) in 434 schizophrenia patients." | 7.83 | Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia. ( Chen, WY; Lin, SK, 2016) |
| "While numerous studies have confirmed the efficacy of risperidone long-acting injectable (RLAI) on many clinical outcomes in patients with schizophrenia, there is no data regarding its influence on employment status." | 7.83 | Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. ( Emsley, R; Filipcic, IS; Grosic, V; Mihaljevic-Peles, A; Pedisic, I; Sagud, M, 2016) |
| "The aim of the study was to use a technique that combines acid hydrolysis and matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI-TOF MS) in order to detect the serum biomarkers of patients diagnosed with schizophrenia both before and after four-week antipsychotic treatment with risperidone." | 7.83 | Rapid detection of alteration of serum IgG in patients with schizophrenia after risperidone treatment by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. ( Huang, TL; Lo, LH; Shiea, J, 2016) |
| "We wanted to present a picture of patients with schizophrenia receiving risperidone long-acting injection (RLAI) treatment in a real-world setting." | 7.81 | Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study. ( Chan, HW; Feng, WJ; Huang, CY; Yen, YC, 2015) |
| "This study evaluated 169 patients with schizophrenia who were receiving risperidone monotherapy." | 7.81 | Factors associated with self-rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapy. ( Bae, KY; Kang, HJ; Kim, JM; Kim, SW; Kim, SY; Lee, JY; Lee, YH; Shin, IS; Yoon, JS, 2015) |
| "SLC6A4 might be susceptible gene for risperidone-induced weight gain within the Chinese Han population." | 7.81 | A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population. ( Du, B; Li, K; Liu, C; Lu, T; Lv, L; Ma, C; Ma, W; Mi, W; Wang, F; Wang, L; Yang, Y; Yue, W; Zhang, D; Zhang, H, 2015) |
| " risperidone long acting injectable (RLAI), paliperidone long acting injectable (PLAI) and olanzapine long acting injectable (OLAI) in the maintenance treatment of chronic, stable schizophrenia patients in the United Kingdom." | 7.81 | Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. ( Beillat, M; Robinson, P; Sapin, C; Tempest, M; Treur, M, 2015) |
| "26 million insured in a Markov-simulation model to assess the cost-effectiveness of long-acting injectable risperidone (LAI-RIS) compared with long-acting injectable flupentixol (LAI-FLX) in the long-term management of schizophrenia." | 7.80 | Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. ( Frey, S; Juckel, G; Linder, R; Stargardt, T, 2014) |
| "The aim of the study was to investigate the prevalence rates of obsessive-compulsive disorder (OCD) and hypochondriasis in schizophrenic patients treated with atypical antipsychotics (AAPs) and to investigate the different comorbidity rates of OCD and hypochondriasis between clozapine-treated patients and patients treated with other AAPs." | 7.80 | Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. ( Cantisani, A; Ferrari, G; Grassi, G; Pallanti, S; Poli, L; Righi, L, 2014) |
| "The present study evaluated the association of the BDNF Val66Met polymorphism with treatment response to atypical antipsychotic olanzapine in schizophrenia and the possible predictive value of the BDNF Val66Met genotype status in treatment response to antipsychotic medication." | 7.80 | Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. ( Kozumplik, O; Mihaljevic-Peles, A; Muck-Seler, D; Nedic Erjavec, G; Nikolac Perkovic, M; Pivac, N; Sagud, M; Uzun, S; Zivkovic, M, 2014) |
| " The main purpose of the present study was to examine the correlations between testosterone, estradiol BMI, and insulin in male patients diagnosed with schizophrenia and treated with olanzapine or risperidone." | 7.80 | Association between serum testosterone levels, body mass index (BMI) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone. ( Galińska-Skok, B; Konarzewska, B; Malus, A; Simonienko, K; Szulc, A; Waszkiewicz, N; Łazarczyk-Kirejczyk, J, 2014) |
| "To explore differences in outcomes for patients with schizophrenia treated with risperidone long-acting treatment (RLAT) or oral antipsychotics (oAP)." | 7.80 | Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). ( Cherubin, P; Princet, P; Schreiner, A; Serazetdinova, L; Svensson, A; Wapenaar, R; Zink, M, 2014) |
| " The aim of this work was designed to investigate the diagnostic possibility of [(123)I]epidepride imaging platform for risperidone-treatment chronic MK-801-induced rat schizophrenia model." | 7.80 | Dopamine D(2)/D(3) receptor binding of [(123)I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging. ( Chang, KW; Chen, MW; Cheng, KH; Huang, YR; Kuo, WI; Pai, CW, 2014) |
| "Here is a case of a woman with schizophrenia who developed rhabdomyolysis following overdose of risperidone, trihexyphenidyl and benzodiazepines." | 7.80 | Multidrug overdose-induced myoclonus complicated by rhabdomyolysis: possible role and mechanism of muscle toxicity of risperidone. ( Hsu, YC; Yeh, YW, 2014) |
| "The FTO gene polymorphisms, especially rs9939609, seem to be related to weight gain after risperidone treatment in Chinese Han patients with first episode schizophrenia." | 7.80 | Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. ( Fan, X; Feng, Y; Gao, J; Li, X; Lv, L; Nemani, K; Pang, L; Song, X; Zhang, H; Zhang, J; Zhang, W, 2014) |
| "Potential differences in psychiatric clinical outcomes and hospitalization rates before and after the initiation of long-acting risperidone among recently and long-term diagnosed schizophrenia patients were studied." | 7.80 | Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schi ( Detraux, J; Dubois, V; Geerts, P; Peuskens, J, 2014) |
| " The aim of the study was to compare the clinical remission rates, number of hospital readmissions and personal and social functioning after 2 years between patients with recent-onset schizophrenia (<2 years) in treatment with risperidone long-acting injectable (RLAI) and patients with recent-onset schizophrenia receiving oral antipsychotics." | 7.79 | Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. ( Barrio, P; Batalla, A; Castellví, P; García, M; Grande, I; Hidalgo, D; Ortiz, A; Parellada, E; Pons, A, 2013) |
| "The aims of this study were to investigate bone mass, body composition and light microscopic pathology examinations of femur in an animal model of schizophrenia (pharmacologically induced by postnatally administered phencyclidine-PCP) and to further examine the effects of chronic treatment with risperidone on these parameters in rats." | 7.79 | Chronic risperidone exposure does not show any evidence of bone mass deterioration in animal model of schizophrenia. ( Doknic, M; Jasovic-Gasic, M; Maric, N; Pekic, S; Petronijevic, M; Petronijevic, N; Popovic, V; Radonjic, N; Sopta, J, 2013) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 7.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "This cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr." | 7.79 | Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. ( Chaves, KM; de Araújo Júnior, RF; de Araújo, AA; de Paula Soares Rachetti, V; do Socorro Costa Feitosa Alves, M; Filgueira Júnior, A; Guerra, GC; Ribeiro, SB; Serrano-Blanco, A; Soares, LA, 2013) |
| "In the present work we analyzed the effect of the chronic administration of risperidone (2mg/kg over 65 days) on behavioural, morphological and molecular aspects in an experimental model of schizophrenia obtained by bilateral injection of ibotenic acid into the ventral hippocampus of new-born rats." | 7.79 | Chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study. ( Arji, M; Carro, J; Castellano, O; de Anchieta de Castro E Horta, J; Gómez-Nieto, R; Herrero-Turrión, MJ; López, DE; Molina, V; Riolobos, AS; Sancho, C, 2013) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 7.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| " We present the case of a 55-year-old patient with schizophrenia, who developed a skin eruption 5 weeks after initiating treatment with olanzapine." | 7.78 | Olanzapine-induced eccrine squamous syringometaplasia. ( Barabash, R; Molina-Ruiz, AM; Molina-Ruiz, RM; Requena, L; Zulueta, T, 2012) |
| "To model the cost effectiveness of paliperidone palmitate (paliperidone long-acting injectable; PLAI), a new once-monthly long-acting antipsychotic therapy, compared with risperidone long-acting injectable (RLAI) and olanzapine pamoate (OLAI), in multi-episode patients (two or more relapses) with schizophrenia in Sweden." | 7.78 | Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. ( Martin, M; McGuire, A; Mehnert, A; Nicholl, D; Pudas, H, 2012) |
| "Objective of this observational trial is to examine the effects of quetiapine in comparison with olanzapine and risperidone on clinical outcomes and quality of life in patients with schizophrenia and schizoaffective disorder in routine care." | 7.78 | Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial. ( Becker, T; Croissant, D; Eschweiler, GW; Frasch, K; Jaeger, S; Kilian, R; Längle, G; Messer, T; Pfiffner, C; Schepp, W; Steinert, T; Weiser, P, 2012) |
| "A total of 35 patients diagnosed for the first time with schizophrenia or acute schizophrenia-like psychotic disorder and treated with risperidone were enrolled in the study." | 7.78 | Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. ( Barteček, R; Juřica, J; Kašpárek, T; Pindurová, E; Žourková, A; Zrůstová, J, 2012) |
| " We investigated the possible association of CYP2E1 polymorphisms with susceptibility to schizophrenia in the Chinese Han Population as well as the relationship with response to risperidone in schizophrenia patients." | 7.78 | Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population. ( Feng, G; Han, X; He, L; Huo, R; Niu, J; Qin, S; Shen, L; Tang, K; Tian, Z; Wei, Z; Wu, X; Xiong, Y; Yang, L, 2012) |
| "This study assessed clinical and functional outcomes following a switch from risperidone to olanzapine in a 1-year naturalistic study of schizophrenia patients in Japan." | 7.78 | Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan. ( Ascher-Svanum, H; Fujikoshi, S; Nakahara, N; Ohmori, T; Takahashi, M; Ye, W, 2012) |
| "Clinically stable patients with schizophrenia (DSM-IV) receiving a stable dose of risperidone long-acting injectable (LAI) as antipsychotic monotherapy for at least 3 months and free of any psychiatric hospitalization over the past 6 months were included." | 7.78 | A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. ( Den, R; Hirano, J; Ikai, S; Mamo, D; Mimura, M; Nishimoto, M; Remington, G; Suzuki, T; Takeuchi, H; Tsuboi, T; Tsunoda, K; Uchida, H; Watanabe, K, 2012) |
| " This study aimed to examine the impact of switching from olanzapine to risperidone and vice versa on clinical status and tolerability outcomes in outpatients with schizophrenia in a naturalistic setting." | 7.78 | Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study. ( Brugnoli, R; Dossenbach, M; Haro, JM; Hong, J; Karagianis, J; Novick, D, 2012) |
| "To compare the prevalence of obsessive-compulsive symptoms (OCS) in a population of patients with schizophrenia taking clozapine, olanzapine, or risperidone or taking no antipsychotic medication." | 7.78 | Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. ( Korver, N; Machielsen, M; Scheltema Beduin, AA; Swets, M, 2012) |
| "The levels of kynurenic acid (KYNA), an astrocyte-derived metabolite of the branched kynurenine pathway (KP) of tryptophan degradation and antagonist of α7 nicotinic acetylcholine and N-methyl-D-aspartate receptors, are elevated in the prefrontal cortex (PFC) of individuals with schizophrenia (SZ)." | 7.77 | Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. ( McMahon, RP; Rassoulpour, A; Roberts, RC; Sathyasaikumar, KV; Schwarcz, R; Stachowski, EK; Wonodi, I, 2011) |
| " In this study, we assessed patterns of health-care utilization following the initiation of risperidone long-acting therapy (RLAT), the first and only second generation long-acting injectable antipsychotic agent, in schizophrenia patients within the Veterans Health Administration." | 7.77 | Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. ( Crivera, C; Dirani, R; Kazis, LE; Qian, S; Ren, XS; Sikirica, M, 2011) |
| " Inter-individual variability in hyperprolactinemia induced antipsychotics particularly risperidone can be explained by smoking status to some extent." | 7.77 | The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. ( Furukori, H; Kaneko, S; Nakagami, T; Ohta, C; Saito, M; Tsuchimine, S; Yasui-Furukori, N; Yoshizawa, K, 2011) |
| "Effect of haloperidol and risperidone on positive, negative, neurocognitive disorders, biological parameters and neurodestruction-neuroreparation processes have been studied in 23 patients with the first episode of paranoid schizophrenia." | 7.77 | [Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia]. ( Govorin, NV; Vasil'eva, AI, 2011) |
| " We reviewed the electronic medical records of patients with schizophrenia who received aripiprazole, olanzapine or risperidone monotherapies for at least three months." | 7.77 | The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. ( Ahn, YM; Jung, DC; Kang, UG; Kim, EY; Kim, SH; Kim, YS; Lee, NY; Sung, KH; Yu, HY, 2011) |
| "The relatively good tolerability profile of sertindole translates into lower costs of schizophrenia management, primarily driven by substantially lower direct and indirect costs." | 7.77 | A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. ( Eberhard, J; Fors, BM; Hansen, K; Lindström, E; Sapin, C, 2011) |
| "Baseline body mass index (BMI), baseline BMI status (normal, overweight, obese) and early (1 month) BMI increases were tested as predictors of 6- and 12-month increases in glucose and lipid measures in 82 olanzapine (OLZ)- and 78 risperidone (RIS)-treated patients with schizophrenia, schizoaffective disorder, or bipolar disorder who participated in a 12-month randomized, prospective metabolic effects study." | 7.77 | Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. ( Bobo, WV; Bonaccorso, S; Jayathilake, K; Meltzer, HY, 2011) |
| "(1) To determine bone remodeling parameters and bone mass in patients with schizophrenia on long-term treatment with long-acting injectable risperidone (LAIR) in naturalistic settings, and (2) to evaluate the change in body weight, metabolic profile and neuroendocrine status in these patients." | 7.77 | Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. ( Britvic, D; Damjanovic, A; Doknic, M; Jasovic Gasic, M; Maric, NP; Miljic, D; Pekic, S; Popovic, V; Radojicic, Z; Stojanovic, M, 2011) |
| "I report a case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection (RLAI)." | 7.77 | [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection]. ( Mori, T, 2011) |
| "D-Amino acid oxidase (DAO) has been established to be involved in the oxidation of D-serine, an allosteric activator of the N-methyl-D-aspartate-type glutamate receptor in the brain, and to be associated with the onset of schizophrenia." | 7.76 | The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia. ( Abou El-Magd, RM; Chung, SP; Fukui, K; Iwana, S; Kawazoe, T; Miyano, M; Ono, K; Park, HK; Sakai, T; Yorita, K, 2010) |
| "This naturalistic retrospective study aims to compare effectiveness of a second-generation antipsychotic medication, risperidone, with first-generation antipsychotic medications (haloperidol and trifluoperazine) in an Asian population with first-episode schizophrenia-spectrum disorders." | 7.76 | Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders. ( Edimansyah, A; Liew, A; Subramaniam, M; Vaingankar, J; Verma, S, 2010) |
| "To estimate changes in resource usage, hospitalization rates, and costs in actual practice in Sweden for schizophrenia patients after switching to long-acting injectable risperidone (Risperdal Consta)." | 7.76 | The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. ( Berntsson, A; Eriksson, B; Löthgren, M; Persson, U; Svensson, M; Willis, M, 2010) |
| " We investigated the influence on startle response in chronic schizophrenia in 20 patients with schizophrenia taking risperidone, 21 patients with schizophrenia taking olanzapine, and 20 patients with schizophrenia taking aripiprazole." | 7.76 | Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia. ( Fujita, K; Fukuo, Y; Furukawa, O; Iwata, N; Kawashima, K; Kishi, T; Kitajima, T; Moriwaki, M; Naitoh, H; Okochi, T, 2010) |
| " The goal of this study was to understand the relationship between clozapine and risperidone with glucose and lipid metabolism and dietary fat intake in patients with schizophrenia." | 7.76 | Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B, 2010) |
| "To evaluate the efficacy and tolerability of long-acting risperidone injection in Thai patients with chronic schizophrenia for 12 weeks treatment." | 7.76 | Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia. ( Arunpongpaisal, S; Kitiwattanagul, K; Kongsakon, R; Samanwongthai, U; Srisurapanont, M, 2010) |
| " Throughout the whole clinical course mentioned above, he was under treatment for schizophrenia with drugs including risperidone which possibly affects glucose metabolism." | 7.76 | The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. ( Tsutsumi, E; Yamaguchi, K, 2010) |
| "This study investigated the variables related to the effectiveness and adherence to treatment with risperidone long-acting injection (RLAI) in patients with schizophrenia." | 7.76 | Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection. ( Chang, CL; Lung, FW; Tzeng, DS, 2010) |
| "Despite the limited number of children included, our results confirm a strong link between prescription of risperidone in EOS and risk of obesity." | 7.76 | [Metabolic side effects of risperidone in early onset schizophrenia]. ( Bordet, R; Delion, P; Duhamel, A; Goeb, JL; Jardri, R; Kechid, G; Marco, S; Thomas, P, 2010) |
| "Hyperprolactinemia is a frequent consequence of treatment with risperidone." | 7.76 | Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. ( Fujii, A; Furukori, H; Kaneko, S; Sugawara, N; Yasui-Furukori, N, 2010) |
| "This study aimed to investigate the effects of treatment with haloperidol, olanzapine and risperidone on cardiovascular variability in patients with recent-onset schizophrenia by means of spectral analysis." | 7.75 | Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia. ( Hempel, RJ; Hengeveld, MW; Röder, CH; Tulen, JH; van Beveren, NJ, 2009) |
| "The ketamine (ket) model reflects features of schizophrenia as well as secondary symptoms such as altered pain sensitivity." | 7.75 | Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ( Becker, A; Grecksch, G; Hiemke, C; Ladstaetter, E; Schmitt, U; Zernig, G, 2009) |
| "Olanzapine and risperidone may impair glucose tolerance due in part to increased insulin resistance." | 7.75 | Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. ( Furukori, H; Kaneko, S; Nakagami, T; Saito, M; Sato, Y; Yasui-Furukori, N, 2009) |
| "To estimate the cost effectiveness of olanzapine and risperidone for the treatment of schizophrenia in Belgium." | 7.75 | Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach. ( De Graeve, D; De Ridder, A, 2009) |
| "The model predicts that it is cost-effective to keep a patient with schizophrenia in Germany on branded risperidone instead of switching him/her to generic risperidone (assuming a 40% reduction in medication costs), if the incremental probability of becoming non-compliant after generic substitution exceeds 5." | 7.75 | A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. ( Heeg, B; Möller, HJ; Schmeding, A; Treur, M; van Hout, B, 2009) |
| " We examined the plasma levels of these 2 factors in schizophrenia patients at the time of admission and after 6 weeks of treatment with risperidone." | 7.75 | Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. ( Kim, YK; Lee, BH, 2009) |
| "Genotyping using the P450 microarray system was performed for 89 Japanese patients with schizophrenia receiving risperidone." | 7.75 | Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. ( Chino, B; Kosaki, K; Mizuno, M; Sakuma, K; Sato, Y; Takao, T; Takebayashi, T; Yagihashi, T, 2009) |
| "To examine hospitalisation rates and resource utilisation following initiation of risperidone long-acting therapy (RLAT) among US veterans with schizophrenia." | 7.75 | Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. ( Dirani, R; Flanders, S; Fuller, M; Russo, P; Secic, M; Shermock, K; Vallow, S, 2009) |
| "A patient taking oral risperidone while using cocaine and alcohol presented with priapism shortly after long-acting, injectable risperidone was prescribed." | 7.75 | Priapism and risperidone. ( Koirala, S; Lippmann, S; Penagaluri, P; Smith, C, 2009) |
| "The study recruited 107 drug-naive Chinese schizophrenia patients who were given 8 weeks of risperidone monotherapy and it explored three of four single nucleotide polymorphisms spanning HTR3A for possible association with therapeutic improvement, using the Positive and Negative Symptom Scale." | 7.74 | Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. ( Feng, GY; Gu, B; He, L; Li, HF; Ma, G; Wang, L; Xing, QH; Zhang, AP; Zhao, XZ, 2008) |
| "This study examined the association between exposure to potentially interacting drugs and nonpersistence in a cohort of patients with schizophrenia newly starting treatment with risperidone." | 7.74 | Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia. ( Caro, JJ; Glass, J; Ishak, KJ; Luong, D; Tan, Y, 2008) |
| "The availability of long-acting injectable risperidone may increase adherence to antipsychotic treatment and lead to improved clinical and economic outcomes for patients with schizophrenia." | 7.74 | Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. ( Alonso-Escolano, D; Burón, JA; Olivares, JM; Rodriguez-Martinez, A; Rodriguez-Morales, A, 2008) |
| "A case of a 46-year-old woman with schizophrenia who was treated with risperidone and followed up for 1 year is reported." | 7.74 | Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment. ( Bozina, N; Jovanović, N; Lovrić, M; Medved, V, 2008) |
| "A total of 120 first-episode neuroleptic-naive schizophrenia patients were treated with risperidone monotherapy for 8 weeks and clinical symptoms were evaluated by the Positive and Negative Syndrome Scale." | 7.74 | Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. ( Hashimoto, S; Ikeda, M; Iwata, N; Kinoshita, Y; Kitajima, T; Nakamura, J; O'Donovan, MC; Ozaki, N; Yamanouchi, Y; Yoshimura, R, 2008) |
| " Patients previously diagnosed with schizophrenia who received a first prescription of olanzapine or risperidone between 1 January 1997 and 31 August 1999 were followed for 365 days." | 7.74 | A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia. ( Abdous, B; Cooper, D; Grégoire, JP; Moisan, J, 2008) |
| "Outpatients initiating or changing antipsychotic therapy for DSM-IV- or ICD-10-defined schizophrenia (N = 7658) were allocated to olanzapine or nonolanzapine cohorts (November 2000 to December 2001)." | 7.74 | Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. ( Anders, M; Dossenbach, M; Irimia, V; Kotler, M; Logozar-Perkovic, D; Lowry, AJ; Pecenak, J; Peciukaitiene, D; Smulevich, AB; Szulc, A; Treuer, T; West, TM, 2008) |
| "Data on the use of long-acting injectable (LAI) risperidone, the first atypical depot antipsychotic, during pregnancy are limited." | 7.74 | Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia. ( Kim, JM; Kim, KM; Kim, SW; Shin, HY; Shin, IS; Yang, SJ; Yoon, JS, 2007) |
| "Risperidone has a relatively low risk of causing obesity and diabetes mellitus and is a first-line treatment for schizophrenia." | 7.74 | Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. ( Hosoda, H; Inoue, T; Itoh, K; Izumi, T; Kangawa, K; Koyama, T; Kusumi, I; Murashita, M; Nakagawa, S; Tanaka, T, 2007) |
| "The study was a retrospective analysis of administrative data from the New York-New Jersey region of the Veterans Health Administration for 2,436 individuals with schizophrenia or schizoaffective disorder who were prescribed risperidone from January 2001 through March 2003." | 7.74 | Impact of splitting risperidone tablets on medication adherence and on clinical outcomes for patients with schizophrenia. ( Dellenbaugh, C; Weissman, EM, 2007) |
| "A 31-year-old patient suffering from schizophrenic psychosis was treated with risperidone, and developed priapism which required surgical intervention and resulted in long-term erectile dysfunction." | 7.74 | Risperidone-induced priapism. ( Makesar, D; Thome, J, 2007) |
| "This study compares 3 cohorts of patients with schizophrenia before, during, and after initiating treatment with fluphenazine decanoate (FD), haloperidol decanoate (HD), or long-acting injectable risperidone (LAR)." | 7.74 | Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. ( Ascher-Svanum, H; Marcus, SC; Olfson, M, 2007) |
| "After a switch from previous treatment to open-label ziprasidone more than half of patients with schizophrenia experienced sustained clinical remission over 6 months and 32% of the patients achieving remission experienced a concurrent NP improvement." | 7.74 | The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. ( Bowie, CR; Buckley, PF; Harvey, PD; Loebel, A, 2007) |
| "To evaluate the cost-effectiveness of three antipsychotic medications (olanzapine, risperidone and haloperidol) in the treatment of schizophrenia using the Positive and Negative Symptom Scale." | 7.74 | Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. ( Bounthavong, M; Okamoto, MP, 2007) |
| "To describe a case of a patient who developed drug-induced cholestasis after being on risperidone maintenance therapy for 8 years." | 7.74 | Risperidone- and quetiapine-induced cholestasis. ( Vandenberg, AM; Wright, TM, 2007) |
| "These findings suggest that RGS4 variances influence clinical manifestations of schizophrenia as well as the treatment response to risperidone, suggesting that RGS4 plays a role in the fundamental process of disease pathophysiology." | 7.74 | RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. ( Chang, YC; Huang, CH; Huang, CL; Lane, HY; Liu, YC; Tsai, GE; Wu, PL, 2008) |
| " We examined the effectiveness of olanzapine and risperidone in schizophrenia in a naturalistic setting." | 7.74 | Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting. ( Kennedy, A; Kilzieh, N; Tapp, AM; Todd-Stenberg, JA; Wood, AE, 2008) |
| "To monitor long-term symptomatic tolerability and remission in patients with stable but suboptimally treated psychoses after switching to risperidone long-acting injectable (RLAI)." | 7.74 | Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. ( Kissling, W; Llorca, PM; Lloyd, K; Medori, R; Sacchetti, E, 2008) |
| "Clozapine is known to be effective in treating schizophrenia patients with comorbid alcohol use disorders (AUD)." | 7.74 | Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. ( Kim, D; Kim, JH; Marder, SR, 2008) |
| "Clozapine may alleviate hyperactivity in the limbic system in schizophrenia and may facilitate activation of the regions involved in cognitive tasks to a greater degree than risperidone, as well as eliciting greater inhibition of the PF region." | 7.74 | Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. ( De Luxán, A; Domínguez-Gil, A; Martin, C; Molina, V; Montes, C; Rivas, N; Sancho, C; Tamayo, P, 2008) |
| "Thirty inpatients with schizophrenia taking risperidone were studied." | 7.74 | Effects of risperidone on glucose metabolism in Chinese patients with schizophrenia: a prospective study. ( Cai, ZJ; Chen, Q; Mao, PX; Mitchell, PB; Tang, YL; Zhai, YM, 2008) |
| "The change in direct medical costs for schizophrenia patients who were started on olanzapine or risperidone and who were privately insured was studied." | 7.73 | Health care costs for schizophrenia patients started on olanzapine versus risperidone. ( Namjoshi, M; Russo, PA; Smith, MW, 2005) |
| "To assess the cost effectiveness of risperidone LAI compared with oral risperidone, oral olanzapine and haloperidol decanoate LAI over a 1-year time period in outpatients with schizophrenia who had previously suffered a relapse requiring hospitalisation." | 7.73 | Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. ( Botteman, MF; Diamond, RJ; Edwards, NC; Pashos, CL; Rupnow, MF, 2005) |
| "Data were collected from medical records from January 1992 to December 2003 and included age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation for clozapine-treated patients with schizophrenia or schizoaffective disorder (DSM-IV criteria)." | 7.73 | Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Freudenreich, O; Goff, DC; Hayden, DL; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "The availability of long-acting risperidone injection may increase adherence and lead to improved clinical and economic outcomes for individuals with schizophrenia." | 7.73 | Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. ( Diamond, RJ; Edwards, NC; Locklear, JC; Rupnow, MF, 2005) |
| "We studied a sample of schizophrenia out-patients to test the hypotheses that serum homocysteine concentrations would correlate positively with measures of glucose metabolism." | 7.73 | Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. ( Baer, L; Borba, CP; Cather, C; Copeland, PM; Eden Evins, A; Freudenreich, O; Goff, DC; Henderson, DC; Nguyen, DD, 2006) |
| "These findings suggest that ethnicity may play a role in symptom presentation and treatment response to risperidone for children and adolescents with schizophrenia-spectrum disorders." | 7.73 | Ethnic variation in symptoms and response to risperidone in youths with schizophrenia-spectrum disorders. ( Crismon, ML; De Leon, A; Lane, DC; Lopez, M; Patel, NC; Shafer, A, 2006) |
| "To study the multiple dose clinical pharmacokinetics of risperidone and its main active metabolite, 9-hydroxyrisperidone, in Chinese female patients with schizophrenia." | 7.73 | Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ( Deng, CY; Li, HD; Li, WB; Li, X; Lin, QX; Lin, SG; Peng, HY; Su, FL; Wang, CY; Wang, F; Yang, M; Yu, XY; Zhou, ZL; Zhu, RH, 2006) |
| "To examine clinical outcomes in Asian patients with schizophrenia receiving monotherapy with olanzapine, risperidone or typical antipsychotics in naturalistic settings." | 7.73 | Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. ( Dyachkova, Y; Habil, H; Lee, C; Lee, P; Wu, KH, 2006) |
| "Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder." | 7.73 | Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. ( Bettcher, BM; Byerly, MJ; Carmody, T; Fisher, R; Nakonezny, PA; Rush, AJ, 2006) |
| "Risperidone, olanzapine, and clozapine are three atypical antipsychotic medications commonly used in the management of chronic schizophrenia." | 7.73 | Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. ( Gonen, N; Kupchik, M; Mester, R; Roitman, S; Schwartz, S; Spivak, B; Strous, RD; Weizman, A, 2006) |
| "We compared fasting lipids and other metabolic parameters in 211 normoglycemic patients meeting the DSM-IV diagnosis of schizophrenia or schizoaffective disorder undergoing continuous treatment with olanzapine, risperidone, or typical antipsychotics for at least 1 year." | 7.73 | Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. ( Cavazzoni, P; Hardy, TA; Kryzhanovskaya, L; Marquez, E; Taylor, CC, 2006) |
| "Prolactin levels returned to normal, and clinical symptoms of hyperprolactinemia resolved in all 3 patients after 2 weeks of tapering and discontinuation of risperidone." | 7.73 | Risperidone-induced hyperprolactinemia in adolescents: A case series. ( Madhusoodanan, S; Moise, D, 2006) |
| "Second-generation atypical antipsychotics such as clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride and ariprazole offer the potential to reduce the significant health care resource demands in the treatment of schizophrenia through improved levels of initial clinical response and reduced levels of long-term acute relapse." | 7.73 | A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. ( Beard, SM; Clouth, J; Maciver, F; Rüther, E, 2006) |
| " High-dose treatment with risperidone may be more beneficial in males for the treatment of acute schizophrenia." | 7.73 | Gender-specific effects in the treatment of acute schizophrenia with risperidone. ( Naber, D; Raedler, TJ; Schreiner, A; Wiedemann, K, 2006) |
| "Twenty-five antipsychotic drug-naive, acutely ill patients with first-episode schizophrenia performed an oculomotor delayed response task at baseline before any drug treatment and again after 6 weeks of risperidone treatment." | 7.73 | Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. ( Harris, MS; Keshavan, MS; Reilly, JL; Sweeney, JA, 2006) |
| "Olanzapine and risperidone are two commonly prescribed atypical antipsychotics for schizophrenia." | 7.73 | Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia. ( Herz, L; Huang, YH; Kazis, LE; Lee, AF; Ren, XS; Yu, W, 2006) |
| "Risperidone and olanzapine-administration data were collected for schizophrenia patients treated at four Taiwanese medical centres." | 7.72 | Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. ( Chiu, NY; Hsiao, MC; Liao, O; Liu, CY; Wu, CK; Yuan, LM, 2003) |
| "To report a case of risperidone-induced hyperprolactinemia that was successfully managed with quetiapine." | 7.72 | Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine. ( Kunwar, AR; Megna, JL, 2003) |
| "Outpatients diagnosed of schizophrenia according to DSM-IV criteria and receiving a single antipsychotic (risperidone, olanzapine, quetiapine or haloperidol) for at least 4 weeks were consecutively recruited." | 7.72 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. ( Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F, 2003) |
| "To examine both schizophrenia-related costs and total (schizophrenia plus non-schizophrenia) healthcare costs among Texas Medicaid recipients who had been diagnosed with a schizophrenic disorder and had been initiated on olanzapine or risperidone." | 7.72 | Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients. ( Barber, BL; Crismon, ML; Johnsrud, MT; Lage, MJ; Rascati, KL, 2003) |
| "The effect of mirtazapine on steady-state plasma concentrations of the newer atypical antipsychotics clozapine, risperidone and olanzapine was investigated in 24 patients with chronic schizophrenia." | 7.72 | Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. ( Canale, A; Crucitti, D; D'Arrigo, C; Malara, G; Muscatello, MR; Spina, E; Torre, DL; Zoccali, R, 2003) |
| "In a cross-sectional study, consecutive premenopausal, female, DSM-IV schizophrenia patients who were treated with either risperidone (N = 12) or olanzapine (N = 14) for at least 2 years were included." | 7.72 | Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. ( Becker, D; Liver, O; Mester, R; Rapoport, M; Weiss, M; Weizman, A, 2003) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 7.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "We report the case of a 44-year-old female patient with paranoid schizophrenia, who developed blepharospasm on risperidone treatment, but who was successfully rechallenged by risperidone without recurrence of blepharospasm." | 7.72 | Successful risperidone rechallenge after blepharospasm in a patient with schizophrenia: 24-month follow-up. ( Gulati, S; Libretto, SE; Singh, AN, 2003) |
| "To assess the impact of switching atypical antipsychotic treatment [from (i) risperidone to olanzapine or (ii) olanzapine to risperidone] on medication use patterns and treatment costs for individuals with schizophrenia." | 7.72 | Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database. ( Barber, BL; Breier, A; Loosbrock, DL; Namjoshi, M; Tunis, SL; Zhao, Z; Zhu, B, 2004) |
| "Nineteen male and female DSM-IV-defined schizophrenic patients who were clinical responders to risperidone but were suffering from symptomatic hyperprolactinemia were treated with cabergoline, 0." | 7.72 | Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. ( Angelone, SM; Cavallaro, R; Cocchi, F; Lattuada, E; Smeraldi, E, 2004) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 7.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "This study, based upon a database analysis, compares a one-year drug treatment course (duration of therapy, concomitant use of typical antipsychotics, anxiolytics/antidepressants or anti-Parkinsonians) and direct health care costs of uncontrolled schizophrenia patients initiated on olanzapine versus risperidone." | 7.72 | Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia. ( Zhao, Z, 2004) |
| "Treatment with olanzapine was associated with significantly greater weight gain than treatment with risperidone in Chinese schizophrenia patients in Hong Kong." | 7.72 | Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. ( Lee, E; Leung, CM; Wong, E, 2004) |
| "We report a case of rhabdomyolysis and acute compartment syndrome of the lower extremity in a schizophrenic patient taking risperidone following the addition of simvastatin to treat hyperlipidemia." | 7.72 | Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. ( Lightfoot, JD; Mahmud, W; Shekhar, A; Webber, MA, 2004) |
| "To evaluate the safety and tolerability of olanzapine in the treatment of elderly patients with schizophrenia." | 7.72 | Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study. ( Ciudad, A; Gómez, JC; Montes, JM; Olivares, JM, 2004) |
| "To investigate the disintegration profile, acceptability, and tolerability of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder." | 7.72 | Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. ( Binder, C; Chue, P; Welch, R, 2004) |
| "Olanzapine and risperidone use was associated with gaining weight in the first year, but only olanzapine was associated with developing diabetes mellitus." | 7.72 | Weight gain and new onset diabetes associated with olanzapine and risperidone. ( Farwell, WR; L'Italien, G; Stump, TE; Tafesse, E; Tierney, WM; Wang, J, 2004) |
| "The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia." | 7.71 | Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002) |
| "Response predictors of risperidone or other newer atypical antipsychotics for schizophrenia treatment remain unclear." | 7.71 | Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics. ( Chang, WH; Chang, YC; Chen, TT; Chiu, CC; Lane, HY; Lee, SH, 2002) |
| "The effect of fluoxetine on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was evaluated in 10 patients with schizophrenia or schizoaffective disorder." | 7.71 | Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. ( Ancione, M; Avenoso, A; Gatti, G; Madia, A; Perucca, E; Scordo, MG; Spina, E, 2002) |
| " The aim of the study was to compare the costs and outcomes of using risperidone versus classical neuroleptics in treatment of schizophrenia in order to see if there was any cost advantage in restricting use of more recent antipsychotics." | 7.71 | Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic. ( Bahbouh, R; Hosák, L, 2002) |
| "We report on the occurrence of galactorrhea and amenorrhea associated with prolactin elevation after 6 months of treatment with risperidone." | 7.71 | Risperidone induced galactorrhea: a case analysis. ( Hariharan, J; Mohsin, J, 2002) |
| "This study compared the discharge rates and drug costs of 789 patients with schizophrenia or schizoaffective disorder who began pharmacotherapy with olanzapine or risperidone between July 1997 and June 1998." | 7.71 | Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. ( Conley, RR; Kelly, DL; Love, RC; Nelson, MW; Yu, Y, 2001) |
| " In order to determine whether newer antipsychotic agents differ from each other with respect to weight gain, we compared two cohorts of patients with DSM-IV schizophrenia who had newly started treatment with either risperidone or olanzapine." | 7.71 | Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. ( Ayrton, Z; Brar, JS; Ganguli, R, 2001) |
| "To report a case of neuroleptic malignant syndrome (NMS) in a patient whose therapy was being switched from haloperidol to risperidone." | 7.71 | Neuroleptic malignant syndrome during a change from haloperidol to risperidone. ( Mack, JE; Reeves, RR; Torres, RA, 2001) |
| "The Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS) programme was an international series of naturalistic studies designed to evaluate drug use patterns and outcomes." | 7.71 | Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. ( Duchesne, I; Kasper, S; Rosillon, D, 2001) |
| "We report the health economic data from the Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS) programme." | 7.71 | Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. ( Duchesne, I; Jones, M; Kasper, S, 2001) |
| "To obtain an in vivo measurement of muscarinic receptor occupancy by olanzapine compared with risperidone in patients with schizophrenia stabilised on medication." | 7.71 | Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. ( Booij, J; Lavalaye, J; Linszen, DH; Reneman, L; van Royen, EA, 2001) |
| "To assess the clinical and cognitive effects of adding donepezil, a reversible acetylcholinesterase inhibitor, to the risperidone treatment of a high functioning stable out-patient with schizophrenia." | 7.71 | Donepezil in schizophrenia--is it helpful? An experimental design case study. ( Ehmann, TS; Khanbhai, I; MacEwan, GW; Wrixon, C, 2001) |
| "This retrospective study evaluates drug treatment patterns and economic outcomes of olanzapine in comparison with risperidone in the treatment of schizophrenia in usual practice." | 7.71 | A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. ( Zhao, Z, 2002) |
| "The aim of the present study is to determine the effect of the atypical antipsychotic drug, risperidone on sleep measures in patients with schizophrenia by polysomnography." | 7.71 | Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol. ( Horiguchi, J; Morinobu, S; Nagao, M; Yamashita, H; Yamawaki, S, 2002) |
| "The authors studied the efficacy of olanzapine and risperidone among patients with treatment-refractory schizophrenia who had been hospitalized for more than five years and who were not suitable candidates for a clozapine trial." | 7.71 | Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients. ( Bopp, JH; Daniels, A; Dinakar, HS; Mauro, S; Sobel, RN, 2002) |
| "The authors compared the changes in health care utilization and costs between a group of patients with schizophrenia who started treatment with risperidone and a group that started treatment with olanzapine." | 7.71 | Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. ( Durkin, MB; Fuller, MA; Laich, JS; Secic, M; Shermock, KM, 2002) |
| "An open-label, multicentre study was conducted to assess the long-term efficacy and safety of risperidone in patients with chronic schizophrenia." | 7.70 | Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. ( Addington, DE; Gagiano, CA; Gaussares, C; Möller, HJ; Torres-Plank, JF; Von Knorring, L, 1998) |
| " Six healthy volunteers, five clozapine- and five risperidone-treated subjects with DSM-IV schizophrenia were studied." | 7.70 | 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. ( Acton, PD; Busatto, GF; Costa, DC; Ell, PJ; Gacinovic, S; Kerwin, RW; Mertens, J; Mulligan, R; Pilowsky, LS; Terrière, D; Travis, MJ, 1998) |
| "Forty-four patients with schizophrenia (16 taking risperidone, 2-12 mg/day; 17 taking olanzapine, 5-60 mg/day; and 11 taking clozapine, 75-900 mg/day) had their D2 and 5-HT2 occupancies determined with the use of [11C]raclopride and [18F]setoperone, respectively, and positron emission tomography imaging." | 7.70 | Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. ( Kapur, S; Remington, G; Zipursky, RB, 1999) |
| "In this study, the benefits and costs of treating schizophrenia with either risperidone or clozapine were examined." | 7.70 | Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel. ( Ginsberg, G; Lev, B; Shani, S, 1998) |
| "Clozapine is the most widely used antipsychotic drug for the treatment of refractory schizophrenia." | 7.70 | Risperidone and clozapine combination for the treatment of refractory schizophrenia. ( Barreiro, P; Cano-Muñoz, JL; Morera, AL, 1999) |
| "Clozapine and risperidone were the first two antipsychotic drugs of a new class of agents for the pharmacotherapy of schizophrenia." | 7.70 | Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. ( Durst, R; Katz, G; Knobler, HY; Raskin, S; Zislin, Z, 2000) |
| "The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia." | 7.70 | Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D, 2000) |
| "Clozapine is effective in up to 60% of patients with refractory schizophrenia, whereas the efficacy of risperidone remains unknown." | 7.70 | Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. ( Ratakonda, SS; Raza, A; Sharif, ZA, 2000) |
| "To compare the costs of 2 atypical drug therapies (olanzapine and risperidone) with one another and with a conventional antipsychotic (haloperidol) in the treatment of schizophrenia." | 7.70 | Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. ( Almond, S; O'Donnell, O, 2000) |
| "To study the therapeutic effect, side effects and cognize improvement of Risperidone in treating different TCM Syndrome-types of first-episode schizophrenia." | 7.70 | [Comparison between therapeutic effect of Risperidone in treating different traditional Chinese medicine syndrome types of first-episode schizophrenia]. ( Cao, X; Wang, W, 2000) |
| "After 9 days of risperidone therapy (2-6 mg/day), a 24-year-old schizophrenic female patient developed a leucopenia with neutropenia < 1000/mm3." | 7.69 | Reversible neutropenia during a cold: possible involvement of risperidone? A case report. ( Aubert, AC; Baumann, P; Bondolfi, G; Meylan, C, 1995) |
| "Patients displaying a moderate-to-marked response to risperidone were more likely to be younger; receive diagnoses of bipolar disorder or schizoaffective disorder, depressive type; and have a shorter duration of illness and shorter length of stay prior to risperidone treatment." | 7.69 | Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. ( Balistreri, TM; DePriest, M; Holtman, HM; Keck, PE; Kizer, DL; McElroy, SL; Strakowski, SM; Wilson, DR, 1995) |
| "The role of risperidone in the management of treatment-resistant schizophrenia remains unclear." | 7.69 | The use of risperidone in treatment-resistant schizophrenia: two case reports. ( Gledhill, JA; Wakeling, A; Warner, JP, 1996) |
| "To determine whether or not risperidone is efficacious in treating self-induced water intoxication in patients with chronic schizophrenia." | 7.69 | Self-induced water intoxication treated with risperidone. ( Emes, CE; Glackman, WG; Millson, RC, 1996) |
| "A prospective, open-label study in a 400-bed state psychiatric hospital evaluated change in therapeutic response among ten patients with treatment-resistant schizophrenia who were switched from clozapine to risperidone." | 7.69 | Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. ( Crismon, ML; Dorson, PG; Pousson, C; Still, DJ, 1996) |
| "Risperidone is a newly available atypical antipsychotic agent that has been reported to be associated with fewer extrapyramidal side effects (EPS) than conventional neuroleptics in adults with schizophrenia." | 7.69 | Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. ( Findling, RL; Friedman, L; Grcevich, SJ; Rowane, WA; Schulz, SC, 1996) |
| " We hypothesized that a low dose of risperidone in combination with sertraline would reduce serious adverse effects without decreasing treatment response." | 7.30 | Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study. ( Lang, X; Wu, F; Xiu, M; Xue, M; Zang, X; Zhang, X, 2023) |
| " Most frequently reported treatment-related adverse events (ie, ≥5% of patients in either TV-46000 group) that occurred more often in patients receiving TV-46000 (once monthly or once every 2 months) versus placebo were injection site nodules (7% for TV-46000 once monthly, 7% for TV-46000 once every 2 months, 3% for placebo), weight increased (4%, 6%, 2%, respectively), and extrapyramidal disorder (5%, 3%, 0% respectively)." | 7.30 | Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. ( Correll, CU; Davis, GL; Eshet, R; Franzenburg, KR; Harary, E; Kane, JM; Leucht, S; Merenlender-Wagner, A; Sharon, N; Suett, M; Tohami, O; Weiser, M, 2023) |
| "With the second-generation antipsychotics (SGAs) widely applied to treat patients with schizophrenia, adverse effects, especially the metabolic syndrome (MetS), were paid more attention following by the efficacy of SGAs." | 6.90 | Efficacy and safety of electroacupuncture on metabolic syndrome due to olanzapine and risperidone: Study protocol for a randomized controlled pilot trial. ( Chen, P; Jia, H; Ning, Y; Yin, D; Zhu, H, 2019) |
| " Overall, 63 (94%) patients experienced at least one treatment-emergent adverse event (TEAE)." | 6.87 | A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. ( Anta, L; Ayani, I; Gutierro, I; Litman, RE; Llaudó, J; Martínez, J, 2018) |
| "Aripiprazole treatment decreased activation of the middle frontal, superior frontal and occipital gyrus (ToL) and medial temporal and inferior frontal gyrus, putamen and cuneus (WoF), while activation increased after risperidone." | 6.84 | Effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia: A single-blind randomized exploratory study. ( Aleman, A; Knegtering, H; Liemburg, EJ; van Es, F, 2017) |
| "Risperidone ISM was generally well tolerated and the most frequently reported adverse events were similar to those observed with other risperidone formulations." | 6.82 | Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review. ( Álamo, C, 2022) |
| "Patients with schizophrenia or schizoaffective disorder participated in the 2-year, randomized, multicentre, open-label, ophthalmologist-masked, flexible-dose, parallel-group study." | 6.80 | Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. ( Baldycheva, I; Earley, W; Flach, AJ; Laties, AM; Pathak, S; Rak, I, 2015) |
| " However, the ideal dosing regimen for this purpose is unknown." | 6.80 | Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. ( Bian, QT; Chen, JX; Correll, C; Liu, YH; Soares, JC; Su, YA; Wang, SL; Wei, LH; Yang, FD; Zhang, RZ; Zhang, XY, 2015) |
| "Aripiprazole-treated participants had better negative symptom outcomes but experienced more akathisia." | 6.80 | A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. ( Addington, J; Bennett, N; Braga, RJ; Correll, CU; Gallego, JA; Greenberg, J; Hassoun, Y; John, M; Kane, JM; Kellner, CH; Lencz, T; Lopez, L; Malhotra, AK; Naraine, M; Petrides, G; Robinson, DG; Sevy, SM; Tohen, M; Zhang, JP, 2015) |
| "Whether treating schizophrenia with risperidone plus add-on DM is more effective than risperidone (RISP) alone, and the association between the ALDH2 polymorphism and treatment response were investigated." | 6.80 | ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan. ( Chang, YH; Chen, KC; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, TY; Yang, YK, 2015) |
| " In the USA, dosing tends to be expressed in mg] or oral risperidone [during initiation of risperidone long-acting injection (RLAI) days 1-28] and biweekly flexible-dose RLAI (n=173; initial injection day 8)." | 6.79 | Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. ( Alphs, L; Bossie, CA; Fu, DJ; Ma, YW; Sliwa, JK, 2014) |
| "Perphenazine was noninferior to all three SGAs during 18 months of intention-to-treat analysis and in several subanalyses." | 6.79 | Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. ( Lin, H; Rosenheck, R, 2014) |
| " However, a higher dosage of risperidone was used for treating the disorder in those taking concomitant lovastatin compared to placebo." | 6.79 | Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial. ( Akhondzadeh, S; Berk, M; Dehbozorgi, S; Ghanizadeh, A; Rezaee, Z, 2014) |
| " Patients with the AQP-4 non-C polymorphism needed a higher dosage of olanzapine for treatment (z = 4." | 6.77 | Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia. ( Chung, TS; Lung, FW, 2012) |
| " The aim of the present study was to analyze on a single case basis the relationship between a sudden increase in suicidality, anxiety symptoms, medication dosing and clinician- and patient-rated akathisia." | 6.77 | The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. ( Bauer, M; Doucette, S; Lewitzka, U; Meyer, S; Möller, HJ; Musil, R; Riedel, M; Schennach, R; Seemüller, F, 2012) |
| "Schizophrenia is a chronic mental health disorder associated with increased hospital admissions and excessive utilization of outpatient services and long-term care." | 6.76 | Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE). ( Crivera, C; DeSouza, C; Dirani, RD; Kozma, CM; Macfadden, W; Mao, L, 2011) |
| "Risperidone is a second generation antipsychotic agent, with potent serotonin 5-HT2A and dopamine D2 receptor blocking effects." | 6.76 | Risperidone in the treatment of schizophrenia. ( Bravo-Mehmedbasic, A, 2011) |
| "Schizophrenia is a chronic disorder that is usually characterized by relapses alternating with periods of full or partial remission." | 6.75 | Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection. ( Choi, TK; Kim, B; Kim, YW; Lee, E; Lee, SH; Suh, S; Yook, KH, 2010) |
| " Sixty-nine per cent of patients completed the trial; 8% discontinued due to adverse events (AEs)." | 6.75 | Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. ( Curtis, V; Hawley, C; Latif, MA; Saleem, PT; Turner, M; Wilton, K, 2010) |
| "Sertindole did not increase all-cause mortality, but cardiac mortality was higher and suicide attempts may be lower with sertindole." | 6.75 | Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). ( Crocq, MA; Drici, MD; Everitt, B; Hall, GC; Lader, MH; Le Jeunne, C; Mann, RD; Mittoux, A; Moore, ND; Naber, D; Peuskens, J; Priori, S; Sturkenboom, M; Tanghøj, P; Thibaut, F; Thomas, SH; Toumi, M, 2010) |
| "Chronic management of schizophrenia and schizoaffective disorders is frequently complicated by symptomatic relapse." | 6.75 | Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. ( Bergmans, P; Cordes, J; de Arce, R; Eriksson, L; Gaebel, W; Rouillon, F; Schreiner, A; Smeraldi, E, 2010) |
| "Hyperprolactinemia is an important but neglected adverse effect of antipsychotic medication." | 6.73 | Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. ( Chen, CH; Lu, ML; Shen, WW, 2008) |
| "Obesity is highly prevalent among patients treated with atypical antipsychotics for schizophrenia." | 6.73 | Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2007) |
| "Propentofylline is a novel xantine derivative which is being developed for treatment of degenerative and vascular dementia." | 6.73 | A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. ( Abbasi, SH; Ahmadi-Abhari, SA; Akhondzadeh, S; Derakhshan, MK; Fotouhi, A; Ghoreishi, A; Hajiazim, M; Khodaie-Ardakani, MR; Mohammadi, MR; Noorbala, AA; Salimi, S, 2008) |
| "Risperidone was hypothesized to have better extrapyramidal tolerability and efficacy in treating negative symptoms." | 6.73 | Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Braus, DF; Buchkremer, G; Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klosterkötter, J; Kühn, KU; Maier, W; Möller, HJ; Ohmann, C; Riedel, M; Riesbeck, M; Schlösser, R; Schneider, F; Wickelmaier, F, 2008) |
| "Hyperprolactinemia is a common adverse effect that occurs as a result of antipsychotic therapies, which often results in discontinuation." | 6.73 | A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. ( Feng, XJ; Liu, RM; Sze, CW; Tan, QR; Tong, Y; Wang, CY; Yuan, HN; Zhang, JZ; Zhang, YB; Zhang, ZJ, 2008) |
| "Haloperidol-treated patients improved only on domains of learning/memory." | 6.72 | One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. ( Breier, A; Gold, JM; Keefe, RS; Purdon, SE; Rock, SL; Young, CA, 2006) |
| " Ninety-four outpatients who had been on a stable drug dosage were evaluated (clozapine group: n=57, mean dose=254." | 6.72 | Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia. ( Ahn, YM; Kim, JH; Kim, SY; Kim, YS, 2006) |
| "Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression." | 6.72 | Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. ( Borisov, A; Feldman, J; May, R; Miller, AH; Nemeroff, CB; Rosenberg, J; Savage, R; Tucker, M; Wang, X; Woolwine, B, 2006) |
| "Treatment with olanzapine resulted in a greater numerical improvement than risperidone in all SFS domains and reached statistical significance in such categories as social engagement or withdrawal (p = 0." | 6.72 | Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial. ( Alvarez, E; Bousoño, M; Ciudad, A; Gómez, JC; Olivares, JM, 2006) |
| "Risperidone treatment did not change P3 amplitudes and latencies." | 6.72 | Effects of risperidone on auditory information processing in neuroleptic-naive patients with schizophrenia spectrum disorders. ( Dapsys, K; Kähkönen, S; Korostenskaja, M; Maciulis, V; Ruksenas, O; Siurkute, A, 2006) |
| " Treatment with divalproex in combination with an atypical antipsychotic agent resulted in earlier improvements in a range of psychotic symptoms among acutely hospitalized patients with schizophrenia." | 6.71 | Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. ( Casey, DE; Daniel, DG; Sommerville, KW; Tracy, KA; Wassef, AA; Wozniak, P, 2003) |
| "Risperidone treatment significantly decreased the initially high blood SOD levels in schizophrenia." | 6.71 | The effect of risperidone treatment on superoxide dismutase in schizophrenia. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2003) |
| "Olanzapine-treated patients showed a significantly greater reduction in Positive and Negative Syndrome Scale (PANSS) total, Brief Psychiatric Rating Scale (BPRS) total, and PANSS General Psychopathology scores at endpoint compared to the risperidone-treated patients." | 6.71 | Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. ( Andersen, S; Catts, S; Crawford, AM; Fraser, A; Grainger, D; Gureje, O; Hustig, H; Keks, N; Lambert, T; McGrath, J; Miles, W; Tran, P, 2003) |
| "Weight gain is an important side effect of antipsychotic (AP) treatment." | 6.71 | The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. ( de Castella, AR; Fitzgerald, PB; Kulkarni, J; Morris, MJ; Scaffidi, A, 2003) |
| "Sarcosine treatment can benefit schizophrenic patients treated by antipsychotics including risperidone." | 6.71 | Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. ( Chong, MY; Lane, HY; Lange, N; Tsai, G; Yang, P, 2004) |
| " Patients were initiated with quetiapine to 400 mg/day over 7 days, and then flexibly dosed (300-750 mg/day) for 11 weeks." | 6.71 | Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. ( Altman, C; de Nayer, A; Jones, AM; Larmo, I; Lindenbauer, B; Platz, T; Rittmannsberger, H; Windhager, E, 2005) |
| "Risperidone was immediately effective against positive and negative symptoms in untreated patients; however, in the previously treated groups, it was initially effective against negative symptoms only; after a 2-week interval, positive symptoms also improved." | 6.71 | Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects. ( Himei, A; Okamura, T, 2005) |
| " In this pilot study, 10 Hispanic and 8 non-Hispanic patients with schizophrenia were enrolled in a double-blind, parallel-group, inpatient risperidone dosing (daily versus twice daily) trial with the novel antipsychotic risperidone." | 6.70 | Risperidone in the treatment of Hispanic inpatients with schizophrenia: a pilot study. ( Collazo, Y; Frackiewicz, EJ; Herrera, JM; Lawson, WB; Sramek, JJ, 2002) |
| "Evaluation of relationships between serum antipsychotic drug concentrations and clinical response may provide valuable information for rational dosage adjustments." | 6.70 | Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. ( Ancione, M; Avenoso, A; Facciolà, G; Madia, AG; Perucca, E; Salemi, M; Scordo, MG; Spina, E, 2001) |
| " This study examined the effect of electroconvulsive therapy (ECT) in combination with risperidone in an open trial in 10 male schizophrenic patients with significant aggressive behaviors." | 6.70 | Effectiveness of ECT combined with risperidone against aggression in schizophrenia. ( Ashby, CR; Hirose, S; Mills, MJ, 2001) |
| "Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate." | 6.70 | Guanfacine treatment of cognitive impairment in schizophrenia. ( Adler, DN; Davis, KL; Friedman, JI; Harvey, PD; Kemether, E; Parrella, M; Temporini, HD; White, L, 2001) |
| "Treatment on risperidone also resulted in significant reduction in the PANSS score." | 6.70 | The effect of risperidone on cognitive functioning in a sample of Asian patients with schizophrenia in Singapore. ( Chan, YH; Chong, SA; Chua, L; Ng, VP; Pang, E, 2001) |
| "Risperidone appears to be a more effective and better tolerated antipsychotic drug in treatment-refractory Chinese schizophrenia than haloperidol." | 6.70 | Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| " Doses were adjusted to maximize efficacy and to minimize adverse events." | 6.70 | A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. ( Jibson, MD; Mullen, J; Sweitzer, D, 2001) |
| "Treatment with risperidone was associated with improvement in antisaccade errors." | 6.70 | Improved antisaccade performance with risperidone in schizophrenia. ( Burke, JG; Reveley, MA, 2002) |
| "Risperidone treatment significantly increased the serum PRL levels of schizophrenic patients." | 6.70 | Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. ( Shen, YC; Wu, GY; Yuan, CL; Zhang, PY; Zhang, XY; Zhou, DF, 2002) |
| " Gradual dosage titration over the first 3 days of treatment was well-tolerated in both groups." | 6.69 | Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. ( Nair, NP, 1998) |
| "Risperidone treatment produced a greater effect on patients' ability to perceive emotion compared with haloperidol treatment." | 6.69 | Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. ( Green, MF; Kee, KS; Kern, RS; Marshall, BD, 1998) |
| "Risperidone treatment was associated with a significant functional in-vivo 5-HT antagonism similar to clozapine." | 6.69 | Risperidone is associated with blunting of D-fenfluramine evoked serotonergic responses in schizophrenia. ( Curtis, VA; Jones, H; Lucey, JV; Wright, PA, 1998) |
| "Risperidone-treated subjects with a greater degree of acute mood change were both 3." | 6.69 | The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. ( Andersen, SW; Tollefson, GD; Tran, PV, 1999) |
| "Risperidone treatment had a greater beneficial effect on verbal working memory than haloperidol treatment across testing conditions (with and without distraction) and study phases (fixed and flexible dose)." | 6.68 | Does risperidone improve verbal working memory in treatment-resistant schizophrenia? ( Ames, D; Green, MF; Kern, RS; Marder, SR; Marshall, BD; McGurk, S; Mintz, J; Wirshing, WC, 1997) |
| "Risperidone 6 mg was the lowest dose that produced substantial change in negative symptoms and no increase in extrapyramidal symptoms and antiparkinsonian medication use." | 6.67 | Negative symptoms in schizophrenia: assessment of the effect of risperidone. ( Schooler, NR, 1994) |
| "Risperidone treatment was statistically superior to placebo, with a trend toward superiority to haloperidol." | 6.67 | Risperidone: clinical safety and efficacy in schizophrenia. ( Borison, RL; Diamond, BI; Meibach, RC; Pathiraja, AP, 1992) |
| "Cariprazine, is an emerging antipsychotic drug, D3/D2 receptor partial agonist, with affinity to several serotonin receptors." | 6.58 | Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia. ( Bieńkowski, P; Misiak, B; Samochowiec, J, 2018) |
| "Schizophrenia is a severe disorder that significantly affects the quality of life and total functioning of patients and their caregivers." | 6.50 | Individualizing clozapine and risperidone treatment for schizophrenia patients. ( Assimakopoulos, K; Bartsakoulia, M; Iconomou, G; Mitropoulos, K; Papadima, EM; Patrinos, GP; Squassina, A; Tsermpini, EE, 2014) |
| "Aripiprazole treatment led to significantly more akathisia incidence in the AD group, compared with the SCZ group." | 6.48 | Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. ( Moteshafi, H; Stip, E, 2012) |
| "Risperidone was specifically evaluated in patients with RS in one of the systematic reviews included, with favorable outcomes, but without definitive superiority compared with other drugs of proven efficacy, like amisulpride, clozapine and olanzapine." | 6.46 | Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. ( Atallah, AN; Melnik, T; Puga, ME; Soares, BG, 2010) |
| "Schizophrenia is a severe and devastating psychiatric disorder affecting about 1 percent of the world's population, is characterized by psychotic episodes, negative symptoms and cognitive deficits." | 6.43 | [Maintenance pharmacotherapy of schizophrenia: remission and the effectiveness of long-acting risperidone therapy]. ( Sárosi, A, 2006) |
| " This series covers four main areas of concern when treating the elderly: low-maintenance dosing minimising the likelihood of adverse events; successful treatment of patients previously uncontrolled and experiencing side effects with other antipsychotics; the possibility of intermittent rather than continuous treatment; and the benefits to patients, carers and the health services." | 6.41 | Risperidone in the treatment of psychoses in the elderly: a case report series. ( Bullock, R; Libretto, S, 2002) |
| " Proper dosing has emerged as a vital factor in the effective use of these newer drugs." | 6.40 | Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. ( Kasper, S, 1998) |
| " At a dosage of 4 to 8 mg/day, risperidone is comparable to 10 mg/day of haloperidol." | 6.39 | A risk-benefit assessment of risperidone in schizophrenia. ( Curtis, VA; Kerwin, RW, 1995) |
| " The proportion of patients failing to reach at least 20% improvement on the positive and negative syndrome scale (PANSS) or brief psychiatric rating scale (BPRS), the proportion of patients discontinuing treatment because of adverse effects and the number of patients who needed antiparkinsonian medication were abstracted for use as outcome measures." | 6.39 | Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. ( Bacaltchuk, J; de Castro-e-Silva, E; de Oliveira, IR; de Sena, EP; Miranda-Scippa, AM; Pereira, EL; Ribeiro, MG, 1996) |
| "Patients with schizophrenia were randomized to monotherapy with risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, perphenazine or haloperidol in a 6-week pharmacological trial." | 6.23 | The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia. ( Chen, Q; Coid, J; Deng, W; Guo, W; Li, K; Li, L; Li, T; Lu, T; Lv, L; Ma, X; Tan, L; Tan, Q; Tao, S; Wang, C; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L, 2024) |
| "In a 6-week trial between December 2000 and January 2002, 1713 patients with DSM-IV schizophrenia and related psychoses were treated with risperidone, with the dose, daily changes in dose, and weekly changes in Brief Psychiatric Rating Scale score documented." | 6.21 | Risperidone dosing pattern and clinical outcome in psychosis: an analysis of 1713 cases. ( Choi, SK; Hong, JP; Joo, YH; Kim, CY; Lee, GH; Shin, YW, 2005) |
| "We conducted a post hoc analysis of an international, multicenter, double-blind, 28-week study of 339 patients who met DSM-IV criteria for schizophrenia, schizophreniform, or schizoaffective disorder and were randomized to treatment with either olanzapine or risperidone." | 6.19 | Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? ( Andersen, SW; Tollefson, GD, 1999) |
| "Risperidone has antiserotonergic and antidopaminergic properties that may make it more effective than conventional antipsychotic agents in the treatment of the negative symptoms of schizophrenia." | 6.17 | Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. ( Carman, J; Peuskens, J; Vangeneugden, A, 1995) |
| "Schizophrenia is a life disabling, multisystem neuropsychiatric disease mostly derived from complex epigenetic-mediated neurobiological changes causing behavioural deficits." | 5.91 | Reversal and Preventive Pleiotropic Mechanisms Involved in the Antipsychotic-Like Effect of Taurine, an Essential β-Amino Acid in Ketamine-Induced Experimental Schizophrenia in Mice. ( Agu, GO; Ajayi, AM; Akaenyi, DE; Ben-Azu, B; Chijioke, BS; Chilaka, KC; Edigbue, NL; Esiekpe, UV; Jarikre, TA; Nwangwa, KE; Ofili, EC; Omonyeme, MG; Ozege, CB; Uruaka, CI; Warekoromor, EB, 2023) |
| "The most common way to treat schizophrenia is antipsychotic medication." | 5.91 | Risperidone response in patients with schizophrenia drives DNA methylation changes in immune and neuronal systems. ( Alladi, CG; Bacq-Daian, D; Bélivier, F; Boland-Auge, A; Deleuze, JF; Jamain, S; Latapie, V; Lokmer, A; Marie-Claire, C; RajKumar, RP; Shewade, DG; Troudet, R, 2023) |
| " However, the effects of the low frequency of rTMS combined with antipsychotics on the gut microbiome in chronic SCH have been poorly investigated." | 5.91 | Effects of low-frequency rTMS combined with risperidone on the gut microbiome in hospitalized patients with chronic schizophrenia. ( Bai, J; Chen, YH; Cui, ZQ; Fu, R; Guo, L; Li, R; Peng, ZW; Tan, QR; Yang, JB, 2023) |
| "Schizophrenia is a disorder characterized by cognitive impairment and psychotic symptoms that fluctuate over time and can only be mitigated with the chronic administration of antipsychotics." | 5.72 | Long-lasting rescue of schizophrenia-relevant cognitive impairments via risperidone-loaded microPlates. ( Bellotti, E; Contarini, G; Decuzzi, P; Drago, F; Geraci, F; Leggio, GM; Papaleo, F; Piazza, C; Torrisi, SA, 2022) |
| "The aim of this study was to explore the effectiveness and safety of pentoxifylline as an adjuvant to risperidone in mitigating the negative symptoms in patients with chronic schizophrenia." | 5.69 | Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial. ( Abdallah, MS; El-Berri, EI; Hassan, A; Mosalam, EM; Omara-Reda, H; Ramadan, AN; Samman, WA; Zidan, AA, 2023) |
| "A total of 3010 patients with schizophrenia enrolled in a randomized controlled trial (RCT) and received a 6-week treatment with one antipsychotic drug randomly chosen from five atypical antipsychotics (risperidone 2-6 mg/d, olanzapine 5-20 mg/d, quetiapine 400-750 mg/d, aripiprazole 10-30 mg/d, and ziprasidone 80-160 mg/d) and two typical antipsychotics (perphenazine 20-60 mg/d and haloperidol 6-20 mg/d)." | 5.69 | Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial. ( Chen, Q; Deng, W; Du, X; Hao, Q; Hu, X; Li, C; Li, K; Li, L; Li, T; Li, X; Lu, T; Lv, L; Ma, X; Ren, H; Tan, L; Tan, Q; Tang, Y; Wang, C; Wang, L; Wang, Q; Wang, Y; Wu, Y; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, G; Zhang, H; Zhang, Y; Zhao, L, 2023) |
| "Eighty chronic schizophrenia inpatients were equally assigned to receive risperidone (6 mg/day) plus either L-theanine (400 mg/day) or matched placebo in this 8-week, randomized, parallel-group, double-blind, placebo-controlled trial." | 5.69 | L-Theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial. ( A Basti, F; Akhondzadeh, S; Fallahpour, B; Fattollahzadeh-Noor, S; Khodaei Ardakani, MR; Shamabadi, A, 2023) |
| "Rhabdomyolysis is defined by disintegration of skeletal muscle fibres." | 5.62 | [Rhabdomyolysis induced by paliperidone palmitate]. ( Klein, B; Silberbauer, C, 2021) |
| "These results suggest that the antioxidant defense system may have predictive value for the weight gain of ANFE SCZ patients after risperidone treatment." | 5.51 | Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study. ( Gao, Y; Guan, X; Li, X; Liu, H; Thomas, K; Xiu, M; Yu, R; Zhang, X, 2022) |
| "To evaluate long-term efficacy, safety and tolerability of Risperidone ISM® in patients with schizophrenia, a multicenter, open-label extension of the PRISMA-3 study was conducted." | 5.51 | Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. ( Anta, L; Correll, CU; Filts, Y; Litman, RE; Martínez, J; Naber, D, 2022) |
| "This 8-week (trial timepoints: baseline, week 4, week 8), double-blind, placebo-controlled clinical trial randomized patients with schizophrenia in a 1:1 ratio to compare the efficacy and safety of 600 mg twice a day of PEA and matched placebo alongside a stable dose of risperidone." | 5.51 | Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. ( Akhondzadeh, S; Bagheri, S; Khodaei Ardakani, MR; Moradi, K; Namaei, P; Salehi, A; TaghaviZanjani, F, 2022) |
| "We completed a 12-month randomized controlled trial of cognitive remediation and of long-acting injectable (LAI) risperidone with 60 patients with a recent first episode of schizophrenia." | 5.51 | A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning. ( Bell, MD; Boucher, ML; Casaus, LR; Gretchen-Doorly, D; Hayata, JN; Luo, J; Medalia, A; Nuechterlein, KH; Subotnik, KL; Turner, LR; Ventura, J, 2022) |
| "In the antipsychotic treatment of schizophrenia with little medication history, especially in drug-naïve cases, predictors of side effects are important." | 5.51 | Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. ( Sakamoto, S; Sato, K; So, R; Tsukahara, M; Yoshimura, B; Yoshimura, Y, 2019) |
| "Cariprazine is a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, recently approved by the FDA for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder." | 5.43 | Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. ( Adham, N; Ferguson, P; Grayson, B; Gyertyán, I; Kiss, B; Neill, JC, 2016) |
| "Risperidone is a second-generation antipsychotic agent commonly used in the treatment of ~ 31." | 5.43 | Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling of risperidone and its active metabolite in Chinese schizophrenia patients. ( Deng, C; Ji, S; Li, A; Li, L; Li, X; Lu, W; Shang, D; Wang, C; Wu, K; Zhou, T, 2016) |
| "Treatment with risperidone normalized topological parameters in the limbic system, and the enhancement positively correlated with the reduction in PANSS-positive symptoms." | 5.43 | Risperidone-induced topological alterations of anatomical brain network in first-episode drug-naive schizophrenia patients: a longitudinal diffusion tensor imaging study. ( Chen, H; Chen, X; He, Y; Hu, M; Li, Y; Li, Z; Liao, Y; Lv, L; Mann, JJ; Pantazatos, SP; Sang, D; Tang, J; Zhao, H; Zheng, J; Zhou, J; Zong, X, 2016) |
| "He was diagnosed with Meige syndrome." | 5.43 | Marked Improvement of Meige Syndrome in a Japanese Male Patient with Schizophrenia After Switching from Risperidone to Paliperidone: A Case Report. ( Atake, K; Hori, H; Katsuki, A; Yoshimura, R, 2016) |
| "Risperidone has been significant correlated with a direct effect of interleukin-6 (IL-6) levels in patients with schizophrenia." | 5.41 | Effect of risperidone on serum IL-6 levels in individuals with schizophrenia: a systematic review and meta-analysis. ( Castillo-Avila, RG; Genis-Mendoza, AD; González-Castro, TB; Juárez-Rojop, IE; López-Narváez, ML; Martínez-Magaña, JJ; Ramos-Méndez, MA; Tovilla-Zárate, CA; Villar-Juárez, GE; Villar-Soto, M, 2023) |
| "We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of blonanserin and risperidone for the treatment of schizophrenia and to provide reliable pharmacotherapeutic evidence for in the clinical treatment of schizophrenia." | 5.41 | Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. ( Deng, SW; Hong, B; Jiang, WL; Li, BH; Sun, DW; Xu, Q; Yang, HB, 2023) |
| "Risperidone (RIS) is a frequently used efficacious psychotropic drug." | 5.40 | Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia. ( Fukui, N; Inoue, Y; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J, 2014) |
| "Schizophrenia is one of the most expensive psychiatric illnesses." | 5.39 | Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations. ( Chow, DP; Chung, WS; Lee, EH; Lee, KK; Lee, VW; Wong, MC; Wu, DB, 2013) |
| " In the current study, the effect of clozapine (n = 27, mean dosage 350 mg), risperidone (n = 54, mean dosage 3." | 5.38 | Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. ( Beduin, AS; Bruggeman, R; Cahn, W; de Haan, L; Dekker, N; Kahn, RS; Krabbendam, L; Linszen, DH; Machielsen, M; Myin-Germeys, I; van Os, J; Wiersma, D, 2012) |
| "Schizophrenia is a chronic and highly complex psychiatric disorder characterised by cognitive dysfunctions, negative and positive symptoms." | 5.38 | Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. ( Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA, 2012) |
| "Schizophrenia is an extremely costly disease for families and society owing to the age of onset, chronicity and severity of impact in social, academic and vocational domains." | 5.38 | The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. ( Chue, J; Chue, P, 2012) |
| " Chronic administration of RPD or HPD had no significant effect on (13)C-PBT indices in rats." | 5.38 | 13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients. ( Chiba, S; Hattori, K; Higuchi, T; Hori, H; Iijima, Y; Kajiwara, M; Kawamoto, Y; Kinoshita, Y; Kunugi, H; Matsuo, J; Ota, M; Ozeki, Y; Sasayama, D; Tanaka, H; Terada, S; Teraishi, T; Yamamoto, N, 2012) |
| "Schizophrenia is a disorder of a neurodevelopmental origin manifested symptomatically after puberty." | 5.37 | Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. ( Arad, M; Piontkewitz, Y; Weiner, I, 2011) |
| "Risperidone treatment induced a decrement of plasma DA levels and increments of plasma DOPAC and DA TR in the total group of schizophrenic patients." | 5.37 | Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment. ( Cai, HL; Fang, PF; Hu, L; Li, HD; Yang, W; Ye, HS; Zhang, XH, 2011) |
| " The dosage range of paliperidone ER (6-12 mg/day) was compared with 2 risperidone dosage ranges: 2-4 and 4-6 mg/day." | 5.37 | Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. ( Bossie, CA; Canuso, CM; Lindenmayer, JP; Schooler, N; Turkoz, I, 2011) |
| "Risperidone is a widely used atypical antipsychotic agent that produces considerable interindividual differences in patient response." | 5.36 | Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. ( Feng, G; Gao, R; He, L; Li, S; Lin, Z; St Clair, D; Xing, Q; Xu, M, 2010) |
| " Plasma samples were collected before the medications were given and 12h after the bedtime dosing each week." | 5.36 | Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. ( Furukori, H; Kaneko, S; Nakagami, T; Saito, M; Sato, Y; Sugawara, N; Tsuchimine, S; Yasui-Furukori, N, 2010) |
| " Safety was evaluated by recording treatment-emergent adverse events (AE)." | 5.36 | Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. ( Don, L; Kouniakis, F; Parellada, E; Schreiner, A; Siurkute, A, 2010) |
| "Risperidone release was assessed in vitro and in vivo in rats, and Level A, B and C correlations (IVIVCs) attempted for all." | 5.36 | In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. ( Amann, LC; Gandal, MJ; Liang, Y; Lin, R; Siegel, SJ, 2010) |
| " A population pharmacokinetic modeling approach was used to estimate the interindividual variability of the pharmacokinetic parameters in 50 hospitalized patients with acute episode of schizophrenia." | 5.36 | A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. ( Dolzan, V; Grabnar, I; Kastelic, M; Koprivsek, J; Kores-Plesnicar, B; Locatelli, I; Mrhar, A, 2010) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 5.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| "Risperidone-treated participants exhibited lower movement velocities during production of simple loops compared to unmedicated patients." | 5.35 | Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. ( Caligiuri, MP; Dean, CE; Lohr, J; Niculescu, AB; Teulings, HL, 2009) |
| "Patients with an acute episode of schizophrenia (n=11) and predominating positive symptoms were randomized to a 6-week add-on treatment with memantine (10 mg twice a day) versus placebo and patients with chronic schizophrenia (n=13) and negative symptoms were randomized to a 24-week add-on treatment with memantine (10 mg twice a day) versus placebo." | 5.34 | Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
| "To report the efficacy and safety of blonanserin in patients with schizophrenia compared with risperidone in a Japanese multicenter, randomized, double-blind study based on post hoc sensitivity analysis in addition to the previous results reported by Miura and discuss the current approaches for schizophrenia treatment." | 5.34 | Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study. ( Harvey, PD; Miura, S; Nakamura, H, 2020) |
| "Hospitalized schizophrenia patients aged 18-65 were randomized to 6 weeks of double-blind, double-dummy, flexible-dose treatment with lurasidone (40 or 80 mg/day) or risperidone (2, 4 or 6 mg/day)." | 5.34 | Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia. ( Deng, W; Feng, Y; Li, K; Li, L; Liu, Q; Liu, X; Luo, X; Ning, Y; Shi, J; Tan, Y; Wang, G; Wang, L; Wang, X; Xie, S; Xu, X; Zhang, X; Zhao, J, 2020) |
| "This study examined randomized controlled trial data for blonanserin and risperidone in Chinese schizophrenia patients (N = 264)." | 5.34 | Model-based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double-blind study. ( Lei, L; Li, H; Li, Y; Shen, Y; Yu, W; Yu, Y, 2020) |
| "This was an eight-week randomised, double-blind, placebo-controlled, parallel-group clinical trial, in which 78 inpatients with chronic schizophrenia were stabilised with risperidone (4-6 mg/day) for two months before being assigned to adjunctive vortioxetine (10 mg b." | 5.34 | Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. ( Akhondzadeh, S; Bayanati, S; Mesgarpour, B; Moazen-Zadeh, E; Rezaei, F; Ziafat, K, 2020) |
| "The present study explored an efficient new therapy that combined repetitive transcranial magnetic stimulation (rTMS) and family intervention in addition to risperidone to improve schizophrenia." | 5.34 | A synergistic effect between family intervention and rTMS improves cognitive and negative symptoms in schizophrenia: A randomized controlled trial. ( Huang, XF; Kang, Y; Li, X; Liu, Y; Lv, L; Pang, L; Song, X; Yuan, X; Zhu, Q, 2020) |
| "In a randomized, double-blind, and placebo-controlled setting, schizophrenia patients were assigned to receive either 200 mg/d resveratrol or matched placebo in addition to a stable dose of risperidone for 8 weeks." | 5.34 | Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial. ( Akhondzadeh, S; Alikhani, R; Ashraf-Ganjouei, A; Bagheri, S; Moradi, K; Mousavi, SB; Rezaei, F; Samaei, A, 2020) |
| "Diagnosed with diabetic ketoacidosis, he was given insulin and saline with discontinuation of all antipsychotics." | 5.34 | New-onset diabetic ketoacidosis induced by the addition of perospirone hydrochloride in a patient treated with risperidone. ( Hamanaka, S; Kamijo, Y, 2007) |
| "Risperidone treatment significantly increased serum prolactin levels." | 5.34 | Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. ( Du, J; Fang, C; Feng, GY; Gu, NF; He, L; Li, XW; Qin, SY; Wang, L; Xing, QH; Yu, L; Zhang, AP, 2007) |
| "Risperidone is a widely used atypical antipsychotic medication and there is currently considerable interest in individual differences in patient response to it." | 5.34 | Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. ( Du, J; Feng, G; He, L; Li, X; Lin, Z; Wang, L; Xing, Q; Yu, L; Zhang, A, 2007) |
| " After 4 weeks, fluvoxamine dosage was increased to 200 mg/day in five patients and then maintained until the end of week 8." | 5.33 | Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. ( Ancione, M; D'Arrigo, C; Migliardi, G; Morgante, L; Muscatello, MR; Santoro, V; Spina, E, 2005) |
| " Results of the sensitivity analysis confirmed that the results were robust to a wide variation of different input variables (effectiveness, dosing distribution, patient status according to healthcare system)." | 5.33 | Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. ( Caleo, S; De Graeve, D; Lecompte, D; Mehnert, A; Miadi-Fargier, H; Mosqueda, GJ; Peuskens, J; Smet, A, 2005) |
| "To evaluate risk of new-onset type 2 diabetes associated with use of selected antipsychotic agents, the authors conducted a new-user cohort study in a national sample of US Veterans Health Administration patients with schizophrenia (and no preexisting diabetes)." | 5.33 | Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. ( Cunningham, FE; Dalack, GW; Hur, K; Lambert, BL; Miller, DR, 2006) |
| " Failure in switching to monotherapy was associated with higher dosage of antipsychotics at baseline." | 5.33 | Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia. ( Kunugi, H; Murray, RM; Nakanishi, S; Nojima, S; Ogawa, T; Takahashi, T, 2006) |
| "Treatment with risperidone was offered to acutely psychotic schizophrenic patients with the requirement of a minimum score of > or =4 on 2 items of the PANSS positive symptoms subscale." | 5.32 | Risperidone in the treatment of acute schizophrenia. ( Naber, D; Raedler, TJ; Schreiner, A; Wiedemann, K, 2004) |
| "Treatment with risperidone resulted in a significant decrease in the intensity of schizophrenic symptoms and in an improvement in all neuropsychological tests applied." | 5.31 | Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests. ( Araszkiewicz, A; Borkowska, A; Rajewski, A; Rybakowski, JK, 2002) |
| "96 SD were treated with risperidone (RSP) at the dosage of 2-9 mg/die (mean 4." | 5.31 | Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. ( Boscati, L; Laini, V; Mauri, MC; Orlandi, R; Papa, P; Rudelli, R; Salvi, V, 2001) |
| "Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients." | 5.31 | Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). ( Edgell, E; García-Cabeza, I; Gómez, JC; González de Chavez, M; Sacristán, JA, 2001) |
| "Risperidone is an atypical antipsychotic drug that increases plasma norepinephrine (NE) levels, but the mechanism behind this effect is unclear." | 5.31 | Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo. ( Breier, A; Eisenhofer, G; Elman, I; Folio, CJ; Goldstein, DS; Green, AI; Holmes, CS; Pickar, D, 2002) |
| "A double-blind, placebo-controlled study involved 75 patients with schizophrenia who randomly received low dose (100 mg/day) or high dose minocycline (200 mg/day) or placebo added to risperidone." | 5.30 | The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia. ( Kosten, TR; Wu, R; Zhang, L; Zhang, XY; Zhao, J; Zheng, H, 2019) |
| "This study aimed to investigate the efficacy and tolerability of aripiprazole, olanzapine and risperidone in first-episode schizophrenia (FES)." | 5.30 | An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. ( Cai, S; Cheng, Z; Correll, CU; Deng, H; Han, X; Lu, Z; Wang, C; Xiang, Y; Yang, F; Yang, L; Yu, X; Yuan, Y; Zhao, J, 2019) |
| "Hospitalized patients (N = 460) with schizophrenia were randomized to 6 weeks of fixed-dose lurasidone 40 mg/d, lurasidone 80 mg/d, risperidone 4 mg/d, or placebo." | 5.30 | Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial. ( Chen, HK; Chen, JY; Chen, TT; Chou, YH; Higuchi, T; Huang, SY; Ishigouoka, J; Iyo, M; Katoh, T; Kwon, JS; Lee, JS; Saeki, Y; Tanaka, H; Wang, TS; Wu, BJ, 2019) |
| "Deliberate drug overdose is a frequent occurrence in patients with schizophrenia." | 5.30 | A case of risperidone overdose in early schizophrenia: a review of potential complications. ( Day, C; Dillman, B; Gardner, D; Kopala, LC, 1998) |
| "Risperidone was substituted for typical antipsychotics after baseline assessment in the second cohort (n = 10)." | 5.30 | Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. ( Bullmore, ET; Honey, GD; Sharma, T; Soni, W; Varatheesan, M; Williams, SC, 1999) |
| "Priapism was relieved when a hematoma was evacuated from his penis." | 5.29 | [Risperidone-induced priapism]. ( Knobler, HY; Maizel, S; Umansky, L, 1996) |
| "A subcutaneous risperidone implant (RI) formulation was developed to improve medication adherence in schizophrenia." | 5.27 | Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia. ( Adera, M; Dammerman, R; Kim, S; Schwarz, A, 2018) |
| "This study examined the effect of adjunctive minocycline on body metabolism in risperidone-treated patients with schizophrenia." | 5.27 | No Effect of Adjunctive Minocycline Treatment on Body Metabolism in Patients With Schizophrenia. ( Fan, X; Liu, F; Ruan, Y; Xie, L; Xu, X; Zeng, Y; Zhang, B; Zhao, J, 2018) |
| "Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted." | 5.27 | L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. ( Afarideh, M; Akhondzadeh, S; Alavi, AR; Ghajar, A; Ghazizadeh-Hashemi, M; Khoaie-Ardakani, MR; Shahmoradi, Z; Shalbafan, MR, 2018) |
| "This clinical trial was performed on 68 patients with chronic schizophrenia, treated with risperidone at 22 Bahman Hospital of Qazvin, Iran during 2015 to 2016." | 5.27 | Evaluation of the Effect of Fluvoxamine in Patients With Schizophrenia Under Risperidone Treatment: A Clinical Trial. ( Haji Seyed Javadi, A; Khanshir, ZF; Shafikhani, AA; Zamir, SM, 2018) |
| "To evaluate the effects of treatment with risperidone and aripiprazole on serum prolactin, testosterone and estradiol levels in female patients with schizophrenia in China." | 5.27 | Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia. ( Hu, JQ; Jiang, XJ; Lin, WC; Shang, DW; Shi, L; Wen, YG; Wu, FX; Xiao, B; Zhang, JP; Zhu, HZ, 2018) |
| "This study indicated that a risperidone or olanzapine dose reduction of 50% may not lead to more severe symptomatology but can improve speed of processing, working memory and negative symptoms in patients with stabilized schizophrenia." | 5.27 | Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study. ( Cui, H; Li, D; Li, G; Ning, Y; Zhou, Y, 2018) |
| "Schizophrenia patients showed a significant improvement in negative symptoms with the addition of minocycline to risperidone." | 5.27 | Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. ( Kosten, TR; Wu, R; Zhang, L; Zhang, XY; Zhao, J; Zheng, H; Zhu, F, 2018) |
| "Paliperidone palmitate 3-monthly (PP3M) injectable formulation offers an advantage of improved medication adherence and lower relapse risk in patients with schizophrenia." | 5.27 | Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis. ( Alphs, L; Gopal, S; Hough, D; Mathews, M; Nuamah, I; Pei, H; Savitz, A, 2018) |
| "In a double-blind and placebo-controlled study, patients with stable schizophrenia (DSM-5) were randomized to receive either 2,500 mg/day citicoline or placebo in addition to risperidone for 8 weeks." | 5.27 | Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. ( Afarideh, M; Akhondzadeh, S; Ghajar, A; Ghazizadeh-Hashemi, M; Gholamian, F; Rezaei, F; Tabatabei-Motlagh, M, 2018) |
| "Risperidone and paliperidone have been the mainstay treatment for schizophrenia and their potential role in neuroprotection could be associated with brain-derived neurotrophic factor (BDNF) and N400 (an event-related brain potential component)." | 5.27 | Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia. ( Chen, C; Chen, GD; Chen, XS; Huang, ZY; Lin, CG; Lin, XD; Lin, ZG; Wu, RQ; Xu, DL; Zhang, LJ; Zhang, MD; Zhang, W, 2018) |
| "One hundred eleven inpatients with acutely exacerbated schizophrenia were randomized to give optimal therapy of olanzapine, risperidone, and paliperidone in one-week run-in period and 12 weeks' intervention." | 5.27 | Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics. ( Chen, KP; Chen, YL; Chiu, CC; Lung, FW; Tai, MH, 2018) |
| "To evaluate the efficacy and safety of cilostazol, a selective inhibitor of phosphodiesterase III, as an adjunctive to risperidone in alleviating the negative symptoms of schizophrenia." | 5.24 | Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study. ( Akhondzadeh, S; Jeddian, A; Mesgarpour, B; Mohammadinejad, P; Rezaei, F; Salardini, E; Shahriari, M; Zeinoddini, A; Zeionoddini, A, 2017) |
| "Our study aimed at estimating differences in quality-adjusted life year (QALY) gain for patients with predominant negative symptoms of schizophrenia treated with cariprazine compared with risperidone." | 5.24 | Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. ( Akehurst, R; Götze, Á; Horváth, M; Kóczián, K; Molnár, A; Németh, B; Németh, G; Vokó, Z, 2017) |
| "The Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) compared the efficacy of risperidone, olanzapine, and molindone over 8 weeks in 119 youths age 8-19 years with early-onset schizophrenia or schizoaffective disorder." | 5.24 | Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. ( Artukoglu, BB; Bloch, MH; Gabriel, D; Jakubovski, E; Taylor, JH, 2017) |
| "There have been few studies of pregnenolone therapy in schizophrenia and those that exist have been subject to several critical limitations, thus yielding inconsistent results." | 5.24 | Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial. ( Akhondzadeh, S; Karkhaneh-Yousefi, MA; Kashani, L; Khodaie-Ardakani, MR; Moazen-Zadeh, E; Rahiminejad, F; Rezaei, F; Sadighi, G; Shams, N, 2017) |
| "This study aimed to investigate remission following the treatment of schizophrenia patients with risperidone." | 5.24 | Symptomatic remission in schizophrenia: Results from a risperidone maintenance treatment study. ( Bo, Q; Dong, F; He, F; Li, A; Li, F; Li, X; Ma, X; Wang, C; Wang, Z, 2017) |
| "This study compares the efficacy and tolerability of olanzapine versus risperidone among patients with schizophrenia who are established in outpatient psychiatric care and entering supported employment." | 5.24 | Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. ( Glynn, SM; Marder, SR; Noordsy, DL; O'Keefe, CD; Sugar, CA, 2017) |
| " Because early response to antipsychotics represents a sufficiently reliable index of the subsequent treatment response in patients with schizophrenia, we undertook a real-world, genome-wide association study (GWAS) with the aim of identifying genetic predictors of response to risperidone after 2 weeks in 86 patients with schizophrenia." | 5.24 | The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. ( Calza, S; Gennarelli, M; Magri, C; Minelli, A; Sacchetti, E; Traversa, M; Valsecchi, P; Vita, A, 2017) |
| "A new, long-acting, subcutaneous (SC) formulation of risperidone (RBP-7000) has been developed for the treatment of schizophrenia to address issues of non-adherence associated with oral risperidone treatment." | 5.24 | Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone. ( Gobburu, JVS; Gopalakrishnan, M; Heidbreder, C; Ivaturi, V; Laffont, CM; Liu, Y; Zhang, W, 2017) |
| "Our results support the efficacy of cariprazine in the treatment of predominant negative symptoms of schizophrenia." | 5.24 | Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. ( Barabássy, Á; Bitter, I; Czobor, P; Debelle, M; Durgam, S; Fleischhacker, WW; Harsányi, J; Laszlovszky, I; Marder, S; Németh, G; Szalai, E; Szatmári, B, 2017) |
| "We found only one small, short-term trial suggesting that risperidone may improve catatonic and positive symptoms scale scores amongst people with schizophrenia spectrum disorders and catatonic symptoms, but that ECT may result in greater improvement in the first three weeks of treatment." | 5.22 | Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms. ( Caroff, SN; Gibson, RC; Huang, MW; Jayaram, MB, 2022) |
| "To evaluate the cost-effectiveness of lurasidone compared with olanzapine and risperidone in the first-line treatment of patients with schizophrenia from a Chinese healthcare system perspective." | 5.22 | Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China. ( Cao, L; Liu, J; Wu, J, 2022) |
| "Few studies have examined effectiveness and tolerability of risperidone long-acting injections (RLAI) in the early phase of a schizophrenia spectrum (SS) disorder using a randomized controlled trial (RCT) design." | 5.22 | An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. ( Adams, B; Chue, P; Jordan, G; Joseph, A; Koczerginski, D; Malla, A; Manchanda, R; Milliken, H; Oyewumi, K; Roy, MA; Stip, E; Williams, R, 2016) |
| "1 channels play a role in the therapeutic action of antipsychotic drugs, particularly risperidone, and further highlight the promise of optimizing response with genotype-guided therapy for schizophrenia patients." | 5.22 | Differential Response to Risperidone in Schizophrenia Patients by KCNH2 Genotype and Drug Metabolizer Status. ( Bigos, KL; Carr, VJ; Green, MJ; Heide, J; Mann, SA; Shannon Weickert, C; Vandenberg, JI; Weinberger, DR; Zhang, F, 2016) |
| "In acute psychotic schizophrenia patients we investigated if the combination of triiodothyronine (T3) plus risperidone was more effective when compared to risperidone monotherapy." | 5.22 | Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia. ( Bunevicius, A; Bunevicius, R; Nemeroff, CB; Prange, AJ; Savickas, A; Steibliene, V, 2016) |
| "The aim of this study was to compare the effects of risperidone long-acting injection (RLAI) and paliperidone palmitate (PP) on non-acute-phase social functioning in patients with schizophrenia." | 5.22 | The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. ( Fabbri, C; Kato, M; Kinoshita, T; Koshikawa, Y; Nishida, K; Onohara, A; Sakai, S; Serretti, A; Sunada, N; Takekita, Y; Yoshimura, M, 2016) |
| "The risperidone maintenance treatment in schizophrenia study was designed to identify the duration of maintenance treatment required with an initial therapeutic dose in contrast to reducing the dose over time." | 5.22 | Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study. ( Bo, QJ; Li, AN; Li, XB; Ma, X; Wang, CY; Wang, ZM, 2016) |
| "In this randomized, double-blind, placebo-controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks." | 5.22 | The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. ( Akhondzadeh, S; Esalatmanesh, S; Farokhnia, M; Goguol, A; Iranpour, N; Khodaie-Ardakani, MR; Mohammadinejad, P; Salehi, B; Yekehtaz, H; Zandifar, A; Zeinoddini, A; Zeionoddini, A, 2016) |
| "RBP-7000 is a sustained-release formulation of risperidone for the treatment of schizophrenia, designed to be administered by once-monthly subcutaneous injection using the ATRIGEL delivery system." | 5.22 | Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study. ( Fava, M; Fudala, PJ; Heidbreder, C; Henderson, DC; Kouassi, A; Nasser, AF; Twumasi-Ankrah, P, 2016) |
| "Duloxetine adjuvant to risperidone seems to be a tolerable and efficacious treatment for primary negative symptoms of schizophrenia." | 5.22 | Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study. ( Akhondzadeh, S; Arabzadeh, S; Ghaleiha, A; Khalili, Z; Mohammadinejad, P; Nikbakhat, MR; Rezaei, F; Zeinoddini, A, 2016) |
| "We compared clozapine (n = 53) to risperidone (n = 54) in a randomized, double-blind, 29-week trial in schizophrenia patients (diagnosed using DSM-IV) at 3 research outpatient clinics." | 5.22 | Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. ( Ames, D; Baker, RW; Chengappa, KN; Kane, JM; Marder, SR; McMeniman, M; Parepally, H; Petrides, G; Schooler, NR; Umbricht, D; Wirshing, WC, 2016) |
| "The aim of this study was to characterize the pharmacokinetics and to evaluate the safety of risperidone ISM in patients with schizophrenia or schizoaffective disorder after a single gluteal intramuscular injection at three different dose strengths (50, 75, and 100 mg)." | 5.22 | Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ( Anta, L; Ayani, I; Gutierro, I; Ivanov, M; Llaudó, J; Martínez, J; Morozova, M; Schronen, J, 2016) |
| "In this 4-week, double-blind, randomized controlled trial conducted in psychiatric care from September 2012 to March 2015, 103 patients with schizophrenia (ICD-10) who did not respond to olanzapine 10 mg/d or risperidone 3 mg/d were randomly allocated to a dose-increment or -continuation group." | 5.22 | Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial. ( Bies, RR; Kapur, S; Mimura, M; Pollock, BG; Sakurai, H; Suzuki, T; Uchida, H, 2016) |
| "This study aimed to investigate prolactin related symptoms (PRS) in individuals with schizophrenia during risperidone maintenance treatment for one year, as well as to identify the risk factors for PRS." | 5.22 | Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia. ( Bo, Q; Dong, F; Li, X; Ma, X; Wang, C; Wang, Z, 2016) |
| " At 8 US academic centers, 305 patients with schizophrenia or schizoaffective disorder were randomly assigned to LAI risperidone (LAI-R) or physician's choice oral SGAs." | 5.20 | Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. ( Ames, D; Buckley, PF; Bustillo, J; Goff, DC; Hsiao, J; Kane, JM; Kopelowicz, A; Lauriello, J; Manschreck, T; Mendelowitz, AJ; Miller, del D; Mintz, J; Schooler, NR; Severe, JB; Wilson, DR, 2015) |
| "The present analysis assessed the efficacy of extended-release quetiapine fumarate (quetiapine XR) versus risperidone in patients with schizophrenia and depressive symptoms [Hamilton Depression Rating Scale (HAM-D) score≥20 and a HAM-D item 1 score≥2]." | 5.20 | Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. ( Di Fiorino, M; Kasper, S; Montagnani, G; Trespi, G, 2015) |
| "To assess the benefit of short-term treatment with the atypical antipsychotic asenapine versus placebo on depressive symptoms in patients with acute schizophrenia in an exacerbated state." | 5.20 | Management of depressive symptoms in schizophrenia. ( Castle, DJ; Slott Jensen, JK, 2015) |
| "To describe secondary analyses from a 12-week, randomized, open-label trial where adult schizophrenia outpatients receiving risperidone, olanzapine, or aripiprazole were switched to iloperidone." | 5.20 | Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia. ( Alva, G; Citrome, L; Glick, ID; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Weiden, PJ; Winseck, A, 2015) |
| "In this prospective multicentre, open-label, 6-month study (Paliperidone Palmitate Flexible Dosing in Schizophrenia [PALMFlexS]), tolerability, safety and treatment response with paliperidone palmitate (PP) were explored in patients with acute symptoms of schizophrenia following switching from previously unsuccessful treatment with oral antipsychotics." | 5.20 | Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. ( Bergmans, P; Bez, Y; Carpiniello, B; Cherubin, P; Hargarter, L; Keim, S; Parellada, E; Rancans, E; Schreiner, A; Vidailhet, P, 2015) |
| "The present findings suggest that clozapine demonstrates superior antidepressant effects to quetiapine and comparable effects to olanzapine and risperidone in chronic schizophrenia regardless of presence of MDE." | 5.20 | Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. ( Caravaggio, F; Chung, JK; Fervaha, G; Gerretsen, P; Graff-Guerrero, A; Iwata, Y; Mihashi, Y; Mulsant, B; Nakajima, S; Plitman, E; Remington, G; Takeuchi, H, 2015) |
| "The objective of this study was to evaluate the effectiveness and impact of once- versus twice-daily dosing of risperidone and olanzapine on clinical outcomes in patients with schizophrenia." | 5.20 | Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. ( Agid, O; Fervaha, G; Lee, J; Remington, G; Takeuchi, H, 2015) |
| "PALMFlexS, a prospective multicentre, open-label, 6-month, phase IIIb interventional study, explored tolerability, safety and treatment response in adults (n = 231) with non-acute but symptomatic schizophrenia switching to flexibly dosed paliperidone palmitate (PP) after unsuccessful treatment with risperidone long-acting injectable therapy (RLAT) or conventional depot antipsychotics (APs)." | 5.20 | Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics. ( Bergmans, P; Cherubin, P; Corrivetti, G; Cosar, B; Hargarter, L; Keim, S; Llorca, PM; Petralia, A; Schreiner, A, 2015) |
| "To compare the clinical efficacy of the long-acting injectable formulation of risperidone with the oral formulation in the early course of schizophrenia." | 5.20 | Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. ( Casaus, LR; Gretchen-Doorly, D; Hellemann, GS; Luo, JS; Marder, S; Nuechterlein, KH; Subotnik, KL; Ventura, J, 2015) |
| " Twenty-two antipsychotic-naive patients with first-episode schizophrenia received either risperidone long acting injection or flupenthixol decanoate over 13 weeks and were compared by structural MRI with 23 matched healthy volunteers at weeks 0, 4 and 13." | 5.20 | Changes in brain regions associated with food-intake regulation, body mass and metabolic profiles during acute antipsychotic treatment in first-episode schizophrenia. ( Asmal, L; Carr, J; Chiliza, B; du Plessis, S; Emsley, R; Kahn, RS; Kidd, M; Malhotra, AK; Vink, M, 2015) |
| "Ninety-five patients with DSM-IV-TR diagnoses of schizophrenia and alcohol use disorder were randomized to 6 months of oral or LAI risperidone between 2005 and 2008." | 5.20 | Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. ( Brunette, MF; Buckley, P; Dawson, R; Green, AI; Hafez, H; Herz, M; Narasimhan, M; Noordsy, DL; O'Keefe, C; Sommi, RW; Steinbook, RM; Wallace, AE; Weeks, M, 2015) |
| "This randomized, double-blind study compared the efficacy and safety of blonanserin and risperidone to treat Chinese schizophrenia patients aged ≥18 and < 65 years." | 5.20 | Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial. ( Gu, N; Li, H; Li, J; Li, K; Li, L; Liu, C; Luo, X; Qi, S; Shi, J; Wang, C; Wang, L; Wang, Q; Yang, F; Yao, C; Zhang, H, 2015) |
| "The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia." | 5.20 | Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial. ( Ai, X; Ding, M; Ding, S; Gu, X; Huang, G; Li, X; Lv, L; Pang, L; Song, X; Zhao, J, 2015) |
| "Using the recommended dosing regimens for PP and RLAI, both PP and oral risperidone (used during RLAI initiation) improved symptoms of schizophrenia in markedly-to-severely ill subjects at days 4-22." | 5.19 | Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. ( Alphs, L; Bossie, CA; Fu, DJ; Kern Sliwa, J; Ma, YW, 2014) |
| "We aimed to assess the efficacy and tolerability of riluzole, an anti-glutamate agent with neuroprotective properties, as an adjunct to risperidone in improving negative symptoms of schizophrenia." | 5.19 | A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. ( Akhondzadeh, S; Farokhnia, M; Hosseini, SM; Khodaie-Ardakani, MR; Pourmahmoud, H; Rezaei, F; Sabzabadi, M; Salehi, B; Tabrizi, M; Yekehtaz, H, 2014) |
| "This study was to evaluate the effects on clinical symptoms and cognitive function of switching the treatment of elderly patients with schizophrenia from risperidone to paliperidone (PAL)." | 5.19 | The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. ( Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Suzuki, H, 2014) |
| "Our results are consistent with those of a similar post-hoc analysis of hostility in first-episode subjects with schizophrenia enrolled in the European First-Episode Schizophrenia Trial (EUFEST) trial, where olanzapine demonstrated advantages compared with haloperidol, quetiapine, and amisulpride." | 5.19 | Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. ( Citrome, L; Czobor, P; Van Dorn, RA; Volavka, J, 2014) |
| "The purpose of this prospective study was to evaluate the effects of switching from oral risperidone to flexibly dosed oral paliperidone extended-release (ER) in Brazilian adults with schizophrenia because of lack of efficacy, intolerability, or nonadherence after a minimum trial of 30 days on adequate (labeled) doses of oral risperidone, according to individual clinical judgment." | 5.19 | Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study. ( Appolinário, JC; Bressan, RA; Campos, JA; de Oliveira, IR; Elkis, H; Gattaz, WF; Grabowski, HM; Henna, E; Lacerda, AL; Lawson, FL; Louzã, MR; Périco, Cde A; Quevedo, J; Rocha, FL; Ruschel, SI; Sacomani, E; Zorzetto Filho, D, 2014) |
| "The present study aimed to examine the changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia." | 5.19 | Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia. ( Fan, X; Gao, J; Harrington, A; Li, X; Lv, L; Song, X; Zhang, W; Zhao, J; Ziedonis, D, 2014) |
| "Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders." | 5.19 | Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. ( Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S, 2014) |
| "This study aimed to investigate changes in plasma concentrations of risperidone and 9-hydroxy-risperidone (9-OHR) and the associated clinical effects when switching from oral risperidone to extended-release (ER) paliperidone in patients with schizophrenia." | 5.19 | Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia. ( Kwak, KH; Lee, SJ; Lim, MS; Seong, SJ; Yang, DS; Yoon, YR, 2014) |
| "A long-term randomized trial of unstable patients with schizophrenia found no benefit of long-acting injectable (LAI) risperidone over oral treatment in preventing or delaying time to psychiatric hospitalizations or on clinical outcomes." | 5.19 | Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. ( Krystal, JH; Leatherman, SM; Lew, RA; Liang, MH; Rosenheck, RA; Thwin, SS; Valley, D, 2014) |
| "We examined the difference between the effects of olanzapine (OLZ) and risperidone (RIS) on PR and QT intervals among patients with stable schizophrenia using a cohort analysis." | 5.19 | Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia. ( Fukui, N; Ono, S; Saito, M; Sawamura, K; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J, 2014) |
| " The goal of this 8-week, randomized, multicenter, open-label study was to examine the effects of aripiprazole and risperidone on social cognition and neurocognition in individuals with schizophrenia." | 5.19 | Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. ( Aleman, A; Cahn, W; Gijsman, HJ; Hovens, JE; Kahn, RS; Maat, A, 2014) |
| "RBP-7000 is a long-acting formulation of risperidone administered once monthly via subcutaneous (SC) injections for the treatment of schizophrenia." | 5.19 | Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. ( Fudala, PJ; Gomeni, R; Heidbreder, C; Laffont, CM; Nasser, AF; Zheng, B, 2014) |
| "The objective of this study was to assess the efficacy and tolerability of minocycline add-on to risperidone in treatment of negative symptoms of patients with chronic schizophrenia." | 5.19 | Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Farokhnia, M; Hosseini, SM; Khodaie-Ardakani, MR; Mirshafiee, O; Modabbernia, A; Rezaei, F; Salehi, B; Tabrizi, M; Tajdini, M; Yekehtaz, H, 2014) |
| "Ninety-two patients with early stage schizophrenia treated with risperidone entered this 16-week, double blind, randomized, placebo-controlled clinical trial." | 5.19 | Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. ( Guo, X; Liu, F; Ou, J; Ruan, Y; Wu, R; Xie, L; Xu, X; Yang, J; Yang, L; Yang, S; Zeng, Y; Zhang, B; Zhang, L; Zhao, J; Zheng, Y, 2014) |
| "In a 12-week randomized open-label trial, adults diagnosed with schizophrenia experiencing inadequate efficacy and/or poor tolerability on risperidone, olanzapine, or aripiprazole were randomized to switch to iloperidone either gradually (ie, down-titration of current therapy over the first 2weeks [to 50% on Day 1, 25% by Week 1, 0% by Week 2]) or immediately." | 5.19 | A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. ( Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A, 2014) |
| "This study was designed to investigate long-term clinical outcomes of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder." | 5.19 | A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. ( Ahn, YM; Cho, SJ; Chung, YC; Jung, IK; Kim, CY; Kim, DH; Kim, SH; Kim, YS; Lee, DG; Lee, NY; Lee, YH; Lim, WJ; Na, YS; Shin, SE; Woo, JM; Yoon, BH; Yoon, JS, 2014) |
| "Sixty-one patients with schizophrenia stably treated with risperidone or olanzapine were randomly assigned to dose-reduction-by-half group or dose maintenance group." | 5.19 | Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia. ( Mimura, M; Remington, G; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K, 2014) |
| "Antipsychotics, such as aripiprazole and risperidone, are often used to treat individuals with schizophrenia." | 5.19 | Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. ( Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W, 2014) |
| "In this study, we assessed the efficacy of 2 pharmacodynamically different antidepressants, citalopram (a selective serotonin reuptake inhibitor) and reboxetine (a norepinephrine reuptake inhibitor), as adjunctive therapy to risperidone and olanzapine for the treatment of negative symptoms in schizophrenia." | 5.19 | Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. ( Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J, 2014) |
| "In this secondary study of an open-label, 28-week, randomized, controlled trial conducted between April 2009 and August 2011, clinically stable patients with schizophrenia (DSM-IV) treated with risperidone or olanzapine were randomly assigned to the reduction group (dose reduced by 50%) or maintenance group (dose kept constant)." | 5.19 | Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ( Bies, RR; Mimura, M; Remington, G; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K, 2014) |
| "Subjects with schizophrenia age 50 years or more who were clinically stable and previously maintained on oral risperidone for D(2/3) RRO in dorsal putamen was assessed, using the region of interest analysis of [¹¹C]raclopride PET scans, before and after the dose reduction." | 5.19 | Therapeutic window for striatal dopamine D(2/3) receptor occupancy in older patients with schizophrenia: a pilot PET study. ( Arenovich, T; Graff-Guerrero, A; Mamo, DC; Mulsant, BH; Pollock, BG; Rajji, TK; Suzuki, T; Uchida, H, 2014) |
| "There are contradictory reports about the efficacy of minocycline for treating schizophrenia." | 5.19 | Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. ( Dehbozorgi, S; Ghanizadeh, A; OmraniSigaroodi, M; Rezaei, Z, 2014) |
| "We investigated the clinical efficacy and safety of switching to paliperidone (PAL) in elderly schizophrenia patients receiving risperidone." | 5.17 | Study of the efficacy and safety of switching from risperidone to paliperidone in elderly patients with schizophrenia. ( Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Otomo, M; Suzuki, H, 2013) |
| "A prospective, randomized, open-label study was carried out to compare the long-term neurocognitive effectiveness of haloperidol, olanzapine, and risperidone in the first episode of schizophrenia spectrum disorders." | 5.17 | Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. ( Ayesa-Arriola, R; Crespo-Facorro, B; Martínez-García, O; Pérez-Iglesias, R; Rodríguez-Sánchez, JM; Roiz-Santiáñez, R; Sánchez-Moreno, J; Tabarés-Seisdedos, R; Vázquez-Barquero, JL, 2013) |
| "The objective of this study was to assess the efficacy and tolerability of tropisetron add-on to risperidone on negative symptoms in patients with chronic stable schizophrenia." | 5.17 | A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. ( Akhondzadeh, S; Ashrafi, M; Farokhnia, M; Ghasemi, S; Hosseini, SM; Khodaie-Ardakani, MR; Mirshafiee, O; Modabbernia, A; Noroozian, M; Rezaei, F; Salehi, B; Tabrizi, M; Tajdini, M; Yekehtaz, H, 2013) |
| "We examined sex differences in the effect of olanzapine (OLZ), risperidone (RIS), aripiprazole (ARP), or quetiapine (QTP) on mean corrected QT (QTc) intervals among 222 patients with schizophrenia." | 5.17 | Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia. ( Fukui, N; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J, 2013) |
| "We aimed to evaluate the efficacy of memantine add-on in the treatment of primary negative symptoms of patients with stable schizophrenia." | 5.17 | Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Hajiaghaee, R; Hammidi, S; Modabbernia, A; Mohammad-Karimi, M; Motasami, H; Rezaei, F; Salehi, B; Seddighi, S; Tabrizi, M, 2013) |
| "We compared the time to discontinuation due to lack of tolerability over 24 weeks in patients suffering from schizophrenia treated with pomaglumetad methionil (LY2140023 monohydrate, the prodrug of metabotropic glutamate 2/3 receptor agonist, LY404039) or standard of care (SOC: olanzapine, risperidone, or aripiprazole)." | 5.17 | A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. ( Adams, DH; Baygani, S; Kinon, BJ; Kollack-Walker, S; Millen, BA; Velona, I; Walling, DP, 2013) |
| "We sought to assess the effect of the addition of a fixed dose of 5 mg daily of aripiprazole on hyperprolactinemia induced by risperidone long-acting injectable (RLAI) treatment in patients with chronic psychoses and the adverse events related to the addition of aripiprazole and its impact on the disease." | 5.17 | Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. ( Bonete Llácer, JM; García Escudero, MA; Martínez Pastor, CJ; Ziadi Trives, M, 2013) |
| "The current study compared the long-term effectiveness, safety, and tolerability of paliperidone extended-release (ER) among patients with schizophrenia who had switched from risperidone (risperidone group) or other antipsychotic medications (non-risperidone group) due to lack of efficacy, intolerability, or non-adherence." | 5.17 | Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents. ( Ahn, YM; Chang, SM; Joo, EJ; Kim, EY; Kim, JJ; Kim, YS; Shim, JC, 2013) |
| "RBP-7000 is a sustained-release (once-monthly injection for subcutaneous administration) formulation of risperidone using the ATRIGEL® Delivery System, developed for treatment of schizophrenia to address compliance issues associated with oral administration." | 5.17 | A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone. ( Fudala, PJ; Gomeni, R; Heidbreder, C; Nasser, AF, 2013) |
| " Our research group is developing a non-commercial, multicentric and open label study on the differential efficacy between clozapine and risperidone in first-episode schizophrenia." | 5.17 | Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. ( Aragües, M; Del Alamo, C; Molina, V; Ovejero, S; Palomo, T; Sanz-Fuentenebro, J; Taboada, D, 2013) |
| "We examined clinical characteristics including serum olanzapine concentrations for acute schizophrenia patients who required above conventional doses." | 5.17 | The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia. ( Hatta, K; Hirata, T; Ito, S; Kasuya, M; Katayama, S; Kuga, H; Morikawa, F; Nakamura, H; Nakamura, M; Nakase, R; Ohnuma, T; Sawa, Y; Shirai, Y; Sudo, Y; Takebayashi, H; Usui, C, 2013) |
| "This randomised 12-month open study analysed the effectiveness of quetiapine XR (400-800 mg) versus risperidone (2-6 mg) on subjective well-being in schizophrenia (NCT00600756)." | 5.17 | Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER). ( Goltz, M; Haro, JM; Krüger, H; Lambert, M; Naber, D; Peuskens, J; Schwarzmann, N, 2013) |
| " In the primary analyses based on intention to treat groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster decreases of the mean hallucination scores than the risperidone group." | 5.17 | Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. ( Hugdahl, K; Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM; Sinkeviciute, I, 2013) |
| " It was designed as an open-label, multicenter, randomized, comparative study involving 104-week oral treatment with 1 of the 3 drugs (aripiprazole, blonanserin, and paliperidone) in patients with schizophrenia aged 20 years or over who required antipsychotic medication or switching of the current medication to others for reasons such as lack of efficacy and intolerability." | 5.17 | Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia. ( Ishigooka, J; Iwata, N; Nakagome, K; Ohmori, T, 2013) |
| "To compare longer-term safety and effectiveness of the 4 most commonly used atypical antipsychotics (aripiprazole, olanzapine, quetiapine, and risperidone) in 332 patients, aged > 40 years, having psychosis associated with schizophrenia, mood disorders, posttraumatic stress disorder, or dementia, diagnosed using DSM-IV-TR criteria." | 5.17 | Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. ( Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA, 2013) |
| "The objective of this study was to assess the efficacy and tolerability of oxytocin intranasal spray (given as an adjuvant to risperidone) in patients with schizophrenia." | 5.17 | Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Ghaleiha, A; Hosseini, SM; Jafarinia, M; Modabbernia, A; Rezaei, F; Salehi, B; Tabrizi, M; Tajdini, M, 2013) |
| "This was a post hoc analysis of a 52-week, prospective, randomized, double-blind study (N=323) comparing 2 doses of risperidone long-acting injectable (RLAI) in stable subjects with schizophrenia or schizoaffective disorder." | 5.17 | Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. ( Alphs, L; Bilder, R; Pandina, G; Turkoz, I, 2013) |
| "Randomized controlled trial with (50) participants with a diagnosis of schizophrenia randomized to risperidone LAI or oral atypical antipsychotic medication." | 5.17 | Working alliance and its relationship to outcomes in a randomized controlled trial (RCT) of antipsychotic medication. ( David, AS; Rose, D; Williams, P; Wykes, T, 2013) |
| "Clozapine, the most widely used option in treatment-resistant schizophrenia, has been shown to be superior to other antipsychotic medications in improving cognitive function in patients." | 5.17 | Clozapine and visuospatial processing in treatment-resistant schizophrenia. ( Bourque, J; Champagne, J; Lakis, N; Lalonde, P; Lipp, O; Mendrek, A; Stip, E, 2013) |
| " The objective of this study was to determine the prevalence of low BMD in patients with schizophrenia treated with conventional antipsychotics or risperidone and to evaluate any potential relationship with treatment." | 5.17 | Bone loss associated with hyperprolactinemia in patients with schizophrenia. ( Jacob, J; Kinon, BJ; Liu-Seifert, H; Stauffer, VL, 2013) |
| "To evaluate depressive symptoms regarding their association with the acute outcome in first-episode schizophrenia comparing risperidone and haloperidol." | 5.16 | Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Maier, W; Mayr, A; Möller, HJ; Riedel, M; Sauer, H; Schennach-Wolff, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| " Aripiprazole, which is a partial dopamine D2 receptor agonist, may have an impact on cognitive dysfunction in patients with schizophrenia." | 5.16 | Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. ( Kaneda, A; Kaneko, S; Sugawara, N; Tomita, T; Yasui-Furukori, N, 2012) |
| " This 53-wk, Phase-III double-blind study was designed to assess the non-inferiority of PP to risperidone long-acting injectable (RIS-LAI) in schizophrenia treatment." | 5.16 | A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. ( Eerdekens, M; Fleischhacker, WW; Gassmann-Mayer, C; Gopal, S; Hough, D; Lane, R; Lim, P; Remmerie, B, 2012) |
| "Patients with schizophrenia (DSM-IV) were assessed during 2006 and 2007 for response/nonresponse (defined as ≥ 20%/<20% improvement in Positive and Negative Syndrome Scale [PANSS] total score) after 2 weeks of risperidone treatment (2 to 6 mg/d)." | 5.16 | Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. ( Conley, RR; Fijal, BA; Hoffmann, VP; Houston, JP; Kinon, BJ; Stauffer, VL; Witte, MM; Zhao, F, 2012) |
| "In recent years, evidence suggests that modafinil may be useful for certain symptom domains of schizophrenia, especially for the negative and cognitive symptoms." | 5.16 | A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. ( Ahmadi-Abhari, SA; Akhondzadeh, S; Arbabi, M; Bagheri, M; Khalighi-Sigaroudi, F; Rezaei, F; Tabrizi, M, 2012) |
| " The efficacy of sertindole in the treatment of positive and negative schizophrenia symptoms has been shown in various studies." | 5.16 | Driving ability under sertindole. ( Brunnauer, A; Laux, G, 2012) |
| "Haloperidol or trifluoperazine demonstrated similar efficacy as risperidone or olanzapine for patients with schizophrenia who had failed their first trial with a FGA." | 5.16 | Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics. ( Chan, HY; Chen, CH; Chen, JJ; Gau, SS; Hwu, HG, 2012) |
| "The ITT population included both schizoaffective and schizophrenia patients (N = 2401): n = 370, n = 494, and n = 424 for iloperidone 4-8, 10-16, and 20-24 mg/day, respectively; n = 294 for risperidone; n = 114 for haloperidol; n = 144 for ziprasidone; and n = 561 for placebo." | 5.16 | Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. ( Citrome, L; Hochfeld, M; Meng, X; Stahl, SM, 2012) |
| "Patients with an acute psychotic episode underwent HOMA testing for insulin sensitivity (IS) prior to and after 3 weeks of treatment with olanzapine (n = 7) or risperidone (n = 7)." | 5.16 | The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study. ( Deuschle, M; Kopf, D; Paslakis, G; Rüsse, S; Thome, J, 2012) |
| " Sixty-six patients with a diagnosis of schizophrenia that were treated with risperidone or olanzapine and 40 healthy volunteers were enrolled." | 5.16 | Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study. ( Fukui, N; Ono, S; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J, 2012) |
| "This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (RIS-OS) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to RIS-OS." | 5.16 | Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. ( Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S, 2012) |
| "Groups of schizophrenia patients treated with risperidone, olanzapine, clozapine or typical antipsychotics did not differ on the Positive and Negative Syndrome Scale or the Mini Mental State Exam (MMSE) but scored lower than controls on the MMSE." | 5.16 | Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics. ( Barry, RJ; Beninger, RJ; Bradford, L; Delva, NJ; Wasserman, JI, 2012) |
| " This study evaluated the efficacy and safety of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms." | 5.16 | Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. ( Chen, C; Li, G; Li, X; Mitchell, P; Wu, HZ; Xiao, S; Xue, H; Yuan, C; Zhang, M, 2012) |
| " The trial evaluated non-acute adult patients with psychotic disorders treated with a stable olanzapine dose who required a treatment change." | 5.16 | Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. ( Rosa, F; Schreiner, A; Sherif, T; Thomas, P, 2012) |
| "Two plasma samples were collected at 2 separate given time points for the measurement of RIS and 9-OH-RIS concentrations from 50 patients with schizophrenia or schizoaffective disorder maintained on risperidone (mean ± SD age = 56 ± 15 years; 39 men)." | 5.16 | Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. ( Bies, RR; Mamo, DC; Mimura, M; Pollock, BG; Suzuki, T; Tsunoda, K; Uchida, H; Watanabe, K, 2012) |
| "We examined whether augmentation with olanzapine would be superior to increased risperidone dose among acute schizophrenia patients showing early non-response to risperidone." | 5.16 | A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone. ( Hata, K; Hatta, K; Hayakawa, T; Hayashi, H; Hirata, T; Ishii, R; Kasuya, M; Kuga, H; Morikawa, F; Nakamura, H; Nakamura, M; Otachi, T; Sawa, Y; Sudo, Y; Takebayashi, H; Usui, C, 2012) |
| "Patients with schizophrenia or schizoaffective disorder in Australia who were prescribed risperidone long-acting injection (RLAI) between 2003 and 2007 were assessed 12-months retrospectively, at baseline and 24-months prospectively at 3-monthly intervals." | 5.16 | Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. ( Butcher, B; Emmerson, B; Hustig, H; Jacobs, A; Lambert, T; Resseler, S, 2012) |
| "Olanzapine and other second generation antipsychotics have been associated with weight gain, which may be related to changes in appetite and food intake." | 5.16 | Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients. ( Davis, JM; Dwivedi, S; Rachakonda, S; Smith, RC, 2012) |
| "From December 2004 through March 2008, adult outpatients with a Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition diagnosis of schizophrenia or schizoaffective disorder who were taking haloperidol decanoate (n = 40) or fluphenazine decanoate (n = 22) were randomly assigned to stay on current long-acting injectable medication or switch to risperidone microspheres and followed for 6 months under study protocol and an additional 6 months naturalistic follow-up." | 5.16 | Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. ( Covell, NH; Essock, SM; Jackson, CT; McEvoy, JP; Rojas, IA; Schooler, NR; Stroup, TS, 2012) |
| "We applied 2D-CSI MR spectroscopy in 17 recurrent-episode schizophrenia patients off antipsychotics at baseline and at follow-up after 6 weeks, during which 7 patients were treated with haloperidol (10-16 mg/d) and 10 with risperidone (4-6 mg/d)." | 5.16 | Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients. ( Burmeister, HP; Gussew, A; Langbein, K; Reichenbach, JR; Rzanny, R; Sauer, H; Smesny, S, 2012) |
| "There is evidence to suggest that clozapine is underutilized in treatment-refractory schizophrenia." | 5.16 | Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial. ( Hermes, E; Rosenheck, R, 2012) |
| "Neurocognitive functioning of youth (ages 8 to 19 years) with schizophrenia or schizoaffective disorder was evaluated in a four-site, randomized, double-blind clinical trial comparing molindone, olanzapine, and risperidone." | 5.16 | Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. ( Breiger, D; Findling, RL; Frazier, JA; Giuliano, AJ; Hamer, RM; Hooper, SR; Johnson, JL; Lieberman, JA; McClellan, J; Sikich, L; Vitiello, B; Yakutis, L; Youngstrom, EA, 2012) |
| "The main aim was to study the effects of COMT polymorphisms on response of risperidone treatment for schizophrenia and investigate the correlation between memory function of schizophrenia patients and COMT polymorphisms." | 5.16 | Impact of catechol-o-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance. ( Cheng, J; Dong, J; Gao, S; Guo, J; Hu, Z; Huang, M; Li, Z; Liu, S; Xie, S; Xu, Y; Zhou, W, 2012) |
| "Veterans Health Administration patients with unstable schizophrenia or schizoaffective disorder established by the Structured Clinical Interview for DSM-IV (N = 369) were randomized between 2006 and 2009 to long-acting risperidone or physician's choice of oral antipsychotic." | 5.16 | Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. ( Barnett, PG; Krystal, JH; Rosenheck, RA; Scott, JY, 2012) |
| "This study aims to determine the effectiveness of paliperidone extended release (ER) on cognitive function in patients with schizophrenia in comparison with risperidone." | 5.16 | Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. ( Bae, KY; Chung, YC; Kim, JM; Kim, SW; Kim, SY; Lee, JH; Lee, YH; Shin, IS; Yoon, JS, 2012) |
| "Evaluation of risperidone efficacy at psychopathological symptoms, cognitive impairment and formal thought disorder in adolescents with schizophrenia spectrum diagnosis." | 5.16 | Cognition and communication dysfunctions in early-onset schizophrenia: effect of risperidone. ( Namysłowska, I; Remberk, B; Rybakowski, F, 2012) |
| "We investigated the effects of risperidone (N=16), olanzapine (N=18) and low doses of haloperidol (N=18) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients." | 5.16 | Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. ( Ayesa-Arriola, R; Crespo-Facorro, B; Gutiérrez, A; Ortíz-García de la Foz, V; Roiz-Santiáñez, R; Tabarés-Seisdedos, R; Tordesillas-Gutiérrez, D; Vázquez-Barquero, JL, 2012) |
| "In the treatment of acute schizophrenia, risperidone and aripiprazole are both placed the first line antipsychotics." | 5.16 | Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia. ( Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Takeuchi, S; Watanabe, K, 2012) |
| "The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies of 205 white patients with diagnoses other than schizophrenia who were generally likely to have had limited previous antipsychotic exposure." | 5.16 | Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. ( Bishop, JR; Conley, RR; Ellingrod, VL; Fijal, BA; Houston, JP; Kohler, J; Ostbye, KM; Poole Hoffmann, V; Zhao, F, 2012) |
| "In this 6-week, multicenter, randomized, rater single-blind study, a total of 119 patients with schizophrenia were randomly assigned to quetiapine (n = 60, 750 mg/day) or risperidone (n = 59, 4 mg/day)." | 5.16 | Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study. ( Li, H; Li, Y; Liu, Y; Qian, M; Yan, X; Yue, Y, 2012) |
| "This study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching the treatment of schizophrenia patients from haloperidol decanoate depot to risperidone long-acting injection (RLAI) compared with a control group that continued receiving haloperidol decanoate depot." | 5.16 | The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. ( Gen, K; Suzuki, H, 2012) |
| "363 hospital-based psychiatric patients in India, Romania, and United States aged 18 to 65 years and meeting criteria for DSM-IV-TR diagnosis of chronic schizophrenia were randomized double-blind to receive BL-1020 10 mg/d, BL-1020 20-30 mg/d, placebo, or risperidone (2-8 mg/d) for 6 weeks." | 5.16 | Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. ( Anand, R; Davidson, M; Geffen, Y; Keefe, R; Rabinowitz, J, 2012) |
| " The present study evaluates the comparative efficacy, effects on neurocognitive function, and adverse effects of aripiprazole and risperidone in the treatment of hospitalized patients with schizophrenia." | 5.16 | The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia. ( Okamoto, Y; Sato, G; Yamashita, H; Yamawaki, S; Yoshimura, S, 2012) |
| " The sample comprised 16 chronic schizophrenia patients treated with risperidone long-acting injections (RLAI), 16 patients treated with conventional antipsychotic depots (CONV) and 16 healthy controls (HC)." | 5.15 | Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication. ( Anilkumar, AP; Chu, EM; David, AS; Ecker, C; Evans, A; Marshall, N; McDonald, C; Phillips, ML; Surguladze, SA; Timehin, C, 2011) |
| "In this multicenter, phase 3, randomized, double-blind, parallel-group study, only patients with DSM-IV schizophrenia who had failed an adequate antipsychotic treatment within the previous 6 months and who had not responded positively to haloperidol during screening were eligible for enrollment." | 5.15 | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. ( Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG, 2011) |
| "Galantamine, a reversible cholinesterase inhibitor with effects on nicotinic receptors, has shown mixed effects on cognitive impairments in patients with schizophrenia." | 5.15 | Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. ( Khan, A; Lindenmayer, JP, 2011) |
| "Growth mixture modeling (GMM) was applied to data from a randomized, double-blind, 12-week study of 628 patients with schizophrenia or schizo-affective disorder treated with risperidone or olanzapine." | 5.15 | The heterogeneity of antipsychotic response in the treatment of schizophrenia. ( Ascher-Svanum, H; Case, M; Conley, R; Jacob, J; Kane, JM; Kapur, S; Kinon, BJ; Kollack-Walker, S; Stauffer, VL, 2011) |
| "This study was designed to investigate the effect of sildenafil added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind and randomized clinical trial." | 5.15 | Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. ( Akhondzadeh, S; Esfandiari, GR; Ghayyoumi, R; Ghebleh, F; Maroufi, A; Modabbernia, AH; Naderi, M; Rezaei, F; Rezazadeh, SA; Salehi, B; Tabrizi, M, 2011) |
| "In a clinical trial comparing risperidone and lurasidone, 323 clinically-stable outpatients with schizophrenia at 29 sites were assessed with MCCB at screening and a median of 15days later at baseline." | 5.15 | Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. ( Cucchiaro, J; Fox, KH; Harvey, PD; Keefe, RS; Loebel, A; Siu, C, 2011) |
| ") injectable atypical antipsychotic paliperidone palmitate (PP) versus risperidone long-acting injectable (RIS-LAI) in adult patients with schizophrenia." | 5.15 | A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. ( Gassmann-Mayer, C; Gopal, S; Hough, D; Lane, R; Pandina, G; Remmerie, B; Simpson, G, 2011) |
| "This preliminary study aimed to determine if adding mirtazapine to risperidone might improve negative and cognitive symptoms in schizophrenia." | 5.15 | Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. ( Cho, SJ; Choi, TK; Kim, B; Kim, YW; Lee, JE; Lee, KS; Lee, SH; Suh, S; Yook, K; Yook, KH, 2011) |
| " This was a 6-month, open label, multicenter, phase IV trial in recent-onset schizophrenia treated with flexible doses of risperidone long-acting injectable (25-50 mg every 14 days)." | 5.15 | Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable. ( Baylé, FJ; Burba, B; Cavallaro, R; Fischel, T; Martinez, G; Napryeyenko, O; Neznanov, NG; Rabinowitz, J; Schreiner, A; Smeraldi, E, 2011) |
| "To report the design of a study to assess the effect of long-acting injectable risperidone in unstable patients and under more realistic conditions than previously studied and to evaluate the effect of this medication on psychiatric inpatient hospitalization, schizophrenia symptoms, quality of life, medication adherence, side effects, and health care costs." | 5.15 | Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. ( Barnett, PG; Fiore, L; Huang, GD; Krystal, JH; Lew, R; Liang, MH; Neal, C; Rosenheck, RA; Thwin, SS; Valley, D; Vertrees, JE, 2011) |
| "This open-label, rater-blinded, parallel-group study was designed to evaluate noninferiority of paliperidone palmitate (PP), a once-monthly injectable atypical antipsychotic, to once-biweekly risperidone long-acting injectable (RIS-LAI) in adult Chinese patients with acute schizophrenia." | 5.15 | A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. ( Gu, N; Li, H; Ning, X; Rui, Q; Xu, H, 2011) |
| "Long-acting injectable risperidone, a second-generation antipsychotic agent, may improve adherence to treatment and outcomes in schizophrenia, but it has not been tested in a long-term randomized trial involving patients with unstable disease." | 5.15 | Long-acting risperidone and oral antipsychotics in unstable schizophrenia. ( Barnett, PG; Fiore, L; Krystal, JH; Lew, R; Liang, MH; Rosenheck, RA; Thwin, SS; Valley, D; Vertrees, JE, 2011) |
| "The plasma levels of ADA in patients with chronic schizophrenia who received clozapine were significantly higher than patients who received haloperidol." | 5.15 | Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. ( Akhondzadeh, S; Boroumand, MA; Ghaleiha, A; Honarbakhsh, N; Jafarinia, M; Raznahan, M; Rezaei, F; Tabrizi, M, 2011) |
| "In newly admitted patients with acute schizophrenia, non-response to risperidone using CGI-I at 2 weeks can predict subsequent response." | 5.15 | Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. ( Ashizawa, Y; Hamakawa, H; Hatta, K; Hayakawa, T; Hayashi, N; Hirata, T; Ito, S; Nakamura, H; Nakase, R; Otachi, T; Sawa, Y; Sudo, Y; Takebayashi, H; Usui, C, 2011) |
| " Study A consisted of SB-773812 single doses in healthy volunteers-D(2) occupancy measured at 48 (n = 9) and 56 mg (n = 9) and 5-HT(2A) occupancy at 56 mg (n = 9); study B consisted of D(2) and 5-HT(2A) occupancy measured in 12 stabilized-schizophrenia patients on stable doses (16-18 d of 56 mg/d) after washout of previous medication; and study C included D(2) occupancy measured in a double-blind study of patients with acutely exacerbated schizophrenia (n = 10) on stable doses (18-21 d) of SB-773812 (100 mg/d; n = 7) or risperidone (6 mg/d; n = 3)." | 5.15 | Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812. ( Bullich, S; Burgess, C; Catafau, AM; Gray, F; Merlo-Pich, E; Nucci, G, 2011) |
| "This pilot study randomly assigned patients with schizophrenia (N=40) to either aripiprazole or risperidone." | 5.15 | An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. ( Aleman, A; Bous, J; Hollander, K; Knegtering, H; Liemburg, E, 2011) |
| "To assess changes in insulin sensitivity in non-diabetic adults with schizophrenia or schizoaffective disorder treated with olanzapine or risperidone." | 5.15 | Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. ( Campbell, GM; Forrester, TD; Hardy, TA; Henry, RR; Kryzhanovskaya, LA; Marks, DM; Mudaliar, S, 2011) |
| "Between June 2003 and December 2008, 244 individuals with first-episode schizophrenia or schizoaffective disorder according to DSM-IV criteria were treated at the Centre for Addiction and Mental Health, Toronto, Ontario, Canada, following an algorithm that moved them through 2 antipsychotic trials, followed by a trial with clozapine." | 5.15 | An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. ( Agid, O; Arenovich, T; Foussias, G; Kapur, S; Remington, G; Sajeev, G; Zipursky, RB, 2011) |
| "Patients with schizophrenia enrolled in a trial of long-acting injectable risperidone at multiple sites of the Veterans Health Administration (VHA)." | 5.15 | How do clinical trial participants compare to other patients with schizophrenia? ( Barnett, PG; Rosenheck, RA; Scott, JY, 2011) |
| "The purpose of this study is to compare the efficacy of olanzapine and risperidone for the acute treatment of first-episode schizophrenia patients with cannabis use disorders." | 5.15 | Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. ( Kane, J; McCormack, J; Miller, R; Napolitano, B; Robinson, DG; Sevy, S; Sunday, S, 2011) |
| "This study aimed to characterize weight changes in schizophrenia patients taking risperidone as part of a randomized, controlled, open-label clinical trial." | 5.15 | Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. ( Bo, QJ; Chiu, HF; Dixon, LB; Kreyenbuhl, JA; Lai, KY; Lee, EH; Ungvari, GS; Wang, CY; Xiang, YT, 2011) |
| "Patients with schizophrenia or schizoaffective disorder with a body mass index ≥ 27 and non-high-density lipoprotein (non-HDL) cholesterol ≥ 130 mg/dl who were on a stable treatment dosage of olanzapine, quetiapine, or risperidone were randomly assigned to switch to ari-piprazole (N=109) for 24 weeks or stay on their current medication (N=106)." | 5.15 | A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). ( Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS, 2011) |
| "To examine efficacy and safety of acute treatment with paliperidone palmitate in subjects with schizophrenia whose disease remained symptomatic despite recent treatment with oral risperidone." | 5.15 | Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. ( Alphs, L; Bossie, CA; Ma, YW; Sliwa, JK, 2011) |
| "OBJECTIVE To identify whether sarsasapogenin, a sapogenin from the Chinese medicinal herb Anemarrhena Asphodeloides Bunge, would augment the efficacy of risperidone and significantly improve cognitive functions in patients with negative symptoms dominated schizophrenia." | 5.15 | A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. ( Chen, C; Li, GJ; Li, X; Xiao, SF; Xue, HB; Yuan, CM; Zhang, MY, 2011) |
| "This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment." | 5.15 | A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. ( Bobo, WV; Bonaccorso, S; Chen, Y; Jayathilake, K; Meltzer, HY, 2011) |
| "1 years) who presented between November 1998 and October 2004 with a first episode of psychosis and had a DSM-IV diagnosis of schizophrenia or schizophreniform or schizoaffective disorder were randomly assigned to treatment with olanzapine or risperidone for 16 weeks." | 5.15 | Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? ( Gallego, JA; Kane, JM; Lesser, ML; McCormack, J; Napolitano, B; Robinson, DG; Sevy, SM, 2011) |
| "To evaluate effectiveness outcomes in a real-world setting in patients with schizophrenia initiating risperidone long-acting therapy (RLAT)." | 5.15 | Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. ( Crivera, C; DeSouza, C; Dirani, RD; Kozma, CM; Macfadden, W; Mao, L; Rodriguez, SC, 2011) |
| "Eighty hospitalized patients suffering from Schizophrenia or Schizoaffective disorder (male 54, female 26) were first treated with Haloperidol (N=60) or Fluphenazine (N=20), and then were switched to Risperidone." | 5.15 | First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. ( Popović, I; Popović, V; Ravanić, D; Stanojević, A; Stojanović, M; Vladejić, S, 2011) |
| "Data from the 3-year, prospective, observational SOHO study were used to compare the effectiveness (in terms of treatment discontinuation) and the tolerability of olanzapine, risperidone, other atypicals and typical antipsychotics in 1009 previously untreated outpatients with schizophrenia who started monotherapy at baseline." | 5.14 | Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. ( Haro, JM; Novick, D; Roca, M; Suarez, D, 2009) |
| "The efficacy, safety and tolerability of ziprasidone versus the comparators olanzapine, risperidone or quetiapine were investigated in adult patients with chronic schizophrenia, schizoaffective and schizophreniform disorders, with lack of efficacy or intolerance to their previous antipsychotic treatment based on clinical judgement of the investigator." | 5.14 | Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. ( Haug, HJ; Kolb, SA; Koponen, H; Lublin, H; Sigmundsson, T, 2009) |
| "Hyperprolactinemia, an adverse effect associated with the use of typical antipsychotics and the atypical antipsychotic risperidone, has both acute and chronic clinical consequences." | 5.14 | Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. ( Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R, 2009) |
| " One hundred two patients with first episode schizophrenia or schizoaffective disorder were assessed on cognitive measures of speed of processing, episodic memory, executive function, and visual spatial processing at baseline (when patients were drug naive and after 16 weeks of olanzapine or risperidone treatment), so that a change score could be derived." | 5.14 | Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. ( Burdick, KE; Goldberg, TE; Goldman, R; Kane, JM; Lencz, T; Malhotra, AK; McCormack, J; Napolitano, B; Patel, RC; Robinson, DG; Sevy, SM, 2009) |
| "The objective of this study was to evaluate the efficacy and safety of divalproex sodium extended release (divalproex ER) vs placebo in combination with olanzapine or risperidone for the treatment of acute exacerbations of schizophrenia." | 5.14 | Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. ( Abi-Saab, W; Baker, J; Casey, DE; Daniel, DG; Greco, N; Kane, JM; Redden, L; Saltarelli, M; Tamminga, C; Tran-Johnson, T; Wozniak, P, 2009) |
| "The primary objective of this randomised, active-controlled, parallel group, double-blind study was to evaluate the tolerability of treatment with either amisulpride or risperidone in elderly patients with schizophrenia aged over 65 years; evaluation of efficacy was a secondary objective." | 5.14 | A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. ( Eich, FX; Möller, HJ; Riedel, M, 2009) |
| "This randomized, double-blind, multicentre extension study compared the efficacy, tolerability, and safety of ziprasidone and risperidone for schizophrenia or schizoaffective disorder." | 5.14 | A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. ( Addington, DE; Johnson, G; Kulkarni, J; Labelle, A; Loebel, A; Mandel, FS, 2009) |
| " Patients, 13-17 years, with an acute episode of schizophrenia, randomised 1:1 to risperidone 1." | 5.14 | Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. ( Augustyns, I; Eerdekens, M; Haas, M; Kushner, S; Kusumakar, V; Pandina, G; Quiroz, J; Singer, J, 2009) |
| "This randomized, 24-week, flexible-dose study compared changes in glucose metabolism in patients with DSM-IV schizophrenia receiving initial exposure to olanzapine, quetiapine, or risperidone." | 5.14 | A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. ( Brecher, M; Emsley, R; Eriksson, JW; Leong, RW; Leonova-Edlund, J; Meulien, D; Miller, F; Newcomer, JW; Ratner, RE, 2009) |
| "Clinical trial data were evaluated for the association between 22 single-nucleotide polymorphisms (SNPs) and response in acutely ill patients diagnosed with schizophrenia, schizoaffective disorder or schizophreniform disorder, who were treated with oral risperidone." | 5.14 | Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. ( Conley, RR; Fijal, BA; Houston, JP; Jamal, HH; Kane, JM; Kapur, S; Kinon, BJ; Stauffer, VL; Witte, MM, 2009) |
| "This study evaluated the safety/tolerability and effectiveness of aripiprazole titrated-dose versus fixed-dose switching strategies from risperidone in patients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues." | 5.14 | Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. ( Kahn, JP; Kerselaers, W; Lissens, J; McQuade, RD; Modell, S; Ryckmans, V; Sanchez, R; Werner, C, 2009) |
| "To compare the efficacy of electro-acupuncture with that of sham electro-acupuncture for auditory hallucinations in patients with schizophrenia partially responsive or non-responsive to risperidone." | 5.14 | Electro-acupuncture versus sham electro-acupuncture for auditory hallucinations in patients with schizophrenia: a randomized controlled trial. ( , 2009) |
| "To compare the effectiveness of a switch from haloperidol (N=99), olanzapine (N=82), or risperidone (N=104) to 12 weeks of treatment with 80-160 mg/day ziprasidone in patients with stable schizophrenia or schizoaffective disorder." | 5.14 | Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. ( Akkaya, C; Alptekin, K; Brook, S; Danaci, AE; El Tallawy, H; Hafez, J; Karayal, ON; Lowe, W; Tzebelikos, E; Ucok, A, 2009) |
| "Risperidone treatment can improve disgust recognition deficits in patients with schizophrenia." | 5.14 | Effect of risperidone on emotion recognition deficits in antipsychotic-naïve schizophrenia: a short-term follow-up study. ( Arasappa, R; Behere, RV; Gangadhar, BN; Reddy, N; Venkatasubramanian, G, 2009) |
| "Perospirone was as effective as risperidone against positive and negative symptoms in patients with schizophrenia." | 5.14 | Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. ( Kato, M; Kinoshita, T; Kishimoto, T; Koh, J; Matsumoto, N; Morikawa, M; Okugawa, G; Shinosaki, K; Wakeno, M; Yoneda, H, 2009) |
| "To evaluate the quality of life, efficacy and safety of Warm-Supplementing Kidney Yang (WSKY) added to risperidone in patients with schizophrenia." | 5.14 | Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial. ( Chen, ZH; Huo, YX; Li, L; Mei, HB; Wang, GH; Wang, XP; Yang, MH, 2009) |
| "To evaluate the maintenance of efficacy of risperidone long-acting injectable (RLAI) in stable patients with schizophrenia or schizoaffective disorders." | 5.14 | Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. ( Bagalà, A; Bernareggi, MM; Del Curatolo, V; Giustra, MG; Rossi, A; Scapati, F, 2009) |
| "To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long-acting injectable risperidone (LAIR) in patients with schizophrenia." | 5.14 | Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. ( Kim, JM; Kim, SW; Lee, SH; Lee, YH; Shin, IS; Yang, SJ; Yoon, JS, 2009) |
| "Comparisons of diabetic potential, glucose related metabolic levels, and insulin resistance between olanzapine and risperidone have produced variable results in cross-sectional and epidemiologic studies." | 5.14 | Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. ( Cornwell, J; Davis, JM; Hu, Q; Kelly, E; Khan, A; Lindenmayer, JP; Smith, RC; Vaidhyanathaswamy, S; Viviano, TF, 2009) |
| "We identified novel candidate genes for treatment response to risperidone and provide evidence that one of these additionally may confer susceptibility to schizophrenia." | 5.14 | Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. ( Arinami, T; Hashimoto, R; Honda, H; Ikeda, M; Iwata, N; Kinoshita, Y; Koga, M; Mouri, A; Nabeshima, T; Nakamura, J; O'Donovan, MC; Okochi, T; Owen, MJ; Ozaki, N; Takeda, M; Tomita, Y; Williams, HJ; Yamanouchi, Y; Yoshimura, R, 2010) |
| "Previous studies had revealed no specific effect under haloperidol (typical) and risperidone (atypical) neuroleptic (NLP) treatments for schizophrenia (SZ) on a variety of neurocognitive functions relying on the dopaminergic meso-cortico-limbic system (Rémillard et al." | 5.14 | Long-term skill proceduralization in schizophrenia. ( Cohen, H; Pourcher, E; Rémillard, S, 2010) |
| "In this multicenter, double-blind, 16-week, placebo-controlled study conducted at 43 American sites from July 2006 to October 2007, patients with chronic, stable schizophrenia or schizoaffective disorder diagnosed with DSM-IV-TR were randomly assigned to receive aripiprazole (2-15 mg/d) or placebo in addition to a stable regimen of quetiapine (400-800 mg/d) or risperidone (4-8 mg/d)." | 5.14 | A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. ( Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E, 2009) |
| "Stable patients with psychotic disorders requiring medication change were switched to open-label RLAI in the switch to risperidone microspheres (StoRMi) trial." | 5.14 | Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. ( De Marinis, T; Lambert, M; Naber, D; Pfeil, J; Schreiner, A, 2010) |
| "Patients receiving care from old age psychiatrists for their schizophrenia were randomised to treatment with olanzapine or risperidone and were followed for up to 3(1/2) years." | 5.14 | Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration. ( Ames, D; Cheesman, N; Harrigan, S; Macfarlane, S; Mastwyk, M; Ritchie, CW, 2010) |
| "It has been reported that mirtazapine would be helpful for treating negative symptoms in schizophrenia." | 5.14 | The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. ( Abbasi, SH; Akhondzadeh, S; Behpournia, H; Ghoreshi, A; Raznahan, M; Rezaei, F; Rezazadeh, SA; Salehi, B, 2010) |
| "To assess treatment retention on risperidone long-acting injection (RLAI) and outcomes in schizophrenia patients for whom 24 months of follow-up data in the electronic Schizophrenia Treatment Adherence Registry (e-STAR) were available." | 5.14 | Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. ( Akhras, K; Bij de Weg, H; Eriksson, L; Jacobs, A; Olivares, JM; Pecenak, J; Peuskens, J; Resseler, S; Tuma, I, 2010) |
| "The aim of this study was to evaluate the efficacy and safety of two dose ranges of risperidone in adolescents with schizophrenia." | 5.14 | A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. ( Armenteros, J; Copenhaver, MD; Haas, M; Kushner, SF; Quiroz, JA; Unis, AS, 2009) |
| "Long-acting injectable (LAI) risperidone for intramuscular injection into the gluteal muscle every 2 weeks is approved for schizophrenia." | 5.14 | Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. ( Herben, V; Mannaert, E; Quiroz, J; Rusch, S; Thyssen, A, 2010) |
| "The objective of this open-label study was to evaluate treatment benefits of risperidone long-acting injectable (RLAI) in patients with schizophrenia following direct transition from oral risperidone (RIS) compared with transition from other oral second generation antipsychotics." | 5.14 | Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? ( Diekamp, B; Gerwe, M; Ibach, B; Schmauss, M; Schreiner, A, 2010) |
| "The study aimed to evaluate the efficacy of long-acting injectable risperidone (LAR) in Asian patients with schizophrenia spectrum disorders." | 5.14 | Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients. ( Abdin, E; Chong, SA; Lee, N; Sim, K; Su, A; Subramaniam, M; Verma, S, 2010) |
| "It is still common to encounter a partial or no response to antipsychotic treatment in clinical practice, but only individual case reports are currently available concerning the efficacy of long-acting risperidone (RLAI) in treatment-resistant schizophrenia." | 5.14 | Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients. ( Baldi, ML; Cerveri, G; De Gaspari, IF; Mauri, MC; Mencacci, C; Papa, P; Rolandi, ML; Volonteri, LS, 2010) |
| " Sixty patients with DSM-IV schizophrenia (n = 58) or schizoaffective disorder (n = 2) met the DSM-IV research criteria for neuroleptic-induced tardive dyskinesia and were randomly assigned to a risperidone or olanzapine group." | 5.14 | A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. ( Chan, HY; Chang, CJ; Chen, CH; Chen, JJ; Chiang, SC; Gau, SS; Hwu, HG; Lai, MS, 2010) |
| "Hospitalized patients with chronic schizophrenia, most of whom had been treated with multiple antipsychotics in the past, were randomly assigned to treatment with a single antipsychotic, olanzapine or risperidone, for a period of 5 months." | 5.14 | Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. ( Cornwell, J; Davis, JM; Hu, Q; Kelly, E; Lindenmayer, JP; Marcovina, S; Smith, RC; Vaidhyanathaswamy, S; Viviano, TF, 2010) |
| "The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design." | 5.14 | Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. ( Bahk, WM; Cho, HS; Jeon, YW; Jon, DI; Jung, HY; Kim, CH; Kim, HC; Kim, SH; Kim, YH; Kim, YK; Kwon, JS; Lee, SH; Lee, SY; Yang, J; Yi, JS; Yoon, BH, 2010) |
| " We therefore examined the relationship between -141C Ins/Del (rs1799732), a functional promoter region polymorphism in DRD2, and antipsychotic-induced weight gain in 58 first episode schizophrenia patients enrolled in a randomized trial of risperidone versus olanzapine." | 5.14 | DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. ( Goldman, D; Kane, JM; Lencz, T; Malhotra, AK; Napolitano, B; Robinson, DG; Sevy, S, 2010) |
| "A total of 72 patients with a first episode of schizophreniform psychosis (schizophrenia spectrum disorder) with less than 2 weeks of exposure to antipsychotic medication were randomized to quetiapine or risperidone in a single-blind 12-week controlled trial." | 5.14 | Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. ( Craig, TK; Elanjithara, T; Gafoor, R; Landau, S; McGuire, P; Power, P, 2010) |
| "To evaluate the efficacy and tolerability of armodafinil, the longer-lasting isomer of modafinil, as adjunctive therapy in patients with schizophrenia." | 5.14 | Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. ( D'Souza, DC; Kane, JM; Keefe, RS; Patkar, AA; Tiller, JM; Yang, R; Youakim, JM, 2010) |
| "Data are from a one-year, open-label, international, multicenter trial (n=670) of long-acting risperidone in adult symptomatically stable patients with schizophrenia or schizoaffective disorder." | 5.14 | Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder. ( David, AS; Fleischhacker, WW; Rabinowitz, J; Wiffen, BD, 2010) |
| "The incidence of suicide attempts (fatal and non-fatal) was analysed in a prospective cohort of patients with schizophrenia randomly assigned to sertindole (4905 patients) or risperidone (4904 patients) in a parallel-group open-label study with blinded classification of outcomes (the sertindole cohort prospective study--SCoP)." | 5.14 | Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. ( Crocq, MA; Drici, M; Everitt, B; Hall, GC; Lader, MH; Le Jeunne, C; Mann, R; Mittoux, A; Moore, ND; Naber, D; Peuskens, J; Priori, S; Sturkenboom, M; Tanghøj, P; Thibaut, F; Thomas, SH; Toumi, M, 2010) |
| "The role of partial agonism at 5-HT1A receptors in general and of buspirone in particular remains unclear in the treatment of negative symptoms of schizophrenia." | 5.14 | A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. ( Akhondzadeh, S; Farnaghi, F; Ghaleiha, A; Hajiazim, M; Noorbala, AA, 2010) |
| "Prodromal subjects and unmedicated patients with first-episode schizophrenia showed significant PPI deficits, whereas schizophrenia patients treated with risperidone had almost normal PPI." | 5.13 | Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia. ( Berning, J; Frommann, I; Kühn, KU; Maier, W; Quednow, BB; Wagner, M, 2008) |
| " All 200 patients who met the DSM-IV diagnostic criteria for schizophrenia were randomly assigned to double-blind treatment with WSKY capsule (n = 100) or placebo (n = 100) added on risperidone for 8 weeks." | 5.13 | Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial. ( Chen, RY; Chen, ZH; Huo, YX; Mei, HB; Wang, GH; Wang, HL; Wang, XP; Yang, MH, 2008) |
| "In this open-label study, 17 patients with treatment-refractory schizophrenia, who failed to respond to a sequential monotherapy with olanzapine, quetiapine and risperidone, were subsequently treated with a combination therapy with olanzapine plus risperidone for at least 8 weeks." | 5.13 | Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. ( Kashima, H; Nakajima, S; Nomura, K; Suzuki, T; Takeuchi, H; Tanabe, A; Uchida, H; Watanabe, K; Yagi, G, 2008) |
| "In a 6-week, randomized, open-label, rater-blinded study, patients with schizophrenia or schizoaffective disorder, on a stable drug dose for more than 30 days at entry, who were intolerant of or exhibiting a suboptimal symptom response to more than 30 days of olanzapine treatment, were randomly assigned to the following switch strategies (common risperidone initiation scheme; varying olanzapine discontinuation): (i) abrupt strategy, where olanzapine was discontinued at risperidone initiation; (ii) gradual 1 strategy, where olanzapine was given at 50% entry dose for 1 week after risperidone initiation and then discontinued; or (iii) gradual 2 strategy, where olanzapine was given at 100% entry dose for 1 week, then at 50% in the second week, and then discontinued." | 5.13 | Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. ( Berry, SA; Brar, JS; Ganguli, R; Mahmoud, R; Pandina, GJ, 2008) |
| "The current study evaluated the efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia." | 5.13 | Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. ( Casey, DE; Heisterberg, J; Sands, EE; Yang, HM, 2008) |
| "To examine whether subjective well-being and craving for cannabis were different in patients with schizophrenia or related disorders treated with either olanzapine or risperidone." | 5.13 | Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. ( de Haan, L; Linszen, D; van Beveren, NJ; van den Brink, W; van der Helm, M; van Nimwegen, LJ, 2008) |
| "Long-acting risperidone administered intramuscularly biweekly is approved for the management of schizophrenia." | 5.13 | Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. ( Kapur, S; Labelle, A; Mamo, DC; Mann, SW; Mannaert, EJ; Remington, G; Shammi, C; Uchida, H, 2008) |
| "In a larger clinical trial, 108 patients diagnosed with schizophrenia or schizoaffective disorder were randomly assigned to medication groups (risperidone, olanzapine, or conventional medications), treated in an open-label design, and monitored prospectively for 12 months using standard neuropsychological and symptomatology instruments." | 5.13 | Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications. ( Jerrell, JM; Ramirez, PM, 2008) |
| "To evaluate the effect of metformin treatment on the risperidone-induced body weight gain in patients." | 5.13 | A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. ( Arman, S; Koleini, N; Nadi, M; Sadramely, MR, 2008) |
| "Thirty children and adolescents (20 males, 10 females), ages 10-18 years, who met unmodified Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for a schizophrenia-spectrum disorder (schizophrenia, schizoaffective, schizophreniform, psychotic disorder not otherwise specified) were randomized to receive 12 weeks of open-label, flexibly dosed treatment with either risperidone (mean [standard deviation, SD] dose = 3." | 5.13 | A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. ( Anjum, A; Jensen, JB; Kumra, S; Lee, SS; Leitten, W; Oberstar, J; Schulz, SC; White, T; Wozniak, J, 2008) |
| "Risperidone and olanzapine did not demonstrate superior efficacy over molindone for treating early-onset schizophrenia and schizoaffective disorder." | 5.13 | Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. ( Ambler, D; Anderson, R; De Jong, S; Delporto-Bedoya, D; Findling, RL; Frazier, JA; Hamer, RM; Hlastala, S; Lieberman, JA; Maloney, AE; McClellan, J; McNamara, NK; Michael, E; Noyes, N; Pierson, L; Puglia, M; Ritz, L; Sikich, L; Slifka, K; Vitiello, B, 2008) |
| " This study was designed to investigate the effect of ritanserin added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double blind and randomized clinical trial." | 5.13 | Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. ( Akhondzadeh, S; Ghoreishi, A; Malek-Hosseini, M; Raznahan, M; Rezazadeh, SA, 2008) |
| "Aripiprazole should be considered as first line treatment in some patients affected by psychotic disorders visited in the emergency psychiatric setting." | 5.13 | Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting. ( Azzoni, A; Raja, M, 2008) |
| "The aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (SOC), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (The Schizophrenia Trial of Aripiprazole [STAR] study [NCT00237913])." | 5.13 | The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). ( Hanssens, L; Kerselaers, W; L'Italien, G; Loze, JY; Marcus, RN; Pans, M, 2008) |
| "This study seeks to replicate previous results indicating that T102C in the serotonin 2A receptor (HTR2A) and Ser9Gly in the dopamine D3 receptor (DRD3) were associated with a risperidone response to acutely exacerbated schizophrenia, and to determine whether possession of these alleles predicts clinical improvement in a naturalistic setting." | 5.13 | Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. ( Choi, EY; Joo, YH; Kim, B; Kim, CY; Song, K, 2008) |
| "This was a randomized, flexible-dose, rater-blind, parallel-group, quasi-naturalistic trial comparing the efficacy, safety, and tolerability of quetiapine, risperidone, and olanzapine in patients with schizophrenia hospitalized for severe psychotic symptoms." | 5.13 | A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial. ( Parrinello, G; Sacchetti, E; Valsecchi, P, 2008) |
| "It has been reported that selegiline, a Selective Monoamine Oxidase Inhibitor B (MAOI-B), at low doses would be helpful for treating negative symptoms in schizophrenia." | 5.13 | Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. ( Akhondzadeh, S; Amiri, A; Derakhshan, MK; Ghoreishi, A; Hajiazim, M; Khodaie-Ardakani, MR; Nejatisafa, AA; Noorbala, AA; Raznahan, M, 2008) |
| "This post hoc analysis used data from a 1-year, randomized, open-label study of olanzapine, risperidone, and typical antipsychotics in the treatment of schizophrenia." | 5.13 | Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. ( Ascher-Svanum, H; Baker, RW; Faries, DE; Kinon, BJ; Nyhuis, AW; Shekhar, A, 2008) |
| "Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment." | 5.13 | The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. ( Canive, JM; Davis, SM; Hsiao, JK; Khan, A; Lieberman, JA; McEvoy, JP; McGee, M; Miller, DD; Reimherr, F; Stroup, TS; Swanson, JW; Swartz, MS; Wagner, HR, 2008) |
| "Newly diagnosed patients with first-episode schizophrenia treated with antipsychotic medication-olanzapine, risperidone, or haloperidol-and matched healthy controls were followed for 6 weeks." | 5.13 | Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. ( Akhtar, S; Ameen, S; Saddichha, S, 2008) |
| "We performed a 6-month, randomized, double-blind study to evaluate the effects of risperidone and olanzapine in patients with schizophrenia." | 5.13 | Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. ( Ader, M; Bergman, RN; Berry, SA; Garvey, WT; Gharabawi, G; Greenspan, A; Mahmoud, R; Mao, L; Morein, J; Musselman, DL; Nemeroff, CB; Phillips, LS; Zhu, Y, 2008) |
| "First-episode patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder (DSM-IV) were randomly assigned to olanzapine (2." | 5.13 | Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. ( Gu, H; Hamer, RM; Lieberman, JA; McEvoy, JP; Perkins, DO; Weiden, PJ, 2008) |
| "One hundred twenty-two patients with a Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder were randomized in a double-blind design to groups of 6 weeks' treatment with olanzapine (n = 59) or risperidone (n = 63), with a mean dose of 11." | 5.13 | Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. ( de Haan, L; Laan, W; Linszen, D; van Beveren, N; van den Brink, W; van Nimwegen, L, 2008) |
| " We examined changes in weight and weight-related quality of life among community patients with schizophrenia treated with aripiprazole (ARI) versus standard of care (SOC), consisting of other marketed atypical antipsychotics (olanzapine, quetiapine, and risperidone)." | 5.13 | Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. ( Corey-Lisle, PK; Crosby, RD; Kan, HJ; Kolotkin, RL; McQuade, RD, 2008) |
| "This post-hoc analysis used data from the risperidone arm of a randomized, open-label, 1-year study of patients with schizophrenia." | 5.13 | Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. ( Ascher-Svanum, H; Faries, DE; Kinon, BJ; Nyhuis, AW, 2008) |
| "This multicentre, observational, prospective, nonrandomized study compared the effectiveness and tolerability of quetiapine and risperidone in the acute and long-term treatment of schizophrenia in a clinical setting." | 5.13 | A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. ( Cañas, F; Perez, V; Tafalla, M, 2008) |
| "The use of ketamine for depression has increased rapidly in the past decades." | 5.12 | Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021) |
| "We searched MEDLINE, Central, EMBASE and PsycINFO until December 2020 for randomised placebo-controlled trials of Risperidone, Paliperidone or Paliperidone palmitate in patients with schizophrenia or bipolar disorder." | 5.12 | Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports. ( Heneghan, C; Hodkinson, A; Kontopantelis, E; Mahtani, KR; Panagioti, M, 2021) |
| "Celecoxib augmentation therapy has been reported to enhance the rate of clinical response for patients with schizophrenia." | 5.12 | The effects of celecoxib augmentation on cytokine levels in schizophrenia. ( Ahmadpour, O; Bresee, CJ; Delrahim, K; Dolnak, D; Maddux, RE; Rapaport, MH, 2006) |
| "Sertindole is a non-sedating atypical antipsychotic effective in the management of schizophrenia and is associated with placebo-level incidence of extrapyramidal symptoms (EPS)." | 5.12 | A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. ( Azorin, JM; Loft, H; Strub, N, 2006) |
| "Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effects." | 5.12 | A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. ( Ames, D; Chiu, E; Hall, K; Halliday, G; Harrigan, S; Hassett, A; Hustig, H; MacFarlane, S; Mastwyk, M; Nagalingam, V; O'Connor, DW; Opie, J; Ritchie, CW; Snowdon, J, 2006) |
| "In this short-term study, the addition of risperidone to clozapine did not improve symptoms in patients with severe schizophrenia." | 5.12 | Clozapine alone versus clozapine and risperidone with refractory schizophrenia. ( Bergmann, A; Chan, RC; Chen, EY; Falkai, P; Honer, WG; MacEwan, GW; McKenna, PJ; Pomarol-Clotet, E; Procyshyn, R; Stip, E; Thornton, AE; Wasan, K; Williams, R; Wong, JO, 2006) |
| "This open-label, prospective, 4-month study in hyperprolactinemic patients with schizophrenia explored whether prolactin levels decrease after switching antipsychotic therapy to olanzapine." | 5.12 | Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. ( Ahl, J; Kinon, BJ; Liu-Seifert, H; Maguire, GA, 2006) |
| "Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two DRD2 promoter region polymorphisms (A-241G and -141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either risperidone or olanzapine." | 5.12 | DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. ( Ekholm, J; Goldman, D; Gunduz-Bruce, H; Kane, JM; Lencz, T; Malhotra, AK; Robinson, DG; Sevy, S; Woerner, MG; Xu, K, 2006) |
| "Outpatients with schizophrenia, who initiated or changed antipsychotic treatment, and entered this 3-year, prospective, observational study were classified according to the monotherapy prescribed at baseline: olanzapine (N=2638), risperidone (N=860), quetiapine (N=142) or haloperidol (N=188)." | 5.12 | Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. ( Akram, A; Anders, M; Araszkiewicz, A; Dossenbach, M; Dyachkova, Y; Khalil, A; McBride, M; Pecenak, J; Pirildar, S; Shakhnovich, T; Treuer, T, 2006) |
| "When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine." | 5.12 | Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| "Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason." | 5.12 | Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| "The present study aimed to investigate the effects of clozapine, olanzapine, risperidone, and sulpiride on glucose and lipid metabolism in first-episode schizophrenia." | 5.12 | Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. ( Guo, WB; Guo, XF; Liu, ZN; Tang, JS; Wu, RR; Zhai, JG; Zhao, JP, 2006) |
| " This study aimed to simultaneously explore the effects of multiple candidate genes and environment factors on body weight of schizophrenia patients who received risperidone, a commonly used atypical antipsychotic agent." | 5.12 | Risperidone-related weight gain: genetic and nongenetic predictors. ( Chang, WH; Chang, YC; Huang, CL; Lane, HY; Liu, YC; Lu, CT; Wu, PL, 2006) |
| "The purpose of this study was to assess the effect of switching to risperidone in the treatment of first-episode schizophrenia who had failed to respond to an initial-prescribed antipsychotic, olanzapine." | 5.12 | Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. ( Higuchi, H; Ishigooka, J; Takahashi, H; Yoshida, K, 2006) |
| "This study compared the effects of atypical antipsychotics (risperidone or quetiapine) with placebo and with each other in recently exacerbated patients with schizophrenia requiring hospitalization." | 5.12 | A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. ( Bossie, CA; Burtea, V; Davidson, M; Gharabawi, GM; Greenspan, AJ; Kosik-Gonzalez, C; Mahmoud, R; Potkin, SG; Rupnow, MF; Trivedi, JK; Zhu, Y, 2006) |
| "Adjunctive treatment with galantamine improves memory and attention in patients with schizophrenia who are stabilized on risperidone, providing the opportunity to improve functional outcome in these patients." | 5.12 | Galantamine improves cognition in schizophrenic patients stabilized on risperidone. ( Hicks, PB; Schubert, MH; Young, KA, 2006) |
| "This study examined specific predictors of the efficacy of risperidone (RP), olanzapine (OL) and first-generation antipsychotic agents (FGAs), the role of confounding factors, and concomitant agents such as antidepressants, anxiolytics, and mood stabilizers in the treatment of health related quality of life (HRQL) impairment of schizophrenia patients." | 5.12 | The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers. ( Gibel, A; Ritsner, MS, 2006) |
| " Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)." | 5.12 | Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006) |
| "To compare the efficacy and tolerability of quetiapine and risperidone in the treatment of schizophrenia." | 5.12 | Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. ( Hamer, RM; Lieberman, JA; Sweitzer, DE; Zhong, KX, 2006) |
| "This study aimed to compare the efficacy of long-acting risperidone and zuclopenthixol in subjects with schizophrenia and substance abuse." | 5.12 | Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. ( Alamo, C; Jiménez-Arriero, MA; López-Muñoz, F; Martínez, I; Ponce, G; Rubio, G, 2006) |
| "This study examined the effects of 2 doses of long-acting risperidone injection in patients with schizophrenia or schizoaffective disorder." | 5.12 | A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. ( Bossie, CA; Gharabawi, GM; Kujawa, M; Lasser, RA; Mahmoud, RA; Rodriguez, S; Simpson, GM; Turkoz, I, 2006) |
| "The effect of lamotrigine on the steady-state plasma concentrations of the atypical antipsychotics clozapine, olanzapine, and risperidone was investigated in patients with schizophrenia or bipolar disorder stabilized on chronic treatment with clozapine (200-500 mg/day; n = 11), risperidone (3-6 mg/day; n = 10) or olanzapine (10-20 mg/day; n = 14))." | 5.12 | Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ( D'Amico, G; D'Arrigo, C; Micò, U; Migliardi, G; Muscatello, MR; Perucca, E; Santoro, V; Spina, E, 2006) |
| "Subjects were patients with schizophrenia or schizoaffective disorder enrolled in extension studies (Study A and Study B) after participating in 12-week studies of long-acting injectable risperidone [Kane, J." | 5.12 | Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. ( Eerdekens, M; Khan, A; Kushner, S; Lindenmayer, JP; Van Hove, I, 2007) |
| "Patients with schizophrenia were randomly assigned in a 1:1 ratio to receive treatment with either quetiapine (dose range: 200-800 mg/day) or risperidone (dose range: 2-8 mg/day) for an 8-week period." | 5.12 | Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. ( Brecher, M; Harvey, PD; Patterson, TL; Potter, LS; Zhong, K, 2006) |
| " In this study we evaluated the role of six polymorphisms of the DRD2 gene in 125 risperidone-treated Chinese schizophrenia patients following the hypothesis that variation in the DRD2 gene could affect drug response." | 5.12 | The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. ( Duan, S; Feng, G; Gao, J; Gao, R; He, L; Li, H; Meng, J; Qian, X; Qin, W; Wong, S; Wu, S; Xing, Q; Xu, M, 2007) |
| "The efficacy and safety of switching to olanzapine were investigated in patients with first-episode schizophrenia who failed to attain an adequate clinical response to an initial therapeutic trial of risperidone (2-6 mg/day for 12 weeks)." | 5.12 | Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. ( Higuchi, H; Ishigooka, J; Kamata, M; Takahashi, H; Yoshida, K, 2006) |
| "One hundred twenty-three inpatients with acutely exacerbated schizophrenia were given optimal therapy of risperidone, a commonly used second-generation antipsychotic agent." | 5.12 | Optimizing early prediction for antipsychotic response in schizophrenia. ( Chang, YC; Huang, CL; Lane, HY; Yang, KH, 2006) |
| "Forty-eight patients with remitted DSM-IV schizophrenia and comorbid major depression were randomized to placebo for 6 weeks or sertraline 50 mg for 4 weeks followed by sertraline 50 mg to 100 mg for 2 weeks for nonresponders." | 5.12 | Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication. ( Addington, D; Addington, J; Patten, S; Pierson, K, 2006) |
| "The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders." | 5.12 | Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. ( Gunduz-Bruce, H; Kane, JM; Khadivi, A; Lesser, ML; Lorell, BS; McCormack, J; Mendelowitz, A; Miller, R; Napolitano, B; Patel, RC; Robinson, DG; Schooler, NR; Sevy, SM; Soto-Perello, JM; Woerner, MG, 2006) |
| "To investigate the effects of risperidone on the polysomnography (PSG) in the patients with first-episode schizophrenia." | 5.12 | [Effects of risperidone on polysomnography in patients with first-episode schizophrenia]. ( Chen, C; Chen, XS; Chen, XW; Gao, CY; Liang, JH; Liu, L; Liu, P; Liu, XW; Lou, FY; Wang, HX; Wang, JJ; Zhang, MD, 2006) |
| "This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria." | 5.12 | Patient-based and clinician-based support for the remission criteria in schizophrenia. ( Bossie, CA; Bouhours, P; Docherty, JP; Gharabawi, GM; Lachaux, B; Lasser, R; Zhu, Y, 2007) |
| "Adjunctive treatment with risperidone for 6 weeks in patients with schizophrenia who had received chronic treatment with clozapine does not significantly improve cognitive function." | 5.12 | A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. ( Akdede, BB; Alptekin, K; Anil Yağcioğlu, AE; Göğüş, A; Jayathilake, K; Meltzer, HY; Tümüklü, M; Tunca, Z; Turgut, TI; Yazici, MK, 2006) |
| "In this observational study, 48 inpatients with acutely decompensated schizophrenia were offered antipsychotic treatment with oral risperidone." | 5.12 | Early onset of treatment effects with oral risperidone. ( Naber, D; Raedler, TJ; Schreiner, A; Wiedemann, K, 2007) |
| "This subgroup analysis of symptomatically stable patients with schizophrenia or other psychotic disorders in the StoRMi trial determined the efficacy and tolerability of risperidone long-acting injectable in patients changed from oral risperidone monotherapy." | 5.12 | Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. ( Kahn, JP; Medori, R; Sacchetti, E; Schmauss, M, 2007) |
| "Risperidone augmentation of clozapine in refractory schizophrenia has theoretical but only inconsistent support from clinical trials." | 5.12 | Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. ( Culhane, MA; Freudenreich, O; Goff, DC; Henderson, DC; Walsh, JP, 2007) |
| "Subjects with schizophrenia (N=114) who had been randomly assigned to and then discontinued perphenazine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were reassigned randomly to double-blinded treatment with olanzapine, 7." | 5.12 | Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. ( Belz, I; Capuano, GA; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007) |
| "Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen." | 5.12 | Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. ( DeVane, CL; Horner, MD; Markowitz, JS; McGurk, SR; Nahas, Z; Palecko, S; Risch, SC, 2007) |
| "To evaluate the clinical efficacy of modified Daotan Decoction (DD) combining low dosage of risperidone in treating chronic schizophrenia patients of phlegm-dampness blockage type, and compare with patients treated with risperidone alone." | 5.12 | [Clinical observation on effect of modified Daotan Decoction combined with small dose risperidone in treating chronic schizophrenia]. ( Liu, JL; Ma, L; Wang, Y, 2007) |
| "To compare olanzapine and risperidone outcome on some neurocognitive dimensions in chronic schizophrenia patients with prominent negative symptoms." | 5.12 | Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. ( Alvarez, E; Bousoño, M; Carlos Gómez, J; Ciudad, A; Gurpegui, M; Olivares, JM, 2007) |
| "Randomized, double-blind study of patients with schizophrenia assigned to receive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months as reported previously by Lieberman et al." | 5.12 | Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. ( Bilder, RM; Capuano, G; Davis, CE; Davis, SM; Gold, JM; Green, MF; Harvey, PD; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Palmer, BW; Perkins, DO; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007) |
| "To compare long-acting risperidone and oral olanzapine in 377 patients with DSM-IV schizophrenia or schizoaffective disorder." | 5.12 | Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. ( Ingham, M; Karcher, K; Keks, NA; Khan, A, 2007) |
| "The Treatment of Early Onset Schizophrenia Spectrum Disorders Study is a publicly funded clinical trial designed to compare the therapeutic benefits, safety, and tolerability of risperidone, olanzapine, and molindone in youths with early-onset schizophrenia spectrum disorders." | 5.12 | Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. ( Ambler, D; Anderson, R; Findling, RL; Frazier, JA; Hamer, RM; Hlastala, SA; Hunt-Harrison, T; Lieberman, JA; Maloney, AE; McCLELLAN, J; Ritz, L; Sikich, L; Vitiello, B; Williams, E, 2007) |
| "To determine the effectiveness of amisulpride on depression in patients with schizophrenia, in comparison to risperidone." | 5.12 | Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. ( Hwang, MY; Kim, JM; Kim, SW; Lee, JH; Lee, SH; Shin, IS; Yang, SJ; Yoon, BH; Yoon, JS, 2007) |
| "The data for this study represent a subset of data from a randomized, double-blinded trial that evaluated subjects with schizophrenia who demonstrated a poor treatment response to clozapine." | 5.12 | Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. ( Barr, AM; Birmingham, CL; Chen, EY; Honer, WG; Macewan, GW; Pomarol-Clotet, E; Procyshyn, RM; Stip, E; Thornton, AE; Wasan, KM; Williams, R, 2007) |
| "Previous studies showed clinical benefit of risperidone long-acting injection in the treatment of schizophrenia." | 5.12 | Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. ( Bai, YM; Chang, WH; Chen, JY; Hung, CH; Kuo Lin, W; Ting Chen, T; Wu, B, 2007) |
| "To report the results on cognition of a randomized comparison of 2 widely prescribed second-generation antipsychotic medications, olanzapine and risperidone, in patients with first-episode schizophrenia and a healthy control group." | 5.12 | Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? ( Burdick, KE; Goldberg, TE; Goldman, RS; Kane, JM; Lencz, T; Malhotra, AK; Patel, RC; Robinson, DG; Schooler, NR; Woerner, MG, 2007) |
| "The efficacy and safety of risperidone, quetiapine, and placebo were compared in a 14-day monotherapy phase in patients experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder." | 5.12 | Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. ( Gharabawi, GM; Greenspan, A; Kosik-Gonzalez, C; Rupnow, MF; Stahl, SM; Zhu, Y, 2007) |
| "The objective of the study was to compare the antiaggressive efficacy of risperidone monotherapy versus risperidone plus valproate in patients with schizophrenia." | 5.12 | Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. ( Citrome, L; Czobor, P; Nolan, KA; Shope, CB; Volavka, J, 2007) |
| "This 6-week trial assessed the efficacy, tolerability, and safety of the investigational psychopharmacologic agent asenapine versus placebo and risperidone in patients with acute schizophrenia (DSM-IV criteria)." | 5.12 | Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. ( Cohen, M; Panagides, J; Potkin, SG, 2007) |
| " Accordingly, the hypothesis of whether 1-year relapse rate in first-episode schizophrenia under maintenance treatment with risperidone is lower compared to haloperidol in low dose was tested." | 5.12 | Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Bechdolf, A; Bender, S; Buchkremer, G; Degner, D; Eickhoff, M; Falkai, P; Gaebel, W; Häfner, H; Jäger, M; Jockers-Scherübl, MC; Klimke, A; Klingberg, S; Köpcke, W; Kühn, KU; Lemke, M; Maier, W; Möller, HJ; Ohmann, C; Riesbeck, M; Salize, HJ; Schlösser, R; Schmidt, LG; Schmitt, A; Schneider, F; von Wilmsdorff, M; Wölwer, W, 2007) |
| "This post hoc analysis explored the role of insight as a mediator of functioning in a 52-week, double-blind, international trial of 323 patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable." | 5.12 | The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. ( Bossie, C; Gharabawi, G; Kujawa, M; Mahmoud, R; Simpson, G; Turkoz, I, 2007) |
| "Risperidone doses for acute schizophrenia were rather high in most recent studies." | 5.11 | Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants. ( Chang, WH; Chang, YC; Chiu, CC; Lane, HY; Lee, SH; Lin, CY, 2004) |
| "This open-label study included patients with schizophrenia or a related psychotic illness who were randomized to quetiapine (200-1200 mg/d) or risperidone (1-6 mg/d) for 6 weeks." | 5.11 | A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. ( Bous, H; Bruggeman, R; Castelein, S; Kluiter, H; Knegtering, R; van den Bosch, RJ; Van Der Linde, J, 2004) |
| "To test the hypothesis that administration of risperidone to healthy subjects produces reductions in metabolism in the frontal cortex similar to those produced by administration of risperidone to patients experiencing a first episode of schizophrenia." | 5.11 | Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia. ( Lane, CJ; Liddle, PF; Ngan, ET; Ruth, TJ; Yatham, LN, 2004) |
| "Clinical trials indicate that glycine site agonists of the N-methyl-D-aspartate (NMDA) receptors may reduce negative and cognitive symptoms in treatment-resistant schizophrenia when used as adjuvants to conventional antipsychotics but possibly not to clozapine." | 5.11 | High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. ( Bar, G; Ermilov, M; Heresco-Levy, U; Javitt, DC; Lichtenberg, P, 2004) |
| "Treatment-resistant patients (133 men, 24 women) diagnosed with DSM-IV schizophrenia or schizoaffective disorder participated in a double-blind, randomized, 14-week trial comparing clozapine (N = 40), olanzapine (N = 39), risperidone (N = 41), and haloperidol (N = 37)." | 5.11 | Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. ( Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2004) |
| "In a 6-week open-label trial, sildenafil was administered to 12 male schizophrenia (DSM-IV) patients, treated with risperidone and reporting erectile dysfunction." | 5.11 | An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. ( Aviv, A; Shelef, A; Weizman, A, 2004) |
| "Over 3 months, 41 patients with schizophrenia were randomized to treatment with risperidone 1-12 mg (n=21) or haloperidol 2-20 mg (n=20) daily." | 5.11 | Adverse effects of risperidone and haloperidol treatment in schizophrenia. ( Chong, MY; Lung, FW; Yen, YC, 2004) |
| "The purpose of this investigation was to evaluate the effects of clozapine and risperidone on social skill and problem solving in patients with schizophrenia." | 5.11 | Do clozapine and risperidone affect social competence and problem solving? ( Bellack, AS; Brown, CH; Kane, JM; Marder, SR; Schooler, NR; Yang, Y, 2004) |
| " Dopamine D2 receptor occupancies and plasma concentrations of risperidone were measured in five patients with schizophrenia using positron emission tomography with [11C]FLB 457." | 5.11 | Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. ( Ichimiya, T; Ikoma, Y; Inoue, M; Maeda, J; Okubo, Y; Sudo, Y; Suhara, T; Takano, A; Yasuno, F, 2004) |
| "This study compared the specific antihostility effects of atypical antipsychotic monotherapy (olanzapine or risperidone) with that of combination treatment with divalproex sodium among patients with schizophrenia experiencing an acute psychotic episode." | 5.11 | Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. ( Casey, DE; Citrome, L; Daniel, DG; Kochan, LD; Tracy, KA; Wozniak, P, 2004) |
| "307 schizophrenia subjects in their first episode of illness were recruited to participate in a clinical trial comparing the long-term efficacy of haloperidol and risperidone." | 5.11 | Correlates of cognitive deficits in first episode schizophrenia. ( Csernansky, JG; DeLisi, LE; Heydebrand, G; Hoff, AL; Rabinowitz, J; Weiser, M, 2004) |
| "To assess changes in cognitive function in stable outpatients with schizophrenia switched to ziprasidone from conventional antipsychotics (n = 108), olanzapine (n = 104), or risperidone (n = 58) because of suboptimal efficacy or poor tolerability." | 5.11 | Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. ( Harvey, PD; Loebel, A; Meltzer, H; Potkin, SG; Romano, SJ; Simpson, GM; Siu, C, 2004) |
| "In two double-blind studies, 552 adult and elderly patients with schizophrenia or schizoaffective disorder were randomly assigned to risperidone or olanzapine treatment for 8 weeks." | 5.11 | Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. ( Gharabawi, G; Lasser, RA; Mao, L, 2004) |
| "Seven patients with schizophrenia taking risperidone 6 mg/day and nine patients with schizophrenia taking olanzapine 10 mg/day underwent an [123I]IBZM SPECT scan after 3 weeks of treatment." | 5.11 | Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. ( Abi-Dargham, A; Cangiano, C; Frankle, WG; Gil, R; Gorman, JM; Hackett, E; Kochan, LD; Laruelle, M; Mawlawi, O; Slifstein, M; Zea-Ponce, Y; Zhu, Z, 2004) |
| " This study does not support efficacy of either risperidone or zuclopenthixol on cognitive functions in drug-naive schizophrenia patients after 3 months of medication, because neither could be distinguished from retest effects of the healthy control group." | 5.11 | Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. ( Fagerlund, B; Gade, A; Glenthøj, BY; Mackeprang, T, 2004) |
| "Treatment outcome was evaluated in outpatients with chronic schizophrenia during long-term administration of risperidone in a study reflecting clinical practice." | 5.11 | Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone. ( Libretto, SE; Reveley, MA, 2004) |
| "We investigated the impact of treatment with long-acting, injectable risperidone versus placebo on health-related quality of life (HRQoL) in patients with schizophrenia." | 5.11 | Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. ( Duchesne, I; Eerdekens, M; Janagap, C; Mehnert, A; Nasrallah, HA, 2004) |
| "Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia." | 5.11 | Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. ( Chang, WH; Chang, YC; Huang, CH; Lane, HY; Lee, CC; Lu, CT, 2004) |
| "The aim of this study was to compare the effects of olanzapine and risperidone on cognitive functions in patients with schizophrenia." | 5.11 | A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia. ( Kang, BJ; Kim, YT, 2004) |
| " In a multicentre, open-label study of 725 patients with schizophrenia or schizoaffective disorder, patients received 25-75 mg of long-acting risperidone every 2 weeks for up to 50 weeks, with performance of standard safety and efficacy assessments." | 5.11 | Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. ( Bossie, CA; Lasser, RA; van Os, J, 2004) |
| "Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone." | 5.11 | Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. ( Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M, 2004) |
| "Treatment with risperidone is associated with prolactin (PRL) elevation, and PRL elevations are associated with erectile dysfunction (ED)." | 5.11 | Prolactin levels and erectile function in patients treated with risperidone. ( Bartztokis, G; Cargile, C; Spollen, JJ; Wooten, RG, 2004) |
| "This UK multicenter, noncomparative, open-trial study assessed risperidone in 74 first-psychotic-episode patients (DSM-IV schizophrenia) treated with flexible doses." | 5.11 | A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. ( Huq, ZU, 2004) |
| "The pharmacokinetics and tolerability of long-acting risperidone (Risperdal Consta) were evaluated in a multicenter, prospective, open-label, 15-week study of 86 patients with schizophrenia." | 5.11 | Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. ( Eerdekens, M; Mannaert, E; Remmerie, B; Van Hove, I, 2004) |
| "The effect of sertraline on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was studied in 11 patients with schizophrenia or schizoaffective disorder." | 5.11 | Plasma risperidone concentrations during combined treatment with sertraline. ( Ancione, M; D'Arrigo, C; Madia, A; Migliardi, G; Morgante, L; Spina, E; Zoccali, R, 2004) |
| "The goal of this study was to compare the effect of risperidone and haloperidol on serum PRL and investigate the relationship between serum PRL levels and clinical response in patients with schizophrenia." | 5.11 | Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2005) |
| "From April 1996 to August 1997, seventy-eight inpatients with a diagnosis of chronic schizophrenia (DSM-III-R) were randomly assigned to 12 weeks of treatment with 6 mg/day of risperidone or 20 mg/day of haloperidol." | 5.11 | Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2004) |
| "The safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications." | 5.11 | Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. ( Berry, SA; Eerdekens, E; Eerdekens, M; Lindenmayer, JP, 2004) |
| "To assess the efficacy and safety of long-acting injectable risperidone in elderly patients with psychotic disorders." | 5.11 | Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. ( Bossie, CA; Davidson, M; Eerdekens, M; Gharabawi, G; Lasser, RA; Zhu, Y, 2004) |
| "Healthcare resource use is significantly reduced in patients with stable schizophrenia or schizoaffective disorder receiving long-acting risperidone." | 5.11 | Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. ( Jarema, M; Leal, A; Mehnert, A; Remington, G; Rosillon, D, 2004) |
| "Sixteen male patients with schizophrenia, who were receiving stable, physician-optimized risperidone (1-4 mg twice daily), and 15 healthy age- and weight-matched male controls, received donepezil HCl 5 mg daily for 7 days." | 5.11 | Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ( Cullen, EI; Khan, A; Kumar, D; Perdomo, CA; Pratt, RD; Preskorn, SH; Reyes, JF, 2004) |
| " Data from a schizophrenia study were reevaluated under the aspect whether an effect on the positive and negative syndrome scale (PANSS) factor cognition can be observed during therapy with the COX-2 inhibitor celecoxib add on to risperidone in comparison to riperidone alone." | 5.11 | Clinical effects of COX-2 inhibitors on cognition in schizophrenia. ( Engel, RR; Müller, N; Riedel, M; Schwarz, MJ, 2005) |
| "To investigate the effects of the atypical antipsychotic drugs risperidone, olanzapine, quetiapine, and perospirone on the subjective quality of sleep in patients with schizophrenia." | 5.11 | Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. ( Mori, K; Morinobu, S; Nagao, M; Okamoto, Y; Yamashita, H; Yamawaki, S, 2004) |
| "Neuroleptic monotherapy with risperidone was administered to schizophrenia patients in a 6-week open dose clinical trial." | 5.11 | Risperidone plasma levels, clinical response and side-effects. ( Möller, HJ; Müller, N; Müller-Arends, A; Riedel, M; Schwarz, MJ; Spellmann, I; Strassnig, M; Weber, K; Zach, J, 2005) |
| "A double-blind study of long-acting injectable risperidone and oral risperidone tablets was conducted in 640 patients with schizophrenia." | 5.11 | Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. ( Augustyns, I; Chue, P; David, AS; Eerdekens, M; Eriksson, L; Lachaux, B; Molcan, P; Pretorius, H, 2005) |
| "The authors evaluated the efficacy and safety of augmenting clozapine with risperidone in patients with treatment-resistant schizophrenia." | 5.11 | Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. ( Dadvand, M; Joseph, A; Josiassen, RC; Kohegyi, E; Paing, WW; Shaughnessy, RA; Stokes, S, 2005) |
| " Thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder." | 5.11 | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. ( Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ, 2004) |
| "This study prospectively examined the effectiveness of treatment with olanzapine versus risperidone in reducing violent behavior among patients with schizophrenia under "usual care" conditions in the community." | 5.11 | Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. ( Elbogen, EB; Swanson, JW; Swartz, MS; Van Dorn, RA, 2004) |
| "Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia." | 5.11 | Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. ( Chang, WH; Chang, YC; Hsu, SK; Huang, CH; Lane, HY; Liu, YC, 2005) |
| "In this 6-week double-blind study, 30 patients with DSM-IV schizophrenia who had partial response to clozapine despite being treated for a mean of 32 months were randomly assigned to risperidone (N = 16) up to 6 mg/day or placebo (N = 14)." | 5.11 | A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. ( Alptekin, K; Anil Yağcioğlu, AE; Ertuğrul, A; Göğüş, A; Jayathilake, K; Kivircik Akdede, BB; Meltzer, HY; Tümüklü, M; Tunca, Z; Turgut, TI; Yazici, MK, 2005) |
| "Thyroid function was assessed in 38 adult DSM-IV-diagnosed schizophrenia patients after 6 weeks of prospective, double-blind, randomized treatment with quetiapine (400 mg/day), risperidone (4 mg/day), or fluphenazine (12." | 5.11 | Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. ( Conley, RR; Kelly, DL, 2005) |
| "This 14-week, multicenter, open-label, rater-blinded, randomized study evaluated the effects of a group-based behavioral treatment (BT) for weight loss in overweight and obese stable patients with DSM-IV schizophrenia or schizoaffective disorder who had been switched from olanzapine to risperidone." | 5.11 | Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. ( Berry, S; Brar, JS; Ganguli, R; Mahmoud, R; Pandina, G; Turkoz, I, 2005) |
| "Thirteen patients with schizophrenia received injections of 25, 50, or 75 mg of long-acting risperidone every 2 wk." | 5.11 | Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ( Björner, A; Eerdekens, M; Eriksson, B; Gefvert, O; Helldin, L; Mannaert, E; Nyberg, S; Persson, P; Remmerie, B, 2005) |
| " The present study investigated the effect of risperidone on pre-existing severe tardive dyskinesia among 40 patients with chronic schizophrenia over 48 weeks." | 5.11 | Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. ( Bai, YM; Chen, JY; Chou, P; Lin, CC; Lin, CY; Yu, SC, 2005) |
| "Thirty-nine risperidone- or olanzapine-treated schizophrenia patients participated in a double-blind, placebo-controlled, 6-week crossover trial with 30 mg/kg/day D-serine added to their antipsychotic medication." | 5.11 | D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. ( Bar, G; Catinari, S; Ebstein, R; Ermilov, M; Heresco-Levy, U; Javitt, DC; Lichtenberg, P; Vass, A, 2005) |
| "The maintained antipsychotic efficacy of risperidone long-acting injectable (RLAI) was investigated in patients with schizophrenia or other psychoses who were transitioned directly from their previous antipsychotic medication." | 5.11 | Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. ( Llorca, PM; Martin, SD; Medori, R; Möller, HJ; Parellada, E; Sacchetti, E, 2005) |
| "An open-label study was performed to investigate the clinical efficacy and mechanisms of risperidone liquid in ameliorating positive symptoms in the acute phase of schizophrenia." | 5.11 | An open study of risperidone liquid in the acute phase of schizophrenia. ( Egami, H; Goto, M; Kaji, K; Kakihara, S; Kohara, K; Maeda, H; Nakamura, J; Ninomiya, H; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2005) |
| "The purpose of this investigation was to evaluate the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia." | 5.11 | The effects of clozapine and risperidone on spatial working memory in schizophrenia. ( Carter, C; Goldman, R; Green, MF; Kane, JM; Marder, SR; McGurk, SR; Schooler, NR; Xie, H, 2005) |
| "This study investigated the effect of clozapine on working memory in 15 subjects with schizophrenia, using an event related potential paradigm designed to separate components reflecting working memory updating from components related to target detection and response." | 5.11 | Clozapine improves working memory updating in schizophrenia. ( Clark, CR; Galletly, CA; McFarlane, AC, 2005) |
| "In a 50-week, open-label trial, stable patients with schizophrenia or schizoaffective disorder who received long-acting risperidone injection every 2 weeks were assessed using the Positive and Negative Syndrome Scale (PANSS)." | 5.11 | Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. ( Bossie, CA; Gharabawi, GM; Kane, JM; Lasser, RA, 2005) |
| "Clinically stable subjects with schizophrenia or schizoaffective disorder participated in a 50-week, open-label trial of long-acting, injectable risperidone." | 5.11 | An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. ( Bossie, CA; Gharabawi, GM; Lasser, RA; Mao, L; Zhu, Y, 2005) |
| " Injection site pain, other skin reactions and patient satisfaction with treatment were assessed in two large, multicentre studies of long-acting injectable risperidone (Risperdal CONSTA, Janssen Pharmaceutica Products, Titusville, New Jersey, USA), the first available long-acting atypical antipsychotic agent." | 5.11 | Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. ( Bossie, CA; Jarboe, K; Lasser, R; Lindenmayer, JP; Mehnert, A; Zhu, Y, 2005) |
| "This analysis aimed to assess the relationship between race and clinical response to long-acting, injectable risperidone treatment in patients with schizophrenia or schizoaffective disorder." | 5.11 | Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. ( Bossie, CA; Ciliberto, N; Lasser, RA; Urioste, R, 2005) |
| "Cerebral cortical gray was examined volumetrically in 19 patients with schizophrenia before and following 28 days of treatment with two SGAs (risperidone and ziprasidone; n = 13) or a FGA (haloperidol; n = 6)." | 5.11 | Cerebral cortical gray expansion associated with two second-generation antipsychotics. ( Christensen, JD; Garver, DL; Holcomb, JA, 2005) |
| " This study evaluated treatment practices over 7 years of initial treatment with oral risperidone in acutely exacerbated patients with schizophrenia and in a subgroup of highly agitated, tense, and aggressive patients." | 5.11 | Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. ( Degner, D; Pajonk, FG; Peters, S; Rettig, K; Rüther, E; Schreiner, A, 2005) |
| "In a 1-year, open-label, international multicentre trial of long-acting risperidone in 615 stable adult patients with schizophrenia, self-rated functioning and well-being were measured every 3 months using the Short Form 36-item questionnaire (SF-36)." | 5.11 | Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. ( Eerdekens, M; Fleischhacker, WW; Kemmler, G; Mehnert, A; Rabinowitz, J, 2005) |
| "As monotherapy, both olanzapine and risperidone were superior to haloperidol and clozapine in reducing aggression." | 5.11 | Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). ( Bitter, I; Czobor, P; Dossenbach, M; Volavka, J, 2005) |
| "The primary aim of this study was to compare the effectiveness of 12 months' treatment with olanzapine, risperidone, quetiapine, or haloperidol in preventing relapse of schizophrenia." | 5.11 | Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. ( Aguilar, J; Arango-Dávila, C; Assunção, S; Caro, O; Dossenbach, M; Landa, E; Leadbetter, J; Silva Ibarra, H, 2005) |
| "To compare the efficacy of two atypical antipsychotic drugs, olanzapine and risperidone, in schizophrenic patients with post-psychotic depression." | 5.11 | Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. ( Chabot, B; Déal, C; Dollfus, S; Olivier, V; Perrin, E, 2005) |
| "The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (< or = 3 years)." | 5.11 | Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. ( Andrezina, R; Gaebel, W; Glue, P; Masiak, M; Medori, R; Milanova, V; Parellada, E; Turner, MS, 2005) |
| "Cognitive assessments were conducted in 533 patients experiencing their first episode of schizophrenia or a related psychosis who had been randomly assigned to receive low doses of risperidone or haloperidol." | 5.11 | Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. ( Davidson, M; Eerdekens, M; Harvey, PD; Rabinowitz, J, 2005) |
| "Agents that enhance N-methyl-D-aspartate (NMDA) function through the glycine modulatory site (D-serine, glycine, or D-cycloserine) or through glycine transporter 1 (sarcosine) improve the symptoms of patients with stable chronic schizophrenia." | 5.11 | Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. ( Chang, YC; Chiu, CC; Lane, HY; Liu, YC; Tsai, GE, 2005) |
| "To assess treatment discontinuation and concomitant use of other antipsychotics among individuals initiated on olanzapine or risperidone for the treatment of schizophrenia." | 5.11 | Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. ( Abdous, B; Cooper, D; Gaudet, M; Grégoire, JP; Moisan, J, 2005) |
| "The aim of this article was to examine the effects of switching from the antipsychotic olanzapine to risperidone on the prevalence of the metabolic syndrome in high-risk overweight or obese patients with schizophrenia or schizoaffective disorder." | 5.11 | Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. ( Bossie, CA; Greenspan, A; Meyer, JM; Pandina, G; Turkoz, I, 2005) |
| "In a prospective, single-blinded, naturalistic study, a cohort of subjects (n=150) with schizophrenia or schizo-affective disorder (DSM-IV) were switched from conventional neuroleptic drugs to either risperidone (n=50), olanzepine (n=50) or quetiapine (n=50), and monitored for a period of 2 to 6 years." | 5.10 | Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. ( Awad, A; Cernovsky, Z; Cortese, L; Kotteda, V; Owyeumi, L; Voruganti, L; Zirul, S, 2002) |
| "We conducted a 6-week, open-label pilot study comparing risperidone with typical neuroleptics in a sample of withdrawn cocaine-dependent schizophrenia patients." | 5.10 | Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. ( Davis, CW; Kaune, M; Losonczy, MF; Smelson, DA; Williams, J; Ziedonis, D, 2002) |
| "Both haloperidol and risperidone have been widely used in the treatment of schizophrenia." | 5.10 | Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. ( De Vries, R; Inoue, Y; Kaneko, S; Kondo, T; Mihara, K; Suzuki, A; Yasui-Furukori, N, 2002) |
| "The purpose of this study was to assess the significance of the hippocampal volume differences and its relation with risperidone treatment in schizophrenia." | 5.10 | Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study. ( Canan, S; Erbagci, H; Gumusburun, E; Herken, H; Inaloz, S; Savas, HA; Unal, B; Zoroglu, SS, 2002) |
| "We investigated the efficacy and safety of augmenting risperidone with fluvoxamine for the treatment of residual positive and negative symptoms in patients with chronic schizophrenia who had shown an incomplete response to risperidone." | 5.10 | Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. ( Higuchi, H; Shimizu, T; Sugita, T; Takahashi, H, 2002) |
| "In a double-blind, fixed-dose study, 49 acutely psychotic, neuroleptic-naive patients who were admitted for the first time and who met DSM-IV criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder were randomly assigned to 2 or 4 mg/day of risperidone." | 5.10 | Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. ( Berger, G; Gekle, W; Hofer, H; Latour, G; Marder, SR; Merlo, MC; Panhuber, I; Ventura, J, 2002) |
| "This multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (DSM IV) with a recent worsening of symptoms." | 5.10 | Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. ( Fleurot, O; Lecrubier, Y; Peuskens, J; Rein, W; Sechter, D, 2002) |
| "This retrospective naturalistic study, conducted on patients with schizophrenia, was undertaken to examine the differences in the clinical characteristics of subjects who were treated with risperidone, but who were discontinued soon after administration, and those who were maintained on the drug for a long-term period." | 5.10 | A naturalistic study of risperidone treatment in seven affiliated university hospitals in Korea. ( Bahk, WM; Chae, JH; Choi, BM; Go, HJ; Han, JH; Han, SI; Jun, TY; Kim, DJ; Kim, KS; Lee, C; Lee, CT; Pae, CU; Tsoh, J, 2003) |
| " The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial." | 5.10 | Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2003) |
| "The effects of risperidone and olanzapine on cognitive functioning in patients with schizophrenia were compared in a randomized, double-blind trial." | 5.10 | Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. ( Green, MF; Harvey, PD; McGurk, SR; Meltzer, HY, 2003) |
| "We have previously reported that risperidone might improve negative symptoms in schizophrenia by influencing noradrenergic neurons." | 5.10 | Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. ( Nakamura, J; Shinkai, K; Ueda, N; Yoshimura, R, 2003) |
| "The prevalence of hyperprolactinemia during treatment with conventional antipsychotic drugs or risperidone is under-recognized and requires further investigation." | 5.10 | Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. ( Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H, 2003) |
| "This study suggests that amisulpride is as effective as risperidone in the treatment of patients with schizophrenia." | 5.10 | Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. ( Chen, YS; Hwang, TJ; Lee, SM; Lee, YC; Lin, HN; Sun, HJ; Tsai, SJ, 2003) |
| "Serum prolactin levels were investigated in 41 patients with schizophrenia who were receiving clinically effective doses of perospirone or risperidone for more than 4 weeks." | 5.10 | Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone. ( Iseki, E; Kase, A; Katsuse, O; Kosaka, K; Oyama, I; Shoji, M; Togo, T; Uchikado, H, 2003) |
| "The results suggest that lower initial body weight, younger age, undifferentiated subtype, higher dosage, and treatment response (for positive, negative, and cognitive symptoms and social functioning) are associated with greater weight gain in acutely ill patients treated with risperidone." | 5.10 | Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. ( Chang, WH; Chang, YC; Cheng, YC; Lane, HY; Lin, XR; Liu, GC, 2003) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 5.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "This study examined the possible association between the polymorphism in the dopamine receptor DRD4 gene and response to risperidone among 24 Israeli Jewish adolescent inpatients with first-episode schizophrenia." | 5.10 | DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. ( Bensason, D; Frisch, A; Gothelf, D; Lev-Ran, S; Martin, A; Michaelovsky, E; Nahshoni, E; Tyano, S; Weizman, A; Zalsman, G, 2003) |
| "To demonstrate the effects upon motor side-effects, efficacy, safety and quality of life (QOL) of switching elderly patients with schizophrenia from conventional antipsychotics to olanzapine or risperidone." | 5.10 | The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. ( Ames, D; Chiu, E; Hall, K; Harrigan, S; Hassett, A; Macfarlane, S; Mastwyk, M; O'Connor, DW; Opie, J; Ritchie, CW, 2003) |
| "The authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperidone) in patients with schizophrenia." | 5.10 | Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. ( Eerdekens, M; Kane, JM; Karcher, K; Keith, SJ; Lesem, M; Lindenmayer, JP, 2003) |
| "Thirty-nine subjects with early phase schizophrenia were randomly assigned to double blind treatment with haloperidol, risperidone, or olanzapine." | 5.10 | Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. ( Lindborg, SR; Purdon, SE; Stip, E; Woodward, N, 2003) |
| "To detail specific effects of long-acting risperidone on individuals with schizophrenia and their way of life in a series of four cases." | 5.10 | Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. ( Brewin, JS; Huq, ZU; Libretto, SE; Martin, SD; Pratt, DJ; Saleh, BT, 2003) |
| "Aripiprazole is effective, safe, and well tolerated for the positive and negative symptoms in schizophrenia and schizoaffective disorder." | 5.10 | Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J, 2003) |
| "Risperidone (RIS) alone was administered to patients with neuroleptic-naïve, first-episode schizophrenia who visited the outpatient clinic of the Department of Psychiatry, Jikei University School of Medicine Hospital between April 1998 and December 2001, and the effectiveness of the drug in alleviating anxiety symptoms was prospectively examined." | 5.10 | [A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone]. ( Katsu, H; Nakayama, K; Sannomiya, M, 2003) |
| "This was a 2-year, randomized, double-blind comparison of 6 mg of risperidone versus haloperidol in 63 patients with stabilized DSM-IV schizophrenia." | 5.10 | Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. ( Blair, KE; Glynn, SM; Liberman, RP; Marder, SR; Mintz, J; Ross, D; Widmark, C; Wirshing, DA; Wirshing, WC, 2003) |
| "To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder." | 5.10 | Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003) |
| " typical (haloperidol) antipsychotic medication on facial emotion perception in schizophrenia (n=28) and healthy control (n=28) groups." | 5.10 | Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. ( Gordon, E; Green, MJ; Harris, AW; Loughland, CM; Williams, LM, 2003) |
| "The symptom response and side-effects of olanzapine and risperidone were compared in patients with recent onset schizophrenia." | 5.10 | Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. ( Dingemans, P; Gersons, B; Linszen, D; Tijssen, J; van Bruggen, J, 2003) |
| "Data on risperidone's efficacy and tolerability in adolescents with schizophrenia are scarce." | 5.10 | Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. ( Bensason, D; Carmon, E; Martin, A; Tyano, S; Weizman, A; Zalsman, G, 2003) |
| "The long-term safety and efficacy of long-acting injectable risperidone, the first long-acting second-generation antipsychotic, were evaluated in stable patients with schizophrenia." | 5.10 | Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. ( Chrzanowski, W; Eerdekens, M; Fleischhacker, WW; Gefvert, O; Karcher, K; Llorca, PM; Martin, S; Remington, G, 2003) |
| "Randomized controlled trial comparing risperidone and haloperidol regarding relapse in patients with schizophrenia treated with flexible doses during one year." | 5.10 | Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol. ( de Sena, EP; Miranda-Scippa, A; Oliveira, IR; Quarantini, Lde C; Santos-Jesus, R, 2003) |
| " We performed a long-term comparison of a newer, atypical antipsychotic drug, risperidone, and an older, conventional neuroleptic drug, haloperidol, in terms of the rate of relapse in patients with schizophrenia and schizoaffective disorder." | 5.10 | A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. ( Brenner, R; Csernansky, JG; Mahmoud, R, 2002) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 5.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "The authors investigated the clinical effects of D-cycloserine when added to treatment with conventional neuroleptics, olanzapine, or risperidone for treatment-resistant schizophrenia." | 5.10 | Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. ( Ermilov, M; Heresco-Levy, U; Javitt, DC; Shapira, B; Shimoni, J; Silipo, G, 2002) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 5.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "The results suggest that risperidone treatment is not associated with weight gain among elderly persons with chronic psychosis." | 5.10 | No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. ( Barak, Y, 2002) |
| "To more clearly clarify the efficacy of the atypical antipsychotics compared to conventional antipsychotics, we add data on the outcome of patients diagnosed with schizophrenia from two large, international clinical trials comparing olanzapine with haloperidol (n = 1996) and olanzapine with risperidone (n = 339)." | 5.10 | Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. ( Berg, PH; Glick, ID, 2002) |
| "The effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics and side-effect profile of quetiapine were investigated in 36 patients with schizophrenia, schizoaffective disorder, or bipolar disorder in a single-center, two-period, multiple-dose, open-label, randomized trial." | 5.10 | The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. ( Alva, G; Arvanitis, LA; Bera, R; Potkin, SG; Thyrum, PT; Yeh, C, 2002) |
| "The effect of risperidone on polydipsia-hyponatremia was evaluated in six hospitalized schizophrenic patients." | 5.10 | Risperidone failed to improve polydipsia-hyponatremia of the schizophrenic patients. ( Baba, A; Kawai, N; Suzuki, T, 2002) |
| "This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction." | 5.10 | Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. ( Bahk, WM; Chae, JH; Dickson, RA; Jun, TY; Kim, DJ; Kim, KS; Pae, CU, 2002) |
| "Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments." | 5.10 | Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002) |
| "In a prospective, double-blind evaluation, 50 patients with an acute exacerbation of schizophrenia were randomly assigned to either risperidone plus celecoxib or risperidone plus placebo." | 5.10 | Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. ( Brandstätter, B; Engel, RR; Krampe, K; Möller, HJ; Müller, N; Riedel, M; Scheppach, C; Schwarz, MJ; Sokullu, S; Ulmschneider, M, 2002) |
| " The purpose of this study was to examine the effects of D-cycloserine when added to risperidone on negative symptoms of schizophrenia." | 5.10 | D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. ( Amico, E; Evins, AE; Goff, DC; Posever, TA; Toker, R, 2002) |
| "The safety and tolerability of short-term treatment with a low dose of risperidone was evaluated in adolescents with prodromal symptoms and a family history of schizophrenia." | 5.10 | Antipsychotic drug treatment in the prodromal phase of schizophrenia. ( Cannon, TD; Dahlström, M; Huttunen, MO; Juriloo, A; Larmo, I; Räsänen, P, 2002) |
| "Clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia." | 5.09 | Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. ( Adler, CM; Breier, AF; Clifton, A; Elman, I; Lafargue, RT; Malhotra, AK; Pickar, D; Pinals, DA; Su, TP, 1999) |
| "There is little information regarding the effects of risperidone addition to neuroleptic treatment in chronic schizophrenia." | 5.09 | Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. ( Oga, T; Okada, M; Takahashi, N; Terao, T, 1999) |
| "We describe the design of a multicenter, randomized clinical trial to compare clinical, quality-of-life, and economic outcomes in patients with schizophrenia or schizoaffective disorder who were treated with risperidone or any of 13 conventional antipsychotic drugs approved for use in the United States." | 5.09 | The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. ( Engelhart, L; Mahmoud, R; Ollendorf, D; Oster, G, 1999) |
| "Combined data from double-blind risperidone studies were used to analyse the severity of extrapyramidal symptoms (EPS) associated with treatment in patients with chronic schizophrenia." | 5.09 | A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. ( Brecher, M; Lemmens, P; Van Baelen, B, 1999) |
| "The authors evaluated the safety, tolerability, and efficacy of risperidone in 103 elderly patients (mean age, 71 years) with schizophrenia (75%) or schizoaffective disorder (25%)." | 5.09 | Risperidone in the treatment of elderly patients with psychotic disorders. ( Brecher, M; Brenner, R; Kasckow, J; Kunik, M; Madhusoodanan, S; Negrón, AE; Pomara, N, 1999) |
| "To evaluate the short-term efficacy and safety of risperidone in a group of Asian patients with schizophrenia in an 8-week open-label, prospective study." | 5.09 | Clinical evaluation of risperidone in Asian patients with schizophrenia in Singapore. ( Chan, AO; Chee, KT; Chong, SA; Choo, CH; Low, BL; Mahendran, R; Wong, KE; Yap, HL, 1999) |
| "We performed a retrospective analysis of 122 clinical records of 92 male patients with DSM-III-R schizophrenia to examine the relative weight gain liabilities of clozapine, risperidone, olanzapine, and sertindole compared with haloperidol." | 5.09 | Novel antipsychotics: comparison of weight gain liabilities. ( Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC, 1999) |
| "The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia." | 5.09 | Risperidone in treatment-refractory schizophrenia. ( Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC, 1999) |
| "To investigate the effects of a newer antipsychotic drug, risperidone (a potent serotonin 5-HT2A/2C and dopamine D2-receptor blocker), on the quantity and quality of sleep in patients with schizophrenia." | 5.09 | Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: a pilot study. ( Burke, JG; Dursun, SM; Patel, JK; Reveley, MA, 1999) |
| "Risperidone and olanzapine have each been demonstrated to be efficacious and safe in the treatment of patients with chronic schizophrenia." | 5.09 | A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. ( Andreasen, NC; Ho, BC; Miller, D; Nopoulos, P, 1999) |
| "Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia." | 5.09 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999) |
| "To help determine whether sustained attention deficits as measured with the Continuous Performance Test (CPT) are stable vulnerability indicators of schizophrenia, we compared the CPT performance of schizophrenic patients before and after treatment with risperidone or haloperidol." | 5.09 | Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. ( Chang, CJ; Chen, WJ; Lin, HN; Liu, SK, 2000) |
| "The optimal risperidone dosing strategy for acute schizophrenia requires elucidation." | 5.09 | Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. ( Chang, WH; Chiu, WC; Chou, JC; Lane, HY; Su, MH; Wu, ST, 2000) |
| "This study compared the long-term (12 months) effectiveness of risperidone (RP) with that of conventional neuroleptics (CNs) in a population with chronic schizophrenia who had shown suboptimal response to CNs." | 5.09 | Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. ( Bouchard, RH; Cliche, D; Demers, MF; Filteau, MJ; Gauthier, Y; Labelle, A; Maziade, M; Mérette, C; Pourcher, E; Roy, MA; Roy-Gagnon, MH; Villeneuve, J, 2000) |
| "Studies have shown that risperidone is safe and efficacious in young and middle-aged adults with chronic schizophrenia, but considerably fewer data are available on the treatment of elderly patients with schizophrenia or other psychotic disorders, particularly long-term outcomes." | 5.09 | A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. ( Barak, Y; Bray, G; Davidson, M; De Hooge, JD; Dose, M; Gagiano, CA; Harvey, PD; Haushofer, M; Vervarcke, J, 2000) |
| " The atypical antipsychotic risperidone may constitute an alternative to clozapine, the current treatment of choice for refractory schizophrenia." | 5.09 | Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. ( Ahokas, A; Cheine, M; Joffe, G; Rimón, R; Tuisku, K; Wahlbeck, K, 2000) |
| "Positron emission tomography (PET) was used to measure the effects of the atypical antipsychotic, risperidone, on glucose metabolism in eight first-episode schizophrenia patients." | 5.09 | Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus. ( Lane, CJ; Liddle, PF; Ngan, ET, 2000) |
| "Two hundred nine outpatients with a DSM-IV diagnosis of schizophrenia or schizo-affective disorder who were clinically stable while being treated with a conventional antipsychotic drug or risperidone were openly randomly assigned to either abrupt or gradual discontinuation of their prior antipsychotic drug." | 5.09 | Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. ( Basson, BR; Gilmore, JA; Kinon, BJ; Malcolm, S; Stauffer, VL, 2000) |
| "Effects of flexible doses of risperidone and haloperidol were compared in 77 psychotic patients (83% with chronic schizophrenia) with disturbing neuroleptic-induced EPS (risperidone 40 patients, haloperidol 37)." | 5.09 | Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. ( de Groot, IW; Haffmans, PM; Heck, AH; Hoencamp, E, 2000) |
| "To compare the clinical and economic outcomes associated with olanzapine and risperidone treatment for schizophrenia." | 5.09 | Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. ( Andersen, SW; Breier, A; Dulisse, B; Edgell, ET; Johnstone, BM; Revicki, D, 2000) |
| "This multicenter, open-label study evaluated the efficacy and safety of olanzapine in patients with schizophrenia who had been nonresponsive or intolerant to a course of risperidone (mean duration of risperidone treatment = 46." | 5.09 | Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. ( Belmaker, RH; Dossenbach, MR; Grundy, SL; Kratky, P; Metcalfe, S; Schneidman, M; Tollefson, GD, 2001) |
| "Seven patients with schizophrenia were scanned during the steady state with risperidone." | 5.09 | Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone. ( Ichimiya, T; Inoue, M; Okubo, Y; Sudo, Y; Suhara, T; Tanada, S; Yasuno, F, 2001) |
| "In order to examine the effects of risperidone on cognitive impairment in schizophrenia, event-related potentials (ERPs) were recorded before and after switching from conventional neuroleptics to risperidone in schizophrenic patients." | 5.09 | Effects of risperidone on event-related potentials in schizophrenic patients. ( Fukuda, M; Hata, A; Isono, H; Iwanami, A; Kamijima, K; Kasai, K; Nakagome, K; Okajima, Y; Shinoda, J, 2001) |
| "From a cohort of 126 patients, 2 groups of 19 first-episode DSM-III-R/DSM-IV schizophrenia patients matched for age, gender, length of illness, and length of treatment and treated with either a typical antipsychotic or risperidone for a minimum of 1 year were compared on a number of outcome dimensions during their course of treatment and at follow-up." | 5.09 | A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. ( Kotteda, V; Malla, AK; Norman, RM; Scholten, DJ; Zirul, S, 2001) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 5.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "Atypical antipsychotics, such as risperidone, have been shown to be more effective for the treatment of the symptoms of schizophrenia and have a greater beneficial effect on neurocognition compared to the conventional antipsychotics." | 5.09 | Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. ( Andreasen, NC; Boles Ponto, LL; Hichwa, RD; Miller, DD; O'Leary, DS; Watkins, GL, 2001) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 5.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 5.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "During an 8-week period, 227 patients with DSM-III chronic schizophrenia received 4 mg/day of risperidone and 226 patients received 10 mg/day of haloperidol." | 5.09 | Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. ( Davidson, M; Hornik, T; Rabinowitz, J, 2001) |
| "This prospective, double-blind, multicenter, parallel-group study compared the efficacy and safety of therapeutic doses of clozapine and risperidone in patients with severe chronic schizophrenia and poor previous treatment response." | 5.09 | A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. ( Azorin, JM; Bourdeix, I; Giguere, M; Péré, JJ; Remington, G; Spiegel, R; Vanelle, JM, 2001) |
| "Given the renewed interest in the role of sex differences in schizophrenia, we undertook a post hoc analysis to determine whether sex differences in treatment response were present among outpatients with schizophrenia who received risperidone in an 8-week, open-label, Phase IV clinical study." | 5.09 | Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response. ( Dunbar, F; Labelle, A; Light, M, 2001) |
| "A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial." | 5.09 | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001) |
| "This study compares the antipsychotic efficacy and the tolerability of risperidone and clozapine in patients with schizophrenia." | 5.08 | Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. ( Heinrich, K; Kinzler, E; Klieser, E; Lehmann, E; Wurthmann, C, 1995) |
| "The hypothesis that differences in drug effects of risperidone and haloperidol on negative symptoms in schizophrenia are secondary to effects on positive, extrapyramidal, and depressive symptoms was investigated by means of an analysis of the data from the USA-Canada risperidone double-blind randomized clinical trial of 523 chronic schizophrenic patients." | 5.08 | A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. ( Borison, RL; Chouinard, G; Möller, HJ; Müller, H; Schooler, NR, 1995) |
| "A double-blind, randomized, multi-center, parallel-group study was conducted in Finland to compare the efficacy and safety of risperidone with zuclopenthixol in patients with acute exacerbations of schizophrenia or schizophreniform disorder." | 5.08 | Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. ( Huttunen, MO; Larmo, I; Nyholm, R; Piepponen, T; Raitasuo, V; Rantanen, H, 1995) |
| "In a multi-national, parallel-group, double-blind study, patients with chronic schizophrenia (DSM-III-R) were randomly assigned to risperidone 1, 4, 8, 12 or 16 mg or haloperidol 10 mg daily for 8 weeks." | 5.08 | Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. ( Peuskens, J, 1995) |
| "Risperidone was used to treat 11 elderly hospitalized patients between 61 and 79 years of age who manifested signs of psychoses related to schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia." | 5.08 | Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. ( Abaza, A; Araujo, L; Brenner, R; Madhusoodanan, S, 1995) |
| "The subjects were 20 outpatients with schizophrenia or schizoaffective disorder who were clinically stable on a regimen of clozapine at the time of screening." | 5.08 | Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. ( Daniel, DG; Goldberg, TE; Kleinman, JE; Lubick, LJ; Pickar, D; Weinberger, DR; Williams, TS, 1996) |
| "The subjects were 62 patients hospitalized for acute exacerbations of schizophrenia and were randomly assigned to receive risperidone (mean dose, 7." | 5.08 | Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. ( Azorin, JM; Blin, O; Bouhours, P, 1996) |
| "Although risperidone has been shown to be an effective antipsychotic medication in schizophrenia, the clinical studies performed for the Food and Drug Administration's approval process focused on only a mixed group of schizophrenic patients." | 5.08 | Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. ( Bhattacharyya, A; Chua, JW; Lipetsker, B; Smith, RC, 1996) |
| "To assess critically the short-term efficacy and safety of risperidone in adolescents with schizophrenia." | 5.08 | Risperidone in adolescents with schizophrenia: an open pilot study. ( Armenteros, JL; Gorman, J; Stedge, DJ; Welikson, M; Whitaker, AH, 1997) |
| "The efficacy and safety of risperidone have previously been demonstrated in controlled clinical trials in hospitalized chronic schizophrenia patients who met strict research criteria." | 5.08 | A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting. ( Brecher, M; Clyde, C; Jeste, DV; Jones, R; Klausner, M, 1997) |
| "The current study uses utility analysis to assess economic and quality-of-life benefits of risperidone in patients with chronic schizophrenia." | 5.08 | Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. ( Albright, PS; Chouinard, G, 1997) |
| "The purpose of this study was to determine the prevalence of extrapyramidal signs or symptoms (EPS) and clinical symptoms in first-episode schizophrenia, before any treatment, during and after treatment with a novel antipsychotic, risperidone." | 5.08 | Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. ( Good, KP; Honer, WG; Kopala, LC, 1997) |
| "The interaction between plasma concentrations of the tricyclic antidepressant amitriptyline and the metabolism of the new antipsychotic risperidone was studied in 12 patients with chronic schizophrenia." | 5.08 | Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients. ( Blom, MW; Huang, ML; Levron, JC; Snyman, JR; Sommers, DK; van Wyk, M, 1997) |
| "The clinical efficacy of two intensive treatment packages (one including the new antipsychotic risperidone and the other not doing so) was compared with that of standard management in 43 patients with long-standing treatment-resistant schizophrenia." | 5.08 | A study of enhanced management in patients with treatment-resistant schizophrenia. ( Finlayson, A; Johnstone, EC; Mercer, G; Murray, C; Owens, DG, 1997) |
| "In two double-blind trials conducted in North America, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo." | 5.08 | The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. ( Chouinard, G; Davis, JM; Marder, SR, 1997) |
| "This study examines the effectiveness of risperidone compared with traditional neuroleptic medications in the areas of clinical functioning and aggressive behaviors in a sample of inpatients diagnosed with chronic schizophrenia." | 5.08 | Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. ( Beck, NC; Gotham, H; Greenfield, SR; Hemme, CA; Menditto, AA; Stuve, P, 1997) |
| " Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks." | 5.08 | Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. ( Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H, 1997) |
| "Clozapine and risperidone are used in treatment-resistant schizophrenia." | 5.08 | An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. ( Altman, S; Flynn, SW; Fredrikson, DH; Honer, WG; Kopala, LC; MacEwan, GW; Smith, GN, 1998) |
| "In a controlled double-blind, multicenter study, 86 inpatients with chronic schizophrenia (DSM-III-R), who were resistant to or intolerant of conventional neuroleptics, were randomly assigned to receive risperidone or clozapine for 8 weeks after a 7-day washout period." | 5.08 | Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. ( Baumann, P; Billeter, U; Bondolfi, G; Dufour, H; Eap, CB; May, JP; Patris, M, 1998) |
| "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia." | 5.08 | A syndrome of increased affect in response to risperidone among patients with schizophrenia. ( Ashleigh, EA; Larsen, PD, 1998) |
| "The effects of the availability of risperidone and olanzapine on the indications for which clozapine is prescribed (treatment-resistance, treatment-intolerance, and/or negative symptoms) were examined for 252 patients with schizophrenia who began treatment at our hospital between June 1990 and June 1997." | 5.08 | The effects of risperidone and olanzapine on the indications for clozapine. ( Brar, JS; Ganguli, R, 1998) |
| "Risperidone is a novel serotonin-dopamine antagonist antipsychotic in a class of benzisoxazole derivative which has been shown to be effective in reducing psychotic symptoms in schizophrenia." | 5.08 | Efficacy and tolerability of risperidone in chronic schizophrenic Thai patients. ( Bunditchate, A; Chaisirikul, S; Charisilp, C; Chrujiporn, W; Kessawai, D; Ratanachata, N; Sanichwannakul, K; Ukranand, P; Visanuyothin, T; Wangdee, P; Werapongset, W, 1998) |
| "Since most clinical trials of atypical antipsychotics have been conducted in hospitalized patients, a Phase-IV, multicentre, 8-week, open-label, flexible-dose study was performed to assess the efficacy and safety of risperidone in outpatients with schizophrenia." | 5.08 | Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. ( Beauclair, L; Chouinard, G; Johnson, SV; Kopala, L; Labelle, A; Singh, KI, 1998) |
| "Clinical improvement (20% reduction in total scores on the Positive and Negative Syndrome Scale for Schizophrenia) at the study end point was shown by 35% of the patients receiving 2 mg of risperidone, 57% receiving 6 mg, 40% receiving 10 mg, and 51% receiving 16 mg; and by 30% receiving haloperidol and 22% receiving placebo." | 5.07 | Risperidone in the treatment of schizophrenia. ( Marder, SR; Meibach, RC, 1994) |
| "In a double-blind study, 135 inpatients with a diagnosis of chronic schizophrenia were randomly assigned to 8 weeks of treatment with one of six parallel treatments: risperidone (a new central 5-hydroxytryptamine2 and dopamine D2 antagonist), 2, 6, 10, 16 mg/day; haloperidol, 20 mg/day; or placebo, after a single-blind placebo washout period." | 5.07 | A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. ( Addington, D; Arnott, W; Beauclair, L; Bloom, D; Chouinard, G; Jones, B; Labelle, A; MacEwan, GW; Remington, G, 1993) |
| "This multicenter trial indicates that risperidone is an effective treatment for the positive and negative symptoms of schizophrenia." | 5.07 | Risperidone: clinical development: north American results. ( Marder, SR, 1992) |
| "A search of multiple electronic databases (through November 2018) was conducted for all placebo-controlled dose-finding studies for 20 second-generation antipsychotic drugs and haloperidol (oral and long-acting injectable, LAI) in people with acute schizophrenia symptoms." | 5.05 | Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. ( Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020) |
| " IL-6 levels were compared in patients with schizophrenia before and after risperidone treatment." | 5.05 | Effects of risperidone on blood levels of interleukin-6 in schizophrenia: A meta-analysis. ( Feng, Z; Hao, W; Liu, Z; Long, Q; Ma, Y; Teng, Z; You, X; Zeng, Y; Zhang, W; Zhang, Y, 2020) |
| "The effect of risperidone treatment in patients with schizophrenia varies according to the dopamine receptor genes." | 5.01 | Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis. ( Cui, Y; Ma, L; Xiang, Q; Xie, Q; Zhang, X; Zhao, N; Zhao, X; Zhou, S; Zhou, Y, 2019) |
| " In an application, we examine the risk of excessive weight gain for patients with schizophrenia treated with the second-generation antipsychotics paliperidone, risperidone, or olanzapine in 14 clinical trials." | 5.01 | Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs. ( Horvitz-Lennon, M; Normand, ST; Spertus, J, 2019) |
| "Cariprazine was approved for treating schizophrenia and bipolar disorder, and currently is being evaluated for treating depression in clinical trials in the United States." | 4.98 | Use of cariprazine in psychiatric disorders: A systematic review. ( Chhatlani, A; Farheen, SA; Setty, MJ; Tampi, RR, 2018) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | 4.95 | Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| "In treatment-resistant schizophrenia, clozapine is considered the standard treatment." | 4.93 | Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. ( Dold, M; Gianatsi, M; Helfer, B; Leucht, S; Nikolakopoulou, A; Salanti, G; Samara, MT, 2016) |
| "To compare the effects of chlorpromazine with atypical or second generation antipsychotic drugs, for the treatment of people with schizophrenia." | 4.93 | Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. ( Bo, L; Saha, KB; Sampson, S; Xia, J; Zaman, RU; Zhao, S, 2016) |
| "To examine the effects of depot risperidone for treatment of schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medication." | 4.93 | Risperidone (depot) for schizophrenia. ( Davis, JM; Furtado, VA; Hosalli, P; Sampson, S, 2016) |
| "To measure the outcomes (both beneficial and harmful) of the clinical effectiveness, safety and cost-effectiveness of oral fluphenazine versus atypical antipsychotics for schizophrenia." | 4.93 | Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. ( Furtado, VA; Li, BG; Sampford, JR; Sampson, S; Xia, J; Zhao, S, 2016) |
| "To determine the clinical effects, safety and cost-effectiveness of risperidone compared with placebo for treating schizophrenia." | 4.93 | Risperidone versus placebo for schizophrenia. ( Jayaram, MB; Li, BG; Rattehalli, RD; Sampson, S; Xia, J; Zhao, S, 2016) |
| "To conduct meta-analyses of all published association studies on the HTR2C -759C/T (rs3813829) polymorphism and olanzapine-induced weight gain in schizophrenia patients and on the HTR2C -759C/T, -697G/C (rs518147) and rs1414334:C> G polymorphisms and olanzapine/clozapine/risperidone-induced metabolic syndrome in schizophrenia patients." | 4.90 | HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. ( Gui, X; Hu, G; Ma, X; Maimaitirexiati, T; Xu, G; Zhang, R; Zhang, W, 2014) |
| "We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses." | 4.89 | Aripiprazole versus other atypical antipsychotics for schizophrenia. ( El-Sayeh, HG; Hunger, H; Khanna, P; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S, 2013) |
| " This was an eight-week randomised trial of risperidone and olanzapine in 44 inpatients with late-onset schizophrenia." | 4.88 | Antipsychotic drug treatment for elderly people with late-onset schizophrenia. ( Ali, G; Essali, A, 2012) |
| "To compare the effects of paliperidone palmitate with any other treatment for people with schizophrenia and schizophrenia-like illnesses." | 4.88 | Paliperidone palmitate for schizophrenia. ( Nussbaum, AM; Stroup, TS, 2012) |
| "To evaluate the effects of risperidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis." | 4.87 | Risperidone versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2011) |
| "Although risperidone is commonly used in the acute and maintenance treatment of schizophrenia, the role of therapeutic drug monitoring has yet to be elucidated." | 4.87 | Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? ( Dumontet, J; Ensom, MH; Seto, K, 2011) |
| "We included randomised, at least single-blind, trials comparing oral amisulpride with oral forms of aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychoses." | 4.86 | Amisulpride versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S; Silveira da Mota Neto, JI, 2010) |
| "We included all randomised control trials comparing oral quetiapine with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis." | 4.86 | Quetiapine versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S; Srisurapanont, M, 2010) |
| "To examine the clinical effects of oral risperidone for people with schizophrenia and schizophrenia-like psychoses in comparison with placebo." | 4.86 | Risperidone versus placebo for schizophrenia. ( Jayaram, MB; Rattehalli, RD; Smith, M, 2010) |
| "We included all randomised trials that used at least single-blind (rater-blind) design, comparing oral olanzapine with oral forms of amisulpride, aripiprazole, clozapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis." | 4.86 | Olanzapine versus other atypical antipsychotics for schizophrenia. ( Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| " Olanzapine produced more weight gain than all other second-generation antipsychotics except for clozapine where no difference was found." | 4.86 | Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. ( Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| "We included only randomised clinical controlled trials that compared zotepine with any forms of amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole or ziprasidone in people suffering from only schizophrenia or schizophrenia-like psychoses." | 4.86 | Zotepine versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S; Subramanian, S, 2010) |
| "Results demonstrated that antipsychotic treatment with risperidone, olanzapine or aripiprazole in adolescents affected by schizophrenia led to significant improvements in symptomatology." | 4.86 | Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. ( Ardizzone, I; Carratelli, TI; Ferrara, M; Marconi, A; Nardecchia, F, 2010) |
| "To compare the clinical effects of clozapine with other atypical antipsychotics (such as amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine) in the treatment of schizophrenia and schizophrenia-like psychoses." | 4.86 | Clozapine versus other atypical antipsychotics for schizophrenia. ( Asenjo Lobos, C; Hunger, H; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| "Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)." | 4.85 | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009) |
| "Risperidone has been approved by the Food and Drug Administration for the treatment of schizophrenia in the adolescent population." | 4.85 | Risperidone: a review of efficacy studies in adolescents with schizophrenia. ( Madaan, V, 2009) |
| "We included all randomised trials comparing oral sertindole with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychosis." | 4.85 | Sertindole versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lewis, R; Rummel-Kluge, C; Schmidt, F; Schwarz, S, 2009) |
| "Although clozapine has been shown to be the treatment of choice in people with schizophrenia that are resistant to treatment, one third to two thirds of people still have persistent positive symptoms despite clozapine monotherapy of adequate dosage and duration." | 4.85 | Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. ( Barbui, C; Boso, M; Cipriani, A, 2009) |
| "We included all randomised trials comparing oral aripiprazole with oral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychoses." | 4.85 | Aripiprazole versus other atypical antipsychotics for schizophrenia. ( El-Sayeh, HG; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2009) |
| "We included all randomised, at least single-blind, controlled trials comparing oral ziprasidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone or zotepine in people with schizophrenia or schizophrenia-like psychoses." | 4.85 | Ziprasidone versus other atypical antipsychotics for schizophrenia. ( Bhoopathi, PS; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S, 2009) |
| "Risperidone is a widely used antipsychotic drug for people with schizophrenia." | 4.85 | Risperidone dose for schizophrenia. ( Li, C; Wang, J; Xia, J, 2009) |
| "This study aimed to retrospectively explore the relationship between clinical efficacy and plasma concentration-dose ratio of risperidone (RIS) in 252 patients with schizophrenia taking RIS orally." | 4.84 | Relationship between clinical efficacy and plasma concentration-dose ratio of risperidone in patients with schizophrenia. ( Chen, Q; Min, J; Shen, Y; Shu, M; Xia, W; Yin, H, 2024) |
| "The aim of this review was to discuss data from double-blind, randomized controlled trials (RCTs) that have investigated the effects of oral and long-acting injectable risperidone on cognitive and psychomotor functioning in patients with schizophrenia or schizoaffective disorder." | 4.84 | Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. ( Houthoofd, SA; Morrens, M; Sabbe, BG, 2008) |
| "In the 10 studies analyzed, the taste of RD risperidone tablets was found to be acceptable in the majority of healthy subjects and patients with schizophrenia or schizoaffective disorder." | 4.84 | Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. ( D'Hoore, P; Kushner, S; Mannaert, E; Remmerie, B; Thyssen, A, 2007) |
| " The three case studies are (1) bupropion versus nicotine replacement therapy for smoking cessation, (2) risperidone versus haloperidol for schizophrenia, and (3) fluoxetine versus imipramine for depressive disorders." | 4.84 | Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. ( Harvey, I; Lilford, R; Song, F, 2008) |
| " We aimed to establish the dose-response relationship for oral risperidone in relapsed schizophrenia." | 4.83 | Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. ( Ezewuzie, N; Taylor, D, 2006) |
| "Studies published between January 2002 and June 2005 that evaluated the pharmacokinetics, efficacy and safety of long-acting risperidone for the treatment of schizophrenia were reviewed, as identified from literature searches using Medline and EMBASE." | 4.83 | Clinical experience and management considerations with long-acting risperidone. ( Parellada, E, 2006) |
| "To determine the clinical effects, safety and cost effectiveness of risperidone compared with olanzapine for treating schizophrenia." | 4.83 | Risperidone versus olanzapine for schizophrenia. ( Hosalli, P; Jayaram, MB; Stroup, S, 2006) |
| " Long-acting risperidone (LAR), the first long-acting injectable atypical anti-psychotic, has been found to be effective in the treatment of schizophrenia and schizoaffective disorder." | 4.83 | Long-acting risperidone: focus on safety. ( Möller, HJ, 2006) |
| " A post hoc pooled analysis of 4 randomized, double-blind, 24- to 28-week schizophrenia clinical trials included 822 olanzapine-treated and 805 risperidone-, quetiapine-, or ziprasidone-treated patients." | 4.83 | Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. ( Adams, DH; Citrome, L; Kinon, BJ; Liu-Seifert, H, 2006) |
| "In schizophrenia, comparing treatment dropouts between olanzapine and risperidone can be useful to better understand their relative effectiveness." | 4.82 | Clinical trial response and dropout rates with olanzapine versus risperidone. ( Messori, A; Santarlasci, B, 2003) |
| "To evaluate the effects of risperidone for schizophrenia in comparison to 'conventional' neuroleptic drugs." | 4.82 | Risperidone versus typical antipsychotic medication for schizophrenia. ( Gilbody, SM; Hunter, RH; Joy, CB; Kennedy, E; Song, F, 2003) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 4.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| "To examine the clinical effects of depot risperidone for people with schizophrenia and schizophrenia-like psychoses." | 4.82 | Depot risperidone for schizophrenia. ( Davis, JM; Hosalli, P, 2003) |
| "Randomised clinical trials comparing new generation antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, sulpiride, ziprasidone, zotepine) with conventional antipsychotics for people with a first episode of schizophrenia or schizophrenia-like psychoses." | 4.82 | New generation antipsychotics for first episode schizophrenia. ( Hamann, J; Kissling, W; Leucht, S; Rummel, C, 2003) |
| "Long-acting risperidone (Risperdal Consta) is a novel, intramuscular formulation of the atypical antipsychotic risperidone, which has shown efficacy in the treatment of patients with schizophrenia." | 4.82 | Long-acting risperidone: a review of its use in schizophrenia. ( Goa, KL; Harrison, TS, 2004) |
| "To review the literature on the healthcare costs associated with olanzapine and risperidone in treating schizophrenia." | 4.82 | Cost comparisons of olanzapine and risperidone in treating schizophrenia. ( Christensen, DB; Liu, GG; Luo, X; Sun, SX, 2004) |
| "During the last few years, several case reports and studies have been published on the potential diabetes mellitus (DM)-inducing effect of some atypical antipsychotics, especially clozapine and olanzapine." | 4.82 | Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. ( Cohen, D, 2004) |
| "The atypical antipsychotics risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole have become first-line treatment for schizophrenia because they reduce the positive symptoms of psychosis but do not have a high incidence of extrapyramidal symptoms." | 4.82 | A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. ( Grady, MM; Stahl, SM, 2004) |
| "With its unique tolerability and efficacy, long-acting risperidone injection has the potential to extend the benefits of assured medication delivery and improved long-term outcomes to more patients with schizophrenia." | 4.82 | Long-acting risperidone injection. ( Conley, RJ; Love, RC, 2004) |
| "To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of long-acting (LA) risperidone for the treatment of schizophrenia." | 4.82 | Long-acting injectable risperidone. ( Ehret, MJ; Fuller, MA, 2004) |
| " In phase III comparative clinical studies, aripiprazole 15-30 mg/day was at least as effective as haloperidol and risperidone in short term treatment of acute exacerbation of schizophrenia but superior to haloperidol in long term maintenance therapy." | 4.82 | Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. ( Lambert, M; Naber, D, 2004) |
| "Several 12-week studies and one 12-month study suggest that long-acting risperidone is an effective and well-tolerated treatment option for the maintenance therapy of schizophrenia." | 4.82 | Clinical review of a long-acting, injectable formulation of risperidone. ( Knox, ED; Stimmel, GL, 2004) |
| "Antipsychotic medication is a mainstay of treatment for schizophrenia and risperidone and olanzapine are the most popular treatment choice of the new generation drugs." | 4.82 | Risperidone versus olanzapine for schizophrenia. ( Hosalli, P; Jayaram, MB, 2005) |
| "Risperidone and other newer atypical antipsychotics are becoming the mainstay for schizophrenia treatment." | 4.82 | Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. ( Chang, WH; Lane, HY; Lee, CC; Liu, YC, 2005) |
| "Risperidone and olanzapine are novel antipsychotic medications that compete as first-line agents in treating patients with schizophrenia." | 4.82 | Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. ( Gibson, JP; Gibson, PJ; Hargreaves, WA, 2005) |
| " The receptor profile for risperidone, an atypical antipsychotic with demonstrated efficacy in schizophrenia, is consistent with possible antidepressant activity." | 4.81 | Risperidone: review of its therapeutic utility in depression. ( Myers, JE; Thase, ME, 2001) |
| "There is a now a substantial body of evidence that suggests the new antipsychotic agent, risperidone, may be safe and effective for treating psychotic, affective or behavioural symptoms associated with various disorders other than schizophrenia, schizophreniform disorder or schizo-affective disorder." | 4.81 | Does risperidone have a place in the treatment of nonschizophrenic patients? ( Schweitzer, I, 2001) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 4.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "Relevant data relating to the dosage of risperidone identified through an online (MEDLINE) search using the keywords risperidone, schizophrenia, schizoaffective disorder dementia, bipolar disorder, and dose were supplemented by a review of international and U." | 4.81 | Optimal dosing with risperidone: updated recommendations. ( Williams, R, 2001) |
| " In the present quantitative review the published evidence regarding the effects of risperidone on hostility and aggression in schizophrenia is evaluated." | 4.81 | Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. ( Aleman, A; Kahn, RS, 2001) |
| "Combined data on efficacy were available from 12 double-blind short-term (maximum 8 weeks) trials comparing risperidone and other antipsychotics in patients with chronic schizophrenia." | 4.81 | Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. ( Glick, ID; Lemmens, P; Vester-Blokland, E, 2001) |
| " Ziprasidone, a recently launched agent, is available in tablet form for schizophrenia/schizoaffective disorder, psychotic depression and mania." | 4.81 | Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. ( Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP, 2002) |
| "The authors' goal was to analyze reported cases of neuroleptic malignant syndrome in patients given clozapine and risperidone." | 4.80 | Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. ( Buckley, P; Hasan, S, 1998) |
| " The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)." | 4.80 | Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998) |
| "To summarize published data to date by Canadian authors and from Canadian sources on risperidone, a novel neuroleptic indicated in the management of schizophrenia and related psychotic disorders." | 4.80 | The Canadian experience with risperidone for the treatment of schizophrenia: an overview. ( Hux, M; Iskedjian, M; Remington, GJ, 1998) |
| "The most convincing evidence of the efficacy of atypical neuroleptics in children and adolescents concerns clozapine in the treatment of schizophrenia." | 4.80 | Use of atypical neuroleptics in child and adolescent psychiatry. ( Laor, N; Toren, P; Weizman, A, 1998) |
| "The objective of this meta-analysis is to summarize the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics." | 4.80 | Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. ( Abraham, D; Kissling, W; Leucht, S; Pitschel-Walz, G, 1999) |
| "Despite its high acquisition cost, risperidone does not increase, and may even reduce, overall treatment costs of schizophrenia by reducing hospitalisation compared with standard treatment regimens." | 4.80 | Risperidone. A pharmacoeconomic review of its use in schizophrenia. ( Foster, RH; Goa, KL, 1998) |
| "Three atypical antipsychotics are currently considered to be first-line therapies for schizophrenia, namely risperidone, olanzapine, and quetiapine." | 4.80 | Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. ( Stahl, SM, 1999) |
| "The introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome P450 (CYP) enzymes." | 4.80 | Drug metabolism and atypical antipsychotics. ( Baker, GB; Chue, PS; Prior, TI; Tibbo, P, 1999) |
| " Olanzapine shows a superior and broader spectrum of efficacy in the treatment of schizophrenia, particularly its negative symptoms, with a substantially more favorable safety profile than conventional antipsychotic agents (e." | 4.80 | [Clinical efficacy of olanzapine]. ( Yui, K, 1999) |
| "To evaluate the effectiveness of risperidone for schizophrenia in comparison to 'conventional' neuroleptic drugs." | 4.80 | Risperidone versus typical antipsychotic medication for schizophrenia. ( Clarke, A; Gilbody, S; Hunter, R; Kennedy, E; Song, F, 2000) |
| " Risperidone is associated with relatively few motor side effects compared with the traditional antipsychotics, and weight gain is less likely with risperidone than with either clozapine or olanzapine." | 4.80 | Risperidone side effects. ( Conley, RR, 2000) |
| " Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia." | 4.80 | Adverse events related to olanzapine. ( Conley, RR; Meltzer, HY, 2000) |
| "Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics." | 4.80 | Risperidone versus other atypical antipsychotic medication for schizophrenia. ( Bagnall, AM; Duggan, L; Gilbody, SM; Tuunainen, A, 2000) |
| "The effects of olanzapine, risperidone, and haloperidol on PRL were assessed in patients with schizophrenia or related psychoses participating in 3 double-blind clinical trials: (1) a 6-week acute trial comparing olanzapine 5 to 20 mg/d (n = 1,336) and haloperidol 5 to 20 mg/d (n = 660), with a 1-year, open-label olanzapine extension for responders; (2) a 54-week study comparing olanzapine 5 to 20 mg/d (n = 21), risperidone 4 to 10 mg/d (n = 21), and haloperidol 5 to 20 mg/d (n = 23) in early illness; and (3) a 28-week study comparing olanzapine 10 to 20 mg/d (n = 172) and risperidone 4 to 12 mg/d (n = 167)." | 4.80 | The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. ( Breier, A; David, SR; Kinon, BJ; Taylor, CC, 2000) |
| "The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia." | 4.80 | Effects of risperidone on affective symptoms in patients with schizophrenia. ( De Smedt, C; Lemmens, P; Peuskens, J; Van Baelen, B, 2000) |
| "Clozapine has proved effective in alleviating a wide range of psychiatric symptoms in schizophrenia." | 4.79 | The effects of clozapine on neurocognition: an overview. ( Goldberg, TE; Weinberger, DR, 1994) |
| "The major advance in the psychopharmacology of schizophrenia has been the rediscovery of clozapine and the development of other novel antipsychotic drugs, all of which are superior to typical neuroleptic drugs with regard to extrapyramidal symptoms." | 4.79 | Recent advances in the pharmacotherapy of schizophrenia. ( Lee, MA; Meltzer, HY; Ranjan, R, 1994) |
| "Clozapine, risperidone and remoxipride are three neuroleptics that represent an interesting alternative in the psychopharmacological treatment of schizophrenia." | 4.79 | [New psychopharmacologic alternatives in treatment of schizophrenia]. ( Bryois, C, 1994) |
| "To review pharmacologic, pharmacokinetic, therapeutic, and safety information for the antipsychotic agent risperidone and to evaluate its place in the treatment of schizophrenia." | 4.79 | Risperidone: review and assessment of its role in the treatment of schizophrenia. ( Cardoni, AA, 1995) |
| "The therapeutic success of clozapine and risperidone has focused attention on the interaction between serotonin and dopamine systems as an avenue for superior therapeutics in schizophrenia." | 4.79 | Serotonin-dopamine interaction and its relevance to schizophrenia. ( Kapur, S; Remington, G, 1996) |
| "This article reviews the evidence for the efficacy and effectiveness of risperidone in persons with schizophrenia." | 4.79 | Risperidone: efficacy and safety. ( Kane, JM; Umbricht, D, 1995) |
| "Clozapine represented the first significant advance in the pharmacotherapy of schizophrenia since the introduction of conventional antipsychotic drugs in the 1950's." | 4.79 | Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. ( Lieberman, JA, 1996) |
| "This study evaluates the relative effectiveness and side-effects of risperidone as compared with conventional neuroleptics in the treatment of schizophrenia, by meta-analysis of 11 double-blind, randomized controlled trials." | 4.79 | Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. ( Song, F, 1997) |
| "The unprecedented level of activity in the development of new antipsychotic medications can be traced to the 1989 approval of clozapine by the US Food and Drug Administration for treatment of refractory schizophrenia." | 4.79 | New antipsychotic medications: strategies for evaluation and selected findings. ( Schooler, NR, 1997) |
| "Phase II clinical trials with risperidone have proven it to have a potent antipsychotic effect, improving both positive and negative symptoms of schizophrenia." | 4.78 | Clinical review of risperidone. ( Arnott, W; Chouinard, G, 1993) |
| "Our study suggests that switching from risperidone to PP in patients with schizophrenia is associated with an improvement in social functioning and cognitive performance." | 4.31 | Switching from risperidone to paliperidone palmitate in schizophrenia: Changes in social functioning and cognitive performance. ( Aguayo, R; Álvarez, A; Barbero, JD; Gabernet, R; González-Rodríguez, A; Izquierdo, E; Labad, J; Merodio, I; Monreal, JA; Montalvo, I; Palao, D; Tost, M, 2023) |
| "Forty-two treatment-naive first-episode schizophrenia patients were scanned by TI weighted (T1W) imaging and DTI before and after 8-week risperidone monotherapy, and their peripheral blood genomic DNAm values were examined in parallel with MRI scanning." | 4.31 | Virtual histology of morphometric similarity network after risperidone monotherapy and imaging-epigenetic biomarkers for treatment response in first-episode schizophrenia. ( Duan, X; Hu, M; Kang, L; Li, L; Liu, Z; Ma, S; Nie, Z; Yao, T; Zhang, J; Zhang, N; Zheng, J; Zong, X, 2023) |
| "To compare the effectiveness of different long-acting injectable antipsychotics (LAIs) (aripiprazole, paliperidone, risperidone, and fluphenazine/haloperidol) in patients with schizophrenia in Japan." | 4.31 | Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan. ( Akazawa, M; Inada, K; Okada, Y, 2023) |
| " The present study examined the hypothesis that schizophrenia itself but not risperidone, an extensively employed SGA, is accountable for metabolic abnormalities." | 4.31 | Effects of Early Risperidone Treatment on Metabolic Parameters in Socially Isolated Rats-Implication of Antipsychotic Intervention across Developmental Stages of Schizophrenia. ( Hsieh, PS; Lin, CC; Liu, YP; Tzeng, NS; Yang, YY, 2023) |
| "This study aimed to assess weight changes following antipsychotic treatment in first-episode schizophrenia (FES) patients and make a comparison of aripiprazole, risperidone and olanzapine." | 4.31 | Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China. ( Cheng, Z; Gao, T; Huang, B; Huang, Z; Pu, C; Shi, C; Yu, X; Zhang, D; Zheng, Y; Zhou, E; Zhou, T, 2023) |
| "46); risperidone related to higher risk of hyperprolactinemia (OR: 12." | 4.31 | Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: Randomized clinical trials and multi-ancestry validation. ( Feng, X; Kang, Z; Liao, Y; Lu, T; Lu, Z; Sun, Y; Wang, L; Yan, H; Yue, W; Zhang, D; Zhang, Y, 2023) |
| " Risperidone, a currently used atypical antipsychotic agent for schizophrenia, is also known to inhibit the activity of D-amino acid oxidase, which degrades certain D-amino acids." | 4.31 | Association Between Risperidone Use and Kidney Function Decline in Patients with Schizophrenia: A Retrospective Cohort Study. ( Hara, A; Horikoshi, K; Iwata, Y; Kikuchi, M; Kinoshita, M; Kitajima, S; Minami, T; Mita, M; Miyagawa, T; Nakada, M; Nakade, Y; Nakagawa, S; Ogura, H; Oshima, M; Sakai, N; Shimizu, M; Toyama, T; Wada, T; Yomogida, D; Yuasa, T, 2023) |
| "These results indicate that after treatment with risperidone, changes in GPx activity were associated with treatment response, suggesting that changes in GPx may be a predictor of response to risperidone treatment in female patients with ANFE schizophrenia." | 4.12 | Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study. ( Chen, Z; Jiang, S; Li, X; Liu, H; Lu, Y; Su, L; Wang, X; Xiu, M; Zhang, X, 2022) |
| "5109 patients aged 2-18 years who initiated antipsychotic treatment with risperidone/aripiprazole for schizophrenia between 2010 and 2017 were identified." | 4.12 | Comparison of prediction methods for treatment continuation of antipsychotics in children and adolescents with schizophrenia. ( Cho, J; Jeon, SM; Kwon, JW; Lee, DY, 2022) |
| "Risperidone is routinely used in the clinical management of schizophrenia, but the treatment response is highly variable among different patients." | 4.12 | Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study. ( Fu, C; He, L; Huai, C; Li, M; Li, X; Ma, J; Qin, S; Shen, L; Shen, R; Tang, T; Wu, H; Wu, S; Yang, K; Zhang, N; Zhao, M; Zhou, W; Zhu, W, 2022) |
| "Second generation antipsychotics such as risperidone are first-line pharmacotherapy treatment choices for schizophrenia." | 4.12 | Risperidone-induced changes in DNA methylation in peripheral blood from first-episode schizophrenia patients parallel changes in neuroimaging and cognitive phenotypes. ( Bishop, JR; Chen, C; Chen, X; Giase, G; He, Y; Hu, M; Li, B; Li, Z; Liao, Y; Liu, C; Rubin, LH; Sweeney, JA; Tang, J; Wang, Y; Xia, Y; Zong, X, 2022) |
| "Risperidone and amisulpride caused hyperprolactinemia and macroprolactinemia; thus, detection of MPRL in the clinical setting should be performed as this phenomenon appears early in treatment (the second week) and continues, that can avoid unnecessary examination and treatment for asymptomatic patients with macroprolactinemia." | 4.12 | Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride. ( Haiying, J; Haizhi, C; Jianhua, L; Jianjun, L; Jing, L; Lilei, L; Xiaocong, F; Zhenhua, W, 2022) |
| "Using pooled baseline data from four cariprazine clinical trials in patients with acute exacerbation of schizophrenia (n = 2193) and the cariprazine-risperidone study in patients with PNS (n = 460), separate network analyses were performed." | 4.02 | Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms. ( Acsai, K; Barabássy, Á; Correll, CU; Demyttenaere, K; Earley, W; Fonticoli, L; Laszlovszky, I; Leenaerts, N; Németh, G; Sebe, B; Szatmári, B, 2021) |
| "To study plasma adipokines (adiponectin, leptin, adipsin) in patients with the first episode of schizophrenia treated with haloperidol and risperidone." | 4.02 | [Changes in adipokines in the blood of patients with the first episode of schizophrenia during treatment with haloperidol and risperidone]. ( Govorin, NV; Ozornin, AS; Sakharov, AV; Tereshkov, PP, 2021) |
| "The study included 23 clozapine-treated schizophrenia patients (CT-SCZ), 19 risperidone-treated schizophrenia patients (RT-SCZ), 23 never-treated schizophrenia patients (NT-SCZ), and 35 healthy controls (HCs)." | 4.02 | Characteristics of the corpus callosum in chronic schizophrenia treated with clozapine or risperidone and those never-treated. ( Cao, H; Gong, Q; Lencer, R; Lui, S; Tao, B; Xiao, Y; Yang, C; Zhang, W, 2021) |
| " In this preliminary report we describe 3 cases of patients with schizophrenia, who are treated with long-term injectable risperidone (Risperdal Consta) and were false positively screened for fentanyl by a rapid commercial screening kit." | 4.02 | False-positive fentanyl screening kit results during treatment with long term injectable risperidone (Risperdal-Consta). ( Even-Tov, S; Peles, E; Schreiber, S; Shroitman, NK; Tene, O, 2021) |
| "A cross-sectional study was performed in 87 men newly diagnosed with schizophrenia and administered for approximately 20 months with olanzapine or risperidone as their first antipsychotic treatment." | 4.02 | Circulating IGFBP-2 levels reveal atherogenic metabolic risk in schizophrenic patients using atypical antipsychotics. ( Alméras, N; Bouchard, RH; Cadrin, C; Demers, MF; Després, JP; Nolin, MA; Picard, F; Rauzier, C; Roy, MA, 2021) |
| "Paliperidone palmitate (PP), a long-acting intramuscular formulation of paliperidone, has been marketed in Europe within the last 10 years and provides an important treatment option for patients with schizophrenia." | 4.02 | Fatal and life-threatening ADRs associated with paliperidone palmitate: an observational study in the French pharmacovigilance database. ( Boels, D; Citterio-Quentin, A; Jolliet, P; Mahé, J; Moragny, J; Olry, A, 2021) |
| "To explore pharmacogenetic relationships of NRG1 genotypes with neurocognitive performance and clinical symptoms after 12 week treatment of risperidone in Chinese Han first-episode schizophrenia." | 4.02 | Pharmacogenetic associations of NRG1 polymorphisms with neurocognitive performance and clinical symptom response to risperidone in the untreated schizophrenia. ( Kang, C; Lin, Y; Wei, Y; Wu, C; Xu, L; Yang, J; Yuan, J; Zeng, L; Zhang, Y; Zhou, F, 2021) |
| "A retrospective self-controlled study was conducted on 90 patients with schizophrenia from a single-center treated with olanzapine or clozapine monotherapy, or combined with aripiprazole or ziprasidone which has a small metabolic impact." | 4.02 | The effect of prohibiting outside food during COVID-19 pandemic on the body weight of schizophrenic patients taking olanzapine or clozapine: a retrospective self-controlled study. ( Ding, W; Hu, C; Hu, M; Li, H; Sun, X; Wang, Q; Wang, X; Wu, M; Zhang, C, 2021) |
| "We found very common hyperprolactinemia and hypoprolactinemia in the risperidone or paliperidone group and aripiprazole group, respectively." | 4.02 | Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. ( Shimoda, K; Shinozaki, M; Sugawara, N; Tasaki, M; Yasui-Furukori, N; Yokoyama, S, 2021) |
| "Risperidone is an atypical antipsychotic agent clinically used to treat schizophrenia, bipolar diseases, and autism." | 4.02 | Determining the release kinetics of risperidone controlled release matrices to treat schizophrenia. ( Akhtar, H; Ali, MM; Ali, SI; Arif, H; Inayat, S; Iqbal, MS; Kashif, SS; Naz, A; Nisa, Z; Perveen, S; Rizvi, M; Shahnaz, S; Sheikh, S; Swaleh, MM; Zehra, A, 2021) |
| "Longitudinal study of the dFC of insular subdivisions was conducted in 42 treatment-naive first-episode patients with schizophrenia at baseline and after 8 weeks of risperidone treatment based on resting-state functional magnetic resonance image (fMRI)." | 3.96 | Effect of Risperidone Monotherapy on Dynamic Functional Connectivity of Insular Subdivisions in Treatment-Naive, First-Episode Schizophrenia. ( Chen, H; Chen, X; Dong, X; Duan, X; He, C; Hu, M; Huang, X; Li, H; Su, C; Tang, J; Xiao, J; Zong, X, 2020) |
| "Brexpiprazole is an oral atypical antipsychotic (OAA) for the treatment of schizophrenia (SCZ)." | 3.96 | Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy. ( Broder, MS; Chang, E; Greene, M; Houle, CR; Tarbox, MH; Waters, HC; Yan, T, 2020) |
| "Antipsychotic medications, including risperidone, are widely used in the treatment of psychiatric disorders, including schizophrenia." | 3.96 | Severe hypothermia, bradycardia and cardiac arrest in association with risperidone. ( Bhat, S; Ochieng, P; Ravi, D; Sharma, N, 2020) |
| "Although clozapine treatment is often discontinued due to limited efficacy or low tolerability, there is a lack of guidelines and evidence on treatment options after discontinuation of clozapine in patients with schizophrenia." | 3.96 | Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics. ( Bijker, BJ; Bos, JHJ; Isphording, L; Luykx, JJ; Okhuijsen-Pfeifer, C; Schuiling-Veninga, CCM; Stam, N; Taipale, H; Tanskanen, A; Tiihonen, J, 2020) |
| " CASE REPORT A 27-year-old woman with schizophrenia on risperidone presented to our Emergency Department with a sensation of choking and respiratory distress, mimicking a panic attack." | 3.96 | Risperidone-Induced Acute Laryngeal Dystonia: A Case Report. ( Alkharboush, GA; Alsalamah, MA, 2020) |
| " This study sought to explore the characteristics of white matter structural networks in chronic never-treated schizophrenia and those treated with clozapine or risperidone, and its potential association with cognitive function." | 3.96 | Characteristics of White Matter Structural Networks in Chronic Schizophrenia Treated With Clozapine or Risperidone and Those Never Treated. ( Gong, Q; Hu, N; Lencer, R; Li, S; Lui, S; Luo, C; Xiao, Y; Zhang, W, 2020) |
| "We used the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to assess the cognition of three groups of schizophrenia patients (318 on clozapine, 125 on risperidone, and 166 on typical antipsychotic drugs) and 399 healthy controls, and used the Positive and Negative Syndrome Scale to assess schizophrenia symptoms of patients." | 3.96 | Differential effects of different antipsychotic drugs on cognitive function in patients with chronic schizophrenia. ( Dillon, BA; Dong, R; Du, XD; Jia, Q; Yang, Y; Yu, L; Yuan, L; Zhang, XY, 2020) |
| " We Propose a text mining approach to detect adverse events and medication episodes from the clinical text to enhance our understanding of adverse effects related to Clozapine, the most effective antipsychotic drug for the management of treatment-resistant schizophrenia, but underutilised due to concerns over its side effects." | 3.96 | The side effect profile of Clozapine in real world data of three large mental health hospitals. ( Broadbent, M; Dobson, RJB; Dzahini, O; Govind, R; Ibrahim, ZM; Iqbal, E; Kim, CH; MacCabe, JH; Romero, A; Smith, T; Stewart, R; Werbeloff, N, 2020) |
| "The present study aimed to investigate the effect of bezafibrate on glucolipid abnormalities induced by antipsychotics in schizophrenia." | 3.91 | The effect of bezafibrate in preventing glucolipid abnormalities induced by the antipsychotic risperidone. ( Wei, XY; Yang, YJ; Zhu, XH, 2019) |
| " To explore further, the present study aimed to assess the influence of DRD2 -141 C Ins/Del, Taq1A and HTR2A -1438 G/A, 102T/C and HTR2C -759 C/T genetic polymorphisms in response to risperidone in patients with schizophrenia." | 3.91 | Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia. ( Adithan, S; Alladi, CG; Bellivier, F; Marie-Claire, C; RajKumar, RP; Shewade, DG, 2019) |
| " We performed diffusion tensor imaging (DTI) and resting-state functional magnetic resonance imaging in 42 drug-naive first-episode schizophrenia patients (FESP) both at baseline and after 8-weeks risperidone monotherapy, and in 38 healthy volunteers." | 3.91 | A Dissociation in Effects of Risperidone Monotherapy on Functional and Anatomical Connectivity Within the Default Mode Network. ( Chen, H; Chen, X; He, Y; Hu, M; Li, Z; Liao, W; Liao, Y; Liu, ZC; Lv, L; Mann, JJ; Pantazatos, SP; Sang, D; Tang, J; Wang, G; Yao, T; Zheng, J; Zong, X, 2019) |
| "The aim of this study was to explore the effectiveness and tolerability of long-acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients while comparing the results with the oral antipsychotic risperidone." | 3.91 | Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients. ( Gačo, N; Graovac, M; Kaštelan, A; Petrić, D; Rački, V, 2019) |
| "This study compared the risk of hospitalization among adults with schizophrenia being treated with equivalent dose ranges of lurasidone versus aripiprazole, olanzapine, quetiapine, or risperidone." | 3.91 | Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics. ( Huang, A; Loebel, A; Messali, A; Ng-Mak, D; Wang, L, 2019) |
| " In this study, 264 Han Chinese inpatients diagnosed with schizophrenia or schizoaffective disorder initiated treatment with olanzapine (n=131) or risperidone (n=133) and were followed for 12weeks." | 3.88 | T ( Gao, M; Gao, Y; He, Y; Jiang, R; Li, J; Li, S; Li, WD; Lv, H; Wang, L; Wang, X; Xu, C; Zhang, M, 2018) |
| "Using near-infrared spectroscopy, we examined changes in the concentration of oxygenated hemoglobin ([oxy-Hb]) in the frontal lobe during a verbal fluency task in 20 patients with schizophrenia (10 patients each receiving olanzapine [OLZ] and risperidone [RIS]) and 10 healthy controls." | 3.88 | Frontal activity measured by near-infrared spectroscopy in patients taking different atypical antipsychotic drugs: A cross-sectional study. ( Hikita, M; Kono, S; Miura, I; Niwa, SI; Oshima, S; Suzuki, R; Wada, A; Yabe, H, 2018) |
| "This study enrolled adults with schizophrenia or bipolar I disorder who initiated APT treatment at various time points: 1) within 8 weeks of initiating risperidone long-acting injectables (RLAIs) or other APTs except paliperidone palmitate (PP), 2) after more than 24 weeks of continuous RLAI treatment, or 3) at any time after initiating PP LAI treatment (schizophrenia only)." | 3.88 | The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia. ( Biondi, DM; Joshi, K; Mao, L; Millet, R, 2018) |
| "This study aimed to assess the comparative effectiveness of risperidone (RIS) versus aripiprazole (ARP) in patients with recent-onset or chronic schizophrenia during maintenance treatment and to examine the interaction between illness duration and the effectiveness of the treatment." | 3.88 | Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study. ( Aoki, S; Harada, T; Kishi, Y; Nomura, A; Sato, K; Takeda, T; Washida, K; Yada, Y; Yoshimura, B; Yoshimura, Y, 2018) |
| "The aim of the nationwide retrospective matched cohort study was to evaluate health service utilization and medical costs between patients with schizophrenia who received long-acting injectable (LAI) risperidone and those who took risperidone orally." | 3.88 | Health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone: a nationwide retrospective matched cohort study in Taiwan. ( Chang, HC; Fan, SJ; Huang, KC; Lu, N; Tang, CH, 2018) |
| " We report a case of an antipsychotic-naive patient with schizophrenia who developed leukopenia after a single dose of olanzapine, which worsened during subsequent treatment with risperidone." | 3.88 | Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction? ( Chan, LF; Deang, KT; Gan, LLY; Tee, CK; Woon, LS, 2018) |
| "Risperidone and paliperidone palmitate are two antipsychotic drugs well tolerated in the management of schizophrenia and other psychiatric conditions." | 3.88 | Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability. ( Tagne Nouemssi, AB, 2018) |
| " After 24-week risperidone treatment, there were significant increases in body weight, BMI, fasting blood-glucose, triglycerides, LDL, hs-CRP, SOD and HOMA-IR (p < 0." | 3.88 | Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia. ( Fan, X; Hei, G; Huang, XF; Kumar, BU; Li, X; Liu, Y; Lv, L; Song, X; Wang, Y; Yuan, X; Zhang, P, 2018) |
| "The Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study randomized 119 youths (age 8-19 years) with schizophrenia or schizoaffective disorder to 8 weeks of antipsychotic treatment with molindone, risperidone, or olanzapine and assessed treatment response and side effects." | 3.88 | Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study. ( Bloch, MH; Gabriel, D; Jakubovski, E; Taylor, JH, 2018) |
| "Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia." | 3.88 | Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018) |
| " The aim of the study was to investigate the association of 14 single nucleotide polymorphisms (SNPs) selected from HTR3C, HTR3D, HTR5A and HTR6 with risperidone response in 201 Han Chinese schizophrenia patients." | 3.88 | Pharmacogenetics analysis of serotonin receptor gene variants and clinical response to risperidone in Han Chinese schizophrenic patients. ( Chang, W; Li, W; Qin, S; Shen, L; Yan, Y; Yi, Z; Zhou, W, 2018) |
| "In this study, we aimed to test if the schizophrenia (SCZ) polygenic risk score (PRS) was associated with clinical symptoms in (a) the first episode of psychosis pre-treatment (FEP), (b) at nine weeks after initiation of risperidone treatment (FEP-9W) and (c) with the response to risperidone." | 3.88 | Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort. ( Belangero, SI; Breen, G; Bressan, RA; Carvalho, CM; Cordeiro, Q; Curtis, C; de Jong, S; Gadelha, A; Gouvea, E; Lee, SH; Moretti, P; Newhouse, S; Noto, C; Ota, V; Patel, H; Santoro, ML; Spindola, LM; Talarico, F, 2018) |
| "We examined whether memantine add-on to antipsychotic treatment is beneficial in schizophrenia treatment." | 3.85 | Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. ( Iwata, N; Kishi, T; Matsuda, Y, 2017) |
| "Risperidone is most commonly used as an antipsychotic in India for treatment of schizophrenia." | 3.85 | Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India. ( Aneja, J; Chavan, BS; Garg, PD; Gautam, S; Gupta, D; Gupta, R; Kaur, G; Khurana, H; Margoob, MA; Prasad, R; Sinhmar, V; Tripathi, A, 2017) |
| "Nowadays, risperidone is an atypical antipsychotic drug that has been increasingly used for treatment and maintenance therapy in schizophrenia." | 3.85 | Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients. ( Cui, D; He, L; Huo, R; Li, M; Li, W; Qin, S; Shen, L; Shi, Y; Song, C; Xing, Q; Xu, Q; Zhao, J, 2017) |
| "To determine the cost-effectiveness of PP3M compared with once-monthly paliperidone (PP1M), haloperidol long-acting therapy (HAL-LAT), risperidone microspheres (RIS-LAT), and oral olanzapine (oral-OLZ) for treating chronic schizophrenia in The Netherlands." | 3.85 | Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. ( Bereza, BG; Denee, TR; Dries, PJT; Einarson, TR; Tedouri, F; Van Impe, K, 2017) |
| "Successful treatment of acute periodic catatonia was achieved with a lorazepam-diazepam protocol, and the patient remained in remission for a longer duration under clozapine treatment." | 3.85 | Periodic catatonia with long-term treatment: a case report. ( Chen, RA; Huang, TL, 2017) |
| "To investigate the clinical effects of aripiprazole on sexual dysfunction induced by amisulpride or risperidone in male patients with schizophrenia." | 3.85 | [Aripiprazole for drug-induced sexual dysfunction in schizophrenic males]. ( Gao, LJ; Guo, HG; Liang, ZT; Yang, Y; Zhong, XX; Zhu, JC, 2017) |
| "Immune dysregulation observed in schizophrenia alters tryptophan metabolism." | 3.85 | Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs. ( Cordeiro, RC; da Silva Araújo, T; de Freitas Lima, R; de Jesus Souza Machado, M; Freitas de Lucena, D; Isabelle de Góis Queiroz, A; Macêdo, D; Maes, M; Maia Chaves Filho, AJ; Monte, AS, 2017) |
| "Thirty-seven clinically stable participants with schizophrenia or schizoaffective disorder, aged 50 years or greater, and having been treated with olanzapine or risperidone monotherapy at the same dose for at least 6 months." | 3.85 | Cognition and Dopamine D ( Caravaggio, F; Gerretsen, P; Graff-Guerrero, A; Mamo, DC; Mar, W; Mulsant, BH; Nakajima, S; Pollock, BG; Rajji, TK; Suzuki, T; Uchida, H, 2017) |
| "The present study demonstrates that co-administration of risperidone and escitalopram may be used to treat positive and negative symptoms of schizophrenia and will allow to minimize the drugs' side effects." | 3.85 | Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects. ( Górska, A; Gołembiowska, K; Jurczak, A; Kamińska, K; Noworyta-Sokołowska, K; Rogóż, Z, 2017) |
| "The aim of this study was to determine whether the incidence of pneumonia in patients taking clozapine was more frequent compared with those taking risperidone or no atypical antipsychotics at all before admission to a tertiary care medical center." | 3.85 | Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. ( Colon, E; George, WT; Jancik, J; O'Brien, JB; Rasimas, JJ; Stoecker, ZR, 2017) |
| "The study was a non-randomized, naturalistic, rater blinded, prospective, 8-12 weeks, comparative trial between the risperidone and aripiprazole in patients with schizophrenia." | 3.85 | A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia. ( Kumar C, N; Kumar P B, S; Kumar P T, S; Pandey, RS; Thirthalli, J, 2017) |
| "Administrative claims of patients with schizophrenia treated with atypical antipsychotics (lurasidone, aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone) from October 2010 to September 2011 were identified from MarketScan Commercial and Medicaid Databases, and were classified by the first (index) antipsychotic." | 3.85 | Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis. ( Loebel, A; Meyer, N; Rajagopalan, K; Wade, S, 2017) |
| "This study aims to determine the optimal tolerability dose ranges of risperidone (RIS) and olanzapine (OLZ) administered during schizophrenia maintenance phase." | 3.85 | Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study. ( Aoki, S; Harada, T; Kishi, Y; Nomura, A; Sato, K; Takeda, T; Washida, K; Yada, Y; Yoshimura, B; Yoshimura, Y, 2017) |
| "32 per cent mean reduction in Positive and Negative Syndrome Scale (PANSS) for Schizophrenia total score while risperidone led to 56." | 3.83 | Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study. ( Chavan, BS; Kalra, P; Kaur, G; Sahni, S; Sidana, A, 2016) |
| "Currently, aripiprazole, olanzapine and risperidone are three anti-psychiatry agents commonly used in the treatment of schizophrenia." | 3.83 | [Using the cumulative odds Logit model to explore the application of the questionnaire derived from PANSS]. ( Dong, F; Ji, SM; Li, AN; Li, L; Lu, W; Wang, CY; Zhou, TY, 2016) |
| "This cross-sectional study compared quality of life and side effects in 108 users of olanzapine or risperidone suffering schizophrenia and being attended at psychiatric ambulatory services in Rio Grande do Norte, Brazil." | 3.83 | Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users. ( de Araújo Júnior, RF; de Araújo, AA; Dos Santos, AC; Guerra, GC; Lemos, TM; Medeiros, CA; Ribeiro, SB; Rubio-Valera, M; Serrano-Blanco, A, 2016) |
| "To determine the cost-effectiveness of aripiprazole (ARI-LAI), paliperidone (PP-LAI), olanzapine (OLZ-LAI), and risperidone (RIS-LAI) in patients with chronic schizophrenia in Finland." | 3.83 | Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. ( Bereza, BG; Einarson, TR; Goswami, P; Pudas, H; van Impe, K, 2016) |
| "Schizophrenia or schizoaffective disorder subjects (n = 218), treated mostly with clozapine and olanzapine for up to 14 weeks, were included." | 3.83 | Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. ( Brandl, EJ; Chowdhury, NI; Freeman, N; Goncalves, VF; Kennedy, JL; Lieberman, JA; Meltzer, HY; Müller, DJ; Tiwari, AK; Zai, CC, 2016) |
| "Previous studies showed functional improvement in stable patients with schizophrenia treated with risperidone long-acting injection (LAI)." | 3.83 | Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study). ( Dassa, D; De Vathaire, F; Garay, RP; Giraud-Baro, E; Obeid, J, 2016) |
| "To describe abnormalities in large scale functional networks in unmedicated patients with schizophrenia and to examine effects of risperidone on networks." | 3.83 | Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone. ( Falola, B; Hadley, JA; Knight, D; Kraguljac, NV; Lahti, AC; ver Hoef, L; Visscher, K; White, DM, 2016) |
| "Scores on the Positive and Negative Syndrome Scale, executive functioning, and social functioning were obtained from 24 patients with schizophrenia receiving either risperidone (n = 12) or trifluoperazine (n = 12), before their social behavior was measured in the interactive Tangrams Game." | 3.83 | Different mechanisms of risperidone result in improved interpersonal trust, social engagement and cooperative behavior in patients with schizophrenia compared to trifluoperazine. ( Bond, AJ; Chan, CK; Chan, F; Pang, AH; Tse, WS; Wong, AS, 2016) |
| "This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia." | 3.83 | Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. ( Guo, Q; Li, C; Ouyang, Q; Qiao, Y; Shen, W; Sheng, J; Wen, H; Yang, F; Zhu, S, 2016) |
| "Eleven single nucleotide polymorphisms (SNPs) of SREBF1 and five of SCAP were genotyped in a Han Chinese population in Beijing, China: a sample of 722 schizophrenia patients on monotherapy with AAPs (clozapine, olanzapine or risperidone)." | 3.83 | Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics. ( Chen, J; Li, Y; Liang, S; Shi, S; Shi, Y; Wang, Y; Xu, Y; Yang, L, 2016) |
| "Hyperprolactinemia is commonly seen in patients with schizophrenia on risperidone." | 3.83 | Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia. ( Chandrasekaran, A; Charan, A; Rajkumar, RP; Shewade, DG, 2016) |
| "Clozapine is the gold-standard antipsychotic medication for treatment-refractory schizophrenia (TRS)." | 3.83 | Fever, confusion, acute kidney injury: is this atypical neuroleptic malignant syndrome following polypharmacy with clozapine and risperidone? ( Cherry, S; Halangoda, P; Siskind, D; Spivak, V; Wysoczanski, D, 2016) |
| "Clozapine is an atypical antipsychotic primarily prescribed for treatment-resistant schizophrenia." | 3.83 | Gene-expression analysis of clozapine treatment in whole blood of patients with psychosis. ( Breen, G; Curtis, CJ; de Jong, S; Dempster, D; Dima, D; Gaughran, F; Harrison, RN; Lee, SH; Murray, RM; Paya Cano, J, 2016) |
| " This open-label, parallel-group study was performed to compare finger-stick-based capillary with corresponding venous plasma concentrations for risperidone, paliperidone, quetiapine, olanzapine, and aripiprazole and their major metabolites after repeated dosing in patients with schizophrenia or related illnesses." | 3.83 | Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole. ( Ariyawansa, J; De Meulder, M; Remmerie, B; Savitz, A, 2016) |
| " Moreover we also investigated their utility as adjunct treatment in depression in combination with the SSRI citalopram." | 3.83 | Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study. ( Björkholm, C; Feltmann, K; Jardemark, K; Konradsson-Geuken, Å; Malmerfelt, A; Marcus, MM; Möller, A; Påhlsson, N; Schilström, B; Svensson, TH, 2016) |
| "This retrospective longitudinal cohort study aimed to compare treatment patterns, healthcare resource utilization (HRU), and costs in patients with schizophrenia treated with second-generation antipsychotic long-acting injectables (SGA-LAIs): biweekly risperidone LAI versus once-monthly paliperidone palmitate." | 3.83 | Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. ( Benson, C; Joshi, K; Pan, X; Wang, R; Yang, E, 2016) |
| "We conducted a cross-sectional study to compare the subjective experiences and clinical effects of first-generation long-acting injectable (FGA-LAI) antipsychotics with those of risperidone long-acting injectables (RIS-LAIs) in 434 schizophrenia patients." | 3.83 | Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia. ( Chen, WY; Lin, SK, 2016) |
| "While numerous studies have confirmed the efficacy of risperidone long-acting injectable (RLAI) on many clinical outcomes in patients with schizophrenia, there is no data regarding its influence on employment status." | 3.83 | Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. ( Emsley, R; Filipcic, IS; Grosic, V; Mihaljevic-Peles, A; Pedisic, I; Sagud, M, 2016) |
| "The aim of the study was to use a technique that combines acid hydrolysis and matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI-TOF MS) in order to detect the serum biomarkers of patients diagnosed with schizophrenia both before and after four-week antipsychotic treatment with risperidone." | 3.83 | Rapid detection of alteration of serum IgG in patients with schizophrenia after risperidone treatment by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. ( Huang, TL; Lo, LH; Shiea, J, 2016) |
| "The addition of amisulpride could lead to an improvement in schizophrenia symptoms in patients that do not, or only partially, respond to risperidone." | 3.81 | Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy. ( Amorin-Díaz, M; Aparicio-Castro, E; López-Rodríguez, E; Molina, JD; Muñoz Algar, MJ; Toledo-Romero, F, 2015) |
| "Second-generation antipsychotic (SGA) monotherapy was the most common type of therapy in both those with dementia and with schizophrenia, and quetiapine and risperidone were the most commonly prescribed drugs for these conditions, respectively." | 3.81 | Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital. ( Chang, YS; Lai, CY; Wu, YH, 2015) |
| "Overall, our data suggest that maternal inflammation may contribute to an increased risk for schizophrenia through mechanisms involving metabolic function and myelin formation and that risperidone in adolescence may prevent or reverse such changes." | 3.81 | Maternal immune activation induces changes in myelin and metabolic proteins, some of which can be prevented with risperidone in adolescence. ( Cagney, G; Cannon, M; Cotter, DR; Dicker, P; English, J; Farrelly, L; Föcking, M; Piontkewitz, Y; Wynne, K, 2015) |
| "We wanted to present a picture of patients with schizophrenia receiving risperidone long-acting injection (RLAI) treatment in a real-world setting." | 3.81 | Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study. ( Chan, HW; Feng, WJ; Huang, CY; Yen, YC, 2015) |
| "Data were reanalyzed on 611 in-patients with acute schizophrenia who participated in three pivotal randomized controlled trials that compared placebo with olanzapine or risperidone (dropout rates placebo: 62." | 3.81 | Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia. ( Davis, JM; Goldberg, Y; Leucht, S; Levine, SZ; Samara, M, 2015) |
| "When choosing between first-generation antipsychotics, clinicians should consider haloperidol as the first-line agent for schizophrenia." | 3.81 | A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda. ( Babigumira, JB; Lubinga, SJ; Mutamba, BB; Nganizi, A, 2015) |
| " As an application, we revisit a risperidone maintenance treatment trial in schizophrenia and use our proposed methodology to redesign it and compare merits of our optimal design." | 3.81 | Optimal treatment allocation for placebo-treatment comparisons in trials with discrete-time survival endpoints. ( Moerbeek, M; Wong, WK, 2015) |
| "This study evaluated 169 patients with schizophrenia who were receiving risperidone monotherapy." | 3.81 | Factors associated with self-rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapy. ( Bae, KY; Kang, HJ; Kim, JM; Kim, SW; Kim, SY; Lee, JY; Lee, YH; Shin, IS; Yoon, JS, 2015) |
| " This study was to explore the relationship between N400 changes and risperidone treatment and rehabilitation infirst-episode schizophrenia (FES)." | 3.81 | Follow-up of N400 in the Rehabilitation of First-episode Schizophrenia. ( Chen, XS; Dong, RX; Du, XD; Gai, HJ; Li, WQ; Li, Z; Pan, NR; Pan, W; Xu, XW; Yang, JG; Yang, Y; Ye, G; Yin, GZ; Yuan, Y; Zhang, GY, 2015) |
| "SLC6A4 might be susceptible gene for risperidone-induced weight gain within the Chinese Han population." | 3.81 | A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population. ( Du, B; Li, K; Liu, C; Lu, T; Lv, L; Ma, C; Ma, W; Mi, W; Wang, F; Wang, L; Yang, Y; Yue, W; Zhang, D; Zhang, H, 2015) |
| "Modafinil or armodafinil (ar/mod) augmentation of antipsychotic medication in schizophrenia patients may be considered with a view to reduce negative symptoms associated with the illness or excessive daytime drowsiness due to any cause." | 3.81 | Delayed drug interactions in psychiatry: armodafinil and risperidone as a potential case in point. ( Andrade, C, 2015) |
| " risperidone long acting injectable (RLAI), paliperidone long acting injectable (PLAI) and olanzapine long acting injectable (OLAI) in the maintenance treatment of chronic, stable schizophrenia patients in the United Kingdom." | 3.81 | Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. ( Beillat, M; Robinson, P; Sapin, C; Tempest, M; Treur, M, 2015) |
| " HMGB1 may play a proinflammatory role in schizophrenia and the decrease of HMGB1 after neuroleptic risperidone treatment may be a marker of mental symptoms remission." | 3.81 | [Analysis of the changes of serum high mobility group protein B1 and cytokines in first-episode schizophrenia patients]. ( Hie, G; Li, X; Lü, L; Song, X; Yuan, X; Zhu, Q, 2015) |
| "26 million insured in a Markov-simulation model to assess the cost-effectiveness of long-acting injectable risperidone (LAI-RIS) compared with long-acting injectable flupentixol (LAI-FLX) in the long-term management of schizophrenia." | 3.80 | Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. ( Frey, S; Juckel, G; Linder, R; Stargardt, T, 2014) |
| "The aim of the study was to investigate the prevalence rates of obsessive-compulsive disorder (OCD) and hypochondriasis in schizophrenic patients treated with atypical antipsychotics (AAPs) and to investigate the different comorbidity rates of OCD and hypochondriasis between clozapine-treated patients and patients treated with other AAPs." | 3.80 | Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. ( Cantisani, A; Ferrari, G; Grassi, G; Pallanti, S; Poli, L; Righi, L, 2014) |
| "We investigated the relationship between basal ganglia volume and treatment response to the atypical antipsychotic medication risperidone in unmedicated patients with schizophrenia." | 3.80 | Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication. ( Bolding, MS; Clark, DG; Hutcheson, NL; Lahti, AC; White, DM, 2014) |
| " Hospitalizations for hyperglycemic emergencies (hyperglycemia, diabetic ketoacidosis, hyperosmolar hyperglycemic state) were compared between new users of risperidone (reference), and new users of olanzapine, other atypical antipsychotics, and typical antipsychotics." | 3.80 | Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data. ( Alessi-Severini, S; Austin, PC; Blackburn, DF; Blais, L; Bresee, L; Filion, KB; Kawasumi, Y; Kurdyak, P; Lipscombe, LL; Paterson, JM; Platt, RW; Tamim, H, 2014) |
| "The present study evaluated the association of the BDNF Val66Met polymorphism with treatment response to atypical antipsychotic olanzapine in schizophrenia and the possible predictive value of the BDNF Val66Met genotype status in treatment response to antipsychotic medication." | 3.80 | Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. ( Kozumplik, O; Mihaljevic-Peles, A; Muck-Seler, D; Nedic Erjavec, G; Nikolac Perkovic, M; Pivac, N; Sagud, M; Uzun, S; Zivkovic, M, 2014) |
| " The main purpose of the present study was to examine the correlations between testosterone, estradiol BMI, and insulin in male patients diagnosed with schizophrenia and treated with olanzapine or risperidone." | 3.80 | Association between serum testosterone levels, body mass index (BMI) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone. ( Galińska-Skok, B; Konarzewska, B; Malus, A; Simonienko, K; Szulc, A; Waszkiewicz, N; Łazarczyk-Kirejczyk, J, 2014) |
| "The purpose of this study was to investigate the change in plasma protein expression in first episode schizophrenia after an 8-week treatment with risperidone, and to explore potential biomarkers for metabolic side effects associated with risperidone treatment." | 3.80 | APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia. ( Fan, X; Gao, J; Li, X; Li, Y; Lv, L; Song, X; Zhao, J, 2014) |
| "To explore differences in outcomes for patients with schizophrenia treated with risperidone long-acting treatment (RLAT) or oral antipsychotics (oAP)." | 3.80 | Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). ( Cherubin, P; Princet, P; Schreiner, A; Serazetdinova, L; Svensson, A; Wapenaar, R; Zink, M, 2014) |
| " The aims of this study were to investigate the antioxidative activity of paraoxonase and assess lipid profile as a cardiovascular risk factor in patients with schizophrenia under long-term clozapine or risperidone treatment." | 3.80 | A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. ( Atanasiu, V; Delia, C; Gaman, L; Gilca, M; Iosif, L; Piriu, G; Stoian, I, 2014) |
| "In this study, 15 patients with schizophrenia receiving risperidone were switched to PAL and treated for 12 weeks." | 3.80 | Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia. ( Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Otomo, M; Suzuki, H, 2014) |
| " The aim of this work was designed to investigate the diagnostic possibility of [(123)I]epidepride imaging platform for risperidone-treatment chronic MK-801-induced rat schizophrenia model." | 3.80 | Dopamine D(2)/D(3) receptor binding of [(123)I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging. ( Chang, KW; Chen, MW; Cheng, KH; Huang, YR; Kuo, WI; Pai, CW, 2014) |
| "The study involved 64 first-episode schizophrenia patients treated with the second-generation oral antipsychotic medication, risperidone, for 12 months." | 3.80 | The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia. ( Agee, ER; Casaus, LR; Gretchen-Doorly, D; Hellemann, GS; Luo, JS; Nuechterlein, KH; Subotnik, KL; Ventura, J; Villa, KF, 2014) |
| "Here is a case of a woman with schizophrenia who developed rhabdomyolysis following overdose of risperidone, trihexyphenidyl and benzodiazepines." | 3.80 | Multidrug overdose-induced myoclonus complicated by rhabdomyolysis: possible role and mechanism of muscle toxicity of risperidone. ( Hsu, YC; Yeh, YW, 2014) |
| "The FTO gene polymorphisms, especially rs9939609, seem to be related to weight gain after risperidone treatment in Chinese Han patients with first episode schizophrenia." | 3.80 | Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. ( Fan, X; Feng, Y; Gao, J; Li, X; Lv, L; Nemani, K; Pang, L; Song, X; Zhang, H; Zhang, J; Zhang, W, 2014) |
| "We recruited 39 first-episode schizophrenia (FES) patients and determined serum profile of total homocysteine (tHcy), folate, vitamin B12, lipoproteins and glucose at baseline and after 12 weeks of treatment with second-generation antipsychotics (SGA) including olanzapine and risperidone in monotherapy." | 3.80 | Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. ( Frydecka, D; Kiejna, A; Misiak, B; Ślęzak, R; Łaczmański, Ł, 2014) |
| "Using Mixed Model Repeated Measures, we tested the relationship between SULT4A1-1 status (+carrier, -noncarrier) and clinical improvement (in Positive and Negative Syndrome Scale total score) among European ancestry patients treated with paliperidone extended release (n=937), paliperidone palmitate (n=990), risperidone (n=507) and olanzapine (n=381) in 12 schizophrenia, two schizoaffective disorder and three bipolar I disorder trials." | 3.80 | SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response. ( Chung, H; Cohen, N; Favis, R; Fu, DJ; Gopal, S; Jadwin, A; Li, Q; Savitz, A; Wang, D, 2014) |
| "A 19-year-old man with schizophrenia and underlying cerebral disease developed rapid-onset mania after risperidone was replaced with amisulpride." | 3.80 | Amisulpride-associated mania in a young adult with schizophrenia and cerebral disease. ( Chen, CY; Chen, TY; Chuang, WC; Kuo, SC; Yeh, YW, 2014) |
| "Potential differences in psychiatric clinical outcomes and hospitalization rates before and after the initiation of long-acting risperidone among recently and long-term diagnosed schizophrenia patients were studied." | 3.80 | Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schi ( Detraux, J; Dubois, V; Geerts, P; Peuskens, J, 2014) |
| " The aim of the study was to compare the clinical remission rates, number of hospital readmissions and personal and social functioning after 2 years between patients with recent-onset schizophrenia (<2 years) in treatment with risperidone long-acting injectable (RLAI) and patients with recent-onset schizophrenia receiving oral antipsychotics." | 3.79 | Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. ( Barrio, P; Batalla, A; Castellví, P; García, M; Grande, I; Hidalgo, D; Ortiz, A; Parellada, E; Pons, A, 2013) |
| "The aims of this study were to investigate bone mass, body composition and light microscopic pathology examinations of femur in an animal model of schizophrenia (pharmacologically induced by postnatally administered phencyclidine-PCP) and to further examine the effects of chronic treatment with risperidone on these parameters in rats." | 3.79 | Chronic risperidone exposure does not show any evidence of bone mass deterioration in animal model of schizophrenia. ( Doknic, M; Jasovic-Gasic, M; Maric, N; Pekic, S; Petronijevic, M; Petronijevic, N; Popovic, V; Radonjic, N; Sopta, J, 2013) |
| "Patients with schizophrenia receive medication to alleviate various symptoms, but some efficacious second generation antipsychotics, particularly olanzapine, can cause obesity, dyslipidemia, and diabetes mellitus." | 3.79 | The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation. ( Harding, H; Mori, K; Nadanaka, S; Nagamine, T; Okada, T; Ozasa, R; Ron, D; Zyryanova, A, 2013) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 3.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "This cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr." | 3.79 | Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. ( Chaves, KM; de Araújo Júnior, RF; de Araújo, AA; de Paula Soares Rachetti, V; do Socorro Costa Feitosa Alves, M; Filgueira Júnior, A; Guerra, GC; Ribeiro, SB; Serrano-Blanco, A; Soares, LA, 2013) |
| "In the present work we analyzed the effect of the chronic administration of risperidone (2mg/kg over 65 days) on behavioural, morphological and molecular aspects in an experimental model of schizophrenia obtained by bilateral injection of ibotenic acid into the ventral hippocampus of new-born rats." | 3.79 | Chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study. ( Arji, M; Carro, J; Castellano, O; de Anchieta de Castro E Horta, J; Gómez-Nieto, R; Herrero-Turrión, MJ; López, DE; Molina, V; Riolobos, AS; Sancho, C, 2013) |
| " Generic oral risperidone recently became available in Scotland; however, schizophrenia is a complex disease with advice from respected authorities suggesting that treatment should be individualised." | 3.79 | Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. ( Barbui, C; Bennie, M; Bishop, I; Campbell, S; Godman, B; Gustafsson, LL; Miranda, J; Raschi, E, 2013) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 3.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| " The study included 456 schizophrenia patients treated with clozapine (n=171), olanzapine (n=91) and risperidone (n=194), for an average of 45." | 3.78 | Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. ( Bai, YM; Chen, JY; Chen, TT; Hong, CJ; Lin, E; Liou, YJ; Tsai, SJ, 2012) |
| "Schizophrenic patients treated with clozapine or olanzapine often develop hypertriglyceridemia." | 3.78 | Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment. ( Bai, YM; Chen, TT; Hong, CJ; Liou, YJ; Tsai, SJ, 2012) |
| " We present the case of a 55-year-old patient with schizophrenia, who developed a skin eruption 5 weeks after initiating treatment with olanzapine." | 3.78 | Olanzapine-induced eccrine squamous syringometaplasia. ( Barabash, R; Molina-Ruiz, AM; Molina-Ruiz, RM; Requena, L; Zulueta, T, 2012) |
| "This study was conducted with six patients with schizophrenia, four of whom received the atypical antipsychotic risperidone long-acting injectable (RLAI), and two patients receiving the typical depot injection (TDI)." | 3.78 | Using ultrasonography in evaluating the intramuscular injection techniques used for administering drug treatments to schizophrenic patients in Japan. ( Hirai, E; Inui, T; Kawanishi, C; Locsin, R; Makiguchi, K; Motoki, K; Sakamaki, S; Takase, K; Tanioka, T; Watari, C; Yasuhara, Y, 2012) |
| "To model the cost effectiveness of paliperidone palmitate (paliperidone long-acting injectable; PLAI), a new once-monthly long-acting antipsychotic therapy, compared with risperidone long-acting injectable (RLAI) and olanzapine pamoate (OLAI), in multi-episode patients (two or more relapses) with schizophrenia in Sweden." | 3.78 | Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. ( Martin, M; McGuire, A; Mehnert, A; Nicholl, D; Pudas, H, 2012) |
| "Objective of this observational trial is to examine the effects of quetiapine in comparison with olanzapine and risperidone on clinical outcomes and quality of life in patients with schizophrenia and schizoaffective disorder in routine care." | 3.78 | Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial. ( Becker, T; Croissant, D; Eschweiler, GW; Frasch, K; Jaeger, S; Kilian, R; Längle, G; Messer, T; Pfiffner, C; Schepp, W; Steinert, T; Weiser, P, 2012) |
| "The study population comprised 113 Japanese inpatients with schizophrenia who were treated with olanzapine, risperidone, or quetiapine, and 123 healthy control (CONT) volunteers." | 3.78 | Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia. ( Fukui, N; Ono, S; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J, 2012) |
| "A total of 35 patients diagnosed for the first time with schizophrenia or acute schizophrenia-like psychotic disorder and treated with risperidone were enrolled in the study." | 3.78 | Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. ( Barteček, R; Juřica, J; Kašpárek, T; Pindurová, E; Žourková, A; Zrůstová, J, 2012) |
| " We investigated the possible association of CYP2E1 polymorphisms with susceptibility to schizophrenia in the Chinese Han Population as well as the relationship with response to risperidone in schizophrenia patients." | 3.78 | Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population. ( Feng, G; Han, X; He, L; Huo, R; Niu, J; Qin, S; Shen, L; Tang, K; Tian, Z; Wei, Z; Wu, X; Xiong, Y; Yang, L, 2012) |
| "This study assessed clinical and functional outcomes following a switch from risperidone to olanzapine in a 1-year naturalistic study of schizophrenia patients in Japan." | 3.78 | Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan. ( Ascher-Svanum, H; Fujikoshi, S; Nakahara, N; Ohmori, T; Takahashi, M; Ye, W, 2012) |
| "Perinatal phencyclidine (PCP) administration to rats represents one of the actual animal models of schizophrenia." | 3.78 | Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain. ( Doknić, M; Jevtić, G; Petronijević, ND; Popović, V; Radonjić, NV; Stojković, T; Velimirović, M, 2012) |
| "Clinically stable patients with schizophrenia (DSM-IV) receiving a stable dose of risperidone long-acting injectable (LAI) as antipsychotic monotherapy for at least 3 months and free of any psychiatric hospitalization over the past 6 months were included." | 3.78 | A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. ( Den, R; Hirano, J; Ikai, S; Mamo, D; Mimura, M; Nishimoto, M; Remington, G; Suzuki, T; Takeuchi, H; Tsuboi, T; Tsunoda, K; Uchida, H; Watanabe, K, 2012) |
| "This study evaluated the effect of race-ethnicity and geography on the adoption of a pharmacological innovation (long-acting injectable risperidone [LAIR]) among Medicaid beneficiaries with schizophrenia as well as the contribution of geographic location to observed racial-ethnic disparities." | 3.78 | The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia. ( Alegría, M; Horvitz-Lennon, M; Normand, SL, 2012) |
| " This study aimed to examine the impact of switching from olanzapine to risperidone and vice versa on clinical status and tolerability outcomes in outpatients with schizophrenia in a naturalistic setting." | 3.78 | Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study. ( Brugnoli, R; Dossenbach, M; Haro, JM; Hong, J; Karagianis, J; Novick, D, 2012) |
| "To compare the prevalence of obsessive-compulsive symptoms (OCS) in a population of patients with schizophrenia taking clozapine, olanzapine, or risperidone or taking no antipsychotic medication." | 3.78 | Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. ( Korver, N; Machielsen, M; Scheltema Beduin, AA; Swets, M, 2012) |
| "To explore the changes in serum protein levels of schizophrenics before and after treatment of risperidone and identify the potential markers of diagnosis, treatment and drug side effects of schizophrenia." | 3.78 | [Proteomic analysis of novel serum markers in first-episode schizophrenics before versus after treatment of risperidone]. ( Gao, JS; Hao, YH; Li, X; Li, YH; Lü, LX; Pang, LJ; Song, XQ, 2012) |
| "Both risperidone and clozapine have been shown to be effective against negative symptoms." | 3.78 | New pharmacotherapeutic modalities for negative symptoms in psychosis. ( Lindenmayer, JP, 1995) |
| "The preparation and investigation of sustained-release risperidone-encapsulated microspheres using erodible poly(D, L-lactide-co-glycolide) (PLGA) of lower molecular weight were performed and compared to that of commercial Risperdal Consta™ for the treatment of schizophrenia." | 3.77 | Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation. ( Li, X; Li, YX; Meng, QF; Shi, YN; Su, ZX; Teng, LR; Teng, LS; Wang, LX, 2011) |
| "There have been several case reports of risperidone-associated dysphagia." | 3.77 | Risperidone-induced bulbar palsy-like syndrome. ( Patwa, H; Sico, JJ, 2011) |
| "The levels of kynurenic acid (KYNA), an astrocyte-derived metabolite of the branched kynurenine pathway (KP) of tryptophan degradation and antagonist of α7 nicotinic acetylcholine and N-methyl-D-aspartate receptors, are elevated in the prefrontal cortex (PFC) of individuals with schizophrenia (SZ)." | 3.77 | Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. ( McMahon, RP; Rassoulpour, A; Roberts, RC; Sathyasaikumar, KV; Schwarcz, R; Stachowski, EK; Wonodi, I, 2011) |
| " In this study, we assessed patterns of health-care utilization following the initiation of risperidone long-acting therapy (RLAT), the first and only second generation long-acting injectable antipsychotic agent, in schizophrenia patients within the Veterans Health Administration." | 3.77 | Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. ( Crivera, C; Dirani, R; Kazis, LE; Qian, S; Ren, XS; Sikirica, M, 2011) |
| " Inter-individual variability in hyperprolactinemia induced antipsychotics particularly risperidone can be explained by smoking status to some extent." | 3.77 | The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. ( Furukori, H; Kaneko, S; Nakagami, T; Ohta, C; Saito, M; Tsuchimine, S; Yasui-Furukori, N; Yoshizawa, K, 2011) |
| "Effect of haloperidol and risperidone on positive, negative, neurocognitive disorders, biological parameters and neurodestruction-neuroreparation processes have been studied in 23 patients with the first episode of paranoid schizophrenia." | 3.77 | [Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia]. ( Govorin, NV; Vasil'eva, AI, 2011) |
| " We reviewed the electronic medical records of patients with schizophrenia who received aripiprazole, olanzapine or risperidone monotherapies for at least three months." | 3.77 | The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. ( Ahn, YM; Jung, DC; Kang, UG; Kim, EY; Kim, SH; Kim, YS; Lee, NY; Sung, KH; Yu, HY, 2011) |
| "Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use, with only risperidone having a shorter time to discontinuation than olanzapine." | 3.77 | Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. ( Afful, J; Brown, CH; Dixon, LB; Ehrenreich, B; Kreyenbuhl, J; Medoff, DR; Slade, EP, 2011) |
| "The relatively good tolerability profile of sertindole translates into lower costs of schizophrenia management, primarily driven by substantially lower direct and indirect costs." | 3.77 | A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. ( Eberhard, J; Fors, BM; Hansen, K; Lindström, E; Sapin, C, 2011) |
| "Baseline body mass index (BMI), baseline BMI status (normal, overweight, obese) and early (1 month) BMI increases were tested as predictors of 6- and 12-month increases in glucose and lipid measures in 82 olanzapine (OLZ)- and 78 risperidone (RIS)-treated patients with schizophrenia, schizoaffective disorder, or bipolar disorder who participated in a 12-month randomized, prospective metabolic effects study." | 3.77 | Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. ( Bobo, WV; Bonaccorso, S; Jayathilake, K; Meltzer, HY, 2011) |
| " Sixty patients with acute exacerbations of schizophrenia received 6 mg/d of risperidone for 4 weeks." | 3.77 | Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone. ( Fujii, A; Kaneko, S; Nakagami, T; Saito, M; Sugawara, N; Tsuchimine, S; Yasui-Furukori, N, 2011) |
| "In subproject Ι, 45 patients receiving the 2nd generation antipsychotics risperidone, clozapine or olanzapine were compared regarding prolactin (PRL), body mass index (BMI), insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and blood lipids." | 3.77 | Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. ( Berinder, K; Hulting, AL; Melkersson, K, 2011) |
| "Risperidone long-acting injection (LAI) is mostly administered twice weekly to people with schizophrenia by nurses at community mental health centres (CMHC) or through mobile outreach visits." | 3.77 | The cost associated with administering risperidone long-acting injections in the Australian community. ( Dalton, A; Hertel, J; Lambert, T; Schrover, R; Smith, DK, 2011) |
| "(1) To determine bone remodeling parameters and bone mass in patients with schizophrenia on long-term treatment with long-acting injectable risperidone (LAIR) in naturalistic settings, and (2) to evaluate the change in body weight, metabolic profile and neuroendocrine status in these patients." | 3.77 | Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. ( Britvic, D; Damjanovic, A; Doknic, M; Jasovic Gasic, M; Maric, NP; Miljic, D; Pekic, S; Popovic, V; Radojicic, Z; Stojanovic, M, 2011) |
| "Epidermal growth factor (EGF) is one of the ErbB receptor ligands implicated in schizophrenia neuropathology as well as in dopaminergic development." | 3.77 | Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF. ( Aizawa, M; Iwakura, Y; Mizuno, M; Namba, H; Nawa, H; Shcherbakova, K; Sotoyama, H; Wang, R; Zheng, Y, 2011) |
| "Antipsychotic medications are the mainstay for schizophrenia treatment, and olanzapine and risperidone are popular choices among atypical antipsychotics in Norway." | 3.77 | Cost-effectiveness analysis of olanzapine and risperidone in Norway. ( Aas, E; Kim, K, 2011) |
| "Leptin, ghrelin, and adiponectin play important roles in the regulation of body weight, food intake, and energy homeostasis, and have been suggested to be important biomarkers of metabolic syndrome." | 3.77 | Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls. ( Chang, CM; Chang, PY; Huang, TL; Liu, CY; Tsai, MC, 2011) |
| "I report a case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection (RLAI)." | 3.77 | [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection]. ( Mori, T, 2011) |
| "Analysis of certain aspects of quality of life in patients with schizophrenia treated with depot formulations of a typical antipsychotic (haloperidol) and injection preparation of a long-acting atypical antipsychotic (risperidone)." | 3.77 | Quality of life of schizophrenic patients treated with haloperidol depot and injection preparation of long-lasting risperidone. ( Djukić-Dejanović, S; Janjić, V; Janković, S; Jovanović-Mihajlović, N; Mihajlović, G; Milovanović, N; Petrović, D; Radmanović, B; Radonjić, K; Tomić, K, 2011) |
| "Compared to traditional neuroleptics, most of the new antipsychotics are characterized by a low extrapyramidal side effect (EPS) liability and varying antipsychotic efficacy." | 3.77 | New antipsychotics: classification, efficacy, and adverse effects. ( Gerlach, J, 1991) |
| "D-Amino acid oxidase (DAO) has been established to be involved in the oxidation of D-serine, an allosteric activator of the N-methyl-D-aspartate-type glutamate receptor in the brain, and to be associated with the onset of schizophrenia." | 3.76 | The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia. ( Abou El-Magd, RM; Chung, SP; Fukui, K; Iwana, S; Kawazoe, T; Miyano, M; Ono, K; Park, HK; Sakai, T; Yorita, K, 2010) |
| "This naturalistic retrospective study aims to compare effectiveness of a second-generation antipsychotic medication, risperidone, with first-generation antipsychotic medications (haloperidol and trifluoperazine) in an Asian population with first-episode schizophrenia-spectrum disorders." | 3.76 | Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders. ( Edimansyah, A; Liew, A; Subramaniam, M; Vaingankar, J; Verma, S, 2010) |
| " In the present study we investigated the influence of two common MDR1 polymorphisms on the improvement of psychopathological symptoms and occurrence of extrapyramidal side effects (EPS) in Slovenian schizophrenia patients acutely treated with risperidone." | 3.76 | MDR1 gene polymorphisms and response to acute risperidone treatment. ( Dolzan, V; Grabnar, I; Kastelic, M; Koprivsek, J; Locatelli, I; Mandelli, L; Plesnicar, BK; Serretti, A, 2010) |
| "To estimate changes in resource usage, hospitalization rates, and costs in actual practice in Sweden for schizophrenia patients after switching to long-acting injectable risperidone (Risperdal Consta)." | 3.76 | The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. ( Berntsson, A; Eriksson, B; Löthgren, M; Persson, U; Svensson, M; Willis, M, 2010) |
| " We investigated the influence on startle response in chronic schizophrenia in 20 patients with schizophrenia taking risperidone, 21 patients with schizophrenia taking olanzapine, and 20 patients with schizophrenia taking aripiprazole." | 3.76 | Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia. ( Fujita, K; Fukuo, Y; Furukawa, O; Iwata, N; Kawashima, K; Kishi, T; Kitajima, T; Moriwaki, M; Naitoh, H; Okochi, T, 2010) |
| " The goal of this study was to understand the relationship between clozapine and risperidone with glucose and lipid metabolism and dietary fat intake in patients with schizophrenia." | 3.76 | Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B, 2010) |
| "In this study, 11 healthy male subjects taking different doses of sulpiride and 24 male patients with DSM-IV-diagnosed schizophrenia taking different antipsychotic drugs (risperidone, olanzapine, haloperidol, and sulpiride) participated." | 3.76 | Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. ( Arakawa, R; Ito, H; Maeda, J; Okubo, Y; Okumura, M; Suhara, T; Takahashi, H; Takano, A; Takano, H, 2010) |
| "This was a prospective 6-month, open-label, multicentre, phase IV trial in 303 subjects with recent onset ( | 3.76 | Correlates, change and 'state or trait' properties of insight in schizophrenia. ( David, AS; Lex, A; Rabinowitz, J; Wiffen, BD, 2010) |
| "To evaluate the efficacy and tolerability of long-acting risperidone injection in Thai patients with chronic schizophrenia for 12 weeks treatment." | 3.76 | Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia. ( Arunpongpaisal, S; Kitiwattanagul, K; Kongsakon, R; Samanwongthai, U; Srisurapanont, M, 2010) |
| " Throughout the whole clinical course mentioned above, he was under treatment for schizophrenia with drugs including risperidone which possibly affects glucose metabolism." | 3.76 | The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. ( Tsutsumi, E; Yamaguchi, K, 2010) |
| "This study investigated the variables related to the effectiveness and adherence to treatment with risperidone long-acting injection (RLAI) in patients with schizophrenia." | 3.76 | Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection. ( Chang, CL; Lung, FW; Tzeng, DS, 2010) |
| "Despite the limited number of children included, our results confirm a strong link between prescription of risperidone in EOS and risk of obesity." | 3.76 | [Metabolic side effects of risperidone in early onset schizophrenia]. ( Bordet, R; Delion, P; Duhamel, A; Goeb, JL; Jardri, R; Kechid, G; Marco, S; Thomas, P, 2010) |
| "In Sweden, risperidone long-acting injectable (RLAI) is generally used in a population of schizophrenia patients who are at a high risk of being non-compliant." | 3.76 | Cost effectiveness of long-acting risperidone in Sweden. ( Heeg, B; Hensen, M; Löthgren, M; van Hout, B, 2010) |
| "Hyperprolactinemia is a frequent consequence of treatment with risperidone." | 3.76 | Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. ( Fujii, A; Furukori, H; Kaneko, S; Sugawara, N; Yasui-Furukori, N, 2010) |
| " The in vitro study showed that after olanzapine or risperidone (at final concentrations corresponding to doses used in acute episodes of schizophrenia treatment) no changes of plasma lipid peroxidation were found (P > 0." | 3.76 | Lipid peroxidation in patients with schizophrenia. ( Dietrich-Muszalska, A; Kontek, B, 2010) |
| "Risperidone is a promising agent for the treatment of schizophrenia, Tourette's disorder, mood disorders, and disruptive behavior disorders in young populations." | 3.76 | Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey. ( Erdogan, A; Karaman, MG; Kurcer, MA; Ozdemir, E; Tufan, AE; Yurteri, N, 2010) |
| "This is a case report of ventricular tachycardia in a 35 years old African American male being treated with risperidone for schizophrenia." | 3.76 | Risperidone induced ventricular tachycardia. ( Mazhar, MN; Resch, DS, 2010) |
| "Asenapine is a novel psychopharmacologic agent under development for the treatment of schizophrenia and bipolar disorder." | 3.75 | Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. ( Shahid, M; Walker, GB; Wong, EH; Zorn, SH, 2009) |
| "This study aimed to investigate the effects of treatment with haloperidol, olanzapine and risperidone on cardiovascular variability in patients with recent-onset schizophrenia by means of spectral analysis." | 3.75 | Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia. ( Hempel, RJ; Hengeveld, MW; Röder, CH; Tulen, JH; van Beveren, NJ, 2009) |
| "The ketamine (ket) model reflects features of schizophrenia as well as secondary symptoms such as altered pain sensitivity." | 3.75 | Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ( Becker, A; Grecksch, G; Hiemke, C; Ladstaetter, E; Schmitt, U; Zernig, G, 2009) |
| "Ketamine-induced alterations in EEG power spectra are consistent with abnormalities in the theta and gamma frequency ranges reported in patients with schizophrenia." | 3.75 | N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. ( Contreras, D; Ehrlichman, RS; Finkel, LH; Gandal, MJ; Lazarewicz, MT; Maxwell, CR; Siegel, SJ; Turetsky, BI, 2009) |
| "Olanzapine and risperidone may impair glucose tolerance due in part to increased insulin resistance." | 3.75 | Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. ( Furukori, H; Kaneko, S; Nakagami, T; Saito, M; Sato, Y; Yasui-Furukori, N, 2009) |
| "Clozapine is a superior agent for treatment-refractory patients with schizophrenia, but is underutilized in the US, likely due to the risk of side effects." | 3.75 | Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. ( Feldman, S; Fowler, DR; Kelly, DL; Linthicum, J; Love, RC; McMahon, RP; Shim, JC; Wagner, T; Wehring, HJ, 2009) |
| "A 27-year-old man, who has been using risperidone for two months as the treatment for schizophrenia, with no previous history of diabetes was admitted to the hospital with the presentation of severe diabetes ketoacidosis and subsequent fatal progression." | 3.75 | Risperidone-associated newly diagnosed diabetes and fatal diabetes ketoacidosis in a young schizophrenic patient. ( Lu, CH; Yan, YH, 2009) |
| "To estimate the cost effectiveness of olanzapine and risperidone for the treatment of schizophrenia in Belgium." | 3.75 | Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach. ( De Graeve, D; De Ridder, A, 2009) |
| "Four schizophrenia patients receiving a stable dose of risperidone underwent [(11)C]raclopride positron emission tomography scans on two occasions 5-14 months apart." | 3.75 | Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics. ( Graff-Guerrero, A; Mamo, DC; Mulsant, BH; Pollock, BG; Uchida, H, 2009) |
| "Thirteen subjects aged 50 (mean +/- standard deviation age: 62 +/- 9 years) with schizophrenia or schizoaffective disorder who were receiving risperidone." | 3.75 | Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. ( Graff-Guerrero, A; Kapur, S; Mamo, DC; Mulsant, BH; Pollock, BG; Uchida, H, 2009) |
| "The model predicts that it is cost-effective to keep a patient with schizophrenia in Germany on branded risperidone instead of switching him/her to generic risperidone (assuming a 40% reduction in medication costs), if the incremental probability of becoming non-compliant after generic substitution exceeds 5." | 3.75 | A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. ( Heeg, B; Möller, HJ; Schmeding, A; Treur, M; van Hout, B, 2009) |
| " We examined the plasma levels of these 2 factors in schizophrenia patients at the time of admission and after 6 weeks of treatment with risperidone." | 3.75 | Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. ( Kim, YK; Lee, BH, 2009) |
| "The present study thus indicates that the interacting effects within the COMT gene polymorphisms may influence the disease status and response to risperidone in schizophrenia patients." | 3.75 | Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. ( Baghel, R; Bhasin, Y; Bhatnagar, P; Brahmachari, SK; Chauhan, C; Grover, S; Gupta, M; Jain, S; Kaur, H; Kukreti, R; Manduva, V; Mukherjee, O; Purushottam, M; Sharma, A; Verma, B, 2009) |
| "This was a post-hoc analysis using data from 5 double-blind, randomized, comparative trials of 24 or 28 weeks duration in which olanzapine was compared to risperidone (1 study; N = 339), quetiapine (1 study; N = 346), ziprasidone (2 studies; N = 548 and 394) or aripiprazole (1 study; N = 566) for treatment of schizophrenia." | 3.75 | Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. ( Ascher-Svanum, H; Ball, T; Conley, R; Liu, L; Stauffer, V, 2009) |
| "Genotyping using the P450 microarray system was performed for 89 Japanese patients with schizophrenia receiving risperidone." | 3.75 | Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. ( Chino, B; Kosaki, K; Mizuno, M; Sakuma, K; Sato, Y; Takao, T; Takebayashi, T; Yagihashi, T, 2009) |
| "This 12-week open-label study was designed to investigate the pharmacokinetics and efficacy of a direct switch from a conventional depot to long-acting injectable risperidone in patients with schizophrenia and schizoaffective disorder." | 3.75 | Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders. ( Chen, CH; Chiu, CC; Huang, MC; Lai, YC; Pan, CH; Tsai, CJ, 2009) |
| "This study evaluates the relationship between plasma homovanillic acid (pHVA) levels, which have been used to study the role of central dopamine in schizophrenia, and the positive/negative syndrome in first episode schizophrenic patients before and after antipsychotic treatment." | 3.75 | Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. ( Baeza, I; Bernardo, M; Castro-Fornieles, J; de la Serna, E; Deulofeu, R; Goti, J; Salvà, J, 2009) |
| "To examine hospitalisation rates and resource utilisation following initiation of risperidone long-acting therapy (RLAT) among US veterans with schizophrenia." | 3.75 | Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. ( Dirani, R; Flanders, S; Fuller, M; Russo, P; Secic, M; Shermock, K; Vallow, S, 2009) |
| "A patient taking oral risperidone while using cocaine and alcohol presented with priapism shortly after long-acting, injectable risperidone was prescribed." | 3.75 | Priapism and risperidone. ( Koirala, S; Lippmann, S; Penagaluri, P; Smith, C, 2009) |
| "In total 56 patients acutely treated with haloperidol or risperidone either for the first episode of schizophrenia, schizophreniform or schizoaffective disorders, or for the relapse of these psychotic disorders after tapering their maintenance treatment, were genotyped for the 5-HTTLPR L and S alleles and for the new A/G functional variant within the L alelle (La/g)." | 3.74 | Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. ( Dolzan, V; Kastelic, M; Koprivsek, J; Mandelli, L; Plesnicar, BK; Serretti, A, 2008) |
| "The study recruited 107 drug-naive Chinese schizophrenia patients who were given 8 weeks of risperidone monotherapy and it explored three of four single nucleotide polymorphisms spanning HTR3A for possible association with therapeutic improvement, using the Positive and Negative Symptom Scale." | 3.74 | Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. ( Feng, GY; Gu, B; He, L; Li, HF; Ma, G; Wang, L; Xing, QH; Zhang, AP; Zhao, XZ, 2008) |
| "Plasma NO metabolite (NO(x)) levels were measured in 55 schizophrenia patients before and after 6-week treatment with risperidone and in 55 normal controls." | 3.74 | Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. ( Kim, YK; Lee, BH, 2008) |
| "This study examined the association between exposure to potentially interacting drugs and nonpersistence in a cohort of patients with schizophrenia newly starting treatment with risperidone." | 3.74 | Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia. ( Caro, JJ; Glass, J; Ishak, KJ; Luong, D; Tan, Y, 2008) |
| "We investigated the relationships between functional genetic variants of the 5-HT(2C) receptor and multidrug-resistant protein (MDR1), coding for P-glycoprotein, and second generation antipsychotic (SDA)-induced weight gain among 108 female schizophrenic patients treated with olanzapine or risperidone for up to 4 months." | 3.74 | The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. ( Bilusic, H; Bozina, N; Hotujac, L; Kuzman, MR; Medved, V; Sain, I, 2008) |
| "Nine neuroleptic-naive patients with first-episode schizophrenia (Diagnostic and Statistical Manual for Mental Disorders-IV criteria) with prominent AVH underwent three PET scans using F-fluordeoxyglucose (FDG): (i) shortly after presentation, while experiencing prominent and frequent AVH; (ii) after medication-induced remission (R), using a stable dose of risperidone; (iii) also in remission, during bilateral linguistic auditory activation (LAA) induced by spoken text mimicking the content of the hallucinations experienced while the first PET was performed, using headphones." | 3.74 | Fluordeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic-auditory activation. ( Bernardo, M; Fernández-Egea, E; Font, M; Gutierrez, F; Lomena, F; Parellada, E; Pareto, D; Pavia, J; Ros, D; Simo, M, 2008) |
| "The availability of long-acting injectable risperidone may increase adherence to antipsychotic treatment and lead to improved clinical and economic outcomes for patients with schizophrenia." | 3.74 | Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. ( Alonso-Escolano, D; Burón, JA; Olivares, JM; Rodriguez-Martinez, A; Rodriguez-Morales, A, 2008) |
| "A case of a 46-year-old woman with schizophrenia who was treated with risperidone and followed up for 1 year is reported." | 3.74 | Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment. ( Bozina, N; Jovanović, N; Lovrić, M; Medved, V, 2008) |
| "A total of 120 first-episode neuroleptic-naive schizophrenia patients were treated with risperidone monotherapy for 8 weeks and clinical symptoms were evaluated by the Positive and Negative Syndrome Scale." | 3.74 | Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. ( Hashimoto, S; Ikeda, M; Iwata, N; Kinoshita, Y; Kitajima, T; Nakamura, J; O'Donovan, MC; Ozaki, N; Yamanouchi, Y; Yoshimura, R, 2008) |
| " Patients previously diagnosed with schizophrenia who received a first prescription of olanzapine or risperidone between 1 January 1997 and 31 August 1999 were followed for 365 days." | 3.74 | A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia. ( Abdous, B; Cooper, D; Grégoire, JP; Moisan, J, 2008) |
| "Outpatients initiating or changing antipsychotic therapy for DSM-IV- or ICD-10-defined schizophrenia (N = 7658) were allocated to olanzapine or nonolanzapine cohorts (November 2000 to December 2001)." | 3.74 | Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. ( Anders, M; Dossenbach, M; Irimia, V; Kotler, M; Logozar-Perkovic, D; Lowry, AJ; Pecenak, J; Peciukaitiene, D; Smulevich, AB; Szulc, A; Treuer, T; West, TM, 2008) |
| " The authors report a case of a woman with schizophrenia wherein risperidone was used successfully in two consecutive pregnancies." | 3.74 | Risperidone therapy in two successive pregnancies. ( Lohia, D; Mendhekar, D, 2008) |
| " Consecutively hospitalized, acutely psychotic patients with DSM-IV schizophrenia (n=121) were included in the study if they received treatment with typical antipsychotic medication (TYP, n=72) or TYP plus risperidone (TYP-R, n=49) for at least 2 wk." | 3.74 | Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. ( Ben-Asher, E; Deshpande, SN; Greenbaum, L; Horowitz, A; Kanyas, K; Karni, O; Lancet, D; Lerer, B; Merbl, Y; Olender, T; Strous, RD; Viglin, D, 2007) |
| "Data on the use of long-acting injectable (LAI) risperidone, the first atypical depot antipsychotic, during pregnancy are limited." | 3.74 | Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia. ( Kim, JM; Kim, KM; Kim, SW; Shin, HY; Shin, IS; Yang, SJ; Yoon, JS, 2007) |
| "Risperidone has a relatively low risk of causing obesity and diabetes mellitus and is a first-line treatment for schizophrenia." | 3.74 | Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. ( Hosoda, H; Inoue, T; Itoh, K; Izumi, T; Kangawa, K; Koyama, T; Kusumi, I; Murashita, M; Nakagawa, S; Tanaka, T, 2007) |
| "The study was a retrospective analysis of administrative data from the New York-New Jersey region of the Veterans Health Administration for 2,436 individuals with schizophrenia or schizoaffective disorder who were prescribed risperidone from January 2001 through March 2003." | 3.74 | Impact of splitting risperidone tablets on medication adherence and on clinical outcomes for patients with schizophrenia. ( Dellenbaugh, C; Weissman, EM, 2007) |
| "Fourteen antipsychotic-naïve schizophrenia patients performed an oculomotor delayed response task before and 6 weeks after antipsychotic treatment (risperidone n = 11; olanzapine n = 3)." | 3.74 | Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia. ( Harris, MS; Keshavan, MS; Khine, TT; Reilly, JL; Sweeney, JA, 2007) |
| "A 31-year-old patient suffering from schizophrenic psychosis was treated with risperidone, and developed priapism which required surgical intervention and resulted in long-term erectile dysfunction." | 3.74 | Risperidone-induced priapism. ( Makesar, D; Thome, J, 2007) |
| "This study compares 3 cohorts of patients with schizophrenia before, during, and after initiating treatment with fluphenazine decanoate (FD), haloperidol decanoate (HD), or long-acting injectable risperidone (LAR)." | 3.74 | Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. ( Ascher-Svanum, H; Marcus, SC; Olfson, M, 2007) |
| "Disruptions in 5-CSRTT performance induced by repeated PCP administration are prevented by chronic clozapine treatment and may constitute a useful animal model of some cognitive symptoms of schizophrenia." | 3.74 | Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. ( Amitai, N; Markou, A; Semenova, S, 2007) |
| "After a switch from previous treatment to open-label ziprasidone more than half of patients with schizophrenia experienced sustained clinical remission over 6 months and 32% of the patients achieving remission experienced a concurrent NP improvement." | 3.74 | The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. ( Bowie, CR; Buckley, PF; Harvey, PD; Loebel, A, 2007) |
| "To evaluate the cost-effectiveness of three antipsychotic medications (olanzapine, risperidone and haloperidol) in the treatment of schizophrenia using the Positive and Negative Symptom Scale." | 3.74 | Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. ( Bounthavong, M; Okamoto, MP, 2007) |
| " Patients aged 2 18 years who received an initial prescription for olanzapine, risperidone, quetiapine or amisulpride between April 1 and September 30, 2003; and had an ICD-10-coded diagnosis of schizophrenia were included." | 3.74 | Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis. ( Hui, HY; Law, WL; You, JH; Young, WM, 2007) |
| "Consecutively hospitalized, psychotic patients with Diagnostic and Statistical Manual of Mental Disorder-IV schizophrenia (n=121) were included in the study if they received treatment with typical antipsychotic medication (n=72) or typical antipsychotic drugs and risperidone (n=49) for at least 2 weeks." | 3.74 | Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. ( Ben-Asher, E; Deshpande, SN; Greenbaum, L; Horowitz, A; Kanyas, K; Karni, O; Katz, E; Kotler, M; Lancet, D; Lerer, B; Merbl, Y; Olender, T; Strous, RD, 2007) |
| "Adult Maryland Medicaid patients with schizophrenia were categorized based on initial atypical antipsychotic drug received: aripiprazole (n=446); olanzapine (n=1705); quetiapine (n=1467); risperidone (n=1580); and ziprasidone (n=700)." | 3.74 | Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. ( Cuffel, BJ; Loebel, AD; Mullins, CD; Naradzay, J; Obeidat, NA, 2008) |
| "To describe a case of a patient who developed drug-induced cholestasis after being on risperidone maintenance therapy for 8 years." | 3.74 | Risperidone- and quetiapine-induced cholestasis. ( Vandenberg, AM; Wright, TM, 2007) |
| "Sixty-seven outpatients with schizophrenia receiving stable doses of risperidone or haloperidol were evaluated for akathisia and other extrapyramidal side effects." | 3.74 | Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. ( Byun, HJ; Kim, JH, 2007) |
| "One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol." | 3.74 | Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. ( Braff, DL; Erhart, S; Green, MF; Kee, KS; Marder, SR; Mintz, J; Reist, C; Sergi, MJ; Widmark, C, 2007) |
| "To explore the direct and indirect costs in a cohort of 225 risperidone-treated patients with schizophrenia followed up annually during 5 years." | 3.74 | Costs of schizophrenia during 5 years. ( Eberhard, J; Levander, S; Lindström, E; Neovius, M, 2007) |
| "The SOHO was a prospective, 3-year observational study of the outcomes of schizophrenia treatment in outpatients who initiated therapy or changed to a new antipsychotic performed in 10 European countries with a focus on olanzapine." | 3.74 | The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain. ( Alonso, J; Bousoño, M; Ciudad, A; Gilaberte, I; Haro, JM; Novick, D; Suárez, D, 2008) |
| " Under medication with clozapine he had experienced a single event of seizures which were due to hypocalcemia." | 3.74 | [22q11.2 deletion and schizophrenia in childhood and adolescence]. ( Briegel, W, 2007) |
| "(1) For patients with schizophrenia, risperidone is one of many available neuroleptics." | 3.74 | Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent. ( , 2007) |
| "To evaluate dose effect in response on primary efficacy scales from 2 randomized, double-blind, flexible-dose trials of patients with bipolar mania who received olanzapine (N = 234, 5-20 mg/day), or patients with schizophrenia who received olanzapine (N = 172, 10-20 mg/day), we used marginal structural models, inverse probability of treatment weighting (MSM, IPTW) methodology." | 3.74 | Evaluating dose response from flexible dose clinical trials. ( Adams, DH; Baron, D; Faries, D; Houston, JP; Lipkovich, I; Mallinckrodt, C, 2008) |
| "These findings suggest that RGS4 variances influence clinical manifestations of schizophrenia as well as the treatment response to risperidone, suggesting that RGS4 plays a role in the fundamental process of disease pathophysiology." | 3.74 | RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. ( Chang, YC; Huang, CH; Huang, CL; Lane, HY; Liu, YC; Tsai, GE; Wu, PL, 2008) |
| " We examined the effectiveness of olanzapine and risperidone in schizophrenia in a naturalistic setting." | 3.74 | Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting. ( Kennedy, A; Kilzieh, N; Tapp, AM; Todd-Stenberg, JA; Wood, AE, 2008) |
| "To monitor long-term symptomatic tolerability and remission in patients with stable but suboptimally treated psychoses after switching to risperidone long-acting injectable (RLAI)." | 3.74 | Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. ( Kissling, W; Llorca, PM; Lloyd, K; Medori, R; Sacchetti, E, 2008) |
| "Clozapine is known to be effective in treating schizophrenia patients with comorbid alcohol use disorders (AUD)." | 3.74 | Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. ( Kim, D; Kim, JH; Marder, SR, 2008) |
| "Clozapine may alleviate hyperactivity in the limbic system in schizophrenia and may facilitate activation of the regions involved in cognitive tasks to a greater degree than risperidone, as well as eliciting greater inhibition of the PF region." | 3.74 | Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. ( De Luxán, A; Domínguez-Gil, A; Martin, C; Molina, V; Montes, C; Rivas, N; Sancho, C; Tamayo, P, 2008) |
| "Clozapine had a significantly lower discontinuation rate in individuals with schizophrenia, compared to the other 4 SGAs." | 3.74 | Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. ( Lawrie, SM; Shajahan, P; Taylor, M, 2008) |
| "A sample included 61 patients, 53 men and 8 women, with ICD-10 episodic schizophrenia in the remission after treatment with atypical neuroleptics (risperidon, olanzapine, clozapine)." | 3.74 | [Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics]. ( Danilov, DS; Tiul'pin, IuG, 2007) |
| " It was designed to assess the safety of the antipsychotic sertindole in the treatment of schizophrenia under normal conditions of use." | 3.74 | The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology. ( Mittoux, A; Peuskens, J; Tanghøj, P, 2008) |
| "Thirty inpatients with schizophrenia taking risperidone were studied." | 3.74 | Effects of risperidone on glucose metabolism in Chinese patients with schizophrenia: a prospective study. ( Cai, ZJ; Chen, Q; Mao, PX; Mitchell, PB; Tang, YL; Zhai, YM, 2008) |
| "The primary objective of the present study was to examine the relationship between sexual dysfunction, subjective well-being and prolactin levels in patients with schizophrenia treated either with risperidone or quetiapine." | 3.74 | Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. ( Albrecht, C; Bliesener, N; Cooper-Mahkorn, D; Creutz, C; Cvetanovska, G; Hornung, WP; Klingmüller, D; Kühn, KU; Lemke, MR; Maier, W; Schubert, M; Sträter, B; Westheide, J, 2008) |
| "Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects." | 3.73 | Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. ( Allison, DB; Anderson, EJ; Borba, CP; Cagliero, E; Copeland, PM; Daley, TB; Evins, AE; Goff, DC; Hayden, D; Henderson, DC; Schoenfeld, D; Weber, MT, 2005) |
| "Clozapine is an effective long-term schizophrenia treatment." | 3.73 | The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire. ( Al-tawarah, Y; Belgamwar, R; Hodgson, R; MacKenzie, G, 2005) |
| "We identified patients with schizophrenia from outpatient clinics in the Veterans Health Administration (VA) and defined initiation of olanzapine or risperidone as patients who were not on any antipsychotics for 6 months and subsequently initiated on the target drug between 1/4/1999 and 31/3/2000." | 3.73 | Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. ( Huang, YH; Kazis, L; Lee, AF; Miller, DR; Qian, S; Ren, XS, 2005) |
| "This study used medical record data to examine the use of clozapine in January 2000 for people with schizophrenia in two different countries." | 3.73 | Comparison of clozapine use in Maryland and in Victoria, Australia. ( Conley, RR; Kelly, DL; Lambert, TJ; Love, RC, 2005) |
| "The change in direct medical costs for schizophrenia patients who were started on olanzapine or risperidone and who were privately insured was studied." | 3.73 | Health care costs for schizophrenia patients started on olanzapine versus risperidone. ( Namjoshi, M; Russo, PA; Smith, MW, 2005) |
| "Risperidone is an atypical antipsychotic commonly used for treatment of schizophrenia and other psychotic disorders." | 3.73 | Interpreting serum risperidone concentrations. ( Boerth, JM; Caley, CF; Goethe, JW, 2005) |
| "To examine the risk of developing type 2 diabetes mellitus among people with schizophrenia exposed to atypical antipsychotics (clozapine, olanzapine, quetiapine, risperidone) compared to those exposed to conventional antipsychotics." | 3.73 | Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. ( Carson, W; Chang, KY; Chou, CH; Lambert, BL; Tafesse, E, 2005) |
| "This retrospective study aimed to compare differences in hepatic enzyme elevation during treatment with either risperidone or olanzapine alone in patients with psychotic disorders." | 3.73 | Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. ( Kim, JJ; Kim, TS; Lee, C; Lee, CU; Lee, SJ; Lim, HK; Pae, CU; Paik, IH, 2005) |
| "To assess the cost effectiveness of risperidone LAI compared with oral risperidone, oral olanzapine and haloperidol decanoate LAI over a 1-year time period in outpatients with schizophrenia who had previously suffered a relapse requiring hospitalisation." | 3.73 | Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. ( Botteman, MF; Diamond, RJ; Edwards, NC; Pashos, CL; Rupnow, MF, 2005) |
| " A pilot project was conducted replacing the traditional hardcopy version of the case report form for an electronic one (e-CRF) and with access to Internet within the Naturalistic Randomized Clinical Trial of the Effectiveness of Olanzapine and Risperidone in the Treatment of Schizophrenia." | 3.73 | Internet in clinical research based on a pilot experience. ( Arriaza, E; Bolaños, E; Ciudad, A; Hesen, W; López-Carrero, C; Municio, M; Ramos, J, 2005) |
| "Treatment with risperidone was frequently associated with hyperprolactinemia and related symptoms, whereas the occurrence of PRL elevation and related symptoms was modest in patients receiving olanzapine and nonexistent in those receiving clozapine." | 3.73 | Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. ( Melkersson, K, 2005) |
| "The present study compares the subjective responses of patients in the stable phase of schizophrenia being treated with either olanzapine or risperidone." | 3.73 | Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey. ( McGrath, BM; Tempier, RP, 2005) |
| " The objective of this study was to apply a disease-specific utility mapping function for schizophrenia to data from a large, 1-year, open-label study of long-acting risperidone and to compare its performance with an SF-36-based utility mapping function." | 3.73 | Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. ( Elnitsky, C; Lenert, LA; Rupnow, MF, 2005) |
| "Data were collected from medical records from January 1992 to December 2003 and included age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation for clozapine-treated patients with schizophrenia or schizoaffective disorder (DSM-IV criteria)." | 3.73 | Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Freudenreich, O; Goff, DC; Hayden, DL; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "This study confirms that elevated levels of triglyceride and body weight could be associated with the use of olanzapine as compared with risperidone." | 3.73 | A crossover study on lipid and weight changes associated with olanzapine and risperidone. ( Pariante, CM; Su, KP; Wu, PL, 2005) |
| " Data from a randomized, double-blind trial comparing treatment of schizophrenia with placebo and olanzapine were used to correlate weight change and change in psychopathology." | 3.73 | Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. ( Ascher-Svanum, H; Kinon, BJ; Stensland, MD; Tollefson, GD, 2005) |
| "Striatal D2 receptor occupancy by equivalent doses of olanzapine or risperidone was assessed with [123I]iodobenzamide single-photon emission computed tomography (SPECT) in 36 patients with schizophrenia." | 3.73 | Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. ( Booij, J; de Haan, L; Lavalaye, J; Linszen, D; van Amelsvoort, T, 2006) |
| "The availability of long-acting risperidone injection may increase adherence and lead to improved clinical and economic outcomes for individuals with schizophrenia." | 3.73 | Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. ( Diamond, RJ; Edwards, NC; Locklear, JC; Rupnow, MF, 2005) |
| "We studied a sample of schizophrenia out-patients to test the hypotheses that serum homocysteine concentrations would correlate positively with measures of glucose metabolism." | 3.73 | Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. ( Baer, L; Borba, CP; Cather, C; Copeland, PM; Eden Evins, A; Freudenreich, O; Goff, DC; Henderson, DC; Nguyen, DD, 2006) |
| "These findings suggest that ethnicity may play a role in symptom presentation and treatment response to risperidone for children and adolescents with schizophrenia-spectrum disorders." | 3.73 | Ethnic variation in symptoms and response to risperidone in youths with schizophrenia-spectrum disorders. ( Crismon, ML; De Leon, A; Lane, DC; Lopez, M; Patel, NC; Shafer, A, 2006) |
| "To study the multiple dose clinical pharmacokinetics of risperidone and its main active metabolite, 9-hydroxyrisperidone, in Chinese female patients with schizophrenia." | 3.73 | Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ( Deng, CY; Li, HD; Li, WB; Li, X; Lin, QX; Lin, SG; Peng, HY; Su, FL; Wang, CY; Wang, F; Yang, M; Yu, XY; Zhou, ZL; Zhu, RH, 2006) |
| "After achieving stabilization with one of the doses, nine patients with a diagnosis of schizophrenia or schizoaffective disorder underwent [(11)C]raclopride PET to measure D(2) occupancy." | 3.73 | A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ( Kapur, S; Labelle, A; Mamo, D; Mann, S; Mannaert, E; Reiss, J; Remington, G; Shammi, C, 2006) |
| "The risk of the appearance of diabetes mellitus in patients treated with olanzapine is twice as high as that in patients treated with risperidone, and the risk in patients treated with clozapine is nearly triple as high as that found in patients treated with risperidone." | 3.73 | [Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study]. ( Burón, JA; Gómez-de-la-Cámara, A; Ledesma, F; Martínez-Junquera, G; Rodríguez-Morales, A; Rubio, G, 2006) |
| "To examine clinical outcomes in Asian patients with schizophrenia receiving monotherapy with olanzapine, risperidone or typical antipsychotics in naturalistic settings." | 3.73 | Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. ( Dyachkova, Y; Habil, H; Lee, C; Lee, P; Wu, KH, 2006) |
| "Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder." | 3.73 | Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. ( Bettcher, BM; Byerly, MJ; Carmody, T; Fisher, R; Nakonezny, PA; Rush, AJ, 2006) |
| "Risperidone, olanzapine, and clozapine are three atypical antipsychotic medications commonly used in the management of chronic schizophrenia." | 3.73 | Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. ( Gonen, N; Kupchik, M; Mester, R; Roitman, S; Schwartz, S; Spivak, B; Strous, RD; Weizman, A, 2006) |
| "Plasma prolactin concentration was measured in patients with schizophrenia and schizoaffective disorders receiving therapy with risperidone, olanzapine, and quetiapine and compared with the corresponding parameter in patient receiving typical neuroleptic drug haloperidol." | 3.73 | Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders. ( Gorobets, LN, 2005) |
| "We compared fasting lipids and other metabolic parameters in 211 normoglycemic patients meeting the DSM-IV diagnosis of schizophrenia or schizoaffective disorder undergoing continuous treatment with olanzapine, risperidone, or typical antipsychotics for at least 1 year." | 3.73 | Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. ( Cavazzoni, P; Hardy, TA; Kryzhanovskaya, L; Marquez, E; Taylor, CC, 2006) |
| "A current contribution in the European Journal of Health Economics employs a decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia." | 3.73 | Decision models in the evaluation of psychotropic drugs : useful tool or useless toy? ( Barbui, C; Lintas, C, 2006) |
| "Prolactin levels returned to normal, and clinical symptoms of hyperprolactinemia resolved in all 3 patients after 2 weeks of tapering and discontinuation of risperidone." | 3.73 | Risperidone-induced hyperprolactinemia in adolescents: A case series. ( Madhusoodanan, S; Moise, D, 2006) |
| "Second-generation atypical antipsychotics such as clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride and ariprazole offer the potential to reduce the significant health care resource demands in the treatment of schizophrenia through improved levels of initial clinical response and reduced levels of long-term acute relapse." | 3.73 | A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. ( Beard, SM; Clouth, J; Maciver, F; Rüther, E, 2006) |
| " High-dose treatment with risperidone may be more beneficial in males for the treatment of acute schizophrenia." | 3.73 | Gender-specific effects in the treatment of acute schizophrenia with risperidone. ( Naber, D; Raedler, TJ; Schreiner, A; Wiedemann, K, 2006) |
| "Twenty-five antipsychotic drug-naive, acutely ill patients with first-episode schizophrenia performed an oculomotor delayed response task at baseline before any drug treatment and again after 6 weeks of risperidone treatment." | 3.73 | Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. ( Harris, MS; Keshavan, MS; Reilly, JL; Sweeney, JA, 2006) |
| "Twenty patients with psychotic disorders, on therapy with risperidone, were studied." | 3.73 | Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. ( Melkersson, KI, 2006) |
| "Olanzapine and risperidone are two commonly prescribed atypical antipsychotics for schizophrenia." | 3.73 | Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia. ( Herz, L; Huang, YH; Kazis, LE; Lee, AF; Ren, XS; Yu, W, 2006) |
| "Risperidone and olanzapine-administration data were collected for schizophrenia patients treated at four Taiwanese medical centres." | 3.72 | Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. ( Chiu, NY; Hsiao, MC; Liao, O; Liu, CY; Wu, CK; Yuan, LM, 2003) |
| "To report a case of risperidone-induced hyperprolactinemia that was successfully managed with quetiapine." | 3.72 | Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine. ( Kunwar, AR; Megna, JL, 2003) |
| " This is a case report of subtle, mild hypothermia in a 54-year old female patient receiving risperidone for schizophrenia." | 3.72 | Atypical antipsychotic induced mild hypothermia. ( Brevik, A; Farver, D, 2003) |
| "Factors that influenced the risk of hyperprolactinemia included gender, with females appearing to be more sensitive than males, and drug treatment, with risperidone and conventional antipsychotic agents increasing prolactin more than olanzapine." | 3.72 | Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. ( Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H, 2003) |
| "Texas Medicaid claims were retrieved for persons aged 21-65 years, diagnosed with schizophrenia or schizoaffective disorder, after initiating treatment with olanzapine (n = 1875), risperidone (n = 982), or haloperidol (n = 726) between January 1997 and August 1998." | 3.72 | Role of ethnicity in predicting antipsychotic medication adherence. ( Brown, CM; Gibson, PJ; Opolka, JL; Rascati, KL, 2003) |
| "This study evaluated costs associated with risperidone and olanzapine treatment for schizophrenia." | 3.72 | Cost evaluation of risperidone compared with olanzapine. ( Brooks, D; Byerly, MJ; Casey, SB; Elliot, S; Hawkins, J; Weber, M, 2003) |
| "The study population comprised 56 patients with DSM-IV schizophrenia, who were divided into 4 treatment groups: quetiapine (N = 14), olanzapine (N = 14), risperidone (N = 14), or clozapine (N = 14) monotherapy, and a control group of 11 patients receiving no psychopharmacologic treatment." | 3.72 | Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003) |
| " Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS-UK) program consisted of a retrospective review of medical notes and prescription charts for 501 patients with schizophrenia or schizoaffective disorder who had been admitted to the hospital for the treatment of psychosis." | 3.72 | Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. ( Libretto, SE; Taylor, DM; Wright, T, 2003) |
| "Outpatients diagnosed of schizophrenia according to DSM-IV criteria and receiving a single antipsychotic (risperidone, olanzapine, quetiapine or haloperidol) for at least 4 weeks were consecutively recruited." | 3.72 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. ( Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F, 2003) |
| "To examine both schizophrenia-related costs and total (schizophrenia plus non-schizophrenia) healthcare costs among Texas Medicaid recipients who had been diagnosed with a schizophrenic disorder and had been initiated on olanzapine or risperidone." | 3.72 | Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients. ( Barber, BL; Crismon, ML; Johnsrud, MT; Lage, MJ; Rascati, KL, 2003) |
| "Gains from earning rates for employed persons with schizophrenia, savings in informal caregiver costs and other human benefits could justify an incremental cost of 19,609 US dollars for each additional employable person prescribed risperidone." | 3.72 | Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. ( Ganguly, R; Martin, BC; Miller, LS, 2003) |
| "The effect of mirtazapine on steady-state plasma concentrations of the newer atypical antipsychotics clozapine, risperidone and olanzapine was investigated in 24 patients with chronic schizophrenia." | 3.72 | Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. ( Canale, A; Crucitti, D; D'Arrigo, C; Malara, G; Muscatello, MR; Spina, E; Torre, DL; Zoccali, R, 2003) |
| "This study investigated the effectiveness and tolerability of a switching strategy using quetiapine in 16 women with schizophrenia who were suffering from haloperidol- or risperidone-induced amenorrhea." | 3.72 | Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. ( Higuchi, H; Kamata, M; Naitoh, S; Shimizu, T; Sugita, T; Takahashi, H; Yoshida, K, 2003) |
| "In a cross-sectional study, consecutive premenopausal, female, DSM-IV schizophrenia patients who were treated with either risperidone (N = 12) or olanzapine (N = 14) for at least 2 years were included." | 3.72 | Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. ( Becker, D; Liver, O; Mester, R; Rapoport, M; Weiss, M; Weizman, A, 2003) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 3.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "Most antipsychotic drugs act equivalently and potently on the symptoms of schizophrenia, with clozapine as the notable exception." | 3.72 | Similarities and differences among antipsychotics. ( Tamminga, CA, 2003) |
| "Risperidone is a widely used agent as first-line treatment in schizophrenia with a favorable side-effect profile." | 3.72 | Reduced short-term obsessive-compulsive symptoms in schizophrenic patients treated with risperidone: a single-blind prospective study. ( Bayraktar, E; Ercan, ES; Kayahan, B; Varan, A; Veznedaroglu, B, 2003) |
| "Schizophrenia patients exposed to both risperidone and olanzapine may gain protection from suicidality." | 3.72 | Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period. ( Aizenberg, D; Barak, Y; Knobler, HY; Mirecki, I; Natan, Z, 2004) |
| "Texas Medicaid claims were analyzed for persons aged 21 to 65 years with a diagnosis of schizophrenia or schizoaffective disorder who started treatment with olanzapine (N=1875), risperidone (N=982), or haloperidol (N= 726) between January 1, 1997 and August 31, 1998." | 3.72 | Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. ( Brown, CM; Gibson, PJ; Opolka, JL; Rascati, KL, 2004) |
| "We report the case of a 44-year-old female patient with paranoid schizophrenia, who developed blepharospasm on risperidone treatment, but who was successfully rechallenged by risperidone without recurrence of blepharospasm." | 3.72 | Successful risperidone rechallenge after blepharospasm in a patient with schizophrenia: 24-month follow-up. ( Gulati, S; Libretto, SE; Singh, AN, 2003) |
| "To assess the impact of switching atypical antipsychotic treatment [from (i) risperidone to olanzapine or (ii) olanzapine to risperidone] on medication use patterns and treatment costs for individuals with schizophrenia." | 3.72 | Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database. ( Barber, BL; Breier, A; Loosbrock, DL; Namjoshi, M; Tunis, SL; Zhao, Z; Zhu, B, 2004) |
| " The methodology is motivated by and applied to data from five double-blind randomized clinical trials comparing the effects of risperidone to conventional antipsychotic agents for the treatment of chronic schizophrenia." | 3.72 | Applying linear mixed models to estimate reliability in clinical trial data with repeated measurements. ( Geys, H; Laenen, A; Molenberghs, G; Renard, D; Vangeneugden, T, 2004) |
| "Nineteen male and female DSM-IV-defined schizophrenic patients who were clinical responders to risperidone but were suffering from symptomatic hyperprolactinemia were treated with cabergoline, 0." | 3.72 | Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. ( Angelone, SM; Cavallaro, R; Cocchi, F; Lattuada, E; Smeraldi, E, 2004) |
| " Our objective is to present a case of exposure to risperidone and quetiapine in pregnancy, and additionally to some other drugs." | 3.72 | Use of polypharmacotherapy in pregnancy: a prospective outcome in a case. ( Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F, 2004) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 3.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "Risperidone has been used in Singapore for schizophrenia since 1996." | 3.72 | Drug utilization review of risperidone for outpatients in a tertiary referral hospital in Singapore. ( Koh, Y; Kua, EH; Li, SC; Luo, N; Tan, CH, 2004) |
| "This study, based upon a database analysis, compares a one-year drug treatment course (duration of therapy, concomitant use of typical antipsychotics, anxiolytics/antidepressants or anti-Parkinsonians) and direct health care costs of uncontrolled schizophrenia patients initiated on olanzapine versus risperidone." | 3.72 | Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia. ( Zhao, Z, 2004) |
| "Treatment with olanzapine was associated with significantly greater weight gain than treatment with risperidone in Chinese schizophrenia patients in Hong Kong." | 3.72 | Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. ( Lee, E; Leung, CM; Wong, E, 2004) |
| "Positron emission tomography with the radioligands [(11)C]SCH23390 and [(11)C]raclopride was used to investigate D(1) and D(2) receptor occupancy in vivo in 25 schizophrenia patients receiving atypical antipsychotic treatment with clozapine, olanzapine, quetiapine, or risperidone." | 3.72 | Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. ( Agid, O; Houle, S; Hussain, T; Kapur, S; Remington, G; Tauscher, J; Verhoeff, NP; Wilson, AA; Zipursky, RB, 2004) |
| "Although clozapine and olanzapine have greater diabetes risk, the attributable risk of diabetes mellitus with atypical antipsychotics is small." | 3.72 | Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. ( Leslie, DL; Rosenheck, RA, 2004) |
| "Exposure to multiple second-generation antipsychotics or clozapine or quetiapine significantly increased the risk of treatment-emergent diabetes mellitus." | 3.72 | Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. ( Allingham, B; Citrome, L; Jaffe, A; Levine, J; Robinson, J, 2004) |
| "We report a case of rhabdomyolysis and acute compartment syndrome of the lower extremity in a schizophrenic patient taking risperidone following the addition of simvastatin to treat hyperlipidemia." | 3.72 | Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. ( Lightfoot, JD; Mahmud, W; Shekhar, A; Webber, MA, 2004) |
| "To evaluate the safety and tolerability of olanzapine in the treatment of elderly patients with schizophrenia." | 3.72 | Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study. ( Ciudad, A; Gómez, JC; Montes, JM; Olivares, JM, 2004) |
| "Augmentation strategy in the treatment of schizophrenia with the NMDA receptor co-agonist glycine has demonstrated significant improvement in patient symptoms." | 3.72 | Effects of typical and atypical antipsychotics on human glycine transporters. ( Conn, PJ; Mallorga, PJ; Pettibone, DJ; Sur, C; Williams, JB, 2004) |
| "We identified patients with schizophrenia by >1 inpatient or > or = 2 outpatient ICD-9-CM codes (> or = 7 days apart) between 1 July 1998 and 30 June 1999, and those who were initiated on olanzepine or risperidone during the period 1 April 1999 to 31 March 2000 inclusive." | 3.72 | Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia. ( Hamed, A; Herz, L; Huang, YH; Kazis, LE; Lee, AF; Miller, DR; Ren, XS, 2004) |
| "To investigate the disintegration profile, acceptability, and tolerability of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder." | 3.72 | Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. ( Binder, C; Chue, P; Welch, R, 2004) |
| "Olanzapine and risperidone use was associated with gaining weight in the first year, but only olanzapine was associated with developing diabetes mellitus." | 3.72 | Weight gain and new onset diabetes associated with olanzapine and risperidone. ( Farwell, WR; L'Italien, G; Stump, TE; Tafesse, E; Tierney, WM; Wang, J, 2004) |
| "The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia." | 3.71 | Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002) |
| "Response predictors of risperidone or other newer atypical antipsychotics for schizophrenia treatment remain unclear." | 3.71 | Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics. ( Chang, WH; Chang, YC; Chen, TT; Chiu, CC; Lane, HY; Lee, SH, 2002) |
| "The effect of fluoxetine on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was evaluated in 10 patients with schizophrenia or schizoaffective disorder." | 3.71 | Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. ( Ancione, M; Avenoso, A; Gatti, G; Madia, A; Perucca, E; Scordo, MG; Spina, E, 2002) |
| "Priapism has been associated with many antipsychotic agents, including clozapine, risperidone, and olanzapine." | 3.71 | Priapism associated with two atypical antipsychotic agents. ( Mack, JE; Reeves, RR, 2002) |
| "One hundred Han Chinese patients with acutely exacerbated schizophrenia were given risperidone for up to 42 days." | 3.71 | Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. ( Chang, WH; Chang, YC; Chen, ML; Chiu, CC; Hsieh, MH; Lane, HY, 2002) |
| " The aim of the study was to compare the costs and outcomes of using risperidone versus classical neuroleptics in treatment of schizophrenia in order to see if there was any cost advantage in restricting use of more recent antipsychotics." | 3.71 | Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic. ( Bahbouh, R; Hosák, L, 2002) |
| "Patients with schizophrenia treated with clozapine, haloperidol, risperidone, or thioridazine; a control group of patients with glaucoma; and a control group of patients with psoriasis." | 3.71 | Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. ( Bilker, WB; Glasser, DB; Hennessy, S; Kimmel, SE; Knauss, JS; Margolis, DJ; Morrison, MF; Reynolds, RF; Strom, BL, 2002) |
| "Most patients (81% of adult patients and 91% of elderly patients) received risperidone for a psychiatric disease other than schizophrenia." | 3.71 | Outcomes and costs of treatment with risperidone in adult and elderly patients: the Delta patient using risperidone study. ( Loonen, AJ; Loos, JC; Van Zonneveld, TH, 2002) |
| "We report on the occurrence of galactorrhea and amenorrhea associated with prolactin elevation after 6 months of treatment with risperidone." | 3.71 | Risperidone induced galactorrhea: a case analysis. ( Hariharan, J; Mohsin, J, 2002) |
| "By using Israel's National Psychiatric Hospitalization Case Registry, rehospitalization status was monitored for all patients with schizophrenia who were discharged from any inpatient psychiatric facility in Israel while taking risperidone (N=268) or olanzapine (N=313) between Jan." | 3.71 | Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. ( Davidson, M; Kaplan, Z; Lichtenberg, P; Mark, M; Nahon, D; Rabinowitz, J, 2001) |
| " The patient had long-standing schizophrenia and had been taking risperidone for 2 years, without evidence of abnormal movements." | 3.71 | Hyperthermia and chronic pancerebellar syndrome after cocaine abuse. ( Dissin, J; Selcer, UM; Tanvetyanon, T, 2001) |
| " Patients with schizophrenia who had been stabilized on their antipsychotic medication and subsequently maintained on it for a period of at least 18 months were identified: clozapine (N=15); risperidone (N=15); depot conventional (N=18); oral conventional (N=18)." | 3.71 | Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics. ( Khramov, I; Remington, G, 2001) |
| "This study compared the discharge rates and drug costs of 789 patients with schizophrenia or schizoaffective disorder who began pharmacotherapy with olanzapine or risperidone between July 1997 and June 1998." | 3.71 | Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. ( Conley, RR; Kelly, DL; Love, RC; Nelson, MW; Yu, Y, 2001) |
| " In order to determine whether newer antipsychotic agents differ from each other with respect to weight gain, we compared two cohorts of patients with DSM-IV schizophrenia who had newly started treatment with either risperidone or olanzapine." | 3.71 | Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. ( Ayrton, Z; Brar, JS; Ganguli, R, 2001) |
| "To report a case of neuroleptic malignant syndrome (NMS) in a patient whose therapy was being switched from haloperidol to risperidone." | 3.71 | Neuroleptic malignant syndrome during a change from haloperidol to risperidone. ( Mack, JE; Reeves, RR; Torres, RA, 2001) |
| "The Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS) programme was an international series of naturalistic studies designed to evaluate drug use patterns and outcomes." | 3.71 | Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. ( Duchesne, I; Kasper, S; Rosillon, D, 2001) |
| "We report the health economic data from the Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS) programme." | 3.71 | Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. ( Duchesne, I; Jones, M; Kasper, S, 2001) |
| "To obtain an in vivo measurement of muscarinic receptor occupancy by olanzapine compared with risperidone in patients with schizophrenia stabilised on medication." | 3.71 | Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. ( Booij, J; Lavalaye, J; Linszen, DH; Reneman, L; van Royen, EA, 2001) |
| "Two retrospective cases are described in which patients with schizophrenia developed diabetes while taking the antipsychotic medication risperidone." | 3.71 | Risperidone-associated new-onset diabetes. ( Eyeler, J; Pierre, JM; Weinbach, J; Wirshing, DA; Wirshing, WC, 2001) |
| "Several years ago, we reported that the addition of risperidone to clozapine improved response in some patients with schizophrenia." | 3.71 | Risperidone added to clozapine: impact on serum prolactin levels. ( Borba, CP; Connolly, CE; Goff, DC; Hayden, D; Henderson, DC, 2001) |
| "Prolactin levels in 18 male patients with schizophrenia who were receiving atypical antipsychotics were monitored over the 24-hour period following administration of their daily oral dose of risperidone, olanzapine, or clozapine." | 3.71 | Elevation of prolactin levels by atypical antipsychotics. ( Flint, AJ; Kapur, S; Seeman, MV; Turrone, P, 2002) |
| "To assess the clinical and cognitive effects of adding donepezil, a reversible acetylcholinesterase inhibitor, to the risperidone treatment of a high functioning stable out-patient with schizophrenia." | 3.71 | Donepezil in schizophrenia--is it helpful? An experimental design case study. ( Ehmann, TS; Khanbhai, I; MacEwan, GW; Wrixon, C, 2001) |
| "Clozapine was reserved for more severe forms of schizophrenia, but its cost impact was relatively low." | 3.71 | Service use and costs of treating schizophrenia with atypical antipsychotics. ( Frangou, S; Lewis, M; McCrone, P, 2001) |
| "This retrospective study evaluates drug treatment patterns and economic outcomes of olanzapine in comparison with risperidone in the treatment of schizophrenia in usual practice." | 3.71 | A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. ( Zhao, Z, 2002) |
| "Subjects were 2,515 adult Medicaid recipients treated for schizophrenia in 1995 with one of four types of antipsychotic medication (traditional antipsychotics, clozapine, risperidone, or depot antipsychotics)." | 3.71 | Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. ( Kuno, E; Rothbard, AB, 2002) |
| "The aim of the present study is to determine the effect of the atypical antipsychotic drug, risperidone on sleep measures in patients with schizophrenia by polysomnography." | 3.71 | Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol. ( Horiguchi, J; Morinobu, S; Nagao, M; Yamashita, H; Yamawaki, S, 2002) |
| "The authors studied the efficacy of olanzapine and risperidone among patients with treatment-refractory schizophrenia who had been hospitalized for more than five years and who were not suitable candidates for a clozapine trial." | 3.71 | Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients. ( Bopp, JH; Daniels, A; Dinakar, HS; Mauro, S; Sobel, RN, 2002) |
| "Mental health service use and costs for patients with psychoses treated with risperidone versus those treated with conventional antipsychotic agents were compared by both between-group and within-group comparisons." | 3.71 | Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents. ( Durkin, MB; Gianfrancesco, F; Mahmoud, R; Wang, RH, 2002) |
| "The authors compared the changes in health care utilization and costs between a group of patients with schizophrenia who started treatment with risperidone and a group that started treatment with olanzapine." | 3.71 | Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. ( Durkin, MB; Fuller, MA; Laich, JS; Secic, M; Shermock, KM, 2002) |
| "They obtained computerized pharmacy data on 1,283 inpatients with the diagnoses of schizophrenia or schizoaffective disorder who were treated with risperidone." | 3.70 | Alteration in the recommended dosing schedule for risperidone. ( Hanrahan, P; Harris, J; Klass, D; Luchins, DJ; Malan, R, 1998) |
| "In 20 patients with schizophrenia [Diagnostic and Statistical Manual of Mental Disorders (Third Edition-Revised)] treated with mean daily doses of risperidone ranging from 0." | 3.70 | Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients. ( Dähne, I; Dresel, S; Hahn, K; Mager, T; Scherer, J; Tatsch, K, 1998) |
| "An open-label, multicentre study was conducted to assess the long-term efficacy and safety of risperidone in patients with chronic schizophrenia." | 3.70 | Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. ( Addington, DE; Gagiano, CA; Gaussares, C; Möller, HJ; Torres-Plank, JF; Von Knorring, L, 1998) |
| "A 26-year-old man with schizophrenia, disorganised type, and depression, developed severe tardive dyskinesia during treatment with risperidone and fluoxetine." | 3.70 | [Severe tardive dyskinesia during treatment with risperidone and fluoxetine]. ( Dubbelman, YD; Heeringa, M; Thung, FH, 1998) |
| "We summarise preliminary findings from our ongoing magnetic resonance imaging and spectroscopy studies of first-episode schizophrenia patients being conducted prospectively from index evaluations through a period of two years; during this period, patients were treated with either a conventional antipsychotic such as haloperidol, or the atypical risperidone." | 3.70 | Research and treatment strategies in first-episode psychoses. The Pittsburgh experience. ( Haas, GL; Keshavan, MS; Pettegrew, JW; Schooler, NR; Sweeney, JA, 1998) |
| " Six healthy volunteers, five clozapine- and five risperidone-treated subjects with DSM-IV schizophrenia were studied." | 3.70 | 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. ( Acton, PD; Busatto, GF; Costa, DC; Ell, PJ; Gacinovic, S; Kerwin, RW; Mertens, J; Mulligan, R; Pilowsky, LS; Terrière, D; Travis, MJ, 1998) |
| "Forty-four patients with schizophrenia (16 taking risperidone, 2-12 mg/day; 17 taking olanzapine, 5-60 mg/day; and 11 taking clozapine, 75-900 mg/day) had their D2 and 5-HT2 occupancies determined with the use of [11C]raclopride and [18F]setoperone, respectively, and positron emission tomography imaging." | 3.70 | Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. ( Kapur, S; Remington, G; Zipursky, RB, 1999) |
| "A model was developed to estimate the medical costs and effectiveness outcomes of three antipsychotic treatments (olanzapine, haloperidol, and risperidone) for patients with schizophrenia." | 3.70 | A cost-effectiveness clinical decision analysis model for schizophrenia. ( Brown, RE; Genduso, LA; Hamilton, SH; Palmer, CS; Revicki, DA, 1998) |
| "In this study, the benefits and costs of treating schizophrenia with either risperidone or clozapine were examined." | 3.70 | Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel. ( Ginsberg, G; Lev, B; Shani, S, 1998) |
| "Clozapine is the most widely used antipsychotic drug for the treatment of refractory schizophrenia." | 3.70 | Risperidone and clozapine combination for the treatment of refractory schizophrenia. ( Barreiro, P; Cano-Muñoz, JL; Morera, AL, 1999) |
| "One hundred sixty patients were discharged on risperidone, 75 having the diagnosis of schizophrenia." | 3.70 | Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. ( Bartko, JJ; Conley, RR; Kelly, DL; Love, RC, 1999) |
| "During clinical experience with the "atypical" neuroleptic drugs clozapine, risperidone, and zotepine, some patients have shown a marked weight gain." | 3.70 | Weight gain: side effect of atypical neuroleptics? ( Müssigbrodt, HE; Wetterling, T, 1999) |
| "To compare inpatient hospital days of a group of "real world" schizophrenia-spectrum patients for 3 years prior to and 3 years after risperidone initiation." | 3.70 | Hospital days in risperidone-treated patients. ( Addington, D; Dalby, JT; Dickson, RA; McDougall, GM; Williams, R, 1999) |
| "Olanzapine (Zyprexa), a neuroleptic, has obtained marketing authorization for treatment of schizophrenia." | 3.70 | Olanzapine. Keep an eye on this neuroleptic. ( , 2000) |
| " Phencyclidine (PCP), a non-competitive NMDA-receptor antagonist, is able to induce schizophrenia-like symptoms in animals and in humans." | 3.70 | Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory. ( Sabel, BA; Schroeder, H; Schroeder, U; Schwegler, H, 2000) |
| "Clozapine and risperidone were the first two antipsychotic drugs of a new class of agents for the pharmacotherapy of schizophrenia." | 3.70 | Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. ( Durst, R; Katz, G; Knobler, HY; Raskin, S; Zislin, Z, 2000) |
| "P50 suppression of 13 patients with schizophrenia receiving clinically effective doses of clozapine, olanzapine, or risperidone (classified as atypical antipsychotic medications) was compared to that of 13 patients receiving conventional antipsychotic medications." | 3.70 | Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. ( Braff, DL; Cadenhead, KS; Clementz, BA; Geyer, MA; Light, GA, 2000) |
| "The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia." | 3.70 | Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D, 2000) |
| "The objectives of this study were to determine the doses of olanzapine (OLZ), risperidone (RIS), and haloperidol (HAL) used in clinical practice in outpatients with schizophrenia and the rates of occurrence of extrapyramidal symptoms (EPS) and other adverse events, clinical response, and use of concomitant medications." | 3.70 | Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. ( Gómez, JC; Gregor, KJ; Montejo, AL; Sacristán, JA; Vieta, E, 2000) |
| "Clozapine is effective in up to 60% of patients with refractory schizophrenia, whereas the efficacy of risperidone remains unknown." | 3.70 | Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. ( Ratakonda, SS; Raza, A; Sharif, ZA, 2000) |
| "To compare the costs of 2 atypical drug therapies (olanzapine and risperidone) with one another and with a conventional antipsychotic (haloperidol) in the treatment of schizophrenia." | 3.70 | Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. ( Almond, S; O'Donnell, O, 2000) |
| "Seventy-four patients (most with schizophrenia) met the inclusion criteria of the risperidone group." | 3.70 | Impact of risperidone on seclusion and restraint at a state psychiatric hospital. ( Atzert, R; Brar, JS; Brienzo, R; Chengappa, KN; Gopalani, A; Levine, J; Parepally, H; Ulrich, R, 2000) |
| "This case report illustrates the improvement of tardive dyskinesia (TD) and psychotic symptoms in an elderly Thai female with chronic schizophrenia with a long history of conventional antipsychotic exposure following the treatment with risperidone 2 mg/day." | 3.70 | Improvement of tardive dyskinesia with risperidone: a case report. ( Kooptiwoot, S; Settachan, T, 2000) |
| "To study the therapeutic effect, side effects and cognize improvement of Risperidone in treating different TCM Syndrome-types of first-episode schizophrenia." | 3.70 | [Comparison between therapeutic effect of Risperidone in treating different traditional Chinese medicine syndrome types of first-episode schizophrenia]. ( Cao, X; Wang, W, 2000) |
| "After 9 days of risperidone therapy (2-6 mg/day), a 24-year-old schizophrenic female patient developed a leucopenia with neutropenia < 1000/mm3." | 3.69 | Reversible neutropenia during a cold: possible involvement of risperidone? A case report. ( Aubert, AC; Baumann, P; Bondolfi, G; Meylan, C, 1995) |
| "In September 1994, the National Institute of Mental Health convened a group of scientists to discuss the clinical effects of rapid clozapine discontinuation, especially in light of the introduction of risperidone for the treatment of schizophrenia." | 3.69 | Clinical implications of clozapine discontinuation: report of an NIMH workshop. ( Cott, J; Lieberman, JA; Matthews, S; Shore, D, 1995) |
| "Patients displaying a moderate-to-marked response to risperidone were more likely to be younger; receive diagnoses of bipolar disorder or schizoaffective disorder, depressive type; and have a shorter duration of illness and shorter length of stay prior to risperidone treatment." | 3.69 | Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. ( Balistreri, TM; DePriest, M; Holtman, HM; Keck, PE; Kizer, DL; McElroy, SL; Strakowski, SM; Wilson, DR, 1995) |
| "The role of risperidone in the management of treatment-resistant schizophrenia remains unclear." | 3.69 | The use of risperidone in treatment-resistant schizophrenia: two case reports. ( Gledhill, JA; Wakeling, A; Warner, JP, 1996) |
| " To develop an animal model for the negative symptoms of schizophrenia, in particular, the depressive symptoms, the effect of phencyclidine (PCP) on immobility in the forced swimming test was investigated in mice, since PCP produces negative symptoms-like behavioral changes in humans." | 3.69 | [Behavioral assessment of neuroleptics (3)--Schizophrenia negative symptoms-like model induced by PCP]. ( Nabeshima, T; Noda, Y, 1996) |
| "To determine whether or not risperidone is efficacious in treating self-induced water intoxication in patients with chronic schizophrenia." | 3.69 | Self-induced water intoxication treated with risperidone. ( Emes, CE; Glackman, WG; Millson, RC, 1996) |
| "A prospective, open-label study in a 400-bed state psychiatric hospital evaluated change in therapeutic response among ten patients with treatment-resistant schizophrenia who were switched from clozapine to risperidone." | 3.69 | Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. ( Crismon, ML; Dorson, PG; Pousson, C; Still, DJ, 1996) |
| "Risperidone is a newly available atypical antipsychotic agent that has been reported to be associated with fewer extrapyramidal side effects (EPS) than conventional neuroleptics in adults with schizophrenia." | 3.69 | Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. ( Findling, RL; Friedman, L; Grcevich, SJ; Rowane, WA; Schulz, SC, 1996) |
| "The effects of risperidone treatment on health care utilization and treatment costs were examined among patients with treatment-refractory schizophrenia or schizoaffective disorder." | 3.69 | Impact of risperidone on the use of mental health care resources. ( Durkin, M; Engelhart, L; Lawrence, BJ; Maislin, G; Mechling, L; Viale, G, 1997) |
| " In one study of the newer antipsychotic agent risperidone, the overall annual costs of treating a patient with schizophrenia were reduced by nearly $8,000 (Canadian dollars), even though medication costs increased by approximately $1,200 (Canadian dollars)." | 3.69 | Looking beyond the formulary budget in cost-benefit analysis. ( Cohen, LJ, 1997) |
| "This study indicated that fingolimod is a safe and effective adjuvant agent for schizophrenia treatment." | 3.30 | Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. ( Akhondzadeh, S; Amanollahi, M; Ardakani, MK; Basti, FA; Jameie, M; Karbalaee, M; Mokhtari, S; Moradi, K; Parsaei, M; TaghaviZanjani, F, 2023) |
| " We hypothesized that a low dose of risperidone in combination with sertraline would reduce serious adverse effects without decreasing treatment response." | 3.30 | Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study. ( Lang, X; Wu, F; Xiu, M; Xue, M; Zang, X; Zhang, X, 2023) |
| " Most frequently reported treatment-related adverse events (ie, ≥5% of patients in either TV-46000 group) that occurred more often in patients receiving TV-46000 (once monthly or once every 2 months) versus placebo were injection site nodules (7% for TV-46000 once monthly, 7% for TV-46000 once every 2 months, 3% for placebo), weight increased (4%, 6%, 2%, respectively), and extrapyramidal disorder (5%, 3%, 0% respectively)." | 3.30 | Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. ( Correll, CU; Davis, GL; Eshet, R; Franzenburg, KR; Harary, E; Kane, JM; Leucht, S; Merenlender-Wagner, A; Sharon, N; Suett, M; Tohami, O; Weiser, M, 2023) |
| " The most common adverse events with Lu AF35700 were increased weight and headache." | 3.11 | Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension. ( Forray, C; Hertel, P; Howes, OD; Kane, JM; Kinon, BJ; Lemming, OM; Mittoux, A; Such, P, 2022) |
| "Risperidone has been shown in several trials to have a statistically significant benefit when used in a therapeutic context." | 3.01 | Neuropharmacological effect of risperidone: From chemistry to medicine. ( Afzal, O; Al-Abbasi, FA; Alfawaz Altamimi, AS; Almalki, WH; Alzarea, SI; Bhat, AA; Dua, K; Gupta, G; Kazmi, I; Singh, SK, 2023) |
| "Schizophrenia is a major psychiatric disorder with unknown aetiology." | 3.01 | Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: A systematic review and meta-analysis. ( Donohoe, G; McKernan, DP; Patlola, SR, 2023) |
| " We applied one-stage random-effects dose-response meta-analyses using restricted cubic splines to model the dose-response relationships." | 3.01 | Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis. ( Burschinski, A; Davis, JM; Leucht, S; Priller, J; Schneider-Thoma, J; Siafis, S; Wang, D; Wu, H, 2023) |
| "With the second-generation antipsychotics (SGAs) widely applied to treat patients with schizophrenia, adverse effects, especially the metabolic syndrome (MetS), were paid more attention following by the efficacy of SGAs." | 2.90 | Efficacy and safety of electroacupuncture on metabolic syndrome due to olanzapine and risperidone: Study protocol for a randomized controlled pilot trial. ( Chen, P; Jia, H; Ning, Y; Yin, D; Zhu, H, 2019) |
| "Schizophrenia is associated with progressive white matter changes, but it is unclear whether antipsychotic medications contribute to these." | 2.90 | Micro- and Macrostructural White Matter Integrity in Never-Treated and Currently Unmedicated Patients With Schizophrenia and Effects of Short-Term Antipsychotic Treatment. ( Anthony, T; Jindal, RD; Kraguljac, NV; Lahti, AC; Marstrander, J; Melas Skefos, NH; Morgan, CJ; Reid, MA; Skidmore, FM; White, DM, 2019) |
| " Overall, 63 (94%) patients experienced at least one treatment-emergent adverse event (TEAE)." | 2.87 | A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. ( Anta, L; Ayani, I; Gutierro, I; Litman, RE; Llaudó, J; Martínez, J, 2018) |
| "Aripiprazole treatment decreased activation of the middle frontal, superior frontal and occipital gyrus (ToL) and medial temporal and inferior frontal gyrus, putamen and cuneus (WoF), while activation increased after risperidone." | 2.84 | Effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia: A single-blind randomized exploratory study. ( Aleman, A; Knegtering, H; Liemburg, EJ; van Es, F, 2017) |
| " The aims of this study were to investigate the effectiveness and adverse effects of LAIR in children and adolescents with conduct disorder, bipolar disorder, and schizophrenia." | 2.84 | Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents. ( Ceylan, MF; Cop, E; Erdogan, B; Tural Hesapcioglu, S, 2017) |
| "To investigate the relationship between patient age and the selection and dosage of antipsychotic drugs (APDs) for treatment of schizophrenia." | 2.82 | Antipsychotic drug treatment of schizophrenia in later life: Results from the European cross-sectional AMSP study. ( Bleich, S; Dahling, V; Greiner, T; Grohmann, R; Heinze, M; Ramin, T; Schneider, M; Seifert, J; Toto, S; Zindler, T; Zolk, O, 2022) |
| "In the treatment of schizophrenia, suboptimal adherence, antipsychotic switching, and antipsychotic augmentation were all associated with high costs of care in comparison to patients who were adherent and did not require antipsychotic switching or augmentation." | 2.82 | Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States. ( Bessonova, L; Cichewicz, A; Doane, MJ; Harvey, PD; Hughes, R; Martin, A; O'Sullivan, AK; Snook, K; Weiden, PJ, 2022) |
| "Risperidone ISM was generally well tolerated and the most frequently reported adverse events were similar to those observed with other risperidone formulations." | 2.82 | Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review. ( Álamo, C, 2022) |
| " Their efficacy and tolerability with long-term use have not been clearly established." | 2.82 | Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions. ( Kyriakopoulos, M; Singappuli, P; Sonuga-Barke, E, 2022) |
| "An urgent need exists for new treatments of schizophrenia that are effective against a broad range of symptoms and free of limiting safety issues." | 2.82 | ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. ( Correll, CU; Davis, RE; Goff, DC; Kane, JM; Lieberman, JA; Mates, S; Tamminga, CA; Vanover, KE, 2016) |
| " Prolactin levels could assist in the determination of appropriate antipsychotic dosing to minimize adverse effects." | 2.82 | Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. ( Caravaggio, F; Chung, JK; Gerretsen, P; Graff-Guerrero, A; Iwata, Y; Mamo, DC; Mar, W; Mulsant, BH; Nakajima, S; Plitman, E; Pollock, BG; Rajji, TK; Suzuki, T; Uchida, H, 2016) |
| "Patients with schizophrenia or schizoaffective disorder participated in the 2-year, randomized, multicentre, open-label, ophthalmologist-masked, flexible-dose, parallel-group study." | 2.80 | Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. ( Baldycheva, I; Earley, W; Flach, AJ; Laties, AM; Pathak, S; Rak, I, 2015) |
| " However, the ideal dosing regimen for this purpose is unknown." | 2.80 | Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. ( Bian, QT; Chen, JX; Correll, C; Liu, YH; Soares, JC; Su, YA; Wang, SL; Wei, LH; Yang, FD; Zhang, RZ; Zhang, XY, 2015) |
| "Aripiprazole-treated participants had better negative symptom outcomes but experienced more akathisia." | 2.80 | A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. ( Addington, J; Bennett, N; Braga, RJ; Correll, CU; Gallego, JA; Greenberg, J; Hassoun, Y; John, M; Kane, JM; Kellner, CH; Lencz, T; Lopez, L; Malhotra, AK; Naraine, M; Petrides, G; Robinson, DG; Sevy, SM; Tohen, M; Zhang, JP, 2015) |
| "Whether treating schizophrenia with risperidone plus add-on DM is more effective than risperidone (RISP) alone, and the association between the ALDH2 polymorphism and treatment response were investigated." | 2.80 | ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan. ( Chang, YH; Chen, KC; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, TY; Yang, YK, 2015) |
| "Diagnosis, cannabis use, duration of untreated psychosis (DUP), smoking and antipsychotic class were examined as possible predictive variables." | 2.79 | Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. ( Crespo-Facorro, B; de León, J; Diaz, FJ; Pelayo-Terán, JM; Pérez-Iglesias, R; Suárez-Pinilla, P; Tabarés-Seisdedos, R, 2014) |
| " In the USA, dosing tends to be expressed in mg] or oral risperidone [during initiation of risperidone long-acting injection (RLAI) days 1-28] and biweekly flexible-dose RLAI (n=173; initial injection day 8)." | 2.79 | Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. ( Alphs, L; Bossie, CA; Fu, DJ; Ma, YW; Sliwa, JK, 2014) |
| "Perphenazine was noninferior to all three SGAs during 18 months of intention-to-treat analysis and in several subanalyses." | 2.79 | Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. ( Lin, H; Rosenheck, R, 2014) |
| "T-tests showed that the PTSD sample had more severe symptoms on the Depressive factor, and the schizophrenia sample on the Positive, Negative, and Disorganized factors, with no significant difference on the Excited factor." | 2.79 | Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia. ( Krystal, JH; Rosenheck, RA; Stefanovics, EA, 2014) |
| " However, a higher dosage of risperidone was used for treating the disorder in those taking concomitant lovastatin compared to placebo." | 2.79 | Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial. ( Akhondzadeh, S; Berk, M; Dehbozorgi, S; Ghanizadeh, A; Rezaee, Z, 2014) |
| "Schizophrenia is a complex illness with unknown aetiology and pathogenesis." | 2.79 | The Chinese First-Episode Schizophrenia Trial: background and study design. ( Chiu, HF; Dong, H; Han, X; Lu, Z; Ungvari, GS; Wang, CY; Wu, YF; Xiang, YT; Yang, FD; Yu, X; Yuan, YB; Zhao, JP, 2014) |
| "Clinicians treating schizophrenia routinely employ high doses and/or antipsychotic switching to achieve response." | 2.78 | Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. ( Agid, O; Arenovich, T; Fervaha, G; Foussias, G; McDonald, K; Remington, G; Sajeev, G; Schulze, L, 2013) |
| "This was a 6-week, multicenter, randomized, open-label, parallel-group, flexible dosing study." | 2.78 | An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. ( Chan, HY; Chen, KP; Chen, YY; Cheng, JS; Lin, AS; Tsai, CJ, 2013) |
| "risperidone) were nausea (16." | 2.77 | Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. ( Citrome, L; Cucchiaro, J; Loebel, A; Phillips, D; Sarma, K; Silva, R; Tsuchiya, S, 2012) |
| " Patients with the AQP-4 non-C polymorphism needed a higher dosage of olanzapine for treatment (z = 4." | 2.77 | Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia. ( Chung, TS; Lung, FW, 2012) |
| " The aim of the present study was to analyze on a single case basis the relationship between a sudden increase in suicidality, anxiety symptoms, medication dosing and clinician- and patient-rated akathisia." | 2.77 | The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. ( Bauer, M; Doucette, S; Lewitzka, U; Meyer, S; Möller, HJ; Musil, R; Riedel, M; Schennach, R; Seemüller, F, 2012) |
| "Olanzapine has a higher propensity to cause derangement of some parameters of lipid profile than risperidone." | 2.77 | Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone. ( Bhutani, G; Gupta, R; Kaushal, J, 2012) |
| "Suicidal ideation was significantly associated with clinician observed akathisia, depressed mood, younger age, and use of propranolol." | 2.77 | Akathisia and suicidal ideation in first-episode schizophrenia. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingenberg, S; Klosterkötter, J; Lewitzka, U; Maier, W; Mayr, A; Möller, HJ; Musil, R; Ohmann, C; Riedel, M; Schennach, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| "risperidone (RIS), produce more extensive blockade of brain serotonin (5-HT)(2A) than dopamine (DA) D(2) receptors." | 2.77 | Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. ( Elkis, H; Hacksell, U; Meltzer, HY; Peters, P; van Kammen, DP; Vanover, K; Weiner, DM, 2012) |
| "Schizophrenia is an often devastating neuropsychiatric illness." | 2.76 | Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. ( Aberg, K; Adkins, DE; Lieberman, JA; McClay, JL; Perkins, DO; Stroup, S; Sullivan, PF; van den Oord, EJ; Vladimirov, VI, 2011) |
| "Individuals in the extended dosing group were not at greater risk of symptom exacerbation, relapse, or rehospitalization; indeed, more rehospitalizations occurred in those receiving regular dosing." | 2.76 | "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. ( Feingold, A; Kapur, S; Mann, S; Remington, G; Seeman, P; Shammi, C, 2011) |
| "112 patients were treated with a mean dosage of 4." | 2.76 | Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response? ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Kühn, KU; Mayr, A; Meyer, S; Möller, HJ; Riedel, M; Schennach-Wolff, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F, 2011) |
| "Schizophrenia is a chronic mental health disorder associated with increased hospital admissions and excessive utilization of outpatient services and long-term care." | 2.76 | Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE). ( Crivera, C; DeSouza, C; Dirani, RD; Kozma, CM; Macfadden, W; Mao, L, 2011) |
| "Risperidone is a second generation antipsychotic agent, with potent serotonin 5-HT2A and dopamine D2 receptor blocking effects." | 2.76 | Risperidone in the treatment of schizophrenia. ( Bravo-Mehmedbasic, A, 2011) |
| "Schizophrenia is a chronic disorder that is usually characterized by relapses alternating with periods of full or partial remission." | 2.75 | Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection. ( Choi, TK; Kim, B; Kim, YW; Lee, E; Lee, SH; Suh, S; Yook, KH, 2010) |
| " Sixty-nine per cent of patients completed the trial; 8% discontinued due to adverse events (AEs)." | 2.75 | Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. ( Curtis, V; Hawley, C; Latif, MA; Saleem, PT; Turner, M; Wilton, K, 2010) |
| "Treatment with risperidone significantly increased the plasma NO(x) levels by 8 weeks (before; 1." | 2.75 | Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study. ( Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Nakano, H; Nakano, Y; Ueda, N; Umene-Nakano, W; Yoshimura, R, 2010) |
| "Sertindole did not increase all-cause mortality, but cardiac mortality was higher and suicide attempts may be lower with sertindole." | 2.75 | Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). ( Crocq, MA; Drici, MD; Everitt, B; Hall, GC; Lader, MH; Le Jeunne, C; Mann, RD; Mittoux, A; Moore, ND; Naber, D; Peuskens, J; Priori, S; Sturkenboom, M; Tanghøj, P; Thibaut, F; Thomas, SH; Toumi, M, 2010) |
| " Adverse effects (n = 15), inadequate efficacy (n = 14), or study nonadherence (n = 8) were the most common reasons for discontinuation." | 2.75 | Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. ( Findling, RL; Frazier, JA; Hamer, RM; Hlastala, S; Johnson, JL; Kaufman, EM; Lieberman, JA; Lingler, J; Maloney, AE; McClellan, J; McNamara, NK; Noyes, N; Pierson, L; Puglia, M; Ritz, L; Sikich, L; Vitiello, B, 2010) |
| "Chronic management of schizophrenia and schizoaffective disorders is frequently complicated by symptomatic relapse." | 2.75 | Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. ( Bergmans, P; Cordes, J; de Arce, R; Eriksson, L; Gaebel, W; Rouillon, F; Schreiner, A; Smeraldi, E, 2010) |
| "Weight gain was positively correlated with changes in insulin levels, insulin resistance index and triglyceride levels." | 2.74 | Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. ( Amado, JA; Berja, A; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Mata, I; Pelayo-Teran, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2009) |
| "Auditory hallucinations are a characteristic symptom of schizophrenia and are usually resistant to treatment." | 2.74 | Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. ( Bagati, D; Nizamie, SH; Prakash, R, 2009) |
| " Based on recent criteria for pediatric populations, patients were considered "at risk for adverse health outcome" if they met at least 1 of the following criteria: (1) > or = 85th BMI percentile plus presence of 1 or more negative weight-related clinical outcomes, or (2) > or = 95th BMI percentile." | 2.73 | Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. ( Arango, C; Cifuentes, A; Fraguas, D; Giráldez, M; Laita, P; Merchán-Naranjo, J; Moreno, D; Parellada, M; Ruiz-Sancho, A, 2008) |
| "Hyperprolactinemia is an important but neglected adverse effect of antipsychotic medication." | 2.73 | Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. ( Chen, CH; Lu, ML; Shen, WW, 2008) |
| "A key feature of schizophrenia is the inability to screen out irrelevant sensory input." | 2.73 | A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics. ( Antonova, E; Ffytche, D; Geyer, MA; Kumari, V; Sharma, T; Williams, SC, 2007) |
| " Therefore, if flupentixol's efficacy on negative symptoms is based on its interaction with 5-HT(2A) and/or D(1) receptors, it should be highly dependent on serum concentration and thus on dosage and metabolism." | 2.73 | Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. ( Bares, R; Bartels, M; Beneke, M; Glaser, T; Machulla, HJ; Noda, S; Reimold, M; Schaefer, JE; Solbach, C; Wormstall, H, 2007) |
| "Treatment with haloperidol could significantly increase the PI than the treatment with risperidone (p<0." | 2.73 | Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients. ( Chou, YH; Lee, SM; Li, MH; Wan, FJ; Yen, MH, 2008) |
| "Patients with schizophrenia are characterized by emotional symptoms such as flattened affect which are accompanied by cerebral dysfunctions." | 2.73 | Stability of emotional dysfunctions? A long-term fMRI study in first-episode schizophrenia. ( Backes, V; Gaebel, W; Habel, U; Jon Shah, N; Kellermann, T; Reske, M; Schneider, F; Stöcker, T; von Wilmsdorff, M, 2007) |
| "Haloperidol was also associated with a significant increase of peripheral blood mononuclear cell membrane peroxidation." | 2.73 | Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. ( Bernardo, M; Cardellach, F; Casademont, J; Garrabou, G; López, S; Miró, O; Pons, A, 2007) |
| "Obesity is highly prevalent among patients treated with atypical antipsychotics for schizophrenia." | 2.73 | Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2007) |
| "The trial was a prospective, open-label, single-center one with a flexible dosing of SGAs." | 2.73 | Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. ( Cejpková, A; Rodáková, I; Svestka, J; Synek, O; Tomanová, J, 2007) |
| "Propentofylline is a novel xantine derivative which is being developed for treatment of degenerative and vascular dementia." | 2.73 | A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. ( Abbasi, SH; Ahmadi-Abhari, SA; Akhondzadeh, S; Derakhshan, MK; Fotouhi, A; Ghoreishi, A; Hajiazim, M; Khodaie-Ardakani, MR; Mohammadi, MR; Noorbala, AA; Salimi, S, 2008) |
| "Perphenazine was not significantly different in overall effectiveness, compared with quetiapine, risperidone, and ziprasidone." | 2.73 | What CATIE found: results from the schizophrenia trial. ( Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Rosenheck, RA; Stroup, TS; Swartz, MS, 2008) |
| "Risperidone was hypothesized to have better extrapyramidal tolerability and efficacy in treating negative symptoms." | 2.73 | Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Braus, DF; Buchkremer, G; Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klosterkötter, J; Kühn, KU; Maier, W; Möller, HJ; Ohmann, C; Riedel, M; Riesbeck, M; Schlösser, R; Schneider, F; Wickelmaier, F, 2008) |
| "Hyperprolactinemia is a common adverse effect that occurs as a result of antipsychotic therapies, which often results in discontinuation." | 2.73 | A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. ( Feng, XJ; Liu, RM; Sze, CW; Tan, QR; Tong, Y; Wang, CY; Yuan, HN; Zhang, JZ; Zhang, YB; Zhang, ZJ, 2008) |
| "Weight gain has become one of the most common and concerning side effects of antipsychotic treatment." | 2.73 | Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. ( Amado, JA; Berja, A; Carrasco-Marín, E; Crespo-Facorro, B; Garcia-Unzueta, MT; Mata, I; Pelayo-Terán, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2008) |
| "Risperidone's ranking has more implications supported by CINeMA." | 2.72 | Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis. ( Jiang, K; Leucht, S; Li, C; Liu, D; Siafis, S; Wang, J; Wu, H; Zhang, C; Zhu, D; Zhu, Y; Zhuo, K, 2021) |
| "Over the last ten years, the treatment of psychosis has seen a near explosion of creative development in both novel agents and new delivery modalities." | 2.72 | New Antipsychotic Medications in the Last Decade. ( El-Mallakh, RS; Elsayed, OH; Good, ME; Pahwa, M; Sleem, A, 2021) |
| "Aripiprazole was significantly inferior to olanzapine (SMD = 1." | 2.72 | Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis. ( Likhitsathian, S; Maneeton, B; Maneeton, N; Oon-Arom, A; Srisurapanont, M; Suradom, C; Suttajit, S, 2021) |
| "Schizophrenia is a complex psychiatric disorder where genetic, epigenetic, and environmental factors play a role in disease onset, course of illness, and treatment outcome." | 2.72 | Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment. ( Chen, CC; Kennedy, JL; Lisoway, AJ; Tiwari, AK; Zai, CC, 2021) |
| "Antipsychotic (AP) dosing is well established in nonelderly patients with acute exacerbations of schizophrenia, but not in special populations." | 2.72 | Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients. ( Baloche, E; Blin, O; Bourgin-Duchesnay, J; Corruble, E; Ferreri, F; Garay, RP; Llorca, PM; Mouaffak, F; Vandel, P; Vidailhet, P, 2021) |
| "Haloperidol-treated patients improved only on domains of learning/memory." | 2.72 | One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. ( Breier, A; Gold, JM; Keefe, RS; Purdon, SE; Rock, SL; Young, CA, 2006) |
| " Ninety-four outpatients who had been on a stable drug dosage were evaluated (clozapine group: n=57, mean dose=254." | 2.72 | Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia. ( Ahn, YM; Kim, JH; Kim, SY; Kim, YS, 2006) |
| "Treatment with risperidone or quetiapine was associated with the lowest overall costs when compared with olanzapine or clozapine." | 2.72 | Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders. ( Balshaw, R; Kopala, L; Love, L; Malla, A; Smith, G; Talling, D; Williams, R, 2006) |
| "Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression." | 2.72 | Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. ( Borisov, A; Feldman, J; May, R; Miller, AH; Nemeroff, CB; Rosenberg, J; Savage, R; Tucker, M; Wang, X; Woolwine, B, 2006) |
| "Treatment with olanzapine resulted in a greater numerical improvement than risperidone in all SFS domains and reached statistical significance in such categories as social engagement or withdrawal (p = 0." | 2.72 | Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial. ( Alvarez, E; Bousoño, M; Ciudad, A; Gómez, JC; Olivares, JM, 2006) |
| "Risperidone treatment did not change P3 amplitudes and latencies." | 2.72 | Effects of risperidone on auditory information processing in neuroleptic-naive patients with schizophrenia spectrum disorders. ( Dapsys, K; Kähkönen, S; Korostenskaja, M; Maciulis, V; Ruksenas, O; Siurkute, A, 2006) |
| "Olanzapine-treated patients had significantly more weight gain compared with the haloperidol and risperidone groups (p < ." | 2.72 | A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. ( Crespo-Facorro, B; Llorca, J; Luis Vázquez-Barquero, J; Martínez-García, O; Pérez-Iglesias, R; Ramirez-Bonilla, M, 2006) |
| ", dosage adjustments, behavioral or psychosocial interventions) before switching medications." | 2.72 | Effectiveness of switching antipsychotic medications. ( Covell, NH; Davis, SM; Essock, SM; Lieberman, JA; Rosenheck, RA; Stroup, TS, 2006) |
| "Clinical trials for the treatment of schizophrenia now often include cognitive assessments in addition to clinical ratings of symptoms." | 2.71 | Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study. ( Artiola i Fortuny, L; De Smedt, G; Harvey, PD; Vester-Blockland, E, 2003) |
| " Treatment with divalproex in combination with an atypical antipsychotic agent resulted in earlier improvements in a range of psychotic symptoms among acutely hospitalized patients with schizophrenia." | 2.71 | Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. ( Casey, DE; Daniel, DG; Sommerville, KW; Tracy, KA; Wassef, AA; Wozniak, P, 2003) |
| "Risperidone treatment significantly decreased the initially high blood SOD levels in schizophrenia." | 2.71 | The effect of risperidone treatment on superoxide dismutase in schizophrenia. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2003) |
| " The patients were treated with conventional antipsychotics for seven days after admission and were then randomised to the treatment arms with risperidone (4 mg/day) or with olanzapine (10 mg/day) at a fixed dosage in the first week and thereafter in flexible dosages for the remaining seven weeks." | 2.71 | Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia. ( Kores Plesnicar, B; Krajnc, I; Tomori, M; Zalar, B, 2003) |
| "Olanzapine-treated patients showed a significantly greater reduction in Positive and Negative Syndrome Scale (PANSS) total, Brief Psychiatric Rating Scale (BPRS) total, and PANSS General Psychopathology scores at endpoint compared to the risperidone-treated patients." | 2.71 | Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. ( Andersen, S; Catts, S; Crawford, AM; Fraser, A; Grainger, D; Gureje, O; Hustig, H; Keks, N; Lambert, T; McGrath, J; Miles, W; Tran, P, 2003) |
| " At the end of the observation, the mean dosage was 5." | 2.71 | [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis]. ( Degner, D; Pajonk, FG; Peters, S; Rettig, K; Rüther, E; Schreiner, A, 2003) |
| "Weight gain is an important side effect of antipsychotic (AP) treatment." | 2.71 | The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. ( de Castella, AR; Fitzgerald, PB; Kulkarni, J; Morris, MJ; Scaffidi, A, 2003) |
| "The risperidone dose was started at 2 mg/day and gradually increased to 6 mg/day over 6 weeks; the 6-mg/day dose was maintained for the remaining 6 weeks of the study." | 2.71 | Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. ( Bai, YM; Lin, CC; Yu, SC, 2003) |
| " This may provide valuable information for rational dosage titration." | 2.71 | Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone. ( Chang, JW; Chen, PS; Liao, YC; Su, SF; Yang, YK; Yeh, TL, 2004) |
| "Sarcosine treatment can benefit schizophrenic patients treated by antipsychotics including risperidone." | 2.71 | Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. ( Chong, MY; Lane, HY; Lange, N; Tsai, G; Yang, P, 2004) |
| "In the second treatment year, relapse rates under continued neuroleptic treatment are compared with those under stepwise drug withdrawal substituting instead prodrome-based early intervention (intermittent treatment)." | 2.71 | Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. ( Bottlender, R; Buchkremer, G; Gaebel, W; Klingberg, S; Möller, HJ; Ohmann, C; Riesbeck, M; Von Wilmsdorff, M; Wölwer, W, 2004) |
| "Risperidone treatment reduced this deficit, suggesting a facilitation of attentional function, but haloperidol treatment did not." | 2.71 | Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia. ( Harris, MS; Keshavan, MS; Reilly, JL; Sweeney, JA, 2005) |
| "Risperidone treatment, however, was more effective in the reduction of negative symptoms." | 2.71 | The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. ( Cohen, H; Pourcher, E; Rémillard, S, 2005) |
| " Patients were initiated with quetiapine to 400 mg/day over 7 days, and then flexibly dosed (300-750 mg/day) for 11 weeks." | 2.71 | Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. ( Altman, C; de Nayer, A; Jones, AM; Larmo, I; Lindenbauer, B; Platz, T; Rittmannsberger, H; Windhager, E, 2005) |
| "Risperidone was immediately effective against positive and negative symptoms in untreated patients; however, in the previously treated groups, it was initially effective against negative symptoms only; after a 2-week interval, positive symptoms also improved." | 2.71 | Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects. ( Himei, A; Okamura, T, 2005) |
| " Treatment was naturalistic, and dosing was based on the discretion of the treating physician." | 2.71 | Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. ( Cook, A; Kraus, JE; Lieberman, JA; Reviere, R; Sheitman, BB, 2005) |
| "6%) with a higher mean daily dosage in the public care setting." | 2.71 | [Neuroleptic drug utilization among schizophrenic outpatients]. ( Blin, P; Cialdella, P; Gérard, A; Hanssens, L; Olié, JP; Petitjean, F; Sechter, D; Westerloppe, J, 2005) |
| " In this pilot study, 10 Hispanic and 8 non-Hispanic patients with schizophrenia were enrolled in a double-blind, parallel-group, inpatient risperidone dosing (daily versus twice daily) trial with the novel antipsychotic risperidone." | 2.70 | Risperidone in the treatment of Hispanic inpatients with schizophrenia: a pilot study. ( Collazo, Y; Frackiewicz, EJ; Herrera, JM; Lawson, WB; Sramek, JJ, 2002) |
| "Evaluation of relationships between serum antipsychotic drug concentrations and clinical response may provide valuable information for rational dosage adjustments." | 2.70 | Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. ( Ancione, M; Avenoso, A; Facciolà, G; Madia, AG; Perucca, E; Salemi, M; Scordo, MG; Spina, E, 2001) |
| " This study examined the effect of electroconvulsive therapy (ECT) in combination with risperidone in an open trial in 10 male schizophrenic patients with significant aggressive behaviors." | 2.70 | Effectiveness of ECT combined with risperidone against aggression in schizophrenia. ( Ashby, CR; Hirose, S; Mills, MJ, 2001) |
| "Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate." | 2.70 | Guanfacine treatment of cognitive impairment in schizophrenia. ( Adler, DN; Davis, KL; Friedman, JI; Harvey, PD; Kemether, E; Parrella, M; Temporini, HD; White, L, 2001) |
| "Treatment on risperidone also resulted in significant reduction in the PANSS score." | 2.70 | The effect of risperidone on cognitive functioning in a sample of Asian patients with schizophrenia in Singapore. ( Chan, YH; Chong, SA; Chua, L; Ng, VP; Pang, E, 2001) |
| "m." | 2.70 | Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. ( Hatzimanolis, J; Lykouras, L; Markianos, M, 2001) |
| "Risperidone appears to be a more effective and better tolerated antipsychotic drug in treatment-refractory Chinese schizophrenia than haloperidol." | 2.70 | Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| " Doses were adjusted to maximize efficacy and to minimize adverse events." | 2.70 | A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. ( Jibson, MD; Mullen, J; Sweitzer, D, 2001) |
| " Subjective impairment, as assessed with the subscale 'mental functioning', was significantly correlated with greater conventional neuroleptic dosage after controlling for psychopathology (P<0." | 2.70 | Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. ( Krausz, M; Moritz, S; Naber, D; Woodward, TS, 2002) |
| "Treatment with risperidone was associated with improvement in antisaccade errors." | 2.70 | Improved antisaccade performance with risperidone in schizophrenia. ( Burke, JG; Reveley, MA, 2002) |
| "Risperidone treatment significantly increased the serum PRL levels of schizophrenic patients." | 2.70 | Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. ( Shen, YC; Wu, GY; Yuan, CL; Zhang, PY; Zhang, XY; Zhou, DF, 2002) |
| " Gradual dosage titration over the first 3 days of treatment was well-tolerated in both groups." | 2.69 | Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. ( Nair, NP, 1998) |
| "Risperidone treatment produced a greater effect on patients' ability to perceive emotion compared with haloperidol treatment." | 2.69 | Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. ( Green, MF; Kee, KS; Kern, RS; Marshall, BD, 1998) |
| "Risperidone, at lower than recommended doses, shows promise in the treatment of late onset delusional disorders and behavior syndrome of dementia." | 2.69 | Risperidone: treatment response in adult and geriatric patients. ( Ancill, RJ; Gibson, RE; Holliday, SG; Kiraly, SJ, 1998) |
| "Risperidone treatment was associated with a significant functional in-vivo 5-HT antagonism similar to clozapine." | 2.69 | Risperidone is associated with blunting of D-fenfluramine evoked serotonergic responses in schizophrenia. ( Curtis, VA; Jones, H; Lucey, JV; Wright, PA, 1998) |
| "Treatment with risperidone, 6 mg/day, is likely to induce unnecessarily high D2 receptor occupancy, with a consequent risk of extrapyramidal side effects." | 2.69 | Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. ( Eriksson, B; Farde, L; Halldin, C; Nyberg, S; Oxenstierna, G, 1999) |
| "Risperidone-treated subjects with a greater degree of acute mood change were both 3." | 2.69 | The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. ( Andersen, SW; Tollefson, GD; Tran, PV, 1999) |
| "Risperidone (6 to 16 mg)-treated patients showed significantly (p < 0." | 2.68 | Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. ( Chouinard, G, 1995) |
| "Risperidone was compared in 2 double blind studies with haloperidol and perphenazine in schizophrenic psychoses." | 2.68 | [Efficacy and tolerance of risperidone in various doses (report of a study)]. ( Cesková, E; Svestka, J, 1996) |
| "Risperidone is a novel and clinically effective atypical antipsychotic medication with a unique biochemical profile." | 2.68 | Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients. ( Bauer, KS; Haas, GL; Keshavan, MS; Kroboth, PD; Schooler, NR; Sweeney, JA, 1997) |
| "Risperidone treatment had a greater beneficial effect on verbal working memory than haloperidol treatment across testing conditions (with and without distraction) and study phases (fixed and flexible dose)." | 2.68 | Does risperidone improve verbal working memory in treatment-resistant schizophrenia? ( Ames, D; Green, MF; Kern, RS; Marder, SR; Marshall, BD; McGurk, S; Mintz, J; Wirshing, WC, 1997) |
| "Risperidone blood levels were measured every 2 weeks after initiation of therapy in 24 refractory chronic schizophrenic patients referred to a locked, skilled nursing facility for long-term treatment." | 2.68 | Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. ( Clark, L; Dabiri, L; Darby, JK; Elfand, L; Herbert, J; Pasta, DJ, 1997) |
| "Risperidone 6 mg was the lowest dose that produced substantial change in negative symptoms and no increase in extrapyramidal symptoms and antiparkinsonian medication use." | 2.67 | Negative symptoms in schizophrenia: assessment of the effect of risperidone. ( Schooler, NR, 1994) |
| "Risperidone was found to have a curvilinear dose-response curve with an optimum effect of 4 mg day on the negative, anxious/depressive and cognitive factors and with an optimum effect of 8 mg day on the positive and excited factors." | 2.67 | Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. ( Lindström, E; von Knorring, L, 1994) |
| " Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278." | 2.67 | Pharmacokinetics of risperidone in chronic schizophrenic patients. ( Borison, RL; Diamond, B; Meibach, RC; Pathiraja, A, 1994) |
| "Nine haloperidol patients were selected from a separate treatment study that had a similar design and selection criteria and used identical EEG methods." | 2.67 | Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients. ( Czobor, P; Volavka, J, 1993) |
| "Risperidone treatment was statistically superior to placebo, with a trend toward superiority to haloperidol." | 2.67 | Risperidone: clinical safety and efficacy in schizophrenia. ( Borison, RL; Diamond, BI; Meibach, RC; Pathiraja, AP, 1992) |
| "Schizophrenia is a severe psychiatric disorder with variable therapeutic responses, the etiology and pathophysiology of which require further elucidation." | 2.66 | [Pharmacotherapy of schizophrenia]. ( Correll, CU, 2020) |
| "Hypothermia is unpredictable and life-threatening adverse effect of atypical antipsychotic drug (APD) treatment, which has been little described." | 2.61 | The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors. ( Araszkiewicz, AS; Szota, AM, 2019) |
| "Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone." | 2.58 | Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. ( Siegfried, N; Stein, DJ; Temmingh, HS; Williams, T, 2018) |
| "Cariprazine, is an emerging antipsychotic drug, D3/D2 receptor partial agonist, with affinity to several serotonin receptors." | 2.58 | Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia. ( Bieńkowski, P; Misiak, B; Samochowiec, J, 2018) |
| " Thus, antipsychotic dose and dosing interval should be optimized for each patient." | 2.52 | [Optimal Antipsychotic Dose and Dosing Interval in the Treatment of Schizophrenia]. ( Takeuchi, H, 2015) |
| "Schizophrenia is a severe disorder that significantly affects the quality of life and total functioning of patients and their caregivers." | 2.50 | Individualizing clozapine and risperidone treatment for schizophrenia patients. ( Assimakopoulos, K; Bartsakoulia, M; Iconomou, G; Mitropoulos, K; Papadima, EM; Patrinos, GP; Squassina, A; Tsermpini, EE, 2014) |
| "Schizophrenia is a common serious mental health condition which has significant morbidity and financial consequences." | 2.50 | Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. ( Adams, CE; Sinclair, D, 2014) |
| "Schizophrenia is a mental illness causing disordered beliefs, ideas and sensations." | 2.50 | Cannabis and schizophrenia. ( Gillies, D; Kalakouti, E; Kyprianou, K; McLoughlin, BC; Pushpa-Rajah, JA; Rathbone, J; Variend, H, 2014) |
| "Treatment with olanzapine, risperidone and clozapine is often associated with weight gain." | 2.49 | Atypical antipsychotics for psychosis in adolescents. ( Datta, SS; Furtado, VA; Kumar, A; Russell, PS; Wright, SD, 2013) |
| "Schizophrenia is a chronic, severe and recurrent brain disorder that requires continuous, long-term treatment with antipsychotic medication to minimize relapse and provide clinical benefit to patients." | 2.49 | Efficacy and safety of long acting injectable atypical antipsychotics: a review. ( Carano, A; Cavuto, M; De Berardis, D; Di Giannantonio, M; Fornaro, M; Iasevoli, F; Lang, AP; Marini, S; Martinotti, G; Mazza, M; Perna, G; Piersanti, M; Valchera, A, 2013) |
| " Higher doses may provide additional benefit as well as dose-related increases in some adverse reactions." | 2.48 | Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. ( Citrome, L, 2012) |
| "Aripiprazole treatment led to significantly more akathisia incidence in the AD group, compared with the SCZ group." | 2.48 | Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. ( Moteshafi, H; Stip, E, 2012) |
| "RLAI and OP show good short- and long-term safety when treating patients with schizophrenia, with uncommon discontinuation due to adverse effects." | 2.46 | Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. ( Cañas, F; Möller, HJ, 2010) |
| "Risperidone was better for CGI endpoint scores (n=42, 1 RCT, RR 2." | 2.46 | Levomepromazine for schizophrenia. ( Jayaram, MB; Rattehalli, RD; Sivaraman, P, 2010) |
| "Risperidone was specifically evaluated in patients with RS in one of the systematic reviews included, with favorable outcomes, but without definitive superiority compared with other drugs of proven efficacy, like amisulpride, clozapine and olanzapine." | 2.46 | Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. ( Atallah, AN; Melnik, T; Puga, ME; Soares, BG, 2010) |
| "Schizophrenia is a chronic disorder, usually necessitating lifelong treatment." | 2.45 | Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. ( Keith, S, 2009) |
| "Studies in schizophrenia have used different tasks that tap different processes within the working memory." | 2.44 | [Working memory in schizophrenia: a review]. ( Kebir, O; Tabbane, K, 2008) |
| "Ten acute trials in mania, 3 in bipolar depression, and 8 in schizophrenia were identified, along with 2 maintenance studies in bipolar disorder and 2 in schizophrenia." | 2.44 | A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. ( Calabrese, JR; Gajwani, P; Ganocy, SJ; Gao, K; Kemp, DE; Muzina, DJ, 2008) |
| " Paliperidone's advanced-generation osmotic release delivery system allows for the avoidance of dosage adjustment when initiating therapy and may decrease the frequency of antido-paminergic effects that would occur with an immediate-release formulation." | 2.44 | Paliperidone for schizophrenia. ( Deyo, Z; Dolder, C; Nelson, M, 2008) |
| " Combining the attributes of the atypical antipsychotic class with the pharmacokinetic profile and compliance advantages of a long-acting formulation could potentially be an important advance in the management of patients requiring continuous anti- psychotic therapy." | 2.43 | Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. ( Ereshefsky, L; Mannaert, E, 2005) |
| "Risperidone was specifically designed by Paul Janssen as a combined 5-HT2A and D2 receptor antagonist, thus following the pharmacological mechanism thought to be responsible for the antipsychotic effects of clozapine." | 2.43 | Risperidone: a review. ( Möller, HJ, 2005) |
| " It is dosed at 25-50 mg every 2 weeks." | 2.43 | [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia]. ( Faludi, G, 2005) |
| "Relapse is the primary cost driver in schizophrenia and is closely related to levels of adherence (compliance) with therapy." | 2.43 | Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. ( Haycox, A, 2005) |
| "Schizophrenia is a severe and chronic illness as well as one of the most expensive illnesses to treat." | 2.43 | [Pharmacoeconomic review of the use of injectable long-acting risperidone]. ( Bartkó, G; Fehér, L, 2005) |
| " Mean CLZ dosage during the combined treatment was 474." | 2.43 | Risperidone augmentation of clozapine: a critical review. ( Christodoulou, GN; Ferentinos, PP; Havaki-Kontaxaki, BJ; Kontaxakis, VP; Paplos, KG; Pappa, DA, 2006) |
| "Schizophrenia is a severe and devastating psychiatric disorder affecting about 1 percent of the world's population, is characterized by psychotic episodes, negative symptoms and cognitive deficits." | 2.43 | [Maintenance pharmacotherapy of schizophrenia: remission and the effectiveness of long-acting risperidone therapy]. ( Sárosi, A, 2006) |
| "Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years." | 2.42 | Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. ( Buckley, PF; Glazer, W; Sebastian, CS, 2004) |
| " The aim of this paper is to review literature about newer antipsychotics, focusing on their advantages in terms of efficacy and side effect profiles when compared to classical and older atypical antipsychotics, and to evaluate the efficacy of the different new antipsychotics when compared to one another." | 2.42 | New antipsychotics and schizophrenia: a review on efficacy and side effects. ( Berardi, D; De Ronchi, D; Lorenzi, C; Serretti, A, 2004) |
| " Surprisingly, there has been little relationship between the pivotal trials designed for FDA approval and current dosing strategies in broader clinical settings." | 2.41 | New antipsychotic medications: more than old wine and new bottles. ( Schulz, SC, 2000) |
| "Schizophrenia is also associated with aggression directed at self and others." | 2.41 | The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. ( Keck, PE; McElroy, SL; Strakowski, SM, 2000) |
| " Safety was monitored by open adverse event reporting, the Simpson-Angus Scale, the Barnes Akathisia Scale and the Abnormal Involuntary Movement scale." | 2.41 | Safety profile of amisulpride in short- and long-term use. ( Coulouvrat, C; Dondey-Nouvel, L; Rein, W, 2000) |
| "Risperidone is a relatively new antipsychotic available world-wide since the early 1990s." | 2.41 | Focus on risperidone. ( Green, B, 2000) |
| " This series covers four main areas of concern when treating the elderly: low-maintenance dosing minimising the likelihood of adverse events; successful treatment of patients previously uncontrolled and experiencing side effects with other antipsychotics; the possibility of intermittent rather than continuous treatment; and the benefits to patients, carers and the health services." | 2.41 | Risperidone in the treatment of psychoses in the elderly: a case report series. ( Bullock, R; Libretto, S, 2002) |
| "Risperidone may be an alternative for treatment-resistant schizophrenia, but this has not yet been clearly proved." | 2.40 | New antipsychotic medications: what advantages do they offer? ( Citrome, L, 1997) |
| "The advantages of newer agents in treatment-resistant schizophrenia may arise in part from their preferential targeting of newer agents in treatment-resistant schizophrenia may arise in part from their preferential targeting of mesolimbic compared with motor and tuberoinfundibular dopaminergic pathways." | 2.40 | Treatment of the refractory schizophrenic patient. ( Daniel, DG; Whitcomb, SR, 1998) |
| "For comprehensive treatment of schizophrenia, the author advocates a polydimensional approach encompassing psychopharmacology, psychotherapy, psychosocial interventions (particularly with family members), and vocational training." | 2.40 | Effects of antipsychotics on the clinical and psychosocial behavior of patients with schizophrenia. ( Ballús, C, 1997) |
| " Proper dosing has emerged as a vital factor in the effective use of these newer drugs." | 2.40 | Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. ( Kasper, S, 1998) |
| " Dosing requirements for elderly patients tend to be much lower than those for younger adults." | 2.40 | Conventional vs. newer antipsychotics in elderly patients. ( Harris, MJ; Jeste, DV; Lacro, J; Lohr, JB; Rockwell, E, 1999) |
| "Olanzapine is a novel antipsychotic agent displaying a unique and pleotrophic pharmacology, which distinguishes it from other existing treatments." | 2.40 | Review of recent clinical studies with olanzapine. ( Kuntz, AJ; Tollefson, GD, 1999) |
| "The pharmacologic treatment of schizophrenia remains a critical component in the short- and long-term management of this disease." | 2.40 | Pharmacologic treatment of schizophrenia. ( Kane, JM, 1999) |
| "Risperidone has these pharmacologic properties." | 2.39 | Extrapyramidal side effects and tolerability of risperidone: a review. ( Owens, DG, 1994) |
| " At a dosage of 4 to 8 mg/day, risperidone is comparable to 10 mg/day of haloperidol." | 2.39 | A risk-benefit assessment of risperidone in schizophrenia. ( Curtis, VA; Kerwin, RW, 1995) |
| "Mood disorders in schizophrenia are common and are associated with a poor outcome, an increased risk of relapse and a high rate of suicide." | 2.39 | Long-term treatment of mood disorders in schizophrenia. ( Azorin, JM, 1995) |
| "When the concepts of dementia praecox and schizophrenia were introduced by Kraepelin and Bleuler, emphasis was laid on the negative symptoms, regarded as fundamental." | 2.39 | Principal components and further possibilities with the PANSS. ( Lindström, E; von Knorring, L, 1995) |
| "Risperidone is an effective antipsychotic with a good safety profile." | 2.39 | Antipsychotic medication in the treatment of schizophrenia. ( Kane, JM, 1995) |
| " Antipsychotic use in the elderly should be accompanied by careful conservative dosing and close patient monitoring." | 2.39 | Management of late-life psychosis. ( Eastham, JH; Field, MG; Gierz, M; Harris, MJ; Jeste, DV; Lacro, JP, 1996) |
| "Once schizophrenia is diagnosed, the classification of schizophrenic symptoms as psychotic, disorganized, or negative can help clinicians predict treatment outcomes and individualize both pharmacologic and psychosocial treatment." | 2.39 | Management of schizophrenia. ( Marder, SR, 1996) |
| " The current clinical pharmacokinetic database for these atypical antipsychotics suggests that much can be learned with additional study that would be of value in individualizing their dosage regimens." | 2.39 | Pharmacokinetics of clozapine and risperidone: a review of recent literature. ( Byerly, MJ; DeVane, CL, 1996) |
| " Therapeutic gains can be accomplished with minimal dosing strategies, targeted drug therapy for medication-refusing patients, psychosocial interventions, and new drugs." | 2.39 | Maintenance therapy of persons with schizophrenia. ( Carpenter, WT, 1996) |
| "Despite the fact that psychiatric illness in the pre-adult era is not rare, few controlled clinical trials have examined the short-term safety and efficacy of these agents in youths with psychosis." | 2.39 | Antipsychotic medications in children and adolescents. ( Findling, RL; Grcevich, SJ; Lopez, I; Schulz, SC, 1996) |
| "Risperidone has not yet been extensively studied in treatment-resistant patients, but may also be a useful alternative." | 2.39 | Treatment-resistant schizophrenic patients. ( Kane, JM, 1996) |
| "Risperidone has a relatively mild side effect profile when compared with conventional antipsychotics." | 2.39 | Clinical experience with risperidone. ( Marder, SR, 1996) |
| " They suggest that as atypical antipsychotics like olanzapine are more widely used, some problems associated with the long-term use of conventional antipsychotics will diminish, but other issues and concerns will be more common." | 2.39 | Atypical antipsychotic drugs and long-term outcome in schizophrenia. ( Aquila, R; Standard, J; Weiden, P, 1996) |
| " Considerable progress has been made in improving the motor side effect profile with the advent of clozapine and risperidone." | 2.39 | Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996) |
| " Side-effects can be minimized by optimization of clinical strategies, including choice of appropriate drug, slow titration and dosage reduction." | 2.39 | Minimizing the non-extrapyramidal side-effects of antipsychotics. ( Keks, NA, 1996) |
| "Risperidone is a recently approved atypical antipsychotic that offers the advantages over existing typical antipsychotics of improved efficacy against negative symptoms and a decreased incidence of extrapyramidal side effects." | 2.39 | Development and implementation of drug use evaluation (DUE) criteria for risperidone in an outpatient psychiatric setting. ( Gross, LS; Gutierrez, MA; Shepski, JC; Wincor, MZ, 1996) |
| " The proportion of patients failing to reach at least 20% improvement on the positive and negative syndrome scale (PANSS) or brief psychiatric rating scale (BPRS), the proportion of patients discontinuing treatment because of adverse effects and the number of patients who needed antiparkinsonian medication were abstracted for use as outcome measures." | 2.39 | Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. ( Bacaltchuk, J; de Castro-e-Silva, E; de Oliveira, IR; de Sena, EP; Miranda-Scippa, AM; Pereira, EL; Ribeiro, MG, 1996) |
| "A number of new agents to treat schizophrenia have been, or will soon be, introduced that address the limitations of traditional neuroleptics." | 2.38 | New antipsychotic medications: do research results relate to clinical practice? ( MacEwan, GW, 1993) |
| " This article discusses the relevant clinical considerations in switching neuroleptics and proposes practical guidelines on issues such as dosing and course of therapy with risperidone." | 2.38 | Clinical considerations in the use of risperidone. ( Remington, GJ, 1993) |
| "Aripiprazole has a high affinity for the D2 receptor, but may have a lesser reduction of psychotic symptoms compared to other antipsychotics." | 1.91 | Aripiprazole: examining the clinical implications of D2 affinity. ( Anam, A; Gekhman, D; Lynch, S; Mosharraf, N; Soukas, C, 2023) |
| "Schizophrenia is a life disabling, multisystem neuropsychiatric disease mostly derived from complex epigenetic-mediated neurobiological changes causing behavioural deficits." | 1.91 | Reversal and Preventive Pleiotropic Mechanisms Involved in the Antipsychotic-Like Effect of Taurine, an Essential β-Amino Acid in Ketamine-Induced Experimental Schizophrenia in Mice. ( Agu, GO; Ajayi, AM; Akaenyi, DE; Ben-Azu, B; Chijioke, BS; Chilaka, KC; Edigbue, NL; Esiekpe, UV; Jarikre, TA; Nwangwa, KE; Ofili, EC; Omonyeme, MG; Ozege, CB; Uruaka, CI; Warekoromor, EB, 2023) |
| "The most common way to treat schizophrenia is antipsychotic medication." | 1.91 | Risperidone response in patients with schizophrenia drives DNA methylation changes in immune and neuronal systems. ( Alladi, CG; Bacq-Daian, D; Bélivier, F; Boland-Auge, A; Deleuze, JF; Jamain, S; Latapie, V; Lokmer, A; Marie-Claire, C; RajKumar, RP; Shewade, DG; Troudet, R, 2023) |
| " In the two studies, estimated increased risks of breast cancer were disconcertingly high (up to 62%), but a third recent study found only a weak dose-response association." | 1.91 | Association between long-term use of prolactin-elevating antipsychotics in women and the risk of breast cancer: What are the clinical implications? ( Copolov, DL; Hope, JD; Keks, NA, 2023) |
| "Schizophrenia is a psychiatric disorder that presents with hallucinations, delusions, thought disorders, and cognitive dysfunctions." | 1.91 | [Antipsychotics]. ( Hashimoto, R; Yamada, H, 2023) |
| " However, the effects of the low frequency of rTMS combined with antipsychotics on the gut microbiome in chronic SCH have been poorly investigated." | 1.91 | Effects of low-frequency rTMS combined with risperidone on the gut microbiome in hospitalized patients with chronic schizophrenia. ( Bai, J; Chen, YH; Cui, ZQ; Fu, R; Guo, L; Li, R; Peng, ZW; Tan, QR; Yang, JB, 2023) |
| "Schizophrenia is a disorder characterized by cognitive impairment and psychotic symptoms that fluctuate over time and can only be mitigated with the chronic administration of antipsychotics." | 1.72 | Long-lasting rescue of schizophrenia-relevant cognitive impairments via risperidone-loaded microPlates. ( Bellotti, E; Contarini, G; Decuzzi, P; Drago, F; Geraci, F; Leggio, GM; Papaleo, F; Piazza, C; Torrisi, SA, 2022) |
| "Among the 15 most widely used antipsychotics, 13 had a U- or J-shaped dose-response curve, showing the lowest risks of relapse for doses of 0." | 1.72 | Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. ( Correll, CU; Leucht, S; Luykx, JJ; Solmi, M; Taipale, H; Tanskanen, A; Tiihonen, J, 2022) |
| "Antipsychotics remain the main treatment for schizophrenia, but their effectiveness is challenging to compare." | 1.72 | Comparative Effectiveness of Antipsychotics in Preventing Readmission for First-Admission Schizophrenia Patients in National Cohorts From 2001 to 2017 in Taiwan. ( Chan, HY; Chen, WJ; Kuo, PH; Lin, YH; Liu, CC; Wu, CS, 2022) |
| "Retrospective studies using spontaneous reporting system databases have provided a great understanding of adverse drug reactions (ADRs) in the real world, complementing the data obtained from randomized controlled trials." | 1.72 | Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. ( Byeon, SJ; Chung, SJ; Oh, S, 2022) |
| "Schizophrenia is analysed as one of the diseases with the highest rate of Disability-Adjusted Life Years - DALY." | 1.72 | Practice of prescribing antipsychotics in schizophrenia during 2013-2018 based on data from the National Health Fund. ( Anczewska, M; Balicki, M; Droździkowska, A; Gorczyca, P; Janus, J; Paciorek, S; Plisko, R; Zięba, M, 2022) |
| "Schizophrenia is a severe neuropsychiatric disease associated with substantially higher mortality." | 1.62 | Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue. ( Bienertova-Vasku, J; Horska, K; Hruska, P; Kucera, J; Kuruczova, D; Micale, V; Ruda-Kucerova, J, 2021) |
| "Rhabdomyolysis is defined by disintegration of skeletal muscle fibres." | 1.62 | [Rhabdomyolysis induced by paliperidone palmitate]. ( Klein, B; Silberbauer, C, 2021) |
| " Additional prospective studies with accurate dosage information are needed to validate our findings." | 1.62 | Occurrence of metabolic diseases associated with antipsychotic use among Korean patients with schizophrenia. ( Kim, BH; Kim, E; Kim, S; Kuk, S; Lee, W; Park, SI, 2021) |
| "To investigate the relationship between -759C/T, functional polymorphism of the HTR2C gene and metabolic adverse effects in Thai psychiatric patients treated with risperidone monotherapy." | 1.62 | Effect of 5-HT2C receptor gene polymorphism (HTR2C-759C/T) on metabolic adverse effects in Thai psychiatric patients treated with risperidone. ( Hongkaew, Y; Jiratjintana, N; Na Nakorn, C; Puangpetch, A; Sukasem, C; Unaharassamee, W; Vanwong, N, 2021) |
| "Schizophrenia is a severe psychiatric disease while its etiology and effective treatment are not completely clear." | 1.62 | Regional brain network and behavioral alterations in EGR3 gene transfected rat model of schizophrenia. ( Chen, Y; Cui, A; Gao, W; Han, X; Li, G; Liu, X; Ma, G; Ma, H; Song, Z; Sun, F; Tang, X; Wang, Y; Zhang, L; Zhao, S, 2021) |
| "Duration of untreated psychosis (DUP) is one of the few potentially modifiable outcome predictors in psychosis." | 1.56 | Impact of duration of untreated psychosis in short-term response to treatment and outcome in antipsychotic naïve first-episode psychosis. ( Belangeiro, SI; Bressan, RA; Cavalcante, DA; Cordeiro, Q; Coutinho, LS; Gadelha, A; Noto, C; Noto, MN; Ortiz, BB; Ota, VK, 2020) |
| "Hyperprolactinemia was found in 120 (70." | 1.56 | Prolactin response to antipsychotics: An inpatient study. ( Bredicean, CA; Dehelean, L; Dumitrascu, V; Papava, I; Romosan, AM; Romosan, RS; Ursoniu, S, 2020) |
| " We showed that chronic administration of risperidone did not affect the DNA methylation status at this CpG site using common marmosets, and that in vitro DNA methylation at this CpG site diminished the promoter activity of SLC6A4." | 1.56 | Promoter Activity-Based Case-Control Association Study on SLC6A4 Highlighting Hypermethylation and Altered Amygdala Volume in Male Patients With Schizophrenia. ( Abe, O; Asai, T; Bundo, M; Fukunaga, M; Hashimoto, R; Ikeda, M; Ikegame, T; Ishigooka, J; Iwamoto, K; Iwashiro, N; Iwata, N; Kakiuchi, C; Kasai, K; Kato, T; Kawamura, Y; Koike, S; Koshiyama, D; Murata, Y; Natsubori, T; Nishimura, F; Okada, N; Owada, K; Saito, T; Sasaki, T; Sugawara, H; Yamashita, F; Yamasue, H; Yoshikawa, A, 2020) |
| "The pharmacological treatment of schizophrenia is often performed with the simultaneous use of two or more antipsychotic agents to achieve the desired control of psychotic symptoms Available AP include both conventional (typical) and new (atypical) antipsychotic medications." | 1.56 | Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis. ( Claro, A; Corte-Real, F; Franco, J; Monteiro, C; Mustra, C; Proença, P, 2020) |
| " The duration of each adequate antipsychotic treatment at an optimal dosage was 4 weeks or more." | 1.51 | Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study. ( Sakamoto, S; Sato, K; Takaki, M; Yamada, N; Yoshimura, B, 2019) |
| "In the antipsychotic treatment of schizophrenia with little medication history, especially in drug-naïve cases, predictors of side effects are important." | 1.51 | Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. ( Sakamoto, S; Sato, K; So, R; Tsukahara, M; Yoshimura, B; Yoshimura, Y, 2019) |
| "The aim of the study is to find a relationship between the individual intervariability of CYP2D6 and the incidence of hyperprolactinemia as side effect of atypical antipsychotics." | 1.51 | Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients. ( Andreescu, N; Grădinaru, R; Nussbaum, L; Puiu, M; Suciu, L, 2019) |
| " The current report presents adverse events in an infant exposed to a combination of risperidone and haloperidol through breast milk." | 1.51 | Adverse Events in a Breastfed Infant Exposed to Risperidone and Haloperidol. ( Uguz, F, 2019) |
| "Olanzapine (6 mg/kg) treatment significantly altered glucose and lipid homeostasis which was further accompanied by elevated levels of proinflammatory cytokines, ghrelin and leptin." | 1.51 | Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor. ( Bansal, Y; Kuhad, A; Medhi, B; Saroj, P; Singh, R; Sodhi, RK, 2019) |
| "We assessed the dosage strengths of paliperidone palmitate 1-month (PP1M) long-acting injectable resulting in similar steady-state (SS) exposures to the dosage strengths of oral risperidone using pharmacokinetic (PK) simulations." | 1.48 | Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations. ( Gopal, S; Kern Sliwa, J; Kim, E; Mathews, M; Ravenstijn, P; Russu, A; Singh, A, 2018) |
| "Patients with schizophrenia have an increased prevalence of metabolic disturbances compared with the general population." | 1.48 | High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey. ( Matsuda, H; Mori, T; Okamoto, K; Ono, S; Ozeki, Y; Sagae, T; Shimoda, K; Someya, T; Sugai, T; Sugawara, N; Suzuki, Y; Yamazaki, M; Yasui-Furukori, N, 2018) |
| "Second-generation long-acting injectable therapies (SGA-LAIs) may reduce health care resource utilization (HRU) and health care costs compared with daily oral atypical antipsychotics (OAAs) in patients with schizophrenia due to reduced dosing frequency, delivery/monitoring by a health care provider, and improved adherence." | 1.46 | Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. ( Emond, B; Joshi, K; Kamstra, R; Lafeuille, MH; Lefebvre, P; Pilon, D; Tandon, N, 2017) |
| " Daily dosage of risperidone did not differ between responders and non-responders." | 1.46 | Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns. ( Gründer, G; Haen, E; Hiemke, C; Paulzen, M; Schoretsanitis, G; Stegmann, B; Unterecker, S, 2017) |
| "Population pharmacokinetics can predict antipsychotic blood concentrations at a given time point prior to a dosage change." | 1.43 | Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. ( Bies, RR; Caravaggio, F; Gerretsen, P; Graff-Guerrero, A; Mamo, DC; Mar, W; Mulsant, BH; Nakajima, S; Plitman, E; Pollock, BG; Suzuki, T; Uchida, H, 2016) |
| "Schizophrenia is a widespread mental disease with a prevalence of about 1% in the world population." | 1.43 | Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population. ( He, L; Huang, H; Li, M; Minica, C; Qin, S; Shen, L; Shi, Y; Wang, G; Wu, X; Xing, Q; Xu, Q; Yi, Z, 2016) |
| "Schizophrenia is associated with behavioral and brain structural abnormalities, of which the hippocampus appears to be one of the most consistent region affected." | 1.43 | Maturation- and sex-sensitive depression of hippocampal excitatory transmission in a rat schizophrenia model. ( Attali, B; Patrich, E; Peretz, A; Piontkewitz, Y; Weiner, I, 2016) |
| "Cariprazine is a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, recently approved by the FDA for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder." | 1.43 | Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. ( Adham, N; Ferguson, P; Grayson, B; Gyertyán, I; Kiss, B; Neill, JC, 2016) |
| "Risperidone monotherapy was the primary antipsychotic treatment." | 1.43 | Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes. ( Badner, JA; Bishop, JR; Harris, MS; Keshavan, MS; Nimgaonkar, VL; Patel, SR; Prasad, KM; Reilly, JL; Stevenson, JM; Sweeney, JA; Weiden, PJ, 2016) |
| " Generally, the antipsychotics significantly enhanced NRG1/ErbB signaling with increased expression of NRG1 and phosphorylation of ErbB4 and ErbB2 in the brain and myocardium, except that clozapine partly blocked the cardiac NRG1/ErbB2 activation, which could be associated with its more severe cardiac adverse actions." | 1.43 | Effects of prolonged antipsychotic administration on neuregulin-1/ErbB signaling in rat prefrontal cortex and myocardium: implications for the therapeutic action and cardiac adverse effect. ( Cai, H; Dang, R; Guo, Y; Jiang, P; Liang, D; Lv, C; Yang, R, 2016) |
| "Risperidone is a second-generation antipsychotic agent commonly used in the treatment of ~ 31." | 1.43 | Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling of risperidone and its active metabolite in Chinese schizophrenia patients. ( Deng, C; Ji, S; Li, A; Li, L; Li, X; Lu, W; Shang, D; Wang, C; Wu, K; Zhou, T, 2016) |
| "Treating schizophrenia is costly for health systems." | 1.43 | Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. ( Bereza, BG; Einarson, TR; Goswami, P; Maia-Lopes, S; Van Impe, K, 2016) |
| "Treatment with risperidone normalized topological parameters in the limbic system, and the enhancement positively correlated with the reduction in PANSS-positive symptoms." | 1.43 | Risperidone-induced topological alterations of anatomical brain network in first-episode drug-naive schizophrenia patients: a longitudinal diffusion tensor imaging study. ( Chen, H; Chen, X; He, Y; Hu, M; Li, Y; Li, Z; Liao, Y; Lv, L; Mann, JJ; Pantazatos, SP; Sang, D; Tang, J; Zhao, H; Zheng, J; Zhou, J; Zong, X, 2016) |
| "He was diagnosed with Meige syndrome." | 1.43 | Marked Improvement of Meige Syndrome in a Japanese Male Patient with Schizophrenia After Switching from Risperidone to Paliperidone: A Case Report. ( Atake, K; Hori, H; Katsuki, A; Yoshimura, R, 2016) |
| " The mean serum PRL was higher in females in the pubertal/postpubertal stage and for risperidone dosage up 1 mg/day." | 1.42 | Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents. ( Lamanna, AL; Margari, F; Margari, L; Matera, E; Palmieri, VO; Pastore, A; Petruzzelli, MG; Simone, M, 2015) |
| "Data for 60,162 subjects with type 1 diabetes up to the age of 25 years registered in the nationwide German/Austrian Diabetes Survey were included in the analysis." | 1.42 | Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV). ( Bartus, B; Bollow, E; Galler, A; Haberland, H; Holl, RW; Meusers, M; Näke, A; Schober, E, 2015) |
| "Risperidone treatment significantly increased PON1 activity and decreased LOOH levels." | 1.42 | Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone. ( Barbosa, DS; Belangero, SI; Bonifácio, KL; Bressan, RA; Brietzke, E; Cordeiro, Q; Gadelha, A; Maes, M; Noto, C; Noto, MN; Nunes, SO; Ota, VK, 2015) |
| "Authors identified different types of eating disorders: external, restrictive and emotiogenic as well as the relationship of their prevalence and severity with sex, drug, presence and grade of obesity." | 1.42 | [Eating disorders in psychiatric patients during treatment with second generation antipsychotics]. ( Bulanov, VS; Gorobets, LN; Ivanova, GP; Litvinov, AV; Polyakovskaya, TP; Tsarenko, MA; Vasilenko, LM, 2015) |
| " One-third of children and adolescents had abnormal serum triglycerides and cholesterol; however, a dose-response was not demonstrated." | 1.40 | Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. ( Amminger, GP; Becker, J; O'Donoghue, B; Papageorgiou, K; Schäfer, MR, 2014) |
| "Schizophrenia has been associated with central nervous system and peripheral immune system imbalances." | 1.40 | Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. ( Bahn, S; de Witte, L; Guest, PC; Kahn, RS; Rahmoune, H; Schwarz, E; Tomasik, J, 2014) |
| "Risperidone (RIS) is a frequently used efficacious psychotropic drug." | 1.40 | Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia. ( Fukui, N; Inoue, Y; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J, 2014) |
| " The five-dimension EuroQoL (EQ-5D) was used to evaluate QoL, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson-Angus Scale." | 1.40 | Quality of life in patients with schizophrenia: the impact of socio-economic factors and adverse effects of atypical antipsychotics drugs. ( Chaves, KM; de Araújo Dantas, D; de Araújo, AA; de Araújo, RF; de Lima Silva, V; de Medeiros, CA; de Souza, DL; do Nascimento, GG; Ribeiro, SB, 2014) |
| "Schizophrenia is a disorder of the executive function of both sensory and central nervous system." | 1.40 | Serum TNF-α, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine. ( Abedian, F; Ajami, A; Akbarian, E; Alizadeh-Navaei, R; Hamzeh Hosseini, S; Taghipour, M, 2014) |
| "The main goal in the treatment of psychotic disorders is to obtain a functional remission and to reduce the incidence of relapse." | 1.39 | [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists]. ( Bouju, S; Chiariny, JF; Comet, D; Delgado, A; Misdrahi, D, 2013) |
| "Schizophrenia is one of the most expensive psychiatric illnesses." | 1.39 | Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations. ( Chow, DP; Chung, WS; Lee, EH; Lee, KK; Lee, VW; Wong, MC; Wu, DB, 2013) |
| " Thus, the aim of this study was to investigate the putative association of genetic markers with the occurrence of four frequently observed adverse events secondary to risperidone treatment: sleepiness, weight gain, extrapyramidal symptoms and sexual adverse events." | 1.39 | Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. ( Abad-Santos, F; Almoguera, B; Ayuso, C; Baca-García, E; Dal-Ré, R; Dorado, P; Fernandez-Piqueras, J; Llerena, A; Lopez-Castroman, J; Riveiro-Alvarez, R; Vaquero-Lorenzo, C, 2013) |
| "In addition, patients with treatment-resistant schizophrenia were on polypharmacy at higher rate than non resistant patients." | 1.39 | The role of ethnicity in treatment refractory schizophrenia. ( Borlido, C; De Luca, V; Kennedy, JL; Teo, C, 2013) |
| "Veterans with schizophrenia or schizoaffective disorder who were actually more satisfied with their current medications and who were currently taking the experimental agent were more likely to agree to participate in this randomized clinical trial in contrast to expectations that individuals who are unsatisfied with their current treatment would be more likely to enroll in such studies." | 1.39 | Veteran subjects willingness to participate in schizophrenia clinical trials. ( Hoblyn, JC; Leatherman, S; Lew, R; Rosenheck, RA; Weil, L, 2013) |
| "A shorter duration of untreated psychosis has been associated with better prognosis in schizophrenia." | 1.39 | Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. ( Higuchi, Y; Kawasaki, Y; Miyanishi, T; Seo, T; Sumiyoshi, T; Suzuki, M, 2013) |
| " We find that, despite not knowing patients' metabolic status, clinicians modify risperidone dosage in order to obtain the best therapeutic option." | 1.38 | Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. ( Alvarez, S; Bernardo, M; Gassò, P; Lafuente, A; Mas, S; Parellada, E, 2012) |
| "Risperidone (n=63) treated patients had higher AUDIT scores and prolactin levels than those on other atypical antipsychotics (n = 113)." | 1.38 | Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia. ( Barnes, M; Connor, JP; Heslop, K; Lawford, BR; Nyst, P; Young, RM, 2012) |
| " In the current study, the effect of clozapine (n = 27, mean dosage 350 mg), risperidone (n = 54, mean dosage 3." | 1.38 | Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. ( Beduin, AS; Bruggeman, R; Cahn, W; de Haan, L; Dekker, N; Kahn, RS; Krabbendam, L; Linszen, DH; Machielsen, M; Myin-Germeys, I; van Os, J; Wiersma, D, 2012) |
| "A probable anaphylactoid reaction to the injectable formulation of the atypical antipsychotic paliperidone in a patient with established tolerability to oral risperidone is reported." | 1.38 | Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone. ( DiCrescento, S; Perry, R; Wolberg, J, 2012) |
| "Schizophrenia is a chronic and highly complex psychiatric disorder characterised by cognitive dysfunctions, negative and positive symptoms." | 1.38 | Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. ( Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA, 2012) |
| "Steady-state plasma RIS, 9-OH-RIS, and active moiety levels were measured in 64 patients treated with an average dosage of 4." | 1.38 | Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients. ( Fukui, N; Inoue, Y; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J, 2012) |
| "Schizophrenia is an extremely costly disease for families and society owing to the age of onset, chronicity and severity of impact in social, academic and vocational domains." | 1.38 | The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. ( Chue, J; Chue, P, 2012) |
| " Chronic administration of RPD or HPD had no significant effect on (13)C-PBT indices in rats." | 1.38 | 13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients. ( Chiba, S; Hattori, K; Higuchi, T; Hori, H; Iijima, Y; Kajiwara, M; Kawamoto, Y; Kinoshita, Y; Kunugi, H; Matsuo, J; Ota, M; Ozeki, Y; Sasayama, D; Tanaka, H; Terada, S; Teraishi, T; Yamamoto, N, 2012) |
| "Clinical relevance of dental caries is often underestimated in patients with schizophrenia." | 1.38 | Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey. ( Den, R; Hirano, J; Kikuchi, T; Kitahata, R; Mimura, M; Nakajima, S; Nio, S; Nishimoto, M; Shibuya, Y; Shimanuki, H; Suzuki, T; Takeuchi, H; Tani, H; Tsuboi, T; Tsunoda, K; Uchida, H; Watanabe, K, 2012) |
| "Schizophrenia is a disorder of a neurodevelopmental origin manifested symptomatically after puberty." | 1.37 | Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. ( Arad, M; Piontkewitz, Y; Weiner, I, 2011) |
| " In contrast, chronic administration of ketamine not only produced significant 'hyperactivity' response but also enhanced the immobility period in animals during the forced swim test and reduced the latency period in the passive avoidance test." | 1.37 | Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis. ( Chatterjee, M; Ganguly, S; Palit, G; Srivastava, M, 2011) |
| "Risperidone LAT was typically used with recommended age and diagnostic groups." | 1.37 | Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population. ( Becker, MA; Boaz, TL; Constantine, RJ; Howe, AM; Robst, J, 2011) |
| "Risperidone treatment induced a decrement of plasma DA levels and increments of plasma DOPAC and DA TR in the total group of schizophrenic patients." | 1.37 | Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment. ( Cai, HL; Fang, PF; Hu, L; Li, HD; Yang, W; Ye, HS; Zhang, XH, 2011) |
| " The dosage range of paliperidone ER (6-12 mg/day) was compared with 2 risperidone dosage ranges: 2-4 and 4-6 mg/day." | 1.37 | Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. ( Bossie, CA; Canuso, CM; Lindenmayer, JP; Schooler, N; Turkoz, I, 2011) |
| "Constipation is thought to be common, and a potential serious side-effect, which has received little attention in recent literature." | 1.37 | Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study. ( Bernagie, C; De Hert, M; Dockx, L; Leucht, S; Peuskens, B; Peuskens, J; Sweers, K; Tack, J; Van de Straete, S; Wampers, M, 2011) |
| "Schizophrenia has been postulated to involve impaired neuronal cooperation in large-scale neural networks, including cortico-cortical circuitry." | 1.37 | Frontal areas contribute to reduced global coordination of resting-state gamma activities in drug-naïve patients with schizophrenia. ( Dierks, T; Hashimoto, T; Hirosawa, T; Kikuchi, M; Koenig, T; Minabe, Y; Nagasawa, T; Strik, W; Yoshimura, M, 2011) |
| " In the patient with laryngeal dystonia these symptoms appeared after restarting risperidone treatment, in the other patient after diminishing the dosage of risperidone and adding sertindole, and in the third patient the syndrome appeared after beginning ziprasidone." | 1.37 | Pisa syndrome and laryngeal dystonia induced by novel antipsychotics. ( Lerner, V; Miodownik, C; Witztum, E, 2011) |
| "Risperidone is a widely used atypical antipsychotic agent that produces considerable interindividual differences in patient response." | 1.36 | Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. ( Feng, G; Gao, R; He, L; Li, S; Lin, Z; St Clair, D; Xing, Q; Xu, M, 2010) |
| " Plasma samples were collected before the medications were given and 12h after the bedtime dosing each week." | 1.36 | Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. ( Furukori, H; Kaneko, S; Nakagami, T; Saito, M; Sato, Y; Sugawara, N; Tsuchimine, S; Yasui-Furukori, N, 2010) |
| " Safety was evaluated by recording treatment-emergent adverse events (AE)." | 1.36 | Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. ( Don, L; Kouniakis, F; Parellada, E; Schreiner, A; Siurkute, A, 2010) |
| " Prolactin concentrations before dosing during risperidone treatment were significantly higher than during treatment with olanzapine and perospirone in females." | 1.36 | Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients. ( Fujii, A; Furukori, H; Inoue, Y; Kaneko, S; Sugawara, N; Tsuchimine, S; Yasui-Furukori, N, 2010) |
| "Risperidone release was assessed in vitro and in vivo in rats, and Level A, B and C correlations (IVIVCs) attempted for all." | 1.36 | In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. ( Amann, LC; Gandal, MJ; Liang, Y; Lin, R; Siegel, SJ, 2010) |
| " A population pharmacokinetic modeling approach was used to estimate the interindividual variability of the pharmacokinetic parameters in 50 hospitalized patients with acute episode of schizophrenia." | 1.36 | A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. ( Dolzan, V; Grabnar, I; Kastelic, M; Koprivsek, J; Kores-Plesnicar, B; Locatelli, I; Mrhar, A, 2010) |
| " Pharmacokinetic study showed that PDs were quickly metabolized to paliperidone to take effect in the treatment of schizophrenia in rats after i." | 1.36 | Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats. ( Li, Y; Meng, Q; Su, Z; Sui, C; Sun, F; Teng, L; Yuan, L; Zhang, C, 2010) |
| "Schizophrenia affects approximately 1% of the population and is associated with a considerable economic burden to society." | 1.36 | Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. ( Carswell, C; Robinson, E; Vanderpyl, J; Wheeler, A, 2010) |
| " After the OGTT, the medication was switched to another by decreasing the previous dosage gradually over 2 to 8 months after the initiation of the second medicine." | 1.36 | A crossover study on the glucose metabolism between treatment with olanzapine and risperidone in schizophrenic patients. ( Furukori, H; Kaneko, S; Nakagami, T; Saito, M; Sato, Y; Yasui-Furukori, N, 2010) |
| "Type 2 diabetes is a major health problem in individuals with schizophrenia." | 1.35 | Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia. ( Dickerson, F; Leister, F; Origoni, A; Rubalcaba, E; Stallings, C; Sullens, A; Viscidi, R; Yang, S; Yolken, R, 2008) |
| " These long-term effects would not be captured by a standard 5-day pharmacokinetic TDM developmental testing model for antipsychotics, and a new model for characterizing variation in C/D by time course is therefore proposed." | 1.35 | Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study. ( Darby, JK; Herbert, J; Pasta, DJ; Wilson, MG, 2008) |
| " Long-term use of AADs in lean, drug-naive, schizophrenics initially free of MetS induced weight gain and truncal fat accumulation associated with decreases in adiponectin and hyperbolic product, explaining the increased fasting glycaemia and impaired fasting glucose seen in predisposed individuals." | 1.35 | Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. ( Ayache, L; Buysschaert, M; Fagnart, O; Feys, JL; Gruson, D; Hermans, MP; Jamart, J; Luts, A; Mertens de Wilmars, S; Misson, A; Oriot, P, 2008) |
| "To characterize pharmacokinetic (PK) variability of risperidone and 9-OH risperidone using sparse sampling and to evaluate the effect of covariates on PK parameters." | 1.35 | Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ( Aravagiri, M; Bies, RR; Coley, K; Feng, Y; Kirshner, M; Marder, S; Miller, D; Pollock, BG; Schneider, L, 2008) |
| " Deficits were unrelated to drug dosage and clinical ratings." | 1.35 | Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia. ( Harris, MS; Keshavan, MS; Lencer, R; Reilly, JL; Sprenger, A; Sweeney, JA, 2008) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 1.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| "Risperidone-treated participants exhibited lower movement velocities during production of simple loops compared to unmedicated patients." | 1.35 | Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. ( Caligiuri, MP; Dean, CE; Lohr, J; Niculescu, AB; Teulings, HL, 2009) |
| "Risperidone is proven to be an efficient product." | 1.35 | [Complex therapy of schizophrenia]. ( Gaszner, P, 2009) |
| "Treatment with risperidone for 4 weeks did not increase daily cigarette consumption or plasma levels of cotinine and caffeine." | 1.35 | Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study. ( Hori, H; Kakihara, S; Nakamura, J; Sugita, A; Ueda, N; Umene-Nakano, W; Yoshimura, R, 2008) |
| "Guidelines for treating schizophrenia have consistently recommended antipsychotic monotherapy." | 1.35 | Combined low-dose clozapine with low-dose aripiprazole in a schizophrenic patient. ( Chen, YY; Hung, GC, 2009) |
| "Weight gain is a risk factor for hypertension, diabetes, ischemic heart disease, respiratory illnesses, various forms of cancer, and the metabolic syndrome." | 1.35 | Weight gain due to long term antipsychotic treatment of persistent mental disorders. ( Melamed, Y; Tadger, S, 2008) |
| "Treatment with risperidone for 8 weeks, but not 2 or 4 weeks, significantly improved working memory performance." | 1.34 | Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task. ( Dawe, GS; Lim, EP; Nagarajah, R; Verma, V, 2007) |
| " Preclinical evidence shows that chronic administration of antipsychotics can cause pituitary adenomas in female mice." | 1.34 | Atypical antipsychotics and pituitary neoplasms in the WHO database. ( Doraiswamy, PM; Edwards, R; Mueller-Oerlinghausen, B; Schott, G; Star, K, 2007) |
| "Significant weight gain is a serious side effect of many antipsychotic medications, yet successful strategies for significant weight loss are lacking." | 1.34 | Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes? ( Akhtar-Danesh, N; Archie, SM; Goldberg, JO; Landeen, J; McColl, L; McNiven, J, 2007) |
| "Diagnosed with diabetic ketoacidosis, he was given insulin and saline with discontinuation of all antipsychotics." | 1.34 | New-onset diabetic ketoacidosis induced by the addition of perospirone hydrochloride in a patient treated with risperidone. ( Hamanaka, S; Kamijo, Y, 2007) |
| "Risperidone has been reported to decrease the reduction of MRI volume during the clinical course of schizophrenia." | 1.34 | Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. ( Hashioka, S; Kanba, S; Kato, T; Monji, A, 2007) |
| "Risperidone treatment reduced anxiety but increased heart rate." | 1.34 | Blood pressure, heart rate, and anxiety in schizophrenia. ( Baier, MB; Becker, JE; Ritchie, MA; Townsend, MH, 2007) |
| " Here we report the effects of acute and chronic administration of established and putative antipsychotics on these PPI deficits." | 1.34 | The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. ( Feifel, D; Melendez, G; Priebe, K; Shilling, PD, 2007) |
| "Risperidone monotherapy treatment was associated with hyperprolactinaemia in 69% of patients ( n = 35) and in 100% of female patients (n = 16) and amisulpride monotherapy in 100% (n = 7)." | 1.34 | Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. ( Bushe, C; Shaw, M, 2007) |
| "Risperidone treatment significantly increased serum prolactin levels." | 1.34 | Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. ( Du, J; Fang, C; Feng, GY; Gu, NF; He, L; Li, XW; Qin, SY; Wang, L; Xing, QH; Yu, L; Zhang, AP, 2007) |
| "Risperidone is a widely used atypical antipsychotic medication and there is currently considerable interest in individual differences in patient response to it." | 1.34 | Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. ( Du, J; Feng, G; He, L; Li, X; Lin, Z; Wang, L; Xing, Q; Yu, L; Zhang, A, 2007) |
| "However, schizophrenia is a heterogeneous disease." | 1.34 | Testosterone in first-episode schizophrenia. ( Cesková, E; Kaspárek, T; Prikryl, R, 2007) |
| "Insulin resistance is the result of the multiple effects of the antipsychotics, among which most common are: increased body mass and direct involvement of the antipsychotics in the glucose metabolism." | 1.34 | Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone. ( Degmecić, D; Filaković, P; Koić, O; Laufer, D; Pozgain, I; Radanović-Grgurić, L, 2007) |
| " In addition, adverse events were also evaluated." | 1.34 | [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]. ( Agoston, T; István, S; Tamás, T; Zoltán, J, 2007) |
| " As ciproxifan and thioperamide are inhibitors of cytochrome P450 enzymes, responsible for metabolizing risperidone and haloperidol, the possibility that the augmentation of antipsychotics by imidazoles resulted from drug-drug interactions was tested." | 1.33 | Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. ( Ballard, ME; Cowart, M; Decker, MW; Esbenshade, TA; Faghih, R; Fox, GB; Hancock, AA; Pan, L; Roberts, S; Rueter, LE; Zhang, M, 2005) |
| " When OCSs appear with clozapine, dosage can be reduced and a serotonin reuptake inhibitor treatment added." | 1.33 | [Obsessive-compulsive symptoms treatment in: schizophrenia]. ( Dardennes, R; Faucher, S; Ghaëm, O; Guelfi, JD, 2005) |
| " After 4 weeks, fluvoxamine dosage was increased to 200 mg/day in five patients and then maintained until the end of week 8." | 1.33 | Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. ( Ancione, M; D'Arrigo, C; Migliardi, G; Morgante, L; Muscatello, MR; Santoro, V; Spina, E, 2005) |
| "Schizophrenia is one of the most expensive psychiatric conditions because of high direct and indirect costs associated with the nature of the illness, its resistance to treatment and the consequences of relapse." | 1.33 | Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. ( Heeg, B; Laux, G; Mehnert, A; van Hout, BA, 2005) |
| " Results of the sensitivity analysis confirmed that the results were robust to a wide variation of different input variables (effectiveness, dosing distribution, patient status according to healthcare system)." | 1.33 | Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. ( Caleo, S; De Graeve, D; Lecompte, D; Mehnert, A; Miadi-Fargier, H; Mosqueda, GJ; Peuskens, J; Smet, A, 2005) |
| "Schizophrenia is a chronic, relapsing disease that requires more healthcare resources to manage than any other single psychiatric illness." | 1.33 | Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. ( Buskens, E; Chue, PS; Heeg, B; van Hout, BA, 2005) |
| "Priapism is a urologic emergency, and a urologic consultation should be obtained as early as possible." | 1.33 | Priapism associated with typical and atypical antipsychotic medications. ( Chen, CD; Kao, WT; Lung, FW; Tung, YP; Wang, CS, 2006) |
| "To evaluate risk of new-onset type 2 diabetes associated with use of selected antipsychotic agents, the authors conducted a new-user cohort study in a national sample of US Veterans Health Administration patients with schizophrenia (and no preexisting diabetes)." | 1.33 | Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. ( Cunningham, FE; Dalack, GW; Hur, K; Lambert, BL; Miller, DR, 2006) |
| "Risperidone plasma levels were determined and psychopathologic evaluations (Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale) were carried out." | 1.33 | Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. ( Alvarez, E; Carrió, I; Catafau, AM; Corripio, I; Martin, JC; Pérez, V; Schotte, A, 2006) |
| " Failure in switching to monotherapy was associated with higher dosage of antipsychotics at baseline." | 1.33 | Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia. ( Kunugi, H; Murray, RM; Nakanishi, S; Nojima, S; Ogawa, T; Takahashi, T, 2006) |
| "Treatment with olanzapine was also associated with a higher frequency of remission compared with other antipsychotic agents." | 1.33 | Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. ( Alonso, J; Haro, JM; Lépine, JP; Novick, D; Ratcliffe, M; Suarez, D, 2006) |
| "Risperidone was the antipsychotic employed and elevation of prolactin concentrations were noted each time." | 1.32 | Delusions of pregnancy associated with increased prolactin concentrations produced by antipsychotic treatment. ( Ali, JA; Ali, LJ; Desai, KD, 2003) |
| "A clear double dissociation of Wisconsin Card Sorting Test and Gambling Task performances was found, with SKZ patients performing the Wisconsin Card Sorting test significantly worse than OCD patients and control subjects and OCD patients performing the Gambling Task significantly worse than SKZ and control subjects." | 1.32 | Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: a controlled, double dissociation study. ( Angelone, SM; Bassi, T; Bellodi, L; Cavallaro, R; Cavedini, P; Mistretta, P; Ubbiali, A, 2003) |
| " However, no correlation between prolactin levels and dosage could be found." | 1.32 | [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. ( Fric, M; Laux, G, 2003) |
| "Atypical antipsychotics successfully treat schizophrenia and other conditions, with a lower incidence of extrapyramidal side effects than other agents used in treatment of these disorders." | 1.32 | Weight change after an atypical antipsychotic switch. ( Acholonu, WW; Bengtson, MA; Renner, BT; Ried, LD; Wilcox, BM, 2003) |
| " The diagnosis of rhabdomyolysis was confirmed by myoglobinemia dosage and ortholuidine test." | 1.32 | [Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment]. ( Busiello, L; Cascella, M; De Robertis, E; Di Domenico, MG; Palmese, S; Pezza, M, 2003) |
| "Risperidone is a widely used atypical antipsychotic with certain advantages over typical antipsychotics." | 1.32 | Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. ( Ikeda, M; Iwata, N; Kitajima, T; Ozaki, N; Suzuki, T; Yamanouchi, Y, 2003) |
| "Risperidone was recently approved by the U." | 1.32 | Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. ( Ereshefsky, L; Mascarenas, CA, 2003) |
| " While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects." | 1.32 | Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004) |
| "Haloperidol was considered as the first choice for the treatment of positive symptoms." | 1.32 | Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. ( Apiquian, R; de la Fuente-Sandoval, C; Fresán, A; Nicolini, H; Ulloa, RE, 2004) |
| "Treatment with risperidone was offered to acutely psychotic schizophrenic patients with the requirement of a minimum score of > or =4 on 2 items of the PANSS positive symptoms subscale." | 1.32 | Risperidone in the treatment of acute schizophrenia. ( Naber, D; Raedler, TJ; Schreiner, A; Wiedemann, K, 2004) |
| "The bilirubin level was significantly lower in the negative subgroup of the patient group." | 1.32 | Decreased plasma antioxidants in schizophrenia. ( Kim, JJ; Lee, C; Lee, CU; Lee, SJ; Pae, CU; Paik, IH, 2004) |
| "Schizophrenia is a chronic disease characterized by psychotic symptoms as well as negative symptoms such as affective flattening, social withdrawal and occupational dysfunction." | 1.32 | [A long-acting second generation anti-psychotic--experience in Israel]. ( Alfici, S; Bleich, A; Melamed, Y; Preisman, O; Stein-Reisner, O, 2004) |
| "2198 risperidone-treated patients were identified versus 3259 treated with other antipsychotics." | 1.31 | A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients. ( Allingham, BH; Cienfuegos, A; Javitt, DC; Levine, J; Miniati, M; Robinson, J; Silipo, G, 2002) |
| "This study examined the short-term efficacy of electroconvulsive therapy (ECT) combined with antipsychotic medication in treatment-resistant schizophrenia (TRS)." | 1.31 | Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial. ( Tang, WK; Ungvari, GS, 2002) |
| "Risperidone is a novel and atypical agent with a dual antagonistic effect on 5-HT and D receptors." | 1.31 | Risperidone-induced obsessive-compulsive symptoms: a series of six cases. ( Alevizos, B; Christodoulou, GN; Lykouras, L; Zervas, IM, 2002) |
| "Nicotine has been shown in a variety of studies to improve memory performance." | 1.31 | Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. ( Addy, N; Levin, ED, 2002) |
| "Treatment with risperidone resulted in a significant decrease in the intensity of schizophrenic symptoms and in an improvement in all neuropsychological tests applied." | 1.31 | Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests. ( Araszkiewicz, A; Borkowska, A; Rajewski, A; Rybakowski, JK, 2002) |
| "Risperidone was not associated with increased odds of hyperlipidemia compared with no antipsychotic exposure (OR, 1." | 1.31 | An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. ( Buchanan, RW; Fedder, DO; Koro, CE; Kreyenbuhl, J; L'Italien, GJ; Magder, LS; Revicki, D; Weiss, S, 2002) |
| "The treatment of schizophrenia is therefore particularly important to reduce deficits across a large number of neurocognitive domains." | 1.31 | Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. ( Cunningham, F; Hamed, A; Huang, YH; Kazis, LE; Lee, AF; Miller, DR; Ren, XS, 2002) |
| "Family history of psychiatric illness and the presence of obstetric complications were estimated by a semistructured questionnaire." | 1.31 | Does risperidone act better in schizophrenic patients who have a family or obstetric history? ( Borkowska, A; Rybakowski, JK, 2002) |
| "Risperidone (4 mg/day) was added to her drug regimen and after increasing the dosage to 6 mg/day, she began to exhibit retrocollis." | 1.31 | Tardive dystonia provoked by concomitantly administered risperidone. ( Hori, M; Hori, T; Kawanishi, Y; Shiraishi, H; Suzuki, T; Tachikawa, H, 2000) |
| "96 SD were treated with risperidone (RSP) at the dosage of 2-9 mg/die (mean 4." | 1.31 | Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. ( Boscati, L; Laini, V; Mauri, MC; Orlandi, R; Papa, P; Rudelli, R; Salvi, V, 2001) |
| "The acute phase of schizophrenia is characterized by the presence of positive, negative and affective symptoms." | 1.31 | Acute phase of schizophrenia: impact of atypical antipsychotics. ( Azorin, JM, 2000) |
| "Treatment with risperidone, though, results in considerably elevated plasma prolactin (PRL) levels which are not observed with other atypical neuroleptics, such as clozapine, indicating a differentiated action on receptors that are involved in PRL release, mainly dopaminergic and serotonergic." | 1.31 | Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone. ( Hatzimanolis, J; Lykouras, L; Markianos, M, 2001) |
| "Susceptibility for malignant hyperthermia was detected by a positive in vitro contracture test." | 1.31 | [Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy]. ( Grohmann, R; Pedrosa Gil, F; Rüther, E; Schneider, C, 2001) |
| "We investigated the relationships between extrapyramidal symptoms (EPS) induced by risperidone, the dosage of risperidone and the combined plasma concentrations of risperidone plus its active metabolite, 9-hydroxyrisperidone, in 20 schizophrenic patients." | 1.31 | Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. ( Nakamura, J; Ueda, N; Yoshimura, R, 2001) |
| " We conducted a survey of Spanish psychiatrists in mental health centers and outpatient treatment units to assess the severity scores that they would assign to a list of the most common adverse events (AEs) that usually occur with antipsychotic treatment." | 1.31 | Global index of safety (GIS): a new instrument to assess drug safety. ( Badía, X; Gómez, JC; Kind, P; Sacristán, JA, 2001) |
| "Converging evidence indicates that, in controlled drug trials, individuals receiving novel antipsychotic medications have fewer adverse effects than those receiving conventional antipsychotic medications." | 1.31 | Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. ( Bromet, EJ; Davidson, M; Rabinowitz, J, 2001) |
| "Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients." | 1.31 | Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). ( Edgell, E; García-Cabeza, I; Gómez, JC; González de Chavez, M; Sacristán, JA, 2001) |
| "Risperidone-treated patients did not differ from healthy subjects for PPI with any prepulse trials." | 1.31 | Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. ( Kumari, V; Sharma, T; Soni, W, 2002) |
| "The novel antipsychotic medications offer a more favorable extrapyramidal side effect profile than conventional agents." | 1.31 | Sexual side effects of novel antipsychotic medications. ( Marder, SR; Pierre, JM; Saunders, CS; Wirshing, DA; Wirshing, WC, 2002) |
| "Risperidone is an atypical antipsychotic drug that increases plasma norepinephrine (NE) levels, but the mechanism behind this effect is unclear." | 1.31 | Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo. ( Breier, A; Eisenhofer, G; Elman, I; Folio, CJ; Goldstein, DS; Green, AI; Holmes, CS; Pickar, D, 2002) |
| "The purpose of this case study is to document hepatic adverse effects associated with long-term risperidone use in pediatric populations." | 1.30 | Case study: risperidone-induced hepatotoxicity in pediatric patients. ( Briguglia, C; Grothe, D; Herion, D; Jacobsen, LK; Kumra, S, 1997) |
| "Sertindole-treated patients exhibited significantly (P < 0." | 1.30 | Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study. ( Asenbaum, S; Barnas, C; Brücke, T; Hesselmann, B; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J, 1998) |
| " In this case, NMS seemed to be induced by bacterial pneumonia after long term administration of LPZ 5 mg per day." | 1.30 | [A study of neuroleptic malignant syndrome in the presenium and senium]. ( Honma, H; Koyama, T; Matsubara, S; Suzuki, I; Watanabe, N, 1998) |
| "Deliberate drug overdose is a frequent occurrence in patients with schizophrenia." | 1.30 | A case of risperidone overdose in early schizophrenia: a review of potential complications. ( Day, C; Dillman, B; Gardner, D; Kopala, LC, 1998) |
| "Risperidone-associated increase in serum prolactin levels was not significantly correlated to the emergence of possible prolactin-related side effects." | 1.30 | Prolactin levels and adverse events in patients treated with risperidone. ( Brecher, M; Davis, JM; de Coster, R; Kleinberg, DL; Van Baelen, B, 1999) |
| "To compare the side effect profile of risperidone with that of oral haloperidol in patients with no previous exposure to antipsychotic drugs (APDs)." | 1.30 | Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. ( Mazurek, MF; Rosebush, PI, 1999) |
| "Olanzapine is a new atypical antipsychotic agent that belongs to the same chemical class as clozapine." | 1.30 | In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. ( Dresel, S; Hahn, K; Mager, T; Meisenzahl, E; Möller, HJ; Rossmüller, B; Tatsch, K, 1999) |
| "Risperidone is a dopaminergic as well as a 5-HT2 antagonist." | 1.30 | Some behavioural effects of risperidone in rats: comparison with haloperidol. ( Chodera, A; Kus, K; Nowakowska, E; Rybakowski, J, 1999) |
| "Risperidone was substituted for typical antipsychotics after baseline assessment in the second cohort (n = 10)." | 1.30 | Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. ( Bullmore, ET; Honey, GD; Sharma, T; Soni, W; Varatheesan, M; Williams, SC, 1999) |
| "Risperidone is a new antipsychotic drug with high affinity in vitro for both central 5-HT2 and D2 receptors." | 1.29 | Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. ( Ericsson, B; Farde, L; Halldin, C; Nakashima, Y; Nyberg, S; Oxenstierna, G, 1995) |
| "Risperidone is a recently introduced neuroleptic distinguished by a decreased incidence of extrapyramidal side effects (EPS)." | 1.29 | The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. ( Houle, S; Kapur, S; Remington, G; Wilson, AA; Zipursky, RB, 1995) |
| "When schizophrenia is first diagnosed antipsychotic therapy should be started quickly as the longer the initial psychosis remains untreated the worse the final outcome will be." | 1.29 | Managing the first episode of schizophrenia: the role of new therapies. ( McCreadie, RG, 1996) |
| "Priapism was relieved when a hematoma was evacuated from his penis." | 1.29 | [Risperidone-induced priapism]. ( Knobler, HY; Maizel, S; Umansky, L, 1996) |
| " Patients were treated with risperidone in two different dosage groups (3 mg and 8 mg) and haloperidol (10-20 mg) and compared with eight healthy control subjects." | 1.29 | Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. ( Asenbaum, S; Brücke, T; Gössler, R; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J; Topitz-Schratzberger, A; Vesely, C, 1996) |
| "Risperidone was initiated at a starting dose of 0." | 1.29 | Use of risperidone in pervasive developmental disorders: a case series. ( Fisman, S; Steele, M, 1996) |
| "Risperidone is a new benzisoxazole derivative displaying a very potent serotonin antagonism and a potent dopamine antagonism in pharmacological studies." | 1.28 | Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. ( Kissling, W; Möller, HJ; Pelzer, E; Riehl, T; Wernicke, T, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.04) | 18.7374 |
| 1990's | 406 (15.21) | 18.2507 |
| 2000's | 1188 (44.51) | 29.6817 |
| 2010's | 902 (33.80) | 24.3611 |
| 2020's | 172 (6.44) | 2.80 |
| Authors | Studies |
|---|---|
| Rowley, M | 1 |
| Bristow, LJ | 1 |
| Hutson, PH | 1 |
| Shahid, M | 1 |
| Walker, GB | 1 |
| Zorn, SH | 1 |
| Wong, EH | 1 |
| Bali, A | 1 |
| Malhotra, S | 1 |
| Dhir, H | 1 |
| Kumar, A | 3 |
| Sharma, A | 2 |
| Carro, L | 1 |
| Raviña, E | 1 |
| Domínguez, E | 1 |
| Brea, J | 1 |
| Loza, MI | 1 |
| Masaguer, CF | 1 |
| Sun, H | 1 |
| Zhu, L | 1 |
| Yang, H | 2 |
| Qian, W | 1 |
| Guo, L | 3 |
| Zhou, S | 2 |
| Gao, B | 1 |
| Li, Z | 9 |
| Zhou, Y | 5 |
| Jiang, H | 1 |
| Chen, K | 3 |
| Zhen, X | 1 |
| Liu, H | 10 |
| Brindisi, M | 1 |
| Butini, S | 1 |
| Franceschini, S | 1 |
| Brogi, S | 1 |
| Trotta, F | 1 |
| Ros, S | 1 |
| Cagnotto, A | 1 |
| Salmona, M | 1 |
| Casagni, A | 1 |
| Andreassi, M | 1 |
| Saponara, S | 1 |
| Gorelli, B | 1 |
| Weikop, P | 1 |
| Mikkelsen, JD | 1 |
| Scheel-Kruger, J | 1 |
| Sandager-Nielsen, K | 1 |
| Novellino, E | 1 |
| Campiani, G | 1 |
| Gemma, S | 1 |
| Huang, L | 3 |
| Zhang, W | 9 |
| Zhang, X | 14 |
| Yin, L | 2 |
| Chen, B | 1 |
| Song, J | 2 |
| Cao, X | 2 |
| Zhang, Y | 17 |
| Chen, Y | 7 |
| Qiu, Y | 2 |
| Yu, M | 1 |
| Xu, X | 6 |
| Liu, X | 4 |
| Liu, BF | 1 |
| Zhang, L | 10 |
| Zhang, G | 4 |
| Gao, L | 1 |
| Hu, J | 2 |
| Song, T | 1 |
| Zhu, Y | 11 |
| Zhang, C | 5 |
| Siafis, S | 3 |
| Zhuo, K | 1 |
| Zhu, D | 1 |
| Wu, H | 3 |
| Liu, D | 1 |
| Jiang, K | 1 |
| Wang, J | 6 |
| Leucht, S | 30 |
| Li, C | 6 |
| Liu, J | 5 |
| Wang, P | 1 |
| Sun, L | 2 |
| Guan, X | 3 |
| Xiu, M | 8 |
| Yu, R | 1 |
| Gao, Y | 2 |
| Li, X | 27 |
| Thomas, K | 1 |
| Le Moigne, A | 1 |
| Csernansky, J | 1 |
| Leadbetter, RA | 1 |
| Andorn, AC | 1 |
| Graham, JA | 1 |
| Heath, AT | 1 |
| Walling, DP | 3 |
| Newcomer, JW | 2 |
| Marder, SR | 35 |
| Katona, L | 1 |
| Bitter, I | 5 |
| Czobor, P | 17 |
| Wu, Z | 2 |
| Liu, Q | 2 |
| Demyttenaere, K | 1 |
| Leenaerts, N | 1 |
| Acsai, K | 2 |
| Sebe, B | 1 |
| Laszlovszky, I | 4 |
| Barabássy, Á | 5 |
| Fonticoli, L | 1 |
| Szatmári, B | 4 |
| Earley, W | 4 |
| Németh, G | 6 |
| Correll, CU | 20 |
| Ozornin, AS | 1 |
| Govorin, NV | 2 |
| Sakharov, AV | 1 |
| Tereshkov, PP | 1 |
| Hassman, HA | 1 |
| Anta, L | 4 |
| Ochoa, L | 1 |
| Ayani, I | 3 |
| Martínez, J | 4 |
| Gutierro, I | 3 |
| Tao, B | 1 |
| Xiao, Y | 3 |
| Cao, H | 3 |
| Yang, C | 1 |
| Lencer, R | 3 |
| Gong, Q | 4 |
| Lui, S | 3 |
| Shroitman, NK | 1 |
| Peles, E | 1 |
| Even-Tov, S | 1 |
| Schreiber, S | 1 |
| Tene, O | 1 |
| Suzuki, H | 16 |
| Hibino, H | 14 |
| Lin, C | 2 |
| Yu, J | 3 |
| Feng, W | 2 |
| Fu, W | 1 |
| Yang, F | 9 |
| Chen, D | 3 |
| Jiang, S | 1 |
| Su, L | 1 |
| Lu, Y | 1 |
| Chen, Z | 2 |
| Wang, X | 10 |
| Dagenais-Beaulé, V | 1 |
| Azimi Sanavi, M | 1 |
| Ghazvini, H | 1 |
| Zargari, M | 1 |
| Ghalehnoei, H | 1 |
| Hosseini-Khah, Z | 1 |
| Shi, H | 2 |
| Yang, G | 9 |
| Yang, Y | 14 |
| Li, W | 9 |
| Song, M | 1 |
| Shao, M | 1 |
| Su, X | 1 |
| Lv, L | 21 |
| Pahwa, M | 1 |
| Sleem, A | 1 |
| Elsayed, OH | 1 |
| Good, ME | 1 |
| El-Mallakh, RS | 1 |
| Filts, Y | 1 |
| Litman, RE | 3 |
| Naber, D | 17 |
| Zolk, O | 2 |
| Greiner, T | 1 |
| Schneider, M | 1 |
| Heinze, M | 1 |
| Dahling, V | 1 |
| Ramin, T | 1 |
| Grohmann, R | 2 |
| Bleich, S | 3 |
| Zindler, T | 1 |
| Toto, S | 1 |
| Seifert, J | 1 |
| Bellotti, E | 1 |
| Contarini, G | 1 |
| Geraci, F | 1 |
| Torrisi, SA | 1 |
| Piazza, C | 1 |
| Drago, F | 1 |
| Leggio, GM | 1 |
| Papaleo, F | 2 |
| Decuzzi, P | 1 |
| Lang, X | 2 |
| Wang, D | 6 |
| Zhou, H | 2 |
| Wang, L | 26 |
| Cao, B | 1 |
| Lu, Z | 6 |
| Yan, H | 9 |
| Su, Y | 5 |
| Liao, Y | 6 |
| Lu, T | 12 |
| Yu, H | 8 |
| Li, J | 7 |
| Xiao, X | 2 |
| Tan, Y | 3 |
| Zhang, D | 12 |
| Yue, W | 11 |
| Motamed, M | 1 |
| Karimi, H | 1 |
| Sanjari Moghaddam, H | 1 |
| Taherzadeh Boroujeni, S | 1 |
| Sanatian, Z | 1 |
| Hasanzadeh, A | 1 |
| Khodaei Ardakani, MR | 3 |
| Akhondzadeh, S | 34 |
| Taurines, R | 1 |
| Fekete, S | 2 |
| Preuss-Wiedenhoff, A | 1 |
| Warnke, A | 1 |
| Wewetzer, C | 1 |
| Plener, P | 1 |
| Burger, R | 1 |
| Gerlach, M | 1 |
| Romanos, M | 1 |
| Egberts, KM | 1 |
| Jeon, SM | 1 |
| Cho, J | 1 |
| Lee, DY | 1 |
| Kwon, JW | 1 |
| Zhao, M | 1 |
| Ma, J | 4 |
| Li, M | 8 |
| Zhu, W | 1 |
| Zhou, W | 5 |
| Shen, L | 6 |
| Zhang, N | 2 |
| Wu, S | 2 |
| Fu, C | 1 |
| Yang, K | 2 |
| Tang, T | 1 |
| Shen, R | 1 |
| He, L | 21 |
| Huai, C | 1 |
| Qin, S | 12 |
| Taipale, H | 3 |
| Tanskanen, A | 3 |
| Luykx, JJ | 2 |
| Solmi, M | 1 |
| Tiihonen, J | 4 |
| Lin, YH | 2 |
| Wu, CS | 1 |
| Liu, CC | 3 |
| Kuo, PH | 1 |
| Chan, HY | 6 |
| Chen, WJ | 3 |
| Oh, S | 1 |
| Byeon, SJ | 1 |
| Chung, SJ | 1 |
| Xu, Q | 7 |
| Li, Y | 14 |
| Ning, A | 1 |
| Yuan, R | 1 |
| Fu, Y | 1 |
| Zhang, R | 3 |
| Zeng, D | 1 |
| Yu, W | 4 |
| Li, H | 13 |
| Yu, S | 1 |
| Mørkved, N | 1 |
| Johnsen, E | 2 |
| Kroken, RA | 2 |
| Winje, D | 1 |
| Larsen, TK | 1 |
| Thimm, JC | 1 |
| Rettenbacher, MA | 2 |
| Johannesen, CAB | 1 |
| Løberg, EM | 3 |
| Lopez-Morinigo, JD | 1 |
| Arango, C | 4 |
| Lin, CH | 5 |
| Lin, HY | 1 |
| Lin, TC | 1 |
| Chen, JJ | 4 |
| Ramos-Méndez, MA | 1 |
| Tovilla-Zárate, CA | 1 |
| Juárez-Rojop, IE | 1 |
| Villar-Soto, M | 1 |
| Genis-Mendoza, AD | 1 |
| González-Castro, TB | 1 |
| López-Narváez, ML | 1 |
| Martínez-Magaña, JJ | 1 |
| Castillo-Avila, RG | 1 |
| Villar-Juárez, GE | 1 |
| Martin, A | 4 |
| Bessonova, L | 1 |
| Hughes, R | 1 |
| Doane, MJ | 1 |
| O'Sullivan, AK | 1 |
| Snook, K | 1 |
| Cichewicz, A | 1 |
| Weiden, PJ | 11 |
| Harvey, PD | 17 |
| Huang, MW | 1 |
| Gibson, RC | 1 |
| Jayaram, MB | 8 |
| Caroff, SN | 2 |
| Salehi, A | 2 |
| Namaei, P | 1 |
| TaghaviZanjani, F | 2 |
| Bagheri, S | 2 |
| Moradi, K | 3 |
| Misawa, F | 2 |
| Fujii, Y | 2 |
| Takeuchi, H | 17 |
| Krishnegowda, S | 1 |
| Udaykumar, P | 1 |
| Yadiyal, A | 1 |
| Tost, M | 1 |
| González-Rodríguez, A | 1 |
| Aguayo, R | 1 |
| Álvarez, A | 1 |
| Montalvo, I | 1 |
| Barbero, JD | 1 |
| Gabernet, R | 1 |
| Izquierdo, E | 1 |
| Merodio, I | 1 |
| Monreal, JA | 1 |
| Palao, D | 1 |
| Labad, J | 1 |
| Álamo, C | 2 |
| Hu, M | 12 |
| Xia, Y | 1 |
| Zong, X | 11 |
| Sweeney, JA | 14 |
| Bishop, JR | 3 |
| Giase, G | 1 |
| Li, B | 2 |
| Rubin, LH | 1 |
| Wang, Y | 13 |
| He, Y | 10 |
| Chen, X | 10 |
| Liu, C | 4 |
| Chen, C | 5 |
| Tang, J | 8 |
| Benarous, X | 1 |
| Lahaye, H | 1 |
| Cottin, G | 1 |
| Garny de la Rivière, S | 1 |
| Guilé, JM | 1 |
| Speranza, M | 1 |
| Bonnot, O | 1 |
| Cohen, D | 6 |
| Kane, JM | 50 |
| Kinon, BJ | 27 |
| Forray, C | 1 |
| Such, P | 1 |
| Mittoux, A | 6 |
| Lemming, OM | 1 |
| Hertel, P | 1 |
| Howes, OD | 2 |
| Anam, A | 1 |
| Lynch, S | 1 |
| Mosharraf, N | 1 |
| Soukas, C | 1 |
| Gekhman, D | 1 |
| Cao, L | 1 |
| Wu, J | 1 |
| Sommer, IE | 1 |
| Brand, BA | 1 |
| Gangadin, S | 1 |
| Chen, N | 2 |
| Yao, J | 1 |
| Chen, S | 3 |
| Wu, F | 3 |
| Abdallah, MS | 1 |
| Mosalam, EM | 1 |
| Hassan, A | 1 |
| Ramadan, AN | 1 |
| Omara-Reda, H | 1 |
| Zidan, AA | 1 |
| Samman, WA | 1 |
| El-Berri, EI | 1 |
| Ben-Azu, B | 3 |
| Uruaka, CI | 1 |
| Ajayi, AM | 3 |
| Jarikre, TA | 1 |
| Nwangwa, KE | 1 |
| Chilaka, KC | 1 |
| Chijioke, BS | 1 |
| Omonyeme, MG | 1 |
| Ozege, CB | 1 |
| Ofili, EC | 1 |
| Warekoromor, EB | 1 |
| Edigbue, NL | 1 |
| Esiekpe, UV | 1 |
| Akaenyi, DE | 1 |
| Agu, GO | 1 |
| Grover, S | 4 |
| Sarkar, S | 4 |
| Sahoo, S | 5 |
| Tang, Y | 4 |
| Wu, Y | 3 |
| Hao, Q | 3 |
| Deng, W | 8 |
| Tan, L | 6 |
| Chen, Q | 7 |
| Zhang, F | 8 |
| Yang, J | 9 |
| Li, K | 9 |
| Tan, Q | 5 |
| Zhang, H | 14 |
| Ma, X | 15 |
| Li, L | 15 |
| Wang, C | 14 |
| Zhao, L | 5 |
| Ren, H | 4 |
| Du, X | 3 |
| Hu, X | 5 |
| Li, T | 8 |
| Wang, Q | 8 |
| Bhat, AA | 2 |
| Gupta, G | 2 |
| Afzal, O | 2 |
| Kazmi, I | 2 |
| Al-Abbasi, FA | 2 |
| Alfawaz Altamimi, AS | 2 |
| Almalki, WH | 2 |
| Alzarea, SI | 2 |
| Singh, SK | 2 |
| Dua, K | 2 |
| Zhang, J | 7 |
| Yao, T | 2 |
| Ma, S | 1 |
| Kang, L | 1 |
| Nie, Z | 1 |
| Liu, Z | 5 |
| Zheng, J | 3 |
| Duan, X | 4 |
| Tao, S | 1 |
| Coid, J | 2 |
| Wei, W | 2 |
| Guo, W | 2 |
| Li, D | 2 |
| Baeza, I | 4 |
| Fortea, A | 1 |
| Ilzarbe, D | 1 |
| Sugranyes, G | 1 |
| Okada, Y | 1 |
| Inada, K | 1 |
| Akazawa, M | 1 |
| Tzeng, NS | 3 |
| Yang, YY | 2 |
| Lin, CC | 4 |
| Hsieh, PS | 1 |
| Liu, YP | 4 |
| Nelson, EA | 2 |
| Kraguljac, NV | 10 |
| Maximo, JO | 2 |
| Armstrong, W | 1 |
| Lahti, AC | 13 |
| Yu, CL | 1 |
| Carvalho, AF | 2 |
| Thompson, T | 1 |
| Tsai, TC | 2 |
| Tseng, PT | 1 |
| Hsu, CW | 4 |
| Hsu, TW | 1 |
| Liang, CS | 3 |
| Patlola, SR | 1 |
| Donohoe, G | 1 |
| McKernan, DP | 1 |
| Karbalaee, M | 1 |
| Jameie, M | 1 |
| Amanollahi, M | 1 |
| Parsaei, M | 1 |
| Basti, FA | 1 |
| Mokhtari, S | 1 |
| Ardakani, MK | 1 |
| Lokmer, A | 1 |
| Alladi, CG | 2 |
| Troudet, R | 1 |
| Bacq-Daian, D | 1 |
| Boland-Auge, A | 1 |
| Latapie, V | 1 |
| Deleuze, JF | 1 |
| RajKumar, RP | 3 |
| Shewade, DG | 3 |
| Bélivier, F | 1 |
| Marie-Claire, C | 2 |
| Jamain, S | 3 |
| Hope, JD | 1 |
| Keks, NA | 3 |
| Copolov, DL | 1 |
| Li, Q | 3 |
| Liao, X | 1 |
| Fang, M | 3 |
| Gao, J | 5 |
| Xu, J | 4 |
| Duan, M | 1 |
| Yan, S | 1 |
| Yao, P | 1 |
| Li, S | 5 |
| Wu, B | 4 |
| Si, T | 1 |
| Anczewska, M | 1 |
| Balicki, M | 1 |
| Droździkowska, A | 1 |
| Gorczyca, P | 1 |
| Janus, J | 1 |
| Paciorek, S | 1 |
| Plisko, R | 1 |
| Zięba, M | 1 |
| Burschinski, A | 1 |
| Schneider-Thoma, J | 1 |
| Priller, J | 1 |
| Davis, JM | 18 |
| Zhou, T | 2 |
| Pu, C | 1 |
| Huang, Z | 2 |
| Gao, T | 1 |
| Zhou, E | 1 |
| Zheng, Y | 5 |
| Huang, B | 1 |
| Cheng, Z | 4 |
| Shi, C | 2 |
| Yu, X | 6 |
| Song, X | 10 |
| Huang, X | 4 |
| Yamada, H | 1 |
| Hashimoto, R | 4 |
| Sun, Y | 1 |
| Kang, Z | 1 |
| Feng, X | 1 |
| Guo, LK | 1 |
| Zhang, YY | 1 |
| Li, WQ | 3 |
| Yang, YF | 2 |
| Lu, TL | 1 |
| Liao, YD | 1 |
| Kang, ZW | 1 |
| Wang, LF | 1 |
| Liu, B | 2 |
| Huang, HL | 1 |
| Lv, LX | 3 |
| Yao, Y | 1 |
| Tan, YL | 4 |
| Breen, G | 3 |
| Everall, I | 1 |
| Wang, HX | 2 |
| Yue, WH | 1 |
| Hieronymus, F | 1 |
| Østergaard, SD | 2 |
| Xue, M | 1 |
| Zang, X | 1 |
| Long, Y | 1 |
| Wu, Q | 2 |
| Cai, J | 1 |
| Xiao, J | 3 |
| Xu, Y | 5 |
| Huang, M | 2 |
| Liu, F | 4 |
| Meng, H | 1 |
| Wang, Z | 3 |
| Liu, T | 1 |
| Wu, X | 5 |
| Wan, C | 1 |
| Zhao, J | 16 |
| Wu, R | 8 |
| Oshima, M | 1 |
| Toyama, T | 1 |
| Nakade, Y | 1 |
| Yomogida, D | 1 |
| Yuasa, T | 1 |
| Horikoshi, K | 1 |
| Minami, T | 1 |
| Ogura, H | 1 |
| Nakagawa, S | 3 |
| Miyagawa, T | 1 |
| Kitajima, S | 1 |
| Hara, A | 1 |
| Sakai, N | 1 |
| Shimizu, M | 1 |
| Mita, M | 1 |
| Kinoshita, M | 1 |
| Nakada, M | 1 |
| Kikuchi, M | 2 |
| Iwata, Y | 3 |
| Wada, T | 1 |
| Min, J | 1 |
| Yin, H | 1 |
| Xia, W | 1 |
| Shen, Y | 4 |
| Shu, M | 1 |
| Li, R | 4 |
| Fu, R | 1 |
| Cui, ZQ | 1 |
| Chen, YH | 2 |
| Bai, J | 1 |
| Yang, JB | 1 |
| Tan, QR | 2 |
| Peng, ZW | 2 |
| Shamabadi, A | 1 |
| Fattollahzadeh-Noor, S | 1 |
| Fallahpour, B | 1 |
| A Basti, F | 1 |
| Deng, SW | 1 |
| Jiang, WL | 1 |
| Hong, B | 1 |
| Li, BH | 1 |
| Sun, DW | 1 |
| Yang, HB | 1 |
| Oloyede, E | 1 |
| Dima, A | 1 |
| Taylor, D | 2 |
| Cheung, H | 1 |
| Dzahini, O | 3 |
| Shergill, S | 1 |
| Whiskey, E | 2 |
| Harary, E | 1 |
| Eshet, R | 1 |
| Tohami, O | 1 |
| Weiser, M | 2 |
| Merenlender-Wagner, A | 1 |
| Sharon, N | 1 |
| Davis, GL | 1 |
| Suett, M | 1 |
| Franzenburg, KR | 1 |
| Schaefer, M | 1 |
| Theophil, I | 1 |
| Leopold, K | 1 |
| Heinz, A | 3 |
| Gallinat, J | 2 |
| Zheng, H | 4 |
| Kosten, TR | 6 |
| Zhang, XY | 19 |
| Yabuki, Y | 1 |
| Wu, L | 1 |
| Fukunaga, K | 1 |
| Yuan, Y | 3 |
| Han, X | 6 |
| Yang, L | 8 |
| Cai, S | 1 |
| Deng, H | 3 |
| Xiang, Y | 1 |
| Ibrahim, I | 1 |
| Tobar, S | 1 |
| Fathi, W | 1 |
| ElSayed, H | 1 |
| Yassein, A | 1 |
| Eissa, A | 1 |
| Elsheshtawy, E | 1 |
| Elboraei, H | 1 |
| Shahda, M | 1 |
| Elwasify, M | 1 |
| Ibrahim, A | 1 |
| Wood, J | 1 |
| Dickerson, F | 3 |
| Yolken, RH | 1 |
| El Chennawi, F | 1 |
| Gur, R | 2 |
| El Bahaey, W | 1 |
| Nimgaonkar, V | 1 |
| Mansour, H | 1 |
| Su, C | 1 |
| Dong, X | 2 |
| He, C | 2 |
| Chen, H | 8 |
| Azizi, E | 1 |
| Zavaran Hosseini, A | 1 |
| Soudi, S | 1 |
| Noorbala, AA | 4 |
| Ning, Y | 3 |
| Jia, H | 1 |
| Chen, P | 1 |
| Zhu, H | 2 |
| Yin, D | 1 |
| Saxena, PP | 1 |
| Small, GW | 1 |
| Wei, XY | 1 |
| Yang, YJ | 1 |
| Zhu, XH | 1 |
| Cavalcante, DA | 1 |
| Coutinho, LS | 1 |
| Ortiz, BB | 1 |
| Noto, MN | 3 |
| Cordeiro, Q | 7 |
| Ota, VK | 7 |
| Belangeiro, SI | 1 |
| Bressan, RA | 13 |
| Gadelha, A | 7 |
| Noto, C | 6 |
| Johnston, K | 1 |
| Sliwa, JK | 4 |
| Bossie, CA | 26 |
| Kim, E | 6 |
| Han, S | 1 |
| Becker, B | 1 |
| Cui, Q | 1 |
| Xin, F | 1 |
| Yang, M | 2 |
| Yu, Y | 3 |
| Liao, W | 2 |
| Radhakrishnan, R | 1 |
| Matuskey, D | 1 |
| Nabulsi, N | 1 |
| Gaiser, E | 1 |
| Gallezot, JD | 1 |
| Henry, S | 1 |
| Planeta, B | 1 |
| Lin, SF | 1 |
| Ropchan, J | 1 |
| Huang, Y | 1 |
| Carson, RE | 1 |
| D'Souza, DC | 2 |
| Roosan, D | 1 |
| Law, A | 1 |
| Truong, H | 1 |
| Karim, M | 1 |
| Chok, J | 1 |
| Roosan, M | 1 |
| Gründer, P | 1 |
| Augustin, M | 1 |
| Paulzen, M | 3 |
| Gründer, G | 3 |
| Nakamura, H | 5 |
| Miura, S | 2 |
| Feng, Y | 3 |
| Shi, J | 4 |
| Xie, S | 4 |
| Luo, X | 3 |
| Wang, G | 4 |
| Lei, L | 1 |
| Crippa, A | 1 |
| Patel, MX | 6 |
| Orsini, N | 1 |
| Armstrong, WP | 1 |
| Yan, T | 2 |
| Greene, M | 3 |
| Chang, E | 3 |
| Houle, CR | 1 |
| Waters, HC | 1 |
| Tarbox, MH | 1 |
| Broder, MS | 3 |
| Gómez-Revuelta, M | 1 |
| Pelayo-Terán, JM | 8 |
| Juncal-Ruiz, M | 2 |
| Vázquez-Bourgon, J | 1 |
| Suárez-Pinilla, P | 4 |
| Romero-Jiménez, R | 1 |
| Setién Suero, E | 1 |
| Ayesa-Arriola, R | 3 |
| Crespo-Facorro, B | 14 |
| Dehelean, L | 1 |
| Romosan, AM | 1 |
| Papava, I | 1 |
| Bredicean, CA | 1 |
| Dumitrascu, V | 1 |
| Ursoniu, S | 1 |
| Romosan, RS | 1 |
| Birur, B | 1 |
| VerHoef, L | 1 |
| Morgan, CJ | 3 |
| Jindal, RD | 3 |
| Reid, MA | 5 |
| Luker, A | 1 |
| Moazen-Zadeh, E | 2 |
| Bayanati, S | 1 |
| Ziafat, K | 1 |
| Rezaei, F | 19 |
| Mesgarpour, B | 2 |
| Liang, W | 1 |
| Pathak, S | 2 |
| Jiang, Y | 1 |
| DiPetrillo, L | 1 |
| Todtenkopf, MS | 1 |
| Liu, Y | 11 |
| Reynolds, GP | 1 |
| Wang, H | 1 |
| Tian, Y | 1 |
| McGuire, PR | 1 |
| Coplan, BM | 1 |
| Puri, S | 1 |
| Feng, Z | 1 |
| You, X | 1 |
| Ma, Y | 2 |
| Long, Q | 1 |
| Hao, W | 1 |
| Zeng, Y | 3 |
| Teng, Z | 1 |
| Chan, S | 1 |
| Chik, I | 1 |
| Wilson, BA | 1 |
| Gurler, D | 1 |
| White, DM | 9 |
| Ver Hoef, L | 4 |
| Martin, C | 2 |
| Tennant, B | 1 |
| Mattingly, GW | 1 |
| Haddad, PM | 2 |
| Tocco, M | 1 |
| Phillips, D | 2 |
| Pikalov, A | 4 |
| Loebel, A | 10 |
| Yuan, X | 3 |
| Kang, Y | 1 |
| Pang, L | 3 |
| Zhu, Q | 2 |
| Huang, XF | 5 |
| Sharma, N | 1 |
| Bhat, S | 1 |
| Ravi, D | 1 |
| Ochieng, P | 1 |
| Stam, N | 1 |
| Isphording, L | 1 |
| Okhuijsen-Pfeifer, C | 1 |
| Schuiling-Veninga, CCM | 1 |
| Bos, JHJ | 1 |
| Bijker, BJ | 1 |
| Maffioletti, E | 1 |
| Valsecchi, P | 3 |
| Minelli, A | 2 |
| Magri, C | 2 |
| Bonvicini, C | 1 |
| Barlati, S | 1 |
| Sacchetti, E | 8 |
| Vita, A | 4 |
| Gennarelli, M | 2 |
| Limandri, BJ | 1 |
| Garcia-Rosa, S | 1 |
| Carvalho, BS | 1 |
| Guest, PC | 4 |
| Steiner, J | 3 |
| Martins-de-Souza, D | 1 |
| Hou, Y | 1 |
| Xie, J | 1 |
| Alkharboush, GA | 1 |
| Alsalamah, MA | 1 |
| Nolin, MA | 1 |
| Demers, MF | 4 |
| Rauzier, C | 1 |
| Bouchard, RH | 3 |
| Cadrin, C | 2 |
| Després, JP | 2 |
| Roy, MA | 6 |
| Alméras, N | 2 |
| Picard, F | 1 |
| Ikegame, T | 2 |
| Bundo, M | 2 |
| Okada, N | 1 |
| Murata, Y | 2 |
| Koike, S | 1 |
| Sugawara, H | 2 |
| Saito, T | 4 |
| Ikeda, M | 5 |
| Owada, K | 1 |
| Fukunaga, M | 1 |
| Yamashita, F | 1 |
| Koshiyama, D | 1 |
| Natsubori, T | 1 |
| Iwashiro, N | 1 |
| Asai, T | 1 |
| Yoshikawa, A | 2 |
| Nishimura, F | 2 |
| Kawamura, Y | 2 |
| Ishigooka, J | 4 |
| Kakiuchi, C | 2 |
| Sasaki, T | 4 |
| Abe, O | 1 |
| Iwata, N | 10 |
| Yamasue, H | 1 |
| Kato, T | 3 |
| Kasai, K | 3 |
| Iwamoto, K | 2 |
| Carlone, D | 1 |
| Delva, N | 1 |
| Taylor, JH | 3 |
| Appel, S | 1 |
| Eli, M | 1 |
| Alexander-Bloch, A | 1 |
| Maayan, L | 1 |
| Gur, RE | 2 |
| Bloch, MH | 3 |
| Chipps, J | 1 |
| Chen, PH | 1 |
| Tsai, SY | 2 |
| Pan, CH | 3 |
| Chang, CK | 1 |
| Su, SS | 1 |
| Chen, CC | 7 |
| Kuo, CJ | 3 |
| Ganoci, L | 2 |
| Trkulja, V | 1 |
| Živković, M | 2 |
| Božina, T | 1 |
| Šagud, M | 4 |
| Lovrić, M | 3 |
| Božina, N | 6 |
| Khorassani, F | 1 |
| Sousonis, F | 1 |
| Lopez, LV | 1 |
| Proença, P | 1 |
| Monteiro, C | 1 |
| Mustra, C | 1 |
| Claro, A | 1 |
| Franco, J | 1 |
| Corte-Real, F | 1 |
| Luo, C | 1 |
| Hu, N | 1 |
| Horska, K | 2 |
| Kotolova, H | 1 |
| Karpisek, M | 1 |
| Babinska, Z | 1 |
| Hammer, T | 1 |
| Prochazka, J | 1 |
| Stark, T | 1 |
| Micale, V | 2 |
| Ruda-Kucerova, J | 2 |
| Dong, R | 1 |
| Yuan, L | 2 |
| Du, XD | 2 |
| Jia, Q | 1 |
| Dillon, BA | 1 |
| Yu, L | 7 |
| Nuechterlein, KH | 8 |
| Ventura, J | 8 |
| Subotnik, KL | 7 |
| Gretchen-Doorly, D | 3 |
| Turner, LR | 1 |
| Casaus, LR | 6 |
| Luo, J | 2 |
| Boucher, ML | 1 |
| Hayata, JN | 1 |
| Bell, MD | 1 |
| Medalia, A | 1 |
| Wu, ZW | 1 |
| Chen, DC | 4 |
| Xiu, MH | 4 |
| Kucera, J | 1 |
| Hruska, P | 1 |
| Kuruczova, D | 1 |
| Bienertova-Vasku, J | 1 |
| Klein, B | 1 |
| Silberbauer, C | 2 |
| Kuk, S | 1 |
| Kim, S | 2 |
| Kim, BH | 1 |
| Lee, W | 1 |
| Park, SI | 1 |
| Iqbal, E | 1 |
| Govind, R | 1 |
| Romero, A | 1 |
| Broadbent, M | 1 |
| Stewart, R | 1 |
| Smith, T | 1 |
| Kim, CH | 2 |
| Werbeloff, N | 1 |
| MacCabe, JH | 1 |
| Dobson, RJB | 1 |
| Ibrahim, ZM | 1 |
| Barbosa, WB | 1 |
| Gomes, RM | 1 |
| Godman, B | 3 |
| Acurcio, FA | 1 |
| Guerra Júnior, AA | 1 |
| Samaei, A | 1 |
| Ashraf-Ganjouei, A | 1 |
| Alikhani, R | 1 |
| Mousavi, SB | 1 |
| Srisurapanont, M | 4 |
| Likhitsathian, S | 1 |
| Suttajit, S | 1 |
| Maneeton, N | 2 |
| Maneeton, B | 1 |
| Oon-Arom, A | 1 |
| Suradom, C | 1 |
| Monteleone, P | 1 |
| Cascino, G | 1 |
| Monteleone, AM | 1 |
| Rocca, P | 2 |
| Rossi, A | 4 |
| Bertolino, A | 1 |
| Aguglia, E | 3 |
| Amore, M | 1 |
| Collantoni, E | 1 |
| Corrivetti, G | 3 |
| Cuomo, A | 1 |
| Bellomo, A | 1 |
| D'Ambrosio, E | 1 |
| Dell'Osso, L | 1 |
| Frascarelli, M | 1 |
| Giordano, GM | 1 |
| Giuliani, L | 1 |
| Marchesi, C | 1 |
| Montemagni, C | 2 |
| Oldani, L | 1 |
| Pinna, F | 2 |
| Pompili, M | 1 |
| Roncone, R | 1 |
| Rossi, R | 1 |
| Siracusano, A | 1 |
| Zeppegno, P | 2 |
| Galderisi, S | 1 |
| Maj, M | 1 |
| Zhao, Q | 1 |
| Hadryś, T | 1 |
| Rymaszewska, J | 1 |
| Boels, D | 1 |
| Mahé, J | 1 |
| Olry, A | 1 |
| Citterio-Quentin, A | 1 |
| Moragny, J | 1 |
| Jolliet, P | 1 |
| Ostuzzi, G | 1 |
| Bertolini, F | 1 |
| Del Giovane, C | 1 |
| Tedeschi, F | 1 |
| Bovo, C | 1 |
| Gastaldon, C | 1 |
| Nosé, M | 1 |
| Ogheri, F | 1 |
| Papola, D | 1 |
| Purgato, M | 1 |
| Turrini, G | 1 |
| Barbui, C | 6 |
| Ning, X | 2 |
| Xia, L | 1 |
| Shi, Y | 4 |
| Hao, R | 1 |
| Geng, F | 1 |
| Zhang, K | 1 |
| Vanwong, N | 1 |
| Puangpetch, A | 1 |
| Unaharassamee, W | 1 |
| Jiratjintana, N | 1 |
| Na Nakorn, C | 1 |
| Hongkaew, Y | 1 |
| Sukasem, C | 1 |
| Gao, W | 1 |
| Li, G | 3 |
| Song, Z | 1 |
| Zhao, S | 4 |
| Sun, F | 2 |
| Ma, H | 2 |
| Cui, A | 1 |
| Ma, G | 2 |
| Tang, X | 1 |
| Varimo, E | 1 |
| Aronen, ET | 1 |
| Mogk, H | 1 |
| Rättö, H | 1 |
| Saastamoinen, LK | 1 |
| Zhenhua, W | 1 |
| Haizhi, C | 1 |
| Jing, L | 1 |
| Xiaocong, F | 1 |
| Jianhua, L | 1 |
| Jianjun, L | 1 |
| Lilei, L | 1 |
| Haiying, J | 1 |
| Aras, N | 1 |
| Kang, C | 2 |
| Wu, C | 1 |
| Lin, Y | 1 |
| Zeng, L | 2 |
| Yuan, J | 2 |
| Wei, Y | 2 |
| Xu, L | 2 |
| Zhou, F | 2 |
| Li, XR | 1 |
| Guan, XN | 1 |
| Wang, YC | 3 |
| Leung, E | 1 |
| Hu, C | 1 |
| Ding, W | 1 |
| Wu, M | 1 |
| Sun, X | 1 |
| Singappuli, P | 1 |
| Sonuga-Barke, E | 1 |
| Kyriakopoulos, M | 1 |
| Lisoway, AJ | 1 |
| Zai, CC | 2 |
| Tiwari, AK | 2 |
| Kennedy, JL | 4 |
| Amani, P | 1 |
| Habibpour, R | 1 |
| Karami, L | 1 |
| Hofmann, A | 1 |
| Veraart, JKE | 1 |
| Smith-Apeldoorn, SY | 1 |
| Bakker, IM | 1 |
| Visser, BAE | 1 |
| Kamphuis, J | 1 |
| Schoevers, RA | 1 |
| Touw, DJ | 1 |
| Tasaki, M | 1 |
| Yasui-Furukori, N | 22 |
| Yokoyama, S | 1 |
| Shinozaki, M | 1 |
| Sugawara, N | 8 |
| Shimoda, K | 2 |
| Fan, YS | 1 |
| Guo, J | 2 |
| Pang, Y | 1 |
| Sheng, W | 1 |
| Gao, Q | 1 |
| Ren, J | 1 |
| Maes, M | 4 |
| Vargas Nunes, SO | 1 |
| Cavalcante, D | 1 |
| Oliveira, G | 1 |
| Rossaneis, AC | 1 |
| Verri, WA | 1 |
| Belangero, SI | 7 |
| Nisa, Z | 1 |
| Naz, A | 1 |
| Ali, SI | 1 |
| Rizvi, M | 1 |
| Iqbal, MS | 1 |
| Shahnaz, S | 1 |
| Zehra, A | 1 |
| Sheikh, S | 1 |
| Perveen, S | 1 |
| Arif, H | 1 |
| Inayat, S | 1 |
| Swaleh, MM | 1 |
| Kashif, SS | 1 |
| Ali, MM | 1 |
| Akhtar, H | 1 |
| Kumar, PNS | 1 |
| Radhika, MK | 1 |
| Suresh, R | 1 |
| Uvais, NA | 1 |
| Tendilla-Beltrán, H | 1 |
| Coatl-Cuaya, H | 1 |
| Meneses-Prado, S | 1 |
| Vázquez-Roque, RA | 1 |
| Brambila, E | 1 |
| Tapia-Rodríguez, M | 1 |
| Martín-Hernández, D | 1 |
| Garcés-Ramírez, L | 1 |
| Madrigal, JLM | 1 |
| Leza, JC | 2 |
| Flores, G | 1 |
| Mouaffak, F | 1 |
| Ferreri, F | 1 |
| Bourgin-Duchesnay, J | 1 |
| Baloche, E | 1 |
| Blin, O | 4 |
| Vandel, P | 1 |
| Garay, RP | 2 |
| Vidailhet, P | 2 |
| Corruble, E | 1 |
| Llorca, PM | 9 |
| Hodkinson, A | 1 |
| Heneghan, C | 1 |
| Mahtani, KR | 1 |
| Kontopantelis, E | 1 |
| Panagioti, M | 1 |
| Dombi, ZB | 1 |
| Inoue, Y | 17 |
| Mikami, A | 5 |
| Matsumoto, H | 5 |
| Mikami, K | 5 |
| Barber, S | 1 |
| Olotu, U | 1 |
| Corsi, M | 1 |
| Cipriani, A | 3 |
| Machielsen, MWJ | 1 |
| Veltman, DJ | 2 |
| van den Brink, W | 4 |
| de Haan, L | 11 |
| Sahni, S | 1 |
| Chavan, BS | 2 |
| Sidana, A | 1 |
| Kalra, P | 1 |
| Kaur, G | 2 |
| Jeddian, A | 1 |
| Zeionoddini, A | 2 |
| Mohammadinejad, P | 3 |
| Salardini, E | 1 |
| Shahriari, M | 1 |
| Zeinoddini, A | 4 |
| Jarema, M | 3 |
| Bieńkowski, P | 3 |
| Heitzman, J | 1 |
| Parnowski, T | 1 |
| Rybakowski, J | 2 |
| Gen, K | 5 |
| Preskorn, SH | 3 |
| Kishi, T | 3 |
| Matsuda, Y | 3 |
| Németh, B | 1 |
| Molnár, A | 1 |
| Akehurst, R | 1 |
| Horváth, M | 1 |
| Kóczián, K | 1 |
| Götze, Á | 1 |
| Vokó, Z | 1 |
| Chaumette, B | 1 |
| Masson, M | 1 |
| Barde, M | 1 |
| Gay, O | 1 |
| Gaillard, R | 1 |
| Takaya, A | 7 |
| Boothby, A | 1 |
| Shad, MU | 1 |
| Liemburg, EJ | 1 |
| van Es, F | 1 |
| Knegtering, H | 3 |
| Aleman, A | 4 |
| Ramirez-Bonilla, M | 3 |
| Gomez-Arnau, J | 1 |
| Ortiz-Garcia de la Foz, V | 3 |
| Martinez-Garcia, O | 7 |
| Neergaard, KD | 1 |
| Tabares-Seisdedos, R | 5 |
| Gabriel, D | 2 |
| Jakubovski, E | 2 |
| Artukoglu, BB | 1 |
| Decuypere, F | 1 |
| Sermon, J | 1 |
| Geerts, P | 2 |
| Denee, TR | 2 |
| De Vos, C | 1 |
| Malfait, B | 1 |
| Lamotte, M | 1 |
| Mulder, CL | 1 |
| Lee, SY | 6 |
| Wang, LJ | 3 |
| Kudlek Mikulic, S | 1 |
| Mihaljevic-Peles, A | 3 |
| Bajs Janovic, M | 1 |
| Grubisin, J | 2 |
| Kuzman Rojnic, M | 1 |
| Vuksan Cusa, B | 1 |
| Bradaš, Z | 1 |
| Kashani, L | 2 |
| Shams, N | 1 |
| Karkhaneh-Yousefi, MA | 1 |
| Sadighi, G | 1 |
| Khodaie-Ardakani, MR | 9 |
| Rahiminejad, F | 1 |
| Gupta, D | 1 |
| Sinhmar, V | 1 |
| Prasad, R | 1 |
| Tripathi, A | 1 |
| Garg, PD | 1 |
| Gupta, R | 2 |
| Khurana, H | 1 |
| Gautam, S | 1 |
| Margoob, MA | 1 |
| Aneja, J | 1 |
| Song, C | 1 |
| Huo, R | 5 |
| Xing, Q | 15 |
| Cui, D | 2 |
| Hattori, S | 3 |
| Kishida, I | 2 |
| Suda, A | 2 |
| Miyauchi, M | 2 |
| Shiraishi, Y | 2 |
| Fujibayashi, M | 2 |
| Tsujita, N | 2 |
| Ishii, C | 2 |
| Ishii, N | 2 |
| Moritani, T | 2 |
| Taguri, M | 2 |
| Hirayasu, Y | 2 |
| Rafaniello, C | 1 |
| Sessa, M | 1 |
| Bernardi, FF | 1 |
| Pozzi, M | 1 |
| Cheli, S | 1 |
| Cattaneo, D | 1 |
| Baldelli, S | 1 |
| Molteni, M | 1 |
| Bernardini, R | 1 |
| Rossi, F | 1 |
| Clementi, E | 1 |
| Bravaccio, C | 1 |
| Radice, S | 1 |
| Capuano, A | 1 |
| Ceylan, MF | 1 |
| Erdogan, B | 1 |
| Tural Hesapcioglu, S | 1 |
| Cop, E | 1 |
| Einarson, TR | 6 |
| Bereza, BG | 3 |
| Tedouri, F | 1 |
| Van Impe, K | 4 |
| Dries, PJT | 1 |
| Foster, A | 1 |
| Buckley, P | 3 |
| Lauriello, J | 4 |
| Looney, S | 1 |
| Schooler, N | 3 |
| Andrade, C | 3 |
| Lenz, K | 1 |
| Perry-Rose, J | 1 |
| Shad, M | 1 |
| Bo, Q | 2 |
| Li, F | 1 |
| Dong, F | 3 |
| He, F | 1 |
| Li, A | 2 |
| Pilon, D | 1 |
| Tandon, N | 1 |
| Lafeuille, MH | 2 |
| Kamstra, R | 1 |
| Emond, B | 1 |
| Lefebvre, P | 2 |
| Joshi, K | 4 |
| Noordsy, DL | 3 |
| Glynn, SM | 5 |
| Sugar, CA | 2 |
| O'Keefe, CD | 1 |
| Seshadri, M | 1 |
| Elsemary, A | 1 |
| Thalitaya, MD | 1 |
| Chikodzore, L | 1 |
| Nagalingam, P | 1 |
| Najim, H | 1 |
| Pathak, A | 2 |
| Chen, RA | 1 |
| Huang, TL | 3 |
| Xue, F | 1 |
| Chen, YC | 1 |
| Zhou, CH | 1 |
| Cai, M | 1 |
| Yan, WJ | 1 |
| Wang, HN | 1 |
| Llaudó, J | 2 |
| You, Y | 1 |
| Song, Y | 1 |
| Wang, M | 1 |
| Kou, C | 1 |
| Jackson, JW | 2 |
| Fulchino, L | 1 |
| Rogers, J | 1 |
| Mogun, H | 1 |
| Polinski, J | 1 |
| Henderson, DC | 9 |
| Schneeweiss, S | 1 |
| Fischer, MA | 1 |
| Lv, H | 1 |
| Zhang, M | 5 |
| Jiang, R | 1 |
| Xu, C | 2 |
| Gao, M | 1 |
| Li, WD | 1 |
| Çelik, B | 1 |
| Limosin, F | 4 |
| Belhadi, D | 1 |
| Comet, D | 2 |
| Pacou, M | 1 |
| Bouju, S | 2 |
| Guillon, P | 2 |
| Kono, S | 1 |
| Miura, I | 2 |
| Oshima, S | 1 |
| Hikita, M | 1 |
| Wada, A | 1 |
| Suzuki, R | 1 |
| Niwa, SI | 1 |
| Yabe, H | 1 |
| Fjukstad, KK | 1 |
| Engum, A | 1 |
| Lydersen, S | 1 |
| Dieset, I | 1 |
| Steen, NE | 1 |
| Andreassen, OA | 1 |
| Spigset, O | 3 |
| Temmingh, HS | 1 |
| Williams, T | 1 |
| Siegfried, N | 1 |
| Stein, DJ | 1 |
| Nesvåg, R | 3 |
| Bramness, JG | 1 |
| Handal, M | 1 |
| Hartz, I | 1 |
| Hjellvik, V | 1 |
| Skurtveit, S | 1 |
| Mao, L | 8 |
| Biondi, DM | 1 |
| Millet, R | 1 |
| Yoshimura, Y | 3 |
| Takeda, T | 2 |
| Kishi, Y | 2 |
| Harada, T | 2 |
| Nomura, A | 2 |
| Washida, K | 2 |
| Yoshimura, B | 5 |
| Sato, K | 4 |
| Yada, Y | 2 |
| Aoki, S | 2 |
| Dammerman, R | 1 |
| Adera, M | 1 |
| Schwarz, A | 1 |
| Xie, L | 2 |
| Zhang, B | 2 |
| Ruan, Y | 2 |
| Fan, X | 6 |
| Omogbiya, IA | 1 |
| Aderibigbe, AO | 2 |
| Umukoro, S | 2 |
| Iwalewa, EO | 2 |
| Ghajar, A | 2 |
| Khoaie-Ardakani, MR | 1 |
| Shahmoradi, Z | 1 |
| Alavi, AR | 1 |
| Afarideh, M | 2 |
| Shalbafan, MR | 1 |
| Ghazizadeh-Hashemi, M | 2 |
| Sawamura, R | 1 |
| Shimanaga, S | 1 |
| Takeoka, Y | 1 |
| Hashimoto, M | 1 |
| Haji Seyed Javadi, A | 1 |
| Shafikhani, AA | 1 |
| Zamir, SM | 1 |
| Khanshir, ZF | 1 |
| Jiang, XJ | 1 |
| Wu, FX | 1 |
| Zhang, JP | 5 |
| Shi, L | 2 |
| Hu, JQ | 1 |
| Zhu, HZ | 1 |
| Xiao, B | 1 |
| Lin, WC | 1 |
| Wen, YG | 1 |
| Shang, DW | 1 |
| Fan, SJ | 1 |
| Lu, N | 1 |
| Chang, HC | 3 |
| Tang, CH | 3 |
| Huang, KC | 1 |
| Cui, H | 1 |
| Sakamoto, S | 2 |
| Takaki, M | 3 |
| Yamada, N | 1 |
| Woon, LS | 1 |
| Tee, CK | 1 |
| Gan, LLY | 1 |
| Deang, KT | 1 |
| Chan, LF | 1 |
| Jakhar, J | 1 |
| Linganna, S | 1 |
| Seshadri, SP | 1 |
| Eneni, AO | 1 |
| Helland, A | 1 |
| Habib, S | 1 |
| Ulvestad, L | 1 |
| Koh, MT | 1 |
| Ahrens, PS | 1 |
| Gallagher, M | 1 |
| Zhu, F | 2 |
| Tagne Nouemssi, AB | 1 |
| Augusto, M | 1 |
| Touya, M | 2 |
| Sweeney, SM | 1 |
| Waters, H | 1 |
| Russu, A | 1 |
| Kern Sliwa, J | 3 |
| Ravenstijn, P | 1 |
| Singh, A | 2 |
| Mathews, M | 2 |
| Gopal, S | 8 |
| Hendouei, N | 1 |
| Farnia, S | 1 |
| Mohseni, F | 1 |
| Bagheri, M | 2 |
| Shadfar, F | 1 |
| Barzegar, F | 1 |
| Hoseini, SD | 1 |
| Charati, JY | 1 |
| Shaki, F | 1 |
| Gao, LJ | 1 |
| Guo, HG | 1 |
| Liang, ZT | 1 |
| Zhong, XX | 1 |
| Zhu, JC | 1 |
| Tishler, TA | 1 |
| Bartzokis, G | 3 |
| Lu, PH | 3 |
| Raven, EP | 3 |
| Khanoyan, M | 1 |
| Kirkpatrick, CJ | 1 |
| Pyle, MH | 1 |
| Villablanca, JP | 1 |
| Altshuler, LL | 2 |
| Mintz, J | 16 |
| Ellingson, BM | 1 |
| Melkote, R | 1 |
| Vermeulen, A | 1 |
| Remmerie, B | 9 |
| Savitz, A | 5 |
| Bhargava, MS | 1 |
| Rehan, HS | 1 |
| Kataria, D | 1 |
| Zhang, P | 1 |
| Kumar, BU | 1 |
| Hei, G | 1 |
| Ono, S | 10 |
| Sugai, T | 8 |
| Suzuki, Y | 9 |
| Yamazaki, M | 1 |
| Mori, T | 3 |
| Ozeki, Y | 2 |
| Matsuda, H | 1 |
| Okamoto, K | 1 |
| Sagae, T | 1 |
| Someya, T | 9 |
| Pei, H | 1 |
| Nuamah, I | 2 |
| Hough, D | 6 |
| Alphs, L | 12 |
| Scheggia, D | 1 |
| Mastrogiacomo, R | 1 |
| Mereu, M | 1 |
| Sannino, S | 1 |
| Straub, RE | 1 |
| Armando, M | 2 |
| Managò, F | 1 |
| Guadagna, S | 1 |
| Piras, F | 1 |
| Kleinman, JE | 2 |
| Hyde, TM | 1 |
| Kaalund, SS | 1 |
| Pontillo, M | 2 |
| Orso, G | 1 |
| Caltagirone, C | 1 |
| Borrelli, E | 1 |
| De Luca, MA | 1 |
| Vicari, S | 2 |
| Weinberger, DR | 6 |
| Spalletta, G | 1 |
| Gholamian, F | 1 |
| Tabatabei-Motlagh, M | 1 |
| Ji, SM | 1 |
| Li, AN | 2 |
| Zhou, TY | 1 |
| Wang, CY | 10 |
| Lu, W | 2 |
| Xue, XJ | 1 |
| He, RL | 1 |
| Li, WX | 1 |
| Xin, JW | 1 |
| Ye, QY | 1 |
| Chen, XC | 1 |
| Pan, XD | 1 |
| Yeung, RK | 1 |
| Xiang, ZH | 1 |
| Tsang, SY | 1 |
| Ho, TYC | 1 |
| Hui, CK | 1 |
| Sham, PC | 2 |
| Qiao, MQ | 1 |
| Xue, H | 2 |
| Dean, B | 1 |
| Gibbons, A | 1 |
| Gogos, A | 1 |
| Udawela, M | 1 |
| Thomas, E | 1 |
| Scarr, E | 1 |
| Chang, W | 1 |
| Yan, Y | 2 |
| Yi, Z | 2 |
| Cadena, EJ | 1 |
| Jindal, R | 1 |
| Pixley, RM | 1 |
| Ma, L | 2 |
| Xiang, Q | 1 |
| Zhao, N | 1 |
| Xie, Q | 1 |
| Zhao, X | 2 |
| Cui, Y | 1 |
| Alonso, A | 5 |
| Van der Elst, W | 2 |
| Molenberghs, G | 8 |
| Foldager, L | 1 |
| Mors, O | 1 |
| Bech, P | 3 |
| Santoro, ML | 4 |
| Ota, V | 1 |
| de Jong, S | 3 |
| Spindola, LM | 1 |
| Talarico, F | 1 |
| Gouvea, E | 1 |
| Lee, SH | 12 |
| Moretti, P | 1 |
| Curtis, C | 1 |
| Patel, H | 1 |
| Newhouse, S | 1 |
| Carvalho, CM | 1 |
| Guo, H | 1 |
| Daniel, D | 1 |
| Nasrallah, H | 2 |
| Durgam, S | 2 |
| Zhong, Y | 1 |
| Patel, M | 1 |
| Robinson, DG | 15 |
| Gallego, JA | 7 |
| John, M | 5 |
| Hanna, LA | 1 |
| Birnbaum, ML | 1 |
| Greenberg, J | 2 |
| Naraine, M | 2 |
| Peters, BD | 1 |
| McNamara, RK | 3 |
| Malhotra, AK | 13 |
| Szeszko, PR | 4 |
| Wu, RQ | 1 |
| Lin, CG | 1 |
| Lin, XD | 1 |
| Chen, XS | 3 |
| Zhang, LJ | 1 |
| Huang, ZY | 1 |
| Chen, GD | 1 |
| Xu, DL | 1 |
| Lin, ZG | 1 |
| Zhang, MD | 2 |
| Dias Alves, M | 1 |
| Micoulaud-Franchi, JA | 1 |
| Simon, N | 1 |
| Vion-Dury, J | 1 |
| Adithan, S | 1 |
| Bellivier, F | 1 |
| Flórez, AJ | 1 |
| Verbeke, G | 1 |
| Abad, AA | 2 |
| Chhatlani, A | 1 |
| Farheen, SA | 1 |
| Setty, MJ | 1 |
| Tampi, RR | 1 |
| Szota, AM | 1 |
| Araszkiewicz, AS | 1 |
| Tsukahara, M | 1 |
| So, R | 1 |
| Smith, RC | 6 |
| Pantazatos, SP | 3 |
| Mann, JJ | 3 |
| Liu, ZC | 1 |
| Sang, D | 3 |
| Chen, YL | 1 |
| Chen, KP | 3 |
| Chiu, CC | 10 |
| Tai, MH | 1 |
| Lung, FW | 5 |
| Salgueiro, M | 1 |
| Segarra, R | 2 |
| Bellavia, A | 1 |
| Centorrino, F | 2 |
| Fitzmaurice, G | 1 |
| Valeri, L | 1 |
| Inagaki, A | 1 |
| Sivaraman, S | 1 |
| Martinak, BK | 1 |
| Misiak, B | 3 |
| Samochowiec, J | 2 |
| Petrić, D | 1 |
| Rački, V | 1 |
| Gačo, N | 1 |
| Kaštelan, A | 1 |
| Graovac, M | 1 |
| Grădinaru, R | 1 |
| Andreescu, N | 1 |
| Nussbaum, L | 1 |
| Suciu, L | 1 |
| Puiu, M | 1 |
| Takahashi, K | 1 |
| Nakagawasai, O | 1 |
| Sakuma, W | 1 |
| Nemoto, W | 1 |
| Odaira, T | 1 |
| Lin, JR | 1 |
| Onogi, H | 1 |
| Srivastava, LK | 1 |
| Tan-No, K | 1 |
| Szalai, E | 2 |
| Harsányi, J | 2 |
| Anthony, T | 1 |
| Skidmore, FM | 2 |
| Marstrander, J | 1 |
| Melas Skefos, NH | 1 |
| Bolu, A | 1 |
| Garip, B | 1 |
| Öznur, T | 1 |
| Uzun, Ö | 1 |
| Dal Mas, C | 1 |
| Nani, JV | 1 |
| Yonamine, CM | 1 |
| da Cunha, GR | 1 |
| Mansur, RB | 1 |
| Kapczinski, F | 2 |
| Brietzke, E | 2 |
| Hayashi, MAF | 1 |
| Kanahara, N | 6 |
| Yoshimura, K | 2 |
| Nakamura, M | 4 |
| Oda, Y | 1 |
| Watanabe, M | 1 |
| Iyo, M | 8 |
| Higuchi, T | 2 |
| Kwon, JS | 2 |
| Chou, YH | 4 |
| Chen, HK | 1 |
| Chen, JY | 6 |
| Chen, TT | 8 |
| Huang, SY | 3 |
| Lee, JS | 1 |
| Saeki, Y | 1 |
| Tanaka, H | 3 |
| Wang, TS | 1 |
| Wu, BJ | 1 |
| Katoh, T | 1 |
| Ishigouoka, J | 1 |
| Nucifora, LG | 1 |
| MacDonald, ML | 1 |
| Lee, BJ | 1 |
| Peters, ME | 1 |
| Norris, AL | 1 |
| Orsburn, BC | 1 |
| Gleason, K | 1 |
| Margolis, RL | 1 |
| Pevsner, J | 1 |
| Tamminga, CA | 6 |
| Sweet, RA | 1 |
| Ross, CA | 1 |
| Sawa, A | 1 |
| Nucifora, FC | 1 |
| El Khoury, AC | 1 |
| Brouillette, M | 1 |
| Smith, D | 1 |
| Seeman, MV | 2 |
| Pitzianti, M | 1 |
| Casarelli, L | 1 |
| Pasini, A | 1 |
| Baymeeva, NV | 2 |
| Platova, AI | 2 |
| Kaleda, VG | 1 |
| Miroshnichenko, II | 2 |
| Uguz, F | 1 |
| de Leon, J | 5 |
| Harmand, S | 1 |
| Ansolabehere, X | 1 |
| Downing, L | 1 |
| Kim, DD | 1 |
| Procyshyn, RM` | 1 |
| Tibbo, P | 2 |
| Fowler, JC | 1 |
| Cope, N | 1 |
| Knights, J | 1 |
| Phiri, P | 1 |
| Makin, A | 1 |
| Peters-Strickland, T | 1 |
| Rathod, S | 1 |
| Singh, R | 1 |
| Bansal, Y | 1 |
| Sodhi, RK | 1 |
| Saroj, P | 1 |
| Medhi, B | 1 |
| Kuhad, A | 1 |
| Taniguchi, M | 1 |
| Hatano, M | 1 |
| Kamei, H | 1 |
| Inagaki, R | 1 |
| Yamada, S | 1 |
| Joo, SW | 1 |
| Shon, SH | 1 |
| Choi, G | 1 |
| Koh, M | 1 |
| Cho, SW | 1 |
| Lee, J | 3 |
| Ng-Mak, D | 1 |
| Messali, A | 1 |
| Huang, A | 1 |
| Spertus, J | 1 |
| Horvitz-Lennon, M | 2 |
| Normand, ST | 1 |
| Bareis, N | 1 |
| Stroup, TS | 19 |
| Li, YG | 1 |
| He, S | 1 |
| Yu, YM | 1 |
| Wen, H | 2 |
| Qiao, Y | 2 |
| Shen, YF | 1 |
| Li, HF | 2 |
| Kimura, H | 5 |
| Watanabe, H | 4 |
| Rogóż, Z | 2 |
| Frey, S | 1 |
| Linder, R | 1 |
| Juckel, G | 3 |
| Stargardt, T | 2 |
| Wei, Z | 6 |
| Yu, T | 1 |
| Wang, T | 3 |
| Feng, G | 13 |
| Sotoyama, H | 2 |
| Namba, H | 2 |
| Chiken, S | 1 |
| Nambu, A | 1 |
| Nawa, H | 2 |
| Otomo, M | 2 |
| Cheung, C | 1 |
| Huang, C | 2 |
| Jiang, L | 3 |
| Collier, DA | 2 |
| Chua, SE | 1 |
| McAlonan, GM | 1 |
| Fu, DJ | 6 |
| Ma, YW | 4 |
| Khanna, P | 1 |
| Komossa, K | 12 |
| Rummel-Kluge, C | 12 |
| Hunger, H | 11 |
| Schwarz, S | 11 |
| El-Sayeh, HG | 2 |
| Rodríguez-Sánchez, JM | 2 |
| Pérez-Iglesias, R | 9 |
| Roiz-Santiáñez, R | 2 |
| Sánchez-Moreno, J | 1 |
| Vázquez-Barquero, JL | 8 |
| Diaz, FJ | 1 |
| Tsuchie, K | 1 |
| Miyaoka, T | 1 |
| Furuya, M | 1 |
| Liaury, K | 1 |
| Ieda, M | 1 |
| Wake, R | 1 |
| Horiguchi, J | 2 |
| Takechi, M | 1 |
| Wang, S | 2 |
| Noroozian, M | 3 |
| Ghasemi, S | 1 |
| Hosseini, SM | 5 |
| Modabbernia, A | 5 |
| Mirshafiee, O | 2 |
| Farokhnia, M | 6 |
| Tajdini, M | 4 |
| Salehi, B | 10 |
| Ashrafi, M | 5 |
| Yekehtaz, H | 5 |
| Tabrizi, M | 11 |
| Yazdi, K | 1 |
| Rosenleitner, J | 1 |
| Pischinger, B | 1 |
| Misdrahi, D | 1 |
| Delgado, A | 1 |
| Chiariny, JF | 1 |
| Kirk Morton, N | 1 |
| Zubek, D | 1 |
| Fukui, N | 8 |
| Watanabe, J | 8 |
| Tsuneyama, N | 7 |
| Saito, M | 15 |
| Ruocco, E | 1 |
| Brunetti, G | 1 |
| Langella, GG | 1 |
| Ruocco, V | 1 |
| Fleischhacker, WW | 12 |
| Müller-Spahn, F | 2 |
| Barrio, P | 1 |
| Batalla, A | 1 |
| Castellví, P | 1 |
| Hidalgo, D | 1 |
| García, M | 1 |
| Ortiz, A | 1 |
| Grande, I | 1 |
| Pons, A | 3 |
| Parellada, E | 10 |
| Mohammad-Karimi, M | 2 |
| Seddighi, S | 2 |
| Hammidi, S | 1 |
| Motasami, H | 1 |
| Hajiaghaee, R | 2 |
| Yanagi, M | 1 |
| Joho, RH | 1 |
| Southcott, SA | 1 |
| Shukla, AA | 1 |
| Ghose, S | 1 |
| Berle, JØ | 1 |
| Fasmer, OB | 1 |
| Acosta, FJ | 1 |
| Chinea, E | 1 |
| Hernández, JL | 1 |
| Rodríguez, F | 1 |
| García-Bello, M | 1 |
| Medina, G | 1 |
| Nieves, W | 1 |
| Takeuchi, K | 1 |
| Sanjo, K | 1 |
| Sakai, A | 1 |
| Margari, L | 2 |
| Matera, E | 2 |
| Craig, F | 1 |
| Petruzzelli, MG | 2 |
| Palmieri, VO | 2 |
| Pastore, A | 2 |
| Margari, F | 2 |
| Adams, DH | 4 |
| Baygani, S | 1 |
| Millen, BA | 2 |
| Velona, I | 1 |
| Kollack-Walker, S | 6 |
| Agid, O | 7 |
| Schulze, L | 1 |
| Arenovich, T | 4 |
| Sajeev, G | 2 |
| McDonald, K | 1 |
| Foussias, G | 2 |
| Fervaha, G | 3 |
| Remington, G | 32 |
| Lammers, L | 1 |
| Zehm, B | 1 |
| Williams, R | 10 |
| Tsuboi, T | 4 |
| Bies, RR | 11 |
| Suzuki, T | 31 |
| Mamo, DC | 16 |
| Pollock, BG | 17 |
| Graff-Guerrero, A | 12 |
| Mimura, M | 13 |
| Uchida, H | 25 |
| Malla, A | 2 |
| Chue, P | 5 |
| Jordan, G | 1 |
| Stip, E | 10 |
| Koczerginski, D | 2 |
| Milliken, H | 1 |
| Joseph, A | 2 |
| Adams, B | 1 |
| Manchanda, R | 2 |
| Oyewumi, K | 1 |
| Ziadi Trives, M | 1 |
| Bonete Llácer, JM | 1 |
| García Escudero, MA | 1 |
| Martínez Pastor, CJ | 1 |
| Kim, EY | 2 |
| Chang, SM | 1 |
| Shim, JC | 2 |
| Joo, EJ | 1 |
| Kim, JJ | 3 |
| Kim, YS | 5 |
| Ahn, YM | 5 |
| Konarzewska, B | 4 |
| Waszkiewicz, N | 3 |
| Galińska, B | 3 |
| Szulc, A | 5 |
| Zilbershtein, R | 3 |
| Skoupá, J | 1 |
| Veselá, S | 1 |
| Garg, M | 1 |
| Hemels, ME | 3 |
| Petronijevic, N | 1 |
| Sopta, J | 1 |
| Doknic, M | 4 |
| Radonjic, N | 1 |
| Petronijevic, M | 1 |
| Pekic, S | 3 |
| Maric, N | 2 |
| Jasovic-Gasic, M | 2 |
| Popovic, V | 5 |
| Ozasa, R | 1 |
| Okada, T | 2 |
| Nadanaka, S | 1 |
| Nagamine, T | 2 |
| Zyryanova, A | 1 |
| Harding, H | 1 |
| Ron, D | 1 |
| Mori, K | 4 |
| Abe, T | 2 |
| Watanabe, K | 14 |
| Kalkavoura, CS | 1 |
| Michopoulos, I | 1 |
| Arvanitakis, P | 1 |
| Theodoropoulou, P | 1 |
| Dimopoulou, K | 1 |
| Tzebelikos, E | 2 |
| Lykouras, L | 7 |
| Pudas, H | 4 |
| Jensen, R | 2 |
| Vicente, C | 2 |
| Piwko, C | 2 |
| Gomeni, R | 2 |
| Heidbreder, C | 5 |
| Fudala, PJ | 3 |
| Nasser, AF | 3 |
| Barry, SJ | 1 |
| Gaughan, TM | 1 |
| Hunter, R | 2 |
| Sanz-Fuentenebro, J | 2 |
| Taboada, D | 2 |
| Palomo, T | 5 |
| Aragües, M | 2 |
| Ovejero, S | 1 |
| Del Alamo, C | 1 |
| Molina, V | 7 |
| Liu, S | 2 |
| Yuan, YB | 2 |
| Guan, LL | 1 |
| Wei, H | 2 |
| Pu, CC | 1 |
| Yang, FD | 4 |
| Zhao, JP | 7 |
| Scanlan, JN | 1 |
| Thorburn, K | 1 |
| Mukai, T | 1 |
| Moriguchi, S | 1 |
| Hatta, K | 4 |
| Takebayashi, H | 4 |
| Sudo, Y | 6 |
| Katayama, S | 2 |
| Kasuya, M | 2 |
| Shirai, Y | 2 |
| Morikawa, F | 3 |
| Nakase, R | 3 |
| Ito, S | 3 |
| Kuga, H | 2 |
| Ohnuma, T | 1 |
| Usui, C | 4 |
| Hirata, T | 4 |
| Sawa, Y | 4 |
| Peuskens, J | 22 |
| Schwarzmann, N | 1 |
| Goltz, M | 1 |
| Krüger, H | 1 |
| Lambert, M | 4 |
| Haro, JM | 8 |
| O'Donoghue, B | 1 |
| Schäfer, MR | 1 |
| Becker, J | 1 |
| Papageorgiou, K | 1 |
| Amminger, GP | 2 |
| Davidson, CK | 1 |
| Johnson, T | 1 |
| Jansen, K | 1 |
| Schwarz, E | 3 |
| Bogerts, B | 1 |
| Bahn, S | 3 |
| Wu, DB | 1 |
| Lee, EH | 4 |
| Chung, WS | 1 |
| Chow, DP | 1 |
| Lee, VW | 1 |
| Wong, MC | 1 |
| Lee, KK | 1 |
| Sabzabadi, M | 1 |
| Pourmahmoud, H | 1 |
| Laliberté-Auger, F | 1 |
| Frois, C | 1 |
| Fastenau, J | 2 |
| Duh, MS | 1 |
| Almoguera, B | 2 |
| Riveiro-Alvarez, R | 2 |
| Lopez-Castroman, J | 2 |
| Dorado, P | 4 |
| Vaquero-Lorenzo, C | 2 |
| Fernandez-Piqueras, J | 2 |
| Llerena, A | 4 |
| Abad-Santos, F | 2 |
| Baca-García, E | 2 |
| Dal-Ré, R | 2 |
| Ayuso, C | 2 |
| Monte, AS | 2 |
| de Souza, GC | 1 |
| McIntyre, RS | 1 |
| Soczynska, JK | 1 |
| dos Santos, JV | 1 |
| Cordeiro, RC | 2 |
| Ribeiro, BM | 1 |
| de Lucena, DF | 1 |
| Vasconcelos, SM | 1 |
| de Sousa, FC | 1 |
| Macêdo, DS | 1 |
| Sinkeviciute, I | 1 |
| Hugdahl, K | 1 |
| Jørgensen, HA | 1 |
| Nakagome, K | 2 |
| Ohmori, T | 3 |
| Lin, AS | 1 |
| Cheng, JS | 1 |
| Chen, YY | 3 |
| Tsai, CJ | 3 |
| Silva, PN | 2 |
| Melaragno, MI | 2 |
| Smith, Mde A | 1 |
| Datta, SS | 1 |
| Wright, SD | 1 |
| Furtado, VA | 3 |
| Russell, PS | 1 |
| Kwak, YT | 1 |
| Koo, MS | 2 |
| Hadley, JA | 3 |
| Nenert, R | 1 |
| Bolding, MS | 2 |
| Visscher, KM | 1 |
| Grassi, G | 1 |
| Poli, L | 1 |
| Cantisani, A | 1 |
| Righi, L | 1 |
| Ferrari, G | 1 |
| Pallanti, S | 1 |
| Hutcheson, NL | 2 |
| Clark, DG | 1 |
| Zhang, HX | 1 |
| Shen, XL | 1 |
| Yang, XM | 1 |
| Wang, HF | 1 |
| Jiang, KD | 1 |
| Asmal, L | 3 |
| Flegar, SJ | 1 |
| Bø, CN | 1 |
| Volavka, J | 16 |
| Citrome, L | 23 |
| Van Dorn, RA | 3 |
| Gattaz, WF | 1 |
| Campos, JA | 1 |
| Lacerda, AL | 1 |
| Henna, E | 1 |
| Ruschel, SI | 1 |
| de Oliveira, IR | 3 |
| Rocha, FL | 1 |
| Grabowski, HM | 1 |
| Sacomani, E | 1 |
| Louzã, MR | 1 |
| Quevedo, J | 1 |
| Elkis, H | 4 |
| Zorzetto Filho, D | 1 |
| Périco, Cde A | 1 |
| Lawson, FL | 1 |
| Appolinário, JC | 1 |
| Zhou, FC | 1 |
| Xiang, YT | 6 |
| Kreyenbuhl, J | 5 |
| Ungvari, GS | 7 |
| Au, RW | 1 |
| Zhou, JJ | 1 |
| Shum, D | 1 |
| Man, D | 1 |
| Lai, KY | 2 |
| Tang, WK | 3 |
| Chiu, HF | 5 |
| Dourish, CT | 2 |
| Dawson, GR | 2 |
| Schmechtig, A | 2 |
| Lees, J | 1 |
| Perkins, A | 1 |
| Altavilla, A | 1 |
| Craig, KJ | 1 |
| William Deakin, JF | 1 |
| Evans, LH | 1 |
| Koychev, I | 1 |
| Weaver, K | 1 |
| Smallman, R | 1 |
| Walters, J | 1 |
| Wilkinson, LS | 1 |
| Morris, R | 1 |
| Williams, SC | 4 |
| Ettinger, U | 2 |
| Tsermpini, EE | 1 |
| Assimakopoulos, K | 1 |
| Bartsakoulia, M | 1 |
| Iconomou, G | 1 |
| Papadima, EM | 1 |
| Mitropoulos, K | 1 |
| Squassina, A | 1 |
| Patrinos, GP | 1 |
| Harrington, A | 1 |
| Ziedonis, D | 2 |
| Birkeland, SF | 1 |
| Walther, S | 2 |
| Moggi, F | 1 |
| Horn, H | 2 |
| Moskvitin, K | 1 |
| Abderhalden, C | 1 |
| Maier, N | 1 |
| Strik, W | 3 |
| Müller, TJ | 2 |
| Yang, DS | 1 |
| Seong, SJ | 1 |
| Yoon, YR | 1 |
| Lim, MS | 1 |
| Kwak, KH | 1 |
| Lee, SJ | 3 |
| Fischer, BA | 1 |
| Leatherman, SM | 1 |
| Liang, MH | 3 |
| Krystal, JH | 5 |
| Lew, RA | 1 |
| Valley, D | 3 |
| Thwin, SS | 3 |
| Rosenheck, RA | 22 |
| Rosenheck, R | 5 |
| Lin, H | 2 |
| Sawamura, K | 1 |
| Jiang, P | 3 |
| Zhu, MQ | 1 |
| Li, HD | 6 |
| Cai, HL | 5 |
| Zhang, LM | 1 |
| Maat, A | 1 |
| Cahn, W | 2 |
| Gijsman, HJ | 1 |
| Hovens, JE | 1 |
| Kahn, RS | 6 |
| Laffont, CM | 2 |
| Zheng, B | 1 |
| Uthayathas, S | 1 |
| Masilamoni, GJ | 1 |
| Shaffer, CL | 1 |
| Schmidt, CJ | 1 |
| Menniti, FS | 1 |
| Papa, SM | 1 |
| Xiong, Y | 3 |
| Gong, X | 1 |
| Guo, X | 2 |
| Ou, J | 1 |
| Yang, S | 2 |
| Sato, S | 1 |
| Iwata, K | 1 |
| Furukawa, S | 1 |
| Hatsuse, N | 1 |
| Watanabe, Y | 1 |
| Anzai, N | 1 |
| Kishimoto, T | 2 |
| Ikebuchi, E | 1 |
| Alva, G | 3 |
| Brams, M | 1 |
| Glick, ID | 7 |
| Jackson, R | 2 |
| Mattingly, G | 2 |
| Kianifard, F | 2 |
| Meng, X | 3 |
| Pestreich, L | 1 |
| Hochfeld, M | 2 |
| Winseck, A | 2 |
| Alaqeel, B | 1 |
| Awad, G | 1 |
| Hassan, M | 1 |
| Hsu, J | 1 |
| Rajagopalan, K | 3 |
| von Schéele, B | 1 |
| Mauskopf, J | 1 |
| Brodtkorb, TH | 1 |
| Ainsworth, C | 1 |
| Berardo, CG | 1 |
| Patel, A | 1 |
| Lipscombe, LL | 1 |
| Austin, PC | 1 |
| Alessi-Severini, S | 1 |
| Blackburn, DF | 2 |
| Blais, L | 2 |
| Bresee, L | 2 |
| Filion, KB | 1 |
| Kawasumi, Y | 1 |
| Kurdyak, P | 1 |
| Platt, RW | 1 |
| Tamim, H | 1 |
| Paterson, JM | 1 |
| de Witte, L | 1 |
| Tomasik, J | 2 |
| Rahmoune, H | 2 |
| Lee, NY | 2 |
| Kim, SH | 5 |
| Cho, SJ | 2 |
| Chung, YC | 2 |
| Jung, IK | 2 |
| Kim, CY | 3 |
| Kim, DH | 1 |
| Lee, DG | 1 |
| Lee, YH | 4 |
| Lim, WJ | 1 |
| Na, YS | 1 |
| Shin, SE | 1 |
| Woo, JM | 2 |
| Yoon, JS | 8 |
| Yoon, BH | 3 |
| Nikolac Perkovic, M | 1 |
| Nedic Erjavec, G | 1 |
| Uzun, S | 3 |
| Kozumplik, O | 3 |
| Muck-Seler, D | 1 |
| Pivac, N | 1 |
| Stefanovics, EA | 1 |
| Tran, D | 1 |
| Crawley, A | 1 |
| Lynds, S | 1 |
| Champagne, A | 1 |
| Remillard, AJ | 1 |
| Galińska-Skok, B | 1 |
| Łazarczyk-Kirejczyk, J | 1 |
| Malus, A | 1 |
| Simonienko, K | 1 |
| Meltzer, HY | 22 |
| Lindenmayer, JP | 21 |
| Kwentus, J | 2 |
| Share, DB | 1 |
| Johnson, R | 1 |
| Jayathilake, K | 7 |
| Gougol, A | 1 |
| Iranpour, N | 2 |
| Ghaleiha, A | 5 |
| Mannheimer, B | 1 |
| Holm, J | 1 |
| Koukel, L | 1 |
| Bertilsson, L | 2 |
| Osby, U | 1 |
| Eliasson, E | 1 |
| Machielsen, MW | 1 |
| Komatsu, N | 3 |
| Ishige, M | 3 |
| Muneoka, K | 3 |
| Yoshimura, M | 5 |
| Yamanaka, H | 3 |
| Komatsu, H | 3 |
| Hashimoto, T | 2 |
| Hasegawa, T | 2 |
| Shiina, A | 1 |
| Ishikawa, M | 1 |
| Sekine, Y | 3 |
| Shiraishi, T | 1 |
| Shimizu, E | 2 |
| Hashimoto, K | 2 |
| Di Fiorino, M | 2 |
| Montagnani, G | 2 |
| Trespi, G | 2 |
| Kasper, S | 11 |
| Dolgin, E | 1 |
| Ding, YQ | 1 |
| Sumiyoshi, T | 3 |
| Mizuki, Y | 2 |
| Miki, T | 1 |
| Schreiner, A | 21 |
| Svensson, A | 1 |
| Wapenaar, R | 1 |
| Cherubin, P | 4 |
| Princet, P | 1 |
| Serazetdinova, L | 1 |
| Zink, M | 4 |
| de Araújo, AA | 3 |
| de Araújo Dantas, D | 1 |
| do Nascimento, GG | 1 |
| Ribeiro, SB | 3 |
| Chaves, KM | 2 |
| de Lima Silva, V | 1 |
| de Araújo, RF | 1 |
| de Souza, DL | 1 |
| de Medeiros, CA | 1 |
| Lozano, R | 1 |
| Marin, R | 1 |
| Santacruz, MJ | 1 |
| Buckley, PF | 7 |
| Schooler, NR | 17 |
| Goff, DC | 15 |
| Hsiao, J | 2 |
| Kopelowicz, A | 2 |
| Manschreck, T | 2 |
| Mendelowitz, AJ | 1 |
| Miller, del D | 1 |
| Severe, JB | 1 |
| Wilson, DR | 3 |
| Ames, D | 7 |
| Bustillo, J | 1 |
| Gilca, M | 1 |
| Piriu, G | 1 |
| Gaman, L | 1 |
| Delia, C | 1 |
| Iosif, L | 1 |
| Atanasiu, V | 1 |
| Stoian, I | 1 |
| Stilhano, RS | 1 |
| Santos, CM | 2 |
| Diana, MC | 2 |
| Han, SW | 1 |
| Abílio, VC | 2 |
| Petzold, M | 1 |
| Bennett, K | 1 |
| Bennie, M | 2 |
| Bucsics, A | 1 |
| Finlayson, AE | 1 |
| Persson, M | 1 |
| Piessnegger, J | 1 |
| Raschi, E | 2 |
| Simoens, S | 1 |
| Zara, C | 1 |
| Huang, YR | 1 |
| Pai, CW | 1 |
| Cheng, KH | 1 |
| Kuo, WI | 1 |
| Chen, MW | 1 |
| Chang, KW | 1 |
| Park, T | 1 |
| Kuntz, KM | 1 |
| Gu, N | 5 |
| Usall, J | 1 |
| López-Carrilero, R | 1 |
| Iniesta, R | 1 |
| Roca, M | 2 |
| Caballero, M | 1 |
| Rodriguez-Jimenez, R | 2 |
| Oliveira, C | 1 |
| Bernardo, M | 8 |
| Corripio, I | 4 |
| Sindreu, SD | 1 |
| González Piqueras, JC | 1 |
| Felipe, AE | 1 |
| Fernandez de Corres, B | 1 |
| Ibáñez, A | 1 |
| Huerta, R | 1 |
| Kianimehr, G | 1 |
| Fatehi, F | 1 |
| Hashempoor, S | 1 |
| Khodaei-Ardakani, MR | 1 |
| Nazari, A | 1 |
| Ghanizadeh, A | 2 |
| Rezaee, Z | 1 |
| Dehbozorgi, S | 2 |
| Berk, M | 3 |
| Karamihalev, S | 1 |
| Prickaerts, J | 2 |
| van Goethem, NP | 1 |
| Otachi, T | 3 |
| Fujita, K | 2 |
| Tomiyama, H | 1 |
| Yamashita, T | 2 |
| Ito, H | 3 |
| Hernández, JA | 1 |
| Hou, YC | 1 |
| Lai, CH | 1 |
| Hellemann, GS | 3 |
| Agee, ER | 1 |
| Luo, JS | 4 |
| Villa, KF | 1 |
| Maimaitirexiati, T | 1 |
| Gui, X | 1 |
| Xu, G | 1 |
| Hu, G | 1 |
| Jiang, J | 1 |
| Nielsen, J | 2 |
| Jensen, SO | 1 |
| Friis, RB | 1 |
| Valentin, JB | 1 |
| Hsu, YC | 1 |
| Yeh, YW | 2 |
| Mulsant, BH | 9 |
| Rajji, TK | 6 |
| Ahadi, M | 1 |
| Sinclair, D | 1 |
| Adams, CE | 1 |
| Lai, EC | 2 |
| Yang, YH | 1 |
| Ajami, A | 1 |
| Abedian, F | 1 |
| Hamzeh Hosseini, S | 1 |
| Akbarian, E | 1 |
| Alizadeh-Navaei, R | 1 |
| Taghipour, M | 1 |
| Nemani, K | 1 |
| Frydecka, D | 2 |
| Łaczmański, Ł | 1 |
| Ślęzak, R | 1 |
| Kiejna, A | 1 |
| McLoughlin, BC | 1 |
| Pushpa-Rajah, JA | 1 |
| Gillies, D | 1 |
| Rathbone, J | 1 |
| Variend, H | 1 |
| Kalakouti, E | 1 |
| Kyprianou, K | 1 |
| Laties, AM | 1 |
| Flach, AJ | 1 |
| Baldycheva, I | 1 |
| Rak, I | 1 |
| Favis, R | 1 |
| Jadwin, A | 1 |
| Chung, H | 1 |
| Cohen, N | 1 |
| OmraniSigaroodi, M | 1 |
| Rezaei, Z | 1 |
| Xu, H | 2 |
| Bossie, C | 3 |
| Burón, JA | 4 |
| Castle, DJ | 2 |
| Slott Jensen, JK | 1 |
| Sarpal, DK | 2 |
| Lencz, T | 9 |
| Argyelan, M | 2 |
| Ikuta, T | 1 |
| Karlsgodt, K | 1 |
| Furukawa, TA | 1 |
| Levine, SZ | 5 |
| Tanaka, S | 1 |
| Goldberg, Y | 2 |
| Samara, M | 2 |
| Toledo-Romero, F | 1 |
| Molina, JD | 1 |
| López-Rodríguez, E | 1 |
| Amorin-Díaz, M | 1 |
| Muñoz Algar, MJ | 1 |
| Aparicio-Castro, E | 1 |
| Chuang, WC | 1 |
| Chen, CY | 2 |
| Kuo, SC | 1 |
| Chen, TY | 1 |
| Dilla, T | 1 |
| Möller, J | 1 |
| O'Donohoe, P | 1 |
| Álvarez, M | 1 |
| Sacristán, JA | 4 |
| Happich, M | 1 |
| Tockhorn, A | 1 |
| Guru, S | 1 |
| Vanamoorthy, U | 1 |
| Loganathan, S | 1 |
| Varghese, M | 1 |
| Hargarter, L | 3 |
| Bergmans, P | 4 |
| Keim, S | 3 |
| Rancans, E | 2 |
| Bez, Y | 1 |
| Carpiniello, B | 2 |
| Ramsey, TL | 2 |
| Brennan, MD | 2 |
| Dong, H | 1 |
| Wu, YF | 1 |
| Sreenivasan, KR | 1 |
| Deshpande, G | 1 |
| Hadley, J | 1 |
| Simone, M | 1 |
| Lamanna, AL | 1 |
| Wu, YH | 1 |
| Lai, CY | 1 |
| Chang, YS | 1 |
| Prieto, C | 1 |
| Sainz, J | 1 |
| Marston, L | 2 |
| Nazareth, I | 2 |
| Petersen, I | 2 |
| Walters, K | 2 |
| Osborn, DP | 1 |
| Ennis, ZN | 1 |
| Damkier, P | 1 |
| Downing, AM | 1 |
| Liu, L | 4 |
| Morozova, MA | 3 |
| Brenner, R | 4 |
| Rayle, TJ | 1 |
| Nisenbaum, L | 1 |
| Zhao, F | 3 |
| Gomez, JC | 6 |
| Nakajima, S | 7 |
| Plitman, E | 3 |
| Chung, JK | 2 |
| Caravaggio, F | 5 |
| Mihashi, Y | 1 |
| Gerretsen, P | 5 |
| Mulsant, B | 1 |
| Han, M | 1 |
| Song, CS | 1 |
| Yu, YH | 1 |
| Farrelly, L | 1 |
| Föcking, M | 1 |
| Piontkewitz, Y | 3 |
| Dicker, P | 1 |
| English, J | 1 |
| Wynne, K | 1 |
| Cannon, M | 1 |
| Cagney, G | 1 |
| Cotter, DR | 1 |
| Kim, SW | 7 |
| Jeong, BO | 1 |
| Kim, JM | 7 |
| Shin, IS | 7 |
| Hwang, MY | 3 |
| Paul Amminger, G | 1 |
| Nelson, B | 2 |
| McGorry, P | 1 |
| Voss, EA | 1 |
| Ryan, PB | 2 |
| Stang, PE | 2 |
| Shinkawa, I | 1 |
| Konishi, A | 1 |
| Zhou, J | 5 |
| Zhao, H | 2 |
| Chan, HW | 1 |
| Huang, CY | 1 |
| Feng, WJ | 1 |
| Yen, YC | 2 |
| Galler, A | 1 |
| Bollow, E | 1 |
| Meusers, M | 1 |
| Bartus, B | 1 |
| Näke, A | 1 |
| Haberland, H | 1 |
| Schober, E | 1 |
| Holl, RW | 1 |
| Imran, TF | 1 |
| Niazi, OT | 1 |
| Amin, R | 1 |
| Mazza, V | 1 |
| Klapholz, M | 1 |
| van der Weide, K | 1 |
| van der Weide, J | 1 |
| Bonaccorso, S | 3 |
| Sodhi, M | 1 |
| Bobo, WV | 5 |
| Tumuklu, M | 3 |
| Theleritis, C | 1 |
| Lubinga, SJ | 1 |
| Mutamba, BB | 1 |
| Nganizi, A | 1 |
| Babigumira, JB | 1 |
| Kumari, V | 3 |
| Lee, SE | 1 |
| Deuschl, C | 1 |
| Anilkumar, AP | 3 |
| Corr, PJ | 1 |
| Ffytche, DH | 1 |
| Chen, JX | 2 |
| Su, YA | 2 |
| Bian, QT | 2 |
| Wei, LH | 1 |
| Zhang, RZ | 1 |
| Liu, YH | 2 |
| Correll, C | 2 |
| Soares, JC | 1 |
| Wang, SL | 2 |
| Cosar, B | 1 |
| Petralia, A | 2 |
| Law, S | 1 |
| Gudbrandsen, M | 1 |
| Magill, N | 1 |
| Sweetman, I | 1 |
| Rose, D | 2 |
| Landau, S | 2 |
| Flanagan, RJ | 1 |
| David, AS | 8 |
| Tan, EM | 1 |
| Marcelin, JR | 1 |
| Sohail, R | 1 |
| Ramar, K | 1 |
| Khosravi, M | 1 |
| Zarinfard, R | 1 |
| Nejati, S | 2 |
| Mohsenian, A | 1 |
| Wartelsteiner, F | 1 |
| Hofer, A | 2 |
| Mohamed, S | 3 |
| Swartz, M | 3 |
| McEvoy, J | 6 |
| Stroup, S | 5 |
| Hu, LY | 1 |
| Lee, YT | 1 |
| Hung, MB | 1 |
| Hung, YY | 1 |
| Carpenter, WT | 3 |
| Buchanan, RW | 4 |
| Marder, S | 5 |
| Moerbeek, M | 1 |
| Wong, WK | 1 |
| Lee, JY | 1 |
| Kang, HJ | 1 |
| Kim, SY | 3 |
| Bae, KY | 2 |
| Mar, W | 4 |
| Emsley, R | 14 |
| Chiliza, B | 2 |
| du Plessis, S | 2 |
| Carr, J | 2 |
| Kidd, M | 2 |
| Vink, M | 2 |
| Meyer, JM | 6 |
| Mao, Y | 1 |
| Cucchiaro, J | 3 |
| Le Clerc, S | 1 |
| Taing, L | 1 |
| Fond, G | 1 |
| Meary, A | 3 |
| Blanc, O | 2 |
| Beaune, P | 1 |
| Rajagopal, K | 1 |
| Tamouza, R | 1 |
| Zagury, JF | 1 |
| Leboyer, M | 3 |
| Dos Santos, AC | 1 |
| Lemos, TM | 1 |
| Medeiros, CA | 1 |
| Guerra, GC | 2 |
| de Araújo Júnior, RF | 2 |
| Serrano-Blanco, A | 2 |
| Rubio-Valera, M | 1 |
| Barbosa, DS | 1 |
| Bonifácio, KL | 1 |
| Nunes, SO | 1 |
| Zhang, GY | 1 |
| Pan, W | 1 |
| Yin, GZ | 1 |
| Dong, RX | 1 |
| Gai, HJ | 1 |
| Ye, G | 1 |
| Yang, JG | 1 |
| Pan, NR | 1 |
| Xu, XW | 1 |
| Huang, H | 2 |
| Minica, C | 1 |
| Xavier, G | 1 |
| Spindola, LN | 1 |
| Moretti, PN | 1 |
| Green, AI | 7 |
| Brunette, MF | 1 |
| Dawson, R | 3 |
| Wallace, AE | 1 |
| Hafez, H | 1 |
| Herz, M | 1 |
| Narasimhan, M | 1 |
| O'Keefe, C | 2 |
| Sommi, RW | 1 |
| Steinbook, RM | 1 |
| Weeks, M | 1 |
| Karlsgodt, KH | 1 |
| Weissman, N | 1 |
| Addington, J | 5 |
| Tohen, M | 3 |
| Patrich, E | 1 |
| Peretz, A | 1 |
| Weiner, I | 2 |
| Attali, B | 1 |
| Petrides, G | 3 |
| Hassoun, Y | 2 |
| Lopez, L | 1 |
| Braga, RJ | 1 |
| Sevy, SM | 4 |
| Kellner, CH | 2 |
| Bennett, N | 1 |
| Chen, SL | 2 |
| Chang, YH | 2 |
| Chen, PS | 4 |
| Lee, IH | 2 |
| Wang, TY | 2 |
| Chen, KC | 2 |
| Yang, YK | 5 |
| Hong, JS | 2 |
| Lu, RB | 2 |
| Yao, C | 1 |
| Qi, S | 1 |
| Vasilenko, LM | 1 |
| Gorobets, LN | 2 |
| Bulanov, VS | 1 |
| Litvinov, AV | 1 |
| Ivanova, GP | 1 |
| Tsarenko, MA | 1 |
| Polyakovskaya, TP | 1 |
| Vernal, DL | 1 |
| Kapoor, S | 1 |
| Al-Jadiri, A | 1 |
| Sheridan, EM | 1 |
| Borenstein, Y | 1 |
| Mormando, C | 1 |
| David, L | 1 |
| Singh, S | 1 |
| Seidman, AJ | 1 |
| Carbon, M | 1 |
| Gerstenberg, M | 1 |
| Saito, E | 1 |
| Steinhausen, HC | 1 |
| Yu, HY | 2 |
| Hsiao, CY | 1 |
| Lee, LT | 1 |
| Chang, WH | 21 |
| Chi, MH | 1 |
| Hui Lee, I | 1 |
| Trampush, JW | 1 |
| DeRosse, P | 1 |
| Burdick, KE | 3 |
| Goldberg, TE | 5 |
| Goswami, P | 2 |
| Willcox, ME | 1 |
| Kudenchuk, PJ | 1 |
| Prutkin, JM | 1 |
| Fernández-Miranda, JJ | 1 |
| Caramés-García, V | 1 |
| Sánchez-García, A | 1 |
| Lieberman, JA | 44 |
| Davis, RE | 1 |
| Mates, S | 2 |
| Vanover, KE | 2 |
| Brandl, EJ | 1 |
| Goncalves, VF | 1 |
| Chowdhury, NI | 1 |
| Freeman, N | 1 |
| Müller, DJ | 1 |
| Ai, X | 1 |
| Gu, X | 1 |
| Huang, G | 1 |
| Ding, M | 1 |
| Ding, S | 1 |
| Heide, J | 1 |
| Bigos, KL | 1 |
| Mann, SA | 1 |
| Carr, VJ | 1 |
| Shannon Weickert, C | 1 |
| Green, MJ | 2 |
| Vandenberg, JI | 1 |
| Brusov, OS | 2 |
| Zlobina, GP | 1 |
| Batki, SL | 1 |
| Petrakis, IL | 1 |
| Lago, SG | 1 |
| Rothermundt, M | 1 |
| Leweke, FM | 2 |
| van Beveren, NJM | 1 |
| Vaisburd, S | 1 |
| Shemer, Z | 1 |
| Yeheskel, A | 1 |
| Giladi, E | 1 |
| Gozes, I | 1 |
| Wang, F | 4 |
| Mi, W | 3 |
| Ma, W | 2 |
| Ma, C | 2 |
| Du, B | 3 |
| Kanaan, RA | 1 |
| Neill, JC | 1 |
| Grayson, B | 1 |
| Kiss, B | 1 |
| Gyertyán, I | 1 |
| Ferguson, P | 1 |
| Adham, N | 1 |
| Steibliene, V | 1 |
| Bunevicius, A | 1 |
| Savickas, A | 1 |
| Prange, AJ | 1 |
| Nemeroff, CB | 3 |
| Bunevicius, R | 1 |
| Dai, L | 1 |
| Dong, M | 1 |
| Tempest, M | 1 |
| Sapin, C | 2 |
| Beillat, M | 1 |
| Robinson, P | 1 |
| Treur, M | 2 |
| Giraud-Baro, E | 1 |
| Dassa, D | 2 |
| De Vathaire, F | 1 |
| Obeid, J | 1 |
| Visscher, K | 1 |
| Knight, D | 1 |
| Falola, B | 1 |
| Koshikawa, Y | 2 |
| Takekita, Y | 2 |
| Kato, M | 3 |
| Sakai, S | 2 |
| Onohara, A | 2 |
| Sunada, N | 2 |
| Nishida, K | 2 |
| Fabbri, C | 2 |
| Serretti, A | 6 |
| Kinoshita, T | 3 |
| Nørbak-Emig, H | 1 |
| Ebdrup, BH | 1 |
| Fagerlund, B | 2 |
| Svarer, C | 1 |
| Rasmussen, H | 1 |
| Friberg, L | 1 |
| Allerup, PN | 1 |
| Rostrup, E | 1 |
| Pinborg, LH | 1 |
| Glenthøj, BY | 2 |
| Beszłej, JA | 1 |
| Moustafa, AA | 1 |
| Tybura, P | 1 |
| Kucharska-Mazur, J | 1 |
| Samochowiec, A | 1 |
| Samara, MT | 1 |
| Dold, M | 1 |
| Gianatsi, M | 1 |
| Nikolakopoulou, A | 1 |
| Helfer, B | 1 |
| Salanti, G | 1 |
| Bo, QJ | 5 |
| Li, XB | 1 |
| Wang, ZM | 1 |
| Traversa, M | 1 |
| Calza, S | 1 |
| Zandifar, A | 1 |
| Goguol, A | 1 |
| Esalatmanesh, S | 1 |
| Fava, M | 2 |
| Twumasi-Ankrah, P | 1 |
| Kouassi, A | 2 |
| Tse, WS | 1 |
| Wong, AS | 1 |
| Chan, F | 1 |
| Pang, AH | 1 |
| Bond, AJ | 1 |
| Chan, CK | 1 |
| Hadley, N | 1 |
| Davis, E | 1 |
| Nikbakhat, MR | 1 |
| Arabzadeh, S | 1 |
| Khalili, Z | 1 |
| Stevenson, JM | 1 |
| Reilly, JL | 9 |
| Harris, MS | 9 |
| Patel, SR | 1 |
| Prasad, KM | 2 |
| Badner, JA | 1 |
| Nimgaonkar, VL | 1 |
| Keshavan, MS | 11 |
| Guo, Q | 1 |
| Zhu, S | 3 |
| Ouyang, Q | 1 |
| Shen, W | 1 |
| Sheng, J | 1 |
| Smith, MA | 1 |
| Doherty, JJ | 1 |
| Cross, A | 1 |
| Raines, S | 1 |
| Gertsik, L | 1 |
| Zukin, SR | 1 |
| Dang, R | 1 |
| Guo, Y | 1 |
| Cai, H | 1 |
| Yang, R | 2 |
| Liang, D | 1 |
| Lv, C | 1 |
| Nasrallah, HA | 7 |
| Turkoz, I | 11 |
| Potanin, SS | 1 |
| Burminskiy, DS | 1 |
| Chen, J | 3 |
| Liang, S | 1 |
| Shi, S | 1 |
| Quintero, J | 1 |
| Oyagüez, I | 1 |
| González, B | 1 |
| Cuervo-Arango, I | 1 |
| García, I | 1 |
| Casado, MA | 1 |
| Ji, S | 1 |
| Shang, D | 1 |
| Wu, K | 1 |
| Deng, C | 3 |
| Chengappa, KN | 3 |
| Wirshing, WC | 13 |
| McMeniman, M | 1 |
| Baker, RW | 4 |
| Parepally, H | 3 |
| Umbricht, D | 3 |
| Saha, KB | 1 |
| Bo, L | 1 |
| Xia, J | 4 |
| Sampson, S | 4 |
| Zaman, RU | 1 |
| Isitt, JJ | 1 |
| Nadipelli, VR | 1 |
| Covell, NH | 4 |
| Hosalli, P | 4 |
| Charan, A | 1 |
| Chandrasekaran, A | 1 |
| Vardigan, JD | 1 |
| Lange, HS | 1 |
| Tye, SJ | 1 |
| Fox, SV | 1 |
| Smith, SM | 1 |
| Uslaner, JM | 1 |
| Maia-Lopes, S | 1 |
| Cherry, S | 1 |
| Siskind, D | 1 |
| Spivak, V | 1 |
| Wysoczanski, D | 1 |
| Halangoda, P | 1 |
| Heintjes, EM | 1 |
| Overbeek, JA | 1 |
| Penning-van Beest, FJ | 1 |
| Brobert, G | 1 |
| Herings, RM | 1 |
| Harrison, RN | 1 |
| Murray, RM | 3 |
| Paya Cano, J | 1 |
| Dempster, D | 1 |
| Curtis, CJ | 1 |
| Dima, D | 1 |
| Gaughran, F | 1 |
| Hie, G | 1 |
| Lü, L | 2 |
| Snyder, GL | 1 |
| Wadenberg, ML | 2 |
| Yao, W | 1 |
| Akkerman, S | 1 |
| Hendrick, JP | 1 |
| Davis, R | 1 |
| Li, P | 1 |
| Wennogle, LP | 1 |
| De Meulder, M | 1 |
| Ariyawansa, J | 1 |
| Sampford, JR | 1 |
| Li, BG | 2 |
| Ino, H | 1 |
| Vanasse, A | 1 |
| Courteau, J | 1 |
| Cohen, AA | 1 |
| Roberge, P | 1 |
| Larouche, A | 1 |
| Grignon, S | 1 |
| Fleury, MJ | 1 |
| Lesage, A | 1 |
| Carrier, JD | 1 |
| Delorme, A | 1 |
| Schronen, J | 1 |
| Morozova, M | 1 |
| Ivanov, M | 1 |
| Lian, J | 1 |
| Pan, B | 1 |
| Xiao, W | 1 |
| He, J | 1 |
| El-Sayed El-Sisi, A | 1 |
| Sokkar, SS | 1 |
| El-Sayed El-Sayad, M | 1 |
| Sayed Ramadan, E | 1 |
| Osman, EY | 1 |
| Marcus, MM | 1 |
| Björkholm, C | 1 |
| Malmerfelt, A | 1 |
| Möller, A | 1 |
| Påhlsson, N | 1 |
| Konradsson-Geuken, Å | 1 |
| Feltmann, K | 1 |
| Jardemark, K | 1 |
| Schilström, B | 1 |
| Svensson, TH | 1 |
| Manschreck, TC | 1 |
| Mendelowitz, A | 2 |
| Miller, DD | 4 |
| Bustillo, JR | 1 |
| Looney, SW | 1 |
| Pan, X | 1 |
| Wang, R | 2 |
| Yang, E | 1 |
| Benson, C | 1 |
| Chen, AT | 1 |
| Chibnall, JT | 1 |
| Ustohal, L | 1 |
| Mayerova, M | 1 |
| Hublova, V | 1 |
| Prikrylova Kucerova, H | 1 |
| Ceskova, E | 5 |
| Kasparek, T | 3 |
| Chen, WY | 1 |
| Lin, SK | 1 |
| Morlán-Coarasa, MJ | 1 |
| Arias-Loste, MT | 1 |
| Alonso-Martín, C | 1 |
| Crespo, J | 1 |
| Romero-Gómez, M | 1 |
| Fábrega, E | 1 |
| Yoshimura, R | 14 |
| Hori, H | 8 |
| Katsuki, A | 1 |
| Atake, K | 1 |
| Starr, HL | 1 |
| Ikai, S | 2 |
| Filipcic, IS | 1 |
| Grosic, V | 1 |
| Pedisic, I | 1 |
| Haen, E | 2 |
| Stegmann, B | 1 |
| Unterecker, S | 1 |
| Hiemke, C | 2 |
| Schoretsanitis, G | 1 |
| da Silva Araújo, T | 1 |
| Maia Chaves Filho, AJ | 1 |
| Isabelle de Góis Queiroz, A | 1 |
| de Jesus Souza Machado, M | 1 |
| de Freitas Lima, R | 1 |
| Freitas de Lucena, D | 1 |
| Macêdo, D | 1 |
| Hu, ML | 1 |
| Zong, XF | 1 |
| Zheng, JJ | 1 |
| Miller, JM | 1 |
| Li, ZC | 1 |
| Liao, YH | 1 |
| Sang, DE | 1 |
| Zhao, HZ | 1 |
| Tang, JS | 2 |
| Chen, XG | 1 |
| Holmes, SE | 1 |
| Hinz, R | 1 |
| Drake, RJ | 1 |
| Gregory, CJ | 1 |
| Conen, S | 1 |
| Matthews, JC | 1 |
| Anton-Rodriguez, JM | 1 |
| Gerhard, A | 1 |
| Talbot, PS | 1 |
| Lo, LH | 1 |
| Shiea, J | 1 |
| Watanabe, T | 1 |
| Yamada, A | 1 |
| Taylor, DM | 7 |
| Sparshatt, A | 2 |
| O'Hagan, M | 1 |
| Kamińska, K | 1 |
| Noworyta-Sokołowska, K | 1 |
| Jurczak, A | 1 |
| Górska, A | 1 |
| Gołembiowska, K | 1 |
| Cheng, X | 1 |
| Ren, G | 1 |
| Chao, YY | 1 |
| Zhao, JY | 1 |
| Du, YH | 1 |
| Li, WW | 1 |
| Song, XQ | 3 |
| Lü, LX | 2 |
| Sakurai, H | 2 |
| Kapur, S | 29 |
| Becker, DR | 1 |
| Drake, RE | 1 |
| Caspi, A | 1 |
| Lara, E | 1 |
| Pinchuk, I | 1 |
| Schuepbach, D | 1 |
| Suleman, S | 1 |
| Look, ML | 1 |
| Boo, YL | 1 |
| Chin, PW | 1 |
| Hoo, FK | 1 |
| Bas, A | 1 |
| Gultekin, G | 1 |
| Incir, S | 1 |
| Bas, TO | 1 |
| Emul, M | 1 |
| Duran, A | 1 |
| Osborn, D | 1 |
| King, MB | 1 |
| Cleymans, S | 1 |
| Morrens, M | 2 |
| Bervoets, C | 1 |
| Mazinani, R | 1 |
| Khodaei, M | 1 |
| Meyvisch, P | 1 |
| Rattehalli, RD | 4 |
| Stoecker, ZR | 1 |
| George, WT | 1 |
| O'Brien, JB | 1 |
| Jancik, J | 1 |
| Colon, E | 1 |
| Rasimas, JJ | 1 |
| Kumar P B, S | 1 |
| Pandey, RS | 1 |
| Thirthalli, J | 1 |
| Kumar P T, S | 1 |
| Kumar C, N | 1 |
| Wade, S | 1 |
| Meyer, N | 1 |
| Schuemie, MJ | 1 |
| Ramcharran, D | 1 |
| Ivaturi, V | 1 |
| Gopalakrishnan, M | 1 |
| Gobburu, JVS | 1 |
| Wan, FJ | 3 |
| Tung, CS | 1 |
| Debelle, M | 1 |
| Benmessaoud, D | 1 |
| Hamdani, N | 1 |
| Boni, C | 1 |
| Ramoz, N | 1 |
| Hamon, M | 1 |
| Kacha, F | 1 |
| Gorwood, P | 1 |
| Quednow, BB | 2 |
| Frommann, I | 1 |
| Berning, J | 1 |
| Kühn, KU | 6 |
| Maier, W | 11 |
| Wagner, M | 2 |
| Davis, VG | 2 |
| McEvoy, JP | 26 |
| Davis, SM | 12 |
| Daumit, GL | 1 |
| Swartz, MS | 13 |
| Chen, ZH | 2 |
| Wang, GH | 3 |
| Wang, XP | 3 |
| Chen, RY | 1 |
| Wang, HL | 1 |
| Yang, MH | 2 |
| Huo, YX | 2 |
| Mei, HB | 2 |
| Wiseman, CL | 1 |
| Nomura, K | 2 |
| Tanabe, A | 2 |
| Yagi, G | 3 |
| Kashima, H | 2 |
| Canuso, CM | 7 |
| Youssef, EA | 1 |
| Simpson, GM | 6 |
| Tiradritti, P | 1 |
| Romeo, F | 1 |
| Kebir, O | 1 |
| Tabbane, K | 1 |
| Hempel, RJ | 1 |
| Tulen, JH | 1 |
| van Beveren, NJ | 2 |
| Röder, CH | 1 |
| Hengeveld, MW | 1 |
| Kuwilsky, A | 2 |
| Krumm, B | 1 |
| Dressing, H | 1 |
| Fusar-Poli, RR | 1 |
| Vargas, HE | 1 |
| Gama, CS | 1 |
| Andreazza, AC | 1 |
| Medeiros, D | 1 |
| Stertz, L | 1 |
| Fries, G | 1 |
| Palha, J | 1 |
| Cereser, KM | 1 |
| Belmonte-de-Abreu, PS | 1 |
| Dolzan, V | 3 |
| Mandelli, L | 2 |
| Koprivsek, J | 3 |
| Kastelic, M | 3 |
| Plesnicar, BK | 2 |
| Fakra, E | 2 |
| Khalfa, S | 1 |
| Da Fonseca, D | 1 |
| Besnier, N | 2 |
| Delaveau, P | 1 |
| Azorin, JM | 9 |
| Snyder, PJ | 1 |
| Jackson, CE | 1 |
| Piskulic, D | 1 |
| Olver, J | 2 |
| Norman, T | 1 |
| Maruff, P | 1 |
| Tsuchimine, S | 6 |
| Nakagami, T | 11 |
| Sato, Y | 7 |
| Kaneko, S | 21 |
| Fraguas, D | 1 |
| Merchán-Naranjo, J | 1 |
| Laita, P | 1 |
| Parellada, M | 1 |
| Moreno, D | 1 |
| Ruiz-Sancho, A | 1 |
| Cifuentes, A | 1 |
| Giráldez, M | 1 |
| Ganguli, R | 8 |
| Brar, JS | 7 |
| Mahmoud, R | 11 |
| Berry, SA | 3 |
| Pandina, GJ | 3 |
| Casey, DE | 6 |
| Sands, EE | 1 |
| Heisterberg, J | 1 |
| Yang, HM | 1 |
| van Nimwegen, LJ | 1 |
| van der Helm, M | 1 |
| Linszen, D | 6 |
| Rubalcaba, E | 1 |
| Viscidi, R | 1 |
| Stallings, C | 1 |
| Sullens, A | 1 |
| Origoni, A | 1 |
| Leister, F | 1 |
| Yolken, R | 1 |
| Tadger, S | 2 |
| Baruch, Y | 2 |
| Barak, Y | 7 |
| Gu, B | 2 |
| Zhang, AP | 3 |
| Zhao, XZ | 2 |
| Feng, GY | 4 |
| Xing, QH | 3 |
| Liu, YC | 6 |
| Huang, CL | 5 |
| Wu, PL | 5 |
| Chang, YC | 12 |
| Huang, CH | 5 |
| Lane, HY | 24 |
| Lee, BH | 2 |
| Kim, YK | 5 |
| Labelle, A | 10 |
| Shammi, C | 3 |
| Mannaert, EJ | 1 |
| Mann, SW | 1 |
| Novick, D | 8 |
| Suarez, D | 4 |
| Darby, JK | 2 |
| Pasta, DJ | 2 |
| Wilson, MG | 1 |
| Herbert, J | 2 |
| Jerrell, JM | 2 |
| Ramirez, PM | 1 |
| Arman, S | 1 |
| Sadramely, MR | 1 |
| Nadi, M | 1 |
| Koleini, N | 1 |
| Ishak, KJ | 1 |
| Glass, J | 1 |
| Luong, D | 1 |
| Caro, JJ | 1 |
| Oriot, P | 1 |
| Feys, JL | 1 |
| Mertens de Wilmars, S | 1 |
| Misson, A | 1 |
| Ayache, L | 1 |
| Fagnart, O | 1 |
| Gruson, D | 1 |
| Luts, A | 1 |
| Jamart, J | 1 |
| Hermans, MP | 1 |
| Buysschaert, M | 1 |
| Kuzman, MR | 2 |
| Medved, V | 4 |
| Hotujac, L | 2 |
| Sain, I | 1 |
| Bilusic, H | 1 |
| Gerami, M | 1 |
| Karamghadiri, N | 2 |
| Ghoreishi, A | 5 |
| Abbasi, SH | 4 |
| Rezazadeh, SA | 4 |
| Jensen, JB | 1 |
| Kumra, S | 2 |
| Leitten, W | 1 |
| Oberstar, J | 1 |
| Anjum, A | 1 |
| White, T | 1 |
| Wozniak, J | 1 |
| Lee, SS | 1 |
| Schulz, SC | 4 |
| Funatogawa, T | 1 |
| Funatogawa, I | 1 |
| Takeuchi, M | 1 |
| Lomena, F | 2 |
| Font, M | 1 |
| Pareto, D | 1 |
| Gutierrez, F | 1 |
| Simo, M | 1 |
| Fernández-Egea, E | 2 |
| Pavia, J | 2 |
| Ros, D | 1 |
| Coley, K | 1 |
| Miller, D | 2 |
| Kirshner, M | 1 |
| Aravagiri, M | 4 |
| Schneider, L | 2 |
| Olivares, JM | 7 |
| Rodriguez-Martinez, A | 1 |
| Alonso-Escolano, D | 1 |
| Rodriguez-Morales, A | 4 |
| Tislerova, B | 1 |
| Brunovsky, M | 1 |
| Horacek, J | 1 |
| Novak, T | 1 |
| Kopecek, M | 1 |
| Mohr, P | 1 |
| Krajca, V | 1 |
| Raignoux, C | 1 |
| Dusouchet, T | 1 |
| Bret, P | 1 |
| Queuille, E | 1 |
| Biscay, ML | 1 |
| Caron, J | 1 |
| Bret, MC | 1 |
| Mohammadi, N | 1 |
| Jamshidi, AH | 1 |
| Forghani, S | 1 |
| Sikich, L | 4 |
| Frazier, JA | 4 |
| McClellan, J | 4 |
| Findling, RL | 7 |
| Vitiello, B | 4 |
| Ritz, L | 3 |
| Ambler, D | 2 |
| Puglia, M | 2 |
| Maloney, AE | 3 |
| Michael, E | 1 |
| Slifka, K | 1 |
| Noyes, N | 2 |
| Hlastala, S | 2 |
| Pierson, L | 2 |
| McNamara, NK | 3 |
| Delporto-Bedoya, D | 1 |
| Anderson, R | 3 |
| Hamer, RM | 11 |
| Marshall, TS | 1 |
| McCombs, JS | 2 |
| Stafkey-Mailey, D | 1 |
| Malek-Hosseini, M | 1 |
| Raznahan, M | 4 |
| Chang, CJ | 3 |
| Chiang, SC | 2 |
| Chen, CH | 6 |
| Sun, HJ | 2 |
| Hwu, HG | 3 |
| Lai, MS | 2 |
| Lublin, H | 3 |
| Haug, HJ | 1 |
| Koponen, H | 1 |
| Sigmundsson, T | 1 |
| Kolb, SA | 1 |
| Jovanović, N | 3 |
| Becker, A | 1 |
| Grecksch, G | 1 |
| Zernig, G | 1 |
| Ladstaetter, E | 1 |
| Schmitt, U | 1 |
| Raja, M | 1 |
| Azzoni, A | 1 |
| Akhapkin, RV | 1 |
| Wołczyński, S | 1 |
| Popławska, R | 1 |
| Sprenger, A | 1 |
| Houthoofd, SA | 1 |
| Sabbe, BG | 1 |
| Morosini, P | 1 |
| Gagnon, DD | 1 |
| Lu, ML | 2 |
| Shen, WW | 1 |
| Rabinowitz, J | 26 |
| Mössner, R | 1 |
| Schuhmacher, A | 1 |
| Cvetanovska, G | 2 |
| Rujescu, D | 1 |
| Zill, P | 1 |
| Rietschel, M | 1 |
| Wölwer, W | 6 |
| Gaebel, W | 15 |
| Oosthuizen, P | 5 |
| Koen, L | 6 |
| Niehaus, DJ | 4 |
| Medori, R | 13 |
| Yamanouchi, Y | 3 |
| Kinoshita, Y | 3 |
| Kitajima, T | 3 |
| Hashimoto, S | 1 |
| O'Donovan, MC | 2 |
| Nakamura, J | 13 |
| Ozaki, N | 4 |
| Cooper, D | 2 |
| Moisan, J | 2 |
| Abdous, B | 2 |
| Grégoire, JP | 2 |
| Davis, S | 1 |
| Covell, N | 1 |
| Essock, S | 1 |
| Lieberman, J | 2 |
| Mata, I | 4 |
| Amado, JA | 2 |
| Garcia-Unzueta, MT | 2 |
| Berja, A | 2 |
| Beniashvili, AG | 1 |
| Rupchev, GE | 1 |
| Lepilkina, TA | 1 |
| Starostin, DS | 1 |
| Vehof, J | 2 |
| Postma, MJ | 2 |
| Bruggeman, R | 4 |
| De Jong-Van Den Berg, LT | 2 |
| Van Den Berg, PB | 1 |
| Stolk, RP | 1 |
| Burger, H | 2 |
| Lee, E | 4 |
| Leung, CM | 2 |
| Jakovljević, M | 2 |
| Folnegović-Smalc, V | 2 |
| Peng, PW | 1 |
| Huang, MC | 6 |
| Dossenbach, M | 6 |
| Pecenak, J | 4 |
| Irimia, V | 1 |
| Anders, M | 2 |
| Logozar-Perkovic, D | 1 |
| Peciukaitiene, D | 1 |
| Kotler, M | 2 |
| Smulevich, AB | 1 |
| West, TM | 1 |
| Lowry, AJ | 1 |
| Treuer, T | 2 |
| Ehrlichman, RS | 2 |
| Gandal, MJ | 3 |
| Maxwell, CR | 1 |
| Lazarewicz, MT | 1 |
| Finkel, LH | 1 |
| Contreras, D | 1 |
| Turetsky, BI | 1 |
| Siegel, SJ | 4 |
| Fischetti, C | 1 |
| Thomas, A | 2 |
| Bishara, D | 1 |
| Cornelius, V | 1 |
| Furukori, H | 10 |
| Keefe, RS | 15 |
| Miller, AL | 4 |
| Hsiao, JK | 10 |
| Kelly, DL | 12 |
| Wehring, HJ | 1 |
| Linthicum, J | 1 |
| Feldman, S | 2 |
| McMahon, RP | 5 |
| Love, RC | 10 |
| Wagner, T | 1 |
| Fowler, DR | 1 |
| Byerly, MJ | 7 |
| Marcus, RN | 3 |
| Tran, QV | 1 |
| Eudicone, JM | 2 |
| Whitehead, R | 1 |
| Baker, RA | 1 |
| McCormack, J | 6 |
| Napolitano, B | 6 |
| Patel, RC | 4 |
| Goldman, R | 2 |
| Daniel, DG | 9 |
| Tamminga, C | 1 |
| Tran-Johnson, T | 1 |
| Wozniak, P | 3 |
| Abi-Saab, W | 1 |
| Baker, J | 1 |
| Redden, L | 1 |
| Greco, N | 1 |
| Saltarelli, M | 1 |
| Reske, M | 2 |
| Habel, U | 2 |
| Kellermann, T | 2 |
| Backes, V | 2 |
| Jon Shah, N | 2 |
| von Wilmsdorff, M | 5 |
| Zilles, K | 1 |
| Schneider, F | 10 |
| Hao, YH | 2 |
| Riedel, M | 15 |
| Eich, FX | 2 |
| Möller, HJ | 39 |
| González-Blanch, C | 1 |
| Alvarez-Jiménez, M | 1 |
| Zung, S | 1 |
| Vallada, H | 1 |
| Keith, S | 1 |
| Hanssens, L | 3 |
| L'Italien, G | 2 |
| Loze, JY | 1 |
| Pans, M | 1 |
| Kerselaers, W | 2 |
| Gillain, B | 1 |
| De Graeve, D | 3 |
| Van Vleymen, B | 1 |
| Albert, A | 1 |
| Weinbrenner, A | 1 |
| Peus, V | 1 |
| Inta, D | 1 |
| Englisch, S | 1 |
| Ladds, B | 1 |
| Thomas, P | 3 |
| Mejia, C | 1 |
| Hauser, D | 1 |
| Lu, CH | 1 |
| Yan, YH | 1 |
| Zhou, DF | 11 |
| Qi, LY | 1 |
| Cao, LY | 9 |
| Wu, GY | 10 |
| Kosten, TA | 3 |
| Mulder, H | 1 |
| Scheffer, H | 1 |
| Gispen-de Wied, C | 1 |
| Arends, J | 2 |
| Wilmink, FW | 1 |
| Franke, B | 1 |
| Egberts, AC | 1 |
| Castro-Costa, E | 1 |
| Andrade, JM | 1 |
| Quites, L | 1 |
| Sainani, A | 1 |
| Cabral, S | 1 |
| Addington, DE | 3 |
| Kulkarni, J | 5 |
| Johnson, G | 1 |
| Mandel, FS | 1 |
| De Ridder, A | 1 |
| He, W | 1 |
| Mead, A | 1 |
| Haas, M | 2 |
| Eerdekens, M | 18 |
| Kushner, S | 3 |
| Singer, J | 1 |
| Augustyns, I | 2 |
| Quiroz, J | 2 |
| Pandina, G | 5 |
| Kusumakar, V | 1 |
| Douglas-Hall, P | 1 |
| Olofinjana, B | 1 |
| Janicak, PG | 2 |
| Crandall, DT | 1 |
| McQuade, RD | 3 |
| Assunção-Talbott, S | 2 |
| Diels, J | 1 |
| Povey, M | 1 |
| Jacobs, A | 4 |
| Zhao, Z | 4 |
| Lam, A | 1 |
| Villalobos Vega, JC | 1 |
| Cuéllar, JA | 1 |
| de Castro, FJ | 1 |
| Quintero, CM | 1 |
| Martíin, JF | 1 |
| Domínguez, P | 1 |
| Ojeda, JL | 1 |
| Cortés, SS | 1 |
| Cala, FI | 1 |
| Marín, CG | 1 |
| Castro, LM | 1 |
| Duaso, MA | 1 |
| Albarracín, JR | 1 |
| Vergara, GN | 1 |
| Benítez, AF | 1 |
| Cleries, FM | 1 |
| Pérez-Brian, JM | 1 |
| Aragón, AB | 1 |
| Navarro, JC | 1 |
| Biedma, JA | 1 |
| de Pedro, RB | 1 |
| González, JF | 1 |
| López, ME | 1 |
| Moreno, HD | 1 |
| López, JA | 1 |
| Rodríguez, EO | 1 |
| de Hoyos, CM | 1 |
| Sacristán, MP | 1 |
| Martín, MD | 1 |
| Ballesteros, EM | 1 |
| Rodríguez, PA | 1 |
| Menéndez, LF | 1 |
| Rivas, RS | 1 |
| del Pino Cuadrado, P | 1 |
| Lauffer, JC | 1 |
| Solano, JJ | 1 |
| Martínez, JM | 1 |
| Solano, FG | 1 |
| Rodríguez, PG | 1 |
| Rodríguez, JA | 1 |
| Cano, TR | 1 |
| Fortacin, MD | 1 |
| Lobeiras, JM | 1 |
| Sampedro, JM | 1 |
| Bravo, AP | 1 |
| Pellicer, AF | 1 |
| López, MD | 1 |
| Liste, JF | 1 |
| Fernández, MR | 1 |
| Losada, AC | 1 |
| Mendez, RV | 1 |
| Romero, SA | 1 |
| Blanco, JJ | 1 |
| Bonaselt, IT | 1 |
| Mahia, MC | 1 |
| del Valle, EF | 1 |
| Yañez, PQ | 1 |
| Camarasa, MG | 1 |
| Alonso, JA | 1 |
| Mendez, GF | 1 |
| Feliz, FD | 1 |
| Lamela, MA | 1 |
| Piñero, MV | 1 |
| Alvarado, PF | 1 |
| Gómez, IL | 1 |
| Martín, PF | 1 |
| Gómez, JL | 1 |
| López, AG | 1 |
| Jiménez, AR | 1 |
| Nafs, AE | 1 |
| Barquero, NC | 1 |
| Ortiz, RF | 1 |
| Noguera, JL | 1 |
| Carrasco, PR | 1 |
| Muñoz, JM | 1 |
| Palma, MM | 1 |
| Hortelano, CM | 1 |
| Bonome, LS | 1 |
| Sevilla, JS | 1 |
| Juan, JM | 1 |
| Ramos, JM | 1 |
| Muñoz, JL | 1 |
| Guisasola, JE | 1 |
| Vazquez, LS | 1 |
| Guerras, FC | 1 |
| Nebot, FJ | 1 |
| Fernández, FJ | 1 |
| Nicolau, AL | 1 |
| Subirats, RC | 1 |
| Kidias, MM | 1 |
| Navarro, VF | 1 |
| García, BF | 1 |
| del Rosal, FM | 1 |
| de Vicente Muñoz, T | 1 |
| Ballester, JA | 1 |
| Lieb, PM | 1 |
| Martel, AD | 1 |
| Bea, ER | 1 |
| Joaquim, IG | 1 |
| Enjuanes, FB | 1 |
| Piñol, MB | 1 |
| Carbonell, EF | 1 |
| Muñoz, RM | 1 |
| Giribets, CA | 1 |
| Sans, LA | 1 |
| Blanco, AS | 1 |
| Felipe, MA | 1 |
| Muñoz, PG | 1 |
| Villanueva, AP | 1 |
| Arroyo, MB | 1 |
| Borri, RC | 1 |
| Fallada, SM | 1 |
| Merola, MC | 1 |
| Rodon, EP | 1 |
| Palmes, JR | 1 |
| Martínez, EP | 1 |
| Catala, JM | 1 |
| Coca, AS | 1 |
| Ferrandiz, FP | 1 |
| Paya, EF | 1 |
| Caballero, GI | 1 |
| Bonet, AF | 1 |
| Figueras, JF | 1 |
| Pagador, PM | 1 |
| Garibo, MM | 1 |
| Camo, VP | 1 |
| Carrillo, CS | 1 |
| Valero, CP | 1 |
| Rebollo, FJ | 1 |
| García Campayo, J | 1 |
| Sala Ayma, JM | 1 |
| Roig, MM | 1 |
| de Uña Mateos, MA | 1 |
| Bertolin, RG | 1 |
| García, AM | 1 |
| Mazo, FJ | 1 |
| Velasco, JL | 1 |
| Pérez, LS | 1 |
| Casado, CJ | 1 |
| Barba, JJ | 1 |
| Diaz, MC | 1 |
| Rubio, JP | 1 |
| Mandoli, AS | 1 |
| Herrero, AU | 1 |
| Martínez, AR | 1 |
| Serrano, PS | 1 |
| Rodríguez, EN | 1 |
| Montesinos, JS | 1 |
| Macia, JF | 1 |
| Mateos Marcos, AM | 1 |
| Soto, JV | 1 |
| Dumont, MV | 1 |
| Pagan, JP | 1 |
| Martínez, VB | 1 |
| Santiuste de Pablos, M | 1 |
| Delgado, CE | 1 |
| Quiles, MD | 1 |
| López, FJ | 1 |
| Navarro, PP | 1 |
| Torres, AM | 1 |
| Ingles, FJ | 1 |
| Arias-Camison, JM | 1 |
| Manzano, JC | 1 |
| Peña, RV | 1 |
| Guitarte, GP | 1 |
| Fontecilla, HB | 1 |
| Romero, JB | 1 |
| Gil, RS | 1 |
| Lozano, JM | 1 |
| Adanez, LD | 1 |
| Zarranz Herrera-Oria, I | 1 |
| Jiménez, JP | 1 |
| Vaz, FC | 1 |
| García, OS | 1 |
| Anton, CC | 1 |
| Casula, RR | 1 |
| Hernandez, MC | 1 |
| Escabias, FT | 1 |
| Torresano, JR | 1 |
| Pérez-Villamil, AH | 1 |
| Estevez, L | 1 |
| Figuero, MA | 1 |
| Muñoz de Morales, A | 1 |
| Calvin, JL | 1 |
| Criado, MD | 1 |
| Rodríguez, VM | 1 |
| Ambrosolio, EB | 1 |
| Madera, PM | 1 |
| Alfaro, GP | 1 |
| Vidal, MM | 1 |
| Valtuille, AG | 1 |
| Ruiz, O | 1 |
| Cabornero, GL | 1 |
| Echevarria Martínez de Bujo, M | 1 |
| Mallen, MJ | 1 |
| Puigros, JS | 1 |
| Martorell, AL | 1 |
| Forteza, AC | 1 |
| Arrebola, ER | 1 |
| Rodríguez de la Torre, M | 1 |
| Saiz, CG | 1 |
| Bardolet I Casas, C | 1 |
| Linde, ER | 1 |
| De Arce Cordon, R | 2 |
| Molina, EM | 1 |
| Carazo, FJ | 1 |
| Romero, JJ | 1 |
| Cano, DV | 1 |
| Dorado, MS | 1 |
| Velazquez, SC | 1 |
| Sánchez, AJ | 1 |
| Leon, SO | 1 |
| Sánchez, KP | 1 |
| Benitez, MH | 1 |
| Zugarramurai, AI | 1 |
| Contreras, MA | 1 |
| De la Varga González, M | 1 |
| Marín, PB | 1 |
| Robina, FG | 1 |
| García, MS | 1 |
| Pérez, FJ | 1 |
| Bros, PC | 1 |
| Gómez, AC | 1 |
| de Dios Molina Martín, J | 1 |
| Perera, JL | 2 |
| Averbach, MC | 1 |
| Palancares, EG | 1 |
| Gallego de Dios, MT | 1 |
| Rojo, CF | 1 |
| Iglesias, SS | 1 |
| Merino, MI | 1 |
| Mestre, NP | 1 |
| Urdaniz, AP | 1 |
| Sánchez, JM | 1 |
| Seco, RG | 1 |
| Muñoz, JF | 1 |
| Agut, MM | 1 |
| Lozano, ML | 1 |
| Herguedas, FM | 1 |
| Pena, AT | 1 |
| García, JV | 1 |
| Martínez, AV | 1 |
| Sanz Granado, OS | 1 |
| Fernández, MA | 1 |
| Canseco, JM | 1 |
| López, PA | 1 |
| Martín, MA | 1 |
| Barrio, JA | 1 |
| Ubago, JG | 1 |
| Bennassar, MR | 1 |
| Díez, JM | 1 |
| Fleta, JL | 1 |
| Fortes, FP | 1 |
| López, CA | 1 |
| Medina, O | 1 |
| Alvarez, DF | 1 |
| Roca, JM | 1 |
| Valladolid, GR | 1 |
| Tavera, JA | 1 |
| García-Castrillon Sales, JA | 1 |
| Llordes, IB | 1 |
| Melgarejo, CA | 1 |
| Cañas de la Paz, F | 1 |
| Callol, VV | 1 |
| García, MB | 1 |
| García, JB | 1 |
| Leal, FJ | 1 |
| Corrales, EC | 1 |
| Iglesias, ES | 1 |
| Gómez, MA | 1 |
| Serrano, GG | 1 |
| Chillarón, EG | 1 |
| Aguado, FJ | 1 |
| Castillo, JJ | 1 |
| González, AG | 1 |
| Vázquez, JG | 1 |
| Peralvarez, MB | 1 |
| Diaz, MR | 1 |
| Mesa, MY | 2 |
| Artiles, FJ | 1 |
| Chao, MA | 1 |
| del Rosario Santana, P | 1 |
| Escudero, MA | 1 |
| Berenguer, MM | 1 |
| Llacer, JM | 1 |
| Berna, JA | 1 |
| Ortiz, JB | 1 |
| Pardell, LT | 1 |
| Hernández-Alvarez de Sotomayor, C | 1 |
| Méndez, MR | 1 |
| Garate, RC | 1 |
| Múgica, BD | 1 |
| González, MC | 1 |
| Domingo, JP | 1 |
| Navarro, CS | 1 |
| Vera, GS | 1 |
| Cuquerella, MA | 1 |
| Monzo, JL | 1 |
| Boada, PC | 1 |
| Pérez, MF | 1 |
| Parrado, EC | 1 |
| Sánchez, JJ | 1 |
| Fernández, JC | 1 |
| Mendhekar, D | 1 |
| Lohia, D | 1 |
| Wobrock, T | 1 |
| Gruber, O | 1 |
| Schneider-Axmann, T | 1 |
| Riesbeck, M | 6 |
| Klosterkötter, J | 7 |
| Buchkremer, G | 5 |
| Schmitt, A | 8 |
| Bender, S | 2 |
| Schlösser, R | 5 |
| Falkai, P | 3 |
| Heeg, B | 4 |
| Schmeding, A | 1 |
| van Hout, B | 2 |
| Silva, R | 2 |
| Xuan, J | 5 |
| Che, R | 2 |
| Du, J | 7 |
| Xing, Y | 1 |
| Tsai, SJ | 8 |
| Yen, FC | 1 |
| Su, KP | 6 |
| Tschoner, A | 1 |
| Engl, J | 1 |
| Kaser, S | 1 |
| Ott, HW | 1 |
| Patsch, JR | 1 |
| Ebenbichler, CF | 1 |
| Madaan, V | 1 |
| Gupta, M | 1 |
| Bhatnagar, P | 1 |
| Kaur, H | 1 |
| Baghel, R | 1 |
| Bhasin, Y | 1 |
| Chauhan, C | 1 |
| Verma, B | 1 |
| Manduva, V | 1 |
| Mukherjee, O | 1 |
| Purushottam, M | 1 |
| Jain, S | 1 |
| Brahmachari, SK | 1 |
| Kukreti, R | 1 |
| Bagati, D | 1 |
| Nizamie, SH | 1 |
| Prakash, R | 1 |
| Caykoylu, A | 1 |
| Ekinci, O | 1 |
| Yilmaz, E | 1 |
| Lindström, E | 10 |
| Jedenius, E | 1 |
| Levander, S | 5 |
| Weinbrenner, S | 1 |
| Assion, HJ | 2 |
| Busse, R | 1 |
| Gericke, CA | 1 |
| Pani, L | 2 |
| Marchese, G | 1 |
| Abou El-Magd, RM | 1 |
| Park, HK | 1 |
| Kawazoe, T | 1 |
| Iwana, S | 1 |
| Ono, K | 1 |
| Chung, SP | 1 |
| Miyano, M | 1 |
| Yorita, K | 1 |
| Sakai, T | 1 |
| Fukui, K | 1 |
| Stauffer, V | 2 |
| Ascher-Svanum, H | 17 |
| Ball, T | 1 |
| Conley, R | 4 |
| Takahashi, T | 2 |
| Wood, SJ | 1 |
| Yung, AR | 4 |
| Soulsby, B | 1 |
| McGorry, PD | 6 |
| Suzuki, M | 2 |
| Kawasaki, Y | 2 |
| Phillips, LJ | 3 |
| Velakoulis, D | 2 |
| Pantelis, C | 3 |
| Ratner, RE | 1 |
| Eriksson, JW | 1 |
| Meulien, D | 1 |
| Miller, F | 1 |
| Leonova-Edlund, J | 1 |
| Leong, RW | 1 |
| Brecher, M | 6 |
| Schmidt, F | 1 |
| Lewis, R | 2 |
| Kissling, W | 18 |
| Yagihashi, T | 1 |
| Mizuno, M | 2 |
| Chino, B | 1 |
| Sakuma, K | 1 |
| Takebayashi, T | 1 |
| Takao, T | 1 |
| Kosaki, K | 1 |
| Zhang, A | 4 |
| Lin, Z | 3 |
| Cuesta, MJ | 2 |
| Jalón, EG | 1 |
| Campos, MS | 1 |
| Peralta, V | 2 |
| Kang, RH | 1 |
| Jung, SM | 2 |
| Kim, KA | 2 |
| Lee, DK | 1 |
| Cho, HK | 2 |
| Jung, BJ | 1 |
| Han, C | 2 |
| Lee, MS | 3 |
| Park, JY | 2 |
| Fijal, BA | 3 |
| Stauffer, VL | 8 |
| Conley, RR | 16 |
| Jamal, HH | 1 |
| Witte, MM | 2 |
| Houston, JP | 4 |
| Ryckmans, V | 1 |
| Kahn, JP | 2 |
| Modell, S | 1 |
| Werner, C | 1 |
| Lissens, J | 1 |
| Sanchez, R | 1 |
| Lai, YC | 2 |
| Ozdemir, V | 2 |
| Suzuki, A | 6 |
| Kondo, T | 8 |
| Jainer, AK | 1 |
| Mahmood, A | 1 |
| Mamo, D | 3 |
| Shammi, CM | 1 |
| Mizrahi, R | 3 |
| Marcon, H | 1 |
| Barsoum, P | 1 |
| Rusjan, P | 3 |
| Houle, S | 4 |
| Wilson, AA | 4 |
| Akhras, KS | 2 |
| Singh, J | 1 |
| Schadrack, J | 1 |
| Palumbo, JM | 1 |
| Rajarethinam, R | 1 |
| Dziuba, J | 1 |
| Manji, S | 1 |
| Pizzuti, A | 1 |
| Lachover, L | 1 |
| Keshavan, M | 3 |
| Castro-Fornieles, J | 1 |
| Deulofeu, R | 1 |
| de la Serna, E | 1 |
| Goti, J | 1 |
| Salvà, J | 1 |
| Amado, I | 1 |
| Bourdel, MC | 1 |
| Daban, C | 1 |
| Poirier, MF | 1 |
| Loo, H | 1 |
| Bouhours, P | 4 |
| Krebs, MO | 2 |
| Alptekin, K | 3 |
| Hafez, J | 1 |
| Brook, S | 1 |
| Akkaya, C | 2 |
| Ucok, A | 1 |
| El Tallawy, H | 1 |
| Danaci, AE | 1 |
| Lowe, W | 1 |
| Karayal, ON | 1 |
| Clark, D | 1 |
| Skrobot, OA | 1 |
| Adebiyi, I | 1 |
| Susce, MT | 2 |
| Blakemore, AF | 1 |
| Arranz, MJ | 2 |
| Behere, RV | 1 |
| Venkatasubramanian, G | 3 |
| Arasappa, R | 1 |
| Reddy, N | 1 |
| Gangadhar, BN | 2 |
| Schwartz, M | 1 |
| Kormilachev, M | 1 |
| Kushnir, M | 2 |
| Weller, B | 2 |
| Rochas, M | 1 |
| Toubi, E | 1 |
| Ravanić, DB | 1 |
| Pantović, MM | 1 |
| Milovanović, DR | 1 |
| Dukić-Dejanović, S | 1 |
| Janjić, V | 2 |
| Ignjatović, DR | 1 |
| Jović, SD | 1 |
| Jurisić, V | 1 |
| Jevtović, I | 1 |
| Okugawa, G | 1 |
| Wakeno, M | 1 |
| Koh, J | 1 |
| Morikawa, M | 1 |
| Matsumoto, N | 1 |
| Shinosaki, K | 1 |
| Yoneda, H | 1 |
| Boso, M | 1 |
| Chittiprol, S | 1 |
| Neelakantachar, N | 1 |
| Reddy, NA | 1 |
| Shetty, KT | 1 |
| Karagianis, J | 2 |
| Davis, L | 1 |
| Procyshyn, R | 2 |
| Monga, N | 1 |
| Hanley, J | 1 |
| Chandrasena, R | 1 |
| Thakur, A | 1 |
| Dickson, R | 2 |
| Lipkovich, IA | 1 |
| Deberdt, W | 1 |
| Csernansky, JG | 4 |
| Sabbe, B | 1 |
| Resseler, S | 3 |
| Price, JR | 1 |
| Bastiampillai, T | 2 |
| Dhillon, RS | 1 |
| Wang, N | 1 |
| Haile, C | 1 |
| Strech, D | 1 |
| Lindner, LM | 1 |
| Marasciulo, AC | 1 |
| Farias, MR | 1 |
| Grohs, GE | 1 |
| Caligiuri, MP | 1 |
| Teulings, HL | 1 |
| Dean, CE | 2 |
| Niculescu, AB | 1 |
| Lohr, J | 1 |
| McClay, JL | 1 |
| Adkins, DE | 1 |
| Aberg, K | 1 |
| Perkins, DO | 11 |
| Vladimirov, VI | 1 |
| Sullivan, PF | 1 |
| van den Oord, EJ | 1 |
| Mowla, A | 1 |
| Dastgheib, SA | 1 |
| Ebrahimi, AA | 1 |
| Pani, A | 1 |
| Gaszner, P | 1 |
| Jones, M | 2 |
| Lancashire, S | 1 |
| Gurney, S | 1 |
| Gray, R | 1 |
| Singh, D | 2 |
| O'Connor, DW | 3 |
| Harpaz-Rotem, I | 1 |
| Leslie, D | 1 |
| Sernyak, MJ | 3 |
| Bagalà, A | 1 |
| Del Curatolo, V | 1 |
| Scapati, F | 1 |
| Bernareggi, MM | 1 |
| Giustra, MG | 1 |
| Yang, SJ | 5 |
| Kelly, E | 2 |
| Viviano, TF | 2 |
| Cornwell, J | 2 |
| Hu, Q | 3 |
| Khan, A | 6 |
| Vaidhyanathaswamy, S | 2 |
| Fuller, M | 1 |
| Shermock, K | 1 |
| Russo, P | 1 |
| Secic, M | 2 |
| Dirani, R | 2 |
| Vallow, S | 1 |
| Flanders, S | 1 |
| Schmid, F | 8 |
| Bhoopathi, PS | 1 |
| Berwaerts, J | 1 |
| Cleton, A | 1 |
| Rossenu, S | 1 |
| Talluri, K | 1 |
| Janssens, L | 1 |
| Boom, S | 1 |
| Kramer, M | 1 |
| Magyar, GI | 1 |
| Fadgyas, I | 1 |
| De la Gándara, J | 2 |
| San Molina, L | 1 |
| Rubio, G | 4 |
| Hidalgo Borrajo, R | 1 |
| Chetty, M | 1 |
| d'Esposito, F | 1 |
| Zhang, WV | 1 |
| Glen, J | 1 |
| Dore, G | 1 |
| Stankovic, Z | 2 |
| Edwards, RJ | 1 |
| Ramzan, I | 1 |
| Murray, M | 1 |
| Martinez-Gras, I | 1 |
| del Manzano, BA | 1 |
| Garcia-Sanchez, F | 1 |
| Bagney, A | 1 |
| Borrell, J | 1 |
| Tomita, Y | 1 |
| Mouri, A | 1 |
| Koga, M | 1 |
| Okochi, T | 2 |
| Williams, HJ | 1 |
| Takeda, M | 1 |
| Nabeshima, T | 4 |
| Owen, MJ | 1 |
| Honda, H | 1 |
| Arinami, T | 1 |
| Chen, L | 2 |
| Alonso, J | 3 |
| Croudace, T | 1 |
| Brown, J | 1 |
| Gasquet, I | 3 |
| Knapp, MR | 1 |
| Rémillard, S | 3 |
| Pourcher, E | 4 |
| Cohen, H | 3 |
| Kirkpatrick, B | 1 |
| Vester-Blokland, E | 2 |
| Sun, W | 1 |
| Carson, WH | 2 |
| Weedon, JC | 2 |
| Elmouchtari, A | 2 |
| Sunakawa, A | 1 |
| Goldfinger, SM | 1 |
| Menon, M | 1 |
| De Marinis, T | 1 |
| Pfeil, J | 1 |
| Ritchie, CW | 3 |
| Harrigan, S | 3 |
| Mastwyk, M | 3 |
| Macfarlane, S | 3 |
| Cheesman, N | 1 |
| Behpournia, H | 1 |
| Ghoreshi, A | 1 |
| Liew, A | 1 |
| Verma, S | 3 |
| Edimansyah, A | 1 |
| Subramaniam, M | 2 |
| Vaingankar, J | 1 |
| Tuma, I | 1 |
| Bij de Weg, H | 1 |
| Eriksson, L | 3 |
| Akhras, K | 1 |
| Koirala, S | 1 |
| Penagaluri, P | 1 |
| Smith, C | 2 |
| Lippmann, S | 2 |
| Choi, TK | 3 |
| Suh, S | 3 |
| Kim, YW | 3 |
| Kim, B | 4 |
| Yook, KH | 3 |
| Unis, AS | 1 |
| Armenteros, J | 1 |
| Copenhaver, MD | 1 |
| Quiroz, JA | 1 |
| Kushner, SF | 1 |
| Quincozes-Santos, A | 1 |
| Bobermin, LD | 1 |
| Tonial, RP | 1 |
| Bambini-Junior, V | 1 |
| Riesgo, R | 1 |
| Gottfried, C | 1 |
| Hawley, C | 1 |
| Turner, M | 5 |
| Latif, MA | 3 |
| Curtis, V | 1 |
| Saleem, PT | 2 |
| Wilton, K | 1 |
| Kang, CY | 1 |
| Xu, XF | 1 |
| Shi, ZY | 1 |
| Yang, JZ | 1 |
| Xu, HH | 1 |
| De Hert, M | 6 |
| Locatelli, I | 2 |
| Grabnar, I | 2 |
| Willis, M | 1 |
| Svensson, M | 1 |
| Löthgren, M | 2 |
| Eriksson, B | 3 |
| Berntsson, A | 1 |
| Persson, U | 1 |
| Xu, M | 3 |
| Gao, R | 3 |
| St Clair, D | 1 |
| Silveira da Mota Neto, JI | 1 |
| Smith, M | 2 |
| Thyssen, A | 2 |
| Rusch, S | 1 |
| Herben, V | 1 |
| Mannaert, E | 7 |
| Rocha, FF | 1 |
| Macfadden, W | 3 |
| Haskins, JT | 1 |
| Schmauss, M | 6 |
| Diekamp, B | 1 |
| Gerwe, M | 2 |
| Ibach, B | 1 |
| Cellard, C | 2 |
| Lefèbvre, AA | 1 |
| Maziade, M | 2 |
| Tremblay, S | 2 |
| Bortolozzi, A | 1 |
| Masana, M | 1 |
| Díaz-Mataix, L | 1 |
| Cortés, R | 1 |
| Scorza, MC | 1 |
| Gingrich, JA | 1 |
| Toth, M | 1 |
| Artigas, F | 1 |
| Pechlivanoglou, P | 1 |
| van Agthoven, M | 1 |
| Moriwaki, M | 1 |
| Kawashima, K | 1 |
| Fukuo, Y | 1 |
| Furukawa, O | 1 |
| Naitoh, H | 1 |
| Khazaal, Y | 1 |
| Chatton, A | 1 |
| Claeys, F | 1 |
| Ribordy, F | 1 |
| Khan, R | 1 |
| Zullino, D | 1 |
| Orfanos, S | 1 |
| Sertic, J | 1 |
| Nakano, Y | 2 |
| Nakano, H | 1 |
| Ikenouchi-Sugita, A | 2 |
| Umene-Nakano, W | 3 |
| Ueda, N | 10 |
| Sharma, B | 1 |
| Copeland, PM | 4 |
| Borba, CP | 5 |
| Freudenreich, O | 6 |
| Cather, C | 3 |
| Evins, AE | 4 |
| Montejo, AL | 2 |
| Majadas, S | 1 |
| Rico-Villademoros, F | 2 |
| Llorca, G | 1 |
| Franco, M | 1 |
| Martín-Carrasco, M | 1 |
| Aguera, L | 1 |
| Prieto, N | 1 |
| Grinspan, A | 1 |
| Kalali, A | 1 |
| Damaraju, CV | 1 |
| Merriman, U | 1 |
| Awad, AG | 3 |
| Rizos, EN | 1 |
| Papadopoulou, A | 1 |
| Laskos, E | 1 |
| Michalopoulou, PG | 1 |
| Kastania, A | 1 |
| Vasilopoulos, D | 1 |
| Katsafouros, K | 1 |
| Cai, ZJ | 2 |
| Weng, YZ | 3 |
| Liu, TQ | 2 |
| Weng, SM | 1 |
| Zhang, HY | 1 |
| Chen, DF | 1 |
| Duggan, L | 2 |
| Aggarwal, A | 1 |
| Khandelwal, A | 1 |
| Garg, A | 1 |
| Jiloha, RC | 1 |
| Kouniakis, F | 1 |
| Siurkute, A | 2 |
| Don, L | 1 |
| Peitl, MV | 1 |
| Pavlović, E | 1 |
| Peitl, A | 1 |
| Peitl, V | 1 |
| Jaffe, A | 3 |
| Levine, J | 5 |
| Surguladze, SA | 2 |
| Chu, EM | 2 |
| Marshall, N | 1 |
| Evans, A | 2 |
| Timehin, C | 2 |
| McDonald, C | 1 |
| Ecker, C | 1 |
| Phillips, ML | 1 |
| Arakawa, R | 2 |
| Okumura, M | 2 |
| Takano, A | 2 |
| Takahashi, H | 7 |
| Takano, H | 2 |
| Maeda, J | 2 |
| Okubo, Y | 3 |
| Suhara, T | 4 |
| Su, ZX | 1 |
| Shi, YN | 1 |
| Teng, LS | 1 |
| Wang, LX | 1 |
| Meng, QF | 1 |
| Teng, LR | 1 |
| Li, YX | 1 |
| Abdin, E | 1 |
| Sim, K | 1 |
| Su, A | 1 |
| Lee, N | 1 |
| Chong, SA | 6 |
| Fujii, A | 3 |
| Lloyd, K | 4 |
| Simpson, S | 1 |
| Shrestha, KL | 1 |
| Hong, CJ | 6 |
| Liou, YJ | 6 |
| Bai, YM | 12 |
| Wiffen, BD | 2 |
| Lex, A | 3 |
| Thomas, SH | 2 |
| Drici, MD | 1 |
| Hall, GC | 2 |
| Crocq, MA | 3 |
| Everitt, B | 2 |
| Lader, MH | 2 |
| Le Jeunne, C | 2 |
| Priori, S | 2 |
| Sturkenboom, M | 2 |
| Thibaut, F | 3 |
| Tanghøj, P | 3 |
| Toumi, M | 2 |
| Moore, ND | 2 |
| Mann, RD | 1 |
| Litière, S | 1 |
| Chan, SS | 2 |
| Arunpongpaisal, S | 1 |
| Kongsakon, R | 2 |
| Kitiwattanagul, K | 1 |
| Samanwongthai, U | 1 |
| Amann, LC | 1 |
| Lin, R | 1 |
| Liang, Y | 3 |
| Volonteri, LS | 1 |
| Cerveri, G | 1 |
| De Gaspari, IF | 1 |
| Baldi, ML | 1 |
| Rolandi, ML | 1 |
| Papa, P | 2 |
| Mauri, MC | 2 |
| Mencacci, C | 1 |
| Chang, JS | 1 |
| Yoo, CS | 1 |
| Yi, SH | 1 |
| Hong, KH | 1 |
| Lee, YS | 1 |
| Oh, HS | 1 |
| Jung, DC | 2 |
| Kripke, C | 1 |
| Arad, M | 1 |
| Gau, SS | 2 |
| Yagmur, F | 1 |
| Ulusoy, HB | 1 |
| Buyukoglan, H | 1 |
| Kaya, MG | 1 |
| Marcovina, S | 1 |
| Mendhekar, DN | 1 |
| Inamdar, A | 1 |
| Yamaguchi, K | 1 |
| Tsutsumi, E | 1 |
| Sevy, S | 5 |
| Gunduz-Bruce, H | 4 |
| Miller, R | 5 |
| Lorell, BS | 2 |
| Kane, J | 3 |
| Brousse, G | 2 |
| Lançon, C | 3 |
| Monshat, K | 1 |
| Carty, B | 1 |
| Castle, D | 2 |
| Bosanac, P | 1 |
| Chang, CL | 1 |
| Tzeng, DS | 1 |
| Johnson, JL | 2 |
| Lingler, J | 1 |
| Kaufman, EM | 1 |
| Schennach-Wolff, R | 3 |
| Seemüller, FH | 1 |
| Mayr, A | 5 |
| Klingberg, S | 7 |
| Heuser, I | 7 |
| Gastpar, M | 6 |
| Häfner, H | 2 |
| Sauer, H | 6 |
| Jäger, M | 8 |
| Wustmann, T | 1 |
| Roettig, S | 1 |
| Marneros, A | 1 |
| Danilov, DS | 2 |
| Razavi, N | 1 |
| Koschorke, P | 1 |
| Wopfner, A | 1 |
| Napryeyenko, O | 2 |
| Burba, B | 2 |
| Martinez, G | 4 |
| Neznanov, NG | 2 |
| Fischel, T | 2 |
| Baylé, FJ | 2 |
| Smeraldi, E | 4 |
| Guirguis-Blake, J | 1 |
| Padurariu, M | 1 |
| Ciobica, A | 1 |
| Dobrin, I | 1 |
| Stefanescu, C | 1 |
| Peleš, AM | 1 |
| Di Lorenzo, R | 1 |
| Fiorini, F | 1 |
| Santachiara, S | 1 |
| Kim, JH | 5 |
| Byun, HJ | 2 |
| Kores-Plesnicar, B | 1 |
| Mrhar, A | 1 |
| Goeb, JL | 1 |
| Marco, S | 1 |
| Duhamel, A | 1 |
| Kechid, G | 1 |
| Bordet, R | 1 |
| Delion, P | 1 |
| Jardri, R | 1 |
| Levine, S | 1 |
| Zhu, RH | 4 |
| Zhang, XH | 3 |
| Hu, L | 3 |
| Yang, W | 3 |
| Ye, HS | 3 |
| Bahk, WM | 3 |
| Cho, HS | 1 |
| Jeon, YW | 1 |
| Jon, DI | 1 |
| Jung, HY | 1 |
| Kim, HC | 1 |
| Kim, YH | 1 |
| Yi, JS | 1 |
| Su, Z | 1 |
| Sui, C | 1 |
| Meng, Q | 1 |
| Teng, L | 1 |
| Goldman, D | 2 |
| Weiner, E | 1 |
| Ball, MP | 1 |
| Gold, JM | 3 |
| Wonodi, I | 2 |
| Gysin, R | 1 |
| Kraftsik, R | 1 |
| Boulat, O | 1 |
| Bovet, P | 1 |
| Conus, P | 1 |
| Comte-Krieger, E | 1 |
| Polari, A | 1 |
| Steullet, P | 1 |
| Preisig, M | 1 |
| Teichmann, T | 1 |
| Cuénod, M | 1 |
| Do, KQ | 1 |
| Potkin, SG | 7 |
| Klimke, A | 2 |
| Eickhoff, M | 2 |
| Lemke, M | 2 |
| Huff, W | 1 |
| Köpcke, W | 2 |
| Ohmann, C | 5 |
| Tang, H | 1 |
| Yue, Q | 1 |
| Chan, RC | 2 |
| Meda, SA | 1 |
| Pearlson, G | 1 |
| Mechelli, A | 1 |
| de Arce, R | 1 |
| Rouillon, F | 3 |
| Cordes, J | 1 |
| Procyshyn, RM | 3 |
| Barr, AM | 2 |
| Flynn, S | 2 |
| Schenk, C | 1 |
| Ganesan, S | 1 |
| Honer, WG | 13 |
| Cañas, F | 2 |
| Lobos, CA | 1 |
| Chatterjee, M | 1 |
| Ganguly, S | 1 |
| Srivastava, M | 1 |
| Palit, G | 1 |
| Fjällström, AK | 1 |
| Federley, M | 1 |
| Persson, P | 2 |
| Stenqvist, P | 1 |
| Carswell, C | 2 |
| Wheeler, A | 2 |
| Vanderpyl, J | 2 |
| Robinson, E | 2 |
| Hung, GC | 2 |
| Kao, LH | 1 |
| Hensen, M | 1 |
| Kuo, CC | 1 |
| Chou, LS | 1 |
| Huang, KH | 1 |
| Gafoor, R | 1 |
| Craig, TK | 1 |
| Elanjithara, T | 1 |
| Power, P | 1 |
| McGuire, P | 1 |
| Campbell, EC | 1 |
| Saltz, BL | 1 |
| Riggio, S | 1 |
| Chakos, MH | 1 |
| Patkar, AA | 2 |
| Youakim, JM | 1 |
| Tiller, JM | 1 |
| Kodaka, F | 1 |
| Miyoshi, M | 1 |
| Otsuka, T | 1 |
| Nakayama, K | 2 |
| Halldin, C | 4 |
| Farde, L | 4 |
| Seeman, P | 2 |
| Feingold, A | 1 |
| Mann, S | 2 |
| Lin, E | 1 |
| Sico, JJ | 1 |
| Patwa, H | 1 |
| Dietrich-Muszalska, A | 1 |
| Kontek, B | 1 |
| Case, M | 2 |
| Jacob, J | 2 |
| Drici, M | 1 |
| Mann, R | 1 |
| Liao, WC | 1 |
| Yang, FW | 2 |
| Ho, PS | 1 |
| Subramanian, S | 1 |
| Sivaraman, P | 1 |
| Fernández-Fernández, FJ | 1 |
| Ghayyoumi, R | 1 |
| Modabbernia, AH | 1 |
| Maroufi, A | 1 |
| Esfandiari, GR | 2 |
| Naderi, M | 1 |
| Ghebleh, F | 1 |
| Melnik, T | 1 |
| Soares, BG | 1 |
| Puga, ME | 1 |
| Atallah, AN | 1 |
| Erdogan, A | 1 |
| Karaman, MG | 1 |
| Ozdemir, E | 1 |
| Yurteri, N | 1 |
| Tufan, AE | 1 |
| Kurcer, MA | 1 |
| Francey, SM | 1 |
| PanYuen, H | 1 |
| Simmons, MB | 1 |
| Ross, ML | 1 |
| Kelly, D | 1 |
| Baker, K | 1 |
| Berger, G | 2 |
| Thompson, AD | 1 |
| Thampi, A | 1 |
| Boaz, TL | 2 |
| Constantine, RJ | 1 |
| Robst, J | 1 |
| Becker, MA | 2 |
| Howe, AM | 1 |
| Sathyasaikumar, KV | 1 |
| Stachowski, EK | 1 |
| Roberts, RC | 1 |
| Rassoulpour, A | 1 |
| Schwarcz, R | 1 |
| Moons, T | 1 |
| Claes, S | 1 |
| Martens, GJ | 1 |
| Van Loo, KM | 1 |
| Van Schijndel, JE | 1 |
| van Winkel, R | 2 |
| Ardizzone, I | 1 |
| Nardecchia, F | 1 |
| Marconi, A | 1 |
| Carratelli, TI | 1 |
| Ferrara, M | 1 |
| Ren, XS | 7 |
| Crivera, C | 3 |
| Sikirica, M | 1 |
| Qian, S | 3 |
| Kazis, LE | 6 |
| Asenjo Lobos, C | 1 |
| Fox, KH | 1 |
| Siu, C | 2 |
| Narr, KL | 1 |
| Phillips, OR | 1 |
| Bilder, RM | 3 |
| Lane, R | 2 |
| Gassmann-Mayer, C | 2 |
| Simpson, G | 3 |
| Yook, K | 1 |
| Lee, KS | 2 |
| Lee, JE | 1 |
| Farnaghi, F | 1 |
| Hajiazim, M | 3 |
| Smesny, S | 2 |
| Kunstmann, C | 1 |
| Kunstmann, S | 1 |
| Willhardt, I | 1 |
| Lasch, J | 1 |
| Yotter, RA | 1 |
| Proffitt, TM | 1 |
| Kerr, M | 1 |
| Marculev, C | 1 |
| Milleit, B | 1 |
| Milleit, C | 1 |
| Nenadic, I | 1 |
| Amminger, P | 1 |
| Berger, GE | 1 |
| Park, MH | 1 |
| Pae, CU | 5 |
| Fang, PF | 2 |
| Mazhar, MN | 1 |
| Resch, DS | 1 |
| Ng, KW | 1 |
| Swapna, V | 1 |
| Kusumi, I | 2 |
| Honda, M | 1 |
| Ito, K | 2 |
| Uemura, K | 1 |
| Kumazawa, Y | 1 |
| Ishikane, T | 1 |
| Niide, Y | 1 |
| Koyama, T | 5 |
| Celikyurt, IK | 1 |
| Kayir, H | 1 |
| Ulak, G | 1 |
| Erden, FB | 1 |
| Ulusoy, GK | 1 |
| Uzbay, TI | 1 |
| Mas, S | 1 |
| Gassò, P | 1 |
| Alvarez, S | 1 |
| Lafuente, A | 1 |
| Cavallaro, R | 3 |
| van Kooten, M | 1 |
| Hu, CH | 1 |
| Pai, N | 1 |
| Kaushik, GN | 1 |
| Gitlin, MJ | 1 |
| Thornton, LA | 1 |
| Singh, IR | 1 |
| Lataster, J | 1 |
| van Os, J | 3 |
| Thewissen, V | 1 |
| Bak, M | 1 |
| Lataster, T | 1 |
| Lardinois, M | 1 |
| Delespaul, PA | 1 |
| Myin-Germeys, I | 2 |
| Ohta, C | 1 |
| Yoshizawa, K | 1 |
| Cerit, C | 1 |
| Vural, M | 1 |
| Bos Gelmez, SÜ | 1 |
| Ozten, E | 1 |
| Aker, AT | 1 |
| Yıldız, M | 1 |
| Meyer, S | 2 |
| Seemüller, F | 5 |
| Lawford, BR | 2 |
| Barnes, M | 2 |
| Connor, JP | 1 |
| Heslop, K | 1 |
| Nyst, P | 1 |
| Young, RM | 2 |
| Lin, TY | 1 |
| Wang, CC | 1 |
| Shuai, HA | 1 |
| Lew, R | 3 |
| Barnett, PG | 4 |
| Fiore, L | 2 |
| Huang, GD | 1 |
| Neal, C | 1 |
| Vertrees, JE | 2 |
| Arshoff, L | 1 |
| Olfson, M | 2 |
| Gerhard, T | 1 |
| Crystal, S | 1 |
| Rui, Q | 3 |
| Ishitobi, M | 2 |
| Kosaka, H | 2 |
| Shukunami, K | 2 |
| Murata, T | 2 |
| Wada, Y | 2 |
| Dockx, L | 1 |
| Bernagie, C | 1 |
| Peuskens, B | 1 |
| Sweers, K | 1 |
| Tack, J | 1 |
| Van de Straete, S | 1 |
| Wampers, M | 2 |
| Honarbakhsh, N | 1 |
| Boroumand, MA | 1 |
| Jafarinia, M | 2 |
| Hayakawa, T | 2 |
| Ashizawa, Y | 1 |
| Hayashi, N | 1 |
| Hamakawa, H | 1 |
| Catafau, AM | 3 |
| Bullich, S | 1 |
| Nucci, G | 1 |
| Burgess, C | 1 |
| Gray, F | 1 |
| Merlo-Pich, E | 1 |
| Vasil'eva, AI | 1 |
| Ortega-Alvaro, A | 1 |
| Aracil-Fernández, A | 1 |
| García-Gutiérrez, MS | 1 |
| Navarrete, F | 1 |
| Manzanares, J | 1 |
| Liemburg, E | 1 |
| Bous, J | 2 |
| Hollander, K | 1 |
| Hardy, TA | 2 |
| Henry, RR | 1 |
| Forrester, TD | 1 |
| Kryzhanovskaya, LA | 1 |
| Campbell, GM | 1 |
| Marks, DM | 1 |
| Mudaliar, S | 2 |
| Seto, K | 1 |
| Dumontet, J | 1 |
| Ensom, MH | 1 |
| Richtand, NM | 3 |
| Ahlbrand, R | 2 |
| Horn, P | 1 |
| Stanford, K | 1 |
| Bronson, SL | 2 |
| Zipursky, RB | 6 |
| Adams, W | 1 |
| van den Buuse, M | 1 |
| Heald, A | 1 |
| Collette, J | 1 |
| Reginster, JY | 1 |
| Scheen, A | 1 |
| Sung, KH | 1 |
| Kang, UG | 1 |
| Scott, JY | 2 |
| Brock, GN | 1 |
| Mehrotra, B | 1 |
| Andel, R | 1 |
| Desmarais, SL | 1 |
| Chandler, K | 1 |
| Howe, A | 1 |
| Chathanchirayil, SJ | 1 |
| Slade, EP | 1 |
| Medoff, DR | 1 |
| Brown, CH | 3 |
| Ehrenreich, B | 1 |
| Afful, J | 1 |
| Dixon, LB | 2 |
| Werneck, AP | 1 |
| Hallak, JC | 1 |
| Nakano, E | 1 |
| Hattori, K | 2 |
| Wakabayashi, C | 1 |
| Yamamoto, N | 2 |
| Uchiyama, H | 1 |
| Teraishi, T | 2 |
| Arima, K | 1 |
| Kunugi, H | 4 |
| Ojeda, N | 1 |
| Zabala, A | 1 |
| García, J | 1 |
| Catalán, A | 1 |
| Eguíluz, JI | 1 |
| Gutiérrez, M | 1 |
| Kaneda, A | 1 |
| Tomita, T | 1 |
| Li, LF | 1 |
| Sunday, S | 1 |
| Rao, N | 1 |
| Korpade, V | 1 |
| Behere, R | 1 |
| Varambally, S | 1 |
| Gangadhar, B | 1 |
| Marquis, KL | 1 |
| Comery, TA | 1 |
| Jow, F | 1 |
| Navarra, RL | 1 |
| Grauer, SM | 1 |
| Pulicicchio, C | 1 |
| Kelley, C | 1 |
| Brennan, JA | 1 |
| Roncarati, R | 1 |
| Scali, C | 1 |
| Haydar, S | 1 |
| Ghiron, C | 1 |
| Terstappen, GC | 1 |
| Dunlop, J | 1 |
| Kwatra, SG | 1 |
| Batson, NE | 1 |
| Kramer, SI | 1 |
| Shao, L | 1 |
| Zeng, Z | 1 |
| Wichniak, A | 1 |
| Skowerska, A | 1 |
| Chojnacka-Wójtowicz, J | 1 |
| Tafliński, T | 1 |
| Wierzbicka, A | 1 |
| Jernajczyk, W | 1 |
| Borlido, C | 2 |
| Suridjan, I | 1 |
| Nagasawa, T | 1 |
| Hirosawa, T | 1 |
| Minabe, Y | 1 |
| Dierks, T | 1 |
| Koenig, T | 1 |
| Roenker, NL | 1 |
| Gudelsky, G | 1 |
| Kern, JR | 1 |
| Waterman, H | 1 |
| Kreyenbuhl, JA | 1 |
| de Boer, MK | 1 |
| Wiersma, D | 2 |
| Sytema, S | 1 |
| van der Moolen, AE | 1 |
| Wilffert, B | 2 |
| Hamamura, T | 1 |
| Chen, ML | 2 |
| Lin, YY | 1 |
| Tsai, YM | 1 |
| Wang, LK | 1 |
| Lee, MC | 1 |
| Tsai, FM | 1 |
| Amar, CP | 2 |
| Detore, NR | 2 |
| Machielsen, M | 2 |
| Beduin, AS | 1 |
| Dekker, N | 1 |
| Linszen, DH | 5 |
| Krabbendam, L | 1 |
| Ring, KD | 1 |
| Hamer, RH | 1 |
| LaVange, LM | 1 |
| Nussbaum, AM | 2 |
| Eberhard, J | 5 |
| Fors, BM | 1 |
| Hansen, K | 1 |
| Lim, P | 1 |
| Xiao, SF | 1 |
| Xue, HB | 1 |
| Li, GJ | 1 |
| Yuan, CM | 1 |
| Zhang, MY | 1 |
| Crabtree, BL | 1 |
| Dostrow, VG | 1 |
| Evans, CJ | 1 |
| Cuffel, BJ | 2 |
| Alvir, JM | 1 |
| Sanders, KN | 1 |
| Eding, E | 1 |
| Marques-Teixeira, J | 1 |
| Milanova, V | 2 |
| Hoffmann, VP | 1 |
| Peritogiannis, V | 1 |
| Tsouli, S | 1 |
| Chung, MT | 1 |
| Chou, J | 2 |
| Makkos, Z | 1 |
| Fejes, L | 1 |
| Inczédy-Farkas, G | 1 |
| Kassai-Farkas, A | 1 |
| Faludi, G | 2 |
| Lazáry, J | 1 |
| Melkersson, K | 2 |
| Berinder, K | 1 |
| Hulting, AL | 1 |
| Kovacs, N | 1 |
| Balas, I | 1 |
| Janszky, J | 1 |
| Simon, M | 1 |
| Komoly, S | 1 |
| Gordon, C | 1 |
| Green, MD | 1 |
| Porcelli, S | 1 |
| Balzarro, B | 1 |
| Mellino, G | 1 |
| Pintore, S | 1 |
| Puddu, L | 1 |
| Martínez-Ortega, JM | 1 |
| Diaz-Atienza, F | 1 |
| Gutiérrez-Rojas, L | 1 |
| Jurado, D | 1 |
| Gurpegui, M | 2 |
| Lesser, ML | 2 |
| Dalton, A | 1 |
| Lambert, T | 3 |
| Schrover, R | 1 |
| Hertel, J | 1 |
| Smith, DK | 1 |
| Arbabi, M | 1 |
| Ahmadi-Abhari, SA | 2 |
| Khalighi-Sigaroudi, F | 1 |
| Tsai, A | 1 |
| Wu, CL | 2 |
| Huang, HH | 1 |
| Maric, NP | 1 |
| Britvic, D | 2 |
| Damjanovic, A | 2 |
| Miljic, D | 2 |
| Stojanovic, M | 2 |
| Radojicic, Z | 1 |
| Jasovic Gasic, M | 1 |
| Brunnauer, A | 2 |
| Laux, G | 5 |
| Bates, JA | 1 |
| Jing, Y | 1 |
| Hebden, T | 1 |
| Forbes, RA | 1 |
| DeSouza, C | 2 |
| Kozma, CM | 2 |
| Dirani, RD | 2 |
| Rodriguez, SC | 1 |
| Pan, G | 1 |
| Su, M | 1 |
| Fang, Y | 1 |
| Jia, W | 1 |
| Iwakura, Y | 1 |
| Aizawa, M | 1 |
| Shcherbakova, K | 1 |
| Iagubov, MI | 1 |
| Shtark, LN | 1 |
| Popović, I | 1 |
| Ravanić, D | 1 |
| Vladejić, S | 1 |
| Stanojević, A | 1 |
| Shi, W | 1 |
| Qi, Y | 1 |
| Liang, G | 1 |
| Zeshan, B | 1 |
| Xiao, Z | 1 |
| Kim, K | 1 |
| Aas, E | 1 |
| Tsai, MC | 1 |
| Chang, CM | 1 |
| Liu, CY | 4 |
| Chang, PY | 1 |
| Grimaldi-Bensouda, L | 1 |
| Astruc, B | 1 |
| Rossignol, M | 1 |
| Benichou, J | 1 |
| Falissard, B | 1 |
| Beaufils, B | 1 |
| Vaiva, G | 1 |
| Verdoux, H | 1 |
| Moride, Y | 1 |
| Fabre, A | 1 |
| Abenhaim, L | 1 |
| Miodownik, C | 1 |
| Lerner, V | 1 |
| Witztum, E | 1 |
| Stahl, SM | 6 |
| Zedkova, I | 1 |
| Dudova, I | 1 |
| Urbanek, T | 1 |
| Hrdlicka, M | 1 |
| Paslakis, G | 1 |
| Deuschle, M | 1 |
| Thome, J | 2 |
| Rüsse, S | 1 |
| Kopf, D | 1 |
| Perry, R | 1 |
| Wolberg, J | 1 |
| DiCrescento, S | 1 |
| Reist, C | 3 |
| Wu, JC | 1 |
| Lilja, Y | 1 |
| Mukherjee, J | 1 |
| Gripeos, D | 1 |
| Constantinescu, C | 1 |
| Raggi, MA | 2 |
| Mercolini, L | 1 |
| Kucharska-Pietura, K | 1 |
| Tylec, A | 1 |
| Czernikiewicz, A | 2 |
| Mortimer, A | 1 |
| Tsao, TY | 1 |
| Berkowitz, RL | 1 |
| Patel, U | 1 |
| Ni, Q | 1 |
| Parks, JJ | 1 |
| Docherty, JP | 2 |
| Shen, YC | 8 |
| Zhang, PY | 6 |
| Zhang, WF | 1 |
| Liang, J | 1 |
| Mizuno, Y | 1 |
| Tseng, CC | 1 |
| Li, LH | 1 |
| Ye, M | 1 |
| Huang, J | 1 |
| Zhang, Q | 2 |
| Wang, B | 1 |
| Wasserman, JI | 1 |
| Barry, RJ | 1 |
| Bradford, L | 1 |
| Delva, NJ | 1 |
| Beninger, RJ | 2 |
| Altamura, AC | 1 |
| Molina-Ruiz, AM | 1 |
| Molina-Ruiz, RM | 1 |
| Zulueta, T | 1 |
| Barabash, R | 1 |
| Requena, L | 1 |
| Yang, SY | 1 |
| Liao, YT | 1 |
| Lee, WC | 1 |
| Shau, WY | 1 |
| Chang, YT | 1 |
| Stroup, ST | 1 |
| Bravo-Mehmedbasic, A | 1 |
| Xiao, S | 1 |
| Yuan, C | 1 |
| Wu, HZ | 1 |
| Mitchell, P | 1 |
| Williams, O | 1 |
| Chang, CH | 1 |
| Kao Yang, YH | 1 |
| Lin, SJ | 1 |
| Lin, CY | 5 |
| Essali, A | 1 |
| Ali, G | 1 |
| Rosa, F | 1 |
| Sherif, T | 1 |
| Mihajlović, G | 1 |
| Jovanović-Mihajlović, N | 1 |
| Radmanović, B | 1 |
| Radonjić, K | 1 |
| Djukić-Dejanović, S | 1 |
| Janković, S | 1 |
| Milovanović, N | 1 |
| Petrović, D | 1 |
| Tomić, K | 1 |
| Tsunoda, K | 4 |
| Millet, B | 1 |
| Gourevitch, R | 1 |
| Levoyer, D | 1 |
| Parmentier, G | 1 |
| Joly, C | 1 |
| Sarma, K | 1 |
| Tsuchiya, S | 1 |
| Jeong, HG | 1 |
| Lee, HY | 1 |
| Ko, YH | 2 |
| Joe, SH | 2 |
| Hayashi, H | 1 |
| Ishii, R | 1 |
| Hata, K | 1 |
| Huang, ST | 1 |
| McCrone, P | 2 |
| Emmerson, B | 1 |
| Hustig, H | 3 |
| Butcher, B | 1 |
| Yasuhara, Y | 1 |
| Hirai, E | 1 |
| Sakamaki, S | 1 |
| Tanioka, T | 1 |
| Motoki, K | 1 |
| Takase, K | 1 |
| Locsin, R | 1 |
| Kawanishi, C | 1 |
| Inui, T | 1 |
| Watari, C | 1 |
| Makiguchi, K | 1 |
| Mehnert, A | 8 |
| Nicholl, D | 1 |
| Martin, M | 1 |
| McGuire, A | 1 |
| Rachakonda, S | 1 |
| Dwivedi, S | 2 |
| Jackson, CT | 2 |
| Rojas, IA | 1 |
| Essock, SM | 3 |
| Hutton, P | 1 |
| Morrison, AP | 1 |
| Taylor, PJ | 1 |
| French, P | 1 |
| Dunn, G | 1 |
| Stone, WS | 2 |
| Hsi, X | 1 |
| Giuliano, AJ | 2 |
| Seidman, LJ | 2 |
| Tsuang, MT | 3 |
| Langbein, K | 1 |
| Rzanny, R | 1 |
| Gussew, A | 1 |
| Burmeister, HP | 1 |
| Reichenbach, JR | 1 |
| Hermes, E | 1 |
| Bachman, P | 1 |
| Jalbrzikowski, M | 1 |
| Bearden, CE | 1 |
| Yakutis, L | 1 |
| Youngstrom, EA | 1 |
| Breiger, D | 1 |
| Hooper, SR | 1 |
| Kilian, R | 1 |
| Steinert, T | 1 |
| Schepp, W | 1 |
| Weiser, P | 1 |
| Jaeger, S | 1 |
| Pfiffner, C | 1 |
| Frasch, K | 1 |
| Eschweiler, GW | 1 |
| Messer, T | 2 |
| Croissant, D | 1 |
| Becker, T | 1 |
| Längle, G | 1 |
| Anandarajan, T | 1 |
| Tibrewal, P | 1 |
| Dhillon, R | 1 |
| Chung, TS | 1 |
| Gao, S | 1 |
| Hu, Z | 1 |
| Cheng, J | 1 |
| Dong, J | 1 |
| Kaufmann, A | 1 |
| Boesch, S | 1 |
| Chindo, BA | 1 |
| Adzu, B | 1 |
| Yahaya, TA | 1 |
| Gamaniel, KS | 1 |
| Oosthuizen, PP | 2 |
| Barteček, R | 1 |
| Juřica, J | 1 |
| Zrůstová, J | 1 |
| Pindurová, E | 1 |
| Žourková, A | 1 |
| Tang, K | 1 |
| Niu, J | 1 |
| Tian, Z | 1 |
| Lewitzka, U | 2 |
| Bauer, M | 1 |
| Musil, R | 3 |
| Schennach, R | 3 |
| Doucette, S | 1 |
| Morita, K | 1 |
| Shoji, Y | 1 |
| Matsuoka, T | 1 |
| Fujiki, R | 1 |
| Uchimura, N | 2 |
| Ye, W | 1 |
| Fujikoshi, S | 1 |
| Nakahara, N | 1 |
| Takahashi, M | 1 |
| Duncan, EJ | 1 |
| Woolson, SL | 1 |
| Abdallah, CG | 1 |
| Wan, X | 1 |
| Liang, C | 1 |
| Hong, X | 2 |
| Huang, Q | 1 |
| Chen, SH | 1 |
| Chu, CH | 1 |
| Yeh, TL | 2 |
| Stojković, T | 1 |
| Radonjić, NV | 1 |
| Velimirović, M | 1 |
| Jevtić, G | 1 |
| Petronijević, ND | 1 |
| Brugnoli, R | 2 |
| Bertsch, J | 1 |
| Hong, J | 2 |
| Morag, A | 1 |
| Oved, K | 1 |
| Gurwitz, D | 1 |
| Stojkovic, M | 1 |
| Yan, XZ | 1 |
| Sun, B | 1 |
| Yan, M | 1 |
| Zhang, WY | 1 |
| Xu, P | 1 |
| Yuan, HY | 1 |
| Sisti, J | 1 |
| Klook, K | 1 |
| Ortinski, PI | 1 |
| Leitman, V | 1 |
| Thieu, T | 1 |
| Pierce, RC | 1 |
| Jonak, G | 1 |
| Carlson, G | 1 |
| Soares, LA | 1 |
| do Socorro Costa Feitosa Alves, M | 1 |
| de Paula Soares Rachetti, V | 1 |
| Filgueira Júnior, A | 1 |
| Couvrette, AJ | 1 |
| Lee, JH | 3 |
| Chue, J | 1 |
| Kaushal, J | 1 |
| Bhutani, G | 1 |
| Remberk, B | 1 |
| Namysłowska, I | 1 |
| Rybakowski, F | 1 |
| Sasayama, D | 1 |
| Chiba, S | 2 |
| Iijima, Y | 1 |
| Matsuo, J | 1 |
| Kawamoto, Y | 1 |
| Ota, M | 1 |
| Kajiwara, M | 1 |
| Terada, S | 1 |
| Yun, HW | 1 |
| Lee, BD | 1 |
| Olszewski, RT | 1 |
| Janczura, KJ | 1 |
| Ball, SR | 1 |
| Madore, JC | 1 |
| Lavin, KM | 1 |
| Lee, JC | 1 |
| Lee, MJ | 1 |
| Der, EK | 1 |
| Hark, TJ | 1 |
| Farago, PR | 1 |
| Profaci, CP | 1 |
| Bzdega, T | 1 |
| Neale, JH | 1 |
| Aizenberg, D | 3 |
| Tordesillas-Gutiérrez, D | 1 |
| Gutiérrez, A | 1 |
| Tani, H | 1 |
| Shibuya, Y | 1 |
| Shimanuki, H | 1 |
| Den, R | 3 |
| Nishimoto, M | 2 |
| Hirano, J | 2 |
| Nio, S | 2 |
| Kitahata, R | 1 |
| Kikuchi, T | 1 |
| Moteshafi, H | 1 |
| Croarkin, PE | 1 |
| Daskalakis, ZJ | 2 |
| Minutolo, G | 1 |
| Dipasquale, S | 1 |
| Schuster, JP | 1 |
| Raucher-Chéné, D | 1 |
| Lemogne, C | 1 |
| Leguay, D | 1 |
| Gierski, F | 1 |
| Klingenberg, S | 1 |
| Takeuchi, S | 1 |
| Katsumi, A | 1 |
| Kanno, K | 1 |
| Mashiko, H | 1 |
| Niwa, S | 1 |
| Zhao, QZ | 1 |
| Liu, BC | 1 |
| Li, XW | 2 |
| Ji, J | 1 |
| Yang, FP | 1 |
| Wan, CL | 1 |
| Xu, YF | 1 |
| He, G | 3 |
| Sunakawa-McMillan, A | 1 |
| Zaytseva, Y | 1 |
| Gurovich, IY | 1 |
| Goland, E | 1 |
| Storozhakova, YA | 1 |
| Vanover, K | 1 |
| Weiner, DM | 1 |
| van Kammen, DP | 1 |
| Peters, P | 1 |
| Hacksell, U | 1 |
| San, L | 2 |
| Arranz, B | 1 |
| Perez, V | 4 |
| Safont, G | 1 |
| Ramirez, N | 1 |
| Dueñas, R | 1 |
| Alvarez, E | 5 |
| Bretag-Norris, R | 1 |
| Alexander, J | 1 |
| Kohler, J | 1 |
| Ellingrod, VL | 1 |
| Ostbye, KM | 1 |
| Poole Hoffmann, V | 1 |
| Faries, D | 5 |
| Phillips, G | 1 |
| Nyhuis, AW | 4 |
| Sugihara, T | 1 |
| Yan, X | 1 |
| Yue, Y | 1 |
| Qian, M | 1 |
| Teo, C | 1 |
| De Luca, V | 1 |
| Alegría, M | 1 |
| Normand, SL | 1 |
| Kandasamy, A | 1 |
| Boyer, L | 1 |
| Guedj, E | 1 |
| Geffen, Y | 1 |
| Keefe, R | 1 |
| Anand, R | 1 |
| Davidson, M | 12 |
| Baandrup, L | 1 |
| Jennum, P | 1 |
| Glenthoj, B | 1 |
| Olson, WH | 1 |
| Hulihan, J | 1 |
| Hoblyn, JC | 1 |
| Leatherman, S | 1 |
| Weil, L | 1 |
| Díaz, I | 1 |
| Rohr-Kirchgraber, T | 1 |
| Raghunath, A | 1 |
| Lazarczyk, MJ | 1 |
| Bhuiyan, ZA | 1 |
| Perrin, N | 1 |
| Giannakopoulos, P | 1 |
| Jin, H | 1 |
| Shih, PA | 1 |
| Golshan, S | 1 |
| Henry, R | 1 |
| Glorioso, DK | 1 |
| Arndt, S | 1 |
| Kraemer, HC | 1 |
| Jeste, DV | 5 |
| Scheltema Beduin, AA | 1 |
| Swets, M | 1 |
| Korver, N | 1 |
| Suresh Kumar, PN | 1 |
| Bilder, R | 1 |
| Lerond, J | 1 |
| Lothe, A | 1 |
| Ryvlin, P | 1 |
| Bouvard, S | 1 |
| d'Amato, T | 1 |
| Ciumas, C | 1 |
| Daléry, J | 1 |
| Poulet, E | 1 |
| Saoud, M | 1 |
| Niehaus, D | 1 |
| Martinez, L | 1 |
| Castellano, O | 1 |
| Arji, M | 1 |
| Sancho, C | 2 |
| Carro, J | 1 |
| Riolobos, AS | 1 |
| Gómez-Nieto, R | 1 |
| de Anchieta de Castro E Horta, J | 1 |
| Herrero-Turrión, MJ | 1 |
| López, DE | 1 |
| Strassnig, M | 5 |
| Awerbuck, J | 1 |
| Bishop, I | 1 |
| Campbell, S | 1 |
| Miranda, J | 1 |
| Gustafsson, LL | 1 |
| Jin, C | 1 |
| Hrisko, S | 1 |
| Wykes, T | 1 |
| Williams, P | 1 |
| Gao, JS | 1 |
| Pang, LJ | 1 |
| Li, YH | 1 |
| Sato, G | 1 |
| Yoshimura, S | 1 |
| Yamashita, H | 4 |
| Okamoto, Y | 3 |
| Yamawaki, S | 4 |
| Dubois, V | 1 |
| Detraux, J | 1 |
| De Berardis, D | 1 |
| Marini, S | 1 |
| Carano, A | 1 |
| Lang, AP | 1 |
| Cavuto, M | 1 |
| Piersanti, M | 1 |
| Fornaro, M | 1 |
| Perna, G | 1 |
| Valchera, A | 1 |
| Mazza, M | 1 |
| Iasevoli, F | 1 |
| Martinotti, G | 1 |
| Di Giannantonio, M | 2 |
| Bourque, J | 1 |
| Lakis, N | 1 |
| Champagne, J | 1 |
| Lalonde, P | 1 |
| Lipp, O | 1 |
| Mendrek, A | 2 |
| Higuchi, Y | 1 |
| Seo, T | 1 |
| Miyanishi, T | 1 |
| Shams-Alizadeh, N | 1 |
| Liu-Seifert, H | 5 |
| McIntosh, AL | 1 |
| Ballard, TM | 1 |
| Steward, LJ | 1 |
| Moran, PM | 1 |
| Fone, KC | 1 |
| Puech, A | 1 |
| Shaw, JW | 1 |
| Goldstein, JM | 1 |
| Wojcik, J | 2 |
| Brandman, D | 1 |
| Klibanski, A | 1 |
| Schildkraut, JJ | 1 |
| Güzelcan, Y | 1 |
| Scholte, WF | 1 |
| Javitt, DC | 5 |
| Cienfuegos, A | 2 |
| Miniati, M | 1 |
| Silipo, G | 2 |
| Allingham, BH | 1 |
| Robinson, J | 2 |
| Koro, CE | 2 |
| Fedder, DO | 2 |
| L'Italien, GJ | 2 |
| Weiss, SS | 1 |
| Magder, LS | 2 |
| Revicki, DA | 3 |
| Spina, E | 8 |
| Avenoso, A | 4 |
| Scordo, MG | 4 |
| Ancione, M | 4 |
| Madia, A | 2 |
| Gatti, G | 1 |
| Perucca, E | 4 |
| Reeves, RR | 3 |
| Mack, JE | 3 |
| Jessen, LM | 1 |
| Drozdov, ES | 1 |
| Hsieh, MH | 1 |
| Voruganti, L | 1 |
| Cortese, L | 1 |
| Owyeumi, L | 1 |
| Kotteda, V | 3 |
| Cernovsky, Z | 1 |
| Zirul, S | 3 |
| Awad, A | 1 |
| Briken, P | 2 |
| Nika, E | 2 |
| Moritz, S | 2 |
| Haasen, C | 2 |
| Perro, C | 1 |
| Yagdiran, O | 1 |
| Krausz, M | 3 |
| Hosák, L | 1 |
| Bahbouh, R | 1 |
| Schmitt, GJ | 1 |
| Meisenzahl, EM | 1 |
| Dresel, S | 3 |
| Tatsch, K | 3 |
| Rossmüller, B | 2 |
| Frodl, T | 1 |
| Preuss, UW | 1 |
| Hahn, K | 3 |
| Alevizos, B | 1 |
| Zervas, IM | 1 |
| Christodoulou, GN | 4 |
| Denisov, MF | 1 |
| Smelson, DA | 2 |
| Losonczy, MF | 3 |
| Davis, CW | 1 |
| Kaune, M | 1 |
| Williams, J | 1 |
| Jones, HM | 4 |
| Pilowsky, LS | 8 |
| Mihara, K | 7 |
| De Vries, R | 6 |
| Yuen, HP | 1 |
| Francey, S | 1 |
| Cosgrave, EM | 1 |
| Germano, D | 1 |
| Bravin, J | 1 |
| McDonald, T | 1 |
| Blair, A | 1 |
| Adlard, S | 1 |
| Jackson, H | 1 |
| Aymard, N | 1 |
| Viala, A | 1 |
| Clement, MN | 1 |
| Jacquot, M | 1 |
| Vacheron, MN | 1 |
| Gauillard, J | 1 |
| Caroli, F | 1 |
| Addy, N | 1 |
| Levin, ED | 1 |
| Savas, HA | 1 |
| Unal, B | 1 |
| Erbagci, H | 1 |
| Inaloz, S | 1 |
| Herken, H | 2 |
| Canan, S | 1 |
| Gumusburun, E | 1 |
| Zoroglu, SS | 1 |
| Borkowska, A | 2 |
| Araszkiewicz, A | 2 |
| Rajewski, A | 1 |
| Rybakowski, JK | 2 |
| Myers, JE | 1 |
| Thase, ME | 1 |
| Mackeprang, T | 3 |
| Kristiansen, KT | 1 |
| Glenthoj, BY | 2 |
| Sugita, T | 2 |
| Higuchi, H | 5 |
| Shimizu, T | 3 |
| Emsley, RA | 1 |
| Roberts, MC | 1 |
| Turner, J | 1 |
| Keyter, L | 1 |
| Keyter, N | 1 |
| Torreman, M | 1 |
| Suzuki, E | 1 |
| Obata, M | 1 |
| Yoshida, Y | 1 |
| Miyaoka, H | 1 |
| Artiola i Fortuny, L | 1 |
| Vester-Blockland, E | 1 |
| De Smedt, G | 2 |
| Merlo, MC | 1 |
| Hofer, H | 1 |
| Gekle, W | 1 |
| Panhuber, I | 1 |
| Latour, G | 1 |
| Weiss, S | 1 |
| Revicki, D | 2 |
| Hennessy, S | 1 |
| Bilker, WB | 1 |
| Knauss, JS | 1 |
| Margolis, DJ | 1 |
| Kimmel, SE | 1 |
| Reynolds, RF | 1 |
| Glasser, DB | 1 |
| Morrison, MF | 1 |
| Strom, BL | 1 |
| Bilici, M | 1 |
| Cakirbay, H | 1 |
| Guler, M | 1 |
| Tosun, M | 1 |
| Ulgen, M | 1 |
| Tan, U | 1 |
| Broerse, A | 1 |
| Crawford, TJ | 1 |
| den Boer, JA | 1 |
| Mirecki, I | 2 |
| Mazeh, D | 2 |
| Achiron, A | 1 |
| Ciu, HJ | 1 |
| Guo, ZZ | 1 |
| van Amelsvoort, T | 2 |
| Tsuang, JW | 1 |
| Eckman, T | 1 |
| Tucker, D | 1 |
| Sechter, D | 2 |
| Fleurot, O | 2 |
| Rein, W | 3 |
| Lecrubier, Y | 1 |
| Lee, AF | 6 |
| Hamed, A | 3 |
| Huang, YH | 5 |
| Cunningham, F | 2 |
| Miller, DR | 7 |
| Chiu, NY | 1 |
| Wu, CK | 1 |
| Yuan, LM | 1 |
| Hsiao, MC | 2 |
| Liao, O | 1 |
| Wassef, AA | 1 |
| Tracy, KA | 2 |
| Sommerville, KW | 1 |
| Duggal, HS | 2 |
| De Vanna, M | 1 |
| Onor, ML | 1 |
| Ferrara, D | 1 |
| Loonen, AJ | 1 |
| Loos, JC | 1 |
| Van Zonneveld, TH | 1 |
| Conlon, L | 1 |
| Fahy, TJ | 1 |
| OToole, R | 1 |
| Gilligan, J | 1 |
| Prescott, P | 1 |
| Burgess, ES | 1 |
| Zimmet, SV | 1 |
| Strous, RD | 5 |
| Berecz, R | 1 |
| de la Rubia, A | 2 |
| Gómez, J | 1 |
| Kellermann, M | 1 |
| Degrell, I | 1 |
| Danese, A | 1 |
| Guaiana, G | 1 |
| Mapelli, L | 1 |
| Miele, L | 1 |
| Monzani, E | 1 |
| Percudani, M | 1 |
| Chae, JH | 2 |
| Kim, KS | 2 |
| Jun, TY | 3 |
| Tsoh, J | 1 |
| Kim, DJ | 3 |
| Lee, CT | 1 |
| Lee, C | 4 |
| Han, SI | 1 |
| Choi, BM | 2 |
| Han, JH | 1 |
| Go, HJ | 2 |
| Frackiewicz, EJ | 1 |
| Herrera, JM | 1 |
| Sramek, JJ | 1 |
| Collazo, Y | 1 |
| Lawson, WB | 1 |
| Erlandsson, K | 2 |
| Mulligan, RS | 1 |
| Ell, PJ | 6 |
| Kunwar, AR | 1 |
| Megna, JL | 3 |
| Hariharan, J | 1 |
| Mohsin, J | 1 |
| Sheitman, B | 9 |
| Cooper, TB | 7 |
| Chakos, M | 5 |
| Green, MF | 12 |
| McGurk, SR | 5 |
| Hudson, TJ | 1 |
| Sullivan, G | 1 |
| Owen, RR | 1 |
| Thrush, CR | 1 |
| Shinkai, K | 5 |
| Hertling, I | 1 |
| Philipp, M | 3 |
| Dvorak, A | 1 |
| Glaser, T | 3 |
| Mast, O | 1 |
| Beneke, M | 2 |
| Ramskogler, K | 1 |
| Saletu-Zyhlarz, G | 1 |
| Walter, H | 1 |
| Lesch, OM | 3 |
| Meibach, RC | 6 |
| Osser, DN | 1 |
| Akhter, A | 1 |
| Messori, A | 2 |
| Gupta, S | 3 |
| Kubota, T | 2 |
| Iga, T | 2 |
| Takarada, Y | 2 |
| Tateishi, T | 2 |
| Brevik, A | 1 |
| Farver, D | 1 |
| Sharkey, L | 1 |
| O'Donovan, A | 1 |
| Bellgrove, MA | 1 |
| Vance, A | 1 |
| Bradshaw, JL | 1 |
| Gilmore, JA | 4 |
| Halbreich, UM | 2 |
| Kores Plesnicar, B | 1 |
| Zalar, B | 1 |
| Tomori, M | 1 |
| Krajnc, I | 1 |
| Santarlasci, B | 1 |
| Hori, K | 1 |
| Oda, T | 1 |
| Tominaga, I | 1 |
| Inada, T | 1 |
| Hwang, TJ | 1 |
| Lee, SM | 4 |
| Lin, HN | 2 |
| Lee, YC | 1 |
| Chen, YS | 1 |
| Togo, T | 3 |
| Iseki, E | 3 |
| Shoji, M | 3 |
| Oyama, I | 1 |
| Kase, A | 3 |
| Uchikado, H | 3 |
| Katsuse, O | 2 |
| Kosaka, K | 3 |
| Theodoulou, G | 1 |
| Milner, G | 1 |
| Jumaian, A | 1 |
| Opolka, JL | 2 |
| Rascati, KL | 3 |
| Brown, CM | 2 |
| Gibson, PJ | 3 |
| Cheng, YC | 1 |
| Liu, GC | 1 |
| Lin, XR | 1 |
| Weber, M | 1 |
| Brooks, D | 1 |
| Casey, SB | 1 |
| Elliot, S | 1 |
| Hawkins, J | 1 |
| Lambert, TJ | 2 |
| Gothelf, D | 2 |
| Apter, A | 1 |
| Reidman, J | 1 |
| Brand-Gothelf, A | 1 |
| Bloch, Y | 1 |
| Gal, G | 1 |
| Kikinzon, L | 1 |
| Tyano, S | 3 |
| Weizman, R | 2 |
| Ratzoni, G | 1 |
| Bromet, EJ | 2 |
| Gureje, O | 1 |
| Miles, W | 1 |
| Keks, N | 1 |
| Grainger, D | 1 |
| McGrath, J | 1 |
| Tran, P | 1 |
| Catts, S | 1 |
| Fraser, A | 1 |
| Andersen, S | 1 |
| Crawford, AM | 2 |
| Zalsman, G | 2 |
| Frisch, A | 1 |
| Lev-Ran, S | 1 |
| Michaelovsky, E | 1 |
| Bensason, D | 2 |
| Nahshoni, E | 1 |
| Weizman, A | 8 |
| Pajonk, FG | 3 |
| Peters, S | 2 |
| Rettig, K | 2 |
| Degner, D | 4 |
| Rüther, E | 5 |
| Søholm, B | 1 |
| O'Sullivan, RL | 1 |
| Atmaca, M | 1 |
| Kuloglu, M | 1 |
| Tezcan, E | 1 |
| Ustundag, B | 1 |
| Wright, T | 2 |
| Libretto, SE | 5 |
| Bobes, J | 1 |
| Rejas, J | 1 |
| Garcia-Garcia, M | 1 |
| García-Portilla, MP | 1 |
| Fernández, I | 1 |
| Hernández, G | 1 |
| Ishida, M | 1 |
| Chiu, E | 2 |
| Hall, K | 2 |
| Hassett, A | 2 |
| Opie, J | 2 |
| Keith, SJ | 3 |
| Lesem, M | 1 |
| Karcher, K | 3 |
| Thürauf, N | 1 |
| Holtmann, M | 1 |
| Gerstner, S | 1 |
| Schmidt, MH | 1 |
| Hunter, RH | 1 |
| Joy, CB | 1 |
| Kennedy, E | 2 |
| Gilbody, SM | 2 |
| Song, F | 4 |
| Woods, SW | 4 |
| Purdon, SE | 7 |
| Woodward, N | 1 |
| Lindborg, SR | 1 |
| Johnsrud, MT | 1 |
| Crismon, ML | 5 |
| Lage, MJ | 1 |
| Barber, BL | 2 |
| Martin, SD | 2 |
| Pratt, DJ | 1 |
| Brewin, JS | 1 |
| Huq, ZU | 2 |
| Saleh, BT | 1 |
| Saha, AR | 1 |
| Kujawa, MJ | 2 |
| Ali, M | 1 |
| Stock, E | 1 |
| Stringfellow, J | 1 |
| Ingenito, G | 1 |
| Sannomiya, M | 1 |
| Katsu, H | 1 |
| Morishita, S | 1 |
| Takeuchi, T | 1 |
| Nishikawa, T | 1 |
| Ali, JA | 1 |
| Desai, KD | 1 |
| Ali, LJ | 1 |
| Ganguly, R | 1 |
| Miller, LS | 1 |
| Martin, BC | 1 |
| Bozikas, VP | 1 |
| Deseri, C | 1 |
| Pitsavas, S | 1 |
| Karavatos, A | 2 |
| Wirshing, DA | 9 |
| Ross, D | 2 |
| Widmark, C | 3 |
| Liberman, RP | 3 |
| Blair, KE | 1 |
| Brunelleschi, S | 1 |
| Risso, F | 1 |
| Cattaneo, CI | 1 |
| Torre, E | 1 |
| Zoccali, R | 2 |
| Muscatello, MR | 3 |
| Torre, DL | 1 |
| Malara, G | 1 |
| Canale, A | 1 |
| Crucitti, D | 1 |
| D'Arrigo, C | 4 |
| Cavedini, P | 1 |
| Mistretta, P | 1 |
| Bassi, T | 1 |
| Angelone, SM | 2 |
| Ubbiali, A | 1 |
| Bellodi, L | 1 |
| Martín, JC | 2 |
| Carlson, CD | 1 |
| Cavazzoni, PA | 1 |
| Berg, PH | 3 |
| Beasley, CM | 2 |
| Kamata, M | 2 |
| Naitoh, S | 1 |
| Yoshida, K | 3 |
| Becker, D | 1 |
| Liver, O | 1 |
| Mester, R | 2 |
| Rapoport, M | 1 |
| Weiss, M | 1 |
| Napolitano, JA | 1 |
| Gharabawi, G | 7 |
| Barkić, J | 1 |
| Filaković, P | 2 |
| Radanović-Grgurić, L | 2 |
| Koić, O | 2 |
| Laufer, D | 2 |
| Pozgain, I | 2 |
| Koić, E | 1 |
| Isaac, MB | 1 |
| Isaac, MT | 1 |
| Kaneda, Y | 2 |
| Williams, LM | 1 |
| Loughland, CM | 1 |
| Harris, AW | 1 |
| Gordon, E | 1 |
| Dose, M | 2 |
| Fric, M | 1 |
| Geiger, E | 1 |
| Copeland, LA | 1 |
| Zeber, JE | 1 |
| Valenstein, M | 1 |
| Blow, FC | 1 |
| Ried, LD | 1 |
| Renner, BT | 1 |
| Bengtson, MA | 1 |
| Wilcox, BM | 1 |
| Acholonu, WW | 1 |
| Fitzgerald, PB | 3 |
| Scaffidi, A | 1 |
| Morris, MJ | 1 |
| de Castella, AR | 2 |
| Hasegawa, K | 1 |
| Hosojima, H | 1 |
| Kojima, K | 2 |
| Strungas, S | 1 |
| Christensen, JD | 2 |
| Holcomb, JM | 1 |
| Garver, DL | 2 |
| Pezza, M | 1 |
| Busiello, L | 1 |
| Palmese, S | 1 |
| Cascella, M | 1 |
| Di Domenico, MG | 1 |
| De Robertis, E | 1 |
| van Bruggen, J | 1 |
| Tijssen, J | 1 |
| Dingemans, P | 2 |
| Gersons, B | 1 |
| Rummel, C | 1 |
| Hamann, J | 2 |
| Apiquian, R | 2 |
| Fresán, A | 2 |
| Herrera, K | 1 |
| Ulloa, RE | 2 |
| Lóyzaga, C | 1 |
| de la Fuente-Sandoval, C | 2 |
| Gutiérrez, D | 1 |
| Nicolini, H | 2 |
| Fortier, P | 1 |
| Mottard, JP | 2 |
| Trudel, G | 1 |
| Even, S | 1 |
| Garyfallos, G | 1 |
| Dimelis, D | 1 |
| Kouniakis, P | 1 |
| Sidiropoulos, N | 1 |
| Karastergiou, A | 1 |
| Lavrentiadis, G | 1 |
| Giouzepas, J | 1 |
| Fokas, K | 1 |
| Reig, S | 3 |
| Pascau, J | 3 |
| Sanz, J | 4 |
| Sarramea, F | 3 |
| Gispert, JD | 2 |
| Luque, R | 1 |
| Benito, C | 3 |
| Desco, M | 3 |
| Romano, SJ | 3 |
| Feldman, PD | 1 |
| Kaiser, CJ | 1 |
| Kennedy, JS | 1 |
| Sutton, VK | 1 |
| Tran, PV | 3 |
| Tollefson, GD | 9 |
| Breier, A | 10 |
| Van-Duong, Q | 1 |
| Carmon, E | 1 |
| Yu, SC | 2 |
| Chrzanowski, W | 2 |
| Martin, S | 1 |
| Gefvert, O | 2 |
| Levy, E | 1 |
| Margolese, HC | 3 |
| Sultan, S | 1 |
| Chouinard, G | 11 |
| Ereshefsky, L | 6 |
| Mascarenas, CA | 1 |
| Turner, MS | 2 |
| Szekeres, G | 1 |
| Kéri, S | 1 |
| Juhász, A | 1 |
| Rimanóczy, A | 1 |
| Szendi, I | 1 |
| Czimmer, C | 1 |
| Janka, Z | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
| Puri, BK | 1 |
| Davey, NJ | 1 |
| Zaman, R | 2 |
| Veznedaroglu, B | 1 |
| Ercan, ES | 1 |
| Kayahan, B | 1 |
| Varan, A | 1 |
| Bayraktar, E | 1 |
| Knegtering, R | 1 |
| Castelein, S | 1 |
| Bous, H | 1 |
| Van Der Linde, J | 1 |
| Kluiter, H | 1 |
| van den Bosch, RJ | 1 |
| Lane, CJ | 3 |
| Ngan, ET | 3 |
| Yatham, LN | 2 |
| Ruth, TJ | 2 |
| Liddle, PF | 3 |
| Harrison, TS | 1 |
| Goa, KL | 2 |
| Heresco-Levy, U | 3 |
| Ermilov, M | 3 |
| Lichtenberg, P | 3 |
| Bar, G | 2 |
| Hsu, SK | 2 |
| Liu, GG | 1 |
| Sun, SX | 1 |
| Christensen, DB | 1 |
| Aviv, A | 1 |
| Shelef, A | 1 |
| Chong, MY | 2 |
| Bellack, AS | 2 |
| Knobler, HY | 3 |
| Natan, Z | 1 |
| Ikoma, Y | 1 |
| Yasuno, F | 2 |
| Ichimiya, T | 2 |
| Inoue, M | 2 |
| Gulati, S | 1 |
| Singh, AN | 1 |
| Meaney, AM | 1 |
| O'Keane, V | 1 |
| Namjoshi, M | 2 |
| Loosbrock, DL | 1 |
| Tunis, SL | 3 |
| Zhu, B | 4 |
| Ziegenbein, M | 2 |
| Kropp, S | 3 |
| Mandrioli, R | 1 |
| Sabbioni, C | 1 |
| Pucci, V | 1 |
| Grady, MM | 1 |
| Sebastian, CS | 1 |
| Glazer, W | 1 |
| De Ronchi, D | 1 |
| Lorenzi, C | 1 |
| Berardi, D | 1 |
| Ryan, MC | 1 |
| Flanagan, S | 1 |
| Kinsella, U | 1 |
| Keeling, F | 1 |
| Thakore, JH | 1 |
| Vangeneugden, T | 4 |
| Laenen, A | 2 |
| Geys, H | 3 |
| Renard, D | 1 |
| Weiner, SK | 1 |
| Müller, N | 6 |
| Ulmschneider, M | 2 |
| Scheppach, C | 2 |
| Schwarz, MJ | 5 |
| Ackenheil, M | 1 |
| Gruber, R | 1 |
| Kochan, LD | 2 |
| Cocchi, F | 1 |
| Lattuada, E | 1 |
| Compton, MT | 2 |
| Hill, HA | 1 |
| Su, SF | 1 |
| Liao, YC | 1 |
| Chang, JW | 1 |
| Bhanji, NH | 1 |
| Tsai, G | 1 |
| Yang, P | 1 |
| Lange, N | 1 |
| Heydebrand, G | 1 |
| Hoff, AL | 1 |
| DeLisi, LE | 2 |
| Meltzer, H | 1 |
| Lasser, RA | 12 |
| Tada, M | 1 |
| Shirakawa, K | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Frankle, WG | 1 |
| Gil, R | 1 |
| Hackett, E | 1 |
| Mawlawi, O | 1 |
| Zea-Ponce, Y | 1 |
| Zhu, Z | 1 |
| Cangiano, C | 1 |
| Slifstein, M | 1 |
| Gorman, JM | 1 |
| Laruelle, M | 1 |
| Abi-Dargham, A | 1 |
| Takahata, T | 1 |
| Yaris, F | 1 |
| Yaris, E | 1 |
| Kadioglu, M | 1 |
| Ulku, C | 1 |
| Kesim, M | 1 |
| Kalyoncu, NI | 1 |
| Erol, A | 1 |
| el Mahfoud Kessaci, M | 1 |
| Shaheen, MO | 1 |
| Sunbol, MM | 1 |
| Boland, J | 1 |
| Hodge, A | 1 |
| O'Halloran, RA | 1 |
| Diaz, E | 2 |
| Neuse, E | 1 |
| Sullivan, MC | 2 |
| Pearsall, HR | 1 |
| Kern, R | 1 |
| Ni, X | 1 |
| Nolan, K | 2 |
| Gade, A | 1 |
| Reveley, MA | 3 |
| Raedler, TJ | 3 |
| Wiedemann, K | 4 |
| Duchesne, I | 3 |
| Janagap, C | 1 |
| Lee, CC | 2 |
| Lu, CT | 2 |
| Bottlender, R | 2 |
| Liberty, IF | 1 |
| Todder, D | 1 |
| Umansky, R | 1 |
| Harman-Boehm, I | 1 |
| Paik, IH | 2 |
| Lee, CU | 2 |
| Schwenkreis, P | 1 |
| Luo, N | 1 |
| Koh, Y | 1 |
| Tan, CH | 5 |
| Kua, EH | 1 |
| Li, SC | 1 |
| Kim, YT | 1 |
| Kang, BJ | 1 |
| Lemon, M | 1 |
| Gharabawi, GM | 12 |
| Young, C | 2 |
| Samele, C | 1 |
| Eerdekens, E | 2 |
| Jacko, M | 1 |
| Spollen, JJ | 1 |
| Wooten, RG | 1 |
| Cargile, C | 1 |
| Bartztokis, G | 1 |
| Ollendorf, DA | 1 |
| Joyce, AT | 1 |
| Rucker, M | 1 |
| Van Hove, I | 3 |
| Ke, CL | 1 |
| Yen, CF | 1 |
| Chung, W | 1 |
| Yang, MJ | 1 |
| Migliardi, G | 3 |
| Morgante, L | 2 |
| Grigor'eva, EA | 1 |
| Ritskov, AS | 1 |
| Burton, SC | 1 |
| Ritchie, T | 1 |
| Ward, WK | 1 |
| Noble, EP | 1 |
| Lejeune, J | 1 |
| Larmo, I | 4 |
| Witte, R | 1 |
| Wong, E | 1 |
| Gandotra, G | 1 |
| Kurland, BF | 1 |
| Heagerty, PJ | 1 |
| Young, CL | 1 |
| Mace, S | 1 |
| de Sena, EP | 2 |
| Santos-Jesus, R | 1 |
| Miranda-Scippa, A | 1 |
| Quarantini, Lde C | 1 |
| Oliveira, IR | 1 |
| Tauscher, J | 3 |
| Hussain, T | 1 |
| Verhoeff, NP | 3 |
| Leslie, DL | 3 |
| Nick, B | 1 |
| Scully, P | 1 |
| Chue, PS | 3 |
| Lachaux, B | 3 |
| Allingham, B | 2 |
| Webber, MA | 1 |
| Mahmud, W | 1 |
| Lightfoot, JD | 1 |
| Shekhar, A | 2 |
| Ciudad, A | 5 |
| Montes, JM | 1 |
| Heveling, T | 1 |
| Emrich, HM | 1 |
| Dietrich, DE | 1 |
| Williams, JB | 1 |
| Mallorga, PJ | 1 |
| Conn, PJ | 1 |
| Pettibone, DJ | 1 |
| Sur, C | 1 |
| Leal, A | 1 |
| Rosillon, D | 2 |
| Conley, RJ | 1 |
| Adler, LE | 1 |
| Olincy, A | 1 |
| Cawthra, EM | 1 |
| McRae, KA | 1 |
| Harris, JG | 1 |
| Nagamoto, HT | 1 |
| Waldo, MC | 1 |
| Hall, MH | 1 |
| Bowles, A | 1 |
| Woodward, L | 1 |
| Ross, RG | 1 |
| Freedman, R | 1 |
| Lang, DJ | 2 |
| Kopala, LC | 12 |
| Vandorpe, RA | 2 |
| Smith, GN | 3 |
| Goghari, VM | 2 |
| Lapointe, JS | 2 |
| Tebartz van Elst, L | 1 |
| Bäumer, D | 1 |
| Ebert, D | 1 |
| Trimble, MR | 1 |
| Basu, A | 2 |
| Shayegan, DK | 1 |
| Herz, L | 4 |
| Reyes, JF | 1 |
| Kumar, D | 1 |
| Cullen, EI | 1 |
| Perdomo, CA | 1 |
| Pratt, RD | 1 |
| Jukić, V | 1 |
| Petrinović-Doresić, J | 1 |
| Dorn, L | 1 |
| Milas, DZ | 1 |
| Mimica, N | 1 |
| Soyka, M | 2 |
| Winter, C | 2 |
| Kagerer, S | 1 |
| Brunnauer, M | 1 |
| Ehret, MJ | 1 |
| Fuller, MA | 3 |
| Stein-Reisner, O | 1 |
| Preisman, O | 1 |
| Alfici, S | 1 |
| Melamed, Y | 3 |
| Bleich, A | 1 |
| Ritsner, M | 1 |
| Gibel, A | 2 |
| Perelroyzen, G | 1 |
| Kurs, R | 1 |
| Jabarin, M | 1 |
| Ratner, Y | 1 |
| Albrecht, A | 1 |
| Morena, PG | 1 |
| Baumann, P | 4 |
| Eap, CB | 2 |
| Engel, RR | 4 |
| Nagao, M | 3 |
| Morinobu, S | 3 |
| Rachid, F | 1 |
| Bertschy, G | 3 |
| Bondolfi, G | 5 |
| Aubry, JM | 2 |
| Nadeem, Z | 2 |
| McIntosh, A | 3 |
| Lawrie, S | 3 |
| Welch, R | 2 |
| Binder, C | 1 |
| Rodriguez, S | 2 |
| Spellmann, I | 3 |
| Müller-Arends, A | 1 |
| Weber, K | 1 |
| Zach, J | 1 |
| Strasser, O | 1 |
| Molcan, P | 1 |
| Pretorius, H | 1 |
| Wilson, WH | 1 |
| Montgomery, JH | 1 |
| Byerly, M | 1 |
| Carmody, T | 2 |
| Varghese, F | 1 |
| Holland, R | 1 |
| Kenward, MG | 1 |
| Farwell, WR | 1 |
| Stump, TE | 1 |
| Tafesse, E | 2 |
| Tierney, WM | 1 |
| Josiassen, RC | 2 |
| Kohegyi, E | 1 |
| Stokes, S | 1 |
| Dadvand, M | 1 |
| Paing, WW | 1 |
| Shaughnessy, RA | 1 |
| Cagliero, E | 1 |
| Hayden, D | 2 |
| Weber, MT | 1 |
| Anderson, EJ | 1 |
| Allison, DB | 1 |
| Daley, TB | 1 |
| Schoenfeld, D | 1 |
| Parker, G | 1 |
| Pinninti, NR | 2 |
| Mago, R | 2 |
| Dineen, M | 1 |
| Benattia, I | 1 |
| Swanson, JW | 2 |
| Elbogen, EB | 1 |
| Hodgson, R | 1 |
| Belgamwar, R | 1 |
| Al-tawarah, Y | 1 |
| MacKenzie, G | 1 |
| Sánchez, J | 2 |
| Santamarta, C | 1 |
| Misiego, JM | 1 |
| Kazis, L | 1 |
| Castberg, I | 1 |
| Pan, RM | 1 |
| Fairchild, M | 1 |
| Koch, WH | 1 |
| Wedlund, PJ | 1 |
| Anil Yağcioğlu, AE | 3 |
| Kivircik Akdede, BB | 1 |
| Turgut, TI | 2 |
| Yazici, MK | 2 |
| Ertuğrul, A | 1 |
| Göğüş, A | 2 |
| Tunca, Z | 2 |
| Ahl, J | 2 |
| Ahmed, S | 1 |
| du Toit, RM | 1 |
| Millson, RC | 2 |
| Heaton, JP | 1 |
| Adams, MA | 1 |
| Abekawa, T | 2 |
| Kitaichi, Y | 1 |
| Matsuyama, T | 1 |
| Edgell, ET | 3 |
| Kennedy, L | 2 |
| Ratcliffe, M | 2 |
| Mladsi, DM | 1 |
| Grogg, AL | 1 |
| Irish, WD | 1 |
| Lopez, RB | 1 |
| Degen, K | 1 |
| Swann, A | 1 |
| Nimsch, CT | 1 |
| Berry, S | 1 |
| Helldin, L | 1 |
| Björner, A | 1 |
| Nyberg, S | 4 |
| Ellard, J | 1 |
| Stone, JM | 1 |
| Kakihara, S | 4 |
| Matsumoto, C | 1 |
| Goto, M | 2 |
| Kaji, K | 2 |
| Yamada, Y | 2 |
| Ohmori, O | 1 |
| Chou, P | 3 |
| Massana, G | 1 |
| Salgado-Pineda, P | 2 |
| Junqué, C | 1 |
| Pérez, M | 1 |
| Massana, J | 1 |
| Navarro, V | 1 |
| Blanch, J | 1 |
| Morer, A | 2 |
| Mercader, JM | 1 |
| Russo, PA | 1 |
| Smith, MW | 1 |
| Boerth, JM | 1 |
| Caley, CF | 1 |
| Goethe, JW | 1 |
| Einfeld, SL | 1 |
| Andrews, D | 1 |
| Selig, R | 1 |
| Williams, G | 1 |
| Ebstein, R | 1 |
| Vass, A | 1 |
| Catinari, S | 1 |
| Woodward, ND | 2 |
| Zald, DH | 1 |
| Lambert, BL | 2 |
| Chou, CH | 1 |
| Chang, KY | 1 |
| Carson, W | 1 |
| Kato, R | 1 |
| Sato, J | 1 |
| Bienentreu, SD | 1 |
| Kronmüller, KT | 1 |
| Baldessarini, RJ | 2 |
| Lim, HK | 1 |
| Kim, TS | 1 |
| Knox, ED | 1 |
| Stimmel, GL | 2 |
| Kohara, K | 1 |
| Ninomiya, H | 1 |
| Egami, H | 1 |
| Maeda, H | 1 |
| Edwards, NC | 2 |
| Rupnow, MF | 6 |
| Pashos, CL | 1 |
| Botteman, MF | 1 |
| Diamond, RJ | 2 |
| López-Carrero, C | 1 |
| Arriaza, E | 1 |
| Bolaños, E | 1 |
| Municio, M | 1 |
| Ramos, J | 1 |
| Hesen, W | 1 |
| Panteleeva, GP | 1 |
| Korenev, AN | 1 |
| Barkhatova, AN | 1 |
| Mukaddes, NM | 1 |
| Topcu, Z | 1 |
| Kopala, L | 4 |
| Swyzen, W | 1 |
| Carter, C | 1 |
| Xie, H | 1 |
| Wolf, K | 1 |
| Mass, R | 1 |
| Kiefer, F | 1 |
| Eckert, K | 1 |
| Stritzky, AV | 1 |
| Galletly, CA | 1 |
| Clark, CR | 1 |
| McFarlane, AC | 1 |
| Hargreaves, WA | 2 |
| Gibson, JP | 1 |
| Ballard, ME | 1 |
| Pan, L | 1 |
| Roberts, S | 1 |
| Faghih, R | 1 |
| Cowart, M | 1 |
| Esbenshade, TA | 1 |
| Fox, GB | 1 |
| Decker, MW | 1 |
| Hancock, AA | 1 |
| Rueter, LE | 1 |
| Nolan, KA | 2 |
| Kline, L | 1 |
| Lepine, JP | 2 |
| Jarboe, K | 1 |
| Lasser, R | 2 |
| Ciliberto, N | 1 |
| Urioste, R | 1 |
| Matsui-Sakata, A | 1 |
| Ohtani, H | 1 |
| Sawada, Y | 1 |
| Holcomb, JA | 1 |
| Bersani, G | 1 |
| Gherardelli, S | 1 |
| Clemente, R | 1 |
| Grilli, A | 1 |
| Conti, CM | 1 |
| Exton, MS | 1 |
| Conti, P | 1 |
| Doyle, R | 1 |
| Pancheri, P | 1 |
| Chiu, YW | 1 |
| Smith, S | 1 |
| Aitchison, KJ | 1 |
| Shin, YW | 1 |
| Joo, YH | 2 |
| Hong, JP | 1 |
| Lee, GH | 1 |
| Choi, SK | 1 |
| McGrath, BM | 1 |
| Tempier, RP | 1 |
| Bresee, CJ | 1 |
| Delrahim, K | 1 |
| Maddux, RE | 1 |
| Dolnak, D | 1 |
| Ahmadpour, O | 1 |
| Rapaport, MH | 1 |
| Tarn, YH | 2 |
| Laio, YC | 1 |
| Wahl, R | 1 |
| Ostroff, R | 1 |
| Kemmler, G | 2 |
| Park, S | 1 |
| Ross-Degnan, D | 1 |
| Adams, AS | 1 |
| Sabin, J | 1 |
| Kanavos, P | 1 |
| Soumerai, SB | 1 |
| Faucher, S | 1 |
| Dardennes, R | 1 |
| Ghaëm, O | 1 |
| Guelfi, JD | 1 |
| Arango-Dávila, C | 1 |
| Silva Ibarra, H | 1 |
| Landa, E | 1 |
| Aguilar, J | 1 |
| Caro, O | 1 |
| Leadbetter, J | 1 |
| Assunção, S | 1 |
| Dollfus, S | 1 |
| Olivier, V | 1 |
| Chabot, B | 1 |
| Déal, C | 1 |
| Perrin, E | 1 |
| Vergouwen, AC | 1 |
| de Bruijn, C | 1 |
| Been, A | 1 |
| Regenthal, R | 1 |
| Kunstler, U | 1 |
| Hesse, S | 1 |
| Sabri, O | 1 |
| Preiss, R | 1 |
| Dursun, S | 1 |
| Andrezina, R | 1 |
| Glue, P | 2 |
| Masiak, M | 1 |
| Heres, S | 3 |
| Machida, N | 1 |
| Shiotsuka, S | 1 |
| Semba, J | 1 |
| Lenert, LA | 1 |
| Elnitsky, C | 1 |
| Kovács, G | 1 |
| Davis, CE | 4 |
| Lebowitz, BD | 1 |
| Severe, J | 3 |
| Ezewuzie, N | 1 |
| Thornton, AE | 3 |
| Van Snellenberg, JX | 1 |
| Sepehry, AA | 1 |
| Honer, W | 1 |
| de Nayer, A | 1 |
| Windhager, E | 1 |
| Lindenbauer, B | 1 |
| Rittmannsberger, H | 1 |
| Platz, T | 1 |
| Jones, AM | 1 |
| Altman, C | 1 |
| Nguyen, DD | 2 |
| Hayden, DL | 1 |
| Louie, PM | 1 |
| Tarasow, E | 1 |
| Dzienis, W | 1 |
| Kubas, B | 1 |
| Walecki, J | 1 |
| Alathiaki, AS | 1 |
| Himei, A | 1 |
| Okamura, T | 1 |
| Tanum, L | 2 |
| Andersen, TH | 1 |
| Larsen, NE | 1 |
| Young, CA | 1 |
| Rock, SL | 1 |
| Mou, XD | 1 |
| Zhang, ZJ | 3 |
| Yao, ZJ | 1 |
| Liu, W | 1 |
| Zhang, XR | 1 |
| Shi, JB | 1 |
| Sun, J | 1 |
| Buyse, M | 1 |
| Dukic, V | 1 |
| Santoro, V | 2 |
| Johnsrud, M | 1 |
| Thompson, A | 1 |
| Grogg, A | 1 |
| Pariante, CM | 3 |
| Greenspan, A | 7 |
| Dehning, S | 2 |
| Douhet, A | 2 |
| Tsai, GE | 2 |
| Stensland, MD | 2 |
| Booij, J | 5 |
| Lavalaye, J | 5 |
| Nakonezny, PA | 3 |
| Fisher, R | 2 |
| Magouirk, B | 1 |
| Rush, AJ | 3 |
| Strub, N | 1 |
| Loft, H | 1 |
| Jung, IG | 1 |
| Park, PW | 1 |
| Byun, WT | 1 |
| Kolivakis, TT | 1 |
| Beauclair, L | 3 |
| Annable, L | 1 |
| Mané, A | 1 |
| Lázaro, ML | 1 |
| Luchins, DJ | 2 |
| Pandiani, JA | 1 |
| Banks, SM | 1 |
| Kraus, JE | 1 |
| Sheitman, BB | 2 |
| Cook, A | 1 |
| Reviere, R | 1 |
| Halliday, G | 1 |
| Nagalingam, V | 1 |
| Snowdon, J | 1 |
| Annemans, L | 1 |
| Haycox, A | 1 |
| van Hout, BA | 2 |
| Smet, A | 1 |
| Caleo, S | 1 |
| Miadi-Fargier, H | 1 |
| Mosqueda, GJ | 1 |
| Lecompte, D | 1 |
| Buskens, E | 1 |
| Locklear, JC | 1 |
| Gupta, N | 2 |
| Basu, D | 2 |
| Jarboe, KS | 1 |
| Littrell, K | 2 |
| Tugrul, K | 1 |
| Eden Evins, A | 1 |
| Baer, L | 1 |
| Blin, P | 1 |
| Olié, JP | 2 |
| Petitjean, F | 1 |
| Cialdella, P | 1 |
| Gérard, A | 1 |
| Westerloppe, J | 1 |
| Davis, J | 1 |
| Maino, K | 1 |
| Jetzinger, E | 1 |
| Chen, EY | 2 |
| Wong, JO | 1 |
| Bergmann, A | 1 |
| Pomarol-Clotet, E | 2 |
| McKenna, PJ | 2 |
| MacEwan, GW | 7 |
| Wasan, K | 1 |
| Patel, NC | 2 |
| Shafer, A | 1 |
| De Leon, A | 1 |
| Lopez, M | 1 |
| Lane, DC | 1 |
| Hillemacher, T | 1 |
| Dibben, CR | 1 |
| Kalavalapalli, SS | 1 |
| Linnington, HE | 1 |
| Hynes, FA | 1 |
| Dinneen, SF | 1 |
| Adler, AI | 1 |
| Maguire, GA | 1 |
| Zhou, ZL | 1 |
| Peng, HY | 1 |
| Yu, XY | 1 |
| Su, FL | 1 |
| Deng, CY | 1 |
| Lin, QX | 1 |
| Li, WB | 1 |
| Lin, SG | 1 |
| Gaudet, M | 1 |
| Bartkó, G | 1 |
| Fehér, L | 1 |
| Landbloom, R | 1 |
| Swanson, J | 1 |
| Reiss, J | 1 |
| Artaloytia, JF | 1 |
| Lahti, A | 1 |
| Pascual, A | 1 |
| Cubero, P | 1 |
| Prieto, D | 1 |
| Xu, K | 1 |
| Ekholm, J | 1 |
| Woerner, MG | 4 |
| Dyachkova, Y | 2 |
| Pirildar, S | 1 |
| Khalil, A | 1 |
| Shakhnovich, T | 1 |
| Akram, A | 1 |
| McBride, M | 1 |
| Köhnke, MD | 2 |
| Lutz, U | 1 |
| Wiatr, G | 1 |
| Schwärzler, F | 1 |
| Schott, K | 1 |
| Leelahanaj, T | 1 |
| Price, N | 1 |
| Birinyi-Strachan, L | 1 |
| Davey, P | 1 |
| Smith, G | 1 |
| Love, L | 1 |
| Talling, D | 1 |
| Balshaw, R | 1 |
| Pillai, A | 1 |
| Parikh, V | 1 |
| Terry, AV | 1 |
| Mahadik, SP | 1 |
| Kantrowitz, JT | 1 |
| Srihari, VH | 1 |
| Tek, C | 1 |
| Wu, RR | 1 |
| Liu, ZN | 1 |
| Zhai, JG | 1 |
| Guo, XF | 1 |
| Guo, WB | 1 |
| Gómez-de-la-Cámara, A | 1 |
| Ledesma, F | 1 |
| Martínez-Junquera, G | 1 |
| Grass, G | 1 |
| Hellmich, M | 1 |
| Akdede, BB | 2 |
| Fink, M | 1 |
| Taylor, MA | 1 |
| Wu, KH | 1 |
| Habil, H | 1 |
| Lee, P | 1 |
| Amador, X | 1 |
| Wang, CS | 1 |
| Kao, WT | 1 |
| Chen, CD | 1 |
| Tung, YP | 1 |
| Schlagenhauf, F | 1 |
| Koslowski, M | 1 |
| Filonov, D | 1 |
| Wüstenberg, T | 1 |
| Villringer, A | 1 |
| Knutson, B | 1 |
| Kienast, T | 1 |
| Wrase, J | 1 |
| Bettcher, BM | 1 |
| Greenbaum, L | 2 |
| Kanyas, K | 2 |
| Merbl, Y | 2 |
| Horowitz, A | 2 |
| Karni, O | 2 |
| Viglin, D | 1 |
| Olender, T | 2 |
| Deshpande, SN | 2 |
| Lancet, D | 2 |
| Ben-Asher, E | 2 |
| Lerer, B | 2 |
| Savage, R | 1 |
| Borisov, A | 1 |
| Rosenberg, J | 1 |
| Woolwine, B | 1 |
| Tucker, M | 1 |
| May, R | 1 |
| Feldman, J | 1 |
| Miller, AH | 1 |
| Hendset, M | 1 |
| Refsum, H | 1 |
| Kupchik, M | 1 |
| Roitman, S | 1 |
| Schwartz, S | 1 |
| Gonen, N | 1 |
| Spivak, B | 2 |
| Greenspan, AJ | 2 |
| Kosik-Gonzalez, C | 3 |
| Burtea, V | 1 |
| Trivedi, JK | 1 |
| Pardo-García, G | 1 |
| Schubert, MH | 1 |
| Young, KA | 1 |
| Hicks, PB | 1 |
| Bousoño, M | 3 |
| Knopf, U | 1 |
| Argiriou, S | 1 |
| Ritsner, MS | 1 |
| Marquez, E | 1 |
| Kryzhanovskaya, L | 1 |
| Taylor, CC | 3 |
| Cavazzoni, P | 1 |
| Lintas, C | 1 |
| Lin, SC | 1 |
| Chen, MC | 1 |
| Wang, SY | 1 |
| Shkedy, Z | 1 |
| Korostenskaja, M | 1 |
| Dapsys, K | 1 |
| Maciulis, V | 1 |
| Ruksenas, O | 1 |
| Kähkönen, S | 1 |
| Zhong, KX | 1 |
| Sweitzer, DE | 1 |
| Madhusoodanan, S | 4 |
| Moise, D | 1 |
| Beard, SM | 1 |
| Maciver, F | 1 |
| Clouth, J | 1 |
| Kontaxakis, VP | 3 |
| Ferentinos, PP | 1 |
| Havaki-Kontaxaki, BJ | 3 |
| Paplos, KG | 1 |
| Pappa, DA | 1 |
| Hung, CH | 3 |
| Lin, WK | 2 |
| Hu, TM | 1 |
| Seo, YJ | 1 |
| Han, CS | 1 |
| Carrasco-Marín, E | 2 |
| Leyva-Cobían, F | 1 |
| Chinnasamy, D | 1 |
| Rudd, R | 1 |
| Antonova, E | 1 |
| Geyer, MA | 2 |
| Ffytche, D | 1 |
| Sharma, T | 4 |
| Chew, ML | 1 |
| Lehman, ME | 1 |
| Kirshner, MA | 1 |
| Martínez, I | 1 |
| Ponce, G | 1 |
| Jiménez-Arriero, MA | 1 |
| López-Muñoz, F | 1 |
| Cunningham, FE | 1 |
| Dalack, GW | 1 |
| Hur, K | 1 |
| Theleritis, CG | 1 |
| Papadimitriou, GN | 1 |
| Papageorgiou, CC | 1 |
| Dikeos, DG | 1 |
| Masdrakis, V | 1 |
| Kostoulas, C | 1 |
| Psarros, C | 1 |
| Soldatos, CR | 1 |
| Mozes, T | 1 |
| Ebert, T | 1 |
| Michal, SE | 1 |
| Dogangün, B | 1 |
| Hergüner, S | 1 |
| Atar, M | 1 |
| Kara, B | 1 |
| Aksoy, MU | 1 |
| Kayaalp, L | 1 |
| Tüzün, U | 1 |
| Mahmoud, RA | 1 |
| Kujawa, M | 3 |
| Viner, MW | 1 |
| Matuszak, JM | 1 |
| Knight, LJ | 1 |
| Liu, HC | 1 |
| Gianfrancesco, FD | 1 |
| Sajatovic, M | 1 |
| Wang, RH | 2 |
| Dowling, NM | 1 |
| Burgdorf, A | 1 |
| Yashaswi, V | 1 |
| Mateos, JJ | 1 |
| Mireia, F | 1 |
| Prats, A | 1 |
| Pons, F | 1 |
| Baptista, T | 1 |
| Martinez, M | 1 |
| Lacruz, A | 1 |
| Arellano, A | 1 |
| Mendoza, S | 1 |
| Beaulieu, S | 1 |
| Hernández, L | 1 |
| Contreras, Q | 1 |
| Galeazzi, T | 1 |
| Vargas, D | 1 |
| Micò, U | 1 |
| D'Amico, G | 1 |
| Duan, S | 2 |
| Meng, J | 2 |
| Kalali, AH | 1 |
| Schotte, A | 1 |
| Carrió, I | 1 |
| Canive, JM | 2 |
| Miller, GA | 1 |
| Irwin, JG | 1 |
| Moses, SN | 1 |
| Thoma, RJ | 1 |
| Edgar, JC | 1 |
| Sherwood, A | 1 |
| Torres, F | 1 |
| Lanoue, M | 1 |
| Lewis, S | 1 |
| Hanlon, FM | 1 |
| Weisend, MP | 1 |
| Mead, V | 1 |
| Tuason, VB | 1 |
| Thomas-Lohrman, S | 1 |
| Patterson, TL | 1 |
| Potter, LS | 1 |
| Zhong, K | 1 |
| Melkersson, KI | 1 |
| Haile, CN | 1 |
| Qian, X | 1 |
| Wong, S | 1 |
| Qin, W | 1 |
| Llorca, J | 1 |
| Luis Vázquez-Barquero, J | 1 |
| Nakanishi, S | 1 |
| Nojima, S | 1 |
| Ogawa, T | 1 |
| Harada, K | 2 |
| Kim, KM | 1 |
| Shin, HY | 1 |
| Yang, KH | 1 |
| Faries, DE | 5 |
| Reimold, M | 1 |
| Solbach, C | 1 |
| Noda, S | 1 |
| Schaefer, JE | 1 |
| Bartels, M | 1 |
| Machulla, HJ | 1 |
| Bares, R | 1 |
| Wormstall, H | 1 |
| Pierson, K | 1 |
| Addington, D | 5 |
| Patten, S | 1 |
| Normann, C | 1 |
| Bakri, N | 1 |
| Demling, JH | 1 |
| Huang, ML | 3 |
| Sperling, W | 1 |
| Polsky, D | 1 |
| Doshi, JA | 1 |
| Bauer, MS | 1 |
| Glick, HA | 1 |
| Soto-Perello, JM | 1 |
| Khadivi, A | 1 |
| Lou, FY | 1 |
| Wang, JJ | 1 |
| Liang, JH | 1 |
| Chen, XW | 1 |
| Gao, CY | 1 |
| Liu, P | 1 |
| Liu, XW | 1 |
| Juruena, MF | 1 |
| Fountoulakis, KN | 1 |
| Kantartzis, S | 1 |
| Siamouli, M | 1 |
| Panagiotidis, P | 1 |
| Kaprinis, SG | 1 |
| Kourila, E | 1 |
| Lacovides, A | 1 |
| Kaprinis, GS | 1 |
| Bogunovic, O | 1 |
| Fischer, RB | 1 |
| Tabatabaee, M | 1 |
| Amini, H | 1 |
| Ahmadi Abhari, SA | 1 |
| Behnam, B | 1 |
| Sárosi, A | 1 |
| Lim, EP | 1 |
| Verma, V | 2 |
| Nagarajah, R | 1 |
| Dawe, GS | 2 |
| Jandacek, R | 1 |
| Rider, T | 1 |
| Tso, P | 1 |
| Hahn, CG | 1 |
| Stanford, KE | 1 |
| Murashita, M | 1 |
| Inoue, T | 1 |
| Itoh, K | 1 |
| Tanaka, T | 1 |
| Izumi, T | 1 |
| Hosoda, H | 1 |
| Kangawa, K | 1 |
| Hay, DP | 1 |
| Tanaka, Y | 1 |
| Yoshida, S | 1 |
| Shimada, Y | 1 |
| Ueda, H | 1 |
| Asai, K | 1 |
| Doraiswamy, PM | 1 |
| Schott, G | 1 |
| Star, K | 1 |
| Edwards, R | 1 |
| Mueller-Oerlinghausen, B | 1 |
| Tang, RQ | 1 |
| Xuan, JK | 1 |
| Gu, NF | 2 |
| Xu, MQ | 1 |
| Weiden, P | 3 |
| Weissman, EM | 2 |
| Dellenbaugh, C | 1 |
| Archie, SM | 1 |
| Goldberg, JO | 1 |
| Akhtar-Danesh, N | 1 |
| Landeen, J | 1 |
| McColl, L | 1 |
| McNiven, J | 1 |
| Khine, TT | 2 |
| Hamanaka, S | 1 |
| Kamijo, Y | 1 |
| Wehmeier, PM | 1 |
| Kluge, M | 1 |
| Schacht, A | 1 |
| Helsberg, K | 1 |
| Schreiber, W | 1 |
| Noda, Y | 2 |
| Nitta, A | 1 |
| Furukawa, H | 2 |
| Walsh, JP | 1 |
| Culhane, MA | 1 |
| Haberfellner, EM | 2 |
| Capuano, G | 2 |
| Reimherr, F | 2 |
| McGee, MF | 1 |
| Capuano, GA | 1 |
| Belz, I | 1 |
| Neovius, M | 2 |
| Glenthoj, A | 1 |
| Pagsberg, AK | 1 |
| Hemmingsen, RP | 1 |
| Jernigan, TL | 1 |
| Baaré, WF | 1 |
| Monji, A | 1 |
| Hashioka, S | 1 |
| Kanba, S | 2 |
| Makesar, D | 1 |
| Kotorii, N | 1 |
| Townsend, MH | 1 |
| Baier, MB | 1 |
| Becker, JE | 1 |
| Ritchie, MA | 1 |
| Tong, Y | 2 |
| Wang, XY | 1 |
| Yao, SM | 1 |
| Jin, GX | 1 |
| Hashimoto, H | 1 |
| Shintani, N | 1 |
| Nakajima, M | 1 |
| Tanaka, K | 1 |
| Kawagishi, N | 1 |
| Nemoto, K | 1 |
| Ohnishi, T | 1 |
| Noguchi, H | 1 |
| Nakabayashi, T | 1 |
| Saitoh, O | 1 |
| Kosuga, A | 1 |
| Tatsumi, M | 1 |
| Kamijima, K | 2 |
| Baba, A | 2 |
| Risch, SC | 1 |
| Horner, MD | 1 |
| Palecko, S | 1 |
| Markowitz, JS | 1 |
| Nahas, Z | 1 |
| DeVane, CL | 2 |
| Graff, A | 1 |
| Li, MH | 2 |
| Yen, MH | 2 |
| Ruhrmann, S | 1 |
| Seemann, U | 1 |
| Linden, M | 1 |
| Pyrkosch, L | 1 |
| Khalili, H | 1 |
| Dashti-Khavidaki, S | 1 |
| Okhovatpour, H | 1 |
| Ghaeli, P | 1 |
| Tang, W | 1 |
| Nishimura, K | 1 |
| Mikami, Y | 1 |
| Tsuchibuchi, S | 1 |
| Horikawa, N | 1 |
| Liu, JL | 1 |
| Cotter, PE | 1 |
| O'Keeffe, ST | 1 |
| Sugita, A | 2 |
| Umene, W | 1 |
| Mitoma, M | 1 |
| Ohta, M | 1 |
| Shinkai, T | 1 |
| Lehoux, C | 1 |
| McCauley-Elsom, K | 1 |
| Stöcker, T | 1 |
| Marcus, SC | 1 |
| Lam, MH | 1 |
| Fong, SY | 1 |
| Wing, YK | 1 |
| D'Hoore, P | 1 |
| Miewald, J | 1 |
| Lamberti, JS | 2 |
| Leon, AC | 1 |
| Patel, J | 1 |
| Johnson, SA | 1 |
| Amitai, N | 1 |
| Semenova, S | 1 |
| Markou, A | 1 |
| Bowie, CR | 1 |
| Casademont, J | 1 |
| Garrabou, G | 1 |
| Miró, O | 1 |
| López, S | 1 |
| Cardellach, F | 1 |
| Hsu, HB | 1 |
| Mishra, B | 2 |
| Akhtar, S | 6 |
| Bounthavong, M | 1 |
| Okamoto, MP | 1 |
| Segal, M | 1 |
| Avital, A | 1 |
| Derevenski, A | 1 |
| Berstein, S | 1 |
| Sandbank, S | 1 |
| Timdahl, K | 1 |
| Carlsson, A | 1 |
| Stening, G | 1 |
| Law, WL | 1 |
| Hui, HY | 1 |
| Young, WM | 1 |
| You, JH | 1 |
| Carlos Gómez, J | 1 |
| Palmer, BW | 1 |
| Katz, E | 1 |
| Niaz, OS | 1 |
| Feifel, D | 1 |
| Melendez, G | 1 |
| Priebe, K | 1 |
| Shilling, PD | 1 |
| Savina, I | 1 |
| Silver, H | 2 |
| Goodman, C | 1 |
| Popovic, S | 1 |
| Miljic, N | 1 |
| Djurovic, M | 1 |
| Dieguez, C | 1 |
| Casanueva, FF | 1 |
| Cilia, J | 1 |
| Hatcher, P | 1 |
| Reavill, C | 1 |
| Jones, DN | 1 |
| Mullins, CD | 1 |
| Obeidat, NA | 1 |
| Naradzay, J | 1 |
| Loebel, AD | 1 |
| Youssef, E | 1 |
| Agius, M | 1 |
| Murphy, CL | 1 |
| Win, A | 1 |
| Bushe, C | 1 |
| Shaw, M | 1 |
| Gu, H | 3 |
| Lazarus, A | 1 |
| Sweitzer, D | 2 |
| Olexy, C | 1 |
| Strakowski, SD | 1 |
| Peñas-Lledó, EM | 1 |
| Cáceres, MC | 1 |
| Opgen-Rhein, M | 1 |
| Valdevit, R | 1 |
| Kleindienst, N | 1 |
| Saddichha, S | 4 |
| Ameen, S | 4 |
| Wynn, JK | 1 |
| Sprock, J | 1 |
| Light, GA | 2 |
| Erhart, S | 2 |
| Braff, DL | 3 |
| Ingham, M | 1 |
| Wright, TM | 1 |
| Vandenberg, AM | 1 |
| Hlastala, SA | 1 |
| Williams, E | 1 |
| Hunt-Harrison, T | 1 |
| Baldaçara, L | 1 |
| de Castro Ferrari, MC | 1 |
| Monteiro, BF | 1 |
| Uchida, RR | 1 |
| Sanches, M | 1 |
| Tomita, M | 1 |
| Manki, H | 1 |
| Wooten, J | 1 |
| Fang, C | 2 |
| Qin, SY | 1 |
| Guillon, MS | 1 |
| Bailey, PE | 1 |
| Provost, D | 1 |
| Rabin, C | 1 |
| Budhian, A | 1 |
| Metzger, KL | 1 |
| Majewski-Tiedeken, C | 1 |
| Winey, KI | 1 |
| Prabhuswamy, M | 1 |
| Srinath, S | 1 |
| Girimaji, S | 1 |
| Seshadri, S | 1 |
| Wasan, KM | 1 |
| Birmingham, CL | 1 |
| Ting Chen, T | 1 |
| Kuo Lin, W | 1 |
| Sarandol, A | 1 |
| Cangur, S | 1 |
| Kirli, S | 1 |
| Chiou, CC | 1 |
| Kumar, R | 2 |
| Belger, M | 1 |
| Castro, AP | 1 |
| Sergi, MJ | 1 |
| Kee, KS | 2 |
| Villari, V | 1 |
| Fonzo, V | 1 |
| Pandullo, P | 1 |
| Bogetto, F | 1 |
| Goldman, RS | 3 |
| Shope, CB | 1 |
| Moriyama, T | 1 |
| Hosalli, PM | 1 |
| Choi, EY | 1 |
| Song, K | 1 |
| Hill, SK | 1 |
| Khine, T | 1 |
| Velligan, DI | 1 |
| Diamond, PM | 1 |
| Maples, N | 1 |
| Zeber, J | 1 |
| Lam, YW | 1 |
| Castillo, D | 1 |
| Parrinello, G | 1 |
| Nordstrom, K | 1 |
| Allen, MH | 1 |
| Cohen, M | 1 |
| Panagides, J | 1 |
| Amiri, A | 1 |
| Nejatisafa, AA | 1 |
| Derakhshan, MK | 2 |
| Bratti, IM | 1 |
| Hudson-Jessop, P | 1 |
| Hughes, B | 1 |
| Brinkley, N | 1 |
| Bick, P | 1 |
| Knoesen, N | 1 |
| Montrose, DM | 1 |
| Miewald, JM | 1 |
| Kupfer, DJ | 1 |
| Gilaberte, I | 1 |
| Marinis, TD | 1 |
| Arnoldussen, WJ | 1 |
| Teijeiro, R | 1 |
| Jockers-Scherübl, MC | 1 |
| Bechdolf, A | 1 |
| Schmidt, LG | 1 |
| Salize, HJ | 1 |
| Manjunatha, N | 1 |
| Al Hadithy, AF | 1 |
| Brouwers, JR | 1 |
| Prikryl, R | 1 |
| Svestka, J | 3 |
| Synek, O | 1 |
| Tomanová, J | 1 |
| Rodáková, I | 1 |
| Cejpková, A | 1 |
| Briegel, W | 1 |
| Miyamoto, S | 1 |
| Miyake, N | 1 |
| Ogino, S | 1 |
| Endo, T | 1 |
| Yamaguchi, N | 1 |
| Szöke, A | 1 |
| Schürhoff, F | 1 |
| Gavaudan, G | 1 |
| Macquin-Mavier, I | 1 |
| Salimi, S | 1 |
| Fotouhi, A | 1 |
| Mohammadi, MR | 1 |
| Ong, WY | 1 |
| Grigoryan, GA | 1 |
| Jones, CA | 1 |
| Stolzberg, D | 1 |
| Salvi, R | 1 |
| Gross, KW | 1 |
| Ratty, AK | 1 |
| Su, JA | 1 |
| Tsang, HY | 1 |
| Chou, SY | 1 |
| Chung, PC | 1 |
| Lipkovich, I | 1 |
| Mallinckrodt, C | 1 |
| Baron, D | 1 |
| Boggs, DL | 1 |
| Wagner, HR | 1 |
| McGee, M | 1 |
| Kilzieh, N | 1 |
| Todd-Stenberg, JA | 1 |
| Kennedy, A | 1 |
| Wood, AE | 1 |
| Tapp, AM | 1 |
| Gao, K | 1 |
| Ganocy, SJ | 1 |
| Gajwani, P | 1 |
| Muzina, DJ | 1 |
| Kemp, DE | 1 |
| Calabrese, JR | 1 |
| Degmecić, D | 1 |
| Jano, E | 1 |
| Johnson, M | 1 |
| Aparasu, RR | 1 |
| Kim, D | 1 |
| Nakato, Y | 1 |
| Tamayo, P | 1 |
| Montes, C | 1 |
| De Luxán, A | 1 |
| Rivas, N | 1 |
| Domínguez-Gil, A | 1 |
| Chiang, HL | 1 |
| Wu, SY | 1 |
| Dopheide, JA | 1 |
| Dolder, C | 1 |
| Nelson, M | 1 |
| Deyo, Z | 1 |
| Ader, M | 1 |
| Garvey, WT | 1 |
| Phillips, LS | 1 |
| Musselman, DL | 1 |
| Morein, J | 1 |
| Bergman, RN | 1 |
| Taylor, M | 2 |
| Currie, A | 1 |
| Price, M | 1 |
| Peperell, K | 1 |
| van Nimwegen, L | 1 |
| van Beveren, N | 1 |
| Laan, W | 1 |
| Shajahan, P | 1 |
| Lawrie, SM | 1 |
| Kolotkin, RL | 1 |
| Corey-Lisle, PK | 1 |
| Crosby, RD | 1 |
| Kan, HJ | 1 |
| Vuković, O | 1 |
| Ille, T | 1 |
| Tiul'pin, IuG | 1 |
| Harvey, I | 1 |
| Lilford, R | 1 |
| István, S | 1 |
| Agoston, T | 1 |
| Tamás, T | 1 |
| Zoltán, J | 1 |
| Tafalla, M | 1 |
| Mao, PX | 1 |
| Zhai, YM | 1 |
| Mitchell, PB | 1 |
| Tang, YL | 1 |
| Nussbaum, A | 1 |
| Sutton, BJ | 1 |
| Martello, D | 1 |
| Westheide, J | 1 |
| Albrecht, C | 1 |
| Bliesener, N | 1 |
| Cooper-Mahkorn, D | 1 |
| Creutz, C | 1 |
| Hornung, WP | 1 |
| Klingmüller, D | 1 |
| Lemke, MR | 1 |
| Schubert, M | 1 |
| Sträter, B | 1 |
| Wickelmaier, F | 1 |
| Braus, DF | 3 |
| Washburn, CF | 1 |
| Yuan, HN | 1 |
| Sze, CW | 1 |
| Feng, XJ | 1 |
| Liu, RM | 1 |
| Zhang, JZ | 1 |
| Zhang, YB | 1 |
| Bader, W | 1 |
| Greiner, C | 1 |
| Mahmood, T | 3 |
| Clothier, EB | 1 |
| Bridgman, R | 1 |
| Pary, R | 1 |
| Tobias, CR | 1 |
| Kerwin, R | 1 |
| Jeffries, JJ | 1 |
| Lacombe, S | 1 |
| Arnott, W | 2 |
| Remington, GJ | 3 |
| Busatto, GF | 3 |
| Costa, DC | 3 |
| Kerwin, RW | 5 |
| Livingston, MG | 1 |
| Høyberg, OJ | 1 |
| Fensbo, C | 1 |
| Remvig, J | 1 |
| Lingjaerde, O | 1 |
| Sloth-Nielsen, M | 1 |
| Salvesen, I | 1 |
| Janssen, PA | 1 |
| Awouters, FH | 1 |
| Mosqueda, RA | 1 |
| Davidson, JE | 1 |
| Edwards, JG | 1 |
| von Knorring, L | 5 |
| Dalby, JT | 3 |
| Land, W | 1 |
| Salzman, C | 2 |
| Schultz, RE | 1 |
| Jahnová, E | 1 |
| Mok, H | 1 |
| Heykants, J | 1 |
| Mannens, G | 1 |
| Meuldermans, W | 1 |
| Snoeck, E | 1 |
| Van Beijsterveldt, L | 1 |
| Van Peer, A | 1 |
| Woestenborghs, R | 1 |
| Owens, DG | 2 |
| Cozza, SJ | 1 |
| Edison, DL | 1 |
| Jones, BD | 2 |
| Finlayson, R | 1 |
| Grant, S | 1 |
| Fitton, A | 1 |
| Eilers, R | 1 |
| Bennett, JA | 1 |
| Keck, PE | 4 |
| Wallhausser, LJ | 1 |
| Bennie, EH | 1 |
| Borison, RL | 6 |
| Diamond, B | 1 |
| Pathiraja, A | 1 |
| Vainer, JL | 1 |
| Bélanger, MC | 1 |
| Turnier, L | 1 |
| Beaudry, P | 1 |
| Roy, JY | 1 |
| Kitaichi, K | 1 |
| Yamada, K | 2 |
| Keegan, D | 1 |
| Villeneuve, A | 1 |
| Sigmundson, HK | 1 |
| Lee, MA | 1 |
| Ranjan, R | 2 |
| Black, DW | 1 |
| Smith, DA | 1 |
| Clarke, DE | 1 |
| Yaeger, SF | 1 |
| Bryois, C | 1 |
| Oxenstierna, G | 2 |
| Nakashima, Y | 2 |
| Ericsson, B | 1 |
| Klieser, E | 1 |
| Lehmann, E | 1 |
| Kinzler, E | 1 |
| Wurthmann, C | 1 |
| Heinrich, K | 1 |
| Perry, PJ | 1 |
| Curtis, VA | 2 |
| Sternlicht, HC | 1 |
| Wells, SR | 1 |
| Pickar, D | 5 |
| Müller, H | 1 |
| Swanson, CL | 1 |
| Price, WA | 1 |
| Greer, RA | 1 |
| Evans, DL | 1 |
| Zimbroff, DL | 1 |
| Dickson, RA | 4 |
| Edwards, AL | 1 |
| Pelonero, AL | 2 |
| Price, PL | 1 |
| Meylan, C | 1 |
| Aubert, AC | 1 |
| Huttunen, MO | 2 |
| Piepponen, T | 1 |
| Rantanen, H | 1 |
| Nyholm, R | 1 |
| Raitasuo, V | 1 |
| Tanner, TB | 1 |
| Reddy, R | 1 |
| Allen, M | 1 |
| Field, K | 1 |
| Shore, D | 1 |
| Matthews, S | 1 |
| Cott, J | 1 |
| Radford, JM | 1 |
| Brown, TM | 1 |
| Musser, WS | 1 |
| Kirisci, L | 1 |
| Goss, JB | 1 |
| Lacey, RL | 1 |
| Jerkovich, GS | 1 |
| Cardoni, AA | 1 |
| McGlashan, TH | 1 |
| Strakowski, SM | 2 |
| McElroy, SL | 3 |
| Kizer, DL | 1 |
| Balistreri, TM | 1 |
| Holtman, HM | 1 |
| DePriest, M | 1 |
| Moseley, C | 1 |
| Rosenfield, S | 1 |
| Wolf, S | 1 |
| Nawroz, S | 1 |
| Quintana, H | 1 |
| Araujo, L | 1 |
| Abaza, A | 1 |
| Jones, B | 2 |
| Bloom, D | 1 |
| Menkes, DB | 1 |
| Van Putten, T | 1 |
| Midha, KK | 1 |
| Min, SK | 1 |
| Rhee, CS | 1 |
| Kim, CE | 2 |
| Kang, DY | 1 |
| Tomlinson, WC | 1 |
| Bacher, NM | 1 |
| Kaup, BA | 1 |
| Diaz, SF | 1 |
| Avnon, M | 1 |
| Kunin, A | 1 |
| Wakefield, TP | 1 |
| Landry, P | 1 |
| Sanderson, DR | 1 |
| Lubick, LJ | 1 |
| Williams, TS | 1 |
| Smith, K | 1 |
| Hyde, T | 1 |
| Egan, M | 1 |
| Eastham, JH | 1 |
| Lacro, JP | 1 |
| Gierz, M | 1 |
| Field, MG | 1 |
| Harris, MJ | 2 |
| Fredrikson, D | 1 |
| Good, KP | 3 |
| Silverstone, T | 2 |
| Spittle, B | 1 |
| Warner, JP | 2 |
| Gledhill, JA | 1 |
| Wakeling, A | 1 |
| Nordström, AL | 1 |
| Carman, J | 1 |
| Vangeneugden, A | 1 |
| Megens, AA | 1 |
| Kennis, LE | 1 |
| Schnierow, BJ | 1 |
| Graeber, DA | 1 |
| McCreadie, RG | 1 |
| Gallhofer, B | 2 |
| Bauer, U | 1 |
| Lis, S | 2 |
| Krieger, S | 1 |
| Gruppe, H | 1 |
| Dufour, H | 2 |
| Glazer, WM | 3 |
| Maizel, S | 1 |
| Umansky, L | 1 |
| Bilsker, D | 1 |
| Grcevich, SJ | 2 |
| Lopez, I | 1 |
| Shumway, M | 1 |
| Simon, MR | 1 |
| Freedman, L | 1 |
| Raleigh, F | 1 |
| Morena, P | 1 |
| Dascal, DR | 1 |
| Negrón, AE | 2 |
| Leiderman, EA | 1 |
| Parkadavil, M | 1 |
| Lussier, I | 2 |
| Chua, JW | 1 |
| Lipetsker, B | 1 |
| Bhattacharyya, A | 1 |
| Kadewari, RP | 1 |
| Takhar, J | 1 |
| Riesenman, C | 1 |
| True, JE | 1 |
| Javors, M | 1 |
| Berman, I | 1 |
| Merson, A | 1 |
| Sison, C | 1 |
| Allan, E | 1 |
| Schaefer, C | 1 |
| Loberboym, M | 1 |
| Aquila, R | 2 |
| Standard, J | 1 |
| Lehman, AF | 1 |
| Heimberg, C | 1 |
| Yearian, AS | 1 |
| Morrison, DP | 1 |
| Emes, CE | 1 |
| Glackman, WG | 1 |
| Ansseau, M | 1 |
| Droney, T | 1 |
| Berent, I | 1 |
| Carabeth, J | 1 |
| Cordero, MM | 1 |
| Cordero, R | 1 |
| Sugerman, B | 1 |
| Robinson, D | 1 |
| Shepski, JC | 1 |
| Wincor, MZ | 1 |
| Gutierrez, MA | 1 |
| Gross, LS | 1 |
| Bosmans, E | 1 |
| Vandoolaeghe, E | 1 |
| De Ley, M | 1 |
| Berghmans, R | 1 |
| Stans, G | 1 |
| Desnyder, R | 1 |
| Lewine, R | 1 |
| Fluker, M | 1 |
| Martzke, JS | 1 |
| Moore, NC | 1 |
| Shukla, P | 1 |
| Küfferle, B | 3 |
| Brücke, T | 2 |
| Topitz-Schratzberger, A | 1 |
| Gössler, R | 1 |
| Vesely, C | 1 |
| Asenbaum, S | 2 |
| Podreka, I | 2 |
| Mattes, JA | 1 |
| Mancini, F | 1 |
| Stratta, P | 1 |
| Mattei, P | 1 |
| Gismondi, R | 1 |
| Pozzi, F | 1 |
| Casacchia, M | 1 |
| Patel, JK | 2 |
| Crockford, DN | 1 |
| Fisher, G | 1 |
| Barker, P | 1 |
| Still, DJ | 2 |
| Dorson, PG | 2 |
| Pousson, C | 1 |
| Miranda-Scippa, AM | 1 |
| Pereira, EL | 1 |
| Ribeiro, MG | 1 |
| de Castro-e-Silva, E | 1 |
| Bacaltchuk, J | 1 |
| Armenteros, JL | 1 |
| Whitaker, AH | 1 |
| Welikson, M | 1 |
| Stedge, DJ | 1 |
| Gorman, J | 1 |
| Herion, D | 1 |
| Jacobsen, LK | 1 |
| Briguglia, C | 1 |
| Grothe, D | 1 |
| Bauer, KS | 1 |
| Haas, GL | 2 |
| Kroboth, PD | 1 |
| Koponen, HJ | 1 |
| Marshall, BD | 4 |
| McGurk, S | 1 |
| Kern, RS | 3 |
| Kirov, GK | 1 |
| Seth, RV | 1 |
| Feeney, S | 1 |
| Klausner, M | 1 |
| Clyde, C | 1 |
| Jones, R | 1 |
| Ibrahim, ZY | 1 |
| Singer, B | 1 |
| Orr, B | 1 |
| Donenwirth, K | 1 |
| Brar, PS | 1 |
| Fisman, S | 1 |
| Steele, M | 1 |
| Rowane, WA | 1 |
| Friedman, L | 1 |
| Albright, PS | 1 |
| Sommers, DK | 1 |
| Snyman, JR | 1 |
| van Wyk, M | 1 |
| Blom, MW | 1 |
| Levron, JC | 1 |
| Viale, G | 1 |
| Mechling, L | 1 |
| Maislin, G | 1 |
| Durkin, M | 1 |
| Engelhart, L | 2 |
| Lawrence, BJ | 1 |
| Franz, M | 1 |
| Plüddemann, K | 1 |
| Hamilton, SH | 2 |
| Kuntz, AJ | 2 |
| Potvin, JH | 1 |
| Andersen, SW | 4 |
| Beasley, C | 1 |
| Kuehnel, TG | 1 |
| Hayden, JL | 1 |
| Robertson, MJ | 1 |
| Murphy, MA | 1 |
| Su, TP | 2 |
| Hadd, K | 1 |
| Siepmann, M | 1 |
| Olbrich, H | 1 |
| Gutierrez-Esteinou, R | 1 |
| Grebb, JA | 2 |
| Bork, J | 1 |
| Elfand, L | 1 |
| Dabiri, L | 1 |
| Clark, L | 1 |
| Fogelson, DL | 1 |
| Sternbach, H | 1 |
| Payne, D | 1 |
| Mercer, G | 1 |
| Finlayson, A | 1 |
| Johnstone, EC | 1 |
| Murray, C | 1 |
| Whitcomb, SR | 1 |
| Beck, NC | 1 |
| Greenfield, SR | 1 |
| Gotham, H | 1 |
| Menditto, AA | 1 |
| Stuve, P | 1 |
| Hemme, CA | 1 |
| Waddington, JL | 1 |
| Scully, PJ | 1 |
| O'Callaghan, E | 1 |
| Ballús, C | 1 |
| Zipursky, R | 2 |
| Bäuml, J | 1 |
| Ferrero, F | 1 |
| Fuger, J | 1 |
| Geretsegger, C | 1 |
| Schubert, H | 1 |
| Klass, D | 1 |
| Hanrahan, P | 1 |
| Malan, R | 1 |
| Harris, J | 1 |
| Miller, CH | 1 |
| Mohr, F | 1 |
| Woerner, M | 1 |
| Chou, JC | 2 |
| Lin, YC | 1 |
| Josefson, D | 1 |
| Flynn, SW | 2 |
| Altman, S | 2 |
| Fredrikson, DH | 1 |
| Tavcar, R | 1 |
| Dernovsek, MZ | 1 |
| Patris, M | 1 |
| May, JP | 1 |
| Billeter, U | 1 |
| Binder, RL | 1 |
| McNiel, DE | 1 |
| Sandberg, DA | 1 |
| Ashleigh, EA | 1 |
| Larsen, PD | 1 |
| Zito, JM | 1 |
| Nair, NP | 1 |
| Gheuens, J | 1 |
| Finley, PR | 1 |
| Sommer, BR | 1 |
| Corbitt, JL | 1 |
| Brunson, GH | 1 |
| Lum, BL | 1 |
| Mahendran, R | 4 |
| Tracy, JI | 1 |
| Monaco, CA | 1 |
| Abraham, G | 1 |
| Barnas, C | 1 |
| Hesselmann, B | 1 |
| Werapongset, W | 1 |
| Chaisirikul, S | 1 |
| Chrujiporn, W | 1 |
| Visanuyothin, T | 1 |
| Kessawai, D | 1 |
| Charisilp, C | 1 |
| Ratanachata, N | 1 |
| Sanichwannakul, K | 1 |
| Wangdee, P | 1 |
| Bunditchate, A | 1 |
| Ukranand, P | 1 |
| Knable, MB | 1 |
| Coppola, R | 1 |
| Gorey, JG | 1 |
| Jones, DW | 1 |
| Wirshing, D | 1 |
| Dähne, I | 1 |
| Mager, T | 2 |
| Scherer, J | 1 |
| Deirmenjian, JM | 1 |
| Erhart, SM | 1 |
| Spellberg, BJ | 1 |
| Gagiano, CA | 2 |
| Torres-Plank, JF | 1 |
| Gaussares, C | 1 |
| Hasan, S | 1 |
| Lee, EL | 1 |
| Liow, PH | 1 |
| Kiraly, SJ | 1 |
| Gibson, RE | 1 |
| Ancill, RJ | 1 |
| Holliday, SG | 1 |
| Lemon, MD | 1 |
| Suzuki, I | 1 |
| Honma, H | 1 |
| Watanabe, N | 1 |
| Matsubara, S | 1 |
| Dubbelman, YD | 1 |
| Thung, FH | 1 |
| Heeringa, M | 1 |
| Pettegrew, JW | 1 |
| Hanau, M | 1 |
| Jhamb, KK | 1 |
| Iskedjian, M | 1 |
| Hux, M | 1 |
| Rudnick, A | 1 |
| Sharif, ZA | 3 |
| Jones, H | 1 |
| Wright, PA | 1 |
| Lucey, JV | 1 |
| Iskander, A | 1 |
| Park, M | 1 |
| Apergi, FS | 1 |
| Smith, R | 1 |
| Allen, D | 1 |
| Elizur, A | 1 |
| Maynard, A | 1 |
| Bloor, K | 1 |
| Yee, CM | 1 |
| Morris, SE | 1 |
| White, PM | 1 |
| Day, C | 1 |
| Dillman, B | 1 |
| Gardner, D | 1 |
| DeQuardo, JR | 1 |
| Johnson, SV | 1 |
| Singh, KI | 1 |
| Moore, DB | 1 |
| Sherr, JD | 1 |
| Rockwell, E | 1 |
| Lohr, JB | 1 |
| Lacro, J | 1 |
| Toren, P | 1 |
| Laor, N | 1 |
| Sanders, RD | 1 |
| Lehrer, DS | 1 |
| Travis, MJ | 1 |
| Mulligan, R | 1 |
| Acton, PD | 1 |
| Gacinovic, S | 1 |
| Mertens, J | 1 |
| Terrière, D | 1 |
| Kleinberg, DL | 1 |
| de Coster, R | 1 |
| Van Baelen, B | 4 |
| Pitschel-Walz, G | 1 |
| Abraham, D | 1 |
| Breier, AF | 1 |
| Pinals, DA | 1 |
| Elman, I | 2 |
| Adler, CM | 1 |
| Lafargue, RT | 1 |
| Clifton, A | 1 |
| Takahashi, N | 1 |
| Terao, T | 2 |
| Oga, T | 1 |
| Okada, M | 1 |
| Ollendorf, D | 1 |
| Oster, G | 1 |
| Hawkins, KA | 2 |
| Rosebush, PI | 1 |
| Mazurek, MF | 1 |
| Lemmens, P | 4 |
| Palmer, CS | 1 |
| Genduso, LA | 1 |
| Brown, RE | 1 |
| Ginsberg, G | 1 |
| Shani, S | 1 |
| Lev, B | 1 |
| Cohen, LJ | 1 |
| Foster, RH | 2 |
| Zolezzi, M | 1 |
| Badr, MG | 1 |
| Caracci, G | 1 |
| Ananthamoorthy, R | 1 |
| Morera, AL | 1 |
| Barreiro, P | 1 |
| Cano-Muñoz, JL | 1 |
| Kasckow, J | 1 |
| Kunik, M | 1 |
| Pomara, N | 1 |
| Tandon, R | 2 |
| Milner, K | 1 |
| Jibson, MD | 2 |
| Campbell, M | 1 |
| Markianos, M | 4 |
| Hatzimanolis, J | 4 |
| Faraone, SV | 1 |
| Zimmet, S | 1 |
| Kelleher, JP | 2 |
| Bartko, JJ | 1 |
| Yap, HL | 1 |
| Low, BL | 2 |
| Choo, CH | 2 |
| Chan, AO | 1 |
| Wong, KE | 2 |
| Chee, KT | 2 |
| Emanuel, M | 1 |
| Lee, HS | 1 |
| Khoo, YM | 1 |
| Yap, JL | 1 |
| Chan, A | 1 |
| See, RE | 1 |
| Fido, AA | 1 |
| Maurice, M | 1 |
| Ibrahim, MM | 1 |
| Salama, GM | 1 |
| Prinssen, EP | 1 |
| Kleven, MS | 1 |
| Koek, W | 1 |
| Malla, AK | 2 |
| Norman, RM | 2 |
| Pies, R | 1 |
| Rubin, E | 1 |
| Dunayevich, E | 1 |
| Chatterjee, A | 1 |
| Kysar, L | 1 |
| Berisford, MA | 1 |
| Goldstein, D | 1 |
| Pashdag, J | 1 |
| Sheth, S | 1 |
| Marcus, S | 1 |
| Gopalani, A | 2 |
| Palmer, A | 1 |
| Prior, TI | 1 |
| Baker, GB | 1 |
| Gabbert, JF | 1 |
| Giannini, AJ | 1 |
| Meisenzahl, E | 1 |
| Wetterling, T | 1 |
| Müssigbrodt, HE | 1 |
| Asai, M | 1 |
| Dewan, M | 1 |
| Hong, KS | 2 |
| Cheong, SS | 1 |
| Kalinyak, CM | 1 |
| Chaki, S | 1 |
| Funakoshi, T | 1 |
| Yoshikawa, R | 1 |
| Okuyama, S | 1 |
| Kumagai, T | 1 |
| Nakazato, A | 1 |
| Nagamine, M | 1 |
| Tomisawa, K | 1 |
| Ende, G | 2 |
| Weber-Fahr, W | 2 |
| Sartorius, A | 1 |
| Krier, A | 1 |
| Hubrich-Ungureanu, P | 1 |
| Ruf, M | 1 |
| Stuck, S | 1 |
| Henn, FA | 2 |
| Amin, S | 1 |
| Yui, K | 1 |
| Whitworth, AB | 1 |
| Liensberger, D | 1 |
| Nichol, MB | 1 |
| Smith, RR | 1 |
| Dursun, SM | 1 |
| Burke, JG | 2 |
| Nowakowska, E | 1 |
| Chodera, A | 1 |
| Kus, K | 1 |
| Ho, BC | 1 |
| Nopoulos, P | 1 |
| Andreasen, NC | 2 |
| Honey, GD | 1 |
| Bullmore, ET | 1 |
| Soni, W | 2 |
| Varatheesan, M | 1 |
| Boulay, LJ | 1 |
| Lapierre, YD | 1 |
| McDougall, GM | 1 |
| Dittert, S | 1 |
| Hale, A | 1 |
| Bale, R | 1 |
| Earnst, KS | 1 |
| Taylor, SF | 1 |
| Smet, IC | 1 |
| Berent, S | 1 |
| Facciolà, G | 2 |
| Johansson, I | 1 |
| Dahl, ML | 1 |
| Iakovlev, VA | 2 |
| Alfaro, CL | 1 |
| Nicolson, R | 1 |
| Lenane, M | 1 |
| Rapoport, JL | 1 |
| Simpson, PM | 1 |
| Ngan, E | 1 |
| Liddle, P | 1 |
| Reneman, L | 3 |
| Gersons, BP | 2 |
| van Royen, EA | 3 |
| Voruganti, LN | 1 |
| Liu, SK | 1 |
| Nagasaki, T | 1 |
| Ohkubo, T | 1 |
| Sugawara, K | 1 |
| Yasui, N | 1 |
| David, SR | 2 |
| Walter, S | 1 |
| Soher, B | 1 |
| Maudsley, AA | 1 |
| Remschmidt, H | 2 |
| Hennighausen, K | 2 |
| Clement, HW | 2 |
| Heiser, P | 2 |
| Schulz, E | 2 |
| Windhaber, J | 1 |
| Urbanits, S | 1 |
| Grisold, W | 1 |
| Kumar, S | 1 |
| Malone, DM | 1 |
| Schroeder, U | 1 |
| Schroeder, H | 1 |
| Schwegler, H | 1 |
| Sabel, BA | 1 |
| Raskin, S | 1 |
| Katz, G | 1 |
| Zislin, Z | 1 |
| Durst, R | 1 |
| Clementz, BA | 1 |
| Cadenhead, KS | 1 |
| Clarke, A | 1 |
| Gilbody, S | 1 |
| Reznik, I | 1 |
| Paleacu, D | 1 |
| Masand, PS | 1 |
| Chiu, WC | 1 |
| Wu, ST | 1 |
| Su, MH | 1 |
| Agarwal, V | 1 |
| Coulouvrat, C | 1 |
| Dondey-Nouvel, L | 1 |
| Hirose, S | 2 |
| Mérette, C | 1 |
| Villeneuve, J | 2 |
| Roy-Gagnon, MH | 1 |
| Gauthier, Y | 1 |
| Cliche, D | 1 |
| Filteau, MJ | 1 |
| Jarskog, LF | 1 |
| Mattioli, MA | 1 |
| Dingemans, PM | 3 |
| Vervarcke, J | 1 |
| De Hooge, JD | 1 |
| Bray, G | 1 |
| Haushofer, M | 1 |
| Doig, A | 1 |
| Sembhi, S | 1 |
| Livingston, G | 1 |
| Vieta, E | 1 |
| Gregor, KJ | 1 |
| Stamouli, SS | 2 |
| Adesanya, A | 1 |
| Hajak, G | 1 |
| Kyosseva, SV | 1 |
| Elbein, AD | 1 |
| Hutton, TL | 1 |
| Griffin, ST | 1 |
| Mrak, RE | 1 |
| Sturner, WQ | 1 |
| Karson, CN | 1 |
| Green, B | 1 |
| Bagnall, AM | 1 |
| Tuunainen, A | 1 |
| Raza, A | 1 |
| Ratakonda, SS | 1 |
| Almond, S | 1 |
| O'Donnell, O | 1 |
| Lal, S | 1 |
| Iskandar, H | 1 |
| Govitrapong, P | 1 |
| Chagkutip, J | 1 |
| Turakitwanakan, W | 1 |
| Srikiatkhachorn, A | 1 |
| Tachikawa, H | 1 |
| Kawanishi, Y | 1 |
| Hori, M | 1 |
| Hori, T | 1 |
| Shiraishi, H | 1 |
| Simon, AE | 1 |
| Mullen, A | 1 |
| Wahlbeck, K | 1 |
| Cheine, M | 1 |
| Tuisku, K | 1 |
| Ahokas, A | 1 |
| Joffe, G | 1 |
| Rimón, R | 1 |
| Azhar, MZ | 1 |
| Geddes, J | 2 |
| Freemantle, N | 1 |
| Harrison, P | 1 |
| Bebbington, P | 1 |
| Basson, BR | 3 |
| Malcolm, S | 1 |
| De Smedt, C | 1 |
| Heck, AH | 2 |
| Haffmans, PM | 1 |
| de Groot, IW | 2 |
| Hoencamp, E | 1 |
| Moriarty, PJ | 1 |
| Serper, MR | 1 |
| Schnur, E | 1 |
| Lieber, D | 1 |
| Ulrich, R | 1 |
| Atzert, R | 1 |
| Brienzo, R | 1 |
| Kaplan, Z | 1 |
| Mark, M | 1 |
| Nahon, D | 1 |
| Habraken, JB | 1 |
| Jureidini, JN | 1 |
| Schweitzer, I | 1 |
| Simoneau, I | 1 |
| Lemieux, I | 1 |
| Hilger, E | 1 |
| Salemi, M | 1 |
| Madia, AG | 1 |
| Kooptiwoot, S | 1 |
| Settachan, T | 1 |
| Bhana, N | 1 |
| Olney, R | 1 |
| Plosker, GL | 1 |
| Snaterse, M | 1 |
| Johnstone, BM | 1 |
| Dulisse, B | 1 |
| Dossenbach, MR | 1 |
| Kratky, P | 1 |
| Schneidman, M | 1 |
| Grundy, SL | 1 |
| Metcalfe, S | 1 |
| Belmaker, RH | 1 |
| Walker, DJ | 1 |
| Orengo, CA | 1 |
| Kunik, ME | 1 |
| Hale, D | 1 |
| Molinari, VA | 1 |
| Laini, V | 1 |
| Boscati, L | 1 |
| Rudelli, R | 1 |
| Salvi, V | 1 |
| Orlandi, R | 1 |
| Seger, A | 1 |
| van Harten, PN | 1 |
| Tanvetyanon, T | 1 |
| Dissin, J | 1 |
| Selcer, UM | 1 |
| Zeger, SL | 1 |
| Zarzuela, A | 1 |
| Riedel, A | 1 |
| Rolfe, TJ | 1 |
| Taffe, J | 1 |
| Ashby, CR | 1 |
| Mills, MJ | 1 |
| Tanada, S | 1 |
| Khramov, I | 1 |
| Iwanami, A | 1 |
| Okajima, Y | 1 |
| Isono, H | 1 |
| Shinoda, J | 1 |
| Hata, A | 1 |
| Fukuda, M | 1 |
| Scholten, DJ | 1 |
| Czekalla, J | 1 |
| Dellva, MA | 1 |
| Grundy, S | 1 |
| O'Leary, DS | 1 |
| Watkins, GL | 1 |
| Boles Ponto, LL | 1 |
| Hichwa, RD | 1 |
| Nelson, MW | 1 |
| Mullen, B | 1 |
| Vagnucci, AH | 1 |
| Taylor, CG | 1 |
| Ehmann, T | 1 |
| Ayrton, Z | 1 |
| Szymanski, KA | 1 |
| Valibhai, F | 1 |
| Phan, NB | 1 |
| True, J | 1 |
| Vesce, J | 1 |
| Comaty, JE | 1 |
| Advokat, C | 1 |
| Torres, RA | 1 |
| Hornik, T | 1 |
| Ipekçi, S | 1 |
| Birsöz, S | 1 |
| Rudge, T | 1 |
| Morse, K | 1 |
| Takei, N | 1 |
| Mori, N | 1 |
| Minami, M | 1 |
| Ohta, T | 1 |
| Sauriol, L | 1 |
| Laporta, M | 1 |
| Edwardes, MD | 1 |
| Deslandes, M | 1 |
| Ricard, N | 1 |
| Suissa, S | 1 |
| Ravasia, S | 1 |
| Flor-Henry, P | 1 |
| Spiegel, R | 1 |
| Vanelle, JM | 1 |
| Péré, JJ | 1 |
| Giguere, M | 1 |
| Bourdeix, I | 1 |
| Friedman, JI | 2 |
| Adler, DN | 2 |
| Temporini, HD | 1 |
| Kemether, E | 1 |
| White, L | 2 |
| Parrella, M | 2 |
| Davis, KL | 2 |
| Kozlova, IA | 1 |
| Burelomova, IV | 1 |
| Goriunov, AV | 1 |
| Grebchenko, IuF | 1 |
| Masikhina, SN | 1 |
| Light, M | 1 |
| Dunbar, F | 1 |
| Pierre, JM | 2 |
| Eyeler, J | 1 |
| Weinbach, J | 1 |
| Khanna, S | 1 |
| Dorovskikh, IV | 1 |
| Belinskiĭ, AV | 1 |
| Shcherbakov, DV | 1 |
| Zhbrykunov, VL | 1 |
| Martyniuk, IuL | 1 |
| Erbağci, AB | 1 |
| Köylüoglu, O | 1 |
| Yilmaz, N | 1 |
| Tarakçioglu, M | 1 |
| Chua, L | 1 |
| Pang, E | 1 |
| Ng, VP | 1 |
| Chan, YH | 1 |
| Connolly, CE | 1 |
| Pedrosa Gil, F | 1 |
| Schneider, C | 1 |
| Arnold, LM | 1 |
| Levine, HB | 1 |
| Cramer, JA | 1 |
| Badía, X | 1 |
| Kind, P | 1 |
| Simpson, MM | 1 |
| Goetz, RR | 1 |
| Devlin, MJ | 1 |
| Goetz, SA | 1 |
| Walsh, BT | 1 |
| Rubin, NJ | 1 |
| Arceneaux, JM | 1 |
| Kim, JG | 1 |
| Koh, HJ | 1 |
| Lee, D | 1 |
| Litvintsev, SV | 1 |
| Snedkov, EV | 1 |
| Mullen, J | 1 |
| Turrone, P | 1 |
| Flint, AJ | 1 |
| Ehmann, TS | 1 |
| Khanbhai, I | 1 |
| Wrixon, C | 1 |
| Tse, G | 1 |
| Sin, O | 1 |
| Wang, W | 1 |
| Roh, HK | 1 |
| Chung, WG | 1 |
| Park, CS | 1 |
| Svensson, JO | 1 |
| Woodward, TS | 1 |
| Kuroki, T | 1 |
| Tashiro, N | 1 |
| Lewis, M | 1 |
| Frangou, S | 1 |
| García-Cabeza, I | 1 |
| Edgell, E | 1 |
| González de Chavez, M | 1 |
| Ratnayake, T | 1 |
| Alao, AO | 1 |
| Naprawa, SA | 1 |
| Cazzullo, CL | 1 |
| Galluzzo, A | 1 |
| Panariello, A | 1 |
| Adorni, A | 1 |
| Pegoraro, M | 1 |
| Bosis, S | 1 |
| Colombo, F | 1 |
| Trabattoni, D | 1 |
| Zagliani, A | 1 |
| Clerici, M | 1 |
| Jensen, HM | 1 |
| Poulsen, HD | 1 |
| Shimoni, J | 1 |
| Shapira, B | 1 |
| Beuk, N | 1 |
| Hoogenboom, B | 1 |
| Sasaki, N | 1 |
| Ikeda, H | 1 |
| Nakano, N | 1 |
| Ozawa, H | 1 |
| Pouzet, B | 1 |
| Didriksen, M | 1 |
| Arnt, J | 1 |
| Howanitz, E | 1 |
| Brenner, G | 1 |
| Temporini, H | 1 |
| Hutton, SB | 1 |
| Shamir, E | 1 |
| Thyrum, PT | 1 |
| Bera, R | 1 |
| Yeh, C | 1 |
| Arvanitis, LA | 1 |
| Stryjer, R | 1 |
| Bar, F | 1 |
| Rabey, JM | 1 |
| Kim, W | 1 |
| Yoon, SJ | 1 |
| Alarcon, RD | 1 |
| Kuno, E | 1 |
| Rothbard, AB | 1 |
| Zavitsanou, K | 1 |
| Kawai, N | 1 |
| Storch, DD | 1 |
| Albert, MJ | 1 |
| Nieman, DH | 1 |
| Koelman, JH | 1 |
| Bour, LJ | 1 |
| Ongerboer de Visser, BW | 1 |
| Yuan, CL | 1 |
| Bullock, R | 1 |
| Libretto, S | 1 |
| Blair, K | 1 |
| Curtin, F | 1 |
| Stalman, SL | 1 |
| Lerner, AG | 1 |
| Shufman, E | 1 |
| Kodesh, A | 1 |
| Rudinski, D | 1 |
| Kretzmer, G | 1 |
| Sigal, M | 1 |
| Pavuluri, M | 1 |
| Heidenreich, J | 1 |
| Mallya, A | 1 |
| Chawla, P | 1 |
| Boyer, SK | 1 |
| DeRosear, L | 1 |
| Hoptman, M | 1 |
| Kunz, M | 1 |
| Horowitz, TL | 1 |
| Brandstätter, B | 1 |
| Sokullu, S | 1 |
| Krampe, K | 1 |
| Weiss, E | 1 |
| Dinakar, HS | 1 |
| Sobel, RN | 1 |
| Bopp, JH | 1 |
| Daniels, A | 1 |
| Mauro, S | 1 |
| Gianfrancesco, F | 1 |
| Durkin, MB | 2 |
| Amico, E | 1 |
| Posever, TA | 1 |
| Toker, R | 1 |
| Saunders, CS | 1 |
| Webster, D | 1 |
| Devarajan, S | 1 |
| Gallant, J | 1 |
| Harris, A | 1 |
| Cannon, TD | 1 |
| Dahlström, M | 1 |
| Räsänen, P | 1 |
| Juriloo, A | 1 |
| Allen, TB | 1 |
| Andersson, C | 1 |
| Lawler, CP | 1 |
| Mailman, RB | 1 |
| Goldstein, DS | 1 |
| Eisenhofer, G | 1 |
| Folio, CJ | 1 |
| Holmes, CS | 1 |
| Shermock, KM | 1 |
| Laich, JS | 1 |
| Edwards, N | 1 |
| Mendelson, S | 1 |
| Brown, TL | 1 |
| Griese, EU | 1 |
| Stösser, D | 1 |
| Gaertner, I | 1 |
| Barth, G | 1 |
| Hofschuster, E | 1 |
| Dobmeier, P | 1 |
| Claus, A | 2 |
| Bollen, J | 2 |
| De Cuyper, H | 2 |
| Eneman, M | 2 |
| Malfroid, M | 2 |
| Heylen, S | 2 |
| Wilms, G | 1 |
| Van Ongeval, C | 1 |
| Baert, AL | 1 |
| Heylen, SL | 1 |
| Gelders, YG | 2 |
| Pathiraja, AP | 1 |
| Diamond, BI | 1 |
| Gerlach, J | 1 |
| Pelzer, E | 1 |
| Riehl, T | 1 |
| Wernicke, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RBP-7000 as a Treatment in Subjects With Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses)[NCT02109562] | Phase 3 | 354 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM® in Patients With Acute Exacerbation of Schizophrenia: Open Label Extension (PRISMA-3_OLE)[NCT03870880] | Phase 3 | 215 participants (Actual) | Interventional | 2017-08-25 | Completed | ||
| Interventional, Open-label, Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia[NCT02892422] | Phase 3 | 528 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Interventional, Randomised, Double-blind, Active-controlled, Fixed-dose Study of Lu AF35700 in Patients With Treatment-resistant Schizophrenia[NCT02717195] | Phase 3 | 1,098 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Phosphodiesterase Inhibitor Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial[NCT04094207] | Phase 1/Phase 2 | 80 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Acute Schizophrenia: Results of a Proof of Concept Study[NCT00148590] | Phase 3 | 24 participants (Actual) | Interventional | 2005-11-30 | Terminated | ||
| Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Chronic Schizophrenia: Results of a Proof of Concept Study[NCT00148616] | Phase 3 | 13 participants (Actual) | Interventional | 2004-04-30 | Terminated | ||
| Glutamate, Brain Connectivity and Duration of Untreated Psychosis[NCT02034253] | 134 participants (Actual) | Observational | 2014-01-31 | Completed | |||
| Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study in Medication-naïve First Episode Psychosis Patients[NCT03442101] | 156 participants (Anticipated) | Observational | 2018-04-01 | Recruiting | |||
| Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up[NCT02526030] | Phase 4 | 203 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| Long-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects With Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial[NCT00641745] | Phase 3 | 629 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Treatment of Schizophrenia and Related Disorders in Children and Adolescents[NCT00053703] | Phase 4 | 116 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Developmental Processes in Schizophrenic Disorders: Cognitive Remediation, Medication Adherence, and Work Outcome in Recent-Onset Schizophrenia[NCT00333177] | Phase 4 | 92 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Analysis of Parameters Indicating the Intensity of Suicidal Behavior in Patients Suffering From Depression and Schizophrenia[NCT05803447] | 120 participants (Actual) | Observational | 2016-09-01 | Completed | |||
| Neuroimaging Biomarker-Guided Personalized Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Major Depressive Episode in Adolescents and Young Adults With Mood Disorders: A Randomized, Double-Blind, Controlled Study[NCT05465928] | 120 participants (Anticipated) | Interventional | 2022-08-01 | Recruiting | |||
| Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations[NCT01181960] | 1,066 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia[NCT01515423] | Phase 3 | 1,429 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment[NCT01786239] | 50 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics[NCT03730857] | Phase 1 | 111 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adult Subjects With Schizophrenia, Schizoaffective Disorder, or First Episode Psychos[NCT03568500] | Phase 4 | 44 participants (Actual) | Interventional | 2018-05-21 | Completed | ||
| A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia[NCT00589914] | Phase 3 | 1,221 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Randomised, Double-blind, Parallel-group, Flexible-dose Trial Evaluating the Efficacy and Safety of 12 Weeks of Treatment With Sertindole or Olanzapine in Patients With Schizophrenia in Asia[NCT00864045] | Phase 3 | 394 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated With Quetiapine XR (SEROQUEL XR™) or Oral Risperidone at Flexible Dose in a Naturalistic Setting[NCT00600756] | Phase 3 | 798 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.[NCT00932529] | Phase 4 | 226 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Multi-centre Comparative Study to Evaluate the Anti-aggression Effect and Safety of Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward[NCT00418873] | Phase 4 | 39 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Study was stopped due to difficulty in patient enrollment) | ||
| A Study to Evaluate Switching From Risperidone to Paliperidone ER (Extended Release) in the Treatment of Stable But Symptomatic Schizophrenia Outpatients: Patients Satisfaction and Quality of Life[NCT01010776] | Phase 4 | 223 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Minocycline add-on Medication to Antipsychotics in the Treatment of Schizophrenia Patients: A Double- Blind Randomized Controlled Trial[NCT02907437] | Phase 3 | 40 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| A Double-Blind,Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Schizophrenia[NCT01493622] | Phase 4 | 78 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Switching Antipsychotics: Abrupt Discontinuation Versus Overlap[NCT02640300] | Phase 4 | 33 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| A Randomized, 6-week, Open-Label, Study Evaluating The Safety, Tolerability, and Efficacy of Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents[NCT01143077] | Phase 3 | 244 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Community-based, Family Navigator Intervention to Improve Cardiometabolic Health of Medicaid-insured Youth Identified Through an Antipsychotic Medication Preauthorization Program[NCT02877823] | 302 participants (Actual) | Interventional | 2016-08-31 | Completed | |||
| Atypical Antipsychotics and Hyperglycemic Emergencies: Multicentre, Retrospective Cohort Study of Administrative Data[NCT02582736] | 725,489 participants (Actual) | Observational | 2012-04-30 | Completed | |||
| A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta)[NCT00216528] | Phase 4 | 527 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Effect of Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in First Episode Untreated Schizophrenia: A Randomized, Open Label, Active Controlled Study[NCT03304457] | Phase 4 | 100 participants (Actual) | Interventional | 2017-08-25 | Completed | ||
| Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone in the Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study[NCT00640562] | Phase 3 | 216 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia[NCT00590577] | Phase 3 | 652 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Preventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE)[NCT00330863] | Phase 4 | 357 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia[NCT01300364] | Phase 4 | 249 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine Positive Control in Subjects With an Acute Exacerbation of Schizophrenia[NCT00156117] | Phase 3 | 417 participants (Actual) | Interventional | 2005-05-12 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Haloperidol Positive Control in Subjects With an Acute Exacerbation of Schizophrenia[NCT00156104] | Phase 3 | 460 participants (Actual) | Interventional | 2005-07-01 | Completed | ||
| Lorazepam Effects on Neuroimaging Measures: A Pilot Study[NCT04671836] | Early Phase 1 | 0 participants (Actual) | Interventional | 2022-01-31 | Withdrawn (stopped due to No longer interested in conducing study) | ||
| Sequenced Atypical Antipsychotics Therapy With Intensive or Basic Psychosocial Intervention for First-episode Schizophrenia: An Effectiveness Study[NCT01057849] | 600 participants (Anticipated) | Interventional | 2008-09-30 | Recruiting | |||
| A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia[NCT01086748] | Phase 2 | 880 participants (Anticipated) | Interventional | 2010-03-31 | Completed | ||
| Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia: A Pilot, Double-Blind, Randomized Controlled Trial[NCT02639702] | Phase 4 | 30 participants (Anticipated) | Interventional | 2016-08-31 | Recruiting | ||
| Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia[NCT00330551] | Phase 4 | 126 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Risk of Breakthrough Symptoms On Antipsychotic Maintenance Medication When Remitted Patients Are Treated With Long-Acting Injectable Medications[NCT05473741] | 180 participants (Anticipated) | Observational | 2023-01-09 | Recruiting | |||
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Preventing Morbidity in First Episode Schizophrenia, Part II[NCT00320671] | Phase 4 | 198 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia[NCT01499563] | Phase 2 | 335 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia: A Randomized, Double-blind, Placebo-controlled Trial[NCT03788759] | Phase 2/Phase 3 | 48 participants (Actual) | Interventional | 2019-09-01 | Completed | ||
| The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia[NCT04076371] | 1,640 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Seroquel Safety Study[NCT01342120] | 18,325 participants (Actual) | Observational | 2010-09-30 | Completed | |||
| A Randomized Trial to Compare the Efficiency and Side Effect Between Olanzapine and Long-acting Paliperidone Palmitate Injection in Schizophrenia[NCT02918825] | 100 participants (Actual) | Interventional | 2016-09-01 | Completed | |||
| Risperidone Maintenance Treatment for Relapse Prevention in Schizophrenia[NCT00848432] | Phase 4 | 404 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| The Minimal Effective Dose of Antipsychotic Medication in Older Patients With Schizophrenia: a PET Study.[NCT00716755] | 45 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| A Randomized Open-Label, Rater Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine[NCT00378183] | Phase 4 | 120 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder[NCT00236353] | Phase 3 | 86 participants (Actual) | Interventional | 2002-05-31 | Completed | ||
| Population Pharmacokinetic Modeling of Qishe Pill in Three Major TCM-defined Constitutional Types of Healthy Chinese Subjects: Study Protocol for a Phase I Clinical Trial[NCT02294448] | Phase 1 | 36 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Aripiprazole, Abilify Maintena Collaborative Clinical Protocol[NCT02717130] | 9 participants (Actual) | Interventional | 2016-06-08 | Terminated (stopped due to The study was terminated due to lack of enrollment.) | |||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| Explorations of the Normal Neural Behavioral and Pathological Bases of Metacognition[NCT03140475] | 100 participants (Anticipated) | Observational | 2017-04-27 | Recruiting | |||
| Effectiveness of the RemedRugby Program, a Program of Ecological Cognitive Remediation of Social Cognition Disorders in Schizophrenia[NCT03775564] | 60 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| Virtual Cognitive Behavioural Therapy for Psychosis: A Randomized Controlled Trial[NCT04752449] | 60 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | |||
| An Open-label Study to Determine the Effect of Switching to Aripiprazole Once Monthly for Subjects With Schizophrenia Experiencing Worsening Sexual Dysfunction With Invega Sustenna or Risperdal Consta[NCT02472652] | Phase 4 | 2 participants (Actual) | Interventional | 2015-06-30 | Terminated (stopped due to Lack of adequate enrollment) | ||
| A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR)[NCT00237913] | Phase 3 | 700 participants | Interventional | 2004-07-31 | Completed | ||
| A Survey of Sexual Function in Schizophrenic Patients[NCT01835522] | 0 participants (Actual) | Observational | 2009-07-31 | Withdrawn | |||
| The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone[NCT00034749] | Phase 3 | 279 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| Seroquel on Glucose Metabolism[NCT00214578] | Phase 4 | 572 participants | Interventional | 2004-04-30 | Completed | ||
| A Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment With Aripiprazole in Schizophrenic Out-patients Who Are Experiencing Insufficient Efficacy With Risperidone and/or Safety and Tolerability Issues, Whil[NCT00232687] | Phase 4 | 450 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder[NCT01198353] | Phase 4 | 67 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism[NCT00287820] | Phase 4 | 46 participants (Anticipated) | Interventional | 2004-02-29 | Completed | ||
| Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670] | 10,347 participants (Actual) | Interventional | 2016-01-20 | Completed | |||
| Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia.[NCT00337662] | Phase 4 | 628 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine o[NCT00325689] | Phase 4 | 323 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Effectiveness of Long-Acting Risperidone in the Maintenance Treatment of First-Episode Schizophrenia[NCT00220714] | Phase 4 | 80 participants | Interventional | 2004-11-30 | Active, not recruiting | ||
| ExPRESS:2 (Experiences of Psychosis Relapse: Early Subjective Signs) Longitudinal Feasibility Study[NCT03558529] | 27 participants (Actual) | Observational | 2015-05-01 | Completed | |||
| A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents[NCT00088075] | Phase 3 | 160 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Characteristics of Prepulse Inhibition (PPI) of Startle Reflex in Patients With Schizophrenia in Relation to Type of Pharmacological Treatment and Duration of Illness[NCT02484521] | 31 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| A Blinded-initiation Study of Medication Satisfaction in Subjects With Schizophrenia Treated With Paliperidone ER After Suboptimal Response to Oral Risperidone[NCT00535132] | Phase 4 | 201 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study[NCT00856583] | Phase 3 | 9,809 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia[NCT00621998] | Phase 4 | 60 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| Clozapine Treatment of Schizophrenic Patients[NCT00056498] | Phase 4 | 65 participants (Actual) | Interventional | 2001-12-31 | Completed | ||
| Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia[NCT00159120] | Phase 4 | 71 participants (Anticipated) | Interventional | 2001-11-30 | Completed | ||
| Risperidone Long Acting: A Healthcare Resource Utilization Pilot Study[NCT00272597] | Phase 4 | 30 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial[NCT05663749] | Phase 4 | 60 participants (Actual) | Interventional | 2022-09-20 | Completed | ||
| A Randomized, Double-blind, Comparison of the Efficacy and Safety of Olanzapine Versus Low-dose Olanzapine Plus Low-dose Trifluoperazine in the Treatment of Schizophrenia[NCT02704962] | Phase 4 | 94 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response[NCT03495024] | Phase 4 | 10 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia[NCT00487942] | Phase 2 | 60 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Antipsychotic Medication Extended Dosing Study[NCT00431574] | 40 participants | Interventional | 2002-08-31 | Completed | |||
| Theta Burst Stimulation for Schizophrenia[NCT03288779] | 6 participants (Actual) | Interventional | 2017-10-24 | Completed | |||
| CSP #555 - Long-Acting Injectable Risperidone in the Treatment of Schizophrenia[NCT00132314] | Phase 3 | 382 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Pinpointing the Factors Affecting Clinical Study Experiences of Schizophrenia Patients[NCT05870722] | 500 participants (Anticipated) | Observational | 2024-06-30 | Not yet recruiting | |||
| Clinical Management of Metabolic Problems in Patients With Schizophrenia[NCT00423878] | Phase 4 | 215 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Metformin and Lorcaserin for Weight Loss in Schizophrenia[NCT02796144] | Phase 4 | 71 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.) | ||
| A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects W[NCT00210717] | Phase 3 | 748 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Effects of Risperidone and Olanzapine on Weight Gain, Physical Health, and Outcome in a Community Sample of Severity and Persistently Ill Patients[NCT00179062] | 300 participants (Actual) | Interventional | 2000-02-29 | Completed | |||
| Preventing Morbidity in First-Episode Schizophrenia[NCT00000374] | Phase 4 | 125 participants (Actual) | Interventional | 1998-09-30 | Completed | ||
| The SOURCE Study: Schizophrenia Outcomes-utilization, Relapse, and Clinical Evaluation: a Prospective 2-year Observational Study of Patients With Schizophrenia Who Initiate Treatment With Injectable Risperidone Long-acting Microspheres (RISPERDAL CONSTA)[NCT00246194] | 532 participants (Actual) | Observational | 2004-09-30 | Completed | |||
| Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR)[NCT00216632] | Phase 4 | 99 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Electronic Schizophrenia Treatment Adherence Registry, eSTAR[NCT00283517] | 2,046 participants (Actual) | Observational | 2003-09-30 | Completed | |||
| Effectiveness of Switching Antipsychotic Medications[NCT00044655] | Phase 4 | 219 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia[NCT00378092] | Phase 4 | 33 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| A Double-blind, Placebo-Controlled, Randomized Study of the Efficacy of Dextromethorphan as Add-On Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia[NCT01189006] | Phase 2/Phase 3 | 161 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Paliperidone ER Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia: a Randomized, Open-label, Controlled Trial[NCT00827840] | Phase 4 | 58 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo[NCT00088036] | Phase 3 | 450 participants | Interventional | 2004-02-29 | Completed | ||
| Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder[NCT00094549] | Phase 4 | 500 participants | Interventional | 2004-10-31 | Completed | ||
| The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features[NCT00035321] | Phase 3 | 600 participants | Interventional | 2002-04-30 | Completed | ||
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo[NCT00091650] | Phase 3 | 300 participants | Interventional | 2004-03-31 | Completed | ||
| A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone[NCT00567710] | Phase 2 | 360 participants (Anticipated) | Interventional | 2008-07-31 | Completed | ||
| Metabolic Effects of Newer Antipsychotics in Older Patients[NCT00245206] | Phase 4 | 406 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Daily Delivery and Supervision of Psychotropic Medication for High-Risk Patients With Severe and Persistent Mental Illness[NCT03766503] | 6 participants (Actual) | Interventional | 2016-10-15 | Completed | |||
| Real-world Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-risk for Psychosis: Study Protocol for a Prospective Observational Study (SHARP-2)[NCT04010864] | 600 participants (Anticipated) | Observational [Patient Registry] | 2019-03-29 | Recruiting | |||
| CLUES (Cognition for Learning and for Understanding Everyday Social Situations): An Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis[NCT02459210] | 58 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging[NCT02095938] | Phase 4 | 20 participants (Actual) | Interventional | 2014-01-31 | Enrolling by invitation | ||
| Effects of Classical and Atypical Antipsychotics on Dopamine Receptor Binding of 123I-epidepride, Cognition, Startle Response and Extrapyramidal Side-effects in Drug-naive First-episode Schizophrenic Patients[NCT00206960] | 56 participants (Actual) | Interventional | 1998-01-31 | Completed | |||
| A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication[NCT02624167] | Phase 2 | 90 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness[NCT00661869] | 295 participants (Actual) | Interventional | 2006-09-30 | Completed | |||
| Risperidone Depot (Microspheres) vs. Placebo in the Treatment of Subjects With Schizophrenia[NCT00253136] | Phase 3 | 458 participants (Actual) | Interventional | 1999-11-30 | Completed | ||
| A Randomized, Double-Blind, Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Combined With Low Dose of Haloperidol in the Treatment of Schizophrenic Disorder[NCT00998608] | Phase 4 | 88 participants (Actual) | Interventional | 2007-08-31 | Terminated (stopped due to terminated) | ||
| Pilot Study of Glycine Augmentation in Carriers of a Mutation in the Gene Encoding Glycine Decarboxylase[NCT01720316] | Phase 2 | 2 participants (Actual) | Interventional | 2012-12-10 | Completed | ||
| An Exploratory Study to Assess the Effects of Fanapt® on Social Cognitive Performance[NCT01929889] | Phase 4 | 19 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Low recruitment) | ||
| A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension[NCT01431313] | Phase 2 | 48 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia[NCT02796859] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| An Open-Label Trial of Tocilizumab in Schizophrenia[NCT01696929] | Phase 1 | 8 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine[NCT02304432] | Early Phase 1 | 2 participants (Actual) | Interventional | 2015-09-27 | Completed | ||
| Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.[NCT01503359] | Phase 2 | 70 participants (Anticipated) | Interventional | 2012-01-31 | Completed | ||
| Behavioral Therapy for Children and Adolescents With Tourette Syndrome: A Randomized Controlled Trial in Taiwan[NCT03621059] | 46 participants (Actual) | Interventional | 2015-01-01 | Completed | |||
| Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepine in Patients With First-Episode Schizophrenia After One Year Maintenance Treatment Under Further Maintenance Treatment vs. Stepwise Discontinued Drugs[NCT00159133] | Phase 4 | 71 participants (Anticipated) | Interventional | 2001-11-30 | Completed | ||
| One Year Maintenance Treatment With Low Dose Haloperidol vs. Risperidone in First-Episode Schizophrenia[NCT00159081] | Phase 4 | 159 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| Comparison of Oral Risperdal in Combination With Oral Lorazepam vs Standard Care Including Initial Conventional Neuroleptic IM Treatment, in Acute Schizophrenic Patients[NCT00249171] | Phase 4 | 226 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Open-Label Trial Exploring A Switching Regimen From Oral Neuroleptics, Other Than Risperidone, To Risperidone Depot Microspheres[NCT00034775] | Phase 3 | 141 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Atypical Antipsychotics and P50 Sensory Gating[NCT00149734] | Phase 3 | 8 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Risperidone Depot (Microspheres) vs. Risperidone Tablets - a Non-inferiority, Efficacy Trial in Subjects With Schizophrenia[NCT00249223] | Phase 3 | 641 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Clinical Trial Of Weight Reduction in Schizophrenia[NCT00158366] | 261 participants (Actual) | Interventional | 2004-05-31 | Completed | |||
| D-Serine Augmentation of Cognitive Retraining in Schizophrenia[NCT00237848] | Phase 3 | 72 participants (Anticipated) | Interventional | 2005-02-28 | Completed | ||
| D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia[NCT00237809] | Phase 3 | 104 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Relative Effectiveness of Schizophrenia Therapy (REST) Study[NCT01245348] | 1,110 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain[NCT05001399] | 60 participants (Actual) | Interventional | 2021-10-25 | Completed | |||
| Clinical Utility of Pharmacogenomics of Psychotropic Medications[NCT03907124] | Phase 4 | 0 participants (Actual) | Interventional | 2019-06-03 | Withdrawn (stopped due to PI left institution prior to recruitment.) | ||
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia[NCT01623713] | Phase 2 | 260 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| A Multicenter Ascending Dose, Double Blind, Placebo-controlled Study of NAP (AL-108) in Chronic Schizophrenia[NCT00505765] | Phase 2 | 63 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A 6-Week, Multicenter, Rater-blind, Randomized, Risperidone-controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia[NCT00817648] | Phase 4 | 120 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| NMDA Enhancers in the Treatment of Schizophrenia[NCT00328276] | Phase 2 | 20 participants | Interventional | 2004-12-31 | Completed | ||
| NMDA Enhancers in the Treatment of Schizophrenia: Sarcosine vs. D-Serine[NCT00491569] | Phase 2 | 60 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| International Study of Improving Treatment for the Most Severely Ill With Schizophrenia[NCT00272584] | Phase 4 | 100 participants | Interventional | 2001-06-30 | Completed | ||
| A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (Risperdal� CONSTA�) in Adults With [NCT00297388] | Phase 3 | 40 participants (Actual) | Interventional | Completed | |||
| A Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder[NCT00061802] | Phase 4 | 225 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Risperidone Augmentation in Patients With Schizophrenia Partially Responsive to Clozapine[NCT00289861] | Phase 4 | 24 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| E-SMART: Examining Strategy Monitoring and Remediation Training for Schizophrenia[NCT04756388] | 90 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | |||
| Effects of Adding Transcranial Direct Current Stimulation to Executive Function Training for Schizophrenia-spectrum Disorders - a Randomized Control Trial[NCT05389345] | 40 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | |||
| A Placebo-Controlled Trial of CX516 (Ampakine) Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia[NCT00235352] | Phase 2/Phase 3 | 105 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison[NCT00034892] | Phase 3 | 0 participants | Interventional | 2002-03-31 | Completed | ||
| The Cognitive Effects of Risperidone and Olanzapine[NCT00108368] | Phase 4 | 0 participants | Interventional | 2003-10-31 | Completed | ||
| Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility[NCT00308360] | Phase 4 | 46 participants | Interventional | 1999-09-30 | Completed | ||
| Effectiveness of Cognitive Adaptation Training Applied to Cognitive Impairment in Schizophrenia - A Randomised Trial[NCT01055509] | 65 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| A Study of Cognitive Adaptation Training in Inpatient Forensic Environments[NCT04294719] | 24 participants (Actual) | Observational | 2019-12-12 | Completed | |||
| The Family CAT (Cognitive Adaptation Training Manual): A Test of Effectiveness[NCT01768000] | 40 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| Metabolic Profile and Anthropometric Changes in Schizophrenia[NCT00534183] | 2,006 participants (Actual) | Interventional | 2006-06-30 | Completed | |||
| Examining the Effects of Estradiol on Neural and Molecular Response to Rewards in Perimenopausal-Onset Anhedonia and Psychosis[NCT05282277] | Phase 4 | 103 participants (Anticipated) | Interventional | 2022-04-20 | Recruiting | ||
| Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia[NCT00249132] | Phase 3 | 523 participants (Actual) | Interventional | Completed | |||
| Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva[NCT00395499] | 19 participants | Observational | 2001-05-31 | Completed | |||
| Optimizing Rehabilitation for Phantom Limb Pain Using Mirror Therapy and Transcranial Direct Current Stimulation (tDCS)[NCT02487966] | 132 participants (Actual) | Interventional | 2015-07-31 | Active, not recruiting | |||
| Open-label, Flexible-dose Adjunctive Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance[NCT03575000] | Phase 4 | 20 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Risperidone in the Treatment of Chronic Schizophrenic Patients: an International Multicentre Double-blind Parallel-group Comparative Study Versus Haloperidol.[NCT00249119] | Phase 3 | 1,579 participants (Actual) | Interventional | Completed | |||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| IBIS: Italian Burden of Illness on Schizophrenia & Bipolar Disorder[NCT01392482] | 751,725 participants (Actual) | Observational | 2011-07-31 | Completed | |||
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study[NCT01399450] | Phase 4 | 11 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders[NCT02983188] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2018-04-25 | Completed | ||
| Quetiapine in the Treatment of Psychotic Depression - a Pilot Study[NCT00751504] | Phase 3 | 16 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [NCT01615185] | Phase 4 | 96 participants (Actual) | Interventional | 2008-01-31 | Terminated | ||
| Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids[NCT00211562] | Phase 3 | 20 participants (Actual) | Interventional | 2005-10-31 | Terminated | ||
| Six Month, Double Blind, Placebo-controlled Trial of the Efficacy of Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women[NCT01573637] | Phase 3 | 78 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain[NCT01043250] | 81 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| Muscarinic M1 Receptor Availability and Cognition in Schizophrenia[NCT05105542] | Phase 2 | 18 participants (Anticipated) | Interventional | 2021-04-20 | Recruiting | ||
| Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum[NCT02524899] | Phase 2 | 45 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects[NCT01600885] | 16 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| An Open-Label Trial of Adjunctive Galantamine Maintenance Therapy to Treat Functional Impairments in Chronic Outpatients With Schizophrenia[NCT00232349] | Phase 4 | 21 participants (Actual) | Interventional | 2005-02-28 | Terminated (stopped due to Study terminated due to no apparent benefit.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Negative change from baseline scores indicate improvement in the severity of illness.~Estimates (least square means and standard errors), 2-sided confidence intervals, and -1-sided P values are based on a repeated-measures linear regression model of the change from baseline score, with fixed effects for visit as a categorical variable, baseline score, treatment and treatment by visit interaction, assuming an unstructured covariance matrix." (NCT02109562)
Timeframe: Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| RBP-7000 90 mg | -0.868 |
| RBP-7000 120 mg | -0.914 |
| Placebo | -0.518 |
"The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor judgement, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicate improvements in symptoms.~Estimates (least square means and standard errors), 2-sided confidence intervals, and -1-sided P values are based on a repeated-measures linear regression model of the change from baseline score, with fixed effects for visit as a categorical variable, baseline score, treatment and treatment by visit interaction, assuming an unstructured covariance matrix." (NCT02109562)
Timeframe: Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| RBP-7000 90 mg | -15.367 |
| RBP-7000 120 mg | -16.456 |
| Placebo | -9.219 |
"An adverse event (AE) is defined as any study-related event that represents a change (positive or negative) in frequency or severity from a baseline (prestudy) event (if any), regardless of the presence of causal relationship or medical significance. Treatment-emergent adverse events are defined as any adverse event with a start date on or after the first study dose date. AEs are determined by the Investigator to be related or not related to the study drug.~A serious AE (SAE) is defined by federal regulation as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Although a subject may have had 2 or more adverse experiences the subject is counted only once in a category. The same subject may appear in different categories." (NCT02109562)
Timeframe: Day 1 to Week 8
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| No TEAEs | 1 or more TEAEs | Related TEAE | Serious TEAE | Serious, related TEAE | TEAE causing discontinuation | Death | |
| Placebo | 37 | 81 | 50 | 1 | 0 | 3 | 0 |
| RBP-7000 120 mg | 26 | 91 | 65 | 1 | 0 | 2 | 0 |
| RBP-7000 90 mg | 34 | 81 | 58 | 0 | 0 | 0 | 0 |
"The Clinical Global Impression - Improvement (CGI-I) is a single 7-point rating score total improvement, regardless of whether or not the change it is due entirely to drug treatment. Raters select one response based on the following question, Compared to your patient's condition at the beginning of treatment, how much has your patient changed? Scores are: 1, Very much improved; 2, Much improved; 3, Minimally improved; 4, No change; 5, Minimally worse; 6, Much worse; or 7, Very much worse.~Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation." (NCT03870880)
Timeframe: Day 365 (or the last post-baseline assessment)
| Intervention | score on a scale (Mean) |
|---|---|
| Rollover Placebo/Risperidone ISM 75 mg | 2.3 |
| Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | 2.9 |
| De Novo/Risperidone ISM 75mg | 3.7 |
| Rollover Placebo/Risperidone ISM 100 mg | 2.4 |
| Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | 2.9 |
| De Novo/Risperidone ISM 100 mg | 3.1 |
"The Clinician Global Impression - Severity (CGI-S) score is a 7-point clinician-rated scale for assessing the global severity of the illness. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Negative change from baseline scores indicate improvement in the severity of illness whereas higher scores mean a worse outcome.~Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation." (NCT03870880)
Timeframe: Baseline and Day 365 (or the last post-baseline assessment)
| Intervention | units on a scale (Mean) |
|---|---|
| Rollover Placebo/Risperidone ISM 75 mg | -1.3 |
| Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | -0.5 |
| De Novo/Risperidone ISM 75mg | 0.0 |
| Rollover Placebo/Risperidone ISM 100 mg | -1.0 |
| Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | -0.3 |
| De Novo/Risperidone ISM 100 mg | -0.1 |
"Overall response was defined as either PANSS total score ≥ 30% decrease from baseline, or CGI-I score of 2 (much improved) or 1 (very much improved).~Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation." (NCT03870880)
Timeframe: Day 365 (or the last post-baseline assessment)
| Intervention | percentage of participants (Number) |
|---|---|
| Rollover Placebo/Risperidone ISM 75 mg | 74.1 |
| Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | 44.8 |
| De Novo/Risperidone ISM 75mg | 9.7 |
| Rollover Placebo/Risperidone ISM 100 mg | 64.3 |
| Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | 45.9 |
| De Novo/Risperidone ISM 100 mg | 20.0 |
"The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The general psychopathology scale consists of 16 items which measure somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. PANSS General Psychopathology Subscale Score ranges from 16 (absence of symptoms) to 112 (extremely severe symptoms).~Endpoint is defined as study day 356 or the last post-baseline assessment if early discontinuation." (NCT03870880)
Timeframe: Baseline and Day 365 (or the last post-baseline assessment)
| Intervention | units on a scale (Mean) |
|---|---|
| Rollover Placebo/Risperidone ISM 75 mg | -12.4 |
| Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | -5.4 |
| De Novo/Risperidone ISM 75mg | 0.2 |
| Rollover Placebo/Risperidone ISM 100 mg | -9.4 |
| Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | -3.9 |
| De Novo/Risperidone ISM 100 mg | -2.5 |
"The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).~Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation." (NCT03870880)
Timeframe: Baseline and Day 365 (or the last post-baseline assessment)
| Intervention | units on a scale (Mean) |
|---|---|
| Rollover Placebo/Risperidone ISM 75 mg | -4.6 |
| Risperidone ISM 75 mg/Risperidone ISM 75 mg | -2.2 |
| De Novo/Risperidone ISM 75 mg | -0.3 |
| Rollover Placebo/Risperidone ISM 100 mg | -2.9 |
| Risperidone ISM 100/Risperidone ISM 100 | -2.1 |
| De Novo/Risperidone ISM 100 mg | -0.7 |
"The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility.~PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).~Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation." (NCT03870880)
Timeframe: Baseline and Day 365 (or the last post-baseline assessment)
| Intervention | units on a scale (Mean) |
|---|---|
| Rollover Placebo/Risperidone ISM 75 mg | -6.0 |
| Rollover Risperidone 75 mg/Risperidone 75 mg | -3.3 |
| De Novo/Risperidone ISM 75 mg | -0.6 |
| Rollover Placebo/Risperidone ISM 100 mg | -6.5 |
| Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | -2.6 |
| De Novo/Risperidone ISM 100 mg | -1.6 |
"The Positive and Negative Syndrome Scale (PANSS) is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia.The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicates improvements in symptoms whereas higher scores mean a worse outcome.~Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation." (NCT03870880)
Timeframe: Baseline and Day 365 (or the last post-baseline assessment)
| Intervention | units on a scale (Mean) |
|---|---|
| Rollover Placebo/Risperidone ISM 75 mg | -22.9 |
| Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | -11.0 |
| De Novo/Risperidone ISM 75mg | -0.8 |
| Rollover Placebo/Risperidone ISM 100 mg | -18.9 |
| Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | -8.7 |
| De Novo/Risperidone ISM 100 mg | -4.8 |
Relapse was defined as either increase from baseline in PANSS total score ≥30% or rehospitalization for psychotic symptoms or use of adjunctive antipsychotic medication after stabilization. (NCT03870880)
Timeframe: Day 365 (or the last post-baseline assessment)
| Intervention | percentage of participants (Number) |
|---|---|
| Rollover Placebo/Risperidone ISM 75 mg | 11.1 |
| Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | 10.3 |
| De Novo/Risperidone ISM 75mg | 12.9 |
| Rollover Placebo/Risperidone ISM 100 mg | 0 |
| Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | 13.1 |
| De Novo/Risperidone ISM 100 mg | 20.0 |
"An Adverse event (AE) is any symptom, physical sign, syndrome, or disease that either emerges during the study (from the informed consent form signature) or, if present at screening, worsens during the study, regardless of the suspected cause of the event.~The treatment-emergent AEs (TEAEs) are defined as events that are newly occurring or worsening from the time of the first dose of the intramuscular study drug." (NCT03870880)
Timeframe: Up to Day 365 (or the last post-baseline assessment)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Patients with at least one TEAE | Patients with at least one treatment-related TEAE | Patients with at least one serious TEAE | Patients with at least one TEAE leading to treatment discontinuation | Patients with at least one TEAE leading to death | |
| Risperidone ISM 100 mg | 59 | 41 | 5 | 8 | 0 |
| Risperidone ISM 75 mg | 81 | 43 | 6 | 7 | 1 |
"An Adverse event (AE) is any symptom, physical sign, syndrome, or disease that either emerges during the study (from the informed consent form signature) or, if present at screening, worsens during the study, regardless of the suspected cause of the event.~The treatment-emergent AEs (TEAEs) are defined as events that are newly occurring or worsening from the time of the first dose of the intramuscular study drug.~The temporal relationship of the AE with the investigational medicinal product makes causality possible, and the AE cannot be due to another cause such as other drugs, a surgical intervention, or an underlying disease" (NCT03870880)
Timeframe: Up to Day 365 (or the last post-baseline assessment)
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Akathisia | Asthenia | Dizziness | Headache | Hyperprolactinemia | Insomnia | Weight increased | |
| Risperidone ISM 100 mg | 4 | 4 | 3 | 10 | 10 | 3 | 3 |
| Risperidone ISM 75 mg | 4 | 7 | 3 | 16 | 11 | 6 | 6 |
TEAEs which resulted in permanent study drug discontinuation (NCT03870880)
Timeframe: Up to Day 365 (or the last post-baseline assessment)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Akathisia | Diabetes mellitus | Extrapyramidal disorder | Gynaecomastia | Hepatic Steatosis | Hepatocellular injury | Libido decreased | Schizophrenia | Suicidal ideation | Weight increased | |
| Risperidone ISM 100 mg | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 5 | 0 | 0 |
| Risperidone ISM 75 mg | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 1 | 1 |
Based on the safety assessments (e.g. clinical safety laboratory tests, vital signs, weight, waist circumference and ECG) (NCT02892422)
Timeframe: From dosing to end of study (57 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Flexible-dose of Lu AF35700 | 289 |
CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate worsening. (NCT02717195)
Timeframe: From Randomization to Week 10
| Intervention | units on a scale (Mean) |
|---|---|
| Double-blind Treatment (DBT) Period, Lu AF35700 10 mg | -0.59 |
| DBT Period, Lu AF35700 20 mg | -0.54 |
| DBT Period, Continued Treatment From PC Period | -0.57 |
PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. (NCT02717195)
Timeframe: From Randomization to Week 10
| Intervention | units on a scale (Mean) |
|---|---|
| Double-blind Treatment (DBT) Period, Lu AF35700 10 mg | -10.01 |
| DBT Period, Lu AF35700 20 mg | -8.22 |
| DBT Period, Continued Treatment From PC Period | -9.90 |
PSP is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. It consists of 4 items: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behaviours. Each items were assessed on a 6-point scale, from 1 (absent) to 6 (very severe). PSP score was calculated as sum of all the items on the scale and ranged from 4 to 100. A higher score represents more severe functional impairment. (NCT02717195)
Timeframe: From Randomization to Week 10
| Intervention | units on a scale (Mean) |
|---|---|
| Double-blind Treatment (DBT) Period, Lu AF35700 10 mg | 4.90 |
| DBT Period, Lu AF35700 20 mg | 3.23 |
| DBT Period, Continued Treatment From PC Period | 3.94 |
"PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.~The Clinical Global Impression scale - severity of illness (CGI-S) is administered by the investigator. The patient is rated on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). A reduction in scale indicates improvement." (NCT02717195)
Timeframe: From Randomization to Week 10
| Intervention | Participants (Count of Participants) |
|---|---|
| Double-blind Treatment (DBT) Period, Lu AF35700 10 mg | 21 |
| DBT Period, Lu AF35700 20 mg | 18 |
| DBT Period, Continued Treatment From PC Period | 12 |
PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement. (NCT02717195)
Timeframe: From Randomization to Week 10
| Intervention | Participants (Count of Participants) |
|---|---|
| Double-blind Treatment (DBT) Period, Lu AF35700 10 mg | 82 |
| DBT Period, Lu AF35700 20 mg | 59 |
| DBT Period, Continued Treatment From PC Period | 77 |
Positive and Negative Syndrome Scale (PANSS) total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement. (NCT02717195)
Timeframe: From Randomization to Week 10
| Intervention | Participants (Count of Participants) |
|---|---|
| Double-blind Treatment (DBT) Period, Lu AF35700 10 mg | 42 |
| DBT Period, Lu AF35700 20 mg | 30 |
| DBT Period, Continued Treatment From PC Period | 45 |
PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement. (NCT02717195)
Timeframe: From Randomization to Week 10
| Intervention | Participants (Count of Participants) |
|---|---|
| Double-blind Treatment (DBT) Period, Lu AF35700 10 mg | 23 |
| DBT Period, Lu AF35700 20 mg | 15 |
| DBT Period, Continued Treatment From PC Period | 16 |
PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement. (NCT02717195)
Timeframe: From Randomization to Week 10
| Intervention | Participants (Count of Participants) |
|---|---|
| Double-blind Treatment (DBT) Period, Lu AF35700 10 mg | 10 |
| DBT Period, Lu AF35700 20 mg | 4 |
| DBT Period, Continued Treatment From PC Period | 6 |
(NCT00641745)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Lurasidone | 395 |
| Risperidone | 189 |
Barnes Akathisia Scale is a clinician rated scale which considers information based on observation of the participant as well as participant report. The scale includes 3 items rated between 0- none to 3 severe and 1 summary item rated between 0 none to 5 severe. All items are summed to obtain the total score. The minimal total score is 0 and the maximal score is 14 with higher scores reflecting more severe akathisia. A score of 4 or more is clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | 0.19 |
| Risperidone | 0.41 |
| Molindone | 1.23 |
Change from baseline in Body Mass Index Change, kg/m2, at week 8, last observation was carried forward for individuals who withdrew from treatment early. (NCT00053703)
Timeframe: 8 weeks
| Intervention | kg/m2 (Mean) |
|---|---|
| Olanzapine | 1.27 |
| Risperidone | 2.20 |
| Molindone | 0.15 |
The PANSS (described above) includes 7 items that reflect negative psychotic symptoms such as amotivation and social withdrawal. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -5.3 |
| Risperidone | -5.1 |
| Molindone | -5.8 |
The PANSS (described above) includes 7 items that reflect positive psychotic symptoms such as hallucinations and delusions. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -8.9 |
| Risperidone | -8.4 |
| Molindone | -8.8 |
Assessed with the Positive and Negative Syndrome Scale in which a clinician rates various psychotic symptoms on the basis of observation of the participant, interview with the participant, and review of all other available information including informant reports. The scale consists of 30 items which are rated categorically between 1 - no symptoms to 7 - extreme symptoms. The minimal score is 0 and the maximal score is 210, with higher scores reflecting more symptoms. Typically scores > that 60 are considered clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -26.6 |
| Risperidone | -23.7 |
| Molindone | -27.0 |
change in weight from baseline to week 8 in kg (NCT00053703)
Timeframe: 8 weeks
| Intervention | Kg (Mean) |
|---|---|
| Olanzapine | 6.12 |
| Risperidone | 3.64 |
| Molindone | 0.34 |
5-point scale (1 = best adherence, 5= nonadherent) based on pill counts, Medication Event Monitoring System (MEMS) cap readings, plasma assays, and psychiatrist judgements for oral risperidone and timing of injections for long-acting injectable risperidone. Averaged over medication study participation. (NCT00333177)
Timeframe: Averaged over study participation (up to 12 months)
| Intervention | units on a 5-point scale (Mean) |
|---|---|
| RLAI | 1.0 |
| Oral Ris | 1.9 |
Rating scale based on clinician's interview of patient to determine level of lack of awareness of having a mental disorder. Range is from 1 (Aware) to 5 (Unaware), so lower scores indicate better outcome. (NCT00333177)
Timeframe: 12 months after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| CT - RLAI | 1.25 |
| HBT - RLAI | 3.29 |
| CT - Oral Ris | 2.00 |
| HBT - Oral Ris | 3.75 |
The Work Motivation scale is a factor score from the Work Personality Profile. The Work Personality Profile is a set of ratings based on interviewing the participant. Scores at each occasion can range from 8 to 32, with higher indicating better motivation. Scores reported here are changes from baseline to 12 months, which could range from -24 to 24 with higher being better. (NCT00333177)
Timeframe: Baseline to 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| CT - RLAI | 3.7 |
| HBT - RLAI | 1.2 |
| CT - Oral Ris | -2.4 |
| HBT - Oral Ris | -1.9 |
Dichotomous measure: Presence of any of 3 psychotic relapse or exacerbation categories scored from the Brief Psychiatric Rating Scale (BPRS) occurring after randomization and until end of study participation (up to 12 months post baseline). BPRS was administered every two weeks throughout study participation. (NCT00333177)
Timeframe: Occurence after randomization and until end of study participation (up to 12 mos.)
| Intervention | participants (Number) |
|---|---|
| RLAI | 2 |
| Oral Ris | 10 |
Modified Work Section of the Social Adjustment Scale (SAS) was used to calculate the total number of weeks in school or competitive work. Range of possible values is 0 to 52, with higher numbers being better outcome. (NCT00333177)
Timeframe: 12 months
| Intervention | weeks (Mean) |
|---|---|
| CT - RLAI | 35.4 |
| HBT - RLAI | 24.4 |
| CT - Oral Ris | 26.7 |
| HBT - Oral Ris | 12.0 |
Values presented here are the changes in MCCB Overall Composite T scores from baseline to 12 months, with higher values representing better outcome. Raw test scores are used to generate T-scores and then the seven MCCB domains are combined to generate an Overall Composite T score. MCCB Overall Composite T scores have a mean in the general population of 50 with a standard deviation of 10. Thus, a positive change of 5 T scores is an improvement of half a standard deviation. (NCT00333177)
Timeframe: Measured at baseline and 12 months
| Intervention | T scores (Mean) |
|---|---|
| CT - RLAI | 6.7 |
| HBT - RLAI | 0.9 |
| CT - Oral Ris | 3.9 |
| HBT - Oral Ris | 5.9 |
Days after randomization that a participant continued to receive at least the assigned CT or HBT psychosocial treatment. If a participant needed to end the assigned medication condition (RLAI vs. Oral Ris), they continued in the psychosocial treatment so this outcome focused on the days in the assigned psychosocial treatment. Possible range is 1 to 365, with higher being a better outcome. (NCT00333177)
Timeframe: 12 months
| Intervention | days (Mean) |
|---|---|
| CT - RLAI | 359.7 |
| HBT - RLAI | 352.2 |
| CT - Oral Ris | 332.4 |
| HBT - Oral Ris | 348.3 |
Change in rating on quality of work/school performance based on patient, employer, and/or teacher reports. The Quality of Work rating at baseline was subtracted from the same rating at 12 mos. Higher scores are better outcome. (NCT00333177)
Timeframe: Baseline to 1 year
| Intervention | score on a rating scale (Mean) |
|---|---|
| CT - RLAI | -6.5 |
| HBT - RLAI | 8.8 |
| CT - Oral Ris | -3.4 |
| HBT - Oral Ris | 0.0 |
Change in role functioning from baseline to the 6 month point (rated on a scale from 1= Extreme Role Dysfunction to 10 = Superior Role Functioning) is presented here. (NCT00333177)
Timeframe: Baseline to 6 months
| Intervention | Changes on a 10-point scale (Mean) |
|---|---|
| CT - RLAI | 2.90 |
| HBT - RLAI | 0.92 |
| CT - Oral Ris | 1.27 |
| HBT - Oral Ris | -0.82 |
Changes in role functioning from baseline to 12 months. Ratings on a 10-point scale with 10 being best. (NCT00333177)
Timeframe: Baseline to 12 months
| Intervention | Changes on a 10-point scale (Mean) |
|---|---|
| CT - RLAI | 2.70 |
| HBT - RLAI | 1.69 |
| CT - Oral Ris | 2.43 |
| HBT - Oral Ris | 0.18 |
Symptomatic remission criterion was defined as having a simultaneous score of mild or less on all selected PANSS items (P1, P2, P3, N1, N4, N6, G5, and G9). Symptomatic remission was defined for the last 6 months of the Double-blind Phase as meeting the remission criterion during the 6 months prior to the End of study visit during the Double-blind Phase, with one excursion allowed. (NCT01515423)
Timeframe: Weeks 41 to 65
| Intervention | Percentage of Participants (Number) |
|---|---|
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 58.4 |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 59.2 |
Relapse defined as: Psychiatric hospitalization;participant had an increase of 25 percent in total PANSS score from randomization for 2 consecutive assessments separated by 3-7 days if score at randomization was greater than (>) 40; had a 10 point increase in total PANSS score from randomization for 2 consecutive assessments separated by 3-7 days if score at randomization was less than or equal to (<=) 40; deliberate self-injury or exhibited violent behavior resulting in suicide, clinically significant injury;suicidal or homicidal ideation and aggressive behavior;For PANSS items-had a score of greater than or equal to (>=) 5 after randomization for 2 consecutive assessments separated by 3-7 days on any of above items if maximum score for these above PANSS items was <=3 at randomization; had a score of >=6 after randomization for 2 consecutive assessments separated by 3-7 days on any of above items if maximum score for these above PANSS items was 4 at randomization. (NCT01515423)
Timeframe: Up to 48 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 91.5 |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 90.0 |
5 PANSS Marder factor scores (positive symptoms [range:8 to 56], negative symptoms [range: 7 to 49], disorganized thoughts [range: 7 to 49], uncontrolled hostility/excitement [range: 4 to 28], and anxiety/depression [range: 4 to 28]) were examined to gain insight into the symptoms affected by treatment with the study drug. Negative change from baseline in subscales score for positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression indicates improvement in various symptoms of schizophrenia. (NCT01515423)
Timeframe: DB Baseline (Week 17) and 48 week or DB Endpoint
| Intervention | Units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Positive symptoms factor: Baseline | Positive symptoms factor:Change at Endpoint | Negative symptoms factor: Baseline | Negative symptoms factor : Change at Endpoint | Disorganized thoughts factor :Baseline | Disorganized thoughts factor:Change at Endpoint | Uncontrolled hostility Factor:Baseline | Uncontrolled hostility Factor:Change at Endpoint | Anxiety/depression factor:Baseline | Anxiety/depression factor:Change at Endpoint | |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 15.8 | -1.4 | 16.3 | -1.3 | 14.3 | -1.2 | 5.4 | -0.2 | 6.3 | -0.2 |
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 15.7 | -1.1 | 16.2 | -1.4 | 14.2 | -1.2 | 5.2 | 0.2 | 6.1 | -0.0 |
The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology). (NCT01515423)
Timeframe: DB Baseline (Week 17) and 48 week or DB Endpoint
| Intervention | Units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Positive subscale: Baseline | Positive subscale:Change at Endpoint | Negative subscale: Baseline | Negative subscale:Change at Endpoint | General psychopathology : Baseline | General psychopathology : Change at Endpoint | |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 12.0 | -0.9 | 17.3 | -1.4 | 28.8 | -2.0 |
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 11.9 | -0.6 | 17.3 | -1.4 | 28.2 | -1.4 |
"The Clinical Global Impression Severity (CGI-S) rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Higher scores indicate worsening." (NCT01515423)
Timeframe: DB Baseline (Week 17) and 48 week or DB Endpoint
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at DB End point | |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 2.9 | -0.1 |
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 2.9 | -0.1 |
The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100. Participants with a score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision. (NCT01515423)
Timeframe: DB Baseline (Week 17) and 48 week or DB Endpoint
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at DB End point | |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 65.0 | 1.9 |
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 65.5 | 1.3 |
The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology). (NCT01515423)
Timeframe: DB Baseline (Week 17) and 48 week or DB Endpoint
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at DB End point | |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 58.1 | -4.3 |
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 57.4 | -3.5 |
The primary outcome measure will be the total Brief Psychiatric Rating Scale Score. The range of the BPRS is 0 to 126 with higher scores indicated more psychological symptoms. (NCT01786239)
Timeframe: 16 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline BPRS Score | Week 16 BPRS Score | |
| Omega-3 Capsules & Risperidone | 41.64 | 22.5868 |
| Placebo & Risperidone | 42.38 | 27.2235 |
The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (MIT). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Participant adherence was measured as the detected MITs over the expected MITs ingested during the trial days with good patch coverage. The more the participant successfully engaged in a number of processes across the 8-week trial, the greater the measured adherence. Descriptive statistics were performed for this outcome measure. (NCT03568500)
Timeframe: Up to 8 weeks
| Intervention | percentage of MITs (Mean) |
|---|---|
| Schizophrenia | 88.94 |
| Schizoaffective Disorder | 72.29 |
| First Episode Psychosis | 91.04 |
| Total | 86.57 |
The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (miniature ingestible event marker in tablet [MIT]). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Good patch coverage for a specific day was defined as having either at least 80% patch data available (80% of the day the patch was worn and data was collected as noted via the accelerometer channel) or the MIT was detected within the 24-hour period, for each day while the participant was in the trial. The percentage of days was calculated as the number of days with good patch coverage divided by the total number of trial days for each participant. Descriptive statistics were performed for this outcome measure. (NCT03568500)
Timeframe: Up to 8 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| Schizophrenia | 64.34 |
| Schizoaffective Disorder | 62.99 |
| First Episode Psychosis | 62.51 |
| Total | 63.37 |
The PANSS scale is used to assess the neuropsychiatric symptoms of schizophrenia. The 30-item PANSS scale provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items),and the general psychopathology subscale (16 items), each item rated on a scale of 1 (absent) to 7 (extreme). (NCT00589914)
Timeframe: Baseline to the last postrandomization assessment in the double-blind treatment period (approximately 13 weeks)
| Intervention | Scores on a scale (Mean) |
|---|---|
| R092670 | -18.6 |
| RISPERDAL CONSTA | -17.9 |
The CGI-S rating scale is used to rate the severity of a patient's psychotic condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe). This scale permits a global evaluation of the patient's condition at a given time. A qualified rater administered the CGI-S. (NCT00589914)
Timeframe: Baseline to the last postrandomization assessment in the double-blind treatment period (approximately 13 weeks)]
| Intervention | Scores on a scale (Mean) |
|---|---|
| R092670 | -0.9 |
| RISPERDAL CONSTA | -0.9 |
The PSP scale is used to assess the degree of dysfunction a patient exhibits over a 7-day period within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The results of the assessment are converted to a numeric score. A score between 71 and 100 indicates a mild degree of difficulty; a score between 31 and 70 indicates a moderate degree of dysfunction, and a patient with a score of 30 or less has functioning so poor he or she requires intensive supervision. (NCT00589914)
Timeframe: Baseline to the last postrandomization assessment in the double-blind treatment period (approximately 13 weeks)
| Intervention | Scores on a scale (Mean) |
|---|---|
| R092670 | 8.5 |
| RISPERDAL CONSTA | 8.8 |
The SWN-K is comprised of 20 questions, each of which is rated using a 6-point scale ranging from 1 (not at all) to 6 (very much). Possible scores range from 20 to 120, with higher scores implying higher subjective well-being. (NCT00600756)
Timeframe: Baseline and Month 12
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Quetiapine XR | 22.7 |
| Risperidone | 19.4 |
The SWN-K is comprised of 20 questions, each of which is rated using a 6-point scale ranging from 1 (not at all) to 6 (very much). Possible scores range from 20 to 120, with higher scores implying higher subjective well-being. (NCT00600756)
Timeframe: Baseline and Month 12
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Quetiapine XR | 23.2 |
| Risperidone | 21.1 |
The SWN-K total score is the sum of 5 subscores (4 questions each): physical functioning, social integration, mental functioning, self-control, and emotional regulation. The subscores are rated using a 6-point scale (the higher the grade, the better the response). Possible subscores range from 4 to 24. (NCT00600756)
Timeframe: Baseline and 12 months
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Quetiapine XR | 4.5 |
| Risperidone | 3.9 |
The SWN-K total score is the sum of 5 subscores (4 questions each): physical functioning, social integration, mental functioning, self-control, and emotional regulation. The subscores are rated using a 6-point scale (the higher the grade, the better the response). Possible subscores range from 4 to 24. (NCT00600756)
Timeframe: Baseline and 12 months
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Quetiapine XR | 4.9 |
| Risperidone | 3.9 |
The SWN-K total score is the sum of 5 subscores (4 questions each): physical functioning, social integration, mental functioning, self-control, and emotional regulation. The subscores are rated using a 6-point scale (the higher the grade, the better the response). Possible subscores range from 4 to 24. (NCT00600756)
Timeframe: Baseline and 12 months
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Quetiapine XR | 4.9 |
| Risperidone | 4.0 |
The SWN-K total score is the sum of 5 subscores (4 questions each): physical functioning, social integration, mental functioning, self-control, and emotional regulation. The subscores are rated using a 6-point scale (the higher the grade, the better the response). Possible subscores range from 4 to 24. (NCT00600756)
Timeframe: Baseline and 12 months
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Quetiapine XR | 4.1 |
| Risperidone | 3.8 |
The SWN-K total score is the sum of 5 subscores (4 questions each): physical functioning, social integration, mental functioning, self-control, and emotional regulation. The subscores are rated using a 6-point scale (the higher the grade, the better the response). Possible subscores range from 4 to 24. (NCT00600756)
Timeframe: Baseline and 12 months
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Quetiapine XR | 4.6 |
| Risperidone | 4.0 |
The Euro Quality of Life - 5 dimension index (EQ-5D) is the result of the application of a formula that essentially attaches values (also called weights) to each of the levels (no, some, or heavy problems) in each dimension (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). These weights are issued from a representative sample of the general population. The total possible maximum value was 1 (healthy life) and the minimum value was 0 (death). (NCT00600756)
Timeframe: 12 months
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Quetiapine XR | 0.193 |
| Risperidone | 0.168 |
"The number of participants who were taking at least 1 antidepressant at Month 12. Antidepressants are all concomitant medications classified in the Anatomical Therapeutic Chemical(ATC)Subgroup N06-Antidepressants." (NCT00600756)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 72 |
| Risperidone | 63 |
Unscheduled visits due to worsening of schizophrenia, dose change or adverse event including the hospitalizations due to psychiatric disorders during the study (i.e. from Visit 1 to Termination date + 30 days) in inpatients units, in emergency wards and in day clinics. (NCT00600756)
Timeframe: Month 12
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 94 |
| Risperidone | 70 |
The SWN-K is comprised of 20 questions, rated on a 6-point scale from 1 (not at all) to 6 (very much). Scores range from 20 to 120, with higher scores implying higher subjective well-being. A responder is defined as a subject with an increase of 10 points or 20% from baseline in SWN-K total score (non-inferiority limit of -9.7% in responder rate) (NCT00600756)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 136 |
| Risperidone | 158 |
(NCT00600756)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 270 |
| Risperidone | 249 |
For the CGI-SCH (Clinical Global Impression-Schizophrenia severity of illness scale) overall severity of illness, the score ranged from 1 (normal, not ill) to 7 (among the most severely ill). Change from baseline in CGI-SCH score was divided into 3 classes: worsening (change score>0), stable (change score=0) and improved (change score<0). (NCT00600756)
Timeframe: 12 months
| Intervention | Scores on a scale (Mean) |
|---|---|
| Quetiapine XR | 3.8 |
| Risperidone | 3.9 |
For the CGI-SCH overall severity of illness, the score ranged from 1 (normal, not ill) to 7 (among the most severely ill). CGI-SCH score was divided into 3 classes: worsening (change score>0), stable (change score=0) and improved (change score<0). Change from baseline in CGI-SCH overall severity of illness in number of participants with CGI-SCH overall severity score improvement. (NCT00600756)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 176 |
| Risperidone | 178 |
The CDSS total score is the sum of 9 questions and ranges from 0 to 27. The higher the score, the more severe are the symptoms. (NCT00600756)
Timeframe: 12 months
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Quetiapine XR | -4.7 |
| Risperidone | -3.7 |
Relapse is defined as at least one increase of greater than or equal to 2 points on the CGI-SCH overall severity score during the treatment period or at least one hospitalization due to psychiatric disorders during the treatment period. (NCT00600756)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 43 |
| Risperidone | 31 |
"Workers and students are defined from the modified vocational status index excluding subjects Retired or Unemployed, whether or not expected to work." (NCT00600756)
Timeframe: 12 months
| Intervention | Days (Mean) |
|---|---|
| Quetiapine XR | 10 |
| Risperidone | 6.7 |
Other psychotropic medications include antiepileptics, anti-parkinson drugs, antipsychotics, and antidepressants. (NCT00600756)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 138 |
| Risperidone | 141 |
All hospitalizations due to psychiatric disorders during the study (i.e. from Visit 1 to Termination date + 30 days) in inpatients units, in emergency wards, and in day clinics. (NCT00600756)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 37 |
| Risperidone | 21 |
(NCT00600756)
Timeframe: 12 months
| Intervention | Days (Mean) |
|---|---|
| Quetiapine XR | 144.3 |
| Risperidone | 152.8 |
Remission was defined as a SWN-K total score greater than or equal to 80. The reported population is participants who showed remission over, time from baseline to Month 12 (NCT00600756)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 139 |
| Risperidone | 128 |
The normal range for men is 0 to 14, and for women is 0 to 24. (NCT00600756)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Quetiapine XR | -7.735 |
| Risperidone | 15.990 |
Extra-pyramidal events include tremor, hypokinesia, muscle rigidity, hyperkinesia, and extrapyramidal disorder. (NCT00600756)
Timeframe: 12 months
| Intervention | Events (Number) |
|---|---|
| Quetiapine XR | 51 |
| Risperidone | 112 |
Symptoms are graded according to degree (not present to severe) and causal relationship (improbable, possible, probable). Hyperprolactinaemia in women is defined as number of women who show the individual adverse event (AE) hyperprolactinaemia. An individual AE Hyperprolactinaemia is defined as an AE with a worse degree of hyperprolactinaemia compared with baseline and with a possible or probable relationship to study drug. (NCT00600756)
Timeframe: Month 12
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 0 |
| Risperidone | 10 |
Symptoms are graded according to degree (not present to severe) and causal relationship (improbable, possible, probable). Sexual dysfunction in men is defined as number of men who show the individual adverse event (AE) sexual dysfunction. An individual AE sexual dysfunction is defined as an AE with a worse degree of sexual dysfunction compared with baseline and with a possible or probable relationship to study drug. (NCT00600756)
Timeframe: Month 12
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 9 |
| Risperidone | 13 |
Treatment-emergent adverse events are defined as adverse events that occurred after the first intake of the study medication (or on the same day). (NCT00600756)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 57 |
| Risperidone | 48 |
Treatment-emergent adverse events are defined as adverse events that occurred after the first intake of the study medication (or on the same day). (NCT00600756)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 22 |
| Risperidone | 17 |
Treatment-emergent adverse events are defined as adverse events that occurred after the first intake of the study medication (or on the same day). (NCT00600756)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 38 |
| Risperidone | 83 |
Treatment-emergent adverse events are defined as adverse events that occurred after the first intake of the study medication (or on the same day). (NCT00600756)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 238 |
| Risperidone | 258 |
Symptoms are graded according to degree (not present to severe) and causal relationship (improbable, possible, probable). An individual AE is defined as an AE with a worse degree compared with Baseline and with a possible or probable relationship to study drug. (NCT00600756)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Quetiapine XR | 4 |
| Risperidone | 20 |
Stable State was defined as having the same status in occupational and residential status as at Baseline. (NCT00600756)
Timeframe: 12 months
| Intervention | Participants with stable state (Number) |
|---|---|
| Quetiapine XR | 160 |
| Risperidone | 171 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. (NCT01010776)
Timeframe: Baseline and Week 26
| Intervention | Units on a scale (Mean) |
|---|---|
| Paliperidone Extended Release (ER) - Main Phase | -22.9 |
Participants with response in PANSS total score was defined as participants with greater than or equal to 20 percent reduction in PANSS total score from Baseline. The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. (NCT01010776)
Timeframe: Week 26
| Intervention | Percentage of participants (Number) |
|---|---|
| Paliperidone ER-Main Phase | 60.1 |
Participants with response in PANSS total score was defined as participants with greater than or equal to 20 percent reduction in PANSS total score from Baseline. The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. (NCT01010776)
Timeframe: Week 52
| Intervention | Percentage of participants (Number) |
|---|---|
| Paliperidone ER-Main Phase Plus Extension Phase | 71.1 |
The SF-36 is designed to assess the health status of participants. The SF-36 includes 1 multi-item scale measuring physical health component and mental health component. Physical health component includes physical functioning, role limitations due to physical health, pain and general health. Mental health component includes role limitations due to emotional problems, energy/fatigue, emotional well being and social functioning. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state. The score for a component (physical or mental) is an average of the individual item scores. Each component is scored on a scale of 1 to 100, where 100=highest level of functioning. (NCT01010776)
Timeframe: Baseline and Week 26
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline: Physical component summary | Baseline: Mental component summary | Week 26: Physical component summary | Week 26: Mental component summary | |
| Paliperidone ER- Main Phase | 47.9 | 35.9 | 48.4 | 38.3 |
The SF-36 is designed to assess the health status of participants. The SF-36 includes 1 multi-item scale measuring physical health component and mental health component. Physical health component includes physical functioning, role limitations due to physical health, pain and general health. Mental health component includes role limitations due to emotional problems, energy/fatigue, emotional well being and social functioning. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state. The score for a component (physical or mental) is an average of the individual item scores. Each component is scored on a scale of 1 to 100, where 100=highest level of functioning. (NCT01010776)
Timeframe: Baseline and Week 52
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline: Physical component summary | Baseline: Mental component summary | Week 52: Physical component summary | Week 52: Mental component summary | |
| Paliperidone ER-Main Phase Plus Extension Phase | 48.7 | 35.7 | 48.8 | 38.5 |
An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. (NCT01010776)
Timeframe: Baseline, Week 4, 8, 13, 26, 39 and 52
| Intervention | Units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (n=159) | Change at Week 4 (n=159) | Change at Week 8 (n=159) | Change at Week 13 (n=159) | Change at Week 26 (n=158) | Change at Week 39 (n=151) | Change at Week 52 (n=154) | |
| Paliperidone ER-Main Plus Extension Phase | 1.41 | -0.51 | -0.49 | -0.68 | -0.77 | -0.81 | -0.75 |
An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. (NCT01010776)
Timeframe: Baseline, Week 4, 8, 13 and 26
| Intervention | Units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (n=215) | Change at Week 4 (n=201) | Change at Week 8 (n=189) | Change at Week 13 (n=182) | Change at Week 26 (n=201) | |
| Paliperidone ER - Main Phase | 1.30 | -0.40 | -0.45 | -0.63 | -0.6 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. (NCT01010776)
Timeframe: Baseline and Week 52
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 52 | |
| Paliperidone (ER) - Main Phase Plus Extension Phase | 93.25 | -26.4 |
The PSP scale evaluates the dysfunction degree exhibited by the participants, regarding 4 behavioral domains: useful social activities, personal and social relations, self-care and agitated and aggressive behavior. Each domain were assessed on a 6-point scale (0=absent to 5=very severe). A transformed score from 1 to 100 is generated from the raw score based on the clinical interpretation of the scores generated in the 4 areas of functioning, with a higher transformed score indicating better function. (NCT01010776)
Timeframe: Baseline, Week 4, 8, 13 and 26
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Change at Week 4 (n=201) | Change at Week 8 (n=191) | Change at Week 13 (n=182) | Change at Week 26 (n=204) | |
| Paliperidone ER-Main Phase | 5.7 | 8.3 | 9.9 | 10.4 |
The PSQI evaluates sleep behavior by means of 7 components: sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disorders, use of sleep medication and daytime dysfunction. The sum of the 7 component scores produces a global score of subjective sleep quality that varies from 0 to 21, with higher scores indicating worse sleep quality. (NCT01010776)
Timeframe: Baseline, Week 4, 8, 13 and 26
| Intervention | Units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (n=198) | Change at Week 4 (n=174) | Change at Week 8 (n=162) | Change at Week 13 (n=156) | Change at Week 26 (n=174) | |
| Paliperidone ER-Main Phase | 6.7 | -1.0 | -1.2 | -1.5 | -1.4 |
The PANSS positive subscale assesses 7 positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology). The PANSS negative subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology). (NCT01010776)
Timeframe: Baseline, Week 4, 8, 13 and 26
| Intervention | Units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Change at Week 4: PANSS positive subscale (n=201) | Change at Week 4: PANSS negative subscale (n=201) | Change at Week 8: PANSS positive subscale (n=191) | Change at Week 8: PANSS negative subscale (n=191) | Change at Week 13: PANSS positive subscale (n=182) | Change at Week 13: PANSS negative subscale (n=182) | Change at Week 26: PANSS positive subscale (n=203) | Change at Week 26: PANSS negative subscale (n=203) | |
| Paliperidone ER-Main Phase | -3.6 | -3.6 | -5.0 | -5.0 | -5.9 | -5.9 | -5.9 | -5.9 |
The PANSS Positive Subscale assesses 7 positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology). The PANSS Negative Subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology). (NCT01010776)
Timeframe: Baseline, Week 4, 8, 13, 26, 39 and 52
| Intervention | Units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: PANSS positive subscale (n=159) | Baseline: PANSS negative subscale (n=159) | Change at Week 4: PANSS positive subscale (n=159) | Change at Week 4: PANSS negative subscale (n=159) | Change at Week 8: PANSS positive subscale (n=159) | Change at Week 8: PANSS negative subscale (n=159) | Change at Week 13: PANSS positive subscale (n=159) | Change at Week 13: PANSS negative subscale (n=159) | Change at Week 26: PANSS positive subscale (n=159) | Change at Week 26: PANSS negative subscale (n=159) | Change at Week 39: PANSS positive subcale (n=152) | Change at Week 39: PANSS negative subscale (n=152) | Change at Week 52: PANSS positive subscale (n=154) | Change at Week 52: PANSS negative subscale (n=154) | |
| Paliperidone ER-Main Phase Plus Extension Phase | 26.65 | 19.25 | -3.4 | -3.4 | -5.4 | -5.4 | -5.9 | -5.9 | -6.8 | -6.8 | -7.3 | -7.3 | -7.5 | -7.5 |
The PSP scale evaluates the dysfunction degree exhibited by the participants, regarding 4 behavioral domains: useful social activities, personal and social relations, self-care and agitated and aggressive behavior. Each domain were assessed on a 6-point scale (0=absent to 5=very severe). A transformed score from 1 to 100 is generated from the raw score based on the clinical interpretation of the scores generated in the 4 areas of functioning, with a higher transformed score indicating better function. (NCT01010776)
Timeframe: Baseline, Week 4, 8, 13, 26, 39 and 52
| Intervention | Units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (n=159) | Change at Week 4 (n=159) | Change at Week 8 (n=159) | Change at Week 13 (n=159) | Change at Week 26 (n=159) | Change at Week 39 (n=151) | Change at Week 52 (n=155) | |
| Paliperidone ER-Main Phase Plus Extension Phase | 45.17 | 5.3 | 9.0 | 9.7 | 12.0 | 12.6 | 14.6 |
The PSQI evaluates sleep behavior by means of 7 components: sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disorders, use of sleep medication and daytime dysfunction. The sum of the 7 component scores produces a global score of subjective sleep quality that varies from 0 to 21, with higher scores indicating worse sleep quality. (NCT01010776)
Timeframe: Baseline, Week 4, 8, 13, 26, 39 and 52
| Intervention | Units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (n=148) | Change at Week 4 (n=140) | Change at Week 8 (n=136) | Change at Week 13 (137) | Change at Week 26 (n=135) | Change at Week 39 (n=133) | Change at Week 52 (n=133) | |
| Paliperidone ER-Main Phase Plus Extension Phase | 6.4 | -1.0 | -1.3 | -1.5 | -1.4 | -1.9 | -1.9 |
"The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.The categories included in the scale are normal, without any disease, borderline, slightly ill, moderately ill, markedly ill, severely ill and extremely ill. A rating of 1=Normal, not at all ill and a rating of 7 =Among the most extremely ill participants. Higher scores indicate worsening." (NCT01010776)
Timeframe: Week 39 and 52
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 39: Normal without any disease (n=152) | Week 39: Borderline (n=152) | Week 39: Slightly ill (n=152) | Week 39: Moderately ill (n=152) | Week 39: Markedely ill (n=152) | Week 39: Severely ill (n=152) | Week 52: Borderline (n=155) | Week 52: Slightly ill (n=155) | Week 52: Moderately ill (n=155) | Week 52: Markedely ill (n=155) | Week 52: Severely ill (n=155) | |
| Paliperidone ER - Extension Phase | 2 | 22 | 41 | 55 | 22 | 10 | 23 | 37 | 58 | 24 | 10 |
"The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.The categories included in the scale are normal, without any disease, borderline, slightly ill, moderately ill, markedly ill, severely ill and extremely ill. A rating of 1=Normal, not at all ill and a rating of 7 =Among the most extremely ill participants. Higher scores indicate worsening." (NCT01010776)
Timeframe: Baseline, Week 4, 8, 13 and 26
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Borderline (n=213) | Baseline: Slightly ill (n=213) | Baseline: Moderately ill (n=213) | Baseline: Markedly ill (n=213) | Baseline: Severely ill (n=213) | Baseline: Extremely ill (n=213) | Week 4: Borderline (n=201) | Week 4: Slightly ill (n=201) | Week 4: Moderately ill (n=201) | Week 4: Markedly ill (n=201) | Week 4: Severely ill (n=201) | Week 8: Borderline (n=191) | Week 8: Slightly ill (n=191) | Week 8: Moderately ill (n=191) | Week 8: Markedly ill (n=191) | Week 8: Severely ill (n=191) | Week 8: extremely ill (n=191) | Week 13: Normal, without any disease (n=182) | Week 13: Borderline (n=182) | Week 13: Slightly ill (n=182) | Week 13: Moderately ill (n=182) | Week 13: Markedly ill (n=182) | Week 13: Severly ill (n=182) | Week 26: Normal without any disease (n=204) | Week 26: Borderline (n=204) | Week 26: Slightly ill (n=204) | Week 26: Moderately ill (n=204) | Week 26: Markedely ill (n=204) | Week 26: Severely ill (n=204) | |
| Paliperidone ER-Main Phase | 2 | 4 | 52 | 114 | 40 | 1 | 4 | 25 | 87 | 61 | 24 | 5 | 35 | 80 | 56 | 15 | 0 | 2 | 7 | 41 | 73 | 47 | 12 | 3 | 16 | 48 | 70 | 48 | 19 |
Participant's response regarding satisfaction with the treatment were recorded. A 5-point evaluation scale was used to evaluate participant satisfaction: very good, good, moderate, bad and very bad. (NCT01010776)
Timeframe: Baseline, Week 4, 8, 13 and 26
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Very good (n=213) | Baseline: Good (n=213) | Baseline: Moderate (n=213) | Baseline: Bad (n=213) | Baseline: Very bad (n=213) | Week 4: Very good (n=200) | Week 4: Good (n=200) | Week 4: Moderate (n=200) | Week 4: Bad (n=200) | Week 4: Very bad (n=200) | Week 8: Very good (n=190) | Week 8: Good (n=190) | Week 8: Moderate (n=190) | Week 8: Bad (n=190) | Week 13: Very good (n=182) | Week 13: Good (n=182) | Week 13: Moderate (n=182) | Week 13: Bad (n=182) | Week 13: Very bad (n=182) | Week 26: Very good (n=204) | Week 26: Good (n=204) | Week 26: Moderate (n=204) | Week 26: Bad (n=204) | Week 26: Very bad (n=204) | |
| Paliperidone ER - Main Phase | 11.7 | 38.5 | 34.3 | 12.7 | 2.8 | 29.5 | 52.5 | 16.5 | 1.0 | 0.5 | 33.7 | 48.9 | 13.7 | 3.7 | 37.4 | 46.2 | 12.1 | 3.8 | 0.5 | 36.3 | 46.1 | 10.8 | 4.4 | 2.5 |
Participant's response regarding satisfaction with the treatment were recorded. A 5-point evaluation scale was used to evaluate participant satisfaction: very good, good, moderate, bad and very bad. (NCT01010776)
Timeframe: Baseline, Week 4, 8, 13, 26, 39 and 52
| Intervention | Percentage of participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Very good (n=159) | Baseline: Good (n=159) | Baseline: Moderate (n=159) | Baseline: Bad (n=159) | Baseline: Very bad (n=159) | Week 4: Very good (n=159) | Week 4: Good (n=159) | Week 4: Moderate (n=159) | Week 4: Very bad (n=159) | Week 8: Very good (n=159) | Week 8: Moderate (n=159) | Week 8: Bad (n=159) | Week 13: Very good (n=159) | Week 13: Good (n=159) | Week 13: Moderate (n=159) | Week 13: Bad (n=159) | Week 13: Very bad (n=159) | Week 26: Very good (n=159) | Week 26: Good (n=159) | Week 26: Moderate (n=159) | Week 26: Very bad (n=159) | Week 39: Very good (n=152) | Week 39: Good (n=152) | Week 39: Moderate (n=152) | Week 39: Bad (n=152) | Week 39: Very bad (n=152) | Week 52: Very good (n=155) | Week 52: Good (n=155) | Week 52: Moderate (n=155) | Week 52: Bad (n=155) | |
| Paliperidone ER-Main Phase Plus Extension Phase | 13.2 | 40.9 | 32.1 | 11.3 | 2.5 | 31.4 | 54.1 | 13.8 | 0.6 | 37.1 | 11.3 | 3.1 | 39.0 | 46.5 | 10.1 | 3.8 | 0.6 | 41.5 | 50.9 | 6.9 | 0.6 | 38.8 | 51.3 | 7.2 | 2.0 | 0.7 | 41.3 | 43.2 | 12.9 | 2.6 |
"Relapse is defined as any occurrence of:~Insufficient clinical response~Exacerbation of underlying disease~Discontinuation due to an adverse event" (NCT01143077)
Timeframe: 6 Weeks
| Intervention | days (Mean) |
|---|---|
| Lurasidone Open-Label Arm 40/40 | 23.8 |
| Lurasidone Open-Label Arm 40/80 | 16.9 |
| Lurasidone Open-Label Arm 80/80 | 17.3 |
Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events (NCT01143077)
Timeframe: 6 Weeks
| Intervention | participants (Number) |
|---|---|
| Lurasidone Open-Label Arm 40/40 | 72 |
| Lurasidone Open-Label Arm 40/80 | 87 |
| Lurasidone Open-Label Arm 80/80 | 81 |
"The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates normal, not at all ill, while a score of 7 indicates among the most extremely ill of patients. The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits" (NCT00640562)
Timeframe: 12 weeks from baseline to last visit
| Intervention | Score on scale (Least Squares Mean) |
|---|---|
| Seroquel XR | -1.50 |
| Risperidone | -1.04 |
Patient weight and height have been be collected in order to assess the Body Mass Index (BMI). The mean BMI values reported are assessed after 12 weeks of treatment. (NCT00640562)
Timeframe: 12 week
| Intervention | Kg/m^2 (Mean) |
|---|---|
| Seroquel XR | 29.07 |
| Risperidone | 28.80 |
"The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates normal, not at all ill, while a score of 7 indicates among the most extremely ill of patients. The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits" (NCT00640562)
Timeframe: 12week: descriptive statistic of CGI by visit and treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Seroquel XR | 91 |
| Risperidone | 88 |
"Extrapyramidal Side Effects (EPS) will be assessed using the Simpson-Angus Scale (SAS; Simpson GN et al 1970) . The CRF is source data for these assessments and day 0 is considered as baseline.~The SAS scale, containing 10 items, will be rated on a five-point scale where 0 is normal and 4 are severe symptoms. Min score =0, max score 40~Change from start of treatment (day 0) will be calculated as the visit score minus the score at start of treatment for each of the neurological assessments." (NCT00640562)
Timeframe: 12 weeks from baseline to last visit
| Intervention | score on scale (Mean) |
|---|---|
| Seroquel XR | 2.74 |
| Risperidone | 3.88 |
"The CDSS scale is used to assess the level of depression in schizophrenia and to estimate the severity of depressive symptoms.~CDSS has 9 items rated on four-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. Anchor point descriptions are provided to aid differentiation between each item score. The first eight items are rated on basis of patients' responses to questions; the 9 item is based on clinician's assessment.~The sum score is derived by adding the point score of all items (from 0 to 27 points); total score 4-5 is considered for minor depression and 6-7 score for major depression." (NCT00640562)
Timeframe: 12 week from baseline to last visit
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Seroquel XR | 7.31 |
| Risperidone | 5.53 |
These items are presented as self-report statements with which the patient agrees or disagrees. Each response is scored as +1 if correct or -1 if incorrect. The final score is the grand total of the positive and negative points. A positive score means a positive subjective response. A negative total score means a negative subjective response (NCT00640562)
Timeframe: 12 week from baseline to last visit
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Seroquel XR | 86.38 |
| Risperidone | 76.64 |
21-item scale for depression. Symptoms are rated finely (on a 5-point scale: absent; doubtful or trivial; mild: moderate severe) or coarsely (on a 3- point scale: absent; doubtful or mild; obvious, distinct, or severe).Total score range 0- 66, higher values represent worse outcome.Number of participants refers to valid for efficacy per protocol. Change:total score at week 12 minus total score at baseline. (NCT00640562)
Timeframe: 12 weeks from baseline to last visit
| Intervention | Score on scale (Mean) |
|---|---|
| Seroquel XR | -29.83 |
| Risperidone | -23.02 |
30-item scale where each symptom is rated on a severity ranging from 1-7. Symptoms are categorized into 7 items referring to positive, 7 items referring to negative and 16 general psychotic. Total score range 30- 210, higher values represent worse outcome. Number of participants analyzed refers to valid for efficacy per protocol population. (NCT00640562)
Timeframe: 12 weeks from baseline to last visit
| Intervention | score on scale (Mean) |
|---|---|
| Seroquel XR | 102.26 |
| Risperidone | 100.51 |
Plasma prolactin live was drawn prior to morning meal at the screening visit at the last visit (NCT00640562)
Timeframe: 12 week from screening visit to last visit
| Intervention | KG (Least Squares Mean) |
|---|---|
| Seroquel XR | 61.20 |
| Risperidone | 90.80 |
Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to ITT/safety population, that is to overall participants excluding the 6 participants who did not assume any study drug administration (NCT00640562)
Timeframe: Change of drug use from baseline to last visi
| Intervention | Participants (Number) |
|---|---|
| Seroquel XR | 14 |
| Risperidone | 17 |
Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to safety population, that is to overall participants excluding 6 participants who did not assume any study drug administration (NCT00640562)
Timeframe: 12 week from baseline to last visi
| Intervention | Participants (Number) |
|---|---|
| Seroquel XR | 12 |
| Risperidone | 11 |
The CGI-S rating scale was used to assess the severity of a subject's overall clinical condition. Scores range from 1 to 7, where 1=best and 7=worst. The change in CGI-S score for all eligible subjects was measured from the beginning of the study to Week 13 (i.e., the end of the double-blind treatment period) or, if the subject left the study early, from the beginning of the study to the last assessment after baseline. (NCT00590577)
Timeframe: Baseline to 13 weeks or the last post-baseline assessment
| Intervention | Scores on a scale (Median) |
|---|---|
| Paliperidone Palmitate 25 mg eq. | -1.0 |
| Paliperidone Palmitate 100 mg eq. | -1.0 |
| Paliperidone Palmitate 150 mg eq. | -1.0 |
| Placebo | 0.0 |
The PSP scale measures the degree of normal function of a subject in interpersonal relationships and social interactions. Scores range from 1 to 100, where 1 is worst and 100 is best. The average change in PSP score for all eligible subjects was measured from the beginning of the study to Week 13 (i.e., the end of the double-blind treatment period) or, if the subject left the study early, from the beginning of the study to the last assessment after baseline. (NCT00590577)
Timeframe: Baseline to 13 weeks or the last post-baseline assessment
| Intervention | Scores on a scale (Mean) |
|---|---|
| Paliperidone Palmitate 25 mg eq. | 2.9 |
| Paliperidone Palmitate 100 mg eq. | 6.1 |
| Paliperidone Palmitate 150 mg eq. | 8.3 |
| Placebo | 1.7 |
The PANSS measures the severity of psychotic symptoms of schizophrenia. Scores range from 30 to 210, where 30=best and 210=worst. The change in PANSS total score for all eligible subjects was measured from the beginning of the study to Week 13 (i.e., the end of the double-blind treatment period) or, if the subject left the study early, from the beginning of the study to the last assessment after baseline. (NCT00590577)
Timeframe: Baseline to 13 weeks or the last post-baseline assessment
| Intervention | Scores on a scale (Mean) |
|---|---|
| Paliperidone Palmitate 25 mg eq. | -8.0 |
| Paliperidone Palmitate 100 mg eq. | -11.6 |
| Paliperidone Palmitate 150 mg eq. | -13.2 |
| Placebo | -2.9 |
(NCT00330863)
Timeframe: Measured throughout study up to 30 months
| Intervention | participants (Number) |
|---|---|
| Injectable | 81 |
| Oral | 80 |
Brief Psychiatric Rating Scale (BPRS) psychosis cluster. Score range is based on the score range for individual items rather than the factor total because is factors have different numbers of items. Score range is 1 -7 where 1 + no symptomatology and 7 = very severe symptoms. (NCT00330863)
Timeframe: Measured throughout study up to 30 months
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Injectable | 1.8 |
| Oral | 2.0 |
The highest severity of each of 24 adverse event (AE) that was assessed.over the 30 month study period. The mean severity on a scale of 1 (none) to 4 very severe symptom was recorded at each biweekly visit. Results for each variable are summarized over time so that each subject has a single mean severity rating for each AE. There is no named scale. Each of the side effects measured is named in ways that are clear to medical readers e.g anorexia. The range is 1 none to 4 very severe. Therefore, a higher scale score is worse. (NCT00330863)
Timeframe: Measured throughout study up to 30 months
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bruising easily | Rash | Urticaria (hives, itching) | Blurred vision | sedation/drowsiness | Restlessness | Insomnia | Malaise (weakness, fatigue) | Stiffness | Tremor | Dizziness | Headache | Fever | Sore Throat | Dry Mouth | Hypersalivation | Enuresis | Constipation | Diarrhea | Anorexia (loss of appetite) | Nausea | Vomiting | Menstrual Irregularity | Breast tenderness/galactorrhea | |
| Injectable | 1.43 | 1.53 | 1.60 | 1.76 | 2.34 | 2.48 | 2.38 | 2.22 | 2.01 | 1.77 | 1.82 | 1.99 | 1.27 | 1.64 | 2.36 | 1.76 | 1.63 | 1.75 | 1.65 | 1.89 | 1.78 | 1.48 | 1.62 | 1.39 |
| Oral | 1.48 | 1.44 | 1.71 | 1.91 | 2.53 | 2.43 | 2.36 | 2.14 | 1.97 | 1.75 | 1.78 | 1.89 | 1.24 | 1.57 | 2.25 | 1.84 | 1.56 | 1.64 | 1.68 | 1.69 | 1.72 | 1.51 | 1.55 | 1.32 |
Rating scale based on clinician's interview of patient to determine level of lack of awareness of having a mental disorder. Range is from 1 (Aware) to 5 (Unaware), so lower scores indicate better outcome. (NCT00330551)
Timeframe: Baseline to 12 months
| Intervention | Change scores on 5-point rating scale (Mean) |
|---|---|
| Long-acting Injectable Risperidone | .07 |
| Oral Risperidone | -.24 |
10-point scale of work/school functioning. Scale range is from 1 (extreme role dysfunction) to 10 (superior role functioning). Measured by subtracting the baseline rating from the rating at 12 months. (NCT00330551)
Timeframe: Measured at Baseline and Month 12
| Intervention | Changes on a 10-point scale (Mean) |
|---|---|
| Long-acting Injectable Risperidone | 1.5 |
| Oral Risperidone | 1.2 |
The MCCB Overall Composite T score is computed by the MCCB Computer Scoring Program from the raw scores for 10 individual cognitive tests. The mean for the general population of comparable age and sex is 50 with a standard deviation of 10. Higher scores indicate better cognitive functioning. The outcome measure was the change from baseline to 12 months, calculated as 12-month T score minus baseline T score. Higher values indicate better outcome. (NCT00330551)
Timeframe: Measured at baseline and 12 months
| Intervention | Change score: change in T scores (Mean) |
|---|---|
| Long-acting Injectable Risperidone | 3.5 |
| Oral Risperidone | 4.4 |
5-point scale (1 = best adherence, 5= nonadherent) based on pill counts, MEMS cap readings, plasma assays, and psychiatrist judgments for oral risperidone and timing of injections for long-acting injectable risperidone averaged over study participation (NCT00330551)
Timeframe: Measured weekly throughout study participation, averaged over study participation
| Intervention | units on a scale (Mean) |
|---|---|
| Long-acting Injectable Risperidone | 1.1 |
| Oral Risperidone | 1.9 |
Dichotomous measure: Presence of any of three psychotic relapse or exacerbation categories scored from the Brief Psychiatric Rating Scale (BPRS) occurring any time after randomization and until end of study participation (up to 12 mos.). (NCT00330551)
Timeframe: Occurrence after randomization and until end of study participation (up to 12 mos.)
| Intervention | Participants (Count of Participants) |
|---|---|
| Long-acting Injectable Risperidone | 2 |
| Oral Risperidone | 14 |
The Social Adjustment Scale records the return to work or school and the number of weeks in work or school during each 3-month period. For this outcome, outcome as dichotomized as 0 if an individual did not return to work or school and 1 if they did return to competitive work or regular school enrollment. (NCT00330551)
Timeframe: Measured from Baseline to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Long-acting Injectable Risperidone | 29 |
| Oral Risperidone | 29 |
Measured as the number of weeks in which a participant has competitive employment or attends regular school courses. Possible range is 0 to 52 weeks. (NCT00330551)
Timeframe: Cumulative total measured from Baseline to Month 12
| Intervention | weeks (Mean) |
|---|---|
| Long-acting Injectable Risperidone | 26.7 |
| Oral Risperidone | 21.1 |
Number of days on the randomized medication before being switched to a different antipsychotic medication or dropping out of the medication trial. Possible range is 0 to 365, with higher numbers indicating better retention in treatment. (NCT00330551)
Timeframe: From baseline to 12 months
| Intervention | days (Mean) |
|---|---|
| Long-acting Injectable Risperidone | 307.6 |
| Oral Risperidone | 270.7 |
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
Brief Psychiatric Rating Scale-Anchored (BPRS-A) 4 items on this scale were examined to determine subjects responder status: Items 4. Conceptual Disorganization 8. Grandiosity 12. Hallucinations and 15. Unusual Thought Content. Scores range from-7 (not assessed) to 7 (very severe) Subjects with scores of 3 or less on all 4 items for 2 consecutive visits are deemed responders, subjects with 4 or greater and any of the aforementioned items for 2 consecutive study visits are non responders. Additionally, the subjects response on the Clinical Global Impressions Scale. A Clinical Global Improvement CGI) rating of much or very much improved on 2 consecutive ratings were deemed a responder. Percentages and confidence intervals were used to report response outcome. Response status was assessed throughout the duration of the study; a participant can be deemed a responder any time between weeks 1-week 12. The possible range for this outcome is a score of 4 to 28 (NCT00320671)
Timeframe: this outcome was assessed throughout the study.
| Intervention | percentage of response (Number) |
|---|---|
| Percentage of Participants That Reposonded to Aripiprazole | 62.8 |
| Percentage of Participants That Reposonded to Risperidone | 56.8 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
Subjects enrolled in this study will be followed for an average of about 5 months. The ASEX will be done at screening to ensure subjects meet criteria for sexual dysfunction as defined by the scale. In addition subjects must remember at least a 2 point change in the scale since starting Invega Sustenna or Risperdal Consta. Subjects must also score no greater than or equal to 25 on the scale to ensure a baseline of minimal sexual activity. The primary outcome of the study is the change in ASEX score from Baseline to Endpoint. Total scores range from 5 - 30 with the higher scores indicating more sexual dysfunction. (NCT02472652)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Number) |
|---|---|
| Abilify Maintena | 11 |
Subjects enrolled in this study will be followed for an average of about 5 months. Serum prolactin concentrations will be measured to assess change from Baseline to Endpoint (NCT02472652)
Timeframe: Baseline and Endpoint average of about 5 months
| Intervention | ng/ml (Number) | |
|---|---|---|
| Baseline | 5 months | |
| Abilify Maintena | 49.2 | 14.2 |
A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit
| Intervention | percentage of annual rate of change (Number) |
|---|---|
| Prioritized Clinical Decision Support | 14.2 |
| Usual Care | 20.8 |
A 12-item instrument assesses observed abnormal movements in different parts of body. Ten items are scored in a 5-point scale (0 = none/normal, 4 = severe) which evaluates abnormal movements in three main anatomic areas (orofacial area, extremities, and trunk). Two items are yes/no questions regarding dentures. Total scores range from 0 to 42. (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| NEO-OLZ | -0.38 |
| NEO-RIS | 0.11 |
| EO-RIS | -0.16 |
Evaluates akathisia associated with use of antipsychotic medications, includes objective and subjective component plus global impression rating for overall disorder. Components rated on scale of 0 to 3 for objective and subjective items and 0 to 5 for global clinical assessment, for total score of 0 (absence of akathisia) to 11 (severe akathisia). (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| NEO-OLZ | -0.31 |
| NEO-RIS | -0.13 |
| EO-RIS | -0.24 |
Measures neuroleptic-induced parkinsonism. Total score consists of the sum of 10 items: 7 items (items 1, 3, 4, 7, 8, 9, 10) rated on a 4-point severity scale where 0=normal and 4=extreme, and 3 items (items 2, 5, 6) rated on a 2-point severity scale where 0=normal and 2=definitely abnormal/present. The total score ranges from 0 to 34. (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| NEO-OLZ | -0.06 |
| NEO-RIS | -0.03 |
| EO-RIS | -0.02 |
Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - single-blind baseline (Week 0). (NCT00337662)
Timeframe: Weeks 0, 3, 4, 6, 8, 12
| Intervention | units on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Change from Week 0 to Week 3 | Change from Week 0 to Week 4 | Change from Week 0 to Week 6 | Change from Week 0 to Week 8 | Change from Week 0 to Week 12 | |
| EO-RIS | -30.80 | -32.53 | -32.90 | -34.10 | -35.09 |
| NEO-RIS | -11.90 | -14.81 | -16.23 | -18.10 | -18.62 |
Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - double-blind baseline (Week 2). (NCT00337662)
Timeframe: Weeks 2, 3, 4, 6, 8, 12
| Intervention | units on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Change from Week 2 to Week 3 | Change from Week 2 to Week 4 | Change from Week 2 to Week 6 | Change from Week 2 to Week 8 | Change from Week 2 to Week 12 | |
| NEO-OLZ | -5.85 | -9.67 | -13.06 | -14.73 | -17.02 |
| NEO-RIS | -6.94 | -9.82 | -11.25 | -13.13 | -13.53 |
'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation. (NCT00337662)
Timeframe: Week 0 to Week 12
| Intervention | participants (Number) | |
|---|---|---|
| >=50% Reduction - Yes | >=50% Reduction - No | |
| EO-RIS | 87 | 51 |
| NEO-RIS | 67 | 122 |
'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation. (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | participants (Number) | |
|---|---|---|
| >=50% Reduction - Yes | >=50% Reduction - No | |
| NEO-OLZ | 67 | 112 |
| NEO-RIS | 67 | 122 |
Psychiatric Hospitalizations were measured by the Modified Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ) from which it could be determined the number of patients with a psychiatric episode that required an overnight stay in a hospital. (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | participants (Number) | |
|---|---|---|
| Required overnight stay in hospital: Yes | Required overnight stay in hospital: No | |
| EO-RIS | 10 | 127 |
| NEO-RIS | 9 | 175 |
Number of participants who experienced abnormal fasting laboratory values at any time during Study Period III. Laboratory reference ranges are dependent on the patient's gender, origin, and age. (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Low total bilirubin | High creatine phosphokinase | High creatinine | High hemoglobin A1c | Low sodium | High prolactin | |
| EO-RIS | 2 | 5 | 3 | 2 | 4 | 7 |
| NEO-OLZ | 5 | 6 | 2 | 6 | 4 | 7 |
| NEO-RIS | 3 | 1 | 4 | 7 | 4 | 8 |
The number of participants who experienced a 20% or greater reduction in their PANSS Total score during the 12 weeks they were on risperidone. (NCT00337662)
Timeframe: Week 0 to Week 12
| Intervention | participants (Number) | |
|---|---|---|
| >=20% Reduction - Yes | >=20% Reduction - No | |
| EO-RIS | 119 | 19 |
| NEO-RIS | 94 | 95 |
The number of not early onset participants who experienced a 20% or greater reduction in PANSS Total Score at any time during the 12 weeks of combined Study Period II and Study Period III. (NCT00337662)
Timeframe: Week 0 to Week 12
| Intervention | participants (Number) | |
|---|---|---|
| >=20% Reduction - Yes | >=20% Reduction - No | |
| NEO-OLZ | 94 | 85 |
| NEO-RIS | 94 | 95 |
Change from Study Period III baseline to endpoint in standing blood pressure. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 80.29 | -1.73 |
| NEO-OLZ | 78.69 | 1.01 |
| NEO-RIS | 78.57 | -0.20 |
Change from Study Period III baseline to endpoint in standing mean arterial pressure. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 94.60 | -1.94 |
| NEO-OLZ | 93.53 | 0.68 |
| NEO-RIS | 93.81 | -0.58 |
Body mass index is an estimate of body fat based on body weight divided by height squared. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 to Week 12
| Intervention | kilogram per square meter (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 31.13 | 0.10 |
| NEO-OLZ | 29.97 | 0.63 |
| NEO-RIS | 31.05 | 0.43 |
Change from Study Period III baseline to endpoint in body weight. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12
| Intervention | kilograms (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 90.67 | 0.30 |
| NEO-OLZ | 88.28 | 1.85 |
| NEO-RIS | 90.25 | 1.29 |
Changes from Study Period III baseline to endpoint in sitting pulse rate. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12
| Intervention | beats per minute (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 77.90 | -0.94 |
| NEO-OLZ | 80.49 | -0.98 |
| NEO-RIS | 80.84 | -2.52 |
Change from Study Period III baseline to endpoint in standing pulse rate. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12
| Intervention | beats per minute (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 82.39 | -0.56 |
| NEO-OLZ | 85.57 | -1.13 |
| NEO-RIS | 85.32 | -2.05 |
Change from Study Period III baseline to endpoint in standing systolic blood pressure. Change = Endpoint minus baseline. (NCT00337662)
Timeframe: Week 2 and Week 12
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| EO-RIS | 123.20 | -2.36 |
| NEO-OLZ | 123.20 | 0.01 |
| NEO-RIS | 124.30 | -1.35 |
"The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a subject. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill subjects. Worst value is 7 and best value is 1." (NCT00535132)
Timeframe: Change from Baseline to Week 6 LOCF
| Intervention | Points on a scale (Mean) |
|---|---|
| PALI ER Immediate Initiation | -0.8 |
| PALI ER Delayed Initiation | -0.8 |
| Overall | -0.8 |
The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied). (NCT00535132)
Timeframe: Change from Baseline in MSQ Score at Week 6 Last Observation Carried Forward (LOCF)
| Intervention | Points on a scale (Mean) |
|---|---|
| PALI ER Immediate Initiation | 2.5 |
| PALI ER Delayed Initiation | 2.3 |
| Overall | 2.4 |
The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied). (NCT00535132)
Timeframe: Change from Baseline in MSQ Score at Week 2
| Intervention | Points on a scale (Mean) |
|---|---|
| PALI ER Immediate Initiation | 2.0 |
| PALI ER Delayed Initiation | 1.6 |
| Overall | 1.8 |
The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied). (NCT00535132)
Timeframe: Change from Baseline in MSQ Score at Week 4
| Intervention | Points on a scale (Mean) |
|---|---|
| PALI ER Immediate Initiation | 2.4 |
| PALI ER Delayed Initiation | 2.1 |
| Overall | 2.3 |
The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied). (NCT00535132)
Timeframe: Change from Baseline in MSQ Score at Week 6
| Intervention | Points on a scale (Mean) |
|---|---|
| PALI ER Immediate Initiation | 2.5 |
| PALI ER Delayed Initiation | 2.4 |
| Overall | 2.5 |
The standard COVI Anxiety Scale is an investigator-assessed measure of the severity of anxiety symptoms on 4 items: verbal report, behavior, somatic symptoms, and relationship to study drug. Each dimension is assessed in 5 to 10 minutes using a 5-point scale as follows: 1=Not at all, 2=Somewhat, 3=Moderately, 4=Considerably, to 5=Very much. For this study, the standard COVI Anxiety Scale was modified to improve psychometric properties by incorporating anchor points for symptom severity, frequency, and duration and for functional impairment. Worst value is 20 and best value is 4. (NCT00535132)
Timeframe: Change from Baseline to Week 6 LOCF
| Intervention | Points on a scale (Mean) |
|---|---|
| PALI ER Immediate Initiation | -1.4 |
| PALI ER Delayed Initiation | -1.3 |
| Overall | -1.3 |
The PSQI is a 2-part questionnaire that assesses sleep quality and disturbances in seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each domain is rated on a 4-point scale as follows: 0=Not during the past month, 1=Less than once a week, 2=Once or twice a week, 3=Three or more times a week. Total scores range from zero to 21; increasing scores indicate poorer sleep quality and total scores greater than 5 suggest significant sleep disturbance. (NCT00535132)
Timeframe: Change from Baseline to Week 6 LOCF
| Intervention | Points on a scale (Mean) |
|---|---|
| PALI ER Immediate Initiation | -2.3 |
| PALI ER Delayed Initiation | -2.2 |
| Overall | -2.3 |
The PANSS is a 30-item scale designed to capture numerous symptoms of schizophrenia, including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale as follows: 1=Absent, 2=Minimal, 3=Mild,4=Moderate, 5=Moderate Severe, 6=Severe, 7=Extreme. This scale has been shown to be sensitive to changes associated with medication treatment. In addition to a total score, this assessment yields separate scores along a Positive Syndrome, a Negative Syndrome, and a General Psychopathology Scales. Worst value is 210, best value is 30. (NCT00535132)
Timeframe: Change from Baseline to Week 6 LOCF
| Intervention | Points on a scale (Mean) |
|---|---|
| PALI ER Immediate Initiation | -13.5 |
| PALI ER Delayed Initiation | -12.3 |
| Overall | -12.9 |
The SF-36 is a well-validated and widely used quality-of-life instrument employed in numerous disease states, including schizophrenia. It is a self-administered survey that measures eight domains of health including: physical functioning, role limitations due to physical health (role-physical), bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems (role-emotional) and general mental health. Scoring of the SF-36 was based on the SF-36 Manual and Interpretation Guide. Worst value is 0 and best value is 100. (NCT00535132)
Timeframe: Change from Baseline to Week 6 LOCF
| Intervention | Scores on a scale (Mean) |
|---|---|
| PALI ER Immediate Initiation | 6.7 |
| PALI ER Delayed Initiation | 7.2 |
| Overall | 7.0 |
The SF-36 is a well-validated and widely used quality-of-life instrument employed in numerous disease states, including schizophrenia. It is a self-administered survey that measures eight domains of health including: physical functioning, role limitations due to physical health (role-physical), bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems (role-emotional) and general mental health. Scoring of the SF-36 was based on the SF-36 Manual and Interpretation Guide. Worst value is 0 and best value is 100. (NCT00535132)
Timeframe: Change from Baseline to Week 6 LOCF
| Intervention | Scores on a scale (Mean) |
|---|---|
| PALI ER Immediate Initiation | 0.8 |
| PALI ER Delayed Initiation | 2.1 |
| Overall | 1.5 |
"The TSQM is a 14-item subject-assessed evaluation of treatment medication including 4 factors, Effectiveness (items 1-3), Side Effects (items 4-8), Convenience (items 9-11)and Global Satisfaction (items 12-14). Item 14 states taking all things into account, how satisfied or dissatisfied are you with this medication? and utilizes the following responses on a 7-point Likert scale: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 0 and best value is 100." (NCT00535132)
Timeframe: Change from Baseline to Week 6 LOCF
| Intervention | Points on a scale (Mean) |
|---|---|
| PALI ER Immediate Initiation | 30.2 |
| PALI ER Delayed Initiation | 26.4 |
| Overall | 28.3 |
The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied). (NCT00535132)
Timeframe: Week 2
| Intervention | Participants (Number) | |
|---|---|---|
| Satisfied (score 5-7) | Dissatisfied (score 1-4) | |
| Overall | 106 | 82 |
| PALI ER Delayed Initiation | 43 | 52 |
| PALI ER Immediate Initiation | 63 | 30 |
The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied). (NCT00535132)
Timeframe: Week 4
| Intervention | Participants (Number) | |
|---|---|---|
| Satisfied (score 5-7) | Dissatisfied (score 1-4) | |
| Overall | 139 | 41 |
| PALI ER Delayed Initiation | 64 | 27 |
| PALI ER Immediate Initiation | 75 | 14 |
The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied). (NCT00535132)
Timeframe: Week 6
| Intervention | Participants (Number) | |
|---|---|---|
| Satisfied (score 5-7) | Dissatisfied (score 1-4) | |
| Overall | 148 | 24 |
| PALI ER Delayed Initiation | 71 | 16 |
| PALI ER Immediate Initiation | 77 | 8 |
The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied). (NCT00535132)
Timeframe: Week 6 LOCF
| Intervention | Participants (Number) | |
|---|---|---|
| Satisfied (score 5-7) | Dissatisfied (score 1-4) | |
| Overall | 158 | 33 |
| PALI ER Delayed Initiation | 75 | 21 |
| PALI ER Immediate Initiation | 83 | 12 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 31 |
| Risperidone | 12 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon the Medical Dictionary for Regulatory Activities (MedDRA) terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 17 |
| Risperidone | 8 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 14 |
| Risperidone | 21 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 13 |
| Risperidone | 21 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 19 |
| Risperidone | 28 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 34 |
| Risperidone | 32 |
The analysis was based on time from start of study drug until stop of study drug for any reason other than sponsor closure of the study (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 3136 |
| Risperidone | 2597 |
The analysis was based on time from start of study drug to first hospitalisation during the WRT+30 days period (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 174 |
| Risperidone | 149 |
"The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 68 |
| Risperidone | 76 |
The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 43 |
| Risperidone | 65 |
Second primary endpoint: a serious adverse event where the patient was hospitalised and for which the Independent Safety Committee (ISC) classified the event as a cardiac event with documented arrhythmia. The analysis of this outcome was not performed due to low number of events. The presented analysis is a replacement analysis using all cardiac events, including arrhythmias, that required hospitalisation (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 10 |
| Risperidone | 6 |
The analysis was based on all deaths from the Whole Randomised Treatment (WRT)+30 days period and the Only Randomised Treatment (ORT) period, respectively (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) | |
|---|---|---|
| Number of deaths (WRT+30 days) | Number of deaths (ORT) | |
| Risperidone | 61 | 44 |
| Sertindole | 64 | 40 |
The Scale for the Assessment of Negative Symptoms (SANS) total score, minus the global items, inappropriate affect, poverty of content of speech, and attention items, used to measure negative symptoms. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms. A mixed model for unbalanced repeated measures analysis of covariance (ANCOVA), in which follow-up symptom score = baseline symptom score + treatment + week + treatment x week, and week is treated as a categorical, rather than a continuous measure. The treatment term estimates the average across weeks of the week-specific group differences, and is used as the main test for treatment effects on symptom change. (NCT00056498)
Timeframe: Baseline and every two weeks for 16 weeks.
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 0 | Week 2 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 | Week 14 | Week 16 | Change Score | |
| Placebo | 33.0 | 34.0 | 32.9 | 33.0 | 34.0 | 33.1 | 32.4 | 34.4 | 34.4 | 1.1 |
| Risperidone | 32.3 | 30.8 | 29.8 | 31.2 | 30.4 | 30.6 | 31.6 | 31.7 | 31.3 | -2.6 |
The neuropsychological testing measured attention, executive function/problem solving, motor speed, processing speed/response generation, and verbal, visual, and working memory. The individual test raw scores were converted to z-scores and an overall composite z-score was computed from the average of the individual test z-scores. Z-scores range from -3 standard deviations up to +3 standard deviations. Higher scores indicate better test performance. (NCT00056498)
Timeframe: Baseline and Week 16
| Intervention | z-score (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Placebo | -0.03 | 0.07 |
| Risperidone | 0.02 | 0.12 |
"The Brief Psychiatric Rating Scale (BPRS) positive symptom items are: conceptual disorganization, hallucinatory behavior, unusual thought content, and suspiciousness. The total score is calculated by adding the scores for each item. Each scale ranges from 1=Not Present to 7=Very Severe. The minimum score is 4 and the maximum score is 28. A higher score indicates a more severe positive symptom rating. A mixed model for unbalanced repeated measures analysis of covariance (ANCOVA), in which follow-up symptom score = baseline symptom score + treatment + week + treatment x week, and week is treated as a categorical, rather than a continuous measure. The treatment term estimates the average across weeks of the week-specific group differences, and is used as the main test for treatment effects on symptom change." (NCT00056498)
Timeframe: Baseline and every two weeks for 16 weeks.
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 0 | Week 2 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 | Week 14 | Week 16 | Change Score | |
| Placebo | 15.5 | 15.1 | 14.4 | 14.7 | 14.9 | 14.9 | 15.3 | 14.2 | 14.1 | -1.5 |
| Risperidone | 15.5 | 14.6 | 13.3 | 13.9 | 13.5 | 13.9 | 13.8 | 13.4 | 13.2 | -2.6 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Endpoint in total activity. (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 175906.8 |
| Armodafinil 100 mg/Day | 45621.4 |
| Armodafinil 200 mg/Day | 144855.3 |
| Placebo | 38708.1 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline in average activity per epoch (counts/epoch). (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -17.6 |
| Armodafinil 100 mg/Day | -0.7 |
| Armodafinil 200 mg/Day | 4.2 |
| Placebo | 0.8 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline in maximum activity to Endpoint. (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -124.3 |
| Armodafinil 100 mg/Day | -73.2 |
| Armodafinil 200 mg/Day | 70.4 |
| Placebo | -5.9 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to endpoint in standard deviation of activity (counts/epoch). (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -5.1 |
| Armodafinil 100 mg/Day | -0.7 |
| Armodafinil 200 mg/Day | 6.0 |
| Placebo | -1.9 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Endpoint in total activity. (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 7037.0 |
| Armodafinil 100 mg/Day | -9164.8 |
| Armodafinil 200 mg/Day | 23631.1 |
| Placebo | -24811.4 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Endpoint in total activity. (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -41210.0 |
| Armodafinil 100 mg/Day | -16150.5 |
| Armodafinil 200 mg/Day | -5159.5 |
| Placebo | -34443.8 |
The SCoRS is an 18-item interview based assessment covering all the cognitive domains in the MATRICS Consensus Cognitive Battery except social cognition. It is administered separately to the patient and an informant (family or friend) who are asked to rate the patient's level of difficulty in performing various cognitive functions on a 4-point scale (higher rating = greater impairment). They also complete a global assessment of cognitive function on a 1-10 scale. The interviewer factors in their own assessment on both the 18-items (Total Score) and the global assessment for the final score. (NCT00487942)
Timeframe: Baseline and Week 4 or last observation after baseline
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -3.9 |
| Armodafinil 100 mg/Day | -0.7 |
| Armodafinil 200 mg/Day | -4.6 |
| Placebo | -3.1 |
ESS is a self-administered subjective measure of daytime sleepiness, based on responses to questions referring to 8 everyday situations (eg. sitting and reading, talking to someone) and reflects a patient's propensity to fall asleep in those situations. Score for the ESS range from 0 to 24 with higher scores indicating greater daytime sleepiness. Data here represents the change from Baseline to Week 1 in the ESS total score. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.2 |
| Armodafinil 100 mg/Day | -1.4 |
| Armodafinil 200 mg/Day | 0.0 |
| Placebo | -1.5 |
SANS is a clinician-rated instrument that rates the severity of negative symptoms of schizophrenia. It contains 25 items in 5 domains: affective flattening/blunting, alogia, avolition-apathy, anhedonia-asociality, attentional impairment. Items in a domain assess symptoms and a global item assesses the overall severity of the domain. Each item is scored on a 6-point severity scale(0=Not at all, 1=questionable decrease, 2=mild, 3=moderate, 4=marked, 5=severe). The total scale ranges from 0-125. Data presented here represents change in total score from Baseline to Week 1. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -1.4 |
| Armodafinil 100 mg/Day | -2.5 |
| Armodafinil 200 mg/Day | -2.2 |
| Placebo | -2.2 |
The BARS is a 4-item clinician-rated scale to measure the presence and severity of drug-induced akathisia. Items related to the assessment of objective akathisia, subjective awareness of restlessness, and distress related to restlessness are rated using various 4-point (0 - 3) scales. A global assessment of akathisia is rated using a 6-point (0=Absent, 1=Questionable akathisia, 2=Mild akathisia, 3=Moderate akathisia, 4=Marked akathisia, 5=Severe akathisia) scale. The total score range is from 0 to 14 with a higher score indicating more severe akathisia. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.4 |
| Armodafinil 100 mg/Day | -0.2 |
| Armodafinil 200 mg/Day | 0.0 |
| Placebo | 0.1 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to week 1 in total activity. (NCT00487942)
Timeframe: Baseline and Week 1
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 92077.4 |
| Armodafinil 100 mg/Day | -28961.9 |
| Armodafinil 200 mg/Day | 18639.8 |
| Placebo | -118038 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline in average activity per epoch (counts/epoch)to Week 1. (NCT00487942)
Timeframe: Baseline and Week 1
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.3 |
| Armodafinil 100 mg/Day | 8.9 |
| Armodafinil 200 mg/Day | 2.1 |
| Placebo | 0.8 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 1 in maximum activity. (NCT00487942)
Timeframe: Baseline and Week 1
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -85.7 |
| Armodafinil 100 mg/Day | 14.8 |
| Armodafinil 200 mg/Day | 20.5 |
| Placebo | 6.2 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 1 in standard deviation of activity (counts/epoch). (NCT00487942)
Timeframe: Baseline and Week 1
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -4.3 |
| Armodafinil 100 mg/Day | 7.6 |
| Armodafinil 200 mg/Day | 4.2 |
| Placebo | 1.7 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to week 1 in total activity. (NCT00487942)
Timeframe: Baseline and Week 1
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 5913.6 |
| Armodafinil 100 mg/Day | -3818.5 |
| Armodafinil 200 mg/Day | 23665.1 |
| Placebo | -12675.4 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 1 in total activity. (NCT00487942)
Timeframe: Baseline and Week 1
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 2419.5 |
| Armodafinil 100 mg/Day | 37665.8 |
| Armodafinil 200 mg/Day | 15892.7 |
| Placebo | 1116.3 |
The Modified Simpson Angus Scale is a clinician-rated scale to assess the presence and severity of extrapyramidal symptoms associated study drug treatment. This is a 10-item scale that focuses on rigidity. The items are rated using a 5-point (0 - 4) scale. The total score ranges between 0 and 40. The data presented here represents the change from Baseline to Week 1. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.0 |
| Armodafinil 100 mg/Day | -0.2 |
| Armodafinil 200 mg/Day | -0.1 |
| Placebo | -0.1 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Negative Scale score ranges from 7 to 49. The data here represents the change in Negative Rating Scale from Baseline to Week 1. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.4 |
| Armodafinil 100 mg/Day | -0.1 |
| Armodafinil 200 mg/Day | -2.5 |
| Placebo | -0.4 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Positive Scale score ranges from 7 to 49. The data here represents the change in Positive Rating Scale from Baseline to Week 1. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.3 |
| Armodafinil 100 mg/Day | -0.1 |
| Armodafinil 200 mg/Day | 0.3 |
| Placebo | -0.6 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Total score ranges from 7 to 210. The data here represents the change in Total score from Baseline to Week 1. (NCT00487942)
Timeframe: Baseline and 1 week following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.5 |
| Armodafinil 100 mg/Day | -0.8 |
| Armodafinil 200 mg/Day | -4.0 |
| Placebo | -2.3 |
ESS is a self-administered subjective measure of daytime sleepiness, based on responses to questions referring to 8 everyday situations (eg. sitting and reading, talking to someone) and reflects a patient's propensity to fall asleep in those situations. Score for the ESS range from 0 to 24 with higher scores indicating greater daytime sleepiness. Data here represents the change from Baseline to Week 2 in the ESS total score. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -1.1 |
| Armodafinil 100 mg/Day | -1.6 |
| Armodafinil 200 mg/Day | 0.3 |
| Placebo | -2.1 |
SANS is a clinician-rated instrument that rates the severity of negative symptoms of schizophrenia. It contains 25 items in 5 domains: affective flattening/blunting, alogia, avolition-apathy, anhedonia-asociality, attentional impairment. Items in a domain assess symptoms and a global item assesses the overall severity of the domain. Each item is scored on a 6-point severity scale(0=Not at all, 1=questionable decrease, 2=mild, 3=moderate, 4=marked, 5=severe). The total scale ranges from 0-125. Data presented here represents change in total score from Baseline to Week 2. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.4 |
| Armodafinil 100 mg/Day | -4.5 |
| Armodafinil 200 mg/Day | -4.4 |
| Placebo | -6.8 |
The BARS is a 4-item clinician-rated scale to measure the presence and severity of drug-induced akathisia. Items related to the assessment of objective akathisia, subjective awareness of restlessness, and distress related to restlessness are rated using various 4-point (0 - 3) scales. A global assessment of akathisia is rated using a 6-point (0=Absent, 1=Questionable akathisia, 2=Mild akathisia, 3=Moderate akathisia, 4=Marked akathisia, 5=Severe akathisia) scale. The total score range is from 0 to 14 with a higher score indicating more severe akathisia. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.2 |
| Armodafinil 100 mg/Day | 0.1 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | 0.4 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 2 in total activity. (NCT00487942)
Timeframe: Baseline and Week 2
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -46326.7 |
| Armodafinil 100 mg/Day | -44034.8 |
| Armodafinil 200 mg/Day | -1954.7 |
| Placebo | -78154.5 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline in average activity per epoch (counts/epoch) to Week 2. (NCT00487942)
Timeframe: Baseline and Week 2
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -15.4 |
| Armodafinil 100 mg/Day | -7.9 |
| Armodafinil 200 mg/Day | -7.2 |
| Placebo | 13.1 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 2 in maximum activity. (NCT00487942)
Timeframe: Baseline and Week 2
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -152.7 |
| Armodafinil 100 mg/Day | -146.3 |
| Armodafinil 200 mg/Day | 11.8 |
| Placebo | -28.4 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 2 in standard deviation of activity (counts/epoch). (NCT00487942)
Timeframe: Baseline and Week 2
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -11.3 |
| Armodafinil 100 mg/Day | -6.6 |
| Armodafinil 200 mg/Day | -6.6 |
| Placebo | -0.3 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 2 in total activity. (NCT00487942)
Timeframe: Baseline and Week 2
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 2346.8 |
| Armodafinil 100 mg/Day | -32082.8 |
| Armodafinil 200 mg/Day | 3103.1 |
| Placebo | 30660.0 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 2 in total activity. (NCT00487942)
Timeframe: Baseline and Week 2
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -3534.2 |
| Armodafinil 100 mg/Day | 27543.3 |
| Armodafinil 200 mg/Day | 7937.0 |
| Placebo | 27759.5 |
The Modified Simpson Angus Scale is a clinician-rated scale to assess the presence and severity of extrapyramidal symptoms associated study drug treatment. This is a 10-item scale that focuses on rigidity. The items are rated using a 5-point (0 - 4) scale. The total score ranges between 0 and 40. The data presented here represents the change from Baseline to Week 2. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.1 |
| Armodafinil 100 mg/Day | -0.4 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | 0.0 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Negative Scale score ranges from 7 to 49. The data here represents the change in Negative Rating Scale from Baseline to Week 2. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.1 |
| Armodafinil 100 mg/Day | -1.4 |
| Armodafinil 200 mg/Day | -2.3 |
| Placebo | -0.8 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Positive Scale score ranges from 7 to 49. The data here represents the change in Positive Rating Scale from Baseline to Week 2. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.3 |
| Armodafinil 100 mg/Day | -1.1 |
| Armodafinil 200 mg/Day | 0.4 |
| Placebo | -0.9 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Total score ranges from 7 to 210. The data here represents the change in Total score from Baseline to Week 2. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.1 |
| Armodafinil 100 mg/Day | -3.2 |
| Armodafinil 200 mg/Day | -3.0 |
| Placebo | -2.8 |
n The SCoRS is an 18-item interview based assessment covering all the cognitive domains in the MATRICS Consensus Cognitive Battery except social cognition. It is administered separately to the patient and an informant (family or friend) who are asked to rate the patient's level of difficulty in performing various cognitive functions on a 4-point scale (higher rating = greater impairment). They also complete a global assessment of cognitive function on a 1-10 scale. The interviewer factors in their own assessment on both the 18-items (Total Score) and the global assessment for the final score. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.0 |
| Armodafinil 100 mg/Day | -0.3 |
| Armodafinil 200 mg/Day | 0.6 |
| Placebo | -0.8 |
The SCoRS is an 18-item interview based assessment covering all the cognitive domains in the MATRICS Consensus Cognitive Battery except social cognition. It is administered separately to the patient and an informant (family or friend) who are asked to rate the patient's level of difficulty in performing various cognitive functions on a 4-point scale (higher rating = greater impairment). They also complete a global assessment of cognitive function on a 1-10 scale. The interviewer factors in their own assessment on both the 18-items (Total Score) and the global assessment for the final score. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -5.0 |
| Armodafinil 100 mg/Day | -3.0 |
| Armodafinil 200 mg/Day | -1.6 |
| Placebo | -3.3 |
The CDSS is a clinician-rated scale that assesses the level of depression in patients with schizophrenia. Each of the 9 items is scored on a 4-point scale (0=absent, 1=mild, 2=moderate, 3=severe). The total score range is 0 - 27. The data presented here represents the change from Baseline to Week 2 in the total score. (NCT00487942)
Timeframe: Baseline and 2 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.7 |
| Armodafinil 100 mg/Day | -1.1 |
| Armodafinil 200 mg/Day | -0.8 |
| Placebo | 0.4 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 3 in total activity. (NCT00487942)
Timeframe: Baseline and Week 3
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 40120.5 |
| Armodafinil 100 mg/Day | 23748.0 |
| Armodafinil 200 mg/Day | 61304.7 |
| Placebo | -41751.7 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline in average activity per epoch (counts/epoch) to Week 3. (NCT00487942)
Timeframe: Baseline and Week 3
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 1.5 |
| Armodafinil 100 mg/Day | 7.2 |
| Armodafinil 200 mg/Day | 9.9 |
| Placebo | -1.6 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 3 in maximum activity. (NCT00487942)
Timeframe: Baseline and Week 3
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 1420.4 |
| Armodafinil 100 mg/Day | 1522.5 |
| Armodafinil 200 mg/Day | 1469.2 |
| Placebo | 1505.1 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 3 in standard deviation of activity (counts/epoch). (NCT00487942)
Timeframe: Baseline and Week 3
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 5.2 |
| Armodafinil 100 mg/Day | -6.6 |
| Armodafinil 200 mg/Day | 15.2 |
| Placebo | 1.1 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 3 in total activity. (NCT00487942)
Timeframe: Baseline and Week 3
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 39831.8 |
| Armodafinil 100 mg/Day | 16850.4 |
| Armodafinil 200 mg/Day | 56889.1 |
| Placebo | 29067.5 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 3 in total activity. (NCT00487942)
Timeframe: Baseline and Week 3
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 89886.7 |
| Armodafinil 100 mg/Day | 91057.2 |
| Armodafinil 200 mg/Day | 126496.5 |
| Placebo | 60259.0 |
ESS is a self-administered subjective measure of daytime sleepiness, based on responses to questions referring to 8 everyday situations (eg. sitting and reading, talking to someone) and reflects a patient's propensity to fall asleep in those situations. Score for the ESS range from 0 to 24 with higher scores indicating greater daytime sleepiness. Data here represents the change from Baseline to Week 4 in the ESS total score. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.0 |
| Armodafinil 100 mg/Day | -0.5 |
| Armodafinil 200 mg/Day | 1.0 |
| Placebo | -1.7 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The composite score combines the individual scores of the 10 tests and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represent the mean change in composite T-score from baseline to 4 weeks. (NCT00487942)
Timeframe: Baseline and 4 weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 2.2 |
| Armodafinil 100 mg/Day | 3.9 |
| Armodafinil 200 mg/Day | 2.9 |
| Placebo | 2.1 |
SANS is a clinician-rated instrument that rates the severity of negative symptoms of schizophrenia. It contains 25 items in 5 domains: affective flattening/blunting, alogia, avolition-apathy, anhedonia-asociality, attentional impairment. Items in a domain assess symptoms and a global item assesses the overall severity of the domain. Each item is scored on a 6-point severity scale(0=Not at all, 1=questionable decrease, 2=mild, 3=moderate, 4=marked, 5=severe). The total scale ranges from 0-125. Data presented here represents change in total score from Baseline to Week 4. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -5.3 |
| Armodafinil 100 mg/Day | -5.6 |
| Armodafinil 200 mg/Day | -7.4 |
| Placebo | -6.3 |
The BARS is a 4-item clinician-rated scale to measure the presence and severity of drug-induced akathisia. Items related to the assessment of objective akathisia, subjective awareness of restlessness, and distress related to restlessness are rated using various 4-point (0 - 3) scales. A global assessment of akathisia is rated using a 6-point (0=Absent, 1=Questionable akathisia, 2=Mild akathisia, 3=Moderate akathisia, 4=Marked akathisia, 5=Severe akathisia) scale. The total score range is from 0 to 14 with a higher score indicating more severe akathisia. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.1 |
| Armodafinil 100 mg/Day | -0.2 |
| Armodafinil 200 mg/Day | -0.2 |
| Placebo | -0.1 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 4 in total activity. (NCT00487942)
Timeframe: Baseline and Week 4
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 7898.0 |
| Armodafinil 100 mg/Day | -10300.1 |
| Armodafinil 200 mg/Day | 123442.9 |
| Placebo | -240840 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline in average activity per epoch (counts/epoch) to Week 4. (NCT00487942)
Timeframe: Baseline and Week 4
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -15.4 |
| Armodafinil 100 mg/Day | 9.0 |
| Armodafinil 200 mg/Day | -0.4 |
| Placebo | -18.7 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to week 4 in maximum activity. (NCT00487942)
Timeframe: Baseline and Week 4
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -173.5 |
| Armodafinil 100 mg/Day | -61.4 |
| Armodafinil 200 mg/Day | 57.5 |
| Placebo | -60.4 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to week 4 in standard deviation of activity (counts/epoch). (NCT00487942)
Timeframe: Baseline and Week 4
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -7.9 |
| Armodafinil 100 mg/Day | 6.3 |
| Armodafinil 200 mg/Day | 7.4 |
| Placebo | -7.6 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to Week 4 in total activity. (NCT00487942)
Timeframe: Baseline and Week 4
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 1341.8 |
| Armodafinil 100 mg/Day | 12620.9 |
| Armodafinil 200 mg/Day | 55151.0 |
| Placebo | -24323.9 |
An actigraphy device was worn by each patient starting with the initial screening. The device continuously measured movement, allowing for an evaluation of spontaneous motor activity. Data from the actigraphy device were downloaded at each visit. The data presented here is the change from baseline to week 4 in total activity. (NCT00487942)
Timeframe: Baseline and Week 4
| Intervention | Counts (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -12493.6 |
| Armodafinil 100 mg/Day | -6742.8 |
| Armodafinil 200 mg/Day | 39458.0 |
| Placebo | 1744.3 |
The Modified Simpson Angus Scale is a clinician-rated scale to assess the presence and severity of extrapyramidal symptoms associated study drug treatment. This is a 10-item scale that focuses on rigidity. The items are rated using a 5-point (0 - 4) scale. The total score ranges between 0 and 40. The data presented here represents the change from Baseline to Week 4. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.1 |
| Armodafinil 100 mg/Day | -0.1 |
| Armodafinil 200 mg/Day | -0.2 |
| Placebo | 0.2 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Negative Scale score ranges from 7 to 49. The data here represents the change in Negative Rating Scale from Baseline to Week 4. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.1 |
| Armodafinil 100 mg/Day | -1.3 |
| Armodafinil 200 mg/Day | -3.4 |
| Placebo | 0.0 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Positive Scale score ranges from 7 to 49. The data here represents the change in Positive Rating Scale from Baseline to Week 4. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.7 |
| Armodafinil 100 mg/Day | -0.8 |
| Armodafinil 200 mg/Day | -0.6 |
| Placebo | -1.0 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Total score ranges from 7 to 210. The data here represents the change in Total score from Baseline to Week 4. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.1 |
| Armodafinil 100 mg/Day | -3.1 |
| Armodafinil 200 mg/Day | -6.3 |
| Placebo | -2.1 |
The SCoRS is an 18-item interview based assessment covering all the cognitive domains in the MATRICS Consensus Cognitive Battery except social cognition. It is administered separately to the patient and an informant (family or friend) who are asked to rate the patient's level of difficulty in performing various cognitive functions on a 4-point scale (higher rating = greater impairment). They also complete a global assessment of cognitive function on a 1-10 scale. The interviewer factors in their own assessment on both the 18-items (Total Score) and the global assessment for the final score. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.1 |
| Armodafinil 100 mg/Day | -0.4 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | -0.5 |
The SCoRS is an 18-item interview based assessment covering all the cognitive domains in the MATRICS Consensus Cognitive Battery except social cognition. It is administered separately to the patient and an informant (family or friend) who are asked to rate the patient's level of difficulty in performing various cognitive functions on a 4-point scale (higher rating = greater impairment). They also complete a global assessment of cognitive function on a 1-10 scale. The interviewer factors in their own assessment on both the 18-items (Total Score) and the global assessment for the final score. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -3.8 |
| Armodafinil 100 mg/Day | -1.8 |
| Armodafinil 200 mg/Day | -4.6 |
| Placebo | -2.6 |
The CDSS is a clinician-rated scale that assesses the level of depression in patients with schizophrenia. Each of the 9 items is scored on a 4-point scale (0=absent, 1=mild, 2=moderate, 3=severe). The total score range is 0 - 27. The data presented here represents the change from Baseline to Week 4 in the total score. (NCT00487942)
Timeframe: Baseline and 4 weeks following the start of study drug administration
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.0 |
| Armodafinil 100 mg/Day | -0.6 |
| Armodafinil 200 mg/Day | 0.3 |
| Placebo | 0.2 |
SANS is a clinician-rated instrument that rates the severity of negative symptoms of schizophrenia. It contains 25 items in 5 domains: affective flattening/blunting, alogia, avolition-apathy, anhedonia-asociality, attentional impairment. Items in a domain assess symptoms and a global item assesses the overall severity of the domain. Each item is scored on a 6-point severity scale(0=Not at all, 1=questionable decrease, 2=mild, 3=moderate, 4=marked, 5=severe). The total scale ranges from 0-125. Data presented here represents change in total score from Baseline to Endpoint. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -5.6 |
| Armodafinil 100 mg/Day | -3.0 |
| Armodafinil 200 mg/Day | -7.4 |
| Placebo | -6.1 |
The MATRICS Consensus Cognitive Battery is an instrument containing 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represent the mean change in Attention/Vigilance Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.4 |
| Armodafinil 100 mg/Day | 3.7 |
| Armodafinil 200 mg/Day | 1.8 |
| Placebo | 3.0 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The BASC SC Test is a component of the Speed of Processing Domain scored on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10). The data here represent the mean change in BASC SC Test T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.6 |
| Armodafinil 100 mg/Day | -0.4 |
| Armodafinil 200 mg/Day | 2.4 |
| Placebo | 4.0 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Fluency Test is a component of the Speed of Processing Domain scored on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10). The data here represent the mean change in Fluency Test T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 2.2 |
| Armodafinil 100 mg/Day | 0.8 |
| Armodafinil 200 mg/Day | -0.5 |
| Placebo | -1.4 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The LNS is a component of the Working Memory Domain scored on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10). The data here represent the mean change in LNS T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 3.1 |
| Armodafinil 100 mg/Day | 2.1 |
| Armodafinil 200 mg/Day | 3.1 |
| Placebo | 4.5 |
The Modified Simpson Angus Scale is a clinician-rated scale to assess the presence and severity of extrapyramidal symptoms associated study drug treatment. This is a 10-item scale that focuses on rigidity. The items are rated using a 5-point (0 - 4) scale. The total score ranges between 0 and 40. The data presented here represents the change from Baseline to Week 4 or the last observation following baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.1 |
| Armodafinil 100 mg/Day | -0.1 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | 0.3 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Negative Scale score ranges from 7 to 49. The data here represents the change in Negative Rating Scale from Baseline to Endpoint. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.3 |
| Armodafinil 100 mg/Day | -0.3 |
| Armodafinil 200 mg/Day | -3.4 |
| Placebo | 0.1 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Positive Scale score ranges from 7 to 49. The data here represents the change in Positive Rating Scale from Baseline to Endpoint. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.7 |
| Armodafinil 100 mg/Day | 0.1 |
| Armodafinil 200 mg/Day | -0.4 |
| Placebo | -0.9 |
The MATRICS Consensus Cognitive Battery is an instrument containing 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10) for the composite. The data here represent the mean change in Reasoning and Problem Solving Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 1.6 |
| Armodafinil 100 mg/Day | -0.4 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | -0.2 |
The SCoRS is an 18-item interview based assessment covering all the cognitive domains in the MATRICS Consensus Cognitive Battery except social cognition. It is administered separately to the patient and an informant (family or friend) who are asked to rate the patient's level of difficulty in performing various cognitive functions on a 4-point scale (higher rating = greater impairment). They also complete a global assessment of cognitive function on a 1-10 scale. The interviewer factors in their own assessment on both the 18-items (Total Score) and the global assessment for the final score. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.3 |
| Armodafinil 100 mg/Day | -0.2 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | -0.4 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10) for the composite. The data here represent the mean change in Social Cognition Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -3.1 |
| Armodafinil 100 mg/Day | -1.3 |
| Armodafinil 200 mg/Day | 3.6 |
| Placebo | 3.8 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represent the mean change in Processing Speed Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline 4 weeks (or last observation after baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 3.0 |
| Armodafinil 100 mg/Day | 0.0 |
| Armodafinil 200 mg/Day | 5.0 |
| Placebo | 0.9 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Trail Making Test is a component of the Speed of Processing Domain scored on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10). The data here represent the mean change in Trail Making Test T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 4.2 |
| Armodafinil 100 mg/Day | -0.2 |
| Armodafinil 200 mg/Day | 9.2 |
| Placebo | -1.0 |
Trail B is an instrument designed to assess set shifting. The patient was given a paper with numbers and letters on it and asked to connect them in an alternating manner (eg. 1-A-2-B-3C). The time required for the patient to complete the test was recorded. The change from Baseline to last observation following Baseline in the time necessary to complete the test is presented here. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Minutes (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -8.7 |
| Armodafinil 100 mg/Day | 17.5 |
| Armodafinil 200 mg/Day | -20.8 |
| Placebo | -27.6 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represent the mean change in Verbal Learning Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -1.2 |
| Armodafinil 100 mg/Day | -0.8 |
| Armodafinil 200 mg/Day | 0.8 |
| Placebo | -2.2 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represent the mean change in Visual Learning Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 4.3 |
| Armodafinil 100 mg/Day | 3.9 |
| Armodafinil 200 mg/Day | 1.3 |
| Placebo | 0.2 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The WMS-III SS is a component of the Working Memory Domain scored on a normative scale to derive a T-score, (mean is 50 and standard deviation is 10). The data here represent the mean change in WMS-III SS T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.7 |
| Armodafinil 100 mg/Day | 4.7 |
| Armodafinil 200 mg/Day | 2.9 |
| Placebo | 2.5 |
"WCST is an instrument administered electronically to assess abstract reasoning and ability to alter problem solving strategies. Patients are given 64 response cards and 4 stimulus cards and asked to match each stimulus card to 1 pile of response cards. The patient is not told how to match the cards, only right or wrong to each placement. Examiner may change matching rules (sorting categories) during the test at which time the subject must alter their sorting category. The change from baseline in number of sorting categories achieved was assessed." (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Categories Completed (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.0 |
| Armodafinil 100 mg/Day | 0.5 |
| Armodafinil 200 mg/Day | -0.3 |
| Placebo | 0.2 |
"WCST is an instrument administered electronically to assess abstract reasoning and ability to alter problem solving strategies. Patients are given 64 response cards and 4 stimulus cards and asked to match each stimulus card to 1 pile of response cards. The patient is not told how to match the cards, only right or wrong to each placement. Examiner may change matching rules (sorting categories) during the test at which time the subject must alter their sorting category. The change from baseline in number of consecutive responses on the final category was assessed." (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Responses (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -1.6 |
| Armodafinil 100 mg/Day | -0.5 |
| Armodafinil 200 mg/Day | 0.3 |
| Placebo | 0.7 |
"WCST is an instrument administered electronically to assess abstract reasoning and ability to alter problem solving strategies. Patients are given 64 response cards and 4 stimulus cards and asked to match each stimulus card to 1 pile of response cards. The patient is not told how to match the cards, only right or wrong to each placement. Examiner may change matching rules during the test. Perseveration errors occur when subject repeats the same error no matter how many times they are told the placement is wrong. The change from baseline in number of perseveration errors was assessed." (NCT00487942)
Timeframe: 4 weeks (or last observation after baseline)
| Intervention | Errors (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 1.6 |
| Armodafinil 100 mg/Day | -8.0 |
| Armodafinil 200 mg/Day | -2.2 |
| Placebo | -1.9 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The Domain score combines the individual test scores of the Domain and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represent the mean change in Working Memory Domain T-score from baseline to last observation after baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 2.3 |
| Armodafinil 100 mg/Day | 4.3 |
| Armodafinil 200 mg/Day | 3.5 |
| Placebo | 4.4 |
The CDSS is a clinician-rated scale that assesses the level of depression in patients with schizophrenia. Each of the 9 items is scored on a 4-point scale (0=absent, 1=mild, 2=moderate, 3=severe). The total score range is 0 - 27. The data presented here represents the change from Baseline to Week 4 or the last observation following baseline in the total score. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 0.2 |
| Armodafinil 100 mg/Day | -0.4 |
| Armodafinil 200 mg/Day | 0.3 |
| Placebo | 0.1 |
ESS is a self-administered subjective measure of daytime sleepiness, based on responses to questions referring to 8 everyday situations (eg. sitting and reading, talking to someone) and reflects a patient's propensity to fall asleep in those situations. Score for the ESS range from 0 to 24 with higher scores indicating greater daytime sleepiness. Data here represents the change from Baseline to Endpoint (Week 4 or last observation following baseline) in the ESS total score. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.1 |
| Armodafinil 100 mg/Day | -0.6 |
| Armodafinil 200 mg/Day | 1.0 |
| Placebo | -0.5 |
The BARS is a 4-item clinician-rated scale to measure the presence and severity of drug-induced akathisia. Items related to the assessment of objective akathisia, subjective awareness of restlessness, and distress related to restlessness are rated using various 4-point (0 - 3) scales. A global assessment of akathisia is rated using a 6-point (0=Absent, 1=Questionable akathisia, 2=Mild akathisia, 3=Moderate akathisia, 4=Marked akathisia, 5=Severe akathisia) scale. The total score range is from 0 to 14 with a higher score indicating more severe akathisia. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -0.3 |
| Armodafinil 100 mg/Day | -0.1 |
| Armodafinil 200 mg/Day | -0.1 |
| Placebo | -0.1 |
PANSS is a clinician-rated instrument that rates the severity of psychopathology in patients with schizophrenia. 7 items measure positive symptoms (eg. delusions, hallucinations), 7 items measure negative symptoms (eg. blunted affect, social withdrawal), 16 items form a General Psychopathology scale (eg. anxiety, motor retardation). Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. The Total score ranges from 7 to 210. The data here represents the change in Total score from Baseline to Endpoint. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | -2.5 |
| Armodafinil 100 mg/Day | -0.9 |
| Armodafinil 200 mg/Day | -6.3 |
| Placebo | -1.7 |
The MATRICS Consensus Cognitive Battery is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The composite score combines the individual scores of the 10 tests and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the composite. The data here represents the change from baseline to last observation after baseline in Composite T-Score. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Units on a scale (Mean) |
|---|---|
| Armodafinil 50 mg/Day | 1.9 |
| Armodafinil 100 mg/Day | 2.8 |
| Armodafinil 200 mg/Day | 2.9 |
| Placebo | 2.2 |
The CGI-S is a standardized, clinician-rated assessment to rate the severity of illness of the patient. The clinician assessed the severity of illness using the following categories: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill. The CGI-S was assessed at Baseline, Week 1, Week 2 and Week 4. Data is presented representing the number of subjects who rated each CGI-S score at Baseline. (NCT00487942)
Timeframe: Baseline
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal | Borderline ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Armodafinil 100 mg/Day | 0 | 0 | 11 | 3 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 0 | 1 | 8 | 3 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 0 | 0 | 10 | 4 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 11 | 2 | 0 | 0 | 0 |
The CGI-S is a standardized, clinician-rated assessment to rate the severity of illness of the patient. The clinician assessed the severity of illness using the following categories: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill. The CGI-S was assessed at Baseline, Week 1, Week 2 and Week 4. Data is presented representing the number of subjects who rated each CGI-S score at week 1. (NCT00487942)
Timeframe: Baseline and 1 week
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal | Borderline ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Armodafinil 100 mg/Day | 0 | 0 | 11 | 2 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 0 | 1 | 8 | 2 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 0 | 0 | 10 | 3 | 1 | 0 | 0 |
| Placebo | 0 | 0 | 11 | 1 | 1 | 0 | 0 |
The CGI-S is a standardized, clinician-rated assessment to rate the severity of illness of the patient. The clinician assessed the severity of illness using the following categories: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill. The CGI-S was assessed at Baseline, Week 1, Week 2 and Week 4. Data is presented representing the number of subjects who rated each CGI-S score at week 2. (NCT00487942)
Timeframe: Baseline and 2 weeks
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal | Borderline ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Armodafinil 100 mg/Day | 0 | 1 | 8 | 3 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 0 | 1 | 10 | 1 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 0 | 0 | 9 | 3 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 11 | 1 | 0 | 0 | 0 |
The CGI-S is a standardized, clinician-rated assessment to rate the severity of illness of the patient. The clinician assessed the severity of illness using the following categories: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill. The CGI-S was assessed at Baseline, Week 1, Week 2 and Week 4. Data is presented representing the number of subjects who rated each CGI-S score at week 4. (NCT00487942)
Timeframe: Baseline and 4 weeks
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal | Borderline ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Armodafinil 100 mg/Day | 0 | 1 | 8 | 3 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 0 | 1 | 10 | 1 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 0 | 0 | 10 | 2 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 11 | 1 | 0 | 0 | 0 |
The CGI-S is a standardized, clinician-rated assessment to rate the severity of illness of the patient. The clinician assessed the severity of illness using the following categories: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill. The CGI-S was assessed at Baseline, Week 1, Week 2 and Week 4. Data is presented representing the number of subjects who rated each CGI-S score at Endpoint which is Week 4 or the last observation following Baseline. (NCT00487942)
Timeframe: Baseline and 4 weeks (or last observation after Baseline)
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal | Borderline ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Armodafinil 100 mg/Day | 0 | 1 | 8 | 5 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 0 | 1 | 10 | 1 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 0 | 0 | 11 | 3 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 11 | 2 | 0 | 0 | 0 |
The PGIC is a patient-rated scale of the change in disease severity. The PGIC uses the following 7 categories and scoring assignments: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. The number of subjects who rated each category at Week 1 is presented here. (NCT00487942)
Timeframe: Week 1
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Armodafinil 100 mg/Day | 2 | 1 | 0 | 10 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 2 | 1 | 6 | 2 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 1 | 1 | 2 | 9 | 0 | 1 | 0 |
| Placebo | 1 | 3 | 4 | 4 | 1 | 0 | 0 |
The PGIC is a patient-rated scale of the change in disease severity. The PGIC uses the following 7 categories and scoring assignments: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. The number of subjects who rated each category at Week 2 is presented here. (NCT00487942)
Timeframe: Week 2
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Armodafinil 100 mg/Day | 2 | 1 | 3 | 6 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 2 | 3 | 5 | 2 | 0 | 0 | 0 |
| Armodafinil 50 mg/Day | 1 | 3 | 2 | 5 | 1 | 0 | 0 |
| Placebo | 3 | 4 | 2 | 3 | 0 | 0 | 0 |
The PGIC is a patient-rated scale of the change in disease severity. The PGIC uses the following 7 categories and scoring assignments: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. The number of subjects who rated each category at Week 4 is presented here. (NCT00487942)
Timeframe: Week 4
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Armodafinil 100 mg/Day | 2 | 2 | 4 | 4 | 0 | 0 | 0 |
| Armodafinil 200 mg/Day | 4 | 1 | 6 | 0 | 1 | 0 | 0 |
| Armodafinil 50 mg/Day | 1 | 3 | 7 | 0 | 0 | 1 | 0 |
| Placebo | 3 | 2 | 5 | 1 | 1 | 0 | 0 |
The PGIC is a patient-rated scale of the change in disease severity. The PGIC uses the following 7 categories and scoring assignments: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. The number of subjects who rated each category at Week 4 or at the last observation following Baseline is presented. (NCT00487942)
Timeframe: Week 4 or last observation following Baseline
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Armodafinil 100 mg/Day | 2 | 2 | 4 | 5 | 1 | 0 | 0 |
| Armodafinil 200 mg/Day | 4 | 1 | 6 | 0 | 1 | 0 | 0 |
| Armodafinil 50 mg/Day | 1 | 3 | 9 | 0 | 0 | 1 | 0 |
| Placebo | 3 | 2 | 5 | 2 | 1 | 0 | 0 |
Performance on tasks included in the Brief Assessment of Cognition in Schizophrenia (BACS) battery, task performed and results recorded on IPAD. The mean change from baseline in total cognitive score on the BACS was calculated as a weighted average of T-scores (normalized for age) from BACS subtests including Verbal Memory, Digit Sequencing, Token Motor, Symbol Coding, Semantic Fluency, Letter Fluency, and Tower of London. The minimum and maximum values possible for this composite T-score of the change from baseline were -131 and 131, respectively. Higher values (positive changes from baseline) indicate better performance. (NCT03288779)
Timeframe: 30 minutes
| Intervention | Composite T- Score (Mean) |
|---|---|
| Theta Burst Stimulation Arm | 37.33 |
A hospitalization-free survival was defined as the time from the date of randomization to the time of a psychiatric hospitalization (in both VA and non-VA hospitals) or, in the case of patients who were hospitalized at randomization, the time from the date of discharge from the initial stay to subsequent hospitalization. Patients without an event were censored at 24 months after the date of randomization. (NCT00132314)
Timeframe: From randomization until date of first re-hospitalization, assessed up to 24 months
| Intervention | years (Median) |
|---|---|
| Injectable Risperidone | NA |
| Oral Antipsychotic | 1.97 |
Hazard ratio of LAI versus Oral for psychiatric hospitalization (in both VA and non-VA hospitals), after randomization up to 24 months, obtained from a Cox proportional hazards model. (NCT00132314)
Timeframe: 24 months
| Intervention | participants (Number) | |
|---|---|---|
| Patients with psychiatric hospitalization | Patients without psychiatric hospitalization | |
| Injectable Risperidone | 72 | 115 |
| Oral Antipsychotic | 81 | 101 |
Change in non-HDL cholesterol measured at baseline and every 4 weeks for 24 weeks. The efficacy analysis corresponded to a comparison of change in non-HDL cholesterol from baseline to 24 weeks between treatment groups (stay versus switch). Repeated measurements mixed effects linear models were fit for the primary analysis. (NCT00423878)
Timeframe: 24 weeks
| Intervention | mg/dL non-HDL cholesterol (Least Squares Mean) |
|---|---|
| Switch Group | -20.2 |
| Stay Group | -10.8 |
(NCT00423878)
Timeframe: Measured at Month 6
| Intervention | participants (Number) |
|---|---|
| Switch Group | 22 |
| Stay Group | 18 |
Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin | -5.18 |
| Placebo | -3.02 |
Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin and Metformin | -13.05 |
| Placebo | -3.02 |
fasting blood glucose (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -4.30 |
| Lorcaserin | -3.27 |
| Placebo | 3.53 |
high-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | 3.8 |
| Lorcaserin | 1.45 |
| Placebo | -0.78 |
glycosylated hemoglobin (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | percentage of glycosylated hemoglobin (Mean) |
|---|---|
| Lorcaserin and Metformin | -0.03 |
| Lorcaserin | 0.07 |
| Placebo | 0.05 |
low-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -7.60 |
| Lorcaserin | -10.86 |
| Placebo | -6.83 |
Total Cholesterol (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -9.05 |
| Lorcaserin | -13.45 |
| Placebo | -9.21 |
serum triglycerides (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -18.60 |
| Lorcaserin | -19.68 |
| Placebo | -3.11 |
(NCT00044655)
Timeframe: Measured at Six Months
| Intervention | participants (Number) |
|---|---|
| Stay | 11 |
| Switch | 23 |
Auditory evoked potentials amplitude: P50 ratio (S2/S1). Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | ratio (Number) |
|---|---|
| Auditory ERPs Amplitude (Deg) Baseline: Subject 2 | 44.51 |
| Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 2 | 35.67 |
Auditory evoked potentials amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2 amplitude; mismatch negativity (MMN) at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | microvolts (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 amplitude at fz | P300 amplitude at cz | P300 amplitude at pz | N100 amplitude at fz | N100 amplitude at cz | P200 amplitude at fz | P200 amplitude at cz | P50 S1 amplitude | P50 S2 amplitude | MMN amplitude at fz | MMN amplitude at cz | |
| Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 2 | 3.74 | 6.6 | 5.57 | -4.71 | -3.89 | 6.29 | 7.8 | 2.2 | 0.78 | -1.004 | -1.322 |
| Auditory ERPs Amplitude (Deg) Baseline: Subject 2 | -0.635 | 6.53 | 5.34 | -3.93 | -3.62 | 1.662 | 6.59 | 2.76 | 1.23 | -3.356 | -4.13 |
Auditory evoked potentials gamma: G40 hz phase locking at fz and cz; G20 hz phase locking response at fz and cz G30 hz phase locking response at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | microvolts squared (Number) | |||||
|---|---|---|---|---|---|---|
| G40 fz | G40 cz | G20 fz | G20 cz | G30 fz | G30 cz | |
| Auditory ERPs Gamma 6 Weeks of Glycine: Subject 2 | 0.255 | 0.29 | 0.107 | 0.108 | 0.177 | 0.242 |
| Auditory ERPs Gamma Baseline: Subject 2 | 0.135 | 0.168 | 0.023 | 0.03 | 0.19 | 0.163 |
Auditory evoked potentials latency: P300 at fz, cz, and pz); N100 at fz and cz); P200 at fz and cz. Participants were assessed at baseline and in week of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | msec (Number) | ||||||
|---|---|---|---|---|---|---|---|
| P300 latency at fz | P300 latency at cz | P300 latency at pz | N100 latency at fz | N100 latency at cz | P200 latency at fz | P200 latency at cz | |
| Auditory ERPs Latency (ms) 6 Weeks of Glycine: Subject 2 | 300.78 | 293 | 294.92 | 94 | 94 | 205 | 203 |
| Auditory ERPs Latency (ms) Baseline: Subject 2 | 279.3 | 279.3 | 279.3 | 97.66 | 91.8 | 197.27 | 193.4 |
Magnetic resonance spectroscopy GABA/Cr. Participants were assessed 1) pre-glycine treatment (baseline) and 2) in week 6 of open-label glycine treatment measured in posterior occipital cortex. (NCT01720316)
Timeframe: Baseline and week 6 of glycine
| Intervention | ratio (Number) | |
|---|---|---|
| Baseline GABA/Cr | Week 6 of glycine tx GABA/Cr | |
| Subject1: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine | 0.16 | 0.22 |
| Subject2: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine | 0.27 | 0.24 |
magnetic resonance spectroscopy - glutamate metabolite level. Participants were assessed 1) pre-glycine treatment and in week 6 of open-label glycine treatment. Measured in posterior occipital cortex. (NCT01720316)
Timeframe: baseline and week 6 of glycine
| Intervention | ratio (Number) | |
|---|---|---|
| Baseline brain glutamate/Cr ratio | Week 6 brain glutamate/Cr ratio | |
| Subject1: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine | 0.98 | 0.84 |
| Subject2: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine | 2.053 | 1.13 |
magnetic resonance spectroscopy: glycine/creatine ratio. Participants were assessed at 1) BASELINE PRE-GLYCINE TREATMENT: pre-glycine challenge drink, 60 minutes post challenge drink, 80 minutes post challenge drink, 100 minutes post challenge drink, and 120 minutes post challenge drink (0.4 g/kg up to max of 30 g); and 2) IN WEEK 6 OF OPEN-LABEL GLYCINE TREATMENT: pre-glycine dose, and 60 minutes, 80 minutes, 100 minutes and 120 minutes post daily dose of glycine. Measured in posterior occipital cortex (NCT01720316)
Timeframe: baseline (pre-challenge, 60, 80, 100, 120 minutes post-challenge), and week 6 of glycine (pre-dose and 60, 80, 100, 120 minutes post-dose
| Intervention | ratio (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline - pre-challenge drink | Baseline 60 minutes post challenge drink | Baseline 80 minutes post challenge drink | Baseline 100 minutes post challenge drink | Baseline 120 minutes post challenge drink | Week 6 of glycine - pre-glycine dose | Week 6 of glycine - 60 minutes post glycine dose | Week 6 of glycine - 80 minutes post glycine dose | Week 6 of glycine - 100 minutes post glycine dose | Week 6 of glycine - 120 minutes post glycine dose | |
| Subject 2:Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine | 0.5691 | 0.3918 | 0.6428 | 0.6363 | 0.9559 | 0.3235 | 0.3807 | 0.5591 | 0.4142 | 0.3545 |
| Subject1: Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine | 0.2558 | 0.6157 | 0.6631 | 0.5938 | 0.6953 | 0.6573 | 0.2983 | 0.4577 | 0.5751 | 0.3842 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within and after each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPRS at baseline | BPRS at 2 weeks intervention 1 | BPRS at 4 weeks intervention 1 | BPRS at 6 weeks intervention 1 | BPRS, end of washout1 | BPRS at 2 weeks intervention 2 | BPRS at 4 weeks intervention 2 | BPRS at 6 weeks intervention 2 | BPRS, end of washout2 | BPRS at 2 weeks open label | BPRS at 4 weeks open label | BPRS at 6 weeks open label | BPRS, end of washout3 | |
| Glycine, Then Placebo | 39 | 38 | 32 | 21 | 22 | 37 | 31 | 37 | 32 | 23 | 22 | 21 | 19 |
| Placebo, Then Glycine | 46 | 38 | 39 | 28 | 34 | 32 | 20 | 23 | 24 | 20 | 18 | 19 | 23 |
Clinical Global Impression (CGI) severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT01720316)
Timeframe: CGI at baseline and at 2 weeks, 4 weeks, and 6 weeks per treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI severity score at baseline | CGI severity score at 2 weeks intervention 1 | CGI severity score at 4 weeks intervention 1 | CGI severity score at 6 weeks intervention 1 | CGI severity score, end of washout1 | CGI severity score at 2 weeks intervention 2 | CGI severity score at 4 weeks intervention 2 | CGI severity score at 6 weeks intervention 2 | CGI severity score, end of washout2 | CGI severity score at 2 weeks open label | CGI severity score at 4 weeks open label | CGI severity score at 6 weeks open label | CGI severity score, end of washout3 | |
| Glycine, Then Placebo | 4 | 4 | 3 | 2 | 2 | 4 | 4 | 4 | 4 | 3 | 3 | 2 | 2 |
| Placebo, Then Glycine | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 |
Clinical Global Impression (CGI) therapeutic effect scores measure degree of improvement as marked (1), moderate (5), minimal (9) or unchanged/worse (13). (NCT01720316)
Timeframe: at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | score (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI therapeutic effect at 2 weeks intervention 1 | CGI therapeutic effect at 4 weeks intervention 1 | CGI therapeutic effect at 6 weeks intervention 1 | CGI therapeutic effect, end of washout1 | CGI therapeutic effect at 2 weeks intervention 2 | CGI therapeutic effect at 4 weeks intervention 2 | CGI therapeutic effect at 6 weeks intervention 2 | CGI therapeutic effect, end of washout2 | CGI therapeutic effect at 2 weeks open label | CGI therapeutic effect at 4 weeks open label | CGI therapeutic effect at 6 weeks open label | CGI therapeutic effect, end of washout3 | |
| Glycine, Then Placebo | 13 | 5 | 5 | 5 | 13 | 13 | 13 | 13 | 5 | 5 | 1 | 1 |
| Placebo, Then Glycine | 5 | 5 | 5 | 5 | 13 | 5 | 5 | 5 | 1 | 1 | 1 | 1 |
Hamilton Depression Scale measures severity of depression symptoms. The sum of ratings for 9 depression symptoms are measured on a scale from 0-2 with 0 meaning no symptoms and 2 meaning some level of severity of that specific symptom. The rating for 1 depression symptom is measured on a scale from 0-3 with 0 meaning no symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms are measured on a scale from 0-4 with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depression symptoms at baseline | Depression symptoms at 2 weeks intervention 1 | Depression symptoms at 4 weeks intervention 1 | Depression symptoms at 6 weeks intervention 1 | Depression symptoms, end of washout1 | Depression symptoms at 2 weeks intervention 2 | Depression symptoms at 4 weeks intervention 2 | Depression symptoms at 6 weeks intervention 2 | Depression symptoms, end of washout2 | Depression symptoms at 2 weeks open label | Depression symptoms at 4 weeks open label | Depression symptoms at 6 weeks open label | Depression symptoms, end of washout3 | |
| Glycine, Then Placebo | 18 | 17 | 11 | 3 | 1 | 19 | 5 | 7 | 3 | 2 | 2 | 1 | 2 |
| Placebo, Then Glycine | 12 | 5 | 5 | 0 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
Plasma glycine levels; normal range is 122-467 nM/mL (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine
| Intervention | nM/mL (Number) | |||
|---|---|---|---|---|
| Baseline | Glycine double-blind | Placebo | Glycine open-label | |
| Glycine Then Placebo | 216 | 410 | 194 | 516 |
| Placebo Then Glycine | 271 | 761 | 347 | 634 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of ratings for 7 symptoms of mania is measured on a scale from 0-4 and the sum of 4 symptoms of mania is measured on a scale from 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manic symptoms at baseline | Manic symptoms at 2 weeks intervention 1 | Manic symptoms at 4 weeks intervention 1 | Manic symptoms at 6 weeks intervention 1 | Manic symptoms, end of washout1 | Manic symptoms at 2 weeks intervention 2 | Manic symptoms at 4 weeks intervention 2 | Manic symptoms at 6 weeks intervention 2 | Manic symptoms, end of washout2 | Manic symptoms at 2 weeks open label | Manic symptoms at 4 weeks open label | Manic symptoms at 6 weeks open label | Manic symptoms, end of washout3 | |
| Glycine, Then Placebo | 4 | 1 | 0 | 0 | 0 | 17 | 0 | 2 | 2 | 1 | 0 | 0 | 0 |
| Placebo, Then Glycine | 7 | 7 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution; standard deviation of 10. Only overall composite score is entered. (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine
| Intervention | units on a scale (Number) | |
|---|---|---|
| Participant 1 | Participant 2 | |
| Baseline | 45 | 48 |
| Composite Score on Glycine, Double-blind | 52 | 52 |
| Composite Score on Glycine, Open-label | 49 | 46 |
| Composite Score on Placebo | 52 | 55 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms are measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period and after each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive symptoms at baseline | Positive symptoms at 2 weeks intervention 1 | Positive symptoms at 4 weeks intervention 1 | Positive symptoms at 6 weeks intervention 1 | Positive symptoms, end of washout1 | Positive symptoms at 2 weeks intervention 2 | Positive symptoms at 4 weeks intervention 2 | Positive symptoms at 6 weeks intervention 2 | Positive symptoms, end of washout2 | Positive symptoms at 2 weeks open label | Positive symptoms at 4 weeks open label | Positive symptoms at 6 weeks open label | Positive symptoms, end of washout3 | |
| Glycine, Then Placebo | 13 | 12 | 9 | 8 | 7 | 12 | 11 | 14 | 14 | 9 | 9 | 7 | 7 |
| Placebo, Then Glycine | 19 | 20 | 19 | 13 | 13 | 12 | 10 | 11 | 11 | 8 | 7 | 8 | 8 |
"Facial Affect Perception Test that assesses the ability to accurately recognize facially expressed emotions as published by Smith et al 2014; Derntl et al., 2009. This scale ranges from 0-100 percent with a total of 30 trials. We examined the percent correct as the total number of correct responses divided by the total number of completed trials. There were no subscales. 100% accurate is the best outcome and 0% accurate is the worst outcome.~Cognitive Empathy Test that assesses the ability to accurately determine the emotional expression of another person as depicted in a static image of a social interaction as published by Smith et al 2014; Derntl et al., 2009. This scale ranges from 0-100 percent with a total of 60 trials. We examined the percent correct as the total number of correct responses divided by the total number of completed trials. There were no subscales. 100% accurate is the best outcome and 0% accurate is the worst outcome." (NCT01929889)
Timeframe: baseline and twelve weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Facial Affect Perception Test | Cognitive Empathy Test | |
| Iloperidone | 0 | -3.333 |
Basal platelet oxygen consumption measured in isolated platelets by extracellular flux analysis (XF24, Seahorse Biosciences, Billerica, MA). (NCT01431313)
Timeframe: Maximal effect at 15 minutes post 45mg or 90mg inhalation vs Pre dose
| Intervention | picomoles O2/min (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -17.58 |
| WHO Group II Pulmonary Hypertension (PH) | 8.62 |
| WHO Group III Pulmonary Hypertension (PH) | -11.64 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of plasma nitrite concentrations in mixed venous blood over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Pre-dose, 15 minutes post 45mg and 90mg inhalation
| Intervention | micromolar (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 9.9 |
| WHO Group II Pulmonary Hypertension (PH) | 7.0 |
| WHO Group III Pulmonary Hypertension (PH) | 7.4 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of pulmonary artery occlusion (capillary) pullback nitrite concentration over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Pre-dose, 15 minutes post 45mg and 90mg inhalation
| Intervention | micromolar (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 9.2 |
| WHO Group III Pulmonary Hypertension (PH) | 2.4 |
Characteristic impedance (Zc) which may be related to compliance effects in the large, conduit arteries. (NCT01431313)
Timeframe: Pre dose and 60 minutes post last dosage inhaled
| Intervention | dyne*sec/cm5 (Median) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -0.004 |
| WHO Group II Pulmonary Hypertension (PH) | -0.34 |
| WHO Group III Pulmonary Hypertension (PH) | -0.20 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. Since pulmonary vascular resistance (PVR) was not normally distributed, it was transformed to natural log prior to analysis. The reported mean is the change from baseline of PVR over all subsequent times and doses (beta from the mixed effects model, converted back from natural log to Woods units), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | Woods units (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 0.77 |
| WHO Group II Pulmonary Hypertension (PH) | 0.40 |
| WHO Group III Pulmonary Hypertension (PH) | -0.39 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of MAP over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | mmHg (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -5.1 |
| WHO Group II Pulmonary Hypertension (PH) | -3.4 |
| WHO Group III Pulmonary Hypertension (PH) | -9.5 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. Since systemic vascular resistance was not normally distributed, it was transformed to natural log prior to analysis. The reported mean is the change from baseline of SVR over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | mmHg⋅min/L (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -0.43 |
| WHO Group II Pulmonary Hypertension (PH) | 1.19 |
| WHO Group III Pulmonary Hypertension (PH) | -2.04 |
Time in minutes to maximum PVR decrease. During study procedure, hemodynamics were measured at 0, 15, 30, 45, and 60 minutes after 45 mg followed by same times after 90 mg dose. The time point at which each patient's maximal decrease in PVR occurred was recorded and reported as the mean and standard deviation in each cohort. (NCT01431313)
Timeframe: 0, 15, 30, 45, and 60 minutes after 45 mg followed by same times after 90 mg dose
| Intervention | minutes (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 42.0 |
| WHO Group II Pulmonary Hypertension (PH) | 33.0 |
| WHO Group III Pulmonary Hypertension (PH) | 42.5 |
The Brief Assessment of Cognition in Schizophrenia (BACS) is the metric used to characterize cognition in this study. The BACS consists of 6 subscales: Verbal Memory (range 0-75), Working Memory (range 0-28), Motor Speed (range 0-100), Verbal Fluency (measure is total number of words generated in two 60 second trials), Attention and Processing speed (range 0-110), and Executive Function (range 0-22). For each subscale, higher scores reflect better cognition. For each subscale, a Standard Deviation Score was calculated based on normative data (Keefe et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research 102 (2008) 108-115). The BACS composite score is calculated as the average Standard Deviation Score of the 6 subscale scores. The change in BACS composite score was calculated as the BACS composite score at 8 weeks minus the BACS composite score at baseline. (NCT01696929)
Timeframe: Change in BACS composite score from baseline to 8 weeks
| Intervention | Change in BACS Composite Score (Mean) |
|---|---|
| Tocilizumab | 0.7 |
The Positive and Negative Symptoms Scale (PANSS) is the metric used to characterize psychotic symptoms in this study. The PANSS consists of 30 items, each scored 1-7. The range for the PANSS total score is 30-210. There are 3 subscales - PANSS positive score (range 7-49), PANSS negative score (range 7-49), and PANSS general score (range 16-112). PANSS total score is the summation of these 3 subscales. Higher values for the total and subscale scores reflect more severe psychopathology. A positive change in PANSS total score reflects an increase in psychopathology. A negative change in PANSS total score reflects a decrease in psychopathology. (NCT01696929)
Timeframe: Change in PANSS total score from baseline to 8 weeks
| Intervention | Change in PANSS Total Score (Mean) |
|---|---|
| Tocilizumab | -2.6 |
Auditory evoked potential amplitude: P50 ratio (P50 S2/S1) (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | ratio (Number) | |
|---|---|---|
| P50 ratio: Baseline | P50 ratio: Week 8 of DCS | |
| First Open Label DCS | 44.51 | 30 |
Auditory evoked potential amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2; mismatch negativity (MMN) at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | microvolts (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 at fz: Baseline | P300 at cz: Baseline | P300 at pz: Baseline | N100 at fz: Baseline | N100 at cz: Baseline | P200 at fz: Baseline | P200 at cz: Baseline | P50 S1: Baseline | P50 S2: Baseline | MMN at fz: Baseline | MMN at cz: Baseline | P300 at fz: Week 8 of DCS | P300 at cz: Week 8 of DCS | P300 at pz: Week 8 of DCS | N100 at fz: Week 8 of DCS | N100 at cz: Week 8 of DCS | P200 at fz: Week 8 of DCS | P200 at cz: Week 8 of DCS | P50 S1: Week 8 of DCS | P50 S2: Week 8 of DCS | MMN at fz: Week 8 of DCS | MMN at cz: Week 8 of DCS | |
| First Open Label DCS | -0.635 | 6.529 | 5.340 | -3.926 | -3.615 | 1.662 | 6.591 | 2.759 | 1.23 | -3.356 | -4.130 | 3.030 | 6.810 | 6.620 | -3.260 | -3.940 | 8.200 | 8.160 | 1.36 | 0.4 | -3.330 | -1.540 |
Auditory evoked potential gamma: G40 hz phase locking at fz and cz; G30 hz phase locking at fz and cz; G20 hz phase locking at fz and cz (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | microvolts squared (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G40 hz phase locking at fz: Baseline | G40 hz phase locking at cz: Baseline | G30 hz phase locking at fz: Baseline | G30 hz phase locking at cz: Baseline | G20 hz phase locking at fz: Baseline | G20 hz phase locking at cz: Baseline | G40 hz phase locking at fz: Week 8 of DCS | G40 hz phase locking at cz: Week 8 of DCS | G30 hz phase locking at fz: Week 8 of DCS | G30 hz phase locking at cz: Week 8 of DCS | G20 hz phase locking at fz: Week 8 of DCS | G20 hz phase locking at cz: Week 8 of DCS | |
| First Open Label DCS | 0.135 | 0.168 | 0.190 | 0.163 | 0.023 | 0.030 | 0.344 | 0.381 | 0.168 | 0.19 | 0.01 | -0.01 |
Auditory evoked potential latency: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | msec (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 at fz: Baseline | P300 at cz: Baseline | P300 at pz: Baseline | N100 at fz: Baseline | N100 at cz: Baseline | P200 at fz: Baseline | P200 at cz: Baseline | P300 at fz: Week 8 of DCS | P300 at cz: Week 8 of DCS | P300 at pz: Week 8 of DCS | N100 at fz: Week 8 of DCS | N100 at cz: Week 8 of DCS | P200 at fz: Week 8 of DCS | P200 at cz: Week 8 of DCS | |
| First Open Label DCS | 279.297 | 279.297 | 279.297 | 97.656 | 91.797 | 197.266 | 193.359 | 294.920 | 294.000 | 294 | 87.9 | 88.000 | 212.890 | 212.000 |
Proton magnetic resonance spectroscopy at 4T: brain glycine/CR ratio. Participants were assessed at baseline (pre-glycine challenge dose and 60, 80, 100 and 120 minutes post glycine dose) and in week 8 of of open-label DCS treatment: pre-DCS dose, and 60, 80, 100 and 120 minutes post DCS dose. Measured in posterior occipital cortex. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | ratio (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Baseline at 60 minutes | Baseline at 80 minutes | Baseline at 100 minutes | Baseline at 120 minutes | Week 8 of DCS: Baseline | Week 8 of DCS: 60 minutes | Week 8 of DCS: 80 minutes | Week 8 of DCS: 100 minutes | Week 8 of DCS: 120 minutes | |
| Open Label DCS | 0.41245 | 0.50375 | 0.65295 | 0.61505 | 0.8256 | 0.10977 | 0.248885 | 0.32609 | 0.32052 | 0.312155 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline BPRS | 2 weeks BPRS | 4 weeks BPRS | 6 weeks BPRS | 8 weeks BPRS | 10 weeks BPRS | 12 weeks BPRS | 14 weeks BPRS | 16 weeks BPRS | 18 weeks BPRS | 20 weeks BPRS | 22 weeks BPRS | 24 weeks BPRS | |
| First Open Label DCS | 37 | 25 | 26 | 24 | 24.5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 31.5 | 30.5 | 28 | 25.5 | 26 | 26.5 | 26 | 25.5 | 28.5 | 27 | 25 | 24.5 | 26.5 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline BPRS for first intervention | 2 weeks BPRS for first intervention | 4 weeks BPRS for first intervention | 6 weeks BPRS for first intervention | Baseline BPRS for second intervention | 2 weeks BPRS for second intervention | 4 weeks BPRS for second intervention | 6 weeks BPRS for second intervention | |
| DCS First, Then Placebo | 26 | 25 | 25 | 26 | 39 | 45 | 45 | 38 |
| Placebo First, Then DCS | 29 | 35 | 33 | 35 | 36 | 30 | 27 | 28 |
CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline CGI | 2 weeks CGI | 4 weeks CGI | 6 weeks CGI | 8 weeks CGI | 10 weeks CGI | 12 weeks CGI | 14 weeks CGI | 16 weeks CGI | 18 weeks CGI | 20 weeks CGI | 22 weeks CGI | 24 weeks CGI | |
| First Open Label DCS | 4 | 2 | 2 | 2 | 2 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 3 | 2.5 | 2 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline CGI for first intervention | 2 weeks CGI for first intervention | 4 weeks CGI for first intervention | 6 weeks CGI for first intervention | Baseline CGI for second intervention | 2 weeks CGI for second intervention | 4 weeks CGI for second intervention | 6 weeks CGI for second intervention | |
| DCS First, Then Placebo | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 |
| Placebo First, Then DCS | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline HAM | 2 weeks HAM | 4 weeks HAM | 6 weeks HAM | 8 weeks HAM | 10 weeks HAM | 12 weeks HAM | 14 weeks HAM | 16 weeks HAM | 18 weeks HAM | 20 weeks HAM | 22 weeks HAM | 24 weeks HAM | |
| First Open Label DCS | 5 | 1.5 | 1 | 0.5 | 1.5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 0.5 | 1 | 1 | 0 | 2.5 | 0 | 0 | 0 | 3.5 | 0 | 0 | 0 | 0 |
Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline HAM for first intervention | 2 weeks HAM for first intervention | 4 weeks HAM for first intervention | 6 weeks HAM for first intervention | Baseline HAM for second intervention | 2 weeks HAM for second intervention | 4 weeks HAM for second intervention | 6 weeks HAM for second intervention | |
| DCS First, Then Placebo | 0 | 1 | 0 | 0 | 2 | 12 | 9 | 2 |
| Placebo First, Then DCS | 4 | 5 | 2 | 10 | 0 | 0 | 0 | 0 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline YMRS | 2 weeks YMRS | 4 weeks YMRS | 6 weeks YMRS | 8 weeks YMRS | 10 weeks YMRS | 12 weeks YMRS | 14 weeks YMRS | 16 weeks YMRS | 18 weeks YMRS | 20 weeks YMRS | 22 weeks YMRS | 24 weeks YMRS | |
| First Open Label DCS | 2 | 1 | 1 | 0 | 0 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline YMRS for first intervention | 2 weeks YMRS for first intervention | 4 weeks YMRS for first intervention | 6 weeks YMRS for first intervention | Baseline YMRS for second intervention | 2 weeks YMRS for second intervention | 4 weeks YMRS for second intervention | 6 weeks YMRS for second intervention | |
| DCS First, Then Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo First, Then DCS | 1 | 0 | 0 | 0 | 4 | 1 | 1 | 1 |
Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution, standard deviation of 10. Higher scores signify better functioning. (NCT02304432)
Timeframe: Baseline and Week 8 of open-label DCS treatment
| Intervention | T scores (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Processing Speed | Baseline Attention/Vigilance | Baseline Working Memory | Baseline Verbal Learning | Baseline Visual Learning | Baseline Reasoning/Problem Solving | Baseline Social Cognition | Baseline Overall Composite Score | Week 8 of open-label DCS Processing Speed | Week 8 of open-label DCS Attention/Vigilance | Week 8 of open-label DCS Working Memory | Week 8 of open-label DCS Verbal Learning | Week 8 of open-label DCS Visual Learning | Week 8 of open-label DCS Reasoning/Problem Solving | Week 8 of open-label DCS Social Cognition | Week 8 of open-label DCS Overall Composite Score | |
| Open Label DCS | 48.5 | 44.5 | 38.5 | 54 | 50.5 | 52.5 | 48 | 46.5 | 52.5 | 47.5 | 50.5 | 43.5 | 54.5 | 66.5 | 44.5 | 51.5 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline positive | Baseline negative | 2 weeks positive | 2 weeks negative | 4 weeks positive | 4 weeks negative | 6 weeks positive | 6 weeks negative | 8 weeks positive | 8 weeks negative | 10 weeks positive | 10 weeks negative | 12 weeks positive | 12 weeks negative | 14 weeks positive | 14 weeks negative | 16 weeks positive | 16 weeks negative | 18 weeks positive | 18 weeks negative | 20 weeks positive | 20 weeks negative | 22 weeks positive | 22 weeks negative | 24 weeks positive | 24 weeks negative | |
| First Open Label DCS | 14.5 | 14.5 | 10 | 12 | 10.5 | 12 | 9 | 12 | 9 | 12 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 11 | 14 | 11 | 14 | 10.5 | 13.5 | 9 | 13 | 9.5 | 12 | 10.5 | 13 | 11 | 12 | 10 | 12 | 10.5 | 12 | 10.5 | 12 | 10.5 | 12 | 9.5 | 12 | 10 | 12 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline positive for first intervention | Baseline negative symptoms for first intervention | 2 weeks positive for first intervention | 2 weeks negative for first intervention | 4 weeks positive for first intervention | 4 weeks negative for first intervention | 6 weeks positive for first intervention | 6 weeks negative for first intervention | Baseline positive for second intervention | Baseline negative for second intervention | 2 weeks positive for second intervention | 2 weeks negative for second intervention | 4 weeks positive for second intervention | 4 weeks negative for second intervention | 6 weeks positive for second intervention | 6 weeks negative for second intervention | |
| DCS First, Then Placebo | 10 | 15 | 10 | 15 | 10 | 15 | 10 | 15 | 15 | 18 | 15 | 18 | 15 | 18 | 14 | 18 |
| Placebo First, Then DCS | 11 | 9 | 12 | 15 | 11 | 13 | 13 | 13 | 13 | 13 | 10 | 11 | 9 | 11 | 9 | 11 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
P50 Sensory Gating as measured by evoked potentials (response to stimuli, in this case, clicking sounds).The P50 potential was identified and measured using a computer algorithm. The amplitude of the P50 test wave was divided by the amplitude of the P50 conditioning wave, expressed as a percentage: the P50 ratio. Lower P50 ratios represent better outcomes. (NCT00149734)
Timeframe: Up to 3 hours
| Intervention | percentage (Mean) |
|---|---|
| Ondansetron | 41.4 |
| Placebo | 80.2 |
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
The Heinrichs-Carpenter Quality of Life Scale is a testing device. It has a range of possible scores, 0-126 used to evaluate social functioning & behavior in patients with schizophrenia-lower scores represent poorer mental health. (NCT00237809)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine/Control | 67.26 |
| Placebo/Cog Rehab | 68.30 |
| D-serine/Cog Rehab | 63.25 |
| Placebo/Control | 63.92 |
The Hopkins Verbal Learning Test is designed to assess verbal learning and memory (immediate recall, delayed recall, delayed recognition). The assessment takes approximately 5-10 minutes with a 25-minute delay to complete and 2 minutes to score. The greater the score, the greater the measured recall. The score ranges from 0 to 24. (NCT00237809)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine/Control | 20.74 |
| Placebo/Cog Rehab | 19.80 |
| D-serine/Cog Rehab | 20.42 |
| Placebo/Control | 21.45 |
The PANSS is a handscored instrument. It uses 25 PANSS items organized into five scales: Negative, Positive, Dysphoric Mood, Activation, and Autistic Preoccupation. The PANSS is based on findings that schizophrenia comprises at least two distinct syndromes. The positive syndrome consists of productive symptoms, while the negative syndrome consists of deficit features. This distinction is useful when developing treatment plans because you can focus on the type of symptoms the patient is experiencing. It is also useful when studying the effects of medication (e.g., in clinical drug trials) because it allows you to determine which type of symptoms are being affected. PANSS Total score minimum = 30, maximum = 210. The greater the score, the greater the symptoms. (NCT00237809)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine/Control | 53.30 |
| Placebo/Cog Rehab | 52.01 |
| D-serine/Cog Rehab | 53.79 |
| Placebo/Control | 53.96 |
Simpson-Angus Scale (SAS) is a 10-item rating scale that has been used widely for assessment in both clinical practice and research settings. Items are rated for severity on a 0-4 scale, with definitions given for each anchor point. The highest possible score is 40. (NCT00237809)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine/Control | 1.41 |
| Placebo/Cog Rehab | 0.72 |
| D-serine/Cog Rehab | 1.04 |
| Placebo/Control | 1.81 |
The Spatial Span subtest of the Wechsler Memory Scale can be used as an indicator of working memory and visuospatial processing. An increase in severity of impairment results in a decrease in Spatial Span Total Score. The range is 1 to 28. (NCT00237809)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine/Control | 13.59 |
| Placebo/Cog Rehab | 13.88 |
| D-serine/Cog Rehab | 13.21 |
| Placebo/Control | 13.58 |
The UCSD Performance-Based Skills Assessment (UPSA) is a role-play test designed to evaluate a person's functional capacity in two selected areas of basic living skills. These areas include Finance and Communication. Subjects being tested utilize props to demonstrate how they perform everyday activities and are assessed on their actual performance. The higher the score, the better the performance of an individual. The scores range from 0 to 100. (NCT00237809)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine/Control | 34.19 |
| Placebo/Cog Rehab | 32.80 |
| D-serine/Cog Rehab | 32.60 |
| Placebo/Control | 31.39 |
"The WCST allows the clinician to speculate to the following frontal lobe functions: strategic planning, organized searching, utilizing environmental feedback to shift cognitive sets, directing behavior toward achieving a goal, and modulating impulsive responding. The test can be administered to those from 6.5 years to 89 years of age.The test takes approximately 12-20 minutes to carry out and generates a number of psychometric scores, including numbers, percentages, and percentiles of: categories achieved, trials, errors, and perseverative errors. Can be interpreted as: the greater the percentage, the greater the measured ability." (NCT00237809)
Timeframe: 12 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| D-serine/Control | 38.43 |
| Placebo/Cog Rehab | 35.79 |
| D-serine/Cog Rehab | 43.14 |
| Placebo/Control | 39.57 |
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 3.9 |
| AL-108, 5 mg/Day | 4.6 |
| Placebo | 3.2 |
The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, week 6
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 1.3 |
| AL-108, 5 mg/Day | 2.3 |
| Placebo | -0.2 |
Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | -0.4 |
| AL-108, 5 mg/Day | -1.2 |
| Placebo | -0.3 |
Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 0.1 |
| AL-108, 5 mg/Day | -0.6 |
| Placebo | -0.1 |
UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 4.9 |
| AL-108, 5 mg/Day | 8.9 |
| Placebo | 0.3 |
UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, week 6
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 2.9 |
| AL-108, 5 mg/Day | 7.2 |
| Placebo | -0.9 |
Room organization will be measured by ratings on the Clutter Image Rating Scale (CIRS; Frost et al., 2008). The CIRS is a 9-picture visual analogue scale used to quantify and standardize the amount of clutter in 3 different living spaces (kitchen, living room, and bedroom). Min is 1 and Max is 9. Higher ratings indicate more clutter. For this project, only the bedroom rating scale will be utilized. The CIRS is used to measure the severity of clutter in compulsive hoarding. Before and after photos will be taken of each participant's room. These photos will be rated by 2 blinded student investigators with the mean rating taken. (NCT04294719)
Timeframe: 2-Month Follow-Up
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | 1.44 |
Room organization will be measured by ratings on the Clutter Image Rating Scale (CIRS; Frost et al., 2008). The CIRS is a 9-picture visual analogue scale used to quantify and standardize the amount of clutter in 3 different living spaces (kitchen, living room, and bedroom). Min is 1 and Max is 9. Higher ratings indicate more clutter. For this project, only the bedroom rating scale will be utilized. The CIRS is used to measure the severity of clutter in compulsive hoarding. Before and after photos will be taken of each participant's room. These photos will be rated by 2 blinded student investigators with the mean rating taken. (NCT04294719)
Timeframe: 4-Weeks Post-Intervention
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | 1.56 |
Room organization will be measured by ratings on the Clutter Image Rating Scale (CIRS; Frost et al., 2008). The CIRS is a 9-picture visual analogue scale used to quantify and standardize the amount of clutter in 3 different living spaces (kitchen, living room, and bedroom). Min is 1 and Max is 9. Higher ratings indicate more clutter. For this project, only the bedroom rating scale will be utilized. The CIRS is used to measure the severity of clutter in compulsive hoarding. Before and after photos will be taken of each participant's room. These photos will be rated by 2 blinded student investigators with the mean rating taken. (NCT04294719)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | 2.28 |
Room organization will be measured by ratings on the Clutter Image Rating Scale (CIRS; Frost et al., 2008). The CIRS is a 9-picture visual analogue scale used to quantify and standardize the amount of clutter in 3 different living spaces (kitchen, living room, and bedroom). Min is 1 and Max is 9. Higher ratings indicate more clutter. For this project, only the bedroom rating scale will be utilized. The CIRS is used to measure the severity of clutter in compulsive hoarding. Before and after photos will be taken of each participant's room. These photos will be rated by 2 blinded student investigators with the mean rating taken. (NCT04294719)
Timeframe: 4-Weeks Post-Intervention
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | 1.56 |
Room organization will be measured by ratings on the Clutter Image Rating Scale (CIRS; Frost et al., 2008). The CIRS is a 9-picture visual analogue scale used to quantify and standardize the amount of clutter in 3 different living spaces (kitchen, living room, and bedroom). Min is 1 and Max is 9. Higher ratings indicate more clutter. For this project, only the bedroom rating scale will be utilized. The CIRS is used to measure the severity of clutter in compulsive hoarding. Before and after photos will be taken of each participant's room. These photos will be rated by 2 blinded student investigators with the mean rating taken. (NCT04294719)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | 1.94 |
The attitudes of the team members towards finCAT will be measured using the Evidence-Based Practice Attitude Scale (EPBAS; Aarons, 2004) adapted to specifically target attitudes towards CAT. The EPBAS is a self-report questionnaire consisting of 36 items measured on a 5-point Likert scale ranging from 0 ('Not at all') to 4 ('To a very great extent') and consists of 12 subscales. Maximum is 4. Minimum is 0. Higher scores indicate a more open attitude towards new types of therapy, interventions or treatments including manualized therapy. (NCT04294719)
Timeframe: 2-Month Follow-Up
| Intervention | score on a scale (Mean) |
|---|---|
| Allied Health Clinicians | 3.22 |
| Nurses | 2.92 |
The attitudes of the team members towards finCAT will be measured using the Evidence-Based Practice Attitude Scale (EPBAS; Aarons, 2004) adapted to specifically target attitudes towards CAT. The EPBAS is a self-report questionnaire consisting of 36 items measured on a 5-point Likert scale ranging from 0 ('Not at all') to 4 ('To a very great extent') and consists of 12 subscales. Maximum is 4. Minimum is 0. Higher scores indicate a more open attitude towards new types of therapy, interventions or treatments including manualized therapy. (NCT04294719)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Allied Health Clinicians | 3.15 |
| Nurses | 2.83 |
Goal Attainment Scaling (GAS) will be employed as a sensitive measure of progress on individually defined goals. Goal attainment scaling involves the setting of 3-5 goals, each operationalized on a 5-point scale. Min is -2. Max is 2. Higher scores indicate greater attainment of the goal. Goals are individualized to the client and assessment of progress is determined through consensus of the clinician and case manager. (NCT04294719)
Timeframe: 2-Month Follow-Up
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | 0.81 |
Goal Attainment Scaling (GAS) will be employed as a sensitive measure of progress on individually defined goals. Goal attainment scaling involves the setting of 3-5 goals, each operationalized on a 5-point scale. Min is -2. Max is 2. Higher scores indicate greater attainment of the goal. Goals are individualized to the client and assessment of progress is determined through consensus of the clinician and case manager. (NCT04294719)
Timeframe: 4-Week Post-Intervention
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | 1.06 |
Goal Attainment Scaling (GAS) will be employed as a sensitive measure of progress on individually defined goals. Goal attainment scaling involves the setting of 3-5 goals, each operationalized on a 5-point scale. Min is -2. Max is 2. Higher scores indicate greater attainment of the goal. Goals are individualized to the client and assessment of progress is determined through consensus of the clinician and case manager. (NCT04294719)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | -1.00 |
Goal Attainment Scaling (GAS) will be employed as a sensitive measure of progress on individually defined goals. Goal attainment scaling involves the setting of 3-5 goals, each operationalized on a 5-point scale. Min is -2. Max is 2. Higher scores indicate greater attainment of the goal. Goals are individualized to the client and assessment of progress is determined through consensus of the clinician and case manager. (NCT04294719)
Timeframe: 2-Month Follow-Up
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | 0.78 |
Goal Attainment Scaling (GAS) will be employed as a sensitive measure of progress on individually defined goals. Goal attainment scaling involves the setting of 3-5 goals, each operationalized on a 5-point scale. Min is -2. Max is 2. Higher scores indicate greater attainment of the goal. Goals are individualized to the client and assessment of progress is determined through consensus of the clinician and case manager. (NCT04294719)
Timeframe: 4-Week Post-Intervention
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | 1.11 |
Goal Attainment Scaling (GAS) will be employed as a sensitive measure of progress on individually defined goals. Goal attainment scaling involves the setting of 3-5 goals, each operationalized on a 5-point scale. Min is -2. Max is 2. Higher scores indicate greater attainment of the goal. Goals are individualized to the client and assessment of progress is determined through consensus of the clinician and case manager. (NCT04294719)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | -1.00 |
Personal hygiene will be measured by scores on the Life Skills Profile (LSP; Rosen, Hadzi-Pavlovic, & Parker, 1989). The LSP consists of 39 clinician-rated questions on a four-point scale and measures various aspects related to daily life activities: self-care; non-turbulence; social contact; communication; responsibility. For this project, only the self-care ratings from the full LSP-39 will be completed by service providers (items 10, 12, 13, 14, 15, 16, 23, 24, 26, and 30). While each item consists of 4 responses, the content of each response is different for each item. Overall, higher scores indicate better functioning. Max total score is 40. Min total score is 10. Current inpatient research on the use of CAT also uses this scale as a primary measure of the effectiveness of CAT. Scores will be obtained from the nursing staff not directly involved in the delivery of the finCAT intervention. (NCT04294719)
Timeframe: 2-Month Follow-Up
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | 24.61 |
Personal hygiene will be measured by scores on the Life Skills Profile (LSP; Rosen, Hadzi-Pavlovic, & Parker, 1989). The LSP consists of 39 clinician-rated questions on a four-point scale and measures various aspects related to daily life activities: self-care; non-turbulence; social contact; communication; responsibility. For this project, only the self-care ratings from the full LSP-39 will be completed by service providers (items 10, 12, 13, 14, 15, 16, 23, 24, 26, and 30). While each item consists of 4 responses, the content of each response is different for each item. Overall, higher scores indicate better functioning. Max total score is 40. Min total score is 10. Current inpatient research on the use of CAT also uses this scale as a primary measure of the effectiveness of CAT. Scores will be obtained from the nursing staff not directly involved in the delivery of the finCAT intervention. (NCT04294719)
Timeframe: 4-Weeks Post-Intervention
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | 24.00 |
Personal hygiene will be measured by scores on the Life Skills Profile (LSP; Rosen, Hadzi-Pavlovic, & Parker, 1989). The LSP consists of 39 clinician-rated questions on a four-point scale and measures various aspects related to daily life activities: self-care; non-turbulence; social contact; communication; responsibility. For this project, only the self-care ratings from the full LSP-39 will be completed by service providers (items 10, 12, 13, 14, 15, 16, 23, 24, 26, and 30). While each item consists of 4 responses, the content of each response is different for each item. Overall, higher scores indicate better functioning. Max total score is 40. Min total score is 10. Current inpatient research on the use of CAT also uses this scale as a primary measure of the effectiveness of CAT. Scores will be obtained from the nursing staff not directly involved in the delivery of the finCAT intervention. (NCT04294719)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Inpatient Clients | 23.56 |
The therapeutic alliance on the unit will be measured by clinician and client ratings on the Essen Climate Evaluation Schema (Essen CES; Schalast et al., 2008). The Essen CES is a 15-item questionnaire measured on a 5-point Likert scale ranging from 'Not at all' to 'Very Much' and consists of three subscales: (1) Patient's Cohesion, (2) Experienced Safety, and (3) Therapeutic Hold. For this study, client and clinician ratings on the Therapeutic Hold and Experienced safety subscales will be collected. For each sub-scale, the max is 20 and minimum is 0. Higher scores indicate greater experienced safety and therapeutic hold. (NCT04294719)
Timeframe: 2-Month Follow-Up
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Experienced Safety | Therapeutic Hold | |
| Allied Health Clinicians | 11.06 | 15.25 |
| Inpatient Clients | 13.15 | 12.77 |
| Nurses | 12.17 | 15.83 |
The therapeutic alliance on the unit will be measured by clinician and client ratings on the Essen Climate Evaluation Schema (Essen CES; Schalast et al., 2008). The Essen CES is a 15-item questionnaire measured on a 5-point Likert scale ranging from 'Not at all' to 'Very Much' and consists of three subscales: (1) Patient's Cohesion, (2) Experienced Safety, and (3) Therapeutic Hold. For this study, client and clinician ratings on the Therapeutic Hold and Experienced safety subscales will be collected. For each sub-scale, the max is 20 and minimum is 0. Higher scores indicate greater experienced safety and therapeutic hold. (NCT04294719)
Timeframe: Baseline
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Experienced Safety | Therapeutic Hold | |
| Allied Health Clinicians | 10.94 | 15.19 |
| Inpatient Clients | 13.46 | 12.85 |
| Nurses | 10.67 | 14.67 |
The Brief Adherence Rating Scale (BARS; Byerly et al., 2008) is a 4-item, valid, reliable, sensitive, measure with which to obtain specific estimates of antipsychotic medication adherence of outpatients with schizophrenia. A total percentage score on a scale ranging from 0 to 100, with 0 indicating less adherence and 100 total adherence. (NCT01768000)
Timeframe: 4 months following baseline assessment
| Intervention | units on a scale (Mean) |
|---|---|
| Family Cognitive Adaptation Training - Caregivers | 77.22 |
| Control Group - Caregivers | 87.50 |
| Family Cognitive Adaptation Training - Family Members | 59.33 |
| Control Group - Family Members | 88.75 |
The 31-item Involvement Evaluation Questionnaire (IEQ; Van Wijngaarden et al., 2000) measures caregiver burden. It has been validated for caregivers of individuals with schizophrenia, covers a broad domain of caregiving consequences and refers to burden experienced within the past 4 weeks. Mean scores are calculated for the total scale and sub-scales. Total scores can range from 29 to 145 with sub-scale domains ranging - tension, 9-45; supervision, 6-30; worrying, 6-30; and urging, 8-40. Lower total and subscale scores indicate less burden and higher scores greater level of caregiver burden. (NCT01768000)
Timeframe: 4 months following baseline assessment
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Total | Tension | Supervision | Worrying | Urging | |
| Control Group - Caregivers | 49.25 | 14.13 | 7.50 | 15.25 | 16.38 |
| Family Cognitive Adaptation Training - Caregivers | 57.72 | 15.50 | 8.22 | 17.89 | 20.56 |
The Multnomah Community Ability Scale (MCAS; Barker et al., 1994) is a 17-item scale assessing functionality in four domains - health, adaptation, social skills and behaviour. Ratings are made on the basis of an interview with the patient and their family member. The MCAS generates a total score ranging from 17 to 85. Items on the MCAS are scored on a five-point scale. The four total domain scores ranges are - health, 5-25; adaptation, 3-15; social skills, 5-25; behaviour, 4-20. Lower ratings indicate less ability. Higher ratings usually mean an assessment of greater ability. (NCT01768000)
Timeframe: 4 months following baseline assessment
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Total | Health | Adaptation | Social Skills | Behaviour | |
| Control Group - Caregivers | 74.63 | 22.13 | 13.25 | 20.63 | 18.63 |
| Control Group - Family Members | 74.38 | 21.50 | 13.00 | 20.75 | 19.13 |
| Family Cognitive Adaptation Training - Caregivers | 67.78 | 21.67 | 10.89 | 17.44 | 17.78 |
| Family Cognitive Adaptation Training - Family Members | 70.00 | 21.56 | 11.78 | 18.33 | 18.33 |
8 out of 18 items from the Satisfaction With Life Scale (Test et al., 2005) will measure the perceived quality of life of the individual with schizophrenia by tapping into global satisfaction in domains relevant to CAT (e.g., How satisfied are you with yourself on the whole? - 5 point scale, not at all - great deal). This scale is well-validated with a schizophrenia population and is being shortened as not all items are relevant to CAT nor expected to be sensitive to change in a 4 month period, and there is a need to abbreviate the battery to reduce the risk of fatigue in a lengthy phone interview. These 8 items comprise four domains of social relationships, employment/work, social and present life and living situation. A low score indicates less satisfaction in these domains and a higher score indicating greater satisfaction. Total scores can range from 8-40 and subscale scores range from 1-5. (NCT01768000)
Timeframe: 4 months following baseline assessment
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Social Relationships | Employment/Work | Social & Present Life | Living Situation | |
| Control Group - Family Members | 2.18 | 2.17 | 2.29 | 3.00 |
| Family Cognitive Adaptation Training - Family Members | 2.06 | 1.63 | 2.00 | 3.11 |
The primary endpoint will be the severity of pain measured by changes in PLP from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS pain scale is a simple 10- point scale (0 = ''no pain'', 10 = ''pain as bad as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -2.84 |
| Active tDCS and Sham Mirror Therapy | -3.35 |
| Sham tDCS and Active Mirror Therapy | -1.78 |
| Sham tDCS and Sham Mirrory Therapy | -2.58 |
The endpoint will be the severity of pain measured by changes in Phantom Limb Sensation from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS Phantom Limb Sensation scale is a simple 10- point scale (0 = ''no Phantom Limb Sensation'', 10 = ''Phantom Limb Sensation as much as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -1.86 |
| Active tDCS and Sham Mirror Therapy | -2.55 |
| Sham tDCS and Active Mirror Therapy | -1.35 |
| Sham tDCS and Sham Mirrory Therapy | -2.83 |
The endpoint will be the severity of pain measured by changes in Stump Pain from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS Phantom Limb Stump Pain scale is a simple 10- point scale (0 = ''no Phantom Limb Stump Pain'', 10 = ''Phantom Limb Stump Pain as bad as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -1.31 |
| Active tDCS and Sham Mirror Therapy | -1.9 |
| Sham tDCS and Active Mirror Therapy | -0.91 |
| Sham tDCS and Sham Mirrory Therapy | -0.96 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
"Scans will be analyzed for task-related prefrontal activation~Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline)" (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
| Intervention | percent change in saline signal (Mean) |
|---|---|
| Guanfacine | -0.17 |
| Placebo | -0.094 |
Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
| Intervention | percent change in saline signal (Mean) |
|---|---|
| Guanfacine | -0.1 |
| Placebo | 0.052 |
Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
| Intervention | percent change in saline signal (Mean) |
|---|---|
| Guanfacine | -0.134 |
| Placebo | -0.086 |
343 reviews available for risperidone and Dementia Praecox
| Article | Year |
|---|---|
Current and novel approaches to the drug treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; E | 2001 |
Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Humans; Network Meta-Analysis; Prolactin; Risperidone; Schizophrenia | 2021 |
A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials?
Topics: Antipsychotic Agents; Humans; Olanzapine; Randomized Controlled Trials as Topic; Risperidone; Schizo | 2021 |
New Antipsychotic Medications in the Last Decade.
Topics: Adult; Antipsychotic Agents; Humans; Olanzapine; Psychotic Disorders; Risperidone; Schizophrenia | 2021 |
Antipsychotic drug treatment of schizophrenia in later life: Results from the European cross-sectional AMSP study.
Topics: Aged; Antipsychotic Agents; Cross-Sectional Studies; Female; Humans; Male; Psychiatry; Risperidone; | 2022 |
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Humans; Lur | 2022 |
Effect of risperidone on serum IL-6 levels in individuals with schizophrenia: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Humans; Interleukin-6; Risperidone; Schizophrenia | 2023 |
Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States.
Topics: Adult; Antipsychotic Agents; Financial Stress; Humans; Olanzapine; Quetiapine Fumarate; Risperidone; | 2022 |
Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.
Topics: Adult; Antipsychotic Agents; Catatonia; Humans; Neuroleptic Malignant Syndrome; Risperidone; Schizop | 2022 |
Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Psychiatric Status Rating Scales; Risperi | 2022 |
Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China.
Topics: Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Humans; Lurasidone Hydrochloride; Olanzap | 2022 |
Augmentation strategies for clozapine resistance: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Clozapine; Humans; Mirtazapine; Risperidone; Schizophrenia | 2023 |
Augmentation strategies for clozapine resistance: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Clozapine; Humans; Mirtazapine; Risperidone; Schizophrenia | 2023 |
Augmentation strategies for clozapine resistance: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Clozapine; Humans; Mirtazapine; Risperidone; Schizophrenia | 2023 |
Augmentation strategies for clozapine resistance: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Clozapine; Humans; Mirtazapine; Risperidone; Schizophrenia | 2023 |
Augmentation strategies for clozapine resistance: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Clozapine; Humans; Mirtazapine; Risperidone; Schizophrenia | 2023 |
Augmentation strategies for clozapine resistance: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Clozapine; Humans; Mirtazapine; Risperidone; Schizophrenia | 2023 |
Augmentation strategies for clozapine resistance: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Clozapine; Humans; Mirtazapine; Risperidone; Schizophrenia | 2023 |
Augmentation strategies for clozapine resistance: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Clozapine; Humans; Mirtazapine; Risperidone; Schizophrenia | 2023 |
Augmentation strategies for clozapine resistance: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Clozapine; Humans; Mirtazapine; Risperidone; Schizophrenia | 2023 |
Neuropharmacological effect of risperidone: From chemistry to medicine.
Topics: Antipsychotic Agents; Humans; Huntington Disease; Psychotic Disorders; Risperidone; Schizophrenia | 2023 |
Neuropharmacological effect of risperidone: From chemistry to medicine.
Topics: Antipsychotic Agents; Humans; Huntington Disease; Psychotic Disorders; Risperidone; Schizophrenia | 2023 |
Neuropharmacological effect of risperidone: From chemistry to medicine.
Topics: Antipsychotic Agents; Humans; Huntington Disease; Psychotic Disorders; Risperidone; Schizophrenia | 2023 |
Neuropharmacological effect of risperidone: From chemistry to medicine.
Topics: Antipsychotic Agents; Humans; Huntington Disease; Psychotic Disorders; Risperidone; Schizophrenia | 2023 |
What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Delayed-Action Preparations; Humans; Paliperidone Pa | 2023 |
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Haloperidol; Humans; Mania; Olanzapine; Quetia | 2023 |
Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: A systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents; Antipsychotic Agents; Benzodiazepines; Clozapine; Cytokines; Humans; Olanz | 2023 |
Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis.
Topics: Adult; Aged; Antipsychotic Agents; Humans; Psychomotor Agitation; Quetiapine Fumarate; Risperidone; | 2023 |
Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Humans; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2023 |
Clozapine augmentation with long-acting antipsychotic injections: A case series and systematic review.
Topics: Antipsychotic Agents; Clozapine; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Risper | 2023 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action P | 2020 |
[Pharmacotherapy of schizophrenia].
Topics: Adult; Antipsychotic Agents; Clozapine; Humans; Olanzapine; Risperidone; Schizophrenia | 2020 |
Effects of risperidone on blood levels of interleukin-6 in schizophrenia: A meta-analysis.
Topics: Adult; Antipsychotic Agents; Biomarkers; Female; Follow-Up Studies; Humans; Interleukin-6; Male; Mid | 2020 |
Risperidone- and paliperidone-induced hepatotoxicity: Case report and review of literature.
Topics: Adult; Antipsychotic Agents; Hospitalization; Humans; Male; Paliperidone Palmitate; Risperidone; Sch | 2020 |
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Methamphetamine; Network M | 2021 |
Amisulpride - is it as all other medicines or is it different? An update.
Topics: Administration, Oral; Amisulpride; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, D | 2020 |
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphen | 2021 |
Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Humans; Me | 2022 |
Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment.
Topics: Antipsychotic Agents; Clozapine; Epigenesis, Genetic; Humans; Precision Medicine; Risperidone; Schiz | 2021 |
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depressio | 2021 |
Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients.
Topics: Aged; Antipsychotic Agents; Humans; Psychomotor Agitation; Psychotic Disorders; Risperidone; Schizop | 2021 |
Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports.
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Male; Paliperidone Palmitate; Risperidone; Schizophr | 2021 |
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Drug Resistan | 2017 |
Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Delayed-Action Preparations; Female | 2017 |
Wendan decoction (Traditional Chinese medicine) for schizophrenia.
Topics: Antipsychotic Agents; Chlorpromazine; Drug Therapy, Combination; Drugs, Chinese Herbal; Dyskinesia, | 2017 |
The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Humans; Insulin; Lurasidone Hydrochloride; Net | 2017 |
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diagnosis, Dual (Psychiatry); Humans; Mental Disor | 2018 |
[Safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms in dementia: a meta-analysis].
Topics: Antipsychotic Agents; Dementia; Europe; Humans; Risperidone; Schizophrenia | 2018 |
Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis.
Topics: Antipsychotic Agents; Humans; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Receptors, | 2019 |
Use of cariprazine in psychiatric disorders: A systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder; Humans; Piperazines; Risp | 2018 |
The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors.
Topics: Antipsychotic Agents; Humans; Hypothermia; Mental Disorders; Olanzapine; Risk Factors; Risperidone; | 2019 |
Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Clozapine; Depression; Humans; Imidazoles; | 2019 |
Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Controlled Clinical Trials as Topic; Delayed-Acti | 2019 |
Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Medication Adherence; | 2018 |
Men and women respond differently to antipsychotic drugs.
Topics: Antipsychotic Agents; Clozapine; Female; Humans; Male; Olanzapine; Psychoses, Substance-Induced; Psy | 2020 |
Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics.
Topics: Antipsychotic Agents; Clozapine; Drug Administration Routes; Drug Monitoring; Humans; Paliperidone P | 2020 |
Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.
Topics: Adult; Antipsychotic Agents; Bayes Theorem; Dose-Response Relationship, Drug; Female; Humans; Male; | 2019 |
Aripiprazole versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Ra | 2013 |
The first-episode of schizophrenia: a challenge for treatment.
Topics: Age Factors; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Medication Adherence; Olanzap | 2002 |
Current use of atypical antipsychotics.
Topics: Antipsychotic Agents; Autoreceptors; Brain; Dose-Response Relationship, Drug; Flupenthixol; Haloperi | 2002 |
[Paliperidone, risperidone].
Topics: Antipsychotic Agents; Humans; Isoxazoles; Japan; Paliperidone Palmitate; Pyrimidines; Receptor, Sero | 2013 |
Schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Risperidone; Schizophrenia; Treatment Outcome | 2012 |
Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
Topics: Antipsychotic Agents; Constipation; Double-Blind Method; Drug Therapy, Combination; Granisetron; Hal | 2014 |
Atypical antipsychotics for psychosis in adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Molindone; Olanzapine; Pipe | 2013 |
Quetiapine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Medication Adherence; | 2013 |
Individualizing clozapine and risperidone treatment for schizophrenia patients.
Topics: Clozapine; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmacogenetics; Precision Medi | 2014 |
Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzocycloheptenes; Haloperidol; Heterocyclic Compounds, 4 | 2014 |
Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Humans; Models, Economic; Olanzapine; | 2014 |
HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.
Topics: Alleles; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Genetic Association Studies; Huma | 2014 |
Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials.
Topics: Antipsychotic Agents; Clozapine; Cognitive Behavioral Therapy; Humans; Randomized Controlled Trials | 2014 |
Cannabis and schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cannabinoids; Humans; Marijuana Abuse; Medical M | 2014 |
Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Drug Monitoring; Female; Humans; Male; Ol | 2015 |
Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review.
Topics: Abnormalities, Drug-Induced; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Hum | 2015 |
[Optimal Antipsychotic Dose and Dosing Interval in the Treatment of Schizophrenia].
Topics: Antipsychotic Agents; Cognition Disorders; Drug Administration Schedule; Humans; Risperidone; Schizo | 2015 |
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Topics: Adult; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Clozapine; Double-Blind Method; Drug Re | 2016 |
Chlorpromazine versus atypical antipsychotic drugs for schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Humans; Olanzapine; Quetiapine Fumarat | 2016 |
Risperidone (depot) for schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delayed-Action Preparatio | 2016 |
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
Topics: Administration, Oral; Amisulpride; Antipsychotic Agents; Benzodiazepines; Fluphenazine; Humans; Olan | 2016 |
Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: A review.
Topics: Acetylcysteine; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Free Radical S | 2016 |
Risperidone versus placebo for schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Humans; Placebos; Publication Bias; Randomized Controlle | 2016 |
[Working memory in schizophrenia: a review].
Topics: Antipsychotic Agents; Cognition Disorders; Humans; Memory Disorders; Memory, Short-Term; Neuropsycho | 2008 |
Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Attention; Cognition; Cognition Disorders; Double-Blind Method; Humans; Psycho | 2008 |
Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
Topics: Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Cost-Benefit Analysis; Delayed-Act | 2009 |
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cross-Sectional Studies; Female; Humans; Linkage Disequilibr | 2009 |
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evi | 2009 |
Risperidone: a review of efficacy studies in adolescents with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Clinical Trials as Topic; Humans; Risperidone; Schizophrenia | 2009 |
Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.
Topics: Antipsychotic Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Humans; Isoxazoles; Pa | 2009 |
Sertindole versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Humans; Imidazoles; Indoles; Randomized Controlled Trials as Topic; Risperidon | 2009 |
Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Drug Resistance; Drug Therapy, Com | 2009 |
Zuclopenthixol dihydrochloride for schizophrenia.
Topics: Antipsychotic Agents; Clopenthixol; Dyskinesia, Drug-Induced; Humans; Randomized Controlled Trials a | 2009 |
Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia.
Topics: Aged; Antipsychotic Agents; Delayed-Action Preparations; Drug-Related Side Effects and Adverse React | 2009 |
Aripiprazole versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Ra | 2009 |
Ziprasidone versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapin | 2009 |
Risperidone dose for schizophrenia.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Randomized Controlled Trials as Topi | 2009 |
Amisulpride versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Piperazines; Randomized Cont | 2010 |
Quetiapine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Medication Adherence; | 2010 |
Risperidone versus placebo for schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Humans; Placebos; Publication Bias; Randomized Controlle | 2010 |
Olanzapine versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hum | 2010 |
Risperidone versus placebo for schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Brief Psychiatric Rating Scale; Humans; Mental Status Sc | 2010 |
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Dyslipidem | 2010 |
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinic | 2010 |
Zotepine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Dibenzothiepins; Humans; Randomized Controlled Trials as Topic; Rem | 2010 |
Levomepromazine for schizophrenia.
Topics: Antipsychotic Agents; Chlorpromazine; Humans; Methotrimeprazine; Randomized Controlled Trials as Top | 2010 |
Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
Topics: Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Humans; Isoxazoles; Meta-Analysis as Topic; | 2010 |
Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; E | 2010 |
Clozapine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Humans; Olanz | 2010 |
Risperidone versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hum | 2011 |
Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?
Topics: Antipsychotic Agents; Drug Monitoring; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Risp | 2011 |
Clozapine resistance: augmentation strategies.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Risperidone; Schizophrenia | 2012 |
Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Combined Modality Therapy; Humans; Olanzapine; Pat | 2011 |
Antipsychotic drug treatment for elderly people with late-onset schizophrenia.
Topics: Age of Onset; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanza | 2012 |
Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.
Topics: Administration, Oral; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Evaluation, Precl | 2012 |
Paliperidone palmitate for schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Palmitates; Randomiz | 2012 |
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
Topics: Adult; Affective Disorders, Psychotic; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; | 2012 |
Second-generation long-acting injectable antipsychotic agents: an overview.
Topics: Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Drug Costs; Humans; Injections; | 2012 |
Treatment options for residual insomnia in schizophrenia.
Topics: Antipsychotic Agents; Central Nervous System Depressants; Humans; Isoxazoles; Melatonin; Paliperidon | 2013 |
Multiple visits for abdominal pain, constipation, and "I need a test for sexually transmitted diseases".
Topics: Abdominal Pain; Adolescent; Antipsychotic Agents; Constipation; Diagnosis, Differential; Humans; Mal | 2012 |
Efficacy and safety of long acting injectable atypical antipsychotics: a review.
Topics: Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Drug Delivery Systems; Humans; I | 2013 |
Economic evaluations of olanzapine and risperidone.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Humans; Olanzapine; Pirenzepine; Rando | 2002 |
Dopamine and antipsychotic drug action revisited.
Topics: Antipsychotic Agents; Cerebellum; Corpus Striatum; Dopamine; Dopamine D2 Receptor Antagonists; Human | 2002 |
Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Delirium; Drug Therapy, Combination; Evid | 2002 |
Risperidone: review of its therapeutic utility in depression.
Topics: Animals; Antipsychotic Agents; Depressive Disorder; Humans; Randomized Controlled Trials as Topic; R | 2001 |
Economic evaluations of novel antipsychotic medications: a literature review.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Drug Costs; Humans; Olanzapine; Pirenz | 2003 |
Clinical trial response and dropout rates with olanzapine versus risperidone.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Patient Compliance; Patient | 2003 |
Pharmacological approaches to the management of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzothiaze | 2003 |
[Risperidone].
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine Antagonists; Dyskinesia, Drug-Induce | 2003 |
Risperidone versus typical antipsychotic medication for schizophrenia.
Topics: Antipsychotic Agents; Humans; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Respon | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Respon | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Respon | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Respon | 2003 |
[Late schizophrenia].
Topics: Adult; Age of Onset; Aged; Antipsychotic Agents; Chlorpromazine; Clozapine; Diagnostic and Statistic | 2003 |
[An introduction to antipsychotics].
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dopamine Antagonists; Humans; Indoles; Is | 2003 |
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Ant | 2003 |
Depot risperidone for schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Randomized Controlled Trials as Topic; Ri | 2003 |
New generation antipsychotics for first episode schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapine; Randomized Controlled Trials | 2003 |
Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; | 2003 |
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 2003 |
Risperidone in acute and long-term therapy of schizophrenia--a clinical profile.
Topics: Acute Disease; Antipsychotic Agents; Chronic Disease; Humans; Risperidone; Schizophrenia | 2004 |
Long-acting risperidone: a review of its use in schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Tolerance; | 2004 |
Cost comparisons of olanzapine and risperidone in treating schizophrenia.
Topics: Benzodiazepines; Fees, Pharmaceutical; Humans; Olanzapine; Risperidone; Schizophrenia; Treatment Out | 2004 |
Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dose | 2004 |
Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.
Topics: Antipsychotic Agents; Benzodiazepines; Chemistry, Pharmaceutical; Clinical Trials as Topic; Clozapin | 2004 |
A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Cycloh | 2004 |
Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothi | 2004 |
New antipsychotics and schizophrenia: a review on efficacy and side effects.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Cognition; Dibenzothiazepines; Drug | 2004 |
A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
Topics: Antipsychotic Agents; Databases as Topic; Drug Administration Schedule; Humans; Injections; Injectio | 2004 |
[Current pharmacotherapy of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapin | 2004 |
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; | 2004 |
Atypical antipsychotics and diabetes mellitus: an association.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Diabetic Ketoacidosis; Female; | 2004 |
Atypical antipsychotics and diabetes mellitus.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Dibenzothiazepines; Glucose; Humans; Insul | 2004 |
Risperidone long-acting injection: a brief overview.
Topics: Antipsychotic Agents; Chronic Disease; Delayed-Action Preparations; Humans; Risperidone; Schizophren | 2004 |
Tardive dyskinesia rates with atypical antipsychotics in older adults.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dose | 2004 |
Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature.
Topics: Adult; Antipsychotic Agents; Clozapine; Humans; Male; Obsessive-Compulsive Disorder; Risperidone; Sc | 2004 |
[The features of atypical neuroleptic amisulpride action].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Clinical | 2004 |
Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Delayed-Action Preparations; Drug Tolerance; Health Pr | 2004 |
Long-acting risperidone injection.
Topics: Antipsychotic Agents; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Double-Blind | 2004 |
Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues.
Topics: Antipsychotic Agents; Cohort Studies; Cost-Benefit Analysis; Humans; Risperidone; Schizophrenia | 2004 |
Long-acting injectable risperidone.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections, | 2004 |
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorde | 2004 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Cognitive Behavioral | 2003 |
A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice.
Topics: Adolescent; Adult; Antipsychotic Agents; Decision Making; Dose-Response Relationship, Drug; Female; | 2004 |
An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Double-Blind Method; Drug Indu | 2004 |
Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials, Phase III as Topic; Haloperidol; Humans; Meta-A | 2004 |
Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Clinical Trials as Topic; Depression; Female; Haloper | 2005 |
N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration.
Topics: Adult; Age Factors; Antipsychotic Agents; Aspartic Acid; Choline; Chronic Disease; Creatine; Female; | 2005 |
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; MEDLINE; Neuropsycholo | 2005 |
Clinical review of a long-acting, injectable formulation of risperidone.
Topics: Antipsychotic Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Humans; Injections, In | 2004 |
Risperidone versus olanzapine for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Male; Olanzapine; Randomized Controlled Trials as Top | 2005 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Haloperidol; Humans; | 2004 |
Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine D2 Receptor An | 2005 |
Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
Topics: Antipsychotic Agents; Humans; Pharmacogenetics; Polymorphism, Genetic; Receptor, Serotonin, 5-HT2A; | 2005 |
Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.
Topics: Antipsychotic Agents; Benzodiazepines; Costs and Cost Analysis; Humans; Olanzapine; Randomized Contr | 2005 |
Risperidone: a review.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Risperidon | 2005 |
Risperidone dosing pattern and clinical outcome in psychosis: an analysis of 1713 cases.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cluster Analysis; Drug Administration S | 2005 |
[The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
Topics: Antipsychotic Agents; Delayed-Action Preparations; Drug Administration Schedule; Humans; Quality of | 2005 |
Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Me | 2006 |
The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Memory Disorders; Olanzapine; Retention, P | 2006 |
Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach.
Topics: Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Computer Simulation; Decision Making; Haloperi | 2006 |
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Dyskinesia, Drug | 2005 |
Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Huma | 2005 |
Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
Topics: Antipsychotic Agents; Cost of Illness; Cost-Benefit Analysis; Economics, Pharmaceutical; Humans; Mod | 2005 |
Long-acting injectable risperidone: an emerging tool in schizophrenia treatment.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Patient Compliance; Patient Selection; Ri | 2005 |
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Bias; Dibenzothiazepines; Dose-Response Relationship, Drug; D | 2006 |
Clinical experience and management considerations with long-acting risperidone.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Drug-Related Sid | 2006 |
[Pharmacoeconomic review of the use of injectable long-acting risperidone].
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Economics, Pharmaceutical; | 2005 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Chlorpromazine; Clozapine; Cognitive Behavioral Therapy; Dibenzot | 2005 |
Risperidone versus olanzapine for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Randomized Controlled Trials as Topic; Ri | 2006 |
Risks versus benefits of different types of long-acting injectable antipsychotics.
Topics: Administration, Oral; Antipsychotic Agents; Fluphenazine; Haloperidol; Health Care Costs; Humans; In | 2006 |
Long-acting risperidone: focus on safety.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Risperidone; Sc | 2006 |
Risperidone augmentation of clozapine: a critical review.
Topics: Antipsychotic Agents; Clozapine; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Dysk | 2006 |
Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; Female; Human | 2006 |
Clinical trial-based cost-effectiveness analyses of antipsychotic use.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; Costs and Cost Analysis; Dr | 2006 |
Treatment of psychosis: 30 years of progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapi | 2006 |
[Maintenance pharmacotherapy of schizophrenia: remission and the effectiveness of long-acting risperidone therapy].
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Patient Compliance; Remission Induction; | 2006 |
The case for long-acting antipsychotic agents in the post-CATIE era.
Topics: Antipsychotic Agents; Attitude to Health; Clinical Trials as Topic; Delayed-Action Preparations; Hum | 2007 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 2006 |
Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chemistry, Pharmaceutical; Clinical Trials, Phase | 2007 |
Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Black People; Delayed-Action Preparations; Humans; I | 2007 |
An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Chlorproma | 2007 |
Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Injections; Patient Compliance; Risperido | 2007 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepine | 2007 |
Managing the acutely agitated and psychotic patient.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Emergencies; Humans; Olanza | 2007 |
Chronic restlessness with antipsychotics.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Chro | 2007 |
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Bl | 2008 |
Paliperidone for schizophrenia.
Topics: Antipsychotic Agents; Controlled Clinical Trials as Topic; Delayed-Action Preparations; Drug Interac | 2008 |
Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bias; Bupropion; Data Interpretation | 2008 |
Paliperidone for schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Randomized Controlled | 2008 |
Problems with CATIE. Phase 1: Looking back--what the clinician needs to know.
Topics: Antidepressive Agents, Second-Generation; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials, | 2008 |
Chronic schizophrenia. Options for pharmacologic management.
Topics: Antipsychotic Agents; Chronic Disease; Clozapine; Drug Therapy, Combination; Humans; Lithium; Psycho | 1995 |
Ethical issues in drug selection for schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Ethics, Medical; Humans; Informed Consent | 1993 |
New antipsychotic medications: do research results relate to clinical practice?
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Dyskinesia, Drug-Induced; Humans; Isoxazo | 1993 |
Pharmacological profile of risperidone.
Topics: Antipsychotic Agents; Brain; Dose-Response Relationship, Drug; Haloperidol; Humans; Isoxazoles; Meta | 1993 |
Clinical review of risperidone.
Topics: Antipsychotic Agents; Clinical Trials, Phase III as Topic; Humans; Isoxazoles; Multicenter Studies a | 1993 |
Clinical considerations in the use of risperidone.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Isoxazoles; Piperidines; Psychia | 1993 |
Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential.
Topics: Antipsychotic Agents; Clozapine; Humans; Isoxazoles; Piperidines; Remoxipride; Risperidone; Schizoph | 1993 |
Risperidone.
Topics: Antipsychotic Agents; Drug Interactions; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.
Topics: Antipsychotic Agents; Brain; Clozapine; Dyskinesia, Drug-Induced; Extrapyramidal Tracts; Humans; Iso | 1994 |
Risperidone: clinical issues in treatment.
Topics: Antipsychotic Agents; Drug Approval; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scal | 1994 |
Extrapyramidal side effects and tolerability of risperidone: a review.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; D | 1994 |
The effects of clozapine on neurocognition: an overview.
Topics: Clozapine; Cognition; Cognition Disorders; Dopamine; Humans; Isoxazoles; Neuropsychological Tests; P | 1994 |
Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.
Topics: Absorption; Adult; Aged; Aging; Animals; Antipsychotic Agents; Central Nervous System; Cross-Over St | 1994 |
Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.
Topics: Antipsychotic Agents; Brain; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Psychiatric | 1994 |
Pathophysiology and treatment of negative symptoms.
Topics: Antipsychotic Agents; Brain; Depression; Dose-Response Relationship, Drug; Humans; Isoxazoles; Piper | 1994 |
Pharmacotherapy of schizophrenia: a review.
Topics: Antipsychotic Agents; Brain; Clozapine; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating S | 1994 |
Recent advances in the pharmacotherapy of schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Clozapine; Dopamine; Humans; Isoxazoles; Piperidines; Risperidon | 1994 |
Risperidone: review of its pharmacology and therapeutic use in schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Placebos; Risperido | 1994 |
[New psychopharmacologic alternatives in treatment of schizophrenia].
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Isoxazoles; Piperidines; Psychot | 1994 |
Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dopamine Antagonists; Humans; Imida | 1995 |
Clinical use of the newer antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Female; Formularies as Topic; Halo | 1995 |
A risk-benefit assessment of risperidone in schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Risk; Risperidone; Schizophrenia | 1995 |
Serotonin, schizophrenia and antipsychotic drug action.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Humans; Isoxazoles; Piperazines; Piperidine | 1995 |
Prospects for pharmacotherapy of schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Humans; Isoxazoles; Piperidines; Receptors, | 1995 |
The negative component in schizophrenia.
Topics: Affective Symptoms; Antipsychotic Agents; Haloperidol; Humans; Isoxazoles; Piperidines; Psychiatric | 1995 |
New pharmacotherapeutic modalities for negative symptoms in psychosis.
Topics: Affective Symptoms; Antipsychotic Agents; Clozapine; Humans; Isoxazoles; Piperidines; Psychiatric St | 1995 |
Long-term treatment of mood disorders in schizophrenia.
Topics: Affective Symptoms; Antidepressive Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combinatio | 1995 |
Principal components and further possibilities with the PANSS.
Topics: Affective Symptoms; Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating | 1995 |
Antipsychotic medication in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug | 1995 |
Risperidone: review and assessment of its role in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Humans; Isoxazo | 1995 |
Treatment of schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Clozapine; Cognitive Behavioral Therapy; Family Therapy; Hum | 1995 |
Serotonin-dopamine interaction and its relevance to schizophrenia.
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Disease Models, Animal; Dopamine | 1996 |
Management of late-life psychosis.
Topics: Adult; Age Factors; Age of Onset; Aged; Clozapine; Drug Administration Schedule; Humans; Middle Aged | 1996 |
Management of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Combined Modality Therapy; Diagnosis, Differential; Humans; Psychia | 1996 |
[Recent developments in antipsychotic medication].
Topics: Antipsychotic Agents; Brain; Dyskinesia, Drug-Induced; Humans; Receptors, Dopamine D2; Receptors, Se | 1995 |
Pharmacokinetics of clozapine and risperidone: a review of recent literature.
Topics: Antipsychotic Agents; Biological Availability; Clozapine; Dose-Response Relationship, Drug; Drug Int | 1996 |
Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis.
Topics: Double-Blind Method; Humans; Risperidone; Schizophrenia | 1995 |
Risperidone: efficacy and safety.
Topics: Acute Disease; Antipsychotic Agents; Double-Blind Method; Humans; Randomized Controlled Trials as To | 1995 |
Risperidone and related 5HT2/D2 antagonists: a new type of antipsychotic agent?
Topics: Animals; Disease Models, Animal; Humans; Molecular Structure; Risperidone; Schizophrenia | 1996 |
Antipsychotic dosing strategies in acute schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administratio | 1996 |
Maintenance therapy of persons with schizophrenia.
Topics: Ambulatory Care; Antipsychotic Agents; Case Management; Clozapine; Combined Modality Therapy; Commun | 1996 |
Antipsychotic medications in children and adolescents.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Cl | 1996 |
Treatment-resistant schizophrenic patients.
Topics: Antipsychotic Agents; Clozapine; Double-Blind Method; Humans; Prospective Studies; Randomized Contro | 1996 |
Clinical experience with risperidone.
Topics: Clinical Trials as Topic; Drug Administration Schedule; Humans; Psychotic Disorders; Risperidone; Sc | 1996 |
Pharmacoeconomics of antipsychotic drug therapy.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Cost-Benefit Analysis; Drug Costs; Econom | 1996 |
Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy.
Topics: Amnesia; Antipsychotic Agents; Cholinergic Antagonists; Clozapine; Dibenzothiazepines; Humans; Menta | 1996 |
Management of treatment-resistant patients with schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Lithium; Risperidone; Schizophre | 1996 |
Atypical antipsychotic drugs and long-term outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Follow-Up Studies | 1996 |
Side effect profiles of new antipsychotic agents.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 1996 |
Evaluating outcomes of treatments for persons with psychotic disorders.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Costs; Health Care Reform; Humans; Olanzapine; Pirenzepi | 1996 |
Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Clozapine; Humans; Middle Aged; Patient Compliance; | 1996 |
Management of treatment refractory schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug R | 1996 |
Schizophrenia, violence, clozapine and risperidone: a review. The Special Hospitals Treatment Resistant Schizophrenia Research Group.
Topics: Antipsychotic Agents; Clozapine; Dangerous Behavior; Humans; Patient Admission; Patient Compliance; | 1996 |
The role of cognition in the risk--benefit and safety analysis of antipsychotic medication.
Topics: Antipsychotic Agents; Cognition Disorders; Humans; Neuropsychological Tests; Prefrontal Cortex; Rece | 1996 |
Spontaneous and drug-induced movement disorders in schizophrenia.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Chronic Disease; Dose-Response Relationship, Drug; Dy | 1996 |
Minimizing the non-extrapyramidal side-effects of antipsychotics.
Topics: Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dys | 1996 |
Development and implementation of drug use evaluation (DUE) criteria for risperidone in an outpatient psychiatric setting.
Topics: Adult; Humans; Outpatients; Risperidone; Schizophrenia | 1996 |
New antipsychotic medications: what advantages do they offer?
Topics: Antipsychotic Agents; Clozapine; Drug Costs; Humans; Psychotic Disorders; Risperidone; Schizophrenia | 1997 |
Risperidone: how good is the evidence for efficacy?
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Psychiatric Status Rating Scales; Risperidon | 1997 |
Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials.
Topics: Basal Ganglia Diseases; Humans; Psychiatric Status Rating Scales; Risperidone; Schizophrenia | 1997 |
The promise of new drugs for schizophrenia treatment.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Imidazoles; Indoles; Olanzapine; Pirenzepi | 1997 |
Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety.
Topics: Antiparkinson Agents; Antipsychotic Agents; Haloperidol; Humans; Risperidone; Schizophrenia | 1996 |
Risperidone: an analysis of the first three years in general use.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dopamine Antagonists; Drug Resistance; Dyskinesia, D | 1997 |
Clinical experience in developing treatment regimens with the novel antipsychotic risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Dopamine Antagonists; | 1997 |
New antipsychotic medications: strategies for evaluation and selected findings.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clinical Trials as Topic; Clozapine; Drug Ad | 1997 |
Treatment of the refractory schizophrenic patient.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Diagnosis, Differential; | 1998 |
Effects of antipsychotics on the clinical and psychosocial behavior of patients with schizophrenia.
Topics: Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Clozapine; Family Health; Humans; Olanza | 1997 |
Facilitating compliance with antipsychotic medication.
Topics: Antipsychotic Agents; Clozapine; Cognition; Drug Monitoring; Haloperidol; Health Care Costs; Humans; | 1998 |
Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Cost-Benefit Analysis; H | 1998 |
A new framework for investigating antipsychotic action in humans: lessons from PET imaging.
Topics: Antipsychotic Agents; Binding, Competitive; Clozapine; Dopamine; Dopamine Antagonists; Dopamine D2 R | 1998 |
Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Clozapine; Confidence Intervals; Female; | 1998 |
Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.
Topics: Adolescent; Adolescent Psychiatry; Age Factors; Antipsychotic Agents; Benzodiazepines; Cholinergic F | 1998 |
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst | 1998 |
Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Cost-Benefit Analysis; Dibenz | 1998 |
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri | 1998 |
Assessing the effects of atypical antipsychotics on negative symptoms. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Delusions; Depressive Disorder; Hallucinati | 1998 |
Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Cognition Disorders; Dibenzothiazepines; | 1998 |
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Clozapine; Comorb | 1998 |
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Adult; Age Factors; Aged; Algorithms; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clini | 1998 |
The Canadian experience with risperidone for the treatment of schizophrenia: an overview.
Topics: Antipsychotic Agents; Canada; Humans; Risperidone; Schizophrenia | 1998 |
Treatment refractory schizophrenia: how should we proceed?
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Humans; Olanzapine; Pire | 1998 |
Building castles on sands or quicksands? The strengths and weaknesses of economic evaluation in pharmaceuticals.
Topics: Clozapine; Decision Making; Drug Costs; Health Care Costs; Health Policy; Humans; Practice Guideline | 1998 |
Common treatment goals of antipsychotics: acute treatment.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedu | 1998 |
Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome.
Topics: Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Electroconvulsive Therapy; Episode o | 1998 |
The routine use of atypical antipsychotic agents: maintenance treatment.
Topics: Antipsychotic Agents; Benzodiazepines; Caregivers; Dyskinesia, Drug-Induced; Humans; Olanzapine; Pir | 1998 |
Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Humans; Olanzapine; Pirenzepine; Ri | 1998 |
Conventional vs. newer antipsychotics in elderly patients.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Dose-Re | 1999 |
Use of atypical neuroleptics in child and adolescent psychiatry.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Child; Child Development Diso | 1998 |
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzothiazepines; Double-Blind Meth | 1999 |
Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Cognition Disorders; Humans; Reaction Time; | 1999 |
Risperidone. A pharmacoeconomic review of its use in schizophrenia.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Economics, Pharmaceutical; Humans; Quality of Life; Ris | 1998 |
Cognitive improvement in schizophrenia with novel antipsychotic medications.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzothiazepines; Humans; O | 1999 |
Tardive dyskinesia and atypical antipsychotic drugs.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 1999 |
Antipsychotic drugs and relapse prevention.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Olanzapine; Pirenzepine; Risperidone; Schi | 1999 |
Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; Humans; Olanzapine; Pirenze | 1999 |
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Comorbidity; D | 1999 |
Tardive dyskinesia in affective disorders.
Topics: Adult; Affective Disorders, Psychotic; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipol | 1999 |
Cognitive deficit in schizophrenia and its neurochemical basis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Glutamic Acid; Haloperidol; H | 1999 |
Review of recent clinical studies with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Drug Resistance; Humans; Olan | 1999 |
Antipsychotics from theory to practice: integrating clinical and basic data.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Cl | 1999 |
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.
Topics: Amoxapine; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dopamine Antagonists; Haloperi | 1999 |
Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepi | 1999 |
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Loxapine; Mental Disorders; Ol | 1999 |
Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials.
Topics: Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Confidence Intervals; Dibenzothiazep | 1999 |
Drug metabolism and atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cytochrome P-450 Enzyme System; Dibenzothiazepines | 1999 |
Schizophrenia treatment: the use of atypical drugs--risperdal, zyperexa, and clozaril.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Nurse Clinicians; Olanzapine; Pirenzepine; | 1998 |
Cost-effectiveness of atypical antipsychotics in chronic schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Cost-Benefit Analysis; Humans; Risperidone; Schizophrenia; Treatmen | 1999 |
[Clinical efficacy of olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Binding Sites; Clinical Trials as Topic; Clozapine; Dopamine | 1999 |
Pharmacologic treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Pirenzepin | 1999 |
Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Humans; Imidazoles; Indoles | 1999 |
New antipsychotic medications: more than old wine and new bottles.
Topics: Agranulocytosis; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzot | 2000 |
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Depression; | 2000 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
The treatment of tardive dyskinesia and tardive dystonia.
Topics: Adult; Akathisia, Drug-Induced; Algorithms; Antipsychotic Agents; Benzodiazepines; Clozapine; Decisi | 2000 |
[Atypical neuroleptics in child- and adolescent psychiatry].
Topics: Adolescent Psychiatry; Antipsychotic Agents; Benzodiazepines; Child; Child Psychiatry; Clozapine; Ge | 2000 |
Risperidone versus typical antipsychotic medication for schizophrenia.
Topics: Antipsychotic Agents; Humans; Risperidone; Schizophrenia | 2000 |
Risperidone side effects.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Inc | 2000 |
Adverse events related to olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass In | 2000 |
Amisulpride: a review of its efficacy in schizophrenia.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; C | 2000 |
Safety profile of amisulpride in short- and long-term use.
Topics: Amisulpride; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Drug Administration Sc | 2000 |
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2000 |
Focus on risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders; Risperidone | 2000 |
Risperidone versus other atypical antipsychotic medication for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Olanzapine; Pirenzepine; Randomized Contro | 2000 |
[Atypical antipsychotic drugs].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Netherlands; Olanzapin | 2000 |
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relationship, Drug; Fe | 2000 |
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Dose-Response Relationship, Drug; Haloper | 2000 |
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Costs; Human | 2000 |
Effects of risperidone on affective symptoms in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Double-Blind Method; Female; Halop | 2000 |
Atypical neuroleptics in child and adolescent psychiatry.
Topics: Adolescent; Adolescent Psychiatry; Antipsychotic Agents; Benzodiazepines; Binding Sites; Brain; Cloz | 2000 |
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2001 |
Does risperidone have a place in the treatment of nonschizophrenic patients?
Topics: Bipolar Disorder; Clinical Trials as Topic; Dementia; Humans; Mental Disorders; Obsessive-Compulsive | 2001 |
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Topics: Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Controlled Clinical Trials as T | 2000 |
Olanzapine: an updated review of its use in the management of schizophrenia.
Topics: Adolescent; Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cognition | 2001 |
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine D2 Receptor Antagonists; Haloperid | 2001 |
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up | 2001 |
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Female; Humans; Longitudin | 2001 |
Optimal dosing with risperidone: updated recommendations.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Top | 2001 |
Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Therapy, Combination; Haloperi | 2001 |
Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials.
Topics: Aggression; Antipsychotic Agents; Controlled Clinical Trials as Topic; Hostility; Humans; Risperidon | 2001 |
Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Metho | 2001 |
Ziprasidone: a new atypical antipsychotic.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Dopamine Antago | 2001 |
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Models, N | 2001 |
[Efficacy of rispolept and zyprexa in the treatment of patients with schizophrenia].
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Quality of Life; Risperidone | 2001 |
[Clinical and pharmacological studies of the second generation antipsychotics].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Cytoskeletal Proteins; Dibenz | 2001 |
[Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients].
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Hostility; Humans; Olanzapine; Pirenze | 2002 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage For | 2002 |
Risperidone in the treatment of psychoses in the elderly: a case report series.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Mal | 2002 |
New antipsychotics: classification, efficacy, and adverse effects.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Humans; Isoxazoles; Piperidines; Receptors | 1991 |
872 trials available for risperidone and Dementia Praecox
| Article | Year |
|---|---|
The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study.
Topics: Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Genotype; Humans; Polymorphism, Genetic; Po | 2021 |
Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study.
Topics: Antioxidants; Antipsychotic Agents; Case-Control Studies; Humans; Longitudinal Studies; Oxidative St | 2022 |
PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly Extended-Release Risperidone) in Schizophrenia Patients.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; | 2021 |
Superoxide Dismutase, BDNF, and Cognitive Improvement in Drug-Naive First-Episode Patients With Schizophrenia: A 12-Week Longitudinal Study.
Topics: Adolescent; Adult; Antioxidants; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Cognition; | 2022 |
Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia.
Topics: Celecoxib; Cytokines; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Male; Risperidone; Schiz | 2021 |
Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Humans; Psychiatric Status Rating Scales; | 2022 |
ATAD3B and SKIL polymorphisms associated with antipsychotic-induced QTc interval change in patients with schizophrenia: a genome-wide association study.
Topics: Antipsychotic Agents; ATPases Associated with Diverse Cellular Activities; Electrocardiography; Geno | 2022 |
Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Adalimumab; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Iran; Psyc | 2022 |
Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial.
Topics: Adverse Childhood Experiences; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Hum | 2022 |
Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial.
Topics: Amides; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Drug Therapy, Combination | 2022 |
Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.
Topics: Antipsychotic Agents; Dopamine; Double-Blind Method; Female; Humans; Male; Olanzapine; Prolactin; Pr | 2022 |
Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.
Topics: Antipsychotic Agents; Dopamine; Double-Blind Method; Female; Humans; Male; Olanzapine; Prolactin; Pr | 2022 |
Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.
Topics: Antipsychotic Agents; Dopamine; Double-Blind Method; Female; Humans; Male; Olanzapine; Prolactin; Pr | 2022 |
Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.
Topics: Antipsychotic Agents; Dopamine; Double-Blind Method; Female; Humans; Male; Olanzapine; Prolactin; Pr | 2022 |
Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial.
Topics: Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Interleukin-6; Pentoxi | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Glucose; Haloperidol; Humans; Inflammation; Olanzapine; Perph | 2024 |
Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
Topics: Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Fingolimod Hydrochloride; Huma | 2023 |
Initial severity of the Positive and Negative Syndrome Scale (PANSS)-30, its main subscales plus the PANSS-6, and the relationship to subsequent improvement and trial dropout: a pooled participant-level analysis of 18 placebo-controlled risperidone and pa
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Paliperidone Palmitate; Psychiatric Status Rating | 2023 |
Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study.
Topics: Antipsychotic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Prolactin; Risperidon | 2023 |
Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Risperidone; Schizophrenia; Tre | 2023 |
L-Theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Inpatients; Iran; Psyc | 2023 |
Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.
Topics: Adult; Antipsychotic Agents; Bulgaria; Chronic Disease; Double-Blind Method; Female; Humans; Male; M | 2023 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Cognitive Dysfunction; Double-Bli | 2019 |
An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Olanzapine; Outcome Ass | 2019 |
Randomized controlled trial of adjunctive Valproate for cognitive remediation in early course schizophrenia.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Cognitive Dysfunction; Double-Blind Metho | 2019 |
Efficacy and safety of electroacupuncture on metabolic syndrome due to olanzapine and risperidone: Study protocol for a randomized controlled pilot trial.
Topics: Antipsychotic Agents; Clinical Protocols; Electroacupuncture; Humans; Metabolic Syndrome; Olanzapine | 2019 |
Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Outcome | 2020 |
Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; China; Double-Blind Method; Female; Humans; Lurasidone Hydrochloride; M | 2020 |
Model-based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Mod | 2020 |
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Human | 2020 |
Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; | 2020 |
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.
Topics: Adult; Alcoholism; Antipsychotic Agents; Comorbidity; Female; Hospitalization; Humans; Male; Olanzap | 2020 |
Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female | 2020 |
Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Lurasidone Hydrochloride; Male; Me | 2020 |
A synergistic effect between family intervention and rTMS improves cognitive and negative symptoms in schizophrenia: A randomized controlled trial.
Topics: Antipsychotic Agents; Cognition; Double-Blind Method; Humans; Risperidone; Schizophrenia; Transcrani | 2020 |
Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Risperidone; Schizophrenia | 2020 |
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.
Topics: Adolescent; Age of Onset; Antipsychotic Agents; Child; Female; Humans; Male; Molindone; Olanzapine; | 2021 |
A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning.
Topics: Antipsychotic Agents; Cognition; Cognitive Remediation; Delayed-Action Preparations; Humans; Risperi | 2022 |
Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial.
Topics: Adult; Antioxidants; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; H | 2020 |
Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study.
Topics: Antipsychotic Agents; Brain; Brain Mapping; Clozapine; Comorbidity; Craving; Cues; Humans; Magnetic | 2018 |
Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Cilostazol; Double-Blind Method; Drug Therapy, Combination; Female; Hum | 2017 |
Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone.
Topics: Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quality-A | 2017 |
Effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia: A single-blind randomized exploratory study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Emotions; Female; Humans; Interview | 2017 |
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloper | 2017 |
Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Early Diagnosis; Fema | 2017 |
Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Middle | 2017 |
Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Conduct Disorder; Delayed-Action Preparat | 2017 |
Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Drug Therapy, Combination; | 2017 |
Symptomatic remission in schizophrenia: Results from a risperidone maintenance treatment study.
Topics: Adult; Antipsychotic Agents; Female; Humans; Male; Recurrence; Risperidone; Schizophrenia; Schizophr | 2017 |
Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Employment, Supported; Female; Hu | 2017 |
A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Adm | 2018 |
Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Risperi | 2018 |
No Effect of Adjunctive Minocycline Treatment on Body Metabolism in Patients With Schizophrenia.
Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Double-Blind Method; Female; Humans; Inflamma | 2018 |
L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Carnosine; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 2018 |
Evaluation of the Effect of Fluvoxamine in Patients With Schizophrenia Under Risperidone Treatment: A Clinical Trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; | 2018 |
Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Estradiol; Female; Humans; Middle Aged; Prolactin; Prospective S | 2018 |
Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition; Dose-Response Relationship, Drug; Female; Humans | 2018 |
Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels.
Topics: Adult; Antipsychotic Agents; Biomarkers; Cytokines; Double-Blind Method; Drug Therapy, Combination; | 2018 |
Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cost-Benefit Analysis; Dela | 2018 |
Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Humans; Male; Medication Adherence; Middle Ag | 2018 |
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disor | 2018 |
Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
Topics: Antipsychotic Agents; Cytidine Diphosphate Choline; Double-Blind Method; Drug Therapy, Combination; | 2018 |
The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Cross-Sectional Studies; Humans; Olanzapine; Outcome Assessment, He | 2018 |
Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle A | 2019 |
A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Anxiety; Bipolar Disorder; Brief Psychiatric Rating Scale; | 2019 |
Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia.
Topics: Antipsychotic Agents; Brain-Derived Neurotrophic Factor; China; Electroencephalography; Evoked Poten | 2018 |
Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Drug Administration Schedule; Drug Therapy, Combinati | 2018 |
The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial.
Topics: Adult; Antipsychotic Agents; Body-Weight Trajectory; Female; Humans; Male; Middle Aged; Olanzapine; | 2019 |
Micro- and Macrostructural White Matter Integrity in Never-Treated and Currently Unmedicated Patients With Schizophrenia and Effects of Short-Term Antipsychotic Treatment.
Topics: Adult; Antipsychotic Agents; Brain; Diffusion Tensor Imaging; Female; Humans; Male; Risperidone; Sch | 2019 |
Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Humans; Lurasidone Hydro | 2019 |
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biosensing Techniques; Cloud Computing; Humans; Medical I | 2019 |
Examination of heterogeneity in treatment response to antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Deprescriptions; Female; Humans; Kaplan-Meier Estimate; Male; Medicatio | 2019 |
Study of the efficacy and safety of switching from risperidone to paliperidone in elderly patients with schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Patient | 2013 |
Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; | 2014 |
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Female; Follow-Up St | 2013 |
Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Female; Haloperidol; Humans | 2014 |
A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female | 2013 |
Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; El | 2013 |
Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Excitatory Amino Acid A | 2013 |
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Amino Acids; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnosti | 2013 |
Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Sub | 2013 |
Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperprolactinemia; | 2013 |
An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Inje | 2016 |
Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Chemistry, Pharmaceutical; Drug Administratio | 2013 |
Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Humans; Isoxazoles; Male; Middle Aged; Palipe | 2013 |
Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Drug Administration Schedule; Fem | 2013 |
A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Delayed-Action Preparations; Femal | 2013 |
Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Weight; Clozapine; Electrocardiography; Female; Follow | 2013 |
Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Dopamine Antagonists; Dopamine D2 Receptor Anta | 2013 |
The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Me | 2013 |
Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER).
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Diagnostic and Statistical Manual of Menta | 2013 |
A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Excita | 2014 |
The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial.
Topics: Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Cognition Disorders; Drug Substitution; Dyskine | 2014 |
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Hallucinations; Hospitaliz | 2013 |
Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Protocols; Female; Humans; Japa | 2013 |
An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dibenzothiepins; Female; Hospitalization; Humans; Hyperp | 2013 |
Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
Topics: Adult; Age of Onset; Antipsychotic Agents; Delayed-Action Preparations; Diagnostic and Statistical M | 2014 |
Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Brain Mapping; Female; Follow-Up Studies; Humans; | 2014 |
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Hostilit | 2014 |
Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.
Topics: Administration, Oral; Adult; Delayed-Action Preparations; Female; Humans; Isoxazoles; Male; Middle A | 2014 |
Predictive value of prospective memory for remission in first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Female; Humans; Male; | 2014 |
The effects of ketamine and risperidone on eye movement control in healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Excitatory Amino Acid Antagonists; Eye | 2013 |
Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Weight; Cytokines; Female; Humans; Interleukin-1beta; | 2014 |
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; | 2014 |
Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relati | 2014 |
Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Chronic Disease; Drug Administration Schedu | 2014 |
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Drug Admini | 2014 |
Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Electrocardiography; Femal | 2014 |
Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental D | 2014 |
Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relati | 2014 |
Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Topics: Adult; Anti-Bacterial Agents; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; | 2014 |
Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; | 2014 |
Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Drug Synergism; Female; Humans; Male | 2014 |
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aortic Bodies; Aripiprazole; Benzodia | 2014 |
Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; F | 2014 |
A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders | 2014 |
Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Combat Disorders; Diagnosis, | 2014 |
A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationsh | 2014 |
Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Topics: Administration, Intranasal; Adolescent; Adult; Antipsychotic Agents; Deamino Arginine Vasopressin; D | 2014 |
The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study.
Topics: Adolescent; Adult; Antipsychotic Agents; Attentional Bias; Brain Mapping; Clozapine; Craving; Humans | 2014 |
Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Depression; Dibenzothiazepines; Dose-Respo | 2014 |
Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Injections; Isoxazoles; Paliperidone Palmitate; P | 2014 |
Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Injections; Isoxazoles; Paliperidone Palmitate; P | 2014 |
Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Injections; Isoxazoles; Paliperidone Palmitate; P | 2014 |
Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Injections; Isoxazoles; Paliperidone Palmitate; P | 2014 |
Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Male | 2014 |
Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Inje | 2015 |
Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Dose-Response Relationship, Drug; Female; | 2014 |
Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Blood Pressure; China; Diagnostic and Stati | 2014 |
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Citalopram; Depression; Double- | 2014 |
Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial.
Topics: Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; | 2014 |
Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Co | 2014 |
Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Substitution; Drug Therapy, Combin | 2014 |
Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Recepto | 2014 |
Therapeutic window for striatal dopamine D(2/3) receptor occupancy in older patients with schizophrenia: a pilot PET study.
Topics: Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Func | 2014 |
L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Depression; Double-Blind Method; Female; Follow-Up Stu | 2014 |
Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cataract; Dibenzothiazepines; Female; Humans; Male; M | 2015 |
Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial.
Topics: Adult; Anti-Bacterial Agents; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; | 2014 |
Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Depression; Dibenzothiazepines; Female; Hu | 2015 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocyclohe | 2015 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocyclohe | 2015 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocyclohe | 2015 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocyclohe | 2015 |
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dizziness; Female; Humans; Isoxazoles; M | 2015 |
Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cerebral Cortex; Connecto | 2015 |
Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Female; Humans; Male; Paliperidone | 2015 |
Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers, Pharmacological; Dibenzothiazepines; Femal | 2014 |
The Chinese First-Episode Schizophrenia Trial: background and study design.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Female; Humans; Male; | 2014 |
Effective connectivity during episodic memory retrieval in schizophrenia participants before and after antipsychotic medication.
Topics: Adult; Antipsychotic Agents; Brain; Brain Mapping; Causality; Female; Humans; Magnetic Resonance Ima | 2015 |
Schizophrenia gene expression profile reverted to normal levels by antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Longitudinal Studies; Ma | 2014 |
A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.
Topics: Adult; Aged; Amino Acids; Antipsychotic Agents; Dopamine Antagonists; Dose-Response Relationship, Dr | 2014 |
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Depressive | 2015 |
Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Fem | 2015 |
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass In | 2015 |
Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brain; Diagnostic and Statistical Manual o | 2015 |
Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blin | 2015 |
Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Outcome | 2015 |
Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Monitoring; Feasibility Studies; Female; Humans; | 2015 |
A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.
Topics: Adult; Antipsychotic Agents; Depression; Double-Blind Method; Drug Therapy, Combination; Humans; Mal | 2015 |
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbi | 2015 |
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Topics: Administration, Oral; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2015 |
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Topics: Administration, Oral; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2015 |
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Topics: Administration, Oral; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2015 |
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Topics: Administration, Oral; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2015 |
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Topics: Administration, Oral; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2015 |
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Topics: Administration, Oral; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2015 |
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Topics: Administration, Oral; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2015 |
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Topics: Administration, Oral; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2015 |
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Topics: Administration, Oral; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2015 |
Changes in brain regions associated with food-intake regulation, body mass and metabolic profiles during acute antipsychotic treatment in first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Mass Index; Brain; Delayed-Action Preparations; Double | 2015 |
Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial.
Topics: Administration, Oral; Adult; Alcoholism; Antipsychotic Agents; Delayed-Action Preparations; Female; | 2015 |
Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Connectome; Corpus Striatum; Female; Humans; | 2016 |
A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Ou | 2015 |
ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan.
Topics: Adult; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Antipsychotic Agents; Dextrome | 2015 |
Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; China; Double-Blind Method; Drug Admini | 2015 |
Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Prospective Stu | 2015 |
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Male; Ou | 2015 |
Effectiveness, Good Tolerability, and High Compliance of Doses of Risperidone Long-Acting Injectable Higher Than 75 mg in People With Severe Schizophrenia: A 3-Year Follow-Up.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Injecti | 2015 |
Dorsal striatal volumes in never-treated patients with first-episode schizophrenia before and during acute treatment.
Topics: Adult; Antipsychotic Agents; Caudate Nucleus; Double-Blind Method; Female; Flupenthixol; Humans; Ima | 2015 |
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Neu | 2016 |
Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Aripiprazole; Blood Glu | 2015 |
Differential Response to Risperidone in Schizophrenia Patients by KCNH2 Genotype and Drug Metabolizer Status.
Topics: Adult; Alternative Splicing; Antipsychotic Agents; ERG1 Potassium Channel; Ether-A-Go-Go Potassium C | 2016 |
Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Drug Synergism; Female; Humans; Male; Middle Aged | 2016 |
The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial.
Topics: Adult; Antipsychotic Agents; Female; Humans; Japan; Male; Middle Aged; Neuropsychological Tests; Pal | 2016 |
Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
Topics: Adult; Antipsychotic Agents; Attention; Clopenthixol; Cognition; Denmark; Dopamine Antagonists; Fema | 2016 |
Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Drug Administration Schedule; Female; Follow-Up | 2016 |
The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.
Topics: Adult; Antipsychotic Agents; Female; Gene Frequency; Genome-Wide Association Study; Genotype; Hetero | 2017 |
The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female | 2016 |
Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Delayed-Action Preparations; Double-Blind Me | 2016 |
Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study.
Topics: Adolescent; Adult; Analgesics; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; | 2016 |
AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study.
Topics: Adolescent; Adult; Allosteric Regulation; Antipsychotic Agents; Double-Blind Method; Female; Humans; | 2016 |
Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy.
Topics: Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Female; H | 2016 |
Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison.
Topics: Brief Psychiatric Rating Scale; Clozapine; Comorbidity; Dose-Response Relationship, Drug; Double-Bli | 2016 |
Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study.
Topics: Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hu | 2016 |
Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.
Topics: Adult; Antipsychotic Agents; Cognition; Delayed-Action Preparations; Drug Administration Schedule; F | 2016 |
Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1).
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Fatigue; Female; Gastrointestinal Dis | 2016 |
Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Inje | 2016 |
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Incidence; Male; Metabolic Diseases; Midd | 2016 |
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazep | 2016 |
The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function.
Topics: Adult; Antipsychotic Agents; Cognition; Combined Modality Therapy; Disease-Free Survival; Electrocon | 2016 |
Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.
Topics: Adult; Aged; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance | 2016 |
An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Employment, Supported; Female; Follo | 2017 |
Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Maint | 2016 |
Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 2017 |
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Corpus Striatum; Dopamine Antagonist | 2016 |
Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.
Topics: Absorbable Implants; Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Delayed-Action Preparatio | 2017 |
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.
Topics: Adult; Antipsychotic Agents; Behavioral Symptoms; Double-Blind Method; Female; Humans; Male; Middle | 2017 |
Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia.
Topics: Acoustic Stimulation; Adult; Analysis of Variance; Antipsychotic Agents; Case-Control Studies; Femal | 2008 |
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Dibenzothiazepines; Female; H | 2008 |
Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Capsules; Chronic Disease; Double-Blind Method; Drug Therap | 2008 |
Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; | 2008 |
Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Isoxazoles; Male; Paliperidone Pal | 2008 |
Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Female; Humans; Long | 2009 |
Decreased serum neurotrophin 3 in chronically medicated schizophrenic males.
Topics: Adult; Antipsychotic Agents; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Enzym | 2008 |
Effect of risperidone versus haloperidol on emotional responding in schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Corpus Striatum; Dopamine; Dopamine D2 Receptor Antagonists | 2008 |
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
Topics: Adolescent; Benzodiazepines; Blood Glucose; Body Mass Index; Child; Diagnostic and Statistical Manua | 2008 |
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female | 2008 |
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female | 2008 |
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female | 2008 |
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female | 2008 |
Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzoxazoles; Body Weight; Cholesterol; Dose-Response Re | 2008 |
Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Disruptive, Impulse Control, | 2008 |
Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain; Delayed-Action Preparations; Diagnostic and Statisti | 2008 |
Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Confidence Intervals; Europe; Female; Follow-Up Studie | 2009 |
Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Follow-Up Studies; Humans | 2008 |
A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.
Topics: Antipsychotic Agents; Child; Double-Blind Method; Humans; Hypoglycemic Agents; Metformin; Risperidon | 2008 |
A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Donepezil; Double-Blind Method; Female; Humans; Indans | 2008 |
A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Diagnostic and Statistical Manual of Menta | 2008 |
[Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Topics: Antipsychotic Agents; Catchment Area, Health; Delayed-Action Preparations; France; Hospitalization; | 2007 |
Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Chronic Disease; Cognition Disorders; Double-Blin | 2009 |
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Male; | 2008 |
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Male; | 2008 |
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Male; | 2008 |
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Male; | 2008 |
Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Co | 2008 |
A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Dystonia; Female; Hu | 2010 |
Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cholesterol; Chronic Disease; Dibenz | 2009 |
Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Diagnostic and Statistical Manu | 2008 |
[The study of therapeutic efficacy of two forms of risperidone--rileptid and rispolept in patients with schizophrenia].
Topics: Adult; Antipsychotic Agents; Drugs, Generic; Female; Humans; Male; Risperidone; Schizophrenia; Thera | 2008 |
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Dru | 2008 |
Trajectories and antecedents of treatment response over time in early-episode psychosis.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Early Diagnosis | 2010 |
Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Genotype; Haloperidol; Humans; Male; Pharm | 2009 |
Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
Topics: Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Administration Schedule; | 2008 |
Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Drug Monitoring; Female; Humans | 2009 |
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Cholesterol, H | 2009 |
[Effects of the anticholinesterase drug neuromidin in patients with schizophrenia with marked neurocognitive deficits].
Topics: Aminoquinolines; Antipsychotic Agents; Brain; Cholinesterase Inhibitors; Cognition Disorders; Drug T | 2008 |
The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Injections, I | 2008 |
Results of phase 3 of the CATIE schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Cloza | 2009 |
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-R | 2009 |
Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Early D | 2009 |
Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Double-Blind M | 2009 |
A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients.
Topics: Age Factors; Aged; Amisulpride; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Di | 2009 |
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Haloperidol; Humans; Male | 2008 |
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male | 2008 |
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male | 2008 |
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male | 2008 |
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male | 2008 |
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male | 2008 |
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male | 2008 |
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male | 2008 |
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male | 2008 |
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male | 2008 |
Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans | 2009 |
A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study.
Topics: Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Met | 2009 |
Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Meth | 2009 |
Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Dru | 2009 |
Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; China; Female; Gene Frequency; Genetic Predisposition to Disease; Genom | 2009 |
Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study.
Topics: Adult; Antipsychotic Agents; Female; Hallucinations; Haloperidol; Humans; International Classificati | 2009 |
Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Bipolar Disorder; Cognitive Behavioral Therapy; Co | 2009 |
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cholesterol, HDL; Cholesterol, LDL; | 2009 |
Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition; Educational Status; Female; Hum | 2009 |
Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Black or African American; Catechol O-Methyltrans | 2009 |
Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Female; Health Status; Humans; Male; Middle Ag | 2009 |
Electro-acupuncture versus sham electro-acupuncture for auditory hallucinations in patients with schizophrenia: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Drug Resistance; Electroacupuncture; Female; Hallucinations; Humans; Ma | 2009 |
The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Benzothiazoles; Binding, Competitive; C | 2009 |
Preattentional processes and disorganization in schizophrenia: Influence of a 6-week risperidone treatment.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Attention; Attention Deficit Disorder with Hypera | 2009 |
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Haloperido | 2009 |
Effect of risperidone on emotion recognition deficits in antipsychotic-naïve schizophrenia: a short-term follow-up study.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Cognitive Behavioral Therapy; Emotions | 2009 |
Long-term efficacy of electroconvulsive therapy combined with different antipsychotic drugs in previously resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Combined Modality Therapy; Dose-Response Relationship, | 2009 |
Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Female; Humans; Isoindoles; M | 2009 |
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Follow-Up Studies; Halope | 2009 |
Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Chromosomes, Human, Pair 4; Dibenzothiazepines; Double-Blind | 2011 |
Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Drugs, Chinese Herbal; | 2009 |
Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow- | 2009 |
Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Cognition; Cognition Disorders; Drug | 2009 |
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Chronic Disease; | 2009 |
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Delayed-Action Preparations; Double-Blind | 2010 |
Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.
Topics: Adult; Cohort Studies; Dopamine Antagonists; Drug Administration Schedule; Drug Delivery Systems; Dr | 2009 |
Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches.
Topics: Animals; Antipsychotic Agents; Case-Control Studies; Databases, Genetic; Gene Frequency; Genetic Pre | 2010 |
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Female; Fo | 2010 |
Long-term skill proceduralization in schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Association Learning; Chloroquinolinols; Confiden | 2010 |
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Men | 2009 |
A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Attitude to Health; Delayed-Action Pr | 2009 |
Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Estonia; Europe; Female; Follow-Up S | 2010 |
Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Kaplan-Meier Estimate; Longitudinal Stu | 2010 |
The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Double-Blind Method; Female; Humans; | 2010 |
Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
Topics: Adult; Antipsychotic Agents; Female; Hospitalization; Humans; Male; Medication Adherence; Prospectiv | 2010 |
Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Middle A | 2010 |
A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blin | 2009 |
Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relati | 2010 |
Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
Topics: Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Human | 2010 |
Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Buttocks; Delayed-Action Preparations; Deltoid Muscle; Drug Administrat | 2010 |
Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Inje | 2010 |
Hunger and negative alliesthesia to aspartame and sucrose in patients treated with antipsychotic drugs and controls.
Topics: Adult; Antipsychotic Agents; Aspartame; Benzodiazepines; Carbonated Beverages; Clozapine; Dibenzothi | 2009 |
Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study.
Topics: Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; | 2010 |
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Isoxa | 2010 |
Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Retention, Psychol | 2010 |
Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Attention; Brain; Brain Mapping; Delayed-Action Prepa | 2011 |
Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients.
Topics: Adult; Asian People; Blood Glucose; Delayed-Action Preparations; Female; Humans; Injections, Intramu | 2010 |
Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Acti | 2010 |
Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Arrhythmias, Cardiac; Female; Hear | 2010 |
Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Biomarkers, Pharmacological; Brief Psychiatric Rating Scale | 2010 |
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dose-Response Relation | 2010 |
Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Pressure; Body Mass Index; Chronic Disease; Double-Blin | 2010 |
Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical M | 2010 |
Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Female; Humans; Logistic Mode | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Risperidone long-acting injectable in recent-onset schizophrenia examined with clinician and patient self-report measures.
Topics: Adult; Age of Onset; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; P | 2010 |
Elevated plasma γ-aminobutyrate/glutamate ratio and responses to risperidone antipsychotic treatment in schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Chromatography, Liquid; Female; gamma-Aminobutyri | 2010 |
Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method | 2010 |
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Huma | 2010 |
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine.
Topics: Adult; Clozapine; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; | 2010 |
A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Drug-Related Side Effects and Adv | 2011 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2011 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2011 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2011 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2011 |
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dibenzothiazepines; | 2010 |
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dibenzothiazepines; | 2010 |
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dibenzothiazepines; | 2010 |
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dibenzothiazepines; | 2010 |
A head-to-head comparison of sertindole and risperidone on metabolic parameters.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Cholesterol; Female; Humans; Imidazoles; Indoles; Lipi | 2010 |
A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; | 2010 |
Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia.
Topics: Adult; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Parkinsonian Disorders; Quetiapine Fum | 2010 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; H | 2011 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; H | 2011 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; H | 2011 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; H | 2011 |
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Benzhydryl Compounds; Benzodiazepines; Central Nervous System Stimulant | 2010 |
Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Blood Glucose; Blood Pressure; Body Mass Index; Chi-Square Distri | 2011 |
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Delayed-Action Preparations; Dose | 2011 |
Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine.
Topics: Adult; Apomorphine; Brain; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists | 2011 |
"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double-Blind Method; D | 2011 |
Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Analysis of Variance; Antipsychotic Ag | 2010 |
The heterogeneity of antipsychotic response in the treatment of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-B | 2011 |
Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Imidazoles; Indoles; Mal | 2010 |
Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hum | 2011 |
Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Co | 2011 |
Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study.
Topics: Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Humans; Longitudinal S | 2011 |
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Humans; Isoindoles; Lurasidone Hydrochlori | 2011 |
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Humans; Isoindoles; Lurasidone Hydrochlori | 2011 |
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Humans; Isoindoles; Lurasidone Hydrochlori | 2011 |
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Humans; Isoindoles; Lurasidone Hydrochlori | 2011 |
A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Drug Delivery Sy | 2011 |
Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Cognition Disorders; Double-Blind Met | 2011 |
A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Buspirone; Chronic Disease; Double-Blind Method; Drug Therapy, Combinat | 2010 |
Risperidone oral solution versus standard tablets for the acute treatment of patients with schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Male; Prolactin; Psychiatric Status Rating Scales; Risperidone | 2011 |
Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable.
Topics: Adolescent; Adult; Age of Onset; Child; Delayed-Action Preparations; Female; Follow-Up Studies; Huma | 2011 |
Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Mal | 2011 |
Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychi | 2011 |
Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Comparative Effectiveness Research; Delayed-Action Prepa | 2011 |
A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Data Interpretation, Statistical; Delayed-Action Preparatio | 2011 |
Long-acting risperidone and oral antipsychotics in unstable schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Follow-Up St | 2011 |
Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial.
Topics: Adenosine; Adenosine Deaminase; Adult; Chronic Disease; Clozapine; Double-Blind Method; Female; Halo | 2011 |
Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug | 2011 |
Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812.
Topics: Adult; Algorithms; Antipsychotic Agents; Brain; Cohort Studies; Diagnostic and Statistical Manual of | 2011 |
An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Dose-Response Relat | 2011 |
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucos | 2011 |
An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.
Topics: Adolescent; Adult; Algorithms; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; | 2011 |
Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.
Topics: Adiponectin; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Humans; Insulin | 2012 |
How do clinical trial participants compare to other patients with schizophrenia?
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Cohort Studies; Costs and Cost Analysis; Fema | 2011 |
How do clinical trial participants compare to other patients with schizophrenia?
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Cohort Studies; Costs and Cost Analysis; Fema | 2011 |
How do clinical trial participants compare to other patients with schizophrenia?
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Cohort Studies; Costs and Cost Analysis; Fema | 2011 |
How do clinical trial participants compare to other patients with schizophrenia?
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Cohort Studies; Costs and Cost Analysis; Fema | 2011 |
Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Depression; Double-Blind Method; Female; Follow-Up St | 2012 |
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Benzodiazepines | 2012 |
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Humans; Longitudinal | 2011 |
Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Body Weight; Brief Psychiatric Rating Scale; China; Di | 2011 |
A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study).
Topics: Adult; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Risperid | 2011 |
Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Female; Frontal | 2011 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Chol | 2011 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Chol | 2011 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Chol | 2011 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Chol | 2011 |
Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Me | 2011 |
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Buttocks; Delayed-Action Preparations; Double-Bli | 2012 |
A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Drugs, Chin | 2011 |
Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Delivery Systems; Female; Humans | 2012 |
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.
Topics: Adult; Antipsychotic Agents; Apoptosis Regulatory Proteins; Benzodiazepines; Biomarkers, Pharmacolog | 2012 |
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; GABA Agents; Hum | 2011 |
Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Humans; Male; Ol | 2011 |
A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Chronic Diseas | 2012 |
TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Genotype; Humans; Male; Middle Aged | 2011 |
Driving ability under sertindole.
Topics: Adult; Antipsychotic Agents; Automobile Driving; Dibenzothiazepines; Female; Humans; Imidazoles; Ind | 2012 |
Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Female; Health Status; Huma | 2011 |
Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE).
Topics: Adult; Delayed-Action Preparations; Emergency Service, Hospital; Female; Health Services; Hospitaliz | 2011 |
First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Substitution; F | 2011 |
Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Female; Haloperidol | 2012 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Dru | 2012 |
The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Homeostasis | 2012 |
Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Circadian Rhythm; Death, Sudden, Cardiac; Electrocardi | 2012 |
Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Ni | 2012 |
Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study.
Topics: Adult; Aged; Benzodiazepines; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Olanzapine | 2012 |
Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia.
Topics: Administration, Oral; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; China; Clonazepam; Diagn | 2012 |
Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Decision Making; Female; Gambling; Humans; | 2012 |
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dopamine D2 Receptor | 2013 |
Risperidone in the treatment of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Dopamine Antagonists; Female; Humans; Male; Middle Aged; Ri | 2011 |
Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms.
Topics: Adult; Aged; Amino Acids; Antipsychotic Agents; Cognition; Double-Blind Method; Drug Therapy, Combin | 2012 |
Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Fem | 2012 |
Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Huma | 2012 |
Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.
Topics: Adult; Ambulatory Care; Analysis of Variance; Antipsychotic Agents; Croatia; Double-Blind Method; Fe | 2012 |
A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Drug Therapy, Combination; Female; Hu | 2012 |
Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database.
Topics: Adolescent; Adult; Antipsychotic Agents; Australia; Chronic Disease; Delayed-Action Preparations; Fe | 2012 |
Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Appetite; Benzodiazepines; Body Weight; Female; Ghrelin; Humans; Male; | 2012 |
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
Topics: Antipsychotic Agents; Connecticut; Delayed-Action Preparations; Drug Substitution; Female; Fluphenaz | 2012 |
Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically?: Results from the Changsha study.
Topics: Adolescent; Adult; Antipsychotic Agents; China; Cluster Analysis; Cognitive Dysfunction; Double-Blin | 2012 |
Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Cerebellum; Cerebral Cortex; Female; Haloperidol; Humans | 2012 |
Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Double-Blind Method; Dr | 2012 |
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Cognition Disorders; Double-Blind Method; | 2012 |
Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aquaporin 4; Benzodiazepines; Diagnostic and Statistical Manual of Ment | 2012 |
Impact of catechol-o-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Catechol O-Methyltransferase; Cognition; Female; | 2012 |
Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Male; Psychiatric Status R | 2012 |
The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone.
Topics: Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Female; Halo | 2012 |
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Topics: Antipsychotic Agents; Comparative Effectiveness Research; Cost-Benefit Analysis; Delayed-Action Prep | 2012 |
Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan.
Topics: Adult; Dextromethorphan; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inflammatio | 2012 |
Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Chi-Square Distribution; Drug Administration Rout | 2012 |
Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Delayed-Action Preparations; Depressio | 2012 |
Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Female; Humans | 2012 |
Cognition and communication dysfunctions in early-onset schizophrenia: effect of risperidone.
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Cognition Disorders; Communication Disorders; | 2012 |
Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Cerebral Corte | 2012 |
Akathisia and suicidal ideation in first-episode schizophrenia.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Depression; Double-Blind Method; | 2012 |
Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Fema | 2012 |
Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Delayed-Action Preparations; Female; Humans; Kaplan | 2012 |
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method | 2012 |
One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; | 2012 |
Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients?
Topics: Adult; Antipsychotic Agents; Disease Progression; Double-Blind Method; Female; Haloperidol; Humans; | 2013 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; Humans; Interview, Ps | 2012 |
Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; China; Dibenzothiazepines; Female; Huma | 2012 |
The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Cognition Disorders; Delayed-Action Preparations; Diagnosis, Comp | 2012 |
Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dopamine Antagonists; Double-Bli | 2012 |
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Educational Status; Female; Haloperidol; Humans; Logis | 2013 |
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bi | 2013 |
Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Topics: Administration, Intranasal; Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Thera | 2013 |
Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; Hum | 2013 |
Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Demography; Dose-Response Relationshi | 2013 |
A comparison of the PANSS pentagonal and Van Der Gaag 5-factor models for assessing change over time.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Humans; Male; M | 2013 |
Working alliance and its relationship to outcomes in a randomized controlled trial (RCT) of antipsychotic medication.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans | 2013 |
The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Cross-Over Studies; Double-Blind Method; Femal | 2012 |
Clozapine and visuospatial processing in treatment-resistant schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Cognition Disorders; | 2013 |
Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gra | 2013 |
Bone loss associated with hyperprolactinemia in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Bone Density; Bone Resorption; Cross-Sectional Studies; Estradiol; Fema | 2013 |
[Rispolept (risperidone) efficacy in the treatment of patients with schizophrenia and psychoactive drug dependence].
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Male; Opioid-Related Disorders; Psychotropi | 2002 |
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Huma | 2002 |
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Benzamides; Benzodiazepines; Contrast Media; Corpus Striatum; Dop | 2002 |
Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence.
Topics: Adult; Antipsychotic Agents; Cocaine-Related Disorders; Comorbidity; Female; Humans; Male; Middle Ag | 2002 |
Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Cross-Over Studies; Cytochrome P-450 CYP2D6; Female; Haloperidol; | 2002 |
Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Australia; Cognitive Behavioral Therapy; Combined Modality | 2002 |
Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Australia; Cognitive Behavioral Therapy; Combined Modality | 2002 |
Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Australia; Cognitive Behavioral Therapy; Combined Modality | 2002 |
Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Australia; Cognitive Behavioral Therapy; Combined Modality | 2002 |
Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study.
Topics: Adult; Algorithms; Antipsychotic Agents; Body Weight; Female; Functional Laterality; Hippocampus; Hu | 2002 |
Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Female; Follow-Up Studies; Habituation, Psychophysiologic | 2002 |
Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.
Topics: Antipsychotic Agents; Chronic Disease; Drug Interactions; Drug Therapy, Combination; Female; Fluvoxa | 2002 |
Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Depression; Double-Blind Metho | 2002 |
Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study.
Topics: Adult; Antipsychotic Agents; Australia; Austria; Canada; Clinical Trials as Topic; Cognition Disorde | 2003 |
Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning.
Topics: Acute Disease; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Administration Schedul | 2002 |
Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Bone Density; Clopenthixol; Cloz | 2002 |
Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Humans; Male; | 2002 |
Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Chi-Square Distribution; Chronic Disease | 2002 |
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Double-Blind Metho | 2003 |
Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow-up of patients on depot medication.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Delayed-Action Preparations; Female; | 2002 |
A naturalistic study of risperidone treatment in seven affiliated university hospitals in Korea.
Topics: Adult; Antipsychotic Agents; Catchment Area, Health; Demography; Female; Hospitals, University; Huma | 2003 |
Risperidone in the treatment of Hispanic inpatients with schizophrenia: a pilot study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Hispanic or Latino; Humans; Male; Pilot Pr | 2002 |
Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.
Topics: Adult; Algorithms; Antipsychotic Agents; Benzamides; Female; Humans; Image Processing, Computer-Assi | 2003 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Bl | 2003 |
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.
Topics: Adolescent; Adult; Arousal; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2003 |
Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Female; Homovanillic Acid; Humans; Mal | 2003 |
Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Attitude to Health; Double-Blind Method; Female; Flup | 2003 |
The effect of risperidone treatment on superoxide dismutase in schizophrenia.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Female; Humans; Male; Psychiatric Status Rating S | 2003 |
Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Estrogens; Female; | 2003 |
Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-I | 2003 |
Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.
Topics: Amisulpride; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Pilot Projects; Psychi | 2003 |
Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Indoles; Isoindoles; Male; M | 2003 |
Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia.
Topics: Acute Disease; Adult; Age Factors; Age of Onset; Antipsychotic Agents; Body Weight; Dose-Response Re | 2003 |
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depression; Dopamine Antagonists; Dyskinesia, Dru | 2003 |
Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice?
Topics: Adolescent; Adult; Antipsychotic Agents; Cohort Studies; Cross-Cultural Comparison; Female; Haloperi | 2003 |
Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
Topics: Adult; Antipsychotic Agents; Australia; Benzodiazepines; Cost-Benefit Analysis; Dose-Response Relati | 2003 |
DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study.
Topics: Adolescent; Alleles; Antipsychotic Agents; DNA; Exons; Female; Gene Frequency; Humans; Israel; Male; | 2003 |
[Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
Topics: Acute Disease; Adult; Aggression; Antipsychotic Agents; Female; Humans; Male; Prospective Studies; P | 2003 |
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Femal | 2003 |
The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; O | 2003 |
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
Topics: Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Dr | 2003 |
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Double-Blin | 2003 |
Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Humans; I | 2003 |
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Female; Hosp | 2003 |
[A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone].
Topics: Adult; Age Factors; Antipsychotic Agents; Anxiety; Humans; Male; Prospective Studies; Risperidone; S | 2003 |
Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Behavior Therapy; Brief Psychiatric Rating | 2003 |
Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients.
Topics: Adult; Amenorrhea; Drug Administration Schedule; Female; Hospitals, Psychiatric; Humans; Hyperprolac | 2003 |
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Human | 2003 |
Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Gonadal Steroid Hormones; Homovanillic Acid; Hu | 2003 |
Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol.
Topics: Adult; Antipsychotic Agents; Attention; Chronic Disease; Emotions; Eye Movements; Facial Expression; | 2003 |
[Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
Topics: Antipsychotic Agents; Chronic Disease; Depression; Double-Blind Method; Dyskinesia, Drug-Induced; Fl | 2003 |
The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Gonadal Steroid Hormones; Humans; Leptin; Midd | 2003 |
Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Patient | 2003 |
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Dose-Response Rel | 2003 |
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Femal | 2003 |
Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug- | 2003 |
Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Me | 2003 |
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
Topics: Administration, Oral; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and | 2003 |
Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Linear Models; Male; | 2004 |
A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning.
Topics: Adolescent; Adult; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Prolactin | 2004 |
Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; Doub | 2004 |
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Cross-Over Studies; Dose-Response | 2004 |
Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Depression; Female; Gen | 2004 |
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Bl | 2004 |
An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Drug Therapy, Combination; Erectile Dysfunction; | 2004 |
Adverse effects of risperidone and haloperidol treatment in schizophrenia.
Topics: Adult; Blood Pressure; Case-Control Studies; Dopamine Antagonists; Dose-Response Relationship, Drug; | 2004 |
Do clozapine and risperidone affect social competence and problem solving?
Topics: Adult; Clozapine; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Neuropsychological | 2004 |
Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
Topics: Adult; Algorithms; Antipsychotic Agents; Brain; Brain Chemistry; Computer Simulation; Dopamine Antag | 2004 |
The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia.
Topics: Abdomen; Adipose Tissue; Adult; Antipsychotic Agents; Benzodiazepines; Body Composition; Female; Hum | 2004 |
COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.
Topics: Analysis of Variance; Antigens, CD; Antipsychotic Agents; Celecoxib; Cyclooxygenase Inhibitors; Cyto | 2004 |
COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.
Topics: Analysis of Variance; Antigens, CD; Antipsychotic Agents; Celecoxib; Cyclooxygenase Inhibitors; Cyto | 2004 |
COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.
Topics: Analysis of Variance; Antigens, CD; Antipsychotic Agents; Celecoxib; Cyclooxygenase Inhibitors; Cyto | 2004 |
COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.
Topics: Analysis of Variance; Antigens, CD; Antipsychotic Agents; Celecoxib; Cyclooxygenase Inhibitors; Cyto | 2004 |
Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Therapy, Combination; H | 2004 |
Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.
Topics: Adult; Antipsychotic Agents; Attention; Brief Psychiatric Rating Scale; Discrimination Learning; Dos | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Topics: Adult; Affective Symptoms; Amino Acid Transport Systems, Neutral; Analysis of Variance; Antipsychoti | 2004 |
Correlates of cognitive deficits in first episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Diagnostic and Statistical Manual of M | 2004 |
Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia.
Topics: Adolescent; Adult; Ambulatory Care; Arousal; Attention; Benzodiazepines; Cognition; Drug Administrat | 2004 |
Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Humans; Male; Middle Aged | 2004 |
Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
Topics: Adult; Algorithms; Antipsychotic Agents; Benzamides; Benzodiazepines; Dopamine; Female; Humans; Male | 2004 |
Adherence to conventional and atypical antipsychotics after hospital discharge.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; | 2004 |
Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benztropine; Cholinergic Antagonists; Cognition Disorders; Female; Huma | 2004 |
Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study.
Topics: Adiponectin; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cross-Sec | 2004 |
Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Cognition; Dose-Response Relationship, Drug; Female; Huma | 2004 |
Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone.
Topics: Adolescent; Adult; Chronic Disease; Cohort Studies; Confidence Intervals; Drug Administration Schedu | 2004 |
Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Drug Administration S | 2004 |
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Factor Analysis, Stati | 2004 |
Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.
Topics: Adult; Antipsychotic Agents; Female; Genotype; Humans; Individuality; Male; Polymorphism, Genetic; P | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Benzodiazepines; Cognition; Cross-Over Studies; Female; Huma | 2004 |
Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Risperidone; S | 2004 |
Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Acti | 2004 |
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, | 2004 |
Prolactin levels and erectile function in patients treated with risperidone.
Topics: Adolescent; Adult; Affect; Aged; Antipsychotic Agents; Circadian Rhythm; Erectile Dysfunction; Human | 2004 |
A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Psychiatric Status Ratin | 2004 |
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Huma | 2004 |
Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Delayed-Action Preparations; Drug Administration Sche | 2004 |
Plasma risperidone concentrations during combined treatment with sertraline.
Topics: Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; | 2004 |
Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aggression; Antipsy | 2004 |
Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Hyperprolactinemia; M | 2005 |
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Haloper | 2004 |
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Haloper | 2004 |
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Haloper | 2004 |
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Haloper | 2004 |
Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Delayed-Action Preparations; Drug Administration | 2004 |
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Diarrhea; Drug Administration Schedule; Dr | 2004 |
Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Follow-Up Studies; Haloperidol; Hospitalization; Humans; Ma | 2003 |
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Topics: Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2004 |
Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Female; Hospitalization; Huma | 2004 |
Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia; Basal Ganglia Diseases; Benzodiazepines; Cau | 2004 |
Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Area Under Curve; Cholinesterase Inhibitors | 2004 |
Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
Topics: Adult; Antipsychotic Agents; Attention; Automobile Driving; Case-Control Studies; Female; Haloperido | 2005 |
Clinical effects of COX-2 inhibitors on cognition in schizophrenia.
Topics: Adult; Antipsychotic Agents; Celecoxib; Cognition; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Doub | 2005 |
Clinical effects of COX-2 inhibitors on cognition in schizophrenia.
Topics: Adult; Antipsychotic Agents; Celecoxib; Cognition; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Doub | 2005 |
Clinical effects of COX-2 inhibitors on cognition in schizophrenia.
Topics: Adult; Antipsychotic Agents; Celecoxib; Cognition; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Doub | 2005 |
Clinical effects of COX-2 inhibitors on cognition in schizophrenia.
Topics: Adult; Antipsychotic Agents; Celecoxib; Cognition; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Doub | 2005 |
Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule | 2004 |
Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Drug Admi | 2005 |
Risperidone plasma levels, clinical response and side-effects.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chromatography, High Pressure | 2005 |
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationsh | 2005 |
Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Double-Blind Method; Drug Ad | 2005 |
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies | 2004 |
Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Community Mental Health Centers; Diagnostic and | 2004 |
Dopamine D3 receptor Ser9Gly polymorphism and risperidone response.
Topics: Adult; Amino Acid Substitution; Antipsychotic Agents; China; DNA; Dose-Response Relationship, Drug; | 2005 |
Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction.
Topics: Adult; Aged; Antipsychotic Agents; Biotransformation; Cytochrome P-450 CYP2D6; Drug Interactions; Fe | 2005 |
Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Brain Stem; Female; Fixation, Ocular; Follow-Up Studies; Hal | 2005 |
Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service.
Topics: Administration, Oral; Adult; Aged; Delayed-Action Preparations; Drug Administration Schedule; Drug M | 2005 |
A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Double-Blind Method; Drug Administration Sc | 2005 |
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Drug Resistance; Female; Fluph | 2005 |
Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Lipids; Longitudinal Studies; Olanzapine; Prospective | 2004 |
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co | 2005 |
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co | 2005 |
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co | 2005 |
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co | 2005 |
Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Binding, Competitive; Brain; Delayed-Action Prepa | 2005 |
Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzamides; Binding, Competitive; Brain Mapping; Case-Cont | 2005 |
Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female | 2005 |
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Urea Nitrogen; Creatinine; Cross-Over Studies; D | 2005 |
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Urea Nitrogen; Creatinine; Cross-Over Studies; D | 2005 |
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Urea Nitrogen; Creatinine; Cross-Over Studies; D | 2005 |
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Urea Nitrogen; Creatinine; Cross-Over Studies; D | 2005 |
Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration | 2005 |
Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Delayed-Action Preparations; Female | 2005 |
An open study of risperidone liquid in the acute phase of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Chromatography, High Pressure Liquid; | 2005 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind | 2005 |
The effects of clozapine and risperidone on spatial working memory in schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Diagnosis, Computer-Assisted | 2005 |
The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia--preliminary results of a facial electromyogram study.
Topics: Adult; Benzodiazepines; Chi-Square Distribution; Electromyography; Emotions; Facial Expression; Faci | 2005 |
Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepin | 2005 |
Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Double-Blind Method; Drug Resistance; Female; Hal | 2005 |
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Bli | 2005 |
Clozapine improves working memory updating in schizophrenia.
Topics: Adult; Antipsychotic Agents; Biperiden; Clozapine; Electroencephalography; Evoked Potentials; Female | 2005 |
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; | 2005 |
An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antipsychotic Agents; Delayed-Action Preparati | 2005 |
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule; Fema | 2005 |
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; Nursing | 2005 |
Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone.
Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Subcutaneous; M | 2005 |
Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; | 2005 |
Cerebral cortical gray expansion associated with two second-generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Atrophy; Cerebral Cortex; Cognition Disorders; Female; Follow-Up Studie | 2005 |
Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; | 2005 |
Risperidone dosing pattern and clinical outcome in psychosis: an analysis of 1713 cases.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cluster Analysis; Drug Administration S | 2005 |
The effects of celecoxib augmentation on cytokine levels in schizophrenia.
Topics: Adult; Benzodiazepines; Celecoxib; Cytokines; Double-Blind Method; Drug Synergism; Female; Humans; M | 2006 |
Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety; Dep | 2005 |
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Cohort Studies; Dibenzothiazepi | 2005 |
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cross-Cultural Comparison; Dibenzothi | 2005 |
Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Depression; Double-Blind Method; Fem | 2005 |
Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Female; Hu | 2005 |
Direct transition to long-acting risperidone--analysis of long-term efficacy.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Endpoint Determination; Female; Humans; In | 2005 |
The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.
Topics: Adult; Antipsychotic Agents; Brain; Cognition; Cognition Disorders; Double-Blind Method; Female; Fol | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperi | 2005 |
The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS).
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Choline; Creatine; Energy Metabolism; Female; Frontal Lo | 2005 |
Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
Topics: Adult; Antipsychotic Agents; Biperiden; Cholinergic Antagonists; Cytochrome P-450 CYP2D6; Drug Thera | 2005 |
Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Buspirone; Denmark; Drug Thera | 2005 |
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; | 2006 |
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; | 2006 |
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; | 2006 |
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; | 2006 |
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Drug Administra | 2005 |
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Benzodiazepines; Double-Blind Method; Female; Ha | 2006 |
Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; Humans; Male; Middle A | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2005 |
Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Dose-Response Relations | 2005 |
Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Attitude; Chi-Square Distribution; Clozapine; Drug Therapy, Combination | 2006 |
A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Imidazoles; Indoles; M | 2006 |
Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Topics: Adult; Antifungal Agents; Antipsychotic Agents; Chromatography, High Pressure Liquid; Cytochrome P-4 | 2005 |
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; | 2005 |
The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study.
Topics: Antipsychotic Agents; Double-Blind Method; Haloperidol; Humans; Prolactin; Psychiatric Status Rating | 2006 |
A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Parkinsonian Disorder | 2006 |
[Neuroleptic drug utilization among schizophrenic outpatients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; | 2005 |
Clozapine alone versus clozapine and risperidone with refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition; Double-Blind Method; Drug Therapy, Combination; F | 2006 |
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Estradiol; Female; Galactorrhea; Gynecomastia; H | 2006 |
Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia.
Topics: Adult; Aged; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Clozapine; Cohort Studies; Dibe | 2005 |
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bias; Clozapine; Drug Administration Schedule; Episode | 2006 |
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Blood Pressure; Body Mass Index; Bod | 2005 |
Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Behavioral Symptoms; Brief Psychiat | 2006 |
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Genetic Predisposition to Disease; | 2006 |
Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Halo | 2006 |
Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Canada; Clozapine; Cohort Studie | 2006 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Ove | 2006 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Ove | 2006 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Ove | 2006 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Ove | 2006 |
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Chronic Disease; Cross-Over Studies; Dibe | 2006 |
Time course for antipsychotic treatment response in first-episode schizophrenia.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Sch | 2006 |
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol | 2006 |
Risperidone-related weight gain: genetic and nongenetic predictors.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; China; Cyto | 2006 |
Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Data Interpretation, Statistical; Drug The | 2006 |
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Chronic Disease; Double-Blind Method; Fem | 2006 |
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Fem | 2006 |
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Comorbidity; F | 2007 |
Galantamine improves cognition in schizophrenic patients stabilized on risperidone.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition; Double-Blind Method; Female; Gala | 2006 |
Premorbid functioning and treatment response in recent-onset schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Female; Haloperidol; Humans | 2006 |
Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Follow | 2006 |
The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Benzodiazepines; Confounding Factors, Epidemiologic | 2006 |
Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Clopenthixol; Double-Blind Method; Female; Haloperidol; Human | 2006 |
Effects of risperidone on auditory information processing in neuroleptic-naive patients with schizophrenia spectrum disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Auditory Perception; Evoked Potentials, Auditory | 2006 |
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cognition Disorders; Dibenzothiazepines; Disord | 2006 |
A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Female; Humans; Injections, Int | 2006 |
Long-term treatment with long-acting risperidone in Korean patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Drug Administration Schedule; Female | 2006 |
A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Attention; Benzodiazepines; Blinking; Brain; Brai | 2007 |
Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Clopenthixol; Comorbidity; Delayed-Action Preparation | 2006 |
Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Cholinergic Antagonists; Data I | 2006 |
An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Body Weight; Child; Dose | 2006 |
A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-B | 2006 |
The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Female; Glucose Tolerance T | 2006 |
A crossover study of prolactin changes associated with risperidone and olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Female; Humans; Hyperprolactinemia | 2006 |
Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.
Topics: Adult; Antipsychotic Agents; Caudate Nucleus; Dopamine Plasma Membrane Transport Proteins; Down-Regu | 2007 |
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
Topics: Adult; Antipsychotic Agents; Appetite; Benzodiazepines; Blood Glucose; Chronic Disease; Delayed-Acti | 2007 |
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Drug Interactions; Female | 2006 |
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Body Weight; Dose-Response Relationship | 2007 |
Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; Humans; Ma | 2006 |
Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Double-Blind Method; Female; Human | 2006 |
Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dibenzothiazepines; Double-Blind | 2006 |
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dysk | 2007 |
The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Asian People; Brief Psychiatric Rating Scale; Chi-Square Distribution; | 2007 |
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Sc | 2006 |
Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Cross-Over | 2006 |
Optimizing early prediction for antipsychotic response in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Female; Humans; Logistic Models; Male; Mi | 2006 |
Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Patient Dropouts; Risperidone; Schizophre | 2006 |
Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Corpus Striatum; Female; Flupenthixol; Frontal Lobe; Haloperidol; Human | 2007 |
Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depressive Disorder, Ma | 2006 |
Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Chemistry, Pharmaceutical; Endpoint De | 2006 |
Effectiveness of switching antipsychotic medications.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Dibenzothiazepin | 2006 |
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass Index; Female; Follo | 2006 |
[Effects of risperidone on polysomnography in patients with first-episode schizophrenia].
Topics: Adult; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Polysomnography; Risperidone; Schizo | 2006 |
Patient-based and clinician-based support for the remission criteria in schizophrenia.
Topics: Adult; Antipsychotic Agents; Female; Humans; Logistic Models; Male; Patients; Physicians; Psychiatri | 2007 |
A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
Topics: Adult; Antipsychotic Agents; Attention; Clozapine; Cognition; Cognition Disorders; Double-Blind Meth | 2006 |
Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Basal Ganglia Diseases; Celeco | 2007 |
Early onset of treatment effects with oral risperidone.
Topics: Administration, Oral; Antipsychotic Agents; Humans; Risperidone; Schizophrenia; Time Factors | 2007 |
An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Logistic Models; Male; Olanzapine; Pat | 2007 |
Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone.
Topics: Administration, Oral; Adult; Body Weight; Cardiovascular System; Female; Hospitalization; Humans; In | 2007 |
Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Clozapine; Double-Blind Method; Female; Humans; Male; Mass Screening; M | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2007 |
Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Caudate Nucleus; Cholinergic Antagonists; Clopenthixol; | 2007 |
Huperzine A as add-on therapy in patients with treatment-resistant schizophrenia: an open-labeled trial.
Topics: Adolescent; Adult; Aged; Alkaloids; Antipsychotic Agents; Chlorpromazine; Cholinesterase Inhibitors; | 2007 |
Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cholinesterase Inhibitors; Clozapine; Cross-Over Studi | 2007 |
Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Carbon Radioisotopes; Corpus Striatum; Fem | 2007 |
Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Cerebral Cortex; Cerebrovascular Circulation; Double-Blind Method; Fema | 2008 |
Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Data Interpretation, Statistical; De | 2007 |
Effects of risperidone on lipid profile.
Topics: Adult; Aged; Antipsychotic Agents; Body Mass Index; Cholesterol; Cross-Sectional Studies; Female; Hu | 2007 |
[Clinical observation on effect of modified Daotan Decoction combined with small dose risperidone in treating chronic schizophrenia].
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Diagnosis, Differential; Drug Therapy, Com | 2007 |
Stability of emotional dysfunctions? A long-term fMRI study in first-episode schizophrenia.
Topics: Adult; Affect; Affective Symptoms; Antipsychotic Agents; Cerebral Cortex; Double-Blind Method; Femal | 2007 |
Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Female; Haloperidol; Humans; Male; Neur | 2007 |
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dioxoles; Double-Blind | 2008 |
Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients.
Topics: Adult; Antipsychotic Agents; Clozapine; Cross-Sectional Studies; Electron Transport; Electron Transp | 2007 |
Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.
Topics: Administration, Oral; Antipsychotic Agents; Humans; Hyperprolactinemia; Injections, Intramuscular; R | 2007 |
A pilot observational crossover study of QTc interval changes associated with switching between olanzapine and risperidone.
Topics: Adult; Benzodiazepines; Cross-Over Studies; Electrocardiography; Female; Humans; Long QT Syndrome; M | 2007 |
Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dopamine Antagonists; Humans; Hyperprolactinemia; Mal | 2007 |
Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Follow- | 2007 |
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Cohort Studies; Dibenzothiazepine | 2007 |
Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antipsychotic Agents; ATP Binding Cassette Transport | 2007 |
Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Body Weight; Clozapine; Femal | 2007 |
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; D | 2007 |
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Cognition Disorders; Dibenzothiaze | 2007 |
Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Attention; Cognition; Data Interpretation, Statistica | 2007 |
Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Humans; Incidence; India; | 2007 |
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.
Topics: Acoustic Stimulation; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Electromyography; | 2007 |
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Fem | 2007 |
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Benzodiazepines; Child; Comorbidity; Depressi | 2007 |
Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Depressive Disorder; Electrocardiography; Endp | 2007 |
How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Topics: Adult; Algorithms; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Sc | 2007 |
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.
Topics: Antipsychotic Agents; Body Weight; Clozapine; Data Interpretation, Statistical; Double-Blind Method; | 2007 |
Risperidone versus haloperidol for facial affect recognition in schizophrenia: findings from a randomised study.
Topics: Acute Disease; Adolescent; Adult; Affect; Antipsychotic Agents; Diagnostic and Statistical Manual of | 2009 |
Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study.
Topics: Administration, Oral; Adult; Aged; Female; Humans; Injections; Male; Middle Aged; Pain; Pain Measure | 2007 |
Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dysmenor | 2007 |
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Basal Ganglia Disea | 2008 |
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Control Groups; Female | 2007 |
Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder.
Topics: Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Humans; Placebos; Polypharmacy; Psych | 2007 |
Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility.
Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Diarrhea; Drug Therapy, Combination; Femal | 2007 |
Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.
Topics: Adult; Antipsychotic Agents; Female; Glycine; Humans; Male; Pharmacogenetics; Polymorphism, Genetic; | 2008 |
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
Topics: Adaptation, Psychological; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanz | 2008 |
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
Topics: Adaptation, Psychological; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanz | 2008 |
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
Topics: Adaptation, Psychological; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanz | 2008 |
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
Topics: Adaptation, Psychological; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanz | 2008 |
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
Topics: Adaptation, Psychological; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanz | 2008 |
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
Topics: Adaptation, Psychological; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanz | 2008 |
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
Topics: Adaptation, Psychological; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanz | 2008 |
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
Topics: Adaptation, Psychological; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanz | 2008 |
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
Topics: Adaptation, Psychological; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanz | 2008 |
A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzothiazepines; Drug Admin | 2008 |
Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Female; Humans; Longitudinal Studies; Ma | 2007 |
Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.
Topics: Acute Disease; Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; D | 2007 |
Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female | 2008 |
Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists.
Topics: Antipsychotic Agents; Australia; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; Humans; O | 2007 |
The effect of long-acting risperidone on working memory in schizophrenia: a functional magnetic resonance imaging study.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antipsychotic Agents; Brain Mapping; Delayed-Action | 2007 |
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Algorithms; Antipsychotic Agents; Biomedical Research; Cooperative Behavior; D | 2007 |
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Diagnosti | 2007 |
Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibe | 2007 |
Concordance of patient and clinical ratings of symptom severity and change of psychotic illness.
Topics: Adolescent; Adult; Antipsychotic Agents; Attitude to Health; Awareness; Health Status; Humans; Psych | 2008 |
Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Attention; Behavioral Symptoms; Case-Control Stud | 2008 |
The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Awareness; Cognition Disorders; Delayed-Act | 2007 |
A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female | 2008 |
Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.
Topics: Activities of Daily Living; Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cost-Bene | 2008 |
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Dibenzothiazepines; Doub | 2008 |
Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Female; Haloperi | 2008 |
Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; Human | 2008 |
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.
Topics: Absorptiometry, Photon; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Gl | 2008 |
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Cognition Disorders; Culture; Dibe | 2008 |
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study.
Topics: Adolescent; Adult; Antidepressive Agents; Blood Glucose; Body Mass Index; Cholesterol; Delayed-Actio | 2008 |
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Capsules; Dose-Response Relationship, Drug | 2008 |
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothi | 2008 |
Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dose-Response Relati | 2008 |
A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepines; Drug Administration S | 2008 |
Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Chi-Square Distribution; Drug Adminis | 2008 |
What CATIE found: results from the schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dibenzothiaze | 2008 |
Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dysk | 2008 |
A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Bromocriptine; Drug Therapy, Combination; Drugs, Chinese He | 2008 |
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Mass I | 2008 |
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Denmark; Double-Blind Method; Female; Humans; Isox | 1993 |
Risperidone in the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Fe | 1994 |
Risperidone in the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Fe | 1994 |
Risperidone in the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Fe | 1994 |
Risperidone in the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Fe | 1994 |
Symptoms in schizophrenic syndromes in relation to age, sex, duration of illness and number of previous hospitalizations.
Topics: Adult; Age Factors; Age of Onset; Aged; Antipsychotic Agents; Female; Haloperidol; Hospitalization; | 1994 |
Negative symptoms in schizophrenia: assessment of the effect of risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Humans; Isoxazoles; Male; Middle | 1994 |
Efficacy of risperidone on positive features of schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Haloperidol; Humans; Isoxazoles; | 1994 |
Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol.
Topics: Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.
Topics: Absorption; Adult; Aged; Aging; Animals; Antipsychotic Agents; Central Nervous System; Cross-Over St | 1994 |
Desmopressin for risperidone-induced enuresis.
Topics: Administration, Intranasal; Adult; Antipsychotic Agents; Deamino Arginine Vasopressin; Double-Blind | 1994 |
Pharmacokinetics of risperidone in chronic schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Cross-Over Studies; Humans; Isoxazoles; Ma | 1994 |
Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperid | 1994 |
Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Cerebral Cortex; Dopamine D2 Receptor Antago | 1995 |
Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Fe | 1995 |
Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middl | 1995 |
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Haloperidol; Hum | 1995 |
The negative component in schizophrenia.
Topics: Affective Symptoms; Antipsychotic Agents; Haloperidol; Humans; Isoxazoles; Piperidines; Psychiatric | 1995 |
New pharmacotherapeutic modalities for negative symptoms in psychosis.
Topics: Affective Symptoms; Antipsychotic Agents; Clozapine; Humans; Isoxazoles; Piperidines; Psychiatric St | 1995 |
Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Clopenthixol; Double-Blind Method; Fem | 1995 |
Critique of the Canadian Multicenter Placebo-Controlled Study of Risperidone and Haloperidol.
Topics: Canada; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Research Design; Risperid | 1995 |
Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; | 1995 |
Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series.
Topics: Aged; Bipolar Disorder; Chronic Disease; Comorbidity; Dementia; Female; Hospitalization; Humans; Hyp | 1995 |
Effect of risperidone on hostility in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Haloperidol; Hostility; Humans; | 1995 |
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind M | 1993 |
Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial.
Topics: Adolescent; Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Isoxazoles; Ma | 1993 |
Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dominance, Cerebral; Dose-Response Relationship, Drug | 1993 |
Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Fema | 1993 |
Lead-in placebo washout period.
Topics: Antipsychotic Agents; Humans; Metabolic Clearance Rate; Risperidone; Schizophrenia; Treatment Outcom | 1995 |
Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study.
Topics: Akathisia, Drug-Induced; Ambulatory Care; Clozapine; Cognition Disorders; Cross-Over Studies; Humans | 1996 |
Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis.
Topics: Double-Blind Method; Humans; Risperidone; Schizophrenia | 1995 |
[Efficacy and tolerance of risperidone in various doses (report of a study)].
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Male; Perphenazine; R | 1996 |
Treatment-resistant schizophrenia: clinical experience with new antipsychotics.
Topics: Clozapine; Humans; Risperidone; Schizophrenia | 1996 |
Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Double-Blind Method; Drug The | 1996 |
Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Female; Hospitalization; Humans; Male; Prospective Stu | 1996 |
Neurological soft signs and response to risperidone in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Female; Humans; Male; Neuropsychological Tests; Risperidone; Schizophre | 1996 |
Serotonin-mediated increase in cytosolic [Ca++] in platelets of risperidone-treated schizophrenia patients.
Topics: Adult; Blood Platelets; Calcium; Female; Humans; Male; Prognosis; Risperidone; Schizophrenia; Seroto | 1996 |
Regional cerebral blood flow changes associated with risperidone treatment in elderly schizophrenia patients: a pilot study.
Topics: Aged; Blood Flow Velocity; Cerebrovascular Circulation; Female; Humans; Male; Pilot Projects; Psychi | 1996 |
Risperidone-associated burning paraesthesia.
Topics: Adult; Aged; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Mood Disorders; Paresthesia; R | 1996 |
Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study.
Topics: Adult; Affective Symptoms; Antipsychotic Agents; Cognition Disorders; Female; Humans; Male; Middle A | 1997 |
Risperidone in adolescents with schizophrenia: an open pilot study.
Topics: Adolescent; Antipsychotic Agents; Child; Female; Humans; Male; Pilot Projects; Risperidone; Schizoph | 1997 |
Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Eye Movements; Female; Haloperidol; Humans; Male; Prospective Studies; | 1997 |
Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
Topics: Adult; Benztropine; Double-Blind Method; Female; Haloperidol; Humans; Male; Memory; Neuropsychologic | 1997 |
Extrapyramidal symptoms in patients treated with risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine Antagonists; Double-Blind Method; Fema | 1997 |
Observations on switching patients with schizophrenia to risperidone treatment. Risperidone Switching Study Group.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Cholinergic Antagonists; Drug | 1997 |
A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Patient Compliance; Psychi | 1997 |
Aggression and schizophrenia: efficacy of risperidone.
Topics: Adult; Aggression; Analysis of Variance; Antipsychotic Agents; Female; Humans; Longitudinal Studies; | 1997 |
Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Canada; Chronic Disease; Cost-Benefit Analysis; Doubl | 1997 |
Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Humans; Male; Psychiatric S | 1997 |
Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Area Under Curve; Biot | 1997 |
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Female; | 1997 |
Effects of risperidone on polydipsia in chronic schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Chronic Disease; Combined Modality Therapy; Double-Bl | 1997 |
Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting.
Topics: Adult; Aged; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Risperidone; Schizophrenia | 1997 |
Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol.
Topics: Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Haloperidol; Humans; Neuropsychologi | 1997 |
A study of enhanced management in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Drug Resistance; Female; Humans; Male; Psychiatric Stat | 1997 |
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Double-Blind Meth | 1997 |
Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility.
Topics: Adult; Aggression; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Forensic Psy | 1997 |
Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland.
Topics: Adult; Antipsychotic Agents; Austria; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; | 1997 |
The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.
Topics: Acute Disease; Adolescent; Adult; Akathisia, Drug-Induced; Ambulatory Care; Antipsychotic Agents; Ba | 1998 |
An open comparison of clozapine and risperidone in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Female; Humans; Male; Psychiatric Status Ra | 1998 |
Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Clozapine; Double-Blind Method; Drug | 1998 |
A syndrome of increased affect in response to risperidone among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Anxiety; Disease Susceptibility; Follow-Up Studies; Humans; Male; Middl | 1998 |
Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Child; Double-Blind Method; Female; | 1998 |
Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting.
Topics: Aged; Antipsychotic Agents; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Retrospective | 1998 |
The effects of risperidone and olanzapine on the indications for clozapine.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Olanzapine; Pirenzepine; Risperidone; Schi | 1998 |
Efficacy and tolerability of risperidone in chronic schizophrenic Thai patients.
Topics: Adult; Aged; Analysis of Variance; Chronic Disease; Female; Humans; Male; Middle Aged; Psychological | 1998 |
Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection.
Topics: Antipsychotic Agents; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Isoxazoles; Pa | 1998 |
Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Emotions; F | 1998 |
Olanzapine-induced reversible priaprism: a case report.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Humans | 1998 |
Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Humans; Olanzapine; Pirenzepine; Psychot | 1998 |
Risperidone: treatment response in adult and geriatric patients.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Drug Administration Schedule; Female; Geriatric Psyc | 1998 |
Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Chronic Disease; Clozapine; Drug Interactions; Drug Th | 1996 |
Risperidone is associated with blunting of D-fenfluramine evoked serotonergic responses in schizophrenia.
Topics: Adult; Antipsychotic Agents; Fenfluramine; Humans; Hydrocortisone; Prolactin; Psychiatric Status Rat | 1998 |
Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.
Topics: Adult; Basal Ganglia Diseases; Clozapine; Cognition Disorders; Female; Humans; Male; Middle Aged; Ne | 1998 |
P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Anxiety; Attention; Cognition; Depression; Evoked | 1998 |
Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Chronic Disease; D | 1998 |
Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Clozapine; Double-Blind Method | 1999 |
Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Behavioral Symptoms; Benzazepines; Chronic Diseas | 1999 |
The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice.
Topics: Antipsychotic Agents; Attitude to Health; Cost-Benefit Analysis; Health Care Costs; Health Status; H | 1999 |
A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Child; Dose- | 1999 |
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Comorbidity; D | 1999 |
Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics.
Topics: Adult; Antipsychotic Agents; Female; Humans; Middle Aged; Premenopause; Prolactin; Psychiatric Statu | 1999 |
Risperidone in the treatment of elderly patients with psychotic disorders.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, D | 1999 |
Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies.
Topics: Adult; Antipsychotic Agents; Attention; Behavioral Symptoms; Cognition Disorders; Family Health; Fem | 1999 |
Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Carbon Radioisotopes; Dose-Response Rela | 1999 |
Clinical evaluation of risperidone in Asian patients with schizophrenia in Singapore.
Topics: Adult; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Risperidone; Schizophrenia; Singapor | 1999 |
Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male | 1999 |
Novel antipsychotics: comparison of weight gain liabilities.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; I | 1999 |
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cluster Analysis; Cognition Disorders; Depressive Diso | 1999 |
A naturalistic study of risperidone maintenance treatment of outpatients with severe mental illness.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Chronic Disease; Drug Administration | 1999 |
Antipsychotic drug effects on motor activation measured by functional magnetic resonance imaging in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Humans; Magnetic Resonance Imaging; Male; Motor Cort | 1999 |
Risperidone in treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Cholinergic Ant | 1999 |
Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: a pilot study.
Topics: Adult; Antipsychotic Agents; Female; Humans; Male; Pilot Projects; Prospective Studies; Risperidone; | 1999 |
A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Follow-Up Studie | 1999 |
Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dose-Response Relation | 1999 |
[Cognition and driving in schizophrenic patients under treatment with risperidone vs. haloperidol].
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Auditory Perception; Automobile Driving; Cognitio | 1999 |
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Body Weight; Double-Blind Method; Female; H | 1999 |
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Topics: Adult; Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Isoxazoles; | 1999 |
Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Brain; Brain Mapping; Contrast | 1999 |
Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol.
Topics: Adult; Antipsychotic Agents; Attention; Double-Blind Method; Female; Haloperidol; Humans; Male; Neur | 2000 |
Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Chromatography, High Pressure Liquid; Drug Administration Schedul | 1999 |
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Me | 2000 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels.
Topics: Acute Disease; Adult; Antipsychotic Agents; Asian People; Drug Administration Schedule; Female; Hosp | 2000 |
Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Female; Humans; Long | 2000 |
A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Delusions; Dyskinesia, Drug-I | 2000 |
Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Isoxazoles; Male; Methoxyhydroxyphenylglyco | 2000 |
Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Humans; Male; Middle Aged; Pilot Projects; Recurrenc | 2000 |
Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Brain; Female; Frontal Lobe; Hippocampus; Humans; Male; | 2000 |
Comparison of risperidone and other neuroleptics in the management of chronic schizophrenia using cognitive therapy.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cognitive Behavioral Therapy; Female; Humans; Male; Mi | 2000 |
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administrat | 2000 |
Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Dose-Response Relation | 2000 |
Practice-related improvement in information processing with novel antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Hospitalization; Hospitals, Psychiatric; H | 2000 |
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chromatography, High Pressure | 2001 |
Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
Topics: Adult; Aged; Benzodiazepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter St | 2000 |
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Female; Humans; Male; | 2001 |
Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Humans; Male; Olanzapine; Pirenz | 2001 |
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Female; Humans; Longitudin | 2001 |
Estrogen - a potential treatment for schizophrenia.
Topics: Administration, Cutaneous; Adult; Analysis of Variance; Antipsychotic Agents; Dose-Response Relation | 2001 |
Estrogen - a potential treatment for schizophrenia.
Topics: Administration, Cutaneous; Adult; Analysis of Variance; Antipsychotic Agents; Dose-Response Relation | 2001 |
Estrogen - a potential treatment for schizophrenia.
Topics: Administration, Cutaneous; Adult; Analysis of Variance; Antipsychotic Agents; Dose-Response Relation | 2001 |
Estrogen - a potential treatment for schizophrenia.
Topics: Administration, Cutaneous; Adult; Analysis of Variance; Antipsychotic Agents; Dose-Response Relation | 2001 |
Effectiveness of ECT combined with risperidone against aggression in schizophrenia.
Topics: Adult; Aggression; Antipsychotic Agents; Combined Modality Therapy; Electroconvulsive Therapy; Human | 2001 |
Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone.
Topics: Adult; Cerebral Cortex; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Limbic Syste | 2001 |
Effects of risperidone on event-related potentials in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Attention; Event-Related Potentials, P300; Female; Humans; Male; Reacti | 2001 |
A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Drug Therapy, Combination; Employment; Female; | 2001 |
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agent | 2001 |
Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cerebrovascular Circulation; Female; Haloperidol; Humans; Magnet | 2001 |
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi | 2001 |
An open trial of risperidone augmentation of partial response to clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Risperidone; Schizophreni | 2001 |
Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis.
Topics: Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Hospitalization; Humans; Length of | 2001 |
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Body Weight; B | 2001 |
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male | 2001 |
A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Clozapine; D | 2001 |
Guanfacine treatment of cognitive impairment in schizophrenia.
Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Fe | 2001 |
Guanfacine treatment of cognitive impairment in schizophrenia.
Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Fe | 2001 |
Guanfacine treatment of cognitive impairment in schizophrenia.
Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Fe | 2001 |
Guanfacine treatment of cognitive impairment in schizophrenia.
Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Fe | 2001 |
[An experience of the application of rispolept in childhood schizophrenia].
Topics: Adolescent; Antipsychotic Agents; Child; Humans; Obsessive-Compulsive Disorder; Risperidone; Schizop | 2001 |
Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Chronic Disease; Dose-Response Relationship, Drug; Drug Ad | 2001 |
[Pharmacoeconomic aspects of the use of rispolept in therapy of patients with psychoses].
Topics: Adult; Antipsychotic Agents; Humans; Middle Aged; Risperidone; Schizophrenia | 2001 |
The effect of risperidone on cognitive functioning in a sample of Asian patients with schizophrenia in Singapore.
Topics: Adult; Antipsychotic Agents; Cognition; Cognition Disorders; Female; Humans; Male; Middle Aged; Risp | 2001 |
Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug Monitoring; Drug Packaging; Female; Humans; Male; Middle Aged; Pat | 2001 |
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Bl | 2001 |
Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine Antagonists; Dose-Response Relatio | 2001 |
Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.
Topics: Adult; Antipsychotic Agents; Asian People; Chronic Disease; Double-Blind Method; Female; Haloperidol | 2001 |
A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dibenzothiazepines; Female; Humans | 2001 |
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Disease-Free Survival; Female; Haloperidol; Humans; Male; Middle Aged; | 2002 |
A pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2001 |
Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naïve schizophrenic patients: correlations with symptom change.
Topics: Adult; Energy Metabolism; Female; Frontal Lobe; Humans; Imaging, Three-Dimensional; Male; Psychiatri | 2002 |
Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dose-Response Relation | 2002 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind M | 2002 |
Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study.
Topics: Adult; Antipsychotic Agents; Cytokines; Female; Follow-Up Studies; Humans; Interferon-gamma; Interle | 2002 |
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Topics: Adult; Antibiotics, Antitubercular; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Cyclo | 2002 |
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Topics: Adult; Antibiotics, Antitubercular; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Cyclo | 2002 |
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Topics: Adult; Antibiotics, Antitubercular; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Cyclo | 2002 |
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Topics: Adult; Antibiotics, Antitubercular; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Cyclo | 2002 |
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Humans; Longitudin | 2002 |
No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment.
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antipsychotic Agents; Dose-Response Rela | 2002 |
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male | 2002 |
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Cognition Disorders; Donepezil; Dose-Response Relationship, Drug; | 2002 |
Improved antisaccade performance with risperidone in schizophrenia.
Topics: Adult; Antipsychotic Agents; Cross-Over Studies; Female; Humans; Male; Risperidone; Saccades; Schizo | 2002 |
The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relatio | 2002 |
Effect of risperidone on serum cytokines.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cytokines; Female; Humans; Immune System; Male; Risperid | 2001 |
Risperidone failed to improve polydipsia-hyponatremia of the schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Humans; Hyponatremia; Male; Risperidone; Schizophrenia; Schizophrenic P | 2002 |
Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia.
Topics: Adult; Chronic Disease; Humans; Male; Middle Aged; Prognosis; Prolactin; Psychiatric Status Rating S | 2002 |
Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia.
Topics: Activities of Daily Living; Adult; Ambulatory Care; Antipsychotic Agents; Behavior Therapy; Clinical | 2002 |
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
Topics: Adolescent; Adult; Amenorrhea; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female | 2002 |
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Double-Blind Method; Female; Hal | 2002 |
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Celecoxib; D | 2002 |
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Celecoxib; D | 2002 |
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Celecoxib; D | 2002 |
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Celecoxib; D | 2002 |
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone.
Topics: Adult; Antipsychotic Agents; Cognition; Dose-Response Relationship, Drug; Female; Haloperidol; Human | 2002 |
D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia.
Topics: Adult; Antipsychotic Agents; Cycloserine; Depression; Dose-Response Relationship, Drug; Double-Blind | 2002 |
Antipsychotic drug treatment in the prodromal phase of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Drug Administration Schedule; Family; Female; Finland; Huma | 2002 |
The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability.
Topics: Antipsychotic Agents; Chronic Disease; Cross-Cultural Comparison; Double-Blind Method; Haloperidol; | 1992 |
Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Hospit | 1992 |
Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients.
Topics: Adult; Aged; Antipsychotic Agents; Brain; Cerebral Ventricles; Chronic Disease; Dilatation, Patholog | 1992 |
Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties.
Topics: Antipsychotic Agents; Dopamine Antagonists; Double-Blind Method; Electrocardiography; Humans; Isoxaz | 1992 |
Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group.
Topics: Antipsychotic Agents; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Psychiatric | 1992 |
Risperidone: clinical development: north American results.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Humans; Isoxazo | 1992 |
Risperidone: clinical safety and efficacy in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Pip | 1992 |
New antipsychotics: classification, efficacy, and adverse effects.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Humans; Isoxazoles; Piperidines; Receptors | 1991 |
Thymosthenic agents, a novel approach in the treatment of schizophrenia.
Topics: Brain; Butyrophenones; Humans; Isoxazoles; Piperidines; Pyrimidinones; Randomized Controlled Trials | 1989 |
1463 other studies available for risperidone and Dementia Praecox
| Article | Year |
|---|---|
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
Topics: Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cloning, Molecular; Clozapine; Dibenzoc | 2009 |
Synthesis and evaluation of 1-(quinoliloxypropyl)-4-aryl piperazines for atypical antipsychotic effect.
Topics: Animals; Antipsychotic Agents; Mice; Oxyquinoline; Schizophrenia; Stereotyped Behavior | 2009 |
Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif.
Topics: Animals; Antipsychotic Agents; Blood-Brain Barrier; CHO Cells; Cricetinae; Cricetulus; Humans; Quina | 2009 |
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Topics: Animals; Antipsychotic Agents; Berberine; Berberine Alkaloids; CHO Cells; Cricetinae; Cricetulus; Do | 2013 |
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
Topics: Amides; Animals; Antipsychotic Agents; Behavior, Animal; Dizocilpine Maleate; Dopamine Antagonists; | 2014 |
Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics.
Topics: Animals; Antipsychotic Agents; Ether-A-Go-Go Potassium Channels; Humans; Mice; Oxazoles; Patch-Clamp | 2015 |
Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.
Topics: Animals; Antipsychotic Agents; Body Weight; Chemistry Techniques, Synthetic; Drug Design; Ether-A-Go | 2018 |
Synthesis and pharmacological evaluation of piperidine (piperazine)-amide substituted derivatives as multi-target antipsychotics.
Topics: Amides; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Cha | 2020 |
Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms.
Topics: Antipsychotic Agents; Humans; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizoph | 2021 |
[Changes in adipokines in the blood of patients with the first episode of schizophrenia during treatment with haloperidol and risperidone].
Topics: Adipokines; Antipsychotic Agents; Haloperidol; Humans; Risperidone; Schizophrenia | 2021 |
The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Area Under Curve; Biological Availability; | 2021 |
Characteristics of the corpus callosum in chronic schizophrenia treated with clozapine or risperidone and those never-treated.
Topics: Anisotropy; Clozapine; Corpus Callosum; Cross-Sectional Studies; Diffusion Tensor Imaging; Humans; R | 2021 |
False-positive fentanyl screening kit results during treatment with long term injectable risperidone (Risperdal-Consta).
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Risperidone; Schizophrenia; United States | 2021 |
Comparison of treatment retention between risperidone long-acting injection, paliperidone palmitate, and aripiprazole once-monthly in elderly patients with schizophrenia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Humans; Paliperidone Palmitate; Risperidone; Schizophrenia | 2022 |
Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients.
Topics: Antipsychotic Agents; Female; Humans; Male; Pharmaceutical Preparations; Psychiatric Status Rating S | 2021 |
Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study.
Topics: Antioxidants; Antipsychotic Agents; Female; Glutathione Peroxidase; Humans; Longitudinal Studies; Ma | 2022 |
Risperidone is not only a prodrug: psychosis induced by medication switch from risperidone to paliperidone - a case report.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Male; Paliperidone Palmitate; Prodrugs; P | 2023 |
Effects of clozapine and risperidone antipsychotic drugs on the expression of CACNA1C and behavioral changes in rat 'Ketamine model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Calcium Channels, L-Type; Clozapine; Cognition; Excitatory Amino Acid | 2022 |
Long-lasting rescue of schizophrenia-relevant cognitive impairments via risperidone-loaded microPlates.
Topics: Animals; Antipsychotic Agents; Cognitive Dysfunction; Delayed-Action Preparations; Dysbindin; Mice; | 2022 |
Association Between Hippocampal Subfields and Clinical Symptoms of First-Episode and Drug Naive Schizophrenia Patients During 12 Weeks of Risperidone Treatment.
Topics: Antipsychotic Agents; Hippocampus; Humans; Magnetic Resonance Imaging; Risperidone; Schizophrenia | 2022 |
Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Child; Drug Monitoring; Humans; Pal | 2022 |
Comparison of prediction methods for treatment continuation of antipsychotics in children and adolescents with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Humans; Machine Learning; Risperidone; Schizo | 2022 |
Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study.
Topics: Antipsychotic Agents; Exome Sequencing; Genome-Wide Association Study; Humans; Risperidone; Schizoph | 2022 |
Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Olanzapine; Perphenazine; Recurrence; Ris | 2022 |
Comparative Effectiveness of Antipsychotics in Preventing Readmission for First-Admission Schizophrenia Patients in National Cohorts From 2001 to 2017 in Taiwan.
Topics: Administration, Oral; Adult; Aftercare; Antipsychotic Agents; Delayed-Action Preparations; Female; H | 2022 |
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Cl | 2022 |
The influence of
Topics: Antipsychotic Agents; China; Genetic Predisposition to Disease; Humans; Polymorphism, Single Nucleot | 2022 |
The relation between second-generation antipsychotics and laxative use in elderly patients with schizophrenia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Constipation; Female; Humans; Laxatives; Piperazines; Q | 2022 |
Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; | 2022 |
Association Between Sexual Dysfunction and Dose of Atypical Antipsychotics: Essential to Learn the Basics.
Topics: Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Dibenzothiazepines; Female; Humans; | 2023 |
Switching from risperidone to paliperidone palmitate in schizophrenia: Changes in social functioning and cognitive performance.
Topics: Antipsychotic Agents; Cognition; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Risper | 2023 |
Risperidone-induced changes in DNA methylation in peripheral blood from first-episode schizophrenia patients parallel changes in neuroimaging and cognitive phenotypes.
Topics: Antipsychotic Agents; Cognition; DNA Methylation; Humans; Neuroimaging; Phenotype; Risperidone; Schi | 2022 |
Trends in the use of long-acting injectable antipsychotics in children and adolescents in France between 2014 and 2018.
Topics: Adolescent; Antipsychotic Agents; Child; Delayed-Action Preparations; France; Humans; Risperidone; S | 2022 |
Aripiprazole: examining the clinical implications of D2 affinity.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Paliperidone Palmitate; Risperidone; Schizophrenia | 2023 |
Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse.
Topics: Aged; Antipsychotic Agents; Female; Humans; Male; Menopause; Middle Aged; Olanzapine; Quetiapine Fum | 2023 |
Smoke, GPx activity and symptoms improvement in patients with drug-naive first-episode schizophrenia: A large-scale 12-week follow-up study.
Topics: Antioxidants; Antipsychotic Agents; Follow-Up Studies; Humans; Prospective Studies; Risperidone; Sch | 2022 |
Reversal and Preventive Pleiotropic Mechanisms Involved in the Antipsychotic-Like Effect of Taurine, an Essential β-Amino Acid in Ketamine-Induced Experimental Schizophrenia in Mice.
Topics: Amino Acids; Animals; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Dopamine; Interleukin | 2023 |
Virtual histology of morphometric similarity network after risperidone monotherapy and imaging-epigenetic biomarkers for treatment response in first-episode schizophrenia.
Topics: Antipsychotic Agents; Biomarkers; Epigenesis, Genetic; Humans; Magnetic Resonance Imaging; Risperido | 2023 |
Epigenetic clock analysis of blood samples in drug-naive first-episode schizophrenia patients.
Topics: Aging; DNA Methylation; Epigenesis, Genetic; Humans; Infant; Infant, Newborn; Psychotic Disorders; R | 2023 |
Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; | 2023 |
Effects of Early Risperidone Treatment on Metabolic Parameters in Socially Isolated Rats-Implication of Antipsychotic Intervention across Developmental Stages of Schizophrenia.
Topics: Animals; Antipsychotic Agents; Body Weight; Insulin Resistance; Insulins; Rats; Risperidone; Schizop | 2023 |
Hippocampal Hyperconnectivity to the Visual Cortex Predicts Treatment Response.
Topics: Antipsychotic Agents; Hippocampus; Humans; Magnetic Resonance Imaging; Psychotic Disorders; Risperid | 2023 |
The importance of early and proactive use of long-acting injectable antipsychotics in the management of schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Risperidone; Schizophrenia | 2023 |
Risperidone response in patients with schizophrenia drives DNA methylation changes in immune and neuronal systems.
Topics: Antipsychotic Agents; Benzodiazepines; DNA Methylation; Humans; Risperidone; Schizophrenia | 2023 |
Association between long-term use of prolactin-elevating antipsychotics in women and the risk of breast cancer: What are the clinical implications?
Topics: Antipsychotic Agents; Breast Neoplasms; Female; Humans; Prolactin; Risperidone; Schizophrenia | 2023 |
Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China.
Topics: Antipsychotic Agents; Aripiprazole; China; Humans; Risperidone; Schizophrenia; Treatment Outcome | 2023 |
Practice of prescribing antipsychotics in schizophrenia during 2013-2018 based on data from the National Health Fund.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapine; Risperidone; Schizoph | 2022 |
Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Humans; Olanzapine; Risperidone; S | 2023 |
Smoking Affects the Predictive Roles of Antioxidant Enzymes in the Clinical Response to Risperidone in Schizophrenia: A Large-scale Cohort Study.
Topics: Antioxidants; Antipsychotic Agents; Cohort Studies; Humans; Psychiatric Status Rating Scales; Risper | 2023 |
[Antipsychotics].
Topics: Antipsychotic Agents; Clozapine; Hallucinations; Humans; Risperidone; Schizophrenia | 2023 |
Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: Randomized clinical trials and multi-ancestry validation.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Lipids; Olanzapine; Randomized Contr | 2023 |
Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Multiomics; Olanzapine; Phospholipases; | 2023 |
Association Between Risperidone Use and Kidney Function Decline in Patients with Schizophrenia: A Retrospective Cohort Study.
Topics: Animals; Antipsychotic Agents; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Mice; Middl | 2023 |
Relationship between clinical efficacy and plasma concentration-dose ratio of risperidone in patients with schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Male; Paliperidone Palmitate; Retrospective Studies; Risperido | 2024 |
Effects of low-frequency rTMS combined with risperidone on the gut microbiome in hospitalized patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Gastrointestinal Microbiome; Humans; Risperidone; RNA, Ribosomal, 16S; | 2023 |
More options, more value: a new long-acting injectable formulation of risperidone.
Topics: Antipsychotic Agents; Humans; Risperidone; Schizophrenia | 2023 |
Cognitive enhancer ST101 improves schizophrenia-like behaviors in neonatal ventral hippocampus-lesioned rats in association with improved CaMKII/PKC pathway.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; | 2019 |
Effect of Risperidone Monotherapy on Dynamic Functional Connectivity of Insular Subdivisions in Treatment-Naive, First-Episode Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cerebral Cortex; Connectome; Female; Follow-Up Studies; Hum | 2020 |
Alteration of Serum Levels of Cytokines in Schizophrenic Patients before and after Treatment with Risperidone.
Topics: Adult; Antipsychotic Agents; Biomarkers; Case-Control Studies; Cytokines; Female; Humans; Inflammati | 2019 |
Invited Perspective on "A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within One Year of Discharge in Elderly Patients With Schizophrenia".
Topics: Aged; Antipsychotic Agents; Humans; Patient Discharge; Risperidone; Schizophrenia | 2020 |
The effect of bezafibrate in preventing glucolipid abnormalities induced by the antipsychotic risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Bezafibrate; Blood Glucose; Body Weight; Drug Therapy, Comb | 2019 |
Impact of duration of untreated psychosis in short-term response to treatment and outcome in antipsychotic naïve first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Male; Prognosis; Psychotic Disorders; Rispe | 2020 |
Long-Acting Injectable Antipsychotics.
Topics: Antipsychotic Agents; Humans; Injections; Risperidone; Schizophrenia | 2019 |
Distinct striatum pathways connected to salience network predict symptoms improvement and resilient functioning in schizophrenia following risperidone monotherapy.
Topics: Adult; Antipsychotic Agents; Connectome; Female; Follow-Up Studies; Humans; Magnetic Resonance Imagi | 2020 |
In vivo 5-HT
Topics: Adult; Antipsychotic Agents; Carbon Radioisotopes; Female; Humans; Male; Middle Aged; Olanzapine; Po | 2020 |
Improving Medication Information Presentation Through Interactive Visualization in Mobile Apps: Human Factors Design.
Topics: Antipsychotic Agents; Data Display; Ergonomics; Humans; Medication Adherence; Mobile Applications; R | 2019 |
Influence of Kidney Function on Serum Risperidone Concentrations in Patients Treated With Risperidone.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Germany; Humans; Kidney Function Tests; Male; | 2019 |
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Magnetic Resonance I | 2020 |
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Magnetic Resonance I | 2020 |
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Magnetic Resonance I | 2020 |
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Magnetic Resonance I | 2020 |
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Care Costs; Hospital | 2020 |
Effects of risperidone monotherapy on the default-mode network in antipsychotic-naïve first-episode schizophrenia: Posteromedial cortex heterogeneity and relationship with the symptom improvements.
Topics: Antipsychotic Agents; Brain; Brain Mapping; Cerebral Cortex; Default Mode Network; Humans; Magnetic | 2020 |
Prolactin response to antipsychotics: An inpatient study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Humans; Hyperprolactinemia; | 2020 |
Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients.
Topics: Antipsychotic Agents; Glutamic Acid; Humans; Psychotic Disorders; Risperidone; Schizophrenia | 2020 |
Variants of GRM7 as risk factor and response to antipsychotic therapy in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Genome-Wide Association Study; Humans; Quetiapine Fumarate; R | 2020 |
Successful Long-Acting Paliperidone Treatment Following Reversible Risperidone-Induced Neutropenia.
Topics: Adolescent; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Neutropenia; Paliperi | 2020 |
Paranoid delusions • ideas of reference • sleep problems • Dx?
Topics: Antipsychotic Agents; Asian People; Delusions; Female; Humans; Late Onset Disorders; Middle Aged; Pr | 2020 |
Neural Signatures of Memory Encoding in Schizophrenia Are Modulated by Antipsychotic Treatment.
Topics: Adult; Antipsychotic Agents; Cognitive Dysfunction; Default Mode Network; Female; Glutamic Acid; Glu | 2021 |
Severe hypothermia, bradycardia and cardiac arrest in association with risperidone.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Bradycardia; Female; Heart Arrest; Humans; Hypothermi | 2020 |
Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Clozapine; Drug Substitution; Drug Therapy, Combi | 2020 |
Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Female; Genotype; Humans; Male; Middle Aged; Olanzapine; Polymorphism, | 2020 |
Lumateperone: New Drug or Same Old Drug With a New Dress?
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dopamine D2 Receptor Antagonists; Heterocyclic Compo | 2020 |
Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Plasma; Proteomics; Risperidone; Schizoph | 2020 |
Risperidone-Induced Acute Laryngeal Dystonia: A Case Report.
Topics: Adult; Antipsychotic Agents; Benztropine; Dystonia; Female; Humans; Laryngeal Diseases; Risperidone; | 2020 |
Circulating IGFBP-2 levels reveal atherogenic metabolic risk in schizophrenic patients using atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Humans; Insulin-Like Growth Factor B | 2021 |
Promoter Activity-Based Case-Control Association Study on SLC6A4 Highlighting Hypermethylation and Altered Amygdala Volume in Male Patients With Schizophrenia.
Topics: Adult; Amygdala; Animals; Antipsychotic Agents; Bipolar Disorder; Callithrix; Case-Control Studies; | 2020 |
Long-acting injectable antipsychotics: choosing the right dose.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Disease Progression; Drug Substitution; Humans; I | 2020 |
Haloperidol Discontinuation for People with Schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Risperidone; Schizophrenia | 2020 |
Age effect of antipsychotic medications on the risk of sudden cardiac death in patients with schizophrenia: A nationwide case-crossover study.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Cross-Over Studies; Death, Sudden, Cardiac; Dibenzot | 2020 |
ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
Topics: Adult; Aged; Alleles; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2021 |
Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chromatography, Liquid; Clo | 2020 |
Characteristics of White Matter Structural Networks in Chronic Schizophrenia Treated With Clozapine or Risperidone and Those Never Treated.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clozapine; Cognitive Dysfunction; Diffusion Tensor Ima | 2020 |
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Lipid Metabolism; Male; | 2020 |
Differential effects of different antipsychotic drugs on cognitive function in patients with chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Case-Control Studies; Chronic Disease; Clozapine; Cog | 2020 |
BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: A prospective 12-week longitudinal study.
Topics: Adult; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disorders; Cogn | 2020 |
Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Intra-Ab | 2021 |
[Rhabdomyolysis induced by paliperidone palmitate].
Topics: Antipsychotic Agents; Humans; Male; Middle Aged; Paliperidone Palmitate; Rhabdomyolysis; Risperidone | 2021 |
Occurrence of metabolic diseases associated with antipsychotic use among Korean patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Metabolic Diseases; Olanzapine; Prospective Studies; | 2021 |
The side effect profile of Clozapine in real world data of three large mental health hospitals.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Databases, Factual; Female; Hospitals, Psyc | 2020 |
Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Brazil; Cohort Studies; Databases, Factual; Female; F | 2021 |
Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life".
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Cognition; Female; Humans; Male | 2021 |
Effect of risperidone treatment on insulin-like growth factor-1 and interleukin-17 in drug naïve first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Humans; Insulin-Like Growth Factor I; Interleu | 2021 |
Fatal and life-threatening ADRs associated with paliperidone palmitate: an observational study in the French pharmacovigilance database.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Drug-Related Side Effects and Adverse Reactions; Fem | 2021 |
Cognitive improvement function of aripiprazole in adolescents with first-episode and repeated-episode schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Cognition; Humans; Risperidone; Schizophrenia; Treat | 2021 |
Effect of 5-HT2C receptor gene polymorphism (HTR2C-759C/T) on metabolic adverse effects in Thai psychiatric patients treated with risperidone.
Topics: Cross-Sectional Studies; Humans; Polymorphism, Genetic; Prospective Studies; Receptor, Serotonin, 5- | 2021 |
Regional brain network and behavioral alterations in EGR3 gene transfected rat model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Early Growth Response Protein 3; Magnetic Resonance Imaging; M | 2021 |
Antipsychotic Treatment Duration in Children and Adolescents: A Register-Based Nationwide Study.
Topics: Adolescent; Aged; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Duration of Therapy; | 2021 |
Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride.
Topics: Amisulpride; Antipsychotic Agents; Humans; Hyperprolactinemia; Prolactin; Risperidone; Schizophrenia | 2022 |
A Case of Self-Cannibalism: An Extremely Rare Type of Self-Mutilation With Multiple Risk Factors.
Topics: Adult; Antipsychotic Agents; Antisocial Personality Disorder; Cannibalism; Electroconvulsive Therapy | 2021 |
Pharmacogenetic associations of NRG1 polymorphisms with neurocognitive performance and clinical symptom response to risperidone in the untreated schizophrenia.
Topics: Antipsychotic Agents; Asian People; China; Humans; Neuregulin-1; Pharmacogenetics; Prospective Studi | 2021 |
Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study.
Topics: Adolescent; Adult; Antioxidants; Antipsychotic Agents; Drug Administration Schedule; Female; Follow- | 2021 |
The effect of prohibiting outside food during COVID-19 pandemic on the body weight of schizophrenic patients taking olanzapine or clozapine: a retrospective self-controlled study.
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; China; Clozapine; COVID-19; Humans; Olanzapine; | 2021 |
Docking Screens of Noncovalent Interaction Motifs of the Human Subtype-D2 Receptor-75 Schizophrenia Antipsychotic Complexes with Physicochemical Appraisal of Antipsychotics.
Topics: Antipsychotic Agents; Humans; Molecular Docking Simulation; Receptors, Dopamine D2; Risperidone; Sch | 2021 |
Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels.
Topics: Antipsychotic Agents; Aripiprazole; Female; Genetic Diseases, Inborn; Humans; Hyperprolactinemia; La | 2021 |
Tracking Positive and Negative Symptom Improvement in First-Episode Schizophrenia Treated with Risperidone Using Individual-Level Functional Connectivity.
Topics: Brain; Brain Mapping; Humans; Magnetic Resonance Imaging; Psychotic Disorders; Risperidone; Schizoph | 2022 |
Rethinking olanzapine therapy for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Risperidone; Schizophrenia | 2021 |
BDNF in antipsychotic naive first episode psychosis: Effects of risperidone and the immune-inflammatory response system.
Topics: Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Humans; Psychotic Disorders; Risperidone; S | 2021 |
Determining the release kinetics of risperidone controlled release matrices to treat schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Differential Thermal Analysis; Drug Liberation; D | 2021 |
Comparative Study of Sexual Side Effects in Female Patients With Schizophrenia Receiving Risperidone or Olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Female; Humans; Olanzapine; Risperid | 2021 |
Neuroplasticity and inflammatory alterations in the nucleus accumbens are corrected after risperidone treatment in a schizophrenia-related developmental model in rats.
Topics: Animals; Antipsychotic Agents; Neuronal Plasticity; Nucleus Accumbens; Rats; Risperidone; Schizophre | 2021 |
Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: evidence from clinical trials, a real-world study, and clinical cases.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Piperazines; Risperidone; Schizophrenia | 2022 |
Benefit of extending the dosing interval of long-acting antipsychotic injections in elderly schizophrenics with cognitive dysfunction.
Topics: Aged; Antipsychotic Agents; Cognitive Dysfunction; Dose-Response Relationship, Drug; Drug Administra | 2017 |
Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study.
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Female; Humans; Male; Pilot Projects; Quality of | 2016 |
Assessments of plasma concentrations, pathology symptoms, and cognition following paliperidone treatment in schizophrenic patients previously treated with risperidone.
Topics: Antipsychotic Agents; Cognition; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Prospect | 2017 |
Switching From the Oral to the Depot Formulation of a Medication: Clinically Relevant Pharmacokinetic Concepts and Considerations.
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Drug Administration Schedul | 2017 |
Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.
Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Humans; Memantine; Risperidone; Schizop | 2017 |
[Switching from antipsychotics to aripiprazole and risk of agitation].
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Psychomotor Agitation; Ris | 2018 |
Treatment retention of risperidone long-acting injection in patients with early-onset schizophrenia in Japan.
Topics: Adolescent; Age of Onset; Antipsychotic Agents; Child; Cohort Studies; Delayed-Action Preparations; | 2017 |
Hyperprolactinemia with low dose of risperidone in a young female.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; R | 2017 |
Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study.
Topics: Adult; Antipsychotic Agents; Belgium; Benzodiazepines; Delayed-Action Preparations; Drug Administrat | 2017 |
Comparison of the effectiveness of brand-name and generic antipsychotic drugs for treating patients with schizophrenia in Taiwan.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Drug Utilization Review; Drugs, Generic; Female; Humans | 2018 |
Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study.
Topics: Acute Disease; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic | 2017 |
Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India.
Topics: Adult; Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Gene Frequency; Humans; India | 2017 |
Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Asian People; Biomarkers; China; Cohort Studies; CpG Islands; DNA Methy | 2017 |
Effects of four atypical antipsychotics on autonomic nervous system activity in schizophrenia.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Autonomic Nervous System Diseases; B | 2018 |
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.
Topics: Adolescent; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transp | 2018 |
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Prepar | 2017 |
Risperidone and sulpiride: Brands vs generics.
Topics: Antipsychotic Agents; Drugs, Generic; Female; Humans; Male; Risperidone; Schizophrenia; Sulpiride | 2018 |
Delayed galactorrhea after discontinuation of risperidone in a schizophrenia patient.
Topics: Adult; Antipsychotic Agents; Galactorrhea; Humans; Male; Risperidone; Schizophrenia; Time | 2017 |
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost S | 2017 |
Study on the prescribing patterns of antipsychotic medication in a rural England Community Mental Health Team.
Topics: Adult; Antipsychotic Agents; Aripiprazole; England; Humans; Mental Health; Practice Patterns, Physic | 2017 |
Does Risperidone Long Acting Injectable Depot (RLAI) Reduce number of Admissions to Hospital.
Topics: Antipsychotic Agents; Delayed-Action Preparations; England; Humans; Injections; Retrospective Studie | 2017 |
Periodic catatonia with long-term treatment: a case report.
Topics: Antipsychotic Agents; Catatonia; Clozapine; Drug Therapy, Combination; Female; Haloperidol; Humans; | 2017 |
Clozapine Reduces All-Cause Mortality.
Topics: Antipsychotic Agents; Clozapine; Humans; Risperidone; Schizophrenia | 2017 |
Risperidone ameliorates cognitive deficits, promotes hippocampal proliferation, and enhances Notch signaling in a murine model of schizophrenia.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Hippocampus; Male; Mice; Mice, Inbred C57BL; R | 2017 |
"Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
Topics: Adult; Antipsychotic Agents; Cost Control; Delayed-Action Preparations; Drug Prescriptions; Female; | 2018 |
T
Topics: Adult; Antipsychotic Agents; Asian People; Benzodiazepines; Biomarkers, Pharmacological; Body Mass I | 2018 |
Risperidone mucoadhesive buccal tablets: formulation design, optimization and evaluation.
Topics: Administration, Buccal; Drug Compounding; Drug Delivery Systems; Humans; Risperidone; Schizophrenia; | 2017 |
Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: Results From a Multicenter Retrospective Cohort Study in France.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Delayed-Action Preparations; Female; Follow-Up Studies; | 2018 |
Frontal activity measured by near-infrared spectroscopy in patients taking different atypical antipsychotic drugs: A cross-sectional study.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Cross-Sectional Studies; Female; Frontal Lobe; He | 2018 |
Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional S | 2018 |
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Comorbidity; Depressive Dis | 2018 |
The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia.
Topics: Administration, Oral; Adult; Ambulatory Care; Antipsychotic Agents; Bipolar Disorder; Community Ment | 2018 |
Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Hospitals, Psychiatric; Humans; Middle | 2018 |
Doxycycline prevents and reverses schizophrenic-like behaviors induced by ketamine in mice via modulation of oxidative, nitrergic and cholinergic pathways.
Topics: Acetylcholinesterase; Animals; Antipsychotic Agents; Catalase; Disease Models, Animal; Doxycycline; | 2018 |
DNA methylation analyses of the candidate genes identified by a methylome-wide association study revealed common epigenetic alterations in schizophrenia and bipolar disorder.
Topics: Adult; Animals; Antipsychotic Agents; Bipolar Disorder; Callithrix; Chromosomes, Human, Pair 16; DNA | 2018 |
Health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone: a nationwide retrospective matched cohort study in Taiwan.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Child; Cohort Studies; Cost-Benefit A | 2018 |
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.
Topics: Administration, Oral; Adult; Algorithms; Antipsychotic Agents; Clozapine; Commitment of Mentally Ill | 2019 |
Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction?
Topics: Antipsychotic Agents; Drug Synergism; Female; Humans; Leukopenia; Middle Aged; Olanzapine; Risperido | 2018 |
Very early onset schizophrenia diagnostic challenge and cognitive remediation-A case report.
Topics: Age of Onset; Antipsychotic Agents; Child; Cognitive Remediation; Diagnosis, Differential; Humans; M | 2018 |
Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.
Topics: Animals; Antioxidants; Behavioral Symptoms; Brain; Brain-Derived Neurotrophic Factor; Catalase; Dise | 2018 |
Systemic Inflammation Complicates the Interpretation of Therapeutic Drug Monitoring of Risperidone.
Topics: Antipsychotic Agents; Drug Monitoring; Humans; Inflammation; Male; Middle Aged; Risperidone; Schizop | 2018 |
Changes in length of hospital stay and number of hospitalization before and after the administration of three second-generation antipsychotics long-acting injections in patients with schizophrenia: Mirror-image study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Hospitalization; Hum | 2018 |
A greater tendency for representation mediated learning in a ketamine mouse model of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Delusions; Disease Mo | 2018 |
Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability.
Topics: Antipsychotic Agents; Autonomic Nervous System; Cardiovascular Diseases; Diagnosis, Differential; Do | 2018 |
Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations.
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Humans; Paliperidone Palmit | 2018 |
Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Biomarkers; Clozapine; Humans; Middle Aged; Oxidative | 2018 |
[Aripiprazole for drug-induced sexual dysfunction in schizophrenic males].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Male; Prolact | 2017 |
Abnormal Trajectory of Intracortical Myelination in Schizophrenia Implicates White Matter in Disease Pathophysiology and the Therapeutic Mechanism of Action of Antipsychotics.
Topics: Adult; Antipsychotic Agents; Female; Frontal Lobe; Humans; Magnetic Resonance Imaging; Male; Myelin | 2018 |
Mortality rate is associated with paliperidone palmitate, risperidone long-acting injection, and oral paliperidone administration.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Cohort Studies; Delayed-Action Preparations; Fema | 2018 |
Olanzapine vs. Risperidone in Schizophrenia: A Cross-sectional Comparison of Quality of Life of Caregivers.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Caregivers; Cross-Sectional Studies; | 2016 |
Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Biomarkers; Body Weight; Feces; Female; Gastrointestinal Microbiome; Hu | 2018 |
High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Mass Index; Cholesterol, HDL; Correlation of D | 2018 |
Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment.
Topics: Adolescent; Adult; Aged; Animals; Antipsychotic Agents; Brain; Cognition; Dysbindin; Executive Funct | 2018 |
Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study.
Topics: Adolescent; Antipsychotic Agents; Female; Humans; Male; Olanzapine; Psychiatric Status Rating Scales | 2018 |
[Using the cumulative odds Logit model to explore the application of the questionnaire derived from PANSS].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Logistic Models; Olanzapine; Risperidon | 2016 |
Gabrb2-knockout mice displayed schizophrenia-like and comorbid phenotypes with interneuron-astrocyte-microglia dysregulation.
Topics: Animals; Antipsychotic Agents; Astrocytes; Behavior Rating Scale; Female; Genetic Predisposition to | 2018 |
Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B; Auto | 2018 |
Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Bipolar Disorder; B | 2018 |
Pharmacogenetics analysis of serotonin receptor gene variants and clinical response to risperidone in Han Chinese schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Asian People; Case-Control Studies; Female; Genetic Variation; Humans; | 2018 |
Cognitive control network dysconnectivity and response to antipsychotic treatment in schizophrenia.
Topics: Adult; Antipsychotic Agents; Cognitive Dysfunction; Connectome; Executive Function; Female; Follow-U | 2019 |
Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Databases, Factual; Delayed-Action Preparations; Fema | 2018 |
A maximum entropy approach for the evaluation of surrogate endpoints based on causal inference.
Topics: Antipsychotic Agents; Bayes Theorem; Biomarkers; Causality; Endpoint Determination; Entropy; Haloper | 2018 |
Comparisons of the effects of second-generation antipsychotics long-acting injections on treatment retention according to severity of patient condition.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Injections; | 2018 |
Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort.
Topics: Adolescent; Adult; Antipsychotic Agents; Brazil; Case-Control Studies; Female; Genetic Predispositio | 2018 |
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cerebral Cortex; Cloz | 2018 |
Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia.
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Female; Genotype; Humans; India; Male; Middle | 2019 |
Treatment Continuation of 3 Second-Generation Antipsychotic Long-Acting Injections, and Oral Paliperidone in Patients With Schizophrenia for 2 Years.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Cohort Studies; Delayed-Action Prep | 2018 |
A closed-form estimator for meta-analysis and surrogate markers evaluation.
Topics: Algorithms; Biomarkers; Cluster Analysis; Computer Simulation; Endpoint Determination; Humans; Likel | 2019 |
Gender differences in the prevalence, comorbidities and antipsychotic prescription of early-onset schizophrenia: a nationwide population-based study in Taiwan.
Topics: Adolescent; Age of Onset; Antipsychotic Agents; Child; Comorbidity; Female; Humans; Male; Population | 2019 |
Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; I | 2019 |
A Dissociation in Effects of Risperidone Monotherapy on Functional and Anatomical Connectivity Within the Default Mode Network.
Topics: Adult; Antipsychotic Agents; Brain; Case-Control Studies; Diffusion Tensor Imaging; Female; Function | 2019 |
[Safety of Long-acting Injectable Antipsychotics Is Long-acting Injection a High-risk Treatment Option?].
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Risk Factors; Risperidone; Schizophrenia; Ti | 2016 |
A longitudinal magnetic resonance spectroscopy study investigating effects of risperidone in the anterior cingulate cortex and hippocampus in schizophrenia.
Topics: Adult; Antipsychotic Agents; Female; Glutamic Acid; Gyrus Cinguli; Hippocampus; Humans; Longitudinal | 2019 |
Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
Topics: Adolescent; Antipsychotic Agents; Brief Psychiatric Rating Scale; Female; Hospitalization; Humans; H | 2019 |
Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients.
Topics: Adolescent; Alleles; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Cytochrome P-450 C | 2019 |
Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Clozapine; Disease Models, Animal; Fe | 2019 |
Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Outcome | 2019 |
Case of risperidone-induced tardive parkinsonism.
Topics: Adult; Antipsychotic Agents; Humans; Male; Parkinson Disease, Secondary; Risperidone; Schizophrenia; | 2019 |
Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Biomarkers; Carrier Proteins; Cohort Studies; Disease Progr | 2019 |
Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia.
Topics: Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Dopamine; Genotype; Humans; Paliperidone Pal | 2019 |
Increased Protein Insolubility in Brains From a Subset of Patients With Schizophrenia.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Brain; Case-Control Studies; Female; Gas Chromatog | 2019 |
Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
Topics: Administration, Oral; Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Comorbidity; Delayed-A | 2019 |
Antipsychotics Do Not Influence Neurological Soft Signs in Children and Adolescents at Ultra-High Risk for Psychosis: A Pilot Study.
Topics: Adolescent; Antipsychotic Agents; Female; Humans; Male; Neuropsychological Tests; Pilot Projects; Ps | 2019 |
[Therapeutic drug monitoring of risperidone and its active metabolite 9-hydroxyrisperidone in the treatment of schizophrenia].
Topics: Antipsychotic Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Isoxazoles; Pal | 2019 |
Adverse Events in a Breastfed Infant Exposed to Risperidone and Haloperidol.
Topics: Antipsychotic Agents; Dietary Exposure; Drug Therapy, Combination; Female; Haloperidol; Humans; Infa | 2019 |
Real-life persistence of long-acting injectable antipsychotics in schizophrenic patients: A retrospective observational study in France
.
Topics: Antipsychotic Agents; Delayed-Action Preparations; France; Haloperidol; Humans; Injections; Paliperi | 2019 |
Management of sexual adverse effects induced by atypical antipsychotic medication
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug-Related Side Effects and Adverse | 2019 |
Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.
Topics: Animals; Antipsychotic Agents; Body Weight; Female; Ghrelin; Hyperglycemia; Leptin; Mice; Mice, Inbr | 2019 |
Factors That Affect Continuation of Antipsychotic Long-Acting Injections.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Medica | 2019 |
Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Therapy, Combin | 2019 |
Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Female; Hospitalization; Humans; | 2019 |
Quantitative efficacy of three antipsychotic drugs for schizophrenia based on a real-world study in China.
Topics: Adult; Antipsychotic Agents; Aripiprazole; China; Female; Humans; Male; Middle Aged; Models, Biologi | 2019 |
Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis.
Topics: Adult; Dopamine Agents; Humans; Longitudinal Studies; Male; Psychotic Disorders; Risperidone; Schizo | 2013 |
Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice.
Topics: Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Dextroamphetamine; Disease Models, An | 2012 |
Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.
Topics: Adult; Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Female; Flupenthixo | 2014 |
Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Asian People; China; Female; Genotype | 2013 |
Exposure to the cytokine EGF leads to abnormal hyperactivity of pallidal GABA neurons: implications for schizophrenia and its modeling.
Topics: Action Potentials; Animals; Animals, Newborn; Antipsychotic Agents; Disease Models, Animal; Electroe | 2013 |
White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.
Topics: Adolescent; Adult; Anisotropy; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Brain Map | 2013 |
The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Haloperidol; Hyperbilirubinemia | 2013 |
Association of estrogen receptor alpha gene polymorphism with age at onset, general psychopathology symptoms, and therapeutic effect of schizophrenia.
Topics: Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Asian People; Data Interpretation, Statisti | 2013 |
[Combination of two depot antipsychotic drugs].
Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Drug Therapy, Combination; F | 2014 |
[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Substitution; Female; France; Humans; | 2013 |
Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Fluphenazine; Haloperidol; Human | 2013 |
Granulomatous skin lesions on an amputated limb: a typical case of an immunocompromised district.
Topics: Amputation Stumps; Antipsychotic Agents; Granuloma; Humans; Hyperprolactinemia; Male; Risperidone; S | 2014 |
Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Case-Control Studies; Delayed-Action Preparations | 2013 |
Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia.
Topics: Adult; Age Factors; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding | 2013 |
Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Brain; Cohort Studies; Haloperidol; Humans; Neocortex; Rats; Risperid | 2014 |
Does changing from a first generation antipsychotic (perphenazin) to a second generation antipsychotic (risperidone) alter brain activation and motor activity? A case report.
Topics: Actigraphy; Antipsychotic Agents; Brain; Brain Waves; Cognition; Drug Substitution; Humans; Magnetic | 2013 |
Influence of antipsychotic treatment type and regimen on the functionality of patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Administration | 2014 |
Tolerability and safety profile of risperidone in a sample of children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Body Composit | 2013 |
Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Canada; Delayed-Action Prepar | 2013 |
Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Insulin; Male; Middle Aged; Olanzapine; Risper | 2013 |
Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit An | 2013 |
Chronic risperidone exposure does not show any evidence of bone mass deterioration in animal model of schizophrenia.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Bone Density; Bone Resorption; Female; Male; Pregna | 2013 |
The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation.
Topics: Animals; Antipsychotic Agents; Apoptosis; Benzodiazepines; Cell Line; Cricetinae; Diabetes Mellitus; | 2013 |
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental D | 2013 |
Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Decision Suppo | 2013 |
MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission.
Topics: Adult; Antipsychotic Agents; Female; Humans; Male; MicroRNAs; Risperidone; Schizophrenia | 2013 |
Long-acting injection formulations of antipsychotics for people with schizophrenia had negative effects on clinical relationships.
Topics: Antipsychotic Agents; Female; Humans; Male; Physician-Patient Relations; Risperidone; Schizophrenia | 2013 |
Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics.
Topics: Adolescent; Age of Onset; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Cholesterol; Diben | 2014 |
Risperidone-induced hypersexuality.
Topics: Aged; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Risperidone; Schizophrenia; Sexual Dy | 2013 |
Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Clozapine; Disease Susceptibility; ErbB Receptors; Fem | 2015 |
Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations.
Topics: Adult; Aged; Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Administ | 2013 |
Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Databases, Factual; Emergency Service, Hospital; | 2013 |
CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.
Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tra | 2013 |
Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways.
Topics: Animals; Antioxidants; Antipsychotic Agents; Corpus Striatum; Drug Therapy, Combination; Glutathione | 2013 |
Neurotransmitter receptor and regulatory gene expression in peripheral blood of Brazilian drug-naïve first-episode psychosis patients before and after antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Brazil; Down-Regulation; Female; Gene Expression; Humans; Male; Psychia | 2013 |
Clozapine-associated asterixis: case report.
Topics: Aged; Antipsychotic Agents; Clozapine; Drug Substitution; Drug Therapy, Combination; Dyskinesia, Dru | 2014 |
Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Fem | 2014 |
Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia; Basal Ganglia Diseases; Caudate Nucleus; Fem | 2014 |
Predictors of response to second generation antipsychotics in drug naïve patients with schizophrenia: a 1 year follow-up study in Shanghai.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; China; Dibenzothiazepines; Female; Follow- | 2014 |
Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost of Illness; Cost-Benefit Analysis; Del | 2014 |
Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia.
Topics: Antipsychotic Agents; Biomarkers; Humans; Ketamine; Magnetic Resonance Imaging; Nicotine; Risperidon | 2014 |
Paranoid personality disorder and the schizophrenia spectrum-Where to draw the line?
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Diagnosis, Differential; Diagnostic and Statistical Ma | 2013 |
Schizophrenia research: where are we?
Topics: Antipsychotic Agents; Cognitive Behavioral Therapy; Family; Humans; Medication Adherence; Nonverbal | 2014 |
Effects of vitamin D receptor polymorphisms on the risk of schizophrenia and metabolic changes caused by risperidone treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Asian People; Case-Control Studies; China; Female; Humans; | 2014 |
Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Corpus Striatum; Female; Frontal Lobe; Macaca mulat | 2014 |
A pharmacogenetic study of risperidone on chemokine (C-C motif) ligand 2 (CCL2) in Chinese Han schizophrenia patients.
Topics: Adult; Alleles; Analysis of Variance; Antipsychotic Agents; Asian People; Case-Control Studies; Chem | 2014 |
Should remission in schizophrenia data be combined from different studies?
Topics: Activities of Daily Living; Behavioral Symptoms; Female; Haloperidol; Humans; Male; Remission Induct | 2014 |
Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Diabetes Complications; Female; Huma | 2014 |
Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Diabetes Complications; Female; Huma | 2014 |
Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Diabetes Complications; Female; Huma | 2014 |
Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Diabetes Complications; Female; Huma | 2014 |
Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cytokines; Female; Humans; Immunoassay; Interleukin 1 | 2014 |
Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; Electrocardiography; Fem | 2014 |
Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Female; | 2014 |
Do prior authorization policies discourage first-line antipsychotic use in patients newly discharged from a hospitalization for schizophrenia in Saskatchewan?
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Databases, Factual; Dibenzothiazepines | 2014 |
Association between serum testosterone levels, body mass index (BMI) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Estradiol; Humans; Insulin; Male; Mid | 2014 |
Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Area Under Curve; Biomarkers; Cytochrome P-450 CYP2D6; Female; Ge | 2014 |
A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Dopamine; Drug Administration R | 2014 |
Therapeutics: Negative feedback.
Topics: Affect; alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Controlled Clinical Trials as | 2014 |
Minocycline and risperidone prevent microglia activation and rescue behavioral deficits induced by neonatal intrahippocampal injection of lipopolysaccharide in rats.
Topics: Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Female; Hippocampus; Immunohistoc | 2014 |
APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Apolipoprotein A-I; Biomarkers; Chromogranins; Female; GTP-Binding Prot | 2014 |
Serotonin(1A) receptors in the action of aripiprazole.
Topics: Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Female; Humans; Male; Piperazines; Quinolone | 2014 |
Blonanserin improved dystonia induced by risperidone or olanzapine in two patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dystonia; Female; Humans; Olanzapine; Piperazines; Pip | 2014 |
Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS).
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Hospitalizat | 2014 |
Quality of life in patients with schizophrenia: the impact of socio-economic factors and adverse effects of atypical antipsychotics drugs.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brazil; Female; Humans; Male; Middle Aged; Olanzapine; | 2014 |
Pathological bone mineral density in patients on long-term risperidone.
Topics: Antipsychotic Agents; Bone Resorption; Female; Humans; Hyperprolactinemia; Male; Risperidone; Schizo | 2014 |
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Aryldialkylphosphatase; Cardiovascular Diseases; Clozapine; Female; Hum | 2014 |
Effect of antipsychotic drugs on gene expression in the prefrontal cortex and nucleus accumbens in the spontaneously hypertensive rat (SHR).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; DNA Methylation; Gene Expression; | 2014 |
Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Blood Chemical Analysis; Chromatography, Liquid; Fema | 2014 |
Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.
Topics: Adult; Antipsychotic Agents; Drug Prescriptions; Drugs, Generic; Europe; Health Resources; Humans; H | 2014 |
Dopamine D(2)/D(3) receptor binding of [(123)I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging.
Topics: Animals; Benzamides; Chronic Disease; Disease Models, Animal; Dizocilpine Maleate; Male; Multimodal | 2014 |
Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; Dibenzothiazepines; | 2014 |
Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia.
Topics: Acetylcholinesterase; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Aza Co | 2014 |
Association of microRNA137 gene polymorphisms with age at onset and positive symptoms of schizophrenia in a Han Chinese population.
Topics: Adult; Age of Onset; Aripiprazole; China; Female; Genetic Predisposition to Disease; Genotype; Human | 2014 |
Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition Disorders; Disease Progression; Female; Follow-Up | 2014 |
The response of psychotic symptoms in a patient with resistant schizophrenia under treatment of high-dose risperidone long-acting injection.
Topics: Antipsychotic Agents; Humans; Male; Middle Aged; Psychotic Disorders; Risperidone; Schizophrenia | 2014 |
The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Female; Humans; Male; Medication Adherence; Psychiatric Status | 2014 |
Association of dopamine receptor D1 (DRD1) polymorphisms with risperidone treatment response in Chinese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Asian People; Female; Genetic Association Studies; Humans; Male; Polymo | 2015 |
Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
Topics: Adult; Antipsychotic Agents; Decanoates; Delayed-Action Preparations; Denmark; Female; Follow-Up Stu | 2015 |
Multidrug overdose-induced myoclonus complicated by rhabdomyolysis: possible role and mechanism of muscle toxicity of risperidone.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Overdose; Female; Humans; Middle Aged; Myoclonus; Rhabdo | 2014 |
No better solution for antipsychotic treatment with regard to long-term safety and effectiveness.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Piperazines; Psycho | 2015 |
Serum TNF-α, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Clozapine; Female; Humans; Interleukin-10; Interl | 2014 |
Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia.
Topics: Adult; Alleles; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antipsychotic Agents; Female; Genetic | 2014 |
Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Carbon; Cholesterol; F | 2014 |
[Effectiveness of long-acting injectable risperidone for patients with treatment refractory schizophrenia].
Topics: Adult; Aged; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Recurrence; Risperidone; Schiz | 2013 |
SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.
Topics: Antipsychotic Agents; Benzodiazepines; Biomarkers, Pharmacological; Bipolar Disorder; Genetic Associ | 2014 |
Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-B | 2014 |
Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy.
Topics: Administration, Oral; Adult; Aged; Amisulpride; Antipsychotic Agents; Drug Therapy, Combination; Fem | 2015 |
Amisulpride-associated mania in a young adult with schizophrenia and cerebral disease.
Topics: Amisulpride; Antipsychotic Agents; Bipolar Disorder; Cerebral Palsy; Drug Administration Schedule; H | 2014 |
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Delayed-Action Preparations; Fem | 2014 |
Neuroleptic malignant syndrome following abrupt anti-cholinergic withdrawal: a case report.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Female; Humans; Lorazepam; Neuroleptic Malignant Synd | 2014 |
Blonanserin ameliorated the tendency toward QTc prolongation associated with risperidone in a patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Female; Humans; Long QT Syndrome; Piperazines; Piperidines; Risperidone | 2015 |
Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Child; Family Health; Female; Humans; Hyperprolactinemia; Male; Pr | 2015 |
Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Drug Therapy, Combination; Female; Hospital | 2015 |
Prescribing of antipsychotics in UK primary care: a cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Bipolar Disorder; Child; Cohort St | 2014 |
Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Case-Control Studies; Clozapine; Cognition Disorders; Cross-Secti | 2015 |
Maternal immune activation induces changes in myelin and metabolic proteins, some of which can be prevented with risperidone in adolescence.
Topics: Aging; Animals; Antipsychotic Agents; Disease Models, Animal; Female; Male; Myelin Sheath; Prefronta | 2015 |
Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness.
Topics: Adult; Antipsychotic Agents; Comorbidity; Depression; Female; Humans; Male; Middle Aged; Obsessive-C | 2015 |
Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Cohort Studies; Databases, Factual; Delayed-Actio | 2015 |
Hospitalization risk in patients with schizophrenia before and after initiation of risperidone long-acting injection in Japan.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Drug Administration Schedule; Female | 2015 |
N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients.
Topics: Adult; Age of Onset; Antipsychotic Agents; Aspartic Acid; Case-Control Studies; Female; Follow-Up St | 2015 |
Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Emergency Service, H | 2015 |
Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV).
Topics: Adolescent; Adult; Albuminuria; Antipsychotic Agents; Blood Glucose; Body Mass Index; Diabetes Compl | 2015 |
Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Male; Models, Theoretical; Patient Dropouts; Psychiatric Statu | 2015 |
Risperidone unmasking an accessory pathway.
Topics: Accessory Atrioventricular Bundle; Antipsychotic Agents; Atrioventricular Node; Electrocardiography; | 2015 |
The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
Topics: Adolescent; Adult; Alleles; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Cytochrome | 2015 |
A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; | 2015 |
Necrotising pyomyositis complicating intramuscular antipsychotic administration.
Topics: Adult; Anti-Bacterial Agents; Antipsychotic Agents; Daptomycin; Female; Gram-Positive Cocci; Humans; | 2015 |
Treating Schizophrenia With 2 Long-Acting Injectable Antipsychotic Drugs: A Case Report.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Humans; Injections, Intra | 2015 |
Using aripiprazole to treat new-onset hyperprolactinemia-related delusion of pregnancy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Hyperprolactinemia; Risperidon | 2015 |
Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With Schizophrenia.
Topics: Early Medical Intervention; Female; Humans; Isoxazoles; Male; Palmitates; Risperidone; Schizophrenia | 2015 |
Optimal treatment allocation for placebo-treatment comparisons in trials with discrete-time survival endpoints.
Topics: Antipsychotic Agents; Endpoint Determination; Humans; Longitudinal Studies; Proportional Hazards Mod | 2015 |
Factors associated with self-rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapy.
Topics: Adolescent; Adult; Antipsychotic Agents; Asian People; Cross-Sectional Studies; Female; Humans; Line | 2015 |
Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brain; Carbon Radioisotopes; Fe | 2015 |
Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Body Mass Index; Delayed-Action Preparations; Dose-Re | 2015 |
A double amino-acid change in the HLA-A peptide-binding groove is associated with response to psychotropic treatment in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; HLA-A Antigens; Humans; Linkage Disequilibrium | 2015 |
Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Body Weights and Measures; Cross-Secti | 2016 |
Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Brain; Carbon Radioisotopes; Chromatography, Liquid; Fe | 2016 |
Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone.
Topics: Antioxidants; Antipsychotic Agents; Biomarkers; Humans; Lipid Peroxidation; Oxidative Stress; Psycho | 2015 |
Follow-up of N400 in the Rehabilitation of First-episode Schizophrenia.
Topics: Adult; Evoked Potentials; Follow-Up Studies; Humans; Middle Aged; Risperidone; Schizophrenia | 2015 |
Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.
Topics: Adolescent; Adult; Antipsychotic Agents; Asian People; Chi-Square Distribution; China; Chlorpromazin | 2016 |
Low expression of Gria1 and Grin1 glutamate receptors in the nucleus accumbens of Spontaneously Hypertensive Rats (SHR).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Gene Expression; Glycine Plasma Me | 2015 |
Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Genetic Loci; Humans; Male; Outcome A | 2015 |
Maturation- and sex-sensitive depression of hippocampal excitatory transmission in a rat schizophrenia model.
Topics: Animals; Disease Models, Animal; Excitatory Postsynaptic Potentials; Female; Hippocampus; Male; Orga | 2016 |
[Eating disorders in psychiatric patients during treatment with second generation antipsychotics].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Feeding and Eating Disorders; Fema | 2015 |
First-Episode Psychosis Research: Time to Move Forward (by Looking Backwards).
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic | 2015 |
A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia--A nationwide study.
Topics: Adult; Antipsychotic Agents; Drug Delivery Systems; Female; Flupenthixol; Haloperidol; Humans; Male; | 2015 |
Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Economi | 2016 |
Very abnormal T waves in a 37-year-old man.
Topics: Adult; Antipsychotic Agents; Defibrillators, Implantable; Electrocardiography; Humans; Male; Risperi | 2016 |
Association of orexin receptor polymorphisms with antipsychotic-induced weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Genetic Association Studies; Humans | 2016 |
Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Neostriatum; Receptors, Dopamine D2; Re | 2015 |
[Peculiarities of Platelet Activation Changes in Patients with Chronic Schizophrenia, Depending on the Severity of Positive and Negative Symptoms during the Remission Formation].
Topics: Adult; Antipsychotic Agents; Behavioral Symptoms; Cohort Studies; Humans; Male; Middle Aged; Moscow; | 2015 |
What is the right pharmacotherapy for alcohol use disorder in patients with schizophrenia?
Topics: Alcoholism; Antipsychotic Agents; Female; Humans; Male; Risperidone; Schizophrenia | 2015 |
How to best treat patients with schizophrenia and co-occurring alcohol use disorder.
Topics: Alcoholism; Antipsychotic Agents; Female; Humans; Male; Risperidone; Schizophrenia | 2015 |
Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; CD36 Antigens; Cohort Studies; Fatty Acid Binding Prot | 2016 |
Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.
Topics: Amino Acid Sequence; Animals; Binding Sites; Cognition; Disease Models, Animal; Doxycycline; Female; | 2015 |
A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population.
Topics: Adult; Antipsychotic Agents; Asian People; China; Female; Follow-Up Studies; Genetic Association Stu | 2015 |
Concerns over your recent paper on risperidone long-acting injectable for treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Male; Psychotic Disorders; Risperidone; Schizophrenia | 2015 |
Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
Topics: Animals; Antipsychotic Agents; Cognition; Cognition Disorders; Conditioning, Operant; Disease Models | 2016 |
Association of telomere length and mitochondrial DNA copy number with risperidone treatment response in first-episode antipsychotic-naïve schizophrenia.
Topics: Adult; Antipsychotic Agents; DNA, Mitochondrial; Drug Administration Schedule; Female; Follow-Up Stu | 2015 |
Delayed drug interactions in psychiatry: armodafinil and risperidone as a potential case in point.
Topics: Antipsychotic Agents; Benzhydryl Compounds; Drug Interactions; Drug Synergism; Humans; Modafinil; Re | 2015 |
Making Progress Toward Individualized Medicine in the Treatment of Psychosis.
Topics: Aripiprazole; Corpus Striatum; Ether-A-Go-Go Potassium Channels; Female; Humans; Male; Risperidone; | 2016 |
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Computer Simulation | 2015 |
Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study).
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Male; Mi | 2016 |
Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone.
Topics: Adult; Attention; Brain; Brain Mapping; Executive Function; Female; Humans; Longitudinal Studies; Ma | 2016 |
Re: Review article titled 'Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia' (Stevens GL et al. Early Interv Psychiatry 2015 Sep 25. doi: 10.1111/eip.12278).
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Risperidone; Schizophrenia | 2016 |
Effects of antipsychotics on insight in schizophrenia: results from independent samples of first-episode and acutely relapsed patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Follow-Up Studies; | 2016 |
Different mechanisms of risperidone result in improved interpersonal trust, social engagement and cooperative behavior in patients with schizophrenia compared to trifluoperazine.
Topics: Antipsychotic Agents; Humans; Interpersonal Relations; Risperidone; Schizophrenia; Social Skills; Tr | 2016 |
Aberrant Hippocampal Connectivity in Unmedicated Patients With Schizophrenia and Effects of Antipsychotic Medication: A Longitudinal Resting State Functional MRI Study.
Topics: Adult; Antipsychotic Agents; Caudate Nucleus; Cerebral Cortex; Connectome; Female; Hippocampus; Huma | 2016 |
Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; Female; Genome-Wide Assoc | 2016 |
Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Estradiol; Female; | 2016 |
Effects of prolonged antipsychotic administration on neuregulin-1/ErbB signaling in rat prefrontal cortex and myocardium: implications for the therapeutic action and cardiac adverse effect.
Topics: Animals; Antipsychotic Agents; Cardiovascular Diseases; Clozapine; Comorbidity; Genetic Predispositi | 2016 |
Reply to "concern over your recent paper on risperidone long-acting injectable for treatment-resistant schizophrenia".
Topics: Antipsychotic Agents; Female; Humans; Male; Psychotic Disorders; Risperidone; Schizophrenia | 2016 |
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapi | 2015 |
Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; China; Clozapine; Femal | 2016 |
Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain.
Topics: Antipsychotic Agents; Cost Control; Cost Savings; Delayed-Action Preparations; Drug Costs; Health Ca | 2016 |
Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling of risperidone and its active metabolite in Chinese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Area Under Curve; Asian People; Biotransformation; China; Female; Human | 2016 |
Changes in length of hospital stay before and after the administration of a long-acting injection in patients with schizophrenia: Mirror-image study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Humans; Injections; Length of Stay; Middle | 2016 |
Long-acting injectable risperidone as an option in first-episode psychosis.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Psychotic Disorders; Risperidone; Schizop | 2016 |
Letters to the Editor.
Topics: Antipsychotic Agents; Glucosephosphate Dehydrogenase Deficiency; Humans; Male; Priapism; Risperidone | 2016 |
Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug Resistance; Female; Genotype; Humans; Hyperprolactinemia; Male; Mi | 2016 |
Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimul | 2016 |
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Prepar | 2016 |
Fever, confusion, acute kidney injury: is this atypical neuroleptic malignant syndrome following polypharmacy with clozapine and risperidone?
Topics: Acute Kidney Injury; Aged; Antipsychotic Agents; Clozapine; Confusion; Fever; Humans; Male; Neurolep | 2016 |
Comparison of hospitalization risk before and after changing from risperidone long-acting injection to another long-acting injection or oral antipsychotic in patients with schizophrenia: Mirror-image study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Hospitalization; Humans; Injection | 2016 |
Severe hypoglycemia associated with risperidone.
Topics: Aged; Antipsychotic Agents; Humans; Hypoglycemia; Male; Risperidone; Schizophrenia | 2016 |
Post authorization safety study comparing quetiapine to risperidone and olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cohort Studies; Female; | 2016 |
Comparison of Treatment Retention Between Risperidone Long-Acting Injection and First-Generation Long-Acting Injections in Patients With Schizophrenia for 5 Years.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Injections; Medication Adherence; Risperi | 2016 |
Gene-expression analysis of clozapine treatment in whole blood of patients with psychosis.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Gene Expression; Gene Expression Profiling; Humans; | 2016 |
[Analysis of the changes of serum high mobility group protein B1 and cytokines in first-episode schizophrenia patients].
Topics: Antipsychotic Agents; Biomarkers; Case-Control Studies; Cytokines; Enzyme-Linked Immunosorbent Assay | 2015 |
Risperidone-induced topological alterations of anatomical brain network in first-episode drug-naive schizophrenia patients: a longitudinal diffusion tensor imaging study.
Topics: Adolescent; Adult; Antipsychotic Agents; Diffusion Tensor Imaging; Follow-Up Studies; Humans; Limbic | 2016 |
Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats.
Topics: Animals; Antipsychotic Agents; Cyclic Nucleotide Phosphodiesterases, Type 1; Drug Interactions; Expl | 2016 |
Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Specimen Collection; C | 2016 |
Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chlorpromazine; Delayed-Action Preparations; Dopamine | 2016 |
Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Middle Aged; Olanzapi | 2016 |
Early antipsychotic exposure affects serotonin and dopamine receptor binding density differently in selected brain loci of male and female juvenile rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Autoradiography; Benzodiazepines; Female; Male; Nucleus | 2016 |
Association of ABCB1 Gene Polymorphisms with Efficacy and Adverse Reaction to Risperidone or Paliperidone in Han Chinese Schizophrenic Patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; ATP Binding Cassette Transporter, Subfa | 2016 |
Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Celecoxib; Disease Models, Animal; Drug Therapy, Comb | 2016 |
Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antidepressive Agents; Antipsychotic Agents; Benza | 2016 |
Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Female; Health Care Costs; Health | 2016 |
Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study.
Topics: Adult; Antipsychotic Agents; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Neural Inhibition; Ps | 2017 |
Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia.
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Delayed-Action Preparations; Female; Humans; I | 2016 |
Marked Improvement of Meige Syndrome in a Japanese Male Patient with Schizophrenia After Switching from Risperidone to Paliperidone: A Case Report.
Topics: Adult; Antipsychotic Agents; Humans; Male; Meige Syndrome; Paliperidone Palmitate; Risperidone; Schi | 2016 |
Plasma levels and estimated dopamine D
Topics: Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cross-Sectional Studies; Delayed- | 2016 |
Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection.
Topics: Adult; Croatia; Delayed-Action Preparations; Employment; Female; Humans; Injections, Intramuscular; | 2016 |
Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dose-Response Relationship, Drug; | 2017 |
Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Immunologic Factors; Immunomodulation; | 2017 |
Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal fMRI Study.
Topics: Adult; Antipsychotic Agents; Brain; Case-Control Studies; Female; Humans; Longitudinal Studies; Magn | 2016 |
In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [
Topics: Adult; Antipsychotic Agents; Brain; Female; Gyrus Cinguli; Humans; Isoquinolines; Male; Microglia; P | 2016 |
Rapid detection of alteration of serum IgG in patients with schizophrenia after risperidone treatment by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry.
Topics: Antipsychotic Agents; Biomarkers; Humans; Immunoglobulin gamma-Chains; Risperidone; Schizophrenia; S | 2016 |
Effects of Discontinuation of Paliperidone Long-Acting Injectable After Switching from Risperidone Long-Acting Injectable Switching.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Retrospective Stu | 2016 |
Paliperidone palmitate: factors predicting continuation with treatment at 2 years.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Delayed-Action Preparations; | 2016 |
Cognition and Dopamine D
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognitive Dysfunction; Corpus Striatum; Female; Humans; | 2017 |
Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects.
Topics: Animals; Antipsychotic Agents; Citalopram; Dopamine; Drug Therapy, Combination; Male; Nucleus Accumb | 2017 |
[Cognitive effectiveness of risperidone and olanzapine in first-episode schizophrenia].
Topics: Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Humans; Olanzapine; Risperido | 2016 |
Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Substitution; Female; Humans; Male; | 2017 |
Risperidone-Associated Rhabdomyolysis Without Neuroleptic Malignant Syndrome: A Case Report.
Topics: Antipsychotic Agents; Humans; Male; Middle Aged; Rhabdomyolysis; Risperidone; Schizophrenia | 2017 |
Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Female; Humans; Mal | 2017 |
Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Cohort Studies; Female; | 2017 |
Prescription preferences in antipsychotics and attitude towards the pharmaceutical industry in Belgium.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Belgium; Benzodiazepines; Cross-Sectional Studies; Drug I | 2017 |
Assessing a surrogate predictive value: a causal inference approach.
Topics: Antipsychotic Agents; Biomarkers; Causality; Data Interpretation, Statistical; Endpoint Determinatio | 2017 |
Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months.
Topics: Antipsychotic Agents; Case-Control Studies; Clozapine; Female; Humans; Incidence; Male; Middle Aged; | 2017 |
A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Follow-Up Studi | 2017 |
Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Insurance Claim Review; | 2017 |
Atypical Antipsychotics and the Risks of Acute Kidney Injury and Related Outcomes Among Older Adults: A Replication Analysis and an Evaluation of Adapted Confounding Control Strategies.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Bipolar Disorde | 2017 |
CYP2D6 polymorphisms are associated with effects of risperidone on neurocognitive performance in schizophrenia.
Topics: Antipsychotic Agents; Asian People; China; Cytochrome P-450 CYP2D6; Follow-Up Studies; Genetic Assoc | 2017 |
Importance of intervention timing in the effectiveness of antipsychotics.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Disease Models, Animal; Dopamine; Male; Motor Activi | 2018 |
Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzap | 2017 |
Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics.
Topics: Adenine; Adult; Algeria; Antipsychotic Agents; Clozapine; Diagnostic and Statistical Manual of Menta | 2008 |
Effects of risperidone on procedural learning in antipsychotic-naive first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition; Electrooculography; Female; Humans; Learning; Ma | 2009 |
Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle | 2008 |
Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Electrocardiography; Female; Haloperid | 2009 |
Clinical experiences and clinical trials.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dyskinesia, Drug-Induced; Humans; Olanzapine | 2008 |
Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Topics: Adult; Alleles; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Genetic Markers; Genotype; H | 2008 |
Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition Disorders; Control Groups; Female; Follow-Up Studi | 2008 |
Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; DNA; Dopamine; Female; Humans; Japan; Male; Polymorphism, Genetic; Prol | 2008 |
Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia.
Topics: 3' Untranslated Regions; Antigens, CD; Antipsychotic Agents; Benzodiazepines; CD48 Antigen; Chromoso | 2008 |
Symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Comorbidity; Delayed-Action Preparations; Female; Fol | 2008 |
Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Asian People; China; Demography; Female; Gene Frequency; Genetic Predis | 2008 |
Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia.
Topics: Adult; Female; Humans; Male; Polymorphism, Single Nucleotide; Prospective Studies; Proto-Oncogene Pr | 2009 |
Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls.
Topics: Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; Electrocardiogra | 2008 |
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antipsychotic Agents; Benzodiazepines; Biotransformation | 2008 |
Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Case-Control Studies; Cohort Studi | 2008 |
Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study.
Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Dibenzothi | 2008 |
The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.
Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodiazepine | 2008 |
An autoregressive linear mixed effects model for the analysis of longitudinal data which include dropouts and show profiles approaching asymptotes.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Haloperidol; Humans; Linear Models; Longitudinal Stu | 2008 |
Fluordeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic-auditory activation.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Brain Mapping; Female; Fluorodeoxyglucose F18; Ha | 2008 |
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Biological Availability; Body Wei | 2008 |
Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Cost-Benefit Analysis; Drug Administration Schedule; F | 2008 |
LORETA functional imaging in antipsychotic-naive and olanzapine-, clozapine- and risperidone-treated patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Brain Mapping; Clozapine; Electroencephalograph | 2008 |
Impact of patient selection criteria and treatment history on comparisons of alternative therapies: a case study of atypical antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; California; Databases, Factual; Deci | 2009 |
Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment.
Topics: Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Humans; Middle Aged; Risperidone; Schizophren | 2008 |
Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Electric Stimul | 2009 |
Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Estradiol; Gonadotropins, Pituitary; Hormones; Humans; | 2009 |
Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Humans; Male; O | 2008 |
Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; | 2008 |
Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; | 2008 |
Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; | 2008 |
Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; | 2008 |
Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; | 2008 |
Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; | 2008 |
Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; | 2008 |
Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; | 2008 |
Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; | 2008 |
Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Dopamine; Dose-Response Relationship, Drug; Female; Genetic Variation; | 2008 |
A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cohort Stud | 2008 |
Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cholinergic Antagonists; | 2008 |
Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; China; Cross-Sectional Studies; Dose-Response Re | 2008 |
Leukopenia during therapy with risperidone long-acting injectable: two case reports.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; | 2008 |
Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost of Illness; Dibe | 2008 |
N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Animals; Antipsychotic Agents; Biological Clocks; Central Nervous | 2009 |
Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Cohort Studies; De | 2009 |
Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gluc | 2009 |
Sexual dysfunction in patients treated with atypical antipsychotics.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Erectile Dysfunction; Female; Humans; Libido | 2008 |
Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Case-Control Studies; Cause of Death; Clozapine; Coron | 2009 |
Differential brain activation during facial emotion discrimination in first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain; Brain Mapping; Cues; Discrimination, Psychological; | 2009 |
The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Case-Control Studies; Cytokines; Female; Humans; Male; Midd | 2009 |
Pisa syndrome induced by rapid increase and high dosage of risperidone.
Topics: Adolescent; Antipsychotic Agents; Dystonia; Humans; Male; Risperidone; Schizophrenia; Syndrome | 2008 |
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Belgium; Benzodiazepines; Brief Psychiatric Rat | 2009 |
Risperidone-associated increase in triglyceride levels.
Topics: Adult; Antipsychotic Agents; Body Weight; Dose-Response Relationship, Drug; Humans; Hypercholesterol | 2009 |
Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, D | 2009 |
Risperidone-associated newly diagnosed diabetes and fatal diabetes ketoacidosis in a young schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Diabetes Mellitus; Diabetic Ketoacidosis; Fatal Outcome; Humans; Male; | 2009 |
Long-acting injectable risperidone improves quality of life in schizophrenic patients: a clinical case series.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Humans; Quality of Life; Risperidone; S | 2008 |
Risperidone and pituitary adenomas.
Topics: Adult; Antipsychotic Agents; Female; Humans; Pituitary Neoplasms; Risperidone; Schizophrenia | 2009 |
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-B | 2008 |
Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Female; Humans; Male; Olanzapin | 2009 |
Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics.
Topics: Aged; Antipsychotic Agents; Brain; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 2009 |
Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Benzodiazepines; Conditioning, | 2009 |
Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Case-Control Studies; Cause of Dea | 2009 |
Risperidone therapy in two successive pregnancies.
Topics: Antipsychotic Agents; Female; Humans; Infant, Newborn; Male; Pregnancy; Pregnancy Complications; Pre | 2008 |
Internal capsule size associated with outcome in first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Follow-Up Studies; Haloperidol; Hippocampus; Humans | 2009 |
Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Case-Control Studies; Cross-S | 2009 |
A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.
Topics: Antipsychotic Agents; Drugs, Generic; Economics, Pharmaceutical; Germany; Humans; Models, Theoretica | 2009 |
Psychopharmacology news.
Topics: Antipsychotic Agents; Bipolar Disorder; Congresses as Topic; Delayed-Action Preparations; Dibenzothi | 2009 |
Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claim-based database in Taiwan.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Health Resources; Humans; | 2009 |
Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Diagnosis, Differential; Female; Humans; Hyper | 2009 |
Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Female; Humans | 2009 |
Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Catechol O-Methyltransferase; Cognition Disorders | 2009 |
Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Qui | 2009 |
A symptom self-rating scale for schizophrenia (4S): psychometric properties, reliability and validity.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Communication; Female; Humans; Longitudinal Studies; | 2009 |
Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Prescriptions; Drug Therapy, Combinati | 2009 |
The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Apoenzymes; Apoproteins; Blotting, Western; Catalysis; Cell Survival; | 2010 |
Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Fe | 2009 |
Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Drug Therapy, Combination; Female; Ge | 2009 |
Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; DNA; Dose- | 2010 |
Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Asian People; Chromatography, High Pressure Liquid; Cytochrome P-450 CY | 2009 |
Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; Delayed-Action Pr | 2009 |
Hypoglycaemia induced by second generation antipsychotic agents in schizophrenic non-diabetic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Hypoglycemia; Male | 2009 |
Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Anxiety; Cognition; Data Interpretation, Statistical; Depression; | 2010 |
Risperidone for adolescent schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Hu | 2009 |
Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres.
Topics: Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Humans; Microspheres; Olanzapine | 2009 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Sch | 2009 |
Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Dopamine; Female; Follow-Up Studies; Homovanillic Acid; Humans; Male; P | 2009 |
Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients.
Topics: Alleles; Antipsychotic Agents; Apolipoproteins E; Body Mass Index; Cardiovascular Diseases; Diabetes | 2009 |
Lupus anticoagulant and anticardiolipin antibodies in serum of patients treated with risperidone.
Topics: Adult; Antibodies, Anticardiolipin; Antipsychotic Agents; Diagnostic and Statistical Manual of Menta | 2009 |
Longitudinal study of beta2-microglobulin abnormalities in schizophrenia.
Topics: Adult; Antipsychotic Agents; beta 2-Microglobulin; Disease Progression; Female; Follow-Up Studies; H | 2009 |
Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cohort Studies; Dibenzothiazepines; Drug Ad | 2009 |
Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.
Topics: Adult; Age of Onset; Antipsychotic Agents; Delayed-Action Preparations; Electronic Data Processing; | 2009 |
Is depot medication safe in the setting of myopathy?
Topics: Adult; Antipsychotic Agents; Contraindications; Delayed-Action Preparations; Humans; Injections, Int | 2009 |
Aripiprazole treatment of risperidone-induced hyperprolactinemia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Piperazines; Prospective Studies; Qu | 2009 |
Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
Topics: Antipsychotic Agents; Benzodiazepines; Brazil; Cost-Benefit Analysis; Drug Costs; Haloperidol; Human | 2009 |
Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone.
Topics: Adult; Age of Onset; Antipsychotic Agents; Confidence Intervals; Depression; Drug Monitoring; Dyskin | 2009 |
Nasal bleeding associated with fluoxetine and risperidone interaction: a case report.
Topics: Depression; Drug Interactions; Epistaxis; Fluoxetine; Follow-Up Studies; Humans; Male; Risperidone; | 2009 |
[Complex therapy of schizophrenia].
Topics: Adolescent; Adult; Antipsychotic Agents; Art Therapy; Benzodiazepines; Clinical Trials as Topic; Clo | 2009 |
Eugenics by the back door? The unintended consequences of restricting people's choices about mental health medicines.
Topics: Antipsychotic Agents; Choice Behavior; Drug Costs; Drug Prescriptions; Drugs, Generic; Eugenics; Hea | 2009 |
Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Drug Administration Routes; Drug Delivery Syst | 2009 |
Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparations; Female; Hospitali | 2009 |
[Use of Hunperdal Richter in psychiatry].
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Drugs, Generic; Female; Humans; Hungary; | 2009 |
In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation.
Topics: Adult; Antipsychotic Agents; Biotransformation; Chromatography, High Pressure Liquid; Clozapine; Cyt | 2009 |
The relationship between prepulse inhibition and general psychopathology in patients with schizophrenia treated with long-acting risperidone.
Topics: Acoustic Stimulation; Adult; Analysis of Variance; Antipsychotic Agents; Drug Delivery Systems; Huma | 2009 |
Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Confidence Intervals; Female; Health Status | 2009 |
D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia.
Topics: Age of Onset; Aged; Attention Deficit Disorder with Hyperactivity; Cross-Sectional Studies; Dopamine | 2009 |
Comments on 'The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia'.
Topics: Antipsychotic Agents; D-Amino-Acid Oxidase; Enzyme Inhibitors; Humans; Receptors, N-Methyl-D-Asparta | 2010 |
The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series.
Topics: Adult; Antipsychotic Agents; Clozapine; Delayed-Action Preparations; Drug Therapy, Combination; Fema | 2010 |
Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Asian People; Female; Haloperidol; Humans; Kaplan-Meier Est | 2010 |
Priapism and risperidone.
Topics: Adolescent; Alcoholism; Anemia, Sickle Cell; Antipsychotic Agents; Cocaine-Related Disorders; Humans | 2009 |
Effects of atypical (risperidone) and typical (haloperidol) antipsychotic agents on astroglial functions.
Topics: Animals; Antipsychotic Agents; Astrocytes; Brain Chemistry; Cell Line; Glutamate-Ammonia Ligase; Glu | 2010 |
Interaction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia.
Topics: Antipsychotic Agents; Asian People; Catechol O-Methyltransferase; Follow-Up Studies; Humans; Methion | 2010 |
Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.
Topics: Adult; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Female; Finland; Haloperidol; Humans; Ma | 2010 |
MDR1 gene polymorphisms and response to acute risperidone treatment.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Me | 2010 |
The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden.
Topics: Adult; Antipsychotic Agents; Confidence Intervals; Female; Health Care Costs; Health Resources; Hosp | 2010 |
Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study.
Topics: Adult; Antipsychotic Agents; Biomarkers, Pharmacological; Brain-Derived Neurotrophic Factor; China; | 2010 |
[Aripiprazole-induced stuttering treated with risperidone].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Risperidone; Sch | 2009 |
Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Delayed-Action Preparations; Endpoint Determination; F | 2010 |
An examination of the relative contribution of saturation and selective attention to memory deficits in patients with recent-onset schizophrenia and their unaffected parents.
Topics: Age of Onset; Antipsychotic Agents; Attention; Clozapine; Dibenzothiazepines; Female; Humans; Male; | 2010 |
Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine; Dopamine Antagonists; Mice; Mic | 2010 |
Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Synergism; Fema | 2010 |
Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Diffusion of Innovation; Drug Administration Sche | 2010 |
Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia.
Topics: Acoustic Stimulation; Adult; Aged; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines | 2010 |
Remission of drug-induced hepatitis after switching from risperidone to paliperidone.
Topics: Adult; Antipsychotic Agents; Biotransformation; Chemical and Drug Induced Liver Injury; Clozapine; D | 2010 |
Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tra | 2011 |
Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Blood Glucose; Clozapine; Cross-Sectional Studies | 2010 |
Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Confidence Intervals; Cross-Sectional Studies; Delayed | 2010 |
Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Case-C | 2010 |
Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic F | 2010 |
Probable risperidone-induced tardive "writer's dystonia".
Topics: Adolescent; Dystonic Disorders; Female; Humans; Risperidone; Schizophrenia | 2010 |
Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparations; Dose- | 2010 |
Amenorrhoea - consequence of combined treatment with sulpiride and risperidone in a patient suffering from schizophrenia.
Topics: Amenorrhea; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Mid | 2010 |
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relati | 2010 |
Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Carbon Radioisotopes; Cerebellar Cortex; Cerebral Cort | 2010 |
Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
Topics: Antipsychotic Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Lactic Acid; Microsphe | 2011 |
Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Circadian Rhythm; Drug Administration Schedule; Drug M | 2010 |
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Clozapine; Female; Genes; Genotype; Haplo | 2010 |
Correlates, change and 'state or trait' properties of insight in schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Clinical Trials as Topic; Cohort Stud | 2010 |
Testing for misspecification in generalized linear mixed models.
Topics: Algorithms; Antipsychotic Agents; Bias; Computer Simulation; Humans; Likelihood Functions; Linear Mo | 2010 |
Sex differences in patients with schizophrenia: A prospective, multi-center study.
Topics: Adolescent; Adult; Age of Onset; Aged; Antipsychotic Agents; Body Mass Index; Female; Humans; Longit | 2010 |
Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Female; Humans; Injections; Male; Middle A | 2010 |
In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia.
Topics: Absorbable Implants; Animals; Antipsychotic Agents; Drug Delivery Systems; Humans; Lactic Acid; Male | 2010 |
Changes in heart rate dynamics of patients with schizophrenia treated with risperidone.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Cluster Analysis; Electrocardiography; Female; He | 2010 |
Risperidone vs. placebo for schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Humans; Medication Adherenc | 2010 |
Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia.
Topics: Age Factors; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Disease Models, Animal; Female; | 2011 |
Acute respiratory distress due to antipsychotic drugs.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Drug Therapy, Co | 2010 |
Withdrawal-emergent respiratory dyskinesia with risperidone treated with clozapine.
Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Female; Humans; M | 2010 |
The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antipsychotic Agents; Benzimidazol | 2010 |
Trends in antipsychotic prescribing practices in an urban community mental health clinic.
Topics: Administration, Oral; Anticonvulsants; Antipsychotic Agents; Case Management; Community Mental Healt | 2010 |
Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection.
Topics: Adult; Antipsychotic Agents; Bayes Theorem; Female; Humans; Male; Medication Adherence; Middle Aged; | 2010 |
An early improvement threshold to predict response and remission in first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Germany; Ha | 2010 |
Palinacousis as discontinuation symptom after antipsychotic treatment in a patient with first-episode schizophrenia.
Topics: Adolescent; Auditory Perceptual Disorders; Humans; Male; Risperidone; Schizophrenia; Substance Withd | 2010 |
[Effect of side-effects and complications caused by atypical neuroleptics on the effectiveness of therapy in patients with schizophrenia].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Que | 2010 |
Higher motor activity in schizophrenia patients treated with olanzapine versus risperidone.
Topics: Adult; Ambulatory Care; Benzodiazepines; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; | 2010 |
Cochrane for clinicians. Aripiprazole vs. other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Ri | 2010 |
Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics.
Topics: Adult; Antioxidants; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Glutathione Peroxida | 2010 |
The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tra | 2010 |
The effectiveness of long-acting injectable risperidone in a population of psychiatric out-patients: 1-year naturalistic study.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Injections; Italy; Length of Stay | 2010 |
The relationship between akathisia and subjective tolerability in patients with schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Autonomic Nervous System Diseases; Basal Gangl | 2010 |
A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Area Under Curve; Base Sequence; Bayes Theorem; Cytochrome P-45 | 2010 |
[Metabolic side effects of risperidone in early onset schizophrenia].
Topics: Adolescent; Age Factors; Antipsychotic Agents; Body Mass Index; Child; Female; Humans; Hypercholeste | 2010 |
Concordance between measures of functioning, symptoms, and change: examining the GAF, CGI-S, CGI-C, and PANSS.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Psychiatric Status Rating Scales; Risperidon | 2010 |
Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Electrocardiography; Exc | 2010 |
Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Case-Control Studies; Cells, Cultured; Female; Fibroblasts | 2011 |
Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging.
Topics: Adult; Antipsychotic Agents; Brain; Brain Mapping; Case-Control Studies; Echo-Planar Imaging; Female | 2010 |
Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Diagnostic and Statistical Manual of Menta | 2010 |
Analysis of antipsychotic dose reduction.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Meta-A | 2010 |
Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine | 2011 |
Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cholinergic Antagoni | 2011 |
Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Act | 2010 |
Sex differences in the association of weight gain and risperidone efficacy among schizophrenic patients.
Topics: Adult; Female; Humans; Male; Middle Aged; Retrospective Studies; Risperidone; Schizophrenia; Sex Cha | 2010 |
Cost effectiveness of long-acting risperidone in Sweden.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Humans; Medication Adherence; Models, Economic; Outcome | 2010 |
Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
Topics: Adult; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Ag | 2010 |
Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Cross-Sectional Studies; Epistas | 2012 |
Risperidone-induced bulbar palsy-like syndrome.
Topics: Antipsychotic Agents; Deglutition Disorders; Humans; Hyperprolactinemia; Male; Middle Aged; Risperid | 2011 |
Lipid peroxidation in patients with schizophrenia.
Topics: Adolescent; Adult; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Biomarkers; | 2010 |
Risperidone-induced sialorrhea: dose-related?
Topics: Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Risperidone; Schizophrenia; Sialorrhe | 2010 |
Telmisartan and obesity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Humans; Obesity; PPAR d | 2010 |
A crossover study on the glucose metabolism between treatment with olanzapine and risperidone in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Female; Glucose; Glucose Tolerance | 2010 |
Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Body Weight; | 2010 |
Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed?
Topics: Antipsychotic Agents; Data Interpretation, Statistical; Heart Diseases; Humans; Imidazoles; Indoles; | 2010 |
Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Comorbidity; Delayed-Action Pre | 2011 |
Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.
Topics: Adult; Aged; Animals; Antipsychotic Agents; Case-Control Studies; Female; Humans; Kynurenine; Kynure | 2011 |
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
Topics: Adult; Age Factors; Alleles; Amisulpride; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodi | 2011 |
Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Topics: Adult; Aged; Alcoholism; Antipsychotic Agents; Comorbidity; Delayed-Action Preparations; Depression; | 2011 |
Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain Mapping; Female; Humans; Magnetic Resonance Imag | 2012 |
Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Movement Disorders; Olanzapine; Psychotic Disorders; | 2010 |
Phospholipase A₂ activity in first episode schizophrenia: associations with symptom severity and outcome at week 12.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Dibenzothiazepines; | 2011 |
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Topics: Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibe | 2011 |
Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Analysis of Variance; Antipsychotic Agents; Biogenic Monoamin | 2011 |
Risperidone induced ventricular tachycardia.
Topics: Adult; Antipsychotic Agents; Echocardiography, Stress; Electrocardiography; Humans; Male; Risperidon | 2010 |
Management of a patient with schizophrenia and underlying pituitary macroadenoma.
Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bromocriptine; Dopamine Antagon | 2010 |
Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats.
Topics: Alcoholism; Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Central Nervous System Dep | 2011 |
Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes.
Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tra | 2012 |
Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Gene Frequency; Genetic Li | 2011 |
Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection.
Topics: Adult; Aripiprazole; Delayed-Action Preparations; Drug Therapy, Combination; Female; Follow-Up Studi | 2011 |
Potential control of risperidone-related cognitive deficits by adjunctive aripiprazole treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Dopamine Antagonists; Dopamine D2 Receptor Antagonist | 2011 |
Re: sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia.
Topics: Antipsychotic Agents; Humans; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Risperidone; Sch | 2011 |
Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia.
Topics: Adult; Female; Humans; Longitudinal Studies; Male; Medication Adherence; Risperidone; Schizophrenia; | 2011 |
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Fe | 2011 |
The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients.
Topics: Adult; Aged; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Prolactin; | 2011 |
Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Chi-Square Distribution; Clopenthixo | 2010 |
Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia.
Topics: Adult; Alcohol-Related Disorders; Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Female; Hu | 2012 |
Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Databases as Topic; Delayed-Action Preparations; | 2011 |
Hospital resource use by patients with schizophrenia: reduction after conversion from oral treatment to risperidone long-acting injection.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Cost Savings; Female; Hospitalization; Hosp | 2011 |
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dibenzothiazepines; Female; | 2012 |
Adjunctive treatment with low-dosage pramipexole for risperidone-associated hyperprolactinemia and sexual dysfunction in a male patient with schizophrenia.
Topics: Adult; Benzothiazoles; Drug Therapy, Combination; Erectile Dysfunction; Humans; Hyperprolactinemia; | 2011 |
Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Apolipoprotein A-V; Apolipoproteins A; Benzodiazepines; Clozapine; Fema | 2012 |
Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Clozapine; Constipat | 2011 |
[Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia].
Topics: Adult; Antipsychotic Agents; Autoantibodies; Biomarkers; Brain-Derived Neurotrophic Factor; Female; | 2011 |
Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Anxiety; Avoidance Learni | 2011 |
Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation.
Topics: Amphetamine; Animals; Animals, Newborn; Antipsychotic Agents; Central Nervous System Stimulants; Dis | 2011 |
Hippocampal serotonin depletion facilitates the enhancement of prepulse inhibition by risperidone: possible role of 5-HT(2C) receptors in the dorsal hippocampus.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Ergolines; Hippocampus; Male; Nerve Tissue Proteins | 2011 |
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Cohort Studie | 2011 |
Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers, Pharmacological; Clinical Trials, Phase I | 2011 |
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; | 2011 |
An importance of dose in antipsychotic combination therapy for schizophrenia.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Haloperidol; Humans; Randomized Controlled Trials a | 2011 |
Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fem | 2011 |
False positive urine drug screening for tricyclic antidepressants in patients taking quetiapine.
Topics: Adult; Antidepressive Agents, Tricyclic; Dibenzothiazepines; False Positive Reactions; Female; Human | 2011 |
Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Drug Utilization; Female; Follow-Up | 2011 |
Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Humans; Longitudinal Studies; Male; Middle Aged; Obs | 2011 |
Expression of Ca²⁺-dependent activator protein for secretion 2 is increased in the brains of schizophrenic patients.
Topics: Adult; Aged; Animals; Antipsychotic Agents; Autopsy; Brain; Calcium-Binding Proteins; Cerebral Corte | 2011 |
Similarities in early course among men and women with a first episode of schizophrenia and schizophreniform disorder.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Female; Humans; Longitudinal St | 2012 |
MultiSimplex optimization of chromatographic separation and dansyl derivatization conditions in the ultra performance liquid chromatography-tandem mass spectrometry analysis of risperidone, 9-hydroxyrisperidone, monoamine and amino acid neurotransmitters
Topics: Biogenic Monoamines; Case-Control Studies; Chromatography, High Pressure Liquid; Dansyl Compounds; H | 2011 |
Risperidone treatment for polydipsia and hyponatremia in schizophrenia: a case report.
Topics: Adult; Antipsychotic Agents; Female; Humans; Hyponatremia; Obesity; Polydipsia, Psychogenic; Risperi | 2011 |
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Avoidance Learning; Cognitio | 2011 |
Long-acting risperidone and oral antipsychotics in schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Hospitalization; Humans; In | 2011 |
Long-acting risperidone and oral antipsychotics in schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Hospitalization; Humans; In | 2011 |
A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Asian People; Brief Psychiatric Rating Scale; Female; Genotype; Humans; | 2012 |
Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone.
Topics: Actigraphy; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Motor Activity; Olan | 2011 |
Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Brain; Dopamine Agonists; Humans; Magnetic Resona | 2011 |
Frontal areas contribute to reduced global coordination of resting-state gamma activities in drug-naïve patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain Mapping; Brain Waves; Electroencephalography; Female; | 2011 |
Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Extracellular Space; Fem | 2011 |
Antipsychotic drugs suppress the AKT/NF-κB pathway and regulate the differentiation of T-cell subsets.
Topics: Antipsychotic Agents; CD4-Positive T-Lymphocytes; Cell Differentiation; Cells, Cultured; Clozapine; | 2011 |
Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cannabis; Clozapine; Cohort Studies; Dopamine; Female; | 2012 |
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Economics, Pharma | 2011 |
Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glu | 2011 |
Outcome assessment of an antipsychotic drug algorithm: effects of the Mississippi State Hospital algorithm project.
Topics: Adult; Algorithms; Antipsychotic Agents; Female; Hospitals, State; Humans; Male; Medication Adherenc | 2011 |
The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Drug Substitution; Dyskinesia, Drug-Induced; Humans; O | 2011 |
Granulomatous cutaneous lesions associated with risperidone-induced hyperprolactinemia in an amputated upper limb.
Topics: Amputation Stumps; Antipsychotic Agents; Aripiprazole; Forearm; Granuloma; Humans; Hyperprolactinemi | 2012 |
Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Drug Monitoring; Female; Genotype; Huma | 2011 |
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diben | 2011 |
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Clozapine; Female; Gluco | 2011 |
Status dystonicus in tardive dystonia successfully treated by bilateral deep brain stimulation.
Topics: Adolescent; Antipsychotic Agents; Clonazepam; Deep Brain Stimulation; Disability Evaluation; Electro | 2011 |
Switching antipsychotic medications: not enough, too often, or just right?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Humans; | 2011 |
Do all relapses in schizophrenia warrant resumption of medication?
Topics: Female; Humans; Male; Medication Adherence; Risperidone; Schizophrenia | 2011 |
[Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Butyrophenones; Clozapine; Delayed-Action Preparations | 2011 |
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disrupti | 2011 |
The cost associated with administering risperidone long-acting injections in the Australian community.
Topics: Adult; Antipsychotic Agents; Australia; Cost Savings; Cross-Sectional Studies; Delayed-Action Prepar | 2011 |
Manic symptoms during a switch from risperidone to paliperidone: a case report.
Topics: Antipsychotic Agents; Bipolar Disorder; Female; Follow-Up Studies; Humans; Isoxazoles; Middle Aged; | 2011 |
Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Female; | 2011 |
Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone.
Topics: Adult; Antipsychotic Agents; Bone and Bones; Bone Density; Bone Remodeling; Case-Control Studies; Co | 2011 |
Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Emergency Service, Hospital; Female; Half-Life; Hospita | 2012 |
Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action.
Topics: Adult; Biomarkers; Case-Control Studies; Citric Acid; Energy Metabolism; Female; Gas Chromatography- | 2011 |
Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF.
Topics: Aging; Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Biomarkers; Catalepsy; Dis | 2011 |
[Sexual disturbances during the treatment with neuroleptics in patients with schizophrenia and schizophrenia spectrum disorders].
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Male; Olanzapine; Quetiapine Fuma | 2011 |
Aberrant expression of serum miRNAs in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Female; Gene Expression Regulation; Human | 2012 |
Cost-effectiveness analysis of olanzapine and risperidone in Norway.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Health Se | 2011 |
Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls.
Topics: Adiponectin; Adult; Antipsychotic Agents; Case-Control Studies; Clozapine; Female; Ghrelin; Humans; | 2011 |
Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS).
Topics: Adult; Antipsychotic Agents; Cohort Studies; Drug Administration Schedule; Female; Follow-Up Studies | 2012 |
Pisa syndrome and laryngeal dystonia induced by novel antipsychotics.
Topics: Adult; Antipsychotic Agents; Dystonia; Humans; Imidazoles; Indoles; Laryngeal Diseases; Male; Middle | 2011 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperido | 2011 |
Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone.
Topics: Administration, Oral; Adult; Anaphylaxis; Antipsychotic Agents; Delayed-Action Preparations; Humans; | 2012 |
[Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection].
Topics: Administration, Ophthalmic; Antipsychotic Agents; Delayed-Action Preparations; Drug Substitution; Hu | 2011 |
Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: role for drug transporters?
Topics: Administration, Oral; Adult; Anti-Allergic Agents; Antipsychotic Agents; ATP Binding Cassette Transp | 2012 |
Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.
Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; Attention; Benzodiazepines; Dibenzot | 2012 |
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.
Topics: Alleles; Drug-Related Side Effects and Adverse Reactions; Genetic Association Studies; Humans; Polym | 2013 |
Idiopathic granulomatous mastitis associated with risperidone-induced hyperprolactinemia.
Topics: Adult; Antipsychotic Agents; Biopsy; Clozapine; Drug Substitution; Female; Granulomatous Mastitis; H | 2012 |
The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chi-Square Distribution; Clozapine; Dibenzothia | 2012 |
Neutropenia during risperidone treatment.
Topics: Antipsychotic Agents; Humans; Male; Middle Aged; Neutropenia; Risperidone; Schizophrenia | 2011 |
Olanzapine-induced eccrine squamous syringometaplasia.
Topics: Antipsychotic Agents; Benzodiazepines; Biopsy; Dermatologic Agents; Drug Substitution; Eccrine Gland | 2012 |
Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Clozapine; Cohort S | 2013 |
A change from risperidone long acting injection to paliperidone palmitate in an elderly patient--a cautionary tale.
Topics: Aged; Antipsychotic Agents; Female; Humans; Isoxazoles; Paliperidone Palmitate; Palmitates; Recurren | 2012 |
Effectiveness of sulpiride in adult patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Female; Haloperidol; | 2013 |
Quality of life of schizophrenic patients treated with haloperidol depot and injection preparation of long-lasting risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Female; Haloperidol; Humans; Male; M | 2011 |
[Study on how schizophrenic patients perceive treatment with injections in the deltoid muscle].
Topics: Adult; Antipsychotic Agents; Buttocks; Delayed-Action Preparations; Deltoid Muscle; Female; France; | 2012 |
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Estradiol; Follicle Stimula | 2012 |
[Effects of smoking and caffeine on pharmacological treatment for patients with schizophrenia and depression].
Topics: Caffeine; Depression; Drug Interactions; Fluvoxamine; Humans; Risperidone; Schizophrenia; Smoking | 2011 |
A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Cost-Benefit Analysis; Female; Humans; I | 2012 |
Using ultrasonography in evaluating the intramuscular injection techniques used for administering drug treatments to schizophrenic patients in Japan.
Topics: Antipsychotic Agents; Buttocks; Drug Monitoring; Female; Humans; Injections, Intramuscular; Male; Mi | 2012 |
Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Drug Substitution; Female; Health Reso | 2012 |
Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Interpretation, Statistical; | 2012 |
The voices go, but the song remains the same: how can we rescue cognition in early-onset schizophrenia?
Topics: Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Humans; Male; Molindone; Neurops | 2012 |
Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Hospital Administration; H | 2012 |
Hyperprolactinaemia on depot risperidone treated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Monitoring; Drug Substi | 2012 |
Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia.
Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cross-Sectiona | 2012 |
Management of a risperidone-induced tardive Pisa syndrome: a case report.
Topics: Abdomen; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Drug Monitoring; Dystonia; Female; Hu | 2012 |
Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Haloperi | 2012 |
Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; H | 2012 |
Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population.
Topics: 5' Flanking Region; Adolescent; Adult; Antipsychotic Agents; Asian People; Case-Control Studies; Chi | 2012 |
State and trait markers of emotionally charged visual event-related potentials (P300) in drug-naïve schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Emotions; Event-Rela | 2012 |
Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Female; Humans; Income; Japan; Male; | 2012 |
Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
Topics: Aged; Antipsychotic Agents; Cohort Studies; Delayed-Action Preparations; Dopamine Antagonists; Drug | 2012 |
Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Auditory Cortex; Benzod | 2012 |
Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain.
Topics: Animals; Antioxidants; Antipsychotic Agents; Brain; Disease Models, Animal; Female; Glutamate-Cystei | 2012 |
Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.
Topics: Adult; Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Humans; Isoxazoles; Japan; Ma | 2012 |
Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Europe; Female; Human | 2012 |
Sex differences in human lymphoblastoid cells sensitivities to antipsychotic drugs.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Antineoplastic Agents; Antipsychotic Agents; Cell D | 2013 |
One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Cohort Studies; Delayed-Action Preparations; Drug Adm | 2012 |
Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naïve schizophrenia patients after treatment with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Biomarkers; Case-Control Studies; Female; Humans; Least-Squ | 2012 |
GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction.
Topics: Animals; Autistic Disorder; Baclofen; Disease Models, Animal; Evoked Potentials, Auditory; Explorato | 2012 |
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia.
Topics: Activities of Daily Living; Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Brazil; C | 2013 |
The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Economics, Pharmaceutical; | 2012 |
13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients.
Topics: Adult; Animals; Antipsychotic Agents; Breath Tests; Carbon Isotopes; Chronic Disease; Dopamine; Halo | 2012 |
Risperidone augmentation with amisulpride: the blue-tongue sign.
Topics: Amisulpride; Dopamine Antagonists; Drug Therapy, Combination; Humans; Male; Melanins; Pigmentation; | 2012 |
NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose | 2012 |
Clinical and psychosocial remission in schizophrenia: correlations with antipsychotic treatment.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Inje | 2012 |
Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Dental Caries; D | 2012 |
Could repetitive transcranial magnetic stimulation improve neurocognition in early-onset schizophrenia spectrum disorders?
Topics: Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Humans; Male; Molindone; Neurops | 2012 |
Nitric oxide in patients with schizophrenia: the relationship with the severity of illness and the antipsychotic treatment.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Female; Halope | 2012 |
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; | 2012 |
Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study.
Topics: Antipsychotic Agents; Catechol O-Methyltransferase; Female; Humans; Male; Pharmacogenetics; Polymorp | 2012 |
Recovery in schizophrenia: focus on neurocognitive functioning.
Topics: Adult; Antipsychotic Agents; Arousal; Attention; Cognition Disorders; Executive Function; Female; Hu | 2012 |
Atypical antipsychotic medication: a nightmarish problem!
Topics: Antipsychotic Agents; Dibenzothiazepines; Dreams; Female; Humans; Male; Middle Aged; Quetiapine Fuma | 2012 |
A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Cross-Sectional Studies; Delayed-Action Preparations; Dose-Respon | 2012 |
The role of ethnicity in treatment refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Canada; Clozapine; Female; Humans; Male; Middle Aged; Polypharmacy; Ris | 2013 |
The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Confidence Intervals; Diffusion of Innovation; Evidence | 2012 |
Paliperidone as an alternative for risperidone in a case of schizophrenia with retrograde ejaculation.
Topics: Adult; Antipsychotic Agents; Ejaculation; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidi | 2012 |
Leber's hereditary optic neuropathy associated with schizophrenia.
Topics: Adult; Antipsychotic Agents; Cerebrovascular Circulation; Humans; Male; Mutation; NADH Dehydrogenase | 2012 |
Optimizing treatment with risperidone long-acting injections.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Female; Humans; | 2012 |
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Topics: Antipsychotic Agents; Drug Costs; Female; Humans; Male; Psychotic Disorders; Risperidone; Schizophre | 2012 |
Veteran subjects willingness to participate in schizophrenia clinical trials.
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Female; Humans; Logistic Models; Male; Middle | 2013 |
Repeated activation of mania by atypical antipsychotics in a patient.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Substitution; Drug Therapy, Combinatio | 2012 |
Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Humans; Middle Aged; Olanzapine; Out | 2012 |
Selective acquired long QT syndrome (saLQTS) upon risperidone treatment.
Topics: Adult; Antipsychotic Agents; Clozapine; Electrocardiography; Female; Humans; Long QT Syndrome; Potas | 2012 |
Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Causality; Clozapine; Cross-Sect | 2012 |
Treating residual insomnia in schizophrenia: examining the options.
Topics: Antipsychotic Agents; Central Nervous System Depressants; Humans; Isoxazoles; Melatonin; Paliperidon | 2013 |
Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Case-Control Studi | 2013 |
Comparison of treatment response in second-episode versus first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Delayed-Action Preparations; Drug Administration Schedu | 2013 |
Neuroleptic malignant syndrome associated with risperidone long-acting injection: a case report.
Topics: Antipsychotic Agents; Chemistry, Pharmaceutical; Humans; Injections; Male; Middle Aged; Neuroleptic | 2013 |
Chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study.
Topics: Age Factors; Animals; Animals, Newborn; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; | 2013 |
Diabetes resolution following discontinuation of a second-generation antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Female; Follow-U | 2013 |
Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.
Topics: Antipsychotic Agents; Drug Utilization; Drugs, Generic; Humans; Practice Patterns, Physicians'; Reim | 2013 |
Association study of NRXN3 polymorphisms with schizophrenia and risperidone-induced bodyweight gain in Chinese Han population.
Topics: Adult; Antipsychotic Agents; Asian People; DNA; Female; Genotype; Haplotypes; Humans; Linkage Disequ | 2013 |
[Proteomic analysis of novel serum markers in first-episode schizophrenics before versus after treatment of risperidone].
Topics: Adolescent; Adult; Female; Humans; Male; Proteomics; Risperidone; Schizophrenia; Young Adult | 2012 |
Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schi
Topics: Adult; Antipsychotic Agents; Belgium; Delayed-Action Preparations; Early Medical Intervention; Emplo | 2014 |
Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Electroencephalography; | 2013 |
The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Conditioning, Psychological; Discrimination Learnin | 2013 |
Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Depression; Double-Blind M | 2002 |
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Estradiol; Female; Humans; Hyperprolactinem | 2002 |
Risperidone may induce mania.
Topics: Adult; Bipolar Disorder; Female; Humans; Male; Risperidone; Schizophrenia | 2002 |
A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Databases as Topic; Female; Hospitalization; Hospitals, | 2002 |
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Cohort Studies; Diabetes M | 2002 |
Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics.
Topics: Adult; Antipsychotic Agents; Educational Status; Female; Hospitalization; Humans; Linear Models; Mal | 2002 |
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.
Topics: Adult; Antipsychotic Agents; Depression; Drug Interactions; Drug Therapy, Combination; Female; Fluox | 2002 |
Priapism associated with two atypical antipsychotic agents.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Humans; Male; Piperazines; Priapism; Risperidone; Schi | 2002 |
The value of atypical antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Drug Lab | 2002 |
Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Combined Modality Therapy; Electroconvulsive Therapy; | 2002 |
Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Genotype; Humans; Male; Pharm | 2002 |
Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients.
Topics: Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiepins; Hostility; Humans; Ola | 2002 |
Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cost-Benefit Analysis; Czech Republic; Female; Hospit | 2002 |
Risperidone-induced obsessive-compulsive symptoms: a series of six cases.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Dose-Response Relationship, Drug; Femal | 2002 |
Re: Prolactin levels and adverse events in patients treated with risperidone.
Topics: Antipsychotic Agents; Humans; Hyperprolactinemia; Prolactin; Risperidone; Schizophrenia | 2002 |
Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanilli
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Female; Follow-Up Studies; Homovanillic Acid; Humans; | 2002 |
Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats.
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Dopamine; Dose-Response Relationship, Drug; Drug In | 2002 |
Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition; Female; Humans; Male; Middle Aged; Neuropsycholo | 2002 |
Tardive dyskinesia with risperidone and anticholinergics.
Topics: Adult; Biperiden; Cholinergic Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Fema | 2002 |
An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Benzodiazepines; Case-Co | 2002 |
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data.
Topics: Adult; Aged; Antipsychotic Agents; Arrhythmias, Cardiac; Clozapine; Cohort Studies; Confidence Inter | 2002 |
Very late-onset schizophrenia-like psychosis: clinical and imaging characteristics in comparison with elderly patients with schizophrenia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Brain; Cerebellum; Cerebral Cortex; Cerebral Ventricl | 2002 |
Risperidone-induced hyperprolactinemia in an elderly woman.
Topics: Aged; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Mastitis; Risperidone; Schizophrenia | 2002 |
Comparable dopamine 2 receptor occupancy.
Topics: Benzodiazepines; Cognition Disorders; Dopamine Antagonists; Haloperidol; Humans; Olanzapine; Pirenze | 2002 |
Can risperidone reduce cocaine use in substance abusing schizophrenic patients?
Topics: Adult; Antipsychotic Agents; Cocaine-Related Disorders; Humans; Male; Psychiatric Status Rating Scal | 2002 |
Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; | 2002 |
Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Dr | 2003 |
Combined use of atypical antipsychotics and cognitive-behavioural therapy in schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognitive Behavioral Therapy; Combined Modality Therapy; Hum | 2002 |
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Cognition Disorders; Female; Hal | 2002 |
Outcomes and costs of treatment with risperidone in adult and elderly patients: the Delta patient using risperidone study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Drug Costs; Female; Hospitals, Ps | 2002 |
Does risperidone act better in schizophrenic patients who have a family or obstetric history?
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Female; Humans; Male; Me | 2002 |
Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone.
Topics: Adult; Aged; Alcohols; Antipsychotic Agents; Cannabis; Clozapine; Female; Humans; Male; Middle Aged; | 2003 |
Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Genotype; Humans; Isoxazoles; Middle Age | 2002 |
Prescribing second-generation antipsychotics and the evolving standard of care in Italy.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Benzodiazepines; Brief Psychiatri | 2002 |
Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine.
Topics: Adult; Comorbidity; Dibenzothiazepines; Female; Humans; Hyperprolactinemia; Quetiapine Fumarate; Ris | 2003 |
Risperidone induced galactorrhea: a case analysis.
Topics: Adult; Antipsychotic Agents; Female; Galactorrhea; Humans; Risperidone; Schizophrenia | 2002 |
Atypical antipsychotic drugs improve cognition in schizophrenia.
Topics: Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Follow-Up Studies; Haloperidol; Huma | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine; | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Chronic Disease; Clozapine; Cohort Effect; Cohort Studies; Haloperidol; Humans | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Chronic Disease; Cohort Effect; Dose-Response Relationship, Drug; Drug Adminis | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Blind Met | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Administrat | 2003 |
Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Half-Life; Humans; Hydroxyla | 2003 |
Atypical antipsychotic induced mild hypothermia.
Topics: Antipsychotic Agents; Female; Humans; Hypothermia; Middle Aged; Risperidone; Schizophrenia | 2003 |
Sexual disinhibition induced by risperidone in a child.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Biperiden; Child; Humans; Male; Muscarinic Antagonist | 2002 |
Local-global processing in early-onset schizophrenia: evidence for an impairment in shifting the spatial scale of attention.
Topics: Adolescent; Affect; Antipsychotic Agents; Attention; Benzodiazepines; Clopenthixol; Diazepam; Female | 2003 |
Olanzapine and risperidone.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Humans; Olanzapine; Pirenzepine; Rispe | 2003 |
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Estrogens | 2003 |
'Awakenings' in demented patients.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Awareness; Cholinesterase Inhibitors; Delusions; Depr | 2003 |
Neuroleptics and family history of Parkinson diseases: case report.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Depressive Disorder; Diagnostic Errors; Female; | 2001 |
Role of ethnicity in predicting antipsychotic medication adherence.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Ethnicity; Female; Haloper | 2003 |
Cost evaluation of risperidone compared with olanzapine.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Costs and Cost Analysis; Hospitalization; Hu | 2003 |
Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dopamine Antagonists; Dose-Response Relationship | 2003 |
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Dibenzothiazepines; Female | 2003 |
Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost-Benefit Analysis; Costs and Cost | 2003 |
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care; Antipsychotic Agents; Benzodiazepin | 2003 |
Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
Topics: Adult; Analysis of Variance; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Isoxazoles; Japan; M | 2003 |
Risperidone-associated ejaculatory and urinary dysfunction in male adolescents.
Topics: Adolescent; Antipsychotic Agents; Ejaculation; Humans; Hyperprolactinemia; Male; Risperidone; Schizo | 2003 |
Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cost of Illness; Drug Costs; Female; Health Care Costs | 2003 |
Rehospitalization risk with second-generation and depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Data Collection; Delayed-Action Preparation | 2003 |
Delusions of pregnancy associated with increased prolactin concentrations produced by antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benztropine; Delusions; Dibenzothiazepines; Female; Humans; Middle Aged | 2003 |
Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Cost-Benefit Analysis; Drug Administration Schedul | 2003 |
Antiaggressive action of combined risperidone and quetiapine in a patient with schizophrenia.
Topics: Adult; Aggression; Antipsychotic Agents; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male | 2003 |
Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clinical Trials | 2003 |
Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: a controlled, double dissociation study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Case-Control Studies; Clozapine; Corpus Striatum; Dissoc | 2003 |
Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients.
Topics: Adolescent; Adult; Analysis of Variance; Biomarkers; Corpus Striatum; Female; Humans; Male; Prognosi | 2003 |
Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea.
Topics: Adult; Amenorrhea; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Female; Haloperid | 2003 |
Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.
Topics: Absorptiometry, Photon; Adolescent; Adult; Benzodiazepines; Bone Density; Female; Humans; Middle Age | 2003 |
The influence of risperidone on cognitive functions in schizophrenia.
Topics: Adult; Antipsychotic Agents; Cognition; Humans; Male; Middle Aged; Risperidone; Schizophrenia; Schiz | 2003 |
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
Topics: Benzodiazepines; Brief Psychiatric Rating Scale; Drug Therapy, Combination; Humans; Male; Olanzapine | 2003 |
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze | 2003 |
[Neuroleptics and cognition].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Drug Therapy, Combinat | 2003 |
Schizophrenia, VI: Treatments.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Perphenazi | 2003 |
Racial disparity in the use of atypical antipsychotic medications among veterans.
Topics: Antipsychotic Agents; Benzodiazepines; Black or African American; Clozapine; Dibenzothiazepines; Dru | 2003 |
Weight change after an atypical antipsychotic switch.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; | 2003 |
Serum ghrelin concentrations in patients receiving olanzapine or risperidone.
Topics: Adult; Analysis of Variance; Benzodiazepines; Ghrelin; Humans; Male; Middle Aged; Olanzapine; Peptid | 2004 |
State-related thalamic changes during antipsychotic treatment in schizophrenia: preliminary observations.
Topics: Adult; Antipsychotic Agents; Dominance, Cerebral; Female; Humans; Image Processing, Computer-Assiste | 2003 |
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].
Topics: Acute Kidney Injury; Adult; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Fever; H | 2003 |
Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; | 2003 |
Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
Topics: Adult; Antipsychotic Agents; Catechol O-Methyltransferase; Chi-Square Distribution; Dopamine D2 Rece | 2003 |
Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Cholesterol; Cohort Studies; Female; | 2003 |
Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Caudate Nucleus; Female; Fluorodeoxyglucose F18; Hippocampus; Hu | 2003 |
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depression; Double | 2003 |
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Clozapine; Dibenzothiazepines; Drug The | 2003 |
Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine.
Topics: Antipsychotic Agents; Chronic Disease; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive D | 2003 |
Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
Topics: Administration, Oral; Antipsychotic Agents; Biological Availability; Clinical Trials as Topic; Delay | 2003 |
Clinical guidelines: Dosing and switching strategies for long-acting risperidone.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administra | 2003 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Hum | 2003 |
Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia.
Topics: Adult; Alleles; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Di | 2004 |
Excitability of the motor cortex in schizophrenia following typical and atypical antipsychotics: two serial case reports.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Electromagnetic Fields; Electromyography; Evoked | 2003 |
Reduced short-term obsessive-compulsive symptoms in schizophrenic patients treated with risperidone: a single-blind prospective study.
Topics: Adult; Antipsychotic Agents; Female; Humans; Male; Obsessive-Compulsive Disorder; Prospective Studie | 2003 |
Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Injections, Intravenous; Monitoring, Phys | 2004 |
Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Catchment Area, Health; Female; | 2004 |
Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Black or African American; Drug | 2004 |
Successful risperidone rechallenge after blepharospasm in a patient with schizophrenia: 24-month follow-up.
Topics: Adult; Antipsychotic Agents; Blepharospasm; Drug Administration Schedule; Female; Humans; Risperidon | 2003 |
Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication.
Topics: Adult; Antipsychotic Agents; Bone Density; Female; Humans; Hyperprolactinemia; Hypogonadism; Male; O | 2003 |
Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database.
Topics: Adult; Aged; Benzodiazepines; Cost-Benefit Analysis; Databases, Factual; Female; Health Care Costs; | 2004 |
Risperidone-induced long-term weight gain in a patient with schizophrenia.
Topics: Adult; Humans; Male; Obesity; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; W | 2004 |
Applying linear mixed models to estimate reliability in clinical trial data with repeated measurements.
Topics: Analysis of Variance; Antipsychotic Agents; Clinical Trials as Topic; Humans; Linear Models; Randomi | 2004 |
First person account: living with the delusions and effects of schizophrenia.
Topics: Adult; Antipsychotic Agents; Autobiographies as Topic; Delusions; Female; Hallucinations; Humans; Qu | 2003 |
Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.
Topics: Adult; Antipsychotic Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergol | 2004 |
Potential for detection bias in the association between olanzapine and diabetes.
Topics: Antipsychotic Agents; Benzodiazepines; Bias; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; H | 2004 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal G | 2004 |
Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female | 2004 |
Use of polypharmacotherapy in pregnancy: a prospective outcome in a case.
Topics: Adult; Antipsychotic Agents; Apgar Score; Dibenzothiazepines; Drug Therapy, Combination; Female; Hum | 2004 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2004 |
Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Therapy, Combination; Dyskine | 2004 |
COMT158 polymorphism and hostility.
Topics: Antipsychotic Agents; Benzodiazepines; Catechol O-Methyltransferase; Clozapine; Genotype; Haloperido | 2004 |
Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.
Topics: Antipsychotic Agents; Attitude of Health Personnel; Drug Administration Schedule; Drug Costs; Drug U | 2004 |
Risperidone in the treatment of acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Risperidone; Schizophreni | 2004 |
Decreased plasma antioxidants in schizophrenia.
Topics: Adult; Antioxidants; Antipsychotic Agents; Bilirubin; Case-Control Studies; Female; Humans; Male; Ri | 2004 |
Drug utilization review of risperidone for outpatients in a tertiary referral hospital in Singapore.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antiparkinson Agents; Antipsychotic Agents; Dose-Response | 2004 |
Prognostic indicators for early discontinuation of risperidone long-acting injection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Databases, Factual; Delayed-Act | 2004 |
Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Fema | 2004 |
Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cohort Studies; Databases as Topic; Female; Health Care Costs | 2004 |
Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Clozapine; Dop | 2004 |
Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Asian People; Benzodiazepines; Female; Hong Kong; Humans; Male; Obesity | 2004 |
Comments on cost analysis of risperidone versus olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Costs and Cost Analysis; Cross-Cult | 2004 |
Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out.
Topics: Antipsychotic Agents; Computer Simulation; Haloperidol; Humans; Longitudinal Studies; Models, Statis | 2004 |
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzazepines; Benzodiazepines; Carbon Radioisotopes; Clozap | 2004 |
Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Diabetic Ketoa | 2004 |
Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Case-Control Studies; Clozapine; Demogr | 2004 |
Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin.
Topics: Acute Disease; Adult; Antipsychotic Agents; Compartment Syndromes; Drug Interactions; Humans; Hyperl | 2004 |
Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study.
Topics: Aged; Antipsychotic Agents; Attitude to Health; Basal Ganglia Diseases; Benzodiazepines; Drug Tolera | 2004 |
Treatment of a rare psychopathological phenomenon: tactile hallucinations and the delusional other.
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Chronic Disease; Delusions; Drug Therapy | 2004 |
Effects of typical and atypical antipsychotics on human glycine transporters.
Topics: Amino Acid Transport Systems, Neutral; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlori | 2004 |
Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Auditory Perception; Benzodiazepines; Clozapine; | 2004 |
Chronic antidopaminergic medication might affect amygdala structure in patients with schizophrenia.
Topics: Amygdala; Antipsychotic Agents; Brain; Clopenthixol; Dose-Response Relationship, Drug; Epilepsy, Tem | 2004 |
Atypical antipsychotics: matching receptor profile to individual patient's clinical profile.
Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Cognition; Dibenzothiazep | 2004 |
Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up | 2004 |
Treatment with risperidone and occurrence of blurred vision: a question of higher dosage.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; | 2004 |
[A long-acting second generation anti-psychotic--experience in Israel].
Topics: Adult; Age of Onset; Antipsychotic Agents; Humans; Israel; Male; Patient Compliance; Risperidone; Sc | 2004 |
Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.
Topics: Adult; Ambulatory Care; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Female; Humans; | 2004 |
High dose of depot risperidone in a nonresponder schizophrenic patient.
Topics: Adult; Delayed-Action Preparations; Humans; Male; Risperidone; Schizophrenia | 2004 |
Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Biological Availability; Diagnostic and Statistic | 2004 |
[Rehospitalization rates of newly diagnosed schizophrenic patients on atypical neuroleptic medication].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Benzodiazepines; Fema | 2004 |
Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach.
Topics: Antipsychotic Agents; Biomarkers; Biometry; Endpoint Determination; Humans; Longitudinal Studies; Me | 2004 |
Weight gain and new onset diabetes associated with olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Diabetes Mellitus; Female; Humans; Mal | 2004 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Use of long-acting risperidone.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Drug Administration Schedule; Drug Tolerance; Hum | 2005 |
Use of long-acting risperidone.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Drug Administration Schedule; Drug Tolerance; Hum | 2005 |
The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Olanzapi | 2005 |
Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Antagonists; Chronic Dise | 2005 |
The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cytochrome P-450 CYP2D6; Dose-Response Relation | 2005 |
Priapism.
Topics: Adult; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male; Priapism; Quetiapine Fumarate; R | 2004 |
[Treatment of "the premonitory state of schizophrenia" with atypical antipsychotics].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Indoles; Isoindoles; Male; Middle Aged | 2004 |
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
Topics: Adult; Ambulatory Care; Amenorrhea; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapin | 2005 |
Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Costs and Cost Analysis; Dibenzothiazepines; Drug Cost | 2004 |
Movement disorders and the treatment of schizophrenia.
Topics: Antipsychotic Agents; Brain; Catatonia; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Lo | 2004 |
Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Catecholamines; Cen | 2005 |
Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia; Cerebral Cortex; Female; Humans; Magnetic Re | 2005 |
Comparison of clozapine use in Maryland and in Victoria, Australia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Australia; Benzodiazepines; Catchment Area, Health; Cl | 2005 |
Health care costs for schizophrenia patients started on olanzapine versus risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Databases, Factual; Female; Health Care Costs; H | 2005 |
Interpreting serum risperidone concentrations.
Topics: Adult; Antipsychotic Agents; Humans; Male; Risperidone; Schizophrenia; Treatment Refusal | 2005 |
Schizophrenia in a 5-year-old.
Topics: Antipsychotic Agents; Child, Preschool; Humans; Male; Risperidone; Schizophrenia | 2005 |
Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Long-Term Care; Olanzapine; Queti | 2005 |
Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cali | 2005 |
[Anesthesia for cesarean section in a parturient taking risperidone and haloperidol].
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antipsychotic Agents; Cesarean Section; Female; | 2005 |
Increase in risperidone plasma level with lamotrigine.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Drug Interactions; Drug Therapy, Combination; Female; | 2005 |
Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Antipsychotic Agents; Aspartate Aminotransferases | 2005 |
Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Decision Support Techniques; Delayed-Action Preparation | 2005 |
Internet in clinical research based on a pilot experience.
Topics: Antipsychotic Agents; Benzodiazepines; Database Management Systems; Humans; Information Storage and | 2005 |
[Correction of acute psychotic states in schizophrenia by rispolept solution per os].
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Data Interpretation, Statistical; Dop | 2004 |
Letter to the editors.
Topics: Adolescent; Antipsychotic Agents; Asperger Syndrome; Comorbidity; Humans; Male; Risperidone; Schizop | 2005 |
Injection site pain with long-acting risperidone.
Topics: Analgesia; Antipsychotic Agents; Delayed-Action Preparations; Drug Administration Schedule; Drug Lab | 2005 |
Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Comorbidity; Fema | 2005 |
Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Benzofurans; Brain Chemistry; Cataplexy; Cytochrome P-450 Enzyme Syst | 2005 |
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Demography; Depr | 2005 |
Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Clozapine; Cross-Sectional Studies; F | 2005 |
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Controlled Clinical Trials | 2005 |
Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Haloperidol; Humans; Male; Nervous System D | 2005 |
Regular-dose risperidone on QTc intervals.
Topics: Age Factors; Antipsychotic Agents; Dose-Response Relationship, Drug; Electrocardiography; Heart Cond | 2005 |
Comments on "Prolactin levels and erectile function in patients treated with risperidone" (J Clin Psychopharmacol 2004;24:161-166).
Topics: Antipsychotic Agents; Erectile Dysfunction; Humans; Male; Prolactin; Risperidone; Schizophrenia | 2005 |
Allergic reaction to depot risperidone but not to oral risperidone.
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Drug Eruptions; Humans; Mal | 2005 |
Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Attitude; Benzodiazepines; Cross-Section | 2005 |
Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost Savings; Costs and Cost Analysis; | 2005 |
Reversal of symptomatic hyperprolactinemia by aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Drug Therapy, Combination; Female | 2005 |
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzod | 2005 |
[Obsessive-compulsive symptoms treatment in: schizophrenia].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obsessive-Compulsive Disorder; Olanzapine; | 2005 |
['Awakening': a confusing improvement during treatment with atypical antipsychotic agents].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Female; Humans; Piperazines; Quality of Life; | 2005 |
D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Brain; Female; Handwriting; Humans; Iodine Radioisotopes; Male; Middle | 2005 |
An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Injections, Intravenous; Risperidone; Sch | 2005 |
[Case of obsessive-compulsive disorder associated with neuroleptics-induced deficit syndrome (NIDS): successfully treated by discontinuation of neuroleptics followed by SSRI].
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Fluvoxamine; Haloperidol; Human | 2005 |
Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia.
Topics: Adult; Antipsychotic Agents; Atrophy; Brain; Chronic Disease; Clozapine; Female; Follow-Up Studies; | 2005 |
Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Male | 2005 |
[Prescription of psychotropic drugs for schizophrenic outpatients in Hungary].
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clozapine; Cross-Sectional St | 2005 |
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
Topics: Adult; Antipsychotic Agents; Black or African American; Cardiovascular Diseases; Cause of Death; Clo | 2005 |
Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate.
Topics: Adult; Anti-Obesity Agents; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Chi | 2005 |
Therapeutic drug monitoring of patients on risperidone depot.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Administration Schedule; Drug Monitor | 2005 |
[No association of -1438G/A polymorphism in promoter region of 5-HT2A receptor gene with antipsychotic agent-induced weight gain].
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Gene Frequency; Genotype; Humans; Male; Polymer | 2005 |
A unifying approach for surrogate marker validation based on Prentice's criteria.
Topics: Antipsychotic Agents; Biomarkers; Data Interpretation, Statistical; Humans; Interferon-alpha; Longit | 2006 |
Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; D | 2005 |
An economic comparison of risperidone and olanzapine use within an integrated managed mental health program.
Topics: Antipsychotic Agents; Benzodiazepines; Delivery of Health Care, Integrated; Drug Costs; Mental Healt | 2006 |
A crossover study on lipid and weight changes associated with olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Cross-Ove | 2005 |
Thyroid dysfunction during treatment with atypical antipsychotics.
Topics: Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Humans; Hyperthyroidism; Hypothyroidi | 2005 |
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Female; Haloperidol; H | 2005 |
The CATIE schizophrenia effectiveness trial.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Drug Administra | 2005 |
Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Binding, Competitive; Female; Humans; Male; Olanzapine | 2006 |
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Dibenzothiazepines; Female; H | 2006 |
Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Catalase; Clozapine; Female; Free Radicals; Glutathione Peroxidase; Hum | 2006 |
Neuroleptic malignant syndrome associated with risperidone in a male with early-onset schizophrenia.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Clozapine; Combined Modality Therapy; Electr | 2005 |
Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Longitudinal Studies; Male; Mi | 2006 |
Interpreting the results of the CATIE study.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; National Institute of Mental Health (U.S.); Perphe | 2006 |
Interpreting the results of the CATIE study.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Perphenazine; Piperazines; Quetiapine Fumarate; Ri | 2006 |
Interpreting the results of the CATIE study.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Perphenazine; Piperazines; Quetiapine Fumarate; Ri | 2006 |
Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Economics, Pharmaceutical; Humans; Models, Economic; Ri | 2005 |
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Cost of Illness; Cost-Benefit Analysis; | 2005 |
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
Topics: Antipsychotic Agents; Belgium; Benzodiazepines; Cost of Illness; Cost-Benefit Analysis; Decision Tre | 2005 |
Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
Topics: Administration, Oral; Antipsychotic Agents; Canada; Cost of Illness; Cost-Benefit Analysis; Delayed- | 2005 |
Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
Topics: Antipsychotic Agents; Cost of Illness; Cost-Benefit Analysis; Decision Trees; Hospitalization; Human | 2005 |
Antipsychotic drugs and schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Developing Countries; Health Policy; H | 2006 |
Antipsychotic drugs and schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dyskinesia, Drug-Induced; Humans; Olanzap | 2006 |
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Chronic Disease; Clozap | 2006 |
Methodological issues in a comparative study of ziprasidone and risperidone.
Topics: Antipsychotic Agents; Drug Administration Schedule; Humans; Piperazines; Randomized Controlled Trial | 2006 |
The choice of drugs for schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Risperidone; Schizophrenia | 2006 |
Ethnic variation in symptoms and response to risperidone in youths with schizophrenia-spectrum disorders.
Topics: Adolescent; Antipsychotic Agents; Black or African American; Brief Psychiatric Rating Scale; Child; | 2006 |
Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Humans; M | 2006 |
Genetic predisposition to neuroleptic malignant syndrome in siblings.
Topics: Adult; Antipsychotic Agents; Citalopram; Female; Humans; Male; Neuroleptic Malignant Syndrome; Polym | 2006 |
Diabetes associated with atypical antipsychotic treatment may be severe but reversible: case report.
Topics: Adult; Antipsychotic Agents; Diabetes Mellitus, Type 2; Dibenzothiazepines; Female; Humans; Hypoglyc | 2005 |
Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Area Under Curve; Asian People; China; Female; Humans | 2006 |
A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Carbon Radioisotopes; Corpus Striatum; D | 2006 |
Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone.
Topics: Adult; Butyrophenones; Cytochrome P-450 CYP2D6 Inhibitors; Humans; Male; Risperidone; Schizophrenia; | 2006 |
Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; | 2005 |
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Cross-Over Studies | 2007 |
Three cases of risperidone-induced enuresis.
Topics: Aripiprazole; Enuresis; Female; Humans; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophr | 2006 |
Practical treatment information for schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Dibenzothiazepines; Female; Humans; Male; Multicenter Studies as To | 2006 |
[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Clozapi | 2006 |
Clozapine alone versus clozapine and risperidone for refractory schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Confidence Intervals; Drug Therapy, Combination; Humans; Risperidon | 2006 |
Clozapine alone versus clozapine and risperidone for refractory schizophrenia.
Topics: Antipsychotic Agents; Bias; Clozapine; Drug Therapy, Combination; Humans; Risperidone; Schizophrenia | 2006 |
Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia.
Topics: Adult; Antipsychotic Agents; Catatonia; Electroshock; Female; Humans; Neuroleptic Malignant Syndrome | 2006 |
Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Asian People; Basal Ganglia Diseases; Benzodiazepines; Diagnostic and S | 2006 |
Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Clinical Trials as Topic; Delayed- | 2006 |
Priapism associated with typical and atypical antipsychotic medications.
Topics: Adrenergic alpha-Antagonists; Adult; Antipsychotic Agents; Chlorpromazine; Humans; Male; Priapism; R | 2006 |
To what extent do the PANSS and CGI-S overlap?
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Female; Humans; Male; Psychiatric Status Rati | 2006 |
Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics.
Topics: Adult; Affect; Antipsychotic Agents; Arousal; Basal Ganglia; Benzodiazepines; Cues; Dominance, Cereb | 2006 |
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dose-Response Re | 2006 |
Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Female; Genotype; Humans; Linkage Dise | 2007 |
Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Delayed-Actio | 2006 |
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.
Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weig | 2006 |
A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Comorbidity; Depressive Disorder, Maj | 2006 |
Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; H | 2005 |
Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cross-Sectional | 2006 |
Decision models in the evaluation of psychotropic drugs : useful tool or useless toy?
Topics: Antipsychotic Agents; Benzodiazepines; Decision Support Techniques; Health Care Costs; Humans; Olanz | 2006 |
Comparison of time to rehospitalization among schizophrenic patients discharged on typical antipsychotics, clozapine or risperidone.
Topics: Adult; Age of Onset; Antipsychotic Agents; Clozapine; Female; Humans; Male; Middle Aged; Patient Com | 2006 |
Risperidone-induced hyperprolactinemia in adolescents: A case series.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Depressive Disorder, Major; Diagnostic and Statistica | 2006 |
A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany.
Topics: Antipsychotic Agents; Benzodiazepines; Decision Support Techniques; Germany; Health Care Costs; Hosp | 2006 |
Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Genotype; Haloperidol; Humans; Interleukin 1 R | 2006 |
A case of schizophrenia with complete agenesis of the corpus callosum.
Topics: Adult; Agenesis of Corpus Callosum; Antidepressive Agents; Antipsychotic Agents; Cognition Disorders | 2006 |
A model of anticholinergic activity of atypical antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Clozapine; Cognition Diso | 2006 |
Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type | 2006 |
Gender-specific effects in the treatment of acute schizophrenia with risperidone.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; | 2006 |
Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bulimia; Depression; Diabetes | 2006 |
The treatment of psychogenic polydipsia with risperidone in two children diagnosed with schizophrenia.
Topics: Antipsychotic Agents; Child; Drinking; Follow-Up Studies; Humans; Male; Psychophysiologic Disorders; | 2006 |
Initial dosing strategies for long-acting injectable risperidone.
Topics: Ambulatory Care; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug | 2006 |
Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule; Drug | 2006 |
Lingual lesions with orally disintegrating risperidone.
Topics: Absorption; Administration, Oral; Adult; Antipsychotic Agents; Chemistry, Pharmaceutical; Female; Hu | 2006 |
Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tra | 2006 |
Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzamides; Brief Psychiatric Rating Scale; Corpus Striatum | 2006 |
Psychometric characteristics of role-play assessments of social skill in schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Comorbidity; Crime Victims; Diabetes Mellitus, Type 2; Femal | 2006 |
Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Mem | 2006 |
Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
Topics: Adult; Antipsychotic Agents; Biotransformation; Female; Humans; Isoxazoles; Male; Middle Aged; Palip | 2006 |
Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics.
Topics: Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Chronic Disease; Clozapine; Female; Humans; | 2007 |
Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia.
Topics: Adult; Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induced | 2006 |
Pisa syndrome-like peculiar posture occurred while running was successfully improved with risperidone.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Jogging; M | 2006 |
Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Female; Humans; Injections; Pregnancy; Ri | 2007 |
Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.
Topics: Adult; Ambulatory Care; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cohort Studie | 2006 |
Pharmacokinetics and safety of combination therapy with lithium and risperidone.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Area Under Curve; Bipolar Disorder; Child; Drug | 2006 |
Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cohort Studies; Comorbidity; Cost Savings; Databases, Factual | 2006 |
Beneficial effect of long-acting injectable risperidone on the neurocognitive deficit of a schizophrenic patient: A case report.
Topics: Adult; Antipsychotic Agents; Female; Humans; Injections, Intramuscular; Patient Compliance; Psychiat | 2006 |
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzodiazepines; Comorbidity; Dementia, Vascular; Dose-R | 2007 |
[Psychiatric illness associated with amphetamines and other stimulants].
Topics: Adult; Amnesia; Amphetamines; Central Nervous System Stimulants; Cognition Disorders; Designer Drugs | 2000 |
Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; | 2007 |
Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications.
Topics: Adult; Aged; Antipsychotic Agents; Arachidonic Acid; Benzodiazepines; Brain; Clozapine; Diagnostic a | 2007 |
Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia.
Topics: Adiponectin; Adult; Antipsychotic Agents; Body Composition; Body Mass Index; Cholesterol, HDL; Femal | 2007 |
Alteration in serum neural cell adhesion molecule in patients of schizophrenia.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Chronic Disease; Diben | 2007 |
Atypical antipsychotics and pituitary neoplasms in the WHO database.
Topics: Adenoma; Adult; Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Causalit | 2007 |
Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Brain; Brain Chemistry; China; DNA Mutational Analysis; Drug Resistance | 2007 |
Splitting and pill splitting.
Topics: Adult; Aged; Borderline Personality Disorder; Cost Savings; Defense Mechanisms; Drug Costs; Female; | 2007 |
Impact of splitting risperidone tablets on medication adherence and on clinical outcomes for patients with schizophrenia.
Topics: Ambulatory Care; Antipsychotic Agents; Cost Savings; Drug Costs; Hospitals, Veterans; Humans; New Je | 2007 |
Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes?
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Dose-Response | 2007 |
Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Benzodiazepines; Cues; Eye Movements; Female; Humans; Male; | 2007 |
New-onset diabetic ketoacidosis induced by the addition of perospirone hydrochloride in a patient treated with risperidone.
Topics: Adult; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug T | 2007 |
Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Olan | 2007 |
Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dopam | 2007 |
Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Drug Interactions; Female; Homovanillic Acid; Humans; | 2007 |
Priapism with sertraline-risperidone combination.
Topics: Adult; Drug Combinations; Humans; Male; Penile Erection; Priapism; Risperidone; Schizophrenia; Selec | 2007 |
A discussion of 2 double-blind studies comparing risperidone and quetiapine in patients with schizophrenia.
Topics: Antipsychotic Agents; Data Interpretation, Statistical; Dibenzothiazepines; Double-Blind Method; Hum | 2007 |
Weight development in patients treated with risperidone: a 5-year naturalistic study.
Topics: Adult; Aged; Antipsychotic Agents; Body Weight; Female; Follow-Up Studies; Humans; Male; Middle Aged | 2007 |
Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.
Topics: AMP-Activated Protein Kinase Kinases; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Hum | 2007 |
Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Cell Line; Disease Models, Animal; Enzyme-Linked I | 2007 |
Risperidone-induced priapism.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Overdose; Erect | 2007 |
[Sleep disorders in schizophrenic patients and the effect of atypical antipsychotic agents].
Topics: Administration, Oral; Adult; Antipsychotic Agents; Drug Administration Schedule; Female; Humans; Mal | 2006 |
Blood pressure, heart rate, and anxiety in schizophrenia.
Topics: Adult; Antipsychotic Agents; Anxiety; Blood Pressure; Female; Heart Rate; Humans; Male; Middle Aged; | 2007 |
Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia.
Topics: Adult; Alleles; Animals; Antipsychotic Agents; Behavior, Animal; Chi-Square Distribution; Disease Mo | 2007 |
Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Drug Utilization; Dyskinesia, | 2007 |
Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study.
Topics: Adult; Age of Onset; Antipsychotic Agents; DNA; Humans; Polymerase Chain Reaction; Polymorphism, Gen | 2008 |
Pisa syndrome resolved after switching to olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; | 2007 |
Improvement in neuroleptic-induced akathisia with intravenous iron treatment in a patient with iron deficiency.
Topics: Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Humans; Infusions, Intravenous; Iron; Iron Defi | 2007 |
Surrogate marker evaluation from an information theory perspective.
Topics: Antipsychotic Agents; Biomarkers; Clinical Trials as Topic; Entropy; Humans; Information Theory; Mod | 2007 |
Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Catecholamines; Ch | 2007 |
Processing spatial-temporal information in recent-onset schizophrenia: the study of short-term memory and its susceptibility to distraction.
Topics: Adult; Antipsychotic Agents; Attention; Diagnostic and Statistical Manual of Mental Disorders; Femal | 2007 |
Managing psychosis in pregnancy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Case Management; Child Custody; Cooperative Behavior; | 2007 |
Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; | 2007 |
Sexual disinhibition in schizophrenia possibly induced by risperidone and quetiapine.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Clonazepam; Dibenzothiazepines; Female; GABA Modulato | 2007 |
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dose- | 2007 |
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.
Topics: Animals; Antipsychotic Agents; Attention; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzoth | 2007 |
The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Humans; Middle Aged; | 2007 |
Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Risperidone; Schizoph | 2007 |
Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Drug Cost | 2007 |
Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; China; Cost of Illness; Cost-Benefit Anal | 2007 |
Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication.
Topics: Adult; Alleles; Antipsychotic Agents; Extrapyramidal Tracts; Female; Haplotypes; Humans; Male; Middl | 2007 |
Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; F | 2007 |
The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Arginine Vasopressin; Clozapine; Deamino Argini | 2007 |
Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Clozapine; Cognition; | 2007 |
Impairment in error monitoring predicts poor executive function in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cognition Disorders; Diagn | 2007 |
(+/-) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics.
Topics: Animals; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid An | 2007 |
Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Follow-Up Studies | 2008 |
Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Paliperidone Palmitate; Prolactin; Pyrimidines; Risperidon | 2007 |
Atypical antipsychotic prescribing and diabetes.
Topics: Antipsychotic Agents; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Humans; Risperidone; Schi | 2007 |
Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Bipolar Disorder; Cohort Studies; Cross-Sectional Studies; | 2007 |
Estimating reliability and generalizability from hierarchical biomedical data.
Topics: Algorithms; Analysis of Variance; Biometry; Clinical Trials as Topic; Double-Blind Method; Humans; L | 2007 |
Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.
Topics: Adult; Aged; Antipsychotic Agents; Female; Gene Frequency; Genetic Predisposition to Disease; Genoty | 2007 |
Early use of clozapine for poorly responding first-episode psychosis.
Topics: Adolescent; Adult; Algorithms; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; | 2007 |
Risperidone- and quetiapine-induced cholestasis.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Antipsychotic Agents; Aspartate Aminotransferases | 2007 |
Pretrial medication bias in randomized antipsychotic drug trials.
Topics: Antipsychotic Agents; Bias; Drug Administration Schedule; Haloperidol; Humans; Randomized Controlled | 2007 |
Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Cross-Sectional Studies; Dibenzothiaze | 2007 |
Hypomania induced by atypical antipsychotics among schizophrenic patients: report of three cases.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Male; Risperidone; Schizophrenia; Sev | 2007 |
Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Humans; Isoxazoles; Male; | 2007 |
Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weigh | 2007 |
In vitro and in vivo demonstration of risperidone implants in mice.
Topics: Animals; Behavior, Animal; Biocompatible Materials; Disease Models, Animal; Drug Delivery Systems; D | 2008 |
Risperidone-induced priapism in a 12-year-old boy with schizophrenia.
Topics: Antipsychotic Agents; Child; Dose-Response Relationship, Drug; Humans; India; Male; Priapism; Risper | 2007 |
Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Databases, Factua | 2007 |
Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale.
Topics: Antipsychotic Agents; Computer Simulation; Controlled Clinical Trials as Topic; Data Interpretation, | 2007 |
Effect of risperidone on ghrelin and glucose in schizophrenia.
Topics: Antipsychotic Agents; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Ghrelin; Hu | 2007 |
Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Cognition Disorders; Fem | 2007 |
Risperidone-induced recurrent giant urticaria.
Topics: Angioedema; Antipsychotic Agents; Humans; Male; Middle Aged; Recurrence; Risperidone; Schizophrenia | 2007 |
Analysis of treatment effectiveness in longitudinal observational data.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Data Interpretation, Statistical; Female; Humans; Long | 2007 |
Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine.
Topics: Adult; Age of Onset; Antipsychotic Agents; Brazil; Clozapine; Epidemiologic Methods; Female; Haloper | 2007 |
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Emotions; Fa | 2007 |
Evidence-based psychiatry: outcomes and decisions.
Topics: Antipsychotic Agents; Benzodiazepines; Decision Making; Evidence-Based Medicine; Humans; Olanzapine; | 2007 |
Show me the evidence: using number needed to treat.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Confidence Intervals; Data Interpretation, Statist | 2007 |
New-onset diabetic ketoacidosis in a schizophrenic patient with multiple autoimmune disease during treatment with risperidone.
Topics: Antipsychotic Agents; Autoimmune Diseases; Comorbidity; Diabetes Mellitus, Type 1; Diabetic Ketoacid | 2008 |
Risperidone versus olanzapine for treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Risperidone; Schizophrenia | 2007 |
Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia.
Topics: Adult; Antipsychotic Agents; Cognition; Cognition Disorders; Female; Humans; Male; Neuropsychologica | 2008 |
Clinical decision-making during 5 years of antipsychotic treatment.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Attitude; Female; Humans; Lo | 2007 |
Costs of schizophrenia during 5 years.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Costs and Cost Analysis; Female; Humans; Male; Middle | 2007 |
Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study.
Topics: Adult; Antipsychotic Agents; DNA; DNA Primers; Dopamine Plasma Membrane Transport Proteins; Female; | 2007 |
New for old? Risperidone long-acting injection in older patients.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Delayed-Action Preparations; Female; Humans; Inj | 2007 |
Sleep quality and architecture in quetiapine, risperidone, or never-treated schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepin | 2007 |
The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain.
Topics: Administration, Oral; Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Clozapine; Dela | 2008 |
Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparations; Dyski | 2007 |
The impact of MDR1 polymorphisms on prolactin concentrations in patients treated with risperidone.
Topics: Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporte | 2008 |
Testosterone in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Humans; Male; Psychiatric Status Rating Scales; Risperidone; Schizophre | 2007 |
[22q11.2 deletion and schizophrenia in childhood and adolescence].
Topics: Adolescent; Antipsychotic Agents; Calcium; Child; Chromosome Deletion; Chromosomes, Human, Pair 22; | 2007 |
Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Fluvoxamine; Humans; Male; Meige Syndrome; Olanzapine; | 2007 |
Pharmacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Genotype; Humans; Male; Norepinephrine Plasma | 2008 |
Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Hu | 2007 |
The chakragati mouse shows deficits in prepulse inhibition of acoustic startle and latent inhibition.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Clozapine; Conditioning, Psychological; Disease | 2008 |
Aripiprazole treatment for risperidone-associated tic movement: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Risperidone; Schiz | 2008 |
Evaluating dose response from flexible dose clinical trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relatio | 2008 |
Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.
Topics: Benzodiazepines; Case-Control Studies; Ethics, Clinical; Feasibility Studies; Haloperidol; Humans; O | 2008 |
Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Benzodiazepines; Electrooculography; Female; Fix | 2008 |
RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Female; Genetic Predisposition to Disease; Genotype; Hu | 2008 |
Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Humans; Male; Middle Ag | 2008 |
Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Diabetes Mellitus, Type 2; Female; Gl | 2007 |
Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; | 2008 |
Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety; Benzodiazepines; Cross-Sectiona | 2008 |
Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia.
Topics: Adolescent; Adult; Alcoholism; Antipsychotic Agents; Clozapine; Diagnosis, Dual (Psychiatry); Female | 2008 |
Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Apoptosis; Behavior, Animal; Benzodiazepines; Disease Models, Animal; | 2008 |
Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Brain; Cerebrovascular Disorders; Clozapine; Cognition; Drug Resistance | 2008 |
Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study.
Topics: Adult; Aged; Antipsychotic Agents; Caffeine; Chromatography, High Pressure Liquid; Coffee; Cotinine; | 2008 |
Applying long-acting injectable antipsychotics in first-episode schizophrenia to achieve first remission.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Female; Flupenthixol; Hum | 2008 |
Paliperidone: An improvement over risperidone?
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Humans; Isoxazoles; Marketi | 2008 |
Combined low-dose clozapine with low-dose aripiprazole in a schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Clozapine; Dose-Response Relation | 2009 |
The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Polymorphism, Genetic; Prolactin; Re | 2008 |
Impact of risperidone long acting injection on resource utilization in psychiatric secondary care.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Female; Health Resources; Humans; In | 2008 |
Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study.
Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Dibenz | 2008 |
Weight gain due to long term antipsychotic treatment of persistent mental disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Follow-Up Studies; Humans; Is | 2008 |
Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
Topics: Administration, Oral; Adult; Age Factors; Ambulatory Care; Antipsychotic Agents; Clozapine; Cross-Se | 2008 |
[Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Prescriptions; Female | 2007 |
The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology.
Topics: Antipsychotic Agents; Endpoint Determination; Humans; Imidazoles; Indoles; Multicenter Studies as To | 2008 |
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Mental Healt | 2008 |
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
Topics: Adult; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzo | 2007 |
Effects of risperidone on glucose metabolism in Chinese patients with schizophrenia: a prospective study.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; C-Peptide; China; Cohort Studies; Femal | 2008 |
Lessons to be learned from CATIE and CUtLASS.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Health Care Cos | 2008 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Hum | 2008 |
Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone.
Topics: Adult; Antipsychotic Agents; Arousal; Dibenzothiazepines; Erectile Dysfunction; Female; Humans; Libi | 2008 |
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Comorbidity; Dopamine Antagonists; Dose-Resp | 2008 |
Increase of risperidone concentration under chlorprothixene comedication--a case report.
Topics: Adult; Antipsychotic Agents; Chlorprothixene; Drug Therapy, Combination; Humans; Male; Risperidone; | 2008 |
Risperidone-induced extrapyramidal reactions.
Topics: Adult; Basal Ganglia Diseases; Dopamine Antagonists; Humans; Male; Risperidone; Schizophrenia | 1995 |
[Therapeutic use of neuroleptics. Satellite symposium "Risperdal: new horizons for the schizophrenic patient". 9th World Congress for Psychiatry, Rio de Janeiro, 6-12 June 1993].
Topics: Antipsychotic Agents; Humans; Risperidone; Schizophrenia | 1993 |
Adverse reaction reporting and new antipsychotics.
Topics: Agranulocytosis; Anemia, Aplastic; Antipsychotic Agents; Clozapine; Drug Monitoring; Humans; Isoxazo | 1993 |
Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone.
Topics: Adult; Antipsychotic Agents; Benzamides; Brain; Brain Mapping; Contrast Media; Dopamine D2 Receptor | 1993 |
Risperidone and remoxipride for schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Isoxazoles; Piperidines; Remoxipride; Risperidone; Schizophren | 1993 |
Risperidone for chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Ri | 1994 |
Risperidone.
Topics: Adult; Clinical Trials as Topic; Humans; Isoxazoles; Multicenter Studies as Topic; Piperidines; Plac | 1994 |
Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Butyrophenones; Dogs; Dopamine D2 Receptor | 1994 |
Schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Risperidone for schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Dystonic reaction and relapse with clozapine discontinuation and risperidone intiation.
Topics: Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedu | 1994 |
Risperidone: a novel antipsychotic medication.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; | 1994 |
New drug offers hope for people with schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Risperidone | 1994 |
The effect of risperidone and ritanserin on human IgG and IgM synthesis in vitro.
Topics: Antipsychotic Agents; B-Lymphocytes; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Im | 1994 |
Response to clozapine as a predictor of risperidone response in schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Humans; Isoxazoles; Piperidines; Receptors, Dopamine | 1994 |
The pharmacokinetics of risperidone in humans: a summary.
Topics: Aged; Animals; Antipsychotic Agents; Biotransformation; Dogs; Half-Life; Humans; Isoxazoles; Liver C | 1994 |
Risperidone: new horizons for the schizophrenic patient. 9th World Congress of Psychiatry of the World Psychiatric Association, Rio de Janeiro, June 1993.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Fluvoxamine; Humans; Isoxazoles; Male; Obses | 1994 |
Risperidone in adolescents.
Topics: Adolescent; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Fe | 1994 |
Risperidone treatment for severe negative symptoms.
Topics: Adult; Antipsychotic Agents; Clonazepam; Depressive Disorder; Drug Therapy, Combination; Humans; Iso | 1994 |
Risperidone's cost.
Topics: Antipsychotic Agents; Delivery of Health Care; Health Services Accessibility; Humans; Isoxazoles; Pi | 1994 |
High-dose antipsychotic medication.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration | 1994 |
Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Chromatography, High Pressure Liquid; | 1994 |
Novel neuroleptics in schizophrenia: theory and clinical relevance.
Topics: Antipsychotic Agents; Brain; Clozapine; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating S | 1994 |
Schizophrenia and severe tardive dyskinesia responsive to risperidone.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Hal | 1994 |
Addressing emerging social needs of patients treated with new neuroleptics.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Humans; Isoxazoles; Male; Middle Aged; Nursing Asses | 1994 |
Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Binding Sites; Brain; Female; Humans; Isoxazoles; Male; Middle Aged; Pi | 1995 |
Recent developments in antipsychotic therapy. Introduction.
Topics: Antipsychotic Agents; Clozapine; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1995 |
Risperidone in childhood schizophrenia.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Drug Therapy, Combinatio | 1995 |
Effects of concomitant risperidone and lithium treatment.
Topics: Antipsychotic Agents; Confusion; Creatine Kinase; Drug Therapy, Combination; Fever; Humans; Isoxazol | 1995 |
Behavioral stimulation associated with risperidone initiation.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Benzodiazepines; Confusion; Female; Humans; | 1995 |
Switching patients from clozapine to risperidone therapy.
Topics: Antipsychotic Agents; Clonazepam; Clozapine; Drug Administration Schedule; Drug Therapy, Combination | 1995 |
Risperidone-induced prolactin elevations in premenopausal women with schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Isoxazoles; Piperidines; Premenopause; Pro | 1995 |
Prescribing risperidone.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Drug Prescriptions; Financing, Government; Health Care | 1995 |
Risperidone for the treatment of schizophrenia: does it have a niche?
Topics: Dopamine Antagonists; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psy | 1995 |
Reversible neutropenia during a cold: possible involvement of risperidone? A case report.
Topics: Adult; Antipsychotic Agents; Cold Temperature; Female; Humans; Influenza, Human; Isoxazoles; Neutrop | 1995 |
Risperidone for treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Humans; Isoxazoles; Male; Piperidines; Risperidone; Schizophrenia; Trea | 1995 |
Clinical implications of clozapine discontinuation: report of an NIMH workshop.
Topics: Antipsychotic Agents; Clozapine; Drug Administration Schedule; Humans; Isoxazoles; Piperidines; Risp | 1995 |
Unexpected dystonia while changing from clozapine to risperidone.
Topics: Adult; Antipsychotic Agents; Clozapine; Dystonia; Humans; Isoxazoles; Male; Piperidines; Risperidone | 1995 |
Concomitant use of thioridazine with risperidone.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Humans; Isoxazoles; Piperidines; Risperidone; Schiz | 1995 |
The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
Topics: Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Humans; Isoxazoles; Male; Piperidines; Recep | 1995 |
Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics?
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Fem | 1995 |
Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
Topics: Adult; Age Factors; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Depressive Disorder; Dr | 1995 |
Cost-benefits of new drugs.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Dyskinesia, Drug-Induced; Humans; Risperidone; Schizoph | 1995 |
Pharmaceuticals and politics.
Topics: Antipsychotic Agents; Clozapine; Drug Costs; Health Policy; Humans; Politics; Risperidone; Schizophr | 1995 |
Case study: risperidone in children and adolescents with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Child; Female; Humans; Male; Psychiatric Status Rating Scales; Ris | 1995 |
Clozapine in the management of schizophrenia. Risperidone is less toxic but equally effective.
Topics: Antipsychotic Agents; Clozapine; Drug Costs; Humans; Isoxazoles; Piperidines; Risperidone; Schizophr | 1993 |
Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients.
Topics: Antipsychotic Agents; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Isoxazoles; Pi | 1993 |
Respiridone and mania.
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Male; Middle Aged; Risperidone; Schizophrenia | 1996 |
Combining risperidone with standard neuroleptics for refractory schizophrenic patients.
Topics: Antipsychotic Agents; Diagnosis, Dual (Psychiatry); Drug Therapy, Combination; Humans; Risperidone; | 1996 |
Mania associated with risperidone use.
Topics: Bipolar Disorder; Humans; Male; Middle Aged; Risperidone; Schizophrenia | 1996 |
Placebo reconsidered.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Placebos; Risperidone; Schizophrenia; Schizo | 1995 |
Risperidone response after no clozapine response.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clozapine; Humans; Male; Psychiatric Status Rating Sca | 1995 |
The combined pharmacotherapy controversy.
Topics: Affective Symptoms; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Chil | 1996 |
Effect of risperidone on polydipsia and hyponatremia in schizophrenia.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drinking; Drug Administration Schedule; Huma | 1995 |
Drug interaction between risperidone and phenytoin resulting in extrapyramidal symptoms.
Topics: Administration, Oral; Adult; Basal Ganglia Diseases; Drug Administration Schedule; Drug Interactions | 1996 |
Neuroleptic-induced tardive dyskinesia.
Topics: Adolescent; Basal Ganglia Diseases; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Fluoxetine; | 1996 |
Tardive dyskinesia induced by risperidone?
Topics: Adult; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Schizophre | 1996 |
Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Admin | 1996 |
Risperidone appears safe in patients with antipsychotic-induced blood dyscrasias.
Topics: Adult; Antipsychotic Agents; Butyrophenones; Female; Humans; Male; Neutropenia; Phenothiazines; Purp | 1996 |
The use of risperidone in treatment-resistant schizophrenia: two case reports.
Topics: Adult; Antipsychotic Agents; Drug Resistance; Female; Humans; Risperidone; Schizophrenia | 1996 |
Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response.
Topics: Antipsychotic Agents; Brain; Clozapine; Dose-Response Relationship, Drug; Humans; Receptors, Dopamin | 1996 |
Manic symptoms associated with initiation of risperidone.
Topics: Adult; Bipolar Disorder; Humans; Male; Middle Aged; Psychotic Disorders; Risperidone; Schizophrenia | 1996 |
Comments on "Clozapine treatment after agranulocytosis induced by classic neuroleptics".
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Haloperidol; Humans; Male; Risperidone; Schizophrenia; | 1996 |
Managing the first episode of schizophrenia: the role of new therapies.
Topics: Haloperidol; Humans; Risperidone; Schizophrenia | 1996 |
Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.
Topics: Clozapine; Cognition; Fluphenazine; Haloperidol; Humans; Maze Learning; Risperidone; Schizophrenia | 1996 |
The impact of managed care systems on relapse prevention and quality of life for patients with schizophrenia.
Topics: Cost-Benefit Analysis; Humans; Managed Care Programs; Quality of Life; Risperidone; Schizophrenia | 1996 |
[Risperidone-induced priapism].
Topics: Adult; Antipsychotic Agents; Hematoma; Humans; Male; Penile Diseases; Priapism; Risperidone; Schizop | 1996 |
Cost-benefits of risperidone.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Haloperidol; Humans; Risperidone; Schizophrenia | 1996 |
Each of the following statements about the newer medications for schizophrenia, risperidone (risperidol) and clozapine (clozaril), is true, except: Patients receiving risperidone are at risk for agranulocytosis.
Topics: Antipsychotic Agents; Clozapine; Humans; Risperidone; Schizophrenia | 1995 |
Risperidone-associated hepatotoxicity.
Topics: Aged; Antipsychotic Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Middle Age | 1996 |
Assessing a drug's cost-benefits.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Haloperidol; Humans; | 1996 |
Risperidone and reversible neutropenia: a negative rechallenge.
Topics: Adult; Female; Humans; Neutropenia; Risperidone; Schizophrenia | 1996 |
A naturalistic outcome study of risperidone treatment among hospital patients.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Depressive Disorder; Female; Hospita | 1996 |
The effect of risperidone on cognition in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Arousal; Attention; Cognition Disorders; Female; Follow-Up Studies; Hum | 1996 |
[Behavioral assessment of neuroleptics (3)--Schizophrenia negative symptoms-like model induced by PCP].
Topics: Animals; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Clozapine; Desipramine; Disease Mod | 1996 |
Acute dystonic reaction with risperidone.
Topics: Adolescent; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dy | 1996 |
Self-induced water intoxication treated with risperidone.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drinking; Humans; Male; Middle Aged; Prospective Studi | 1996 |
[Pharma-clinics. Drug of the month. Risperidone (Risperdal)].
Topics: Antipsychotic Agents; Humans; Risperidone; Schizophrenia | 1996 |
Risperidone: once-daily dosage.
Topics: Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 1996 |
Pancreatitis associated with risperidone treatment?
Topics: Acute Disease; Adult; Humans; Male; Pancreatitis; Risperidone; Schizophrenia | 1997 |
Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs.
Topics: Adult; Age of Onset; Analysis of Variance; Antipsychotic Agents; CD8 Antigens; Chi-Square Distributi | 1996 |
Clinical features of schizophrenia in a woman with hyperandrogenism.
Topics: Adult; Antipsychotic Agents; Brain; Estrogens; Female; Humans; Hyperandrogenism; Perceptual Disorder | 1997 |
Risperidone overdose.
Topics: Adult; Drug Overdose; Humans; Male; Risperidone; Schizophrenia; Suicide, Attempted | 1997 |
[Compliance determines therapeutic success in schizophrenia. Strategy in initial therapy].
Topics: Chronic Disease; Clozapine; Humans; Patient Compliance; Risperidone; Schizophrenia | 1995 |
Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzamides; Brain Mapping; Dopamin | 1996 |
Chronic schizophrenia: response to clozapine, risperidone, and paroxetine.
Topics: Chronic Disease; Clozapine; Drug Therapy, Combination; Humans; Middle Aged; Paroxetine; Risperidone; | 1997 |
Risperidone, weight gain, and bulimia nervosa.
Topics: Antipsychotic Agents; Bulimia; Child; Dose-Response Relationship, Drug; Female; Humans; Risk Factors | 1997 |
Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Chronic Disease; Clozapine; Drug Administratio | 1996 |
[Risperidon--contribution to an integrated therapy of schizophrenia. Yearly session of the German Society for Psychiatry, Psychotherapy and Neurology. Düsseldorf, 17 September 1996].
Topics: Antipsychotic Agents; Dopamine Antagonists; Drug Costs; Female; Humans; Male; Risperidone; Schizophr | 1996 |
[Risperidon: an advance for schizophrenic patients. Why new neuroleptics?].
Topics: Antipsychotic Agents; Humans; Risperidone; Schizophrenia | 1994 |
Case study: risperidone-induced hepatotoxicity in pediatric patients.
Topics: Adolescent; Antipsychotic Agents; Chemical and Drug Induced Liver Injury; Child; Female; Humans; Mal | 1997 |
Risperidone in the treatment of psychosis and concomitant buccolinguomasticatory dyskinesia in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Depressive Disorder; Dyskinesia, Drug-Induced; Female | 1997 |
Use of risperidone in pervasive developmental disorders: a case series.
Topics: Adolescent; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Dopamine; Female; H | 1996 |
Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Humans; Psychotic Disorders; Retrospective Studies; | 1996 |
Impact of risperidone on the use of mental health care resources.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; California; Chronic Disease; Cost-Be | 1997 |
Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Cross-Sectiona | 1997 |
First person account: meaning of psychoses.
Topics: Adult; Antipsychotic Agents; Autobiographies as Topic; Female; Humans; Mental Healing; Religion and | 1997 |
D2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients.
Topics: Adult; Benzamides; Clozapine; Humans; Iodine Radioisotopes; Male; Middle Aged; Psychiatric Status Ra | 1997 |
[Urinary retention with risperidone].
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Male; Risperidone; Schizophre | 1997 |
Risperidone and cytochrome P450 3A.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Carbamazepine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme | 1997 |
[3 years of clinical experience with risperidone: new therapeutic standards in the management of schizophrenia].
Topics: Antipsychotic Agents; Humans; Risperidone; Schizophrenia | 1996 |
A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Psyc | 1997 |
[Schizophrenia and quality of life--new definition of therapeutic targets].
Topics: Antipsychotic Agents; Humans; Psychotherapy; Risperidone; Schizophrenia | 1997 |
[Schizophrenia and quality of life--newly defined therapeutic targets].
Topics: Antipsychotic Agents; Humans; Psychotherapy; Quality of Life; Risperidone; Schizophrenia; Schizophre | 1997 |
[3 years of risperidone: from innovation to example].
Topics: Antipsychotic Agents; Dopamine Antagonists; Humans; Quality of Life; Risperidone; Schizophrenia; Sch | 1997 |
Tardive dyskinesia during treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Risperidone; Schizophrenia | 1997 |
The new antipsychotics, and their potential for early intervention in schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Disease Progression; Dopamine Antagonists; Humans; Risperidone; Sch | 1997 |
The relationship between risperidone plasma levels and dopamine D2 occupancy: a positron emission tomographic study.
Topics: Antipsychotic Agents; Carbon Radioisotopes; Dopamine Antagonists; Humans; Raclopride; Receptors, Dop | 1998 |
Alteration in the recommended dosing schedule for risperidone.
Topics: Adult; Databases as Topic; Drug Administration Schedule; Drug Prescriptions; Female; Hospitalization | 1998 |
Seizure during risperidone treatment in an elderly woman treated with concomitant medications.
Topics: Age Factors; Aged; Antipsychotic Agents; Astemizole; Comorbidity; Dose-Response Relationship, Drug; | 1998 |
Mania induced by risperidone: dose related?
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Dose-Response Relationship, Drug; Fe | 1998 |
Marketing of antipsychotic drugs attacked.
Topics: Advertising; Antipsychotic Agents; Benzodiazepines; Drug Industry; Federal Government; Government Re | 1998 |
Risperidone-induced delirium.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Humans; Risperidone; Schizophrenia | 1998 |
A naturalistic study of clinical use of risperidone.
Topics: Adult; Antipsychotic Agents; Chi-Square Distribution; Drug Utilization; Female; Follow-Up Studies; H | 1998 |
[Schizophrenia and quality of life--therapeutic aims to be re-interpreted].
Topics: Cognitive Behavioral Therapy; Humans; Neurobehavioral Manifestations; Quality of Life; Risperidone; | 1998 |
Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Risperi | 1998 |
Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Risperi | 1998 |
Risperidone-induced tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Schizophrenia | 1998 |
Obsessional symptoms associated with risperidone treatment.
Topics: Adult; Antipsychotic Agents; Clomipramine; Female; Humans; Obsessive Behavior; Psychiatric Status Ra | 1998 |
Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone.
Topics: Adult; Cholinergic Antagonists; Clozapine; Cognition Disorders; Female; Humans; Male; Middle Aged; M | 1998 |
Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
Topics: Adult; Antipsychotic Agents; Benzamides; Clozapine; Female; Haloperidol; Humans; Imidazoles; Indoles | 1998 |
Atypical antipsychotic agents in the treatment of schizophrenia and other psychiatric disorders. Part I: Unique patient populations.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Humans; Mental D | 1998 |
Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzamides; Brain; Dopamine Antagonists; Haloperidol; Hu | 1998 |
Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Clozapine; Contrast Media; D | 1998 |
The new antipsychotic compounds: is a clinical choice algorithm possible?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Pirenzepin | 1998 |
Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Dy | 1998 |
Augmentation of risperidone with valproic acid.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Drug Administration Schedule; Drug Therapy, Co | 1998 |
Two new atypical antipsychotics: advantages and disadvantages.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Interactions; Humans; Ola | 1998 |
Treatment of aggression in schizophrenia.
Topics: Adult; Aggression; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Risperidone; Schizophreni | 1998 |
APA Practice Guideline for schizophrenia: risperidone equivalents. American Psychiatric Association.
Topics: Drug Administration Schedule; Haloperidol; Humans; Practice Guidelines as Topic; Psychiatry; Risperi | 1998 |
[A study of neuroleptic malignant syndrome in the presenium and senium].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Female; Haloperidol; Humans; Male | 1998 |
Choosing among old and new antipsychotics.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Humans; Psychotic Disorders; Receptors, Dop | 1996 |
[Severe tardive dyskinesia during treatment with risperidone and fluoxetine].
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Fluoxetine; Humans | 1998 |
Research and treatment strategies in first-episode psychoses. The Pittsburgh experience.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain Diseases; Developmental Disabilities; Episode of Care | 1998 |
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Benzodiazepines; Female; Galactorrhea; Humans; Hyperprolact | 1998 |
[Social reintegration thanks to improved cognition].
Topics: Antipsychotic Agents; Cognition; Cognitive Behavioral Therapy; Humans; Risperidone; Schizophrenia; S | 1998 |
Quality of life and atypical antipsychotics.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psych | 1998 |
Risperidone treatment for a patient suffering from schizophrenia and IDDM.
Topics: Adult; Diabetes Mellitus, Type 1; Humans; Male; Risperidone; Schizophrenia; Serotonin Antagonists | 1998 |
[A new drug risperidone for treatment of psychosis].
Topics: Antipsychotic Agents; Humans; Risperidone; Schizophrenia | 1995 |
A case of risperidone overdose in early schizophrenia: a review of potential complications.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Drug Interactions; Drug Overd | 1998 |
Manic and psychotic symptoms following risperidone withdrawal in a schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Humans; Male; Psychoses, Substance-I | 1998 |
Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Topics: Antipsychotic Agents; Baltimore; Chronic Disease; Delayed-Action Preparations; Disease-Free Survival | 1998 |
Edema associated with addition of risperidone to valproate treatment.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Dru | 1998 |
5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150.
Topics: Adult; Basal Ganglia Diseases; Clozapine; Female; Humans; Iodine Radioisotopes; Male; Piperidines; R | 1998 |
[Cognitive dysfunction in schizophrenia--new therapeutic possibilities. 11th ECNP. 31 October-4 November 1998, Paris].
Topics: Antipsychotic Agents; Cognition Disorders; Humans; Risperidone; Schizophrenia | 1998 |
Prolactin levels and adverse events in patients treated with risperidone.
Topics: Adult; Antipsychotic Agents; Female; Galactorrhea; Humans; Male; Prolactin; Randomized Controlled Tr | 1999 |
Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Carbon Radioisotopes; Clozapine; Drug Administration S | 1999 |
Risperidone for exclusively negative symptoms.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Hu | 1999 |
Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Mood Disorders; Prospective Studies; Risperid | 1999 |
Hyperprolactinemia and male sexual dysfunction.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Hyperprolactinemia; Male; Olanzapine; Pirenzep | 1999 |
Telephone support service helps keep schizophrenics on track.
Topics: Alzheimer Disease; Antipsychotic Agents; Counseling; Disease Management; Health Services Accessibili | 1997 |
A cost-effectiveness clinical decision analysis model for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; Decision Support Systems, C | 1998 |
Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.
Topics: Antipsychotic Agents; Clozapine; Cost-Benefit Analysis; Humans; Israel; Risperidone; Schizophrenia | 1998 |
Looking beyond the formulary budget in cost-benefit analysis.
Topics: Antipsychotic Agents; Budgets; Clozapine; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Formul | 1997 |
Risperidone-induced mania.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Risperidone; Schizophrenia; Serotonin | 1999 |
Obsessive-compulsive symptoms with risperidone.
Topics: Antipsychotic Agents; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Fluox | 1999 |
Risperidone and clozapine combination for the treatment of refractory schizophrenia.
Topics: Adult; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Risperidone; Schizophrenia | 1999 |
Risperidone-induced tardive dyskinesia in first-episode psychotic patients.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Schizophrenia | 1999 |
Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone.
Topics: Adult; Antipsychotic Agents; Dopamine Antagonists; Haloperidol; Humans; Male; Middle Aged; Pituitary | 1999 |
Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Hospitals, Psychiatric; Hospitals, State; Humans; Ma | 1999 |
Weight gain and antipsychotic medications.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obesity; Olanzapine; Pirenzepine; Risperid | 1999 |
Risperidone treatment of tardive dyskinesia and dystonia.
Topics: Antipsychotic Agents; Diazepam; Dopamine Antagonists; Drug Administration Schedule; Drug Therapy, Co | 1999 |
Serum concentrations and clinical effects of risperidone in schizophrenic patients in Singapore--a preliminary report.
Topics: Adult; Antipsychotic Agents; Humans; Risperidone; Schizophrenia | 1999 |
Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; No | 1999 |
Tardive dystonia induced by risperidone.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Schizophrenia | 1999 |
Switching from therapy with typical antipsychotic agents to risperidone: long-term impact on patient outcome.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Humans; Retrospective Studies; Risperidone; Schizophre | 1999 |
Individualized risperidone dosing.
Topics: Adult; Age Factors; Aged; Ambulatory Care; Antipsychotic Agents; Child; Drug Administration Schedule | 1999 |
Risperidone and clozapine for treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Administration Schedule; Humans; Randomized Controlled Trials | 1999 |
Risperidone and clozapine for treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Humans; Randomized Controlled Trials as Topic; Risperidone; Schizop | 1999 |
Risperidone and clozapine for treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Dibenzothiazepines; Humans; Quetiapine Fumarate; Randomized Control | 1999 |
Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Bipolar Disorder; Clozapine; Dementia; Drug Admin | 1999 |
Seizures after discontinuation of low-dose lorazepam from originally seizure-free clozapine regimen: combined effects?
Topics: Adult; Anti-Anxiety Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedul | 1999 |
Clinical Therapeutic Conference: dopaminergic/serotonergic actions of phencyclidine as a model for schizophreniform psychosis.
Topics: Adult; Female; Hallucinogens; Humans; Male; Models, Psychological; Phencyclidine; Psychoses, Substan | 1997 |
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Case-Control Studi | 1999 |
Weight gain: side effect of atypical neuroleptics?
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Body Mass Index; C | 1999 |
Herbal medicine (Shakuyaku-kanzo-to) in the treatment of risperidone-induced amenorrhea.
Topics: Adult; Amenorrhea; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Drug Combinations; | 1999 |
Risperidone-induced tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Risperidone; Schizophrenia | 1999 |
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Hum | 1999 |
Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Dose-Response Relationship, Drug; Drug Ad | 1999 |
In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats.
Topics: Animals; Antipsychotic Agents; Binding, Competitive; Cerebral Cortex; Clozapine; Corpus Striatum; Do | 1999 |
Transient increase of liver enzymes induced by risperidone: two case reports.
Topics: Adult; Antipsychotic Agents; Humans; Liver; Liver Function Tests; Male; Risperidone; Schizophrenia | 1999 |
Use patterns for antipsychotic medications in medicaid patients with schizophrenia.
Topics: Ambulatory Care; Antipsychotic Agents; California; Clozapine; Cohort Studies; Drug Costs; Drug Utili | 1999 |
Some behavioural effects of risperidone in rats: comparison with haloperidol.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Drug Evaluation, Preclini | 1999 |
Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Frontal Lobe; Humans; Magnetic Resonance Imaging; Male; Memory; Risperi | 1999 |
Hospital days in risperidone-treated patients.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Female; Follow-Up Studies; Hospitalization; Humans; Len | 1999 |
Recommended haloperidol and risperidone doses in first-episode psychosis.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; H | 1999 |
The effects of typical antipsychotics, clozapine, and risperidone on neuropsychological test performance in schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Humans; Mental Recall; Paired-Associate Learning; Psychomotor Perfo | 1999 |
[Neuro-cognition and schizophrenia. 11th World Congress for Psychiatry. Hamburg, 8 August 1999].
Topics: Antipsychotic Agents; Cognition Disorders; Haloperidol; Humans; Risperidone; Schizophrenia | 1999 |
Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Prolactin | 1999 |
[The new antipsychotic preparation Rispolept (risperidone)].
Topics: Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Dopamine Antagonists; Humans; Obsessive | 1999 |
Evidence-based psychopharmacology 2. Appraising a systematic review: is risperidone better than conventional antipsychotics in the treatment of schizophrenia?
Topics: Adult; Antipsychotic Agents; Evidence-Based Medicine; Humans; Male; Randomized Controlled Trials as | 1999 |
Carbamazepine and/or fluvoxamine drug interaction with risperidone in a patient on multiple psychotropic medications.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Carbamazepin | 2000 |
Comparison of clozapine and risperidone.
Topics: Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Clinical Trials as Topic; Cloza | 2000 |
Discriminant cognitive factors in responder and non-responder patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Clozapine; Cognition Disorders; Dibenzothiazepines; Female; | 1999 |
Quality of life and new antipsychotics in schizophrenia. Are patients better off?
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; P | 1999 |
Olanzapine. Keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clinical Trials as Topic; Dopamine Antagonist | 2000 |
Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Chronic Disease; Clozapine; Creatine; Female; Gyrus Cing | 2000 |
Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Dose-Response Relationship, Drug; Halo | 2000 |
Risperidone implicated in the onset of tardive dyskinesia in a young woman.
Topics: Adolescent; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Risperidone; Schizophren | 2000 |
Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory.
Topics: Animals; Antipsychotic Agents; Benzazepines; Brain; Excitatory Amino Acid Antagonists; Glutamic Acid | 2000 |
Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans | 2000 |
Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Auditory Perception; Benzodiazepines; Clozapine; | 2000 |
Risperidone and cognitive functioning in elderly schizophrenic patients.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Mental Status Schedule; Neuropsychological Tests; Risp | 2000 |
Side effects of antipsychotics in the elderly.
Topics: Age Factors; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine | 2000 |
Urinary incontinence with risperidone.
Topics: Antipsychotic Agents; Female; Humans; Male; Middle Aged; Risperidone; Schizophrenia; Urinary Inconti | 2000 |
Effectiveness of risperidone in simple schizophrenia: a single case report.
Topics: Adolescent; Antipsychotic Agents; Clinical Trials as Topic; Humans; Male; Risperidone; Schizophrenia | 2000 |
First-episode psychosis in a managed care setting: clinical management and research.
Topics: Adolescent; Antipsychotic Agents; Direct Service Costs; Episode of Care; Female; Health Care Costs; | 2000 |
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Corpus | 2000 |
Novel antipsychotic use in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dibenzothiepins; Drug Administration Sche | 2000 |
[Atypical antipsychotics].
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; | 2000 |
Acute confusional states during treatment with risperidone.
Topics: Acute Disease; Aged; Antipsychotic Agents; Confusion; Humans; Male; Risperidone; Schizophrenia | 2000 |
Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry.
Topics: Animals; Antipsychotic Agents; Chromatography, Liquid; Humans; Isoxazoles; Mass Spectrometry; Palipe | 2000 |
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Utilizat | 2000 |
Optimal risperidone dose in drug-naive, first-episode schizophrenia.
Topics: Drug Administration Schedule; Humans; Risperidone; Schizophrenia | 2000 |
Adjunctive risperidone treatment in patients with 'clozapine-resistant schizophrenia'.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Drug Therapy, Combination; Humans; Male; Ri | 2000 |
Risperidone in disorganised schizophrenia.
Topics: Adult; Antipsychotic Agents; Humans; Male; Risperidone; Schizophrenia; Severity of Illness Index | 2000 |
Increased levels of transcription factors Elk-1, cyclic adenosine monophosphate response element-binding protein, and activating transcription factor 2 in the cerebellar vermis of schizophrenic patients.
Topics: Activating Transcription Factor 2; Adult; Aged; Animals; Cerebellum; Cyclic AMP Receptor Protein; Cy | 2000 |
Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis.
Topics: Adult; Aggression; Clozapine; Drug Administration Schedule; Humans; Male; Middle Aged; Psychiatric S | 2000 |
Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Costs and Cost Analysis; Haloperido | 2000 |
St. John's wort and schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hypericum; Male; Olanza | 2000 |
Platelet 5-HT(2A) receptors in schizophrenic patients with and without neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Blood Platelets; Case-Control Studies; Dopamine Antagonists; Dose-Respo | 2000 |
Tardive dystonia provoked by concomitantly administered risperidone.
Topics: Adolescent; Antipsychotic Agents; Chlorpromazine; Drug Therapy, Combination; Dyskinesia, Drug-Induce | 2000 |
Severe self-injurious behavior associated with treatment-resistant schizophrenia: treatment with maintenance electroconvulsive therapy.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Electroconvulsive Therapy; Haloperidol; Hum | 2000 |
Risperidone and tardive dyskinesia: a case of blepharospasm.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blepharospasm; Dyskinesia, Drug-Induced; Humans; Male; | 2000 |
Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone.
Topics: Antipsychotic Agents; Haloperidol; Humans; Risperidone; Schizophrenia | 2000 |
Impact of risperidone on seclusion and restraint at a state psychiatric hospital.
Topics: Adult; Aged; Aggression; Cohort Studies; Female; Hospitals, Psychiatric; Hospitals, State; Humans; M | 2000 |
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Female; Hospitalization; Humans; Isra | 2001 |
Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.
Topics: Adult; Benzodiazepines; Brain Mapping; Carrier Proteins; Corpus Striatum; Dopamine Plasma Membrane T | 2001 |
Epidemic of schizophrenia in children or inappropriate prescribing?
Topics: Antipsychotic Agents; Australia; Benzodiazepines; Child; Child, Preschool; Disease Outbreaks; Drug U | 2000 |
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Cardiovascular Diseases; Cross-Sectional | 2001 |
Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Chronic Disease; Cytochrome P-450 CYP2 | 2001 |
Full remission of panic attacks in a schizophrenic patient after switching from haloperidol to risperidone.
Topics: Adult; Female; Haloperidol; Humans; Panic Disorder; Remission, Spontaneous; Risperidone; Schizophren | 2001 |
Improvement of tardive dyskinesia with risperidone: a case report.
Topics: Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Risperidone | 2000 |
Combination risperidone and quetiapine therapy in refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dibenzothiazepines; Drug Therapy, Combination; Humans; | 2001 |
Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels.
Topics: Adult; Age Factors; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chromatography, High Press | 2001 |
Priapism associated with polypharmacy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Fluvoxamine; Humans; Male; | 2001 |
Addition of risperidone to clozapine therapy in chronically psychotic inpatients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clozapine; Drug Therapy, Combination; Female; Hospital | 2001 |
Hyperthermia and chronic pancerebellar syndrome after cocaine abuse.
Topics: Adult; Antipsychotic Agents; Cerebellar Diseases; Chronic Disease; Cocaine-Related Disorders; Diagno | 2001 |
Acute phase of schizophrenia: impact of atypical antipsychotics.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Haloperidol; Humans; Prognosis; Recurrence; Risper | 2000 |
The evaluation of multiple surrogate endpoints.
Topics: Antipsychotic Agents; Biometry; Clinical Trials as Topic; Humans; Longitudinal Studies; Markov Chain | 2001 |
An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Basal Ganglia Diseases; Caudate Nucleus; Female; Globus | 2001 |
Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Clozapi | 2001 |
Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Cost of Illness; Drug Costs; Hospitals, Psychiatric; Hospital | 2001 |
Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone.
Topics: Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Male; Risperidone; Schizophrenia; Sexu | 2001 |
Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Follow-Up Studies; Humans; Ma | 2001 |
Hypothesis and hypothesis testing in the clinical trial.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Humans; Olanzap | 2001 |
Cataracts and quetiapine.
Topics: Adult; Antipsychotic Agents; Cataract; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male; | 2001 |
Dopamine D(2) receptor blockade in schizophrenia.
Topics: Antipsychotic Agents; Benzamides; Brief Psychiatric Rating Scale; Depression; Dopamine D2 Receptor A | 2001 |
Antiaggressive action of atypical antipsychotics in patients with schizophrenia.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Humans; Male; Olanzapine; Pirenzepine; Risperidon | 2001 |
Neuroleptic malignant syndrome during a change from haloperidol to risperidone.
Topics: Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Risper | 2001 |
Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine.
Topics: Adult; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Male; Neurologic Examination; Olanzapine; | 2001 |
Re-awakenings? A discourse analysis of the recovery from schizophrenia after medication change.
Topics: Adaptation, Psychological; Antipsychotic Agents; Attitude to Health; Clozapine; Female; Humans; Inte | 2001 |
[Schizophrenia and diabetes alliance. No increased insulin resistance due to risperidone].
Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Risperidone; Schiz | 2001 |
A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dat | 2001 |
The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Budgets; Clozapine; Comorbidity; Depressiv | 2001 |
Effective risperidone treatment for simple deteriorative disorder (simple schizophrenia): a case report.
Topics: Adult; Antipsychotic Agents; Humans; Male; Risperidone; Schizophrenia; Treatment Outcome | 2001 |
Risperidone-induced edema.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Edema; Female; Humans; Risperidone; S | 2001 |
Asymmetrical hand force persistence and neuroleptic treatment in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studi | 2001 |
Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Benzodiazepines; Cross-Cultural Comparison; Dose-Res | 2001 |
Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study.
Topics: Adult; Benzodiazepines; Cost-Benefit Analysis; Cross-Cultural Comparison; Drug Costs; Europe; Female | 2001 |
Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Brain; Female; Human | 2001 |
Olanzapine: new preparation. Keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Humans; Pirenzepine; Risperidone; Sc | 1999 |
Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
Topics: Adult; Antipsychotic Agents; Clomipramine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; H | 2001 |
Risperidone-associated new-onset diabetes.
Topics: Antipsychotic Agents; Diabetes Mellitus; Humans; Male; Middle Aged; Risperidone; Schizophrenia | 2001 |
Clozapine-risperidone combination in treatment-resistant schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Drug Therapy, Combination; Huma | 2001 |
Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scal | 2001 |
Risperidone added to clozapine: impact on serum prolactin levels.
Topics: Adult; Age of Onset; Ambulatory Care; Antipsychotic Agents; Chronic Disease; Clozapine; Cross-Sectio | 2001 |
[Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Creatine Kinase; Drug Interactions; Genet | 2001 |
Agranulocytosis and neutropenia with typical and atypical neuroleptics.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Leukocyte | 2001 |
Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Humans; Isoxazoles; Male; Middle Aged; | 2001 |
Global index of safety (GIS): a new instrument to assess drug safety.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Benzodiazepines; Consumer Product Saf | 2001 |
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Administration Schedu | 2001 |
Intractable depression or psychosis.
Topics: Aged; Depressive Disorder, Major; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; | 2001 |
Effects of risperidone on information processing and attention in first-episode schizophrenia.
Topics: Adolescent; Adult; Attention; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; H | 2002 |
Does risperidone reduce concomitant substance abuse in cases of schizophrenia?
Topics: Adult; Codeine; Comorbidity; Diagnosis, Dual (Psychiatry); Ephedrine; Humans; Male; Risperidone; Sch | 2001 |
Elevation of prolactin levels by atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Male; Middle Aged; Olanzapine; Pire | 2002 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Patient Compliance; Research Support as Topic; Risperidon | 2002 |
Donepezil in schizophrenia--is it helpful? An experimental design case study.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition; Donepezil; Drug Therapy, Combinat | 2001 |
Concomitant clozapine reduces smoking in patients treated with risperidone.
Topics: Adult; Antipsychotic Agents; Clozapine; Cross-Sectional Studies; Drug Therapy, Combination; Female; | 2002 |
[Comparison between therapeutic effect of Risperidone in treating different traditional Chinese medicine syndrome types of first-episode schizophrenia].
Topics: Adolescent; Adult; Diagnosis, Differential; Dopamine Antagonists; Female; Humans; Male; Medicine, Ch | 2000 |
Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2 | 2001 |
Effects of risperidone on gonadal axis hormones in schizophrenia.
Topics: Antipsychotic Agents; Case-Control Studies; Humans; Hypothalamo-Hypophyseal System; Male; Middle Age | 2001 |
Service use and costs of treating schizophrenia with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cost-Benefit Analysis; Dos | 2001 |
Toxic interaction between risperidone and clozapine: a case report.
Topics: Adult; Antipsychotic Agents; Clozapine; Diagnosis, Differential; Drug Interactions; Humans; Male; Ne | 2002 |
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder, Majo | 2001 |
Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).
Topics: Adult; Antipsychotic Agents; Attitude to Health; Basal Ganglia Diseases; Benzodiazepines; Female; Ha | 2001 |
No complications with risperidone treatment before and throughout pregnancy and during the nursing period.
Topics: Adult; Antipsychotic Agents; Female; Humans; Pregnancy; Pregnancy Complications; Pregnancy Outcome; | 2002 |
Psychiatric complications of hydrocephalus.
Topics: Adult; Antipsychotic Agents; Female; Humans; Hydrocephalus; Risperidone; Schizophrenia | 2001 |
Auto-vampirism in schizophrenia.
Topics: Adult; Antipsychotic Agents; Delusions; Depersonalization; Female; Hallucinations; Humans; Risperido | 2002 |
Risperidone-induced Pisa syndrome.
Topics: Adult; Antipsychotic Agents; Dystonia; Humans; Male; Risperidone; Schizophrenia; Syndrome | 2002 |
Risperidone-induced ejaculatory disturbances.
Topics: Adult; Antipsychotic Agents; Ejaculation; Humans; Male; Risperidone; Schizophrenia; Sexual Dysfuncti | 2002 |
A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost of Illness; Drug Costs; Female; H | 2002 |
Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia.
Topics: Animals; Antipsychotic Agents; Catalepsy; Central Nervous System Stimulants; Dextroamphetamine; Dose | 2002 |
Improved antisaccade performance in schizophrenia with risperidone.
Topics: Antipsychotic Agents; Humans; Randomized Controlled Trials as Topic; Risperidone; Saccades; Schizoph | 2002 |
Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Female; Humans; Long-Term Care; Male | 2002 |
Donepezil management of schizophrenia with associated dementia.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Comorbidity; Dementia; Donepezil; Drug Therapy, Co | 2002 |
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Benzodiazepines; Clozapi | 2002 |
Racial disparities in antipsychotic prescription patterns for patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Black or African American; Clozapine; Cross-Cultural Compar | 2002 |
Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Polysomnography; Psychi | 2002 |
Decreased [(3)H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study.
Topics: Adult; Aged; Antipsychotic Agents; Binding Sites; Binding, Competitive; Butaclamol; Down-Regulation; | 2002 |
Risperidone-induced retrograde ejaculation.
Topics: Adult; Ejaculation; Humans; Male; Risperidone; Schizophrenia; Serotonin Antagonists; Sexual Dysfunct | 2002 |
Clinical and neuropsychological correlates of the P300 in schizophrenia.
Topics: Adult; Benzodiazepines; Depression; Event-Related Potentials, P300; Female; Humans; Male; Neuropsych | 2002 |
Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Arousal; Attention; Auditory Perception; Humans; | 2002 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Patient Dropouts; Risperidone; Schizophrenia; Secondary P | 2002 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Hyperkinesis; Psychomotor Agitation; Risperidone; Schizop | 2002 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Patient Compliance; Risperidone; Schizophrenia; Secondary | 2002 |
Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.
Topics: Adult; Antipsychotic Agents; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Perceptual Dis | 2002 |
Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
Topics: Adolescent; Dopamine Antagonists; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Obsessive- | 2002 |
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Dia | 2002 |
Resolution of hyperglycemia on risperidone discontinuation: a case report.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia | 2002 |
Atypical antipsychotics and cognition in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Dose-Response Relationship, D | 2002 |
Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
Topics: Antipsychotic Agents; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Drug Adminis | 2002 |
Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Female; Hospitals, Psychiatric; | 2002 |
Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Prescription | 2002 |
Clinical profile of an atypical antipsychotic: risperidone.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Neurologic Examination; Psychiatric Status R | 2002 |
Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Child; Female; Health Care Costs; Humans; Male; Manag | 2002 |
Sexual side effects of novel antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Clozapine; Erectile Dysfunction; Fluphenazine; Haloperidol; Humans; Mal | 2002 |
Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Follow-Up Stud | 2002 |
Galantamine for treatment-resistant schizophrenia.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Drug Therapy, Co | 2002 |
Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Caudate Nucleus; Clozapine; Disease Models, Animal; Dose-Response Rel | 2002 |
Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo.
Topics: Adult; Clozapine; Dopamine Antagonists; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; | 2002 |
Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine.
Topics: Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Hospitals, Veterans; Humans; Male; Ment | 2002 |
One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Humans; Middle Aged; Olanzapine; Pat | 2002 |
Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.
Topics: Adult; Carbamazepine; Cytochrome P-450 CYP2D6; Drug Interactions; Female; Genotype; Humans; Male; Mi | 2002 |
Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia.
Topics: Adult; Aged; Female; Haloperidol; Humans; Middle Aged; Prolactin; Risperidone; Schizophrenia; Statis | 2002 |
A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Benzodiazepines; Chi-Square Distribution; Electromagnetic Fields; Evoke | 2002 |
Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.
Topics: Adolescent; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Humans; Male; Risperidone; Schizophrenia | 2002 |
Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Female; Humans; Middle Aged; Neuroleptic Malignant Syn | 2002 |
Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Chronic Disease; Female; Humans; Isoxazoles; Male; Middl | 1991 |